



Effective Health Care Program

Comparative Effectiveness Review
Number 154

Psychosocial and Pharmacologic Interventions for Disruptive Behavior in Children and Adolescents



Agency for Healthcare Research and Quality
Advancing Excellence in Health Care • www.ahrq.gov

Comparative Effectiveness Review

Number 154

Psychosocial and Pharmacologic Interventions for Disruptive Behavior in Children and Adolescents

Prepared for:

Agency for Healthcare Research and Quality
U.S. Department of Health and Human Services
540 Gaither Road
Rockville, MD 20850
www.ahrq.gov

Contract No. 290-2012-00009-I

Prepared by:

Vanderbilt Evidence-based Practice Center
Nashville, TN

Investigators:

Richard Epstein, Ph.D., M.P.H.
Christopher Fonnesebeck, Ph.D.
Edwin Williamson, M.D.
Tarah Kuhn, Ph.D.
Mary Lou Lindegren, M.D., M.P.H.
Katherine Rizzone, M.D.
Shanthi Krishnaswami, M.B.B.S., M.P.H.
Nila Sathe, M.A., M.L.I.S.
Cathy H. Ficzere, Pharm.D., B.C.P.S.
Genevieve Lynn Ness, Pharm.D.
Geoffrey W. Wright, M.S.
Mamata Raj, M.D.
Shannon Potter, M.L.I.S.
Melissa McPheeters, M.D., M.P.H.

**AHRQ Publication No. 15(16)-EHC019-EF
October 2015**

This report is based on research conducted by the Vanderbilt Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-2012-00009-I). The findings and conclusions in this document are those of the authors, who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.

The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information, i.e., in the context of available resources and circumstances presented by individual patients.

AHRQ or U.S. Department of Health and Human Services endorsement of any derivative products that may be developed from this report, such as clinical practice guidelines, other quality enhancement tools, or reimbursement or coverage policies may not be stated or implied.

This report may periodically be assessed for the currency of conclusions. If an assessment is done, the resulting surveillance report describing the methodology and findings will be found on the Effective Health Care Program Web site at www.effectivehealthcare.ahrq.gov. Search on the title of the report.

This document is in the public domain and may be used and reprinted without special permission. Citation of the source is appreciated.

Persons using assistive technology may not be able to fully access information in this report. For assistance contact EffectiveHealthCare@ahrq.hhs.gov.

| |
|-------------------------------------------------------------------------------------------------------------------------------------|
| None of the investigators have any affiliations or financial involvement that conflicts with the material presented in this report. |
|-------------------------------------------------------------------------------------------------------------------------------------|

Suggested citation: Epstein R, Fonnesebeck C, Williamson E, Kuhn T, Lindegren ML, Rizzone K, Krishnaswami S, Sathe N, Ficzer CH, Ness GL, Wright GW, Raj M, Potter S, McPheeters M. Psychosocial and Pharmacologic Interventions for Disruptive Behavior in Children and Adolescents. Comparative Effectiveness Review No. 154. (Prepared by the Vanderbilt Evidence-based Practice Center under Contract No. 290-2012-00009-I.) AHRQ Publication No. 15(16)-EHC019-EF. Rockville, MD: Agency for Healthcare Research and Quality; October 2015. www.effectivehealthcare.ahrq.gov/reports/final.cfm.

Preface

The Agency for Healthcare Research and Quality (AHRQ), through its Evidence-based Practice Centers (EPCs), sponsors the development of systematic reviews to assist public- and private-sector organizations in their efforts to improve the quality of health care in the United States.

These reviews provide comprehensive, science-based information on common, costly medical conditions, and new health care technologies and strategies.

Systematic reviews are the building blocks underlying evidence-based practice; they focus attention on the strength and limits of evidence from research studies about the effectiveness and safety of a clinical intervention. In the context of developing recommendations for practice, systematic reviews can help clarify whether assertions about the value of the intervention are based on strong evidence from clinical studies. For more information about AHRQ EPC systematic reviews, see www.effectivehealthcare.ahrq.gov/reference/purpose.cfm.

AHRQ expects that these systematic reviews will be helpful to health plans, providers, purchasers, government programs, and the health care system as a whole. Transparency and stakeholder input are essential to the Effective Health Care Program. Please visit the Web site (www.effectivehealthcare.ahrq.gov) to see draft research questions and reports or to join an email list to learn about new program products and opportunities for input.

We welcome comments on this systematic review. They may be sent by mail to the Task Order Officer named below at: Agency for Healthcare Research and Quality, 540 Gaither Road, Rockville, MD 20850, or by email to epc@ahrq.hhs.gov.

Richard G. Kronick, Ph.D.
Director
Agency for Healthcare Research and Quality

Stephanie Chang, M.D., M.P.H.
Director
Evidence-based Practice Program
Center for Evidence and Practice Improvement
Agency for Healthcare Research and Quality

Arlene S. Bierman, M.D., M.S.
Director
Center for Evidence and Practice Improvement
Agency for Healthcare Research and Quality

Joanna Siegel, Sc.D.
Task Order Officer
Center for Evidence and Practice Improvement
Agency for Healthcare Research and Quality

Acknowledgments

The authors gratefully acknowledge the following individuals for their contributions to this project: Sanura Latham, B.S.; William Cooper, M.D., M.P.H.; Rachel Walden, M.L.I.S.; Rebecca Jerome, M.L.I.S., M.P.H.; Sarah Elizabeth Williams, M.D.; and Tanya Surawicz, M.P.H.

Key Informants

In designing the study questions, the EPC consulted several Key Informants who represent the end-users of research. The EPC sought the Key Informant input on the priority areas for research and synthesis. Key Informants are not involved in the analysis of the evidence or the writing of the report. Therefore, in the end, study questions, design, methodological approaches, and/or conclusions do not necessarily represent the views of individual Key Informants.

Key Informants must disclose any financial conflicts of interest greater than \$10,000 and any other relevant business or professional conflicts of interest. Because of their role as end-users, individuals with potential conflicts may be retained. The TOO and the EPC work to balance, manage, or mitigate any conflicts of interest.

The list of Key Informants who participated in developing this report follows:

Mina Dulcan, M.D.
Northwestern University Feinberg School
of Medicine
Chicago, IL

Jeff Feix, Ph.D.
Tennessee Department of Mental Health
and Substance Abuse Services
Nashville, TN

Rex Forehand, Ph.D.
University of Vermont
Burlington, VT

Geetha Gopalan, L.C.S.W., Ph.D.
University of Maryland School
of Social Work
Baltimore, MD

Ross Greene, Ph.D.
Harvard Medical School
Boston, MA

Penelope K. Knapp, M.D.
UC Davis MIND Institute
Sacramento, CA

David Kolko, Ph.D.
University of Pittsburgh School of Medicine
Pittsburgh, PA

Laurel Leslie, M.D., M.P.H.
Tufts Clinical and Translational Science
Institute (CTSI)
Boston, MA

Keith McBurnett, Ph.D.
University of California San Francisco
San Francisco, CA

Ukamaka M. Oruche, Ph.D., R.N.
Indiana University School of Nursing
Indianapolis, IN

Millie Sweeney, M.S.
Tennessee Voices for Children
Nashville, TN

Aaron M. Thompson, M.S.W., Ph.D.
University of Missouri School
of Social Work
Columbia, MO

Technical Expert Panel

In designing the study questions and methodology at the outset of this report, the EPC consulted several technical and content experts. Broad expertise and perspectives were sought. Divergent and conflicted opinions are common and perceived as healthy scientific discourse that results in a thoughtful, relevant systematic review. Therefore, in the end, study questions, design, methodologic approaches, and/or conclusions do not necessarily represent the views of individual technical and content experts.

Technical Experts must disclose any financial conflicts of interest greater than \$10,000 and any other relevant business or professional conflicts of interest. Because of their unique clinical or content expertise, individuals with potential conflicts may be retained. The TOO and the EPC work to balance, manage, or mitigate any potential conflicts of interest identified.

The list of Technical Experts who participated in developing this report follows:

Marc S. Atkins, Ph.D.
University of Illinois at Chicago
Chicago, IL

Susan DosReis, Ph.D.
University of Maryland
Baltimore, MD

Tiffany R. Farchione, M.D.
Food and Drug Administration
Silver Spring, MD

Jeri Fitzpatrick, M.D.
Private Practice
Nashville, TN

Robert J. McMahon, Ph.D.
Simon Fraser University
Burnaby, BC, Canada
Child & Family Research Institute
Vancouver, BC, Canada

Erik von Hahn, M.D.
Tufts University School of Medicine
Boston, MA

Peer Reviewers

Prior to publication of the final evidence report, EPCs sought input from independent Peer Reviewers without financial conflicts of interest. However, the conclusions and synthesis of the scientific literature presented in this report do not necessarily represent the views of individual reviewers.

Peer Reviewers must disclose any financial conflicts of interest greater than \$10,000 and any other relevant business or professional conflicts of interest. Because of their unique clinical or content expertise, individuals with potential nonfinancial conflicts may be retained. The TOO and the EPC work to balance, manage, or mitigate any potential nonfinancial conflicts of interest identified.

The list of Peer Reviewers follows:

Barbara J. Burns, Ph.D.
Professor of Medical Psychology
Duke University School of Medicine
Durham, NC

Karol L. Kumpfer, Ph.D.
Professor
Department of Health Promotion
and Education
College of Health, University of Utah
Salt Lake City, UT

John E. Lochman, Ph.D.
University of Alabama
Tuscaloosa, AL
Roberto Sassi, M.D.
McMaster University
Hamilton, ON, Canada

Bonnie T. Zima, M.D., M.P.H.
Professor-in-Residence
Child & Adolescent Psychiatry
David Geffen School of Medicine
University of California at Los Angeles
Associate Director
Center for Health Services & Society
UCLA-Semel Institute for Neuroscience
and Human Behavior
Los Angeles, CA

Psychosocial and Pharmacologic Interventions for Disruptive Behavior in Children and Adolescents

Structured Abstract

Objectives. We systematically reviewed evidence on psychosocial and/or pharmacologic treatment for children with disruptive behavior disorders.

Data sources. We searched MEDLINE[®] via PubMed[®] and PsycInfo[®], as well as the reference lists of included studies. We used the Comparative Effectiveness Plus interface for the Iowa Drug Information Service (IDIS) database to identify regulatory information.

Review methods. We included studies published in English from January 1994 to June 2014, did dual data extraction, and rated risk of bias and strength of evidence of the literature in accordance with the Agency for Healthcare Research and Quality Methods Guide. We analyzed data qualitatively and quantitatively. Our quantitative analysis was based on a Bayesian estimation approach, and we therefore did not conduct statistical significance tests.

Results. We identified 84 unique studies that addressed one or more Key Questions. Of these, 66 studies assessed psychosocial interventions and 13 assessed pharmacologic interventions. The active treatment arms of studies of psychosocial interventions were categorized as interventions including only a child component ($n = 2$) or only a parent component ($n = 25$), or as multicomponent interventions ($n = 39$). Multicomponent interventions included were defined as including two or more of a child component, parent component, or other component (e.g., teacher, family together). All interventions included in this study that were categorized as multicomponent interventions included a parent component. Studies provided consistent evidence that multicomponent interventions and interventions including only a parent component resulted in significantly greater improvement on parent reports of child disruptive behavior than controls. Our quantitative analysis of the 28 of these studies that met additional criteria for inclusion in our Bayesian multivariate network meta-analysis indicated that all three intervention types were more effective than control conditions. The probability of being the best treatment (i.e., having the largest effect) was the same for multicomponent interventions (43%) and for interventions with only a parent component (43%), followed by interventions with only a child component (14%). Pharmacologic studies evaluated the effectiveness of antipsychotics, antiepileptics, and stimulants and nonstimulants used to treat attention deficit hyperactivity disorder. Studies of antipsychotic medications and valproic acid, an antiepileptic medication, had mixed results over the short term. Two randomized controlled trials (RCTs) of atomoxetine suggested it was more effective at reducing oppositional defiant disorder (ODD) symptoms than placebo. One RCT of guanfacine extended release also reported significant reductions over placebo in ODD symptoms. Two RCTs reported that stimulants were more effective than placebo at reducing ODD and conduct disorder symptoms. We included related publications and an additional four studies to address harms and predictors of treatment effects.

Conclusions. Qualitative and quantitative analyses generally suggest that psychosocial interventions for children with disruptive behavior disorders that include a parent component, either alone or in combination with other components, are likely to be more effective at reducing

disruptive child behaviors than interventions that include only a child component or control conditions. Small studies of antipsychotics and stimulants report positive effects in the very short term. The most commonly reported outcomes are parent-reported outcomes. Long-term and functional outcomes were not consistently reported. There was variability in the duration of long-term followup and functional outcomes reported.

Contents

| | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| Executive Summary | ES-1 |
| Background | 1 |
| Treatment | 1 |
| Systematic Reviews and Guidelines | 2 |
| Scope of the Review | 3 |
| Key Questions | 4 |
| Analytic Framework | 5 |
| Organization of This Report | 6 |
| Methods | 7 |
| Topic Refinement and Review Protocol | 7 |
| Searching for the Evidence | 7 |
| Search Strategy | 7 |
| Screening..... | 8 |
| Inclusion and Exclusion Criteria..... | 8 |
| Data Extraction and Data Management | 11 |
| Data Extraction | 11 |
| Data Management | 12 |
| Assessment of Methodological Risk of Bias of Individual Studies..... | 12 |
| Determining Risk of Bias Ratings | 12 |
| Data Synthesis..... | 13 |
| Qualitative Synthesis of Results | 13 |
| Quantitative Synthesis of Results | 13 |
| Incorporating Existing Systematic Reviews | 14 |
| Grading the Strength of Evidence..... | 15 |
| Strength of Evidence Assessments | 15 |
| Overall Strength of Evidence..... | 15 |
| Assessing Applicability | 16 |
| Findings | 17 |
| Description of Included Studies..... | 17 |
| Key Question 1: In children under 18 years of age treated for disruptive behaviors, are any psychosocial interventions more effective for improving short-term and long-term psychosocial outcomes than no treatment or other psychosocial interventions? | 18 |
| Overview of the Literature for KQ1 | 18 |
| Key Points for KQ1 | 20 |
| Preschool Children..... | 22 |
| School-Age Children | 38 |
| Teenage Children | 57 |
| Bayesian Meta-Analysis of Psychosocial Interventions | 68 |

| | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| Key Question 2: In children under 18 years of age treated for disruptive behaviors, are alpha-agonists, anticonvulsants, beta-blockers, central nervous system stimulants, first-generation antipsychotics, second-generation (atypical) antipsychotics, and selective serotonin reuptake inhibitors more effective for improving short-term and long-term psychosocial outcomes than placebo or other pharmacologic interventions?..... | 73 |
| Overview of the Literature for KQ2 | 73 |
| Key Points for KQ2 | 74 |
| Detailed Analysis | 74 |
| Key Question 3: In children under 18 years of age treated for disruptive behaviors, what is the relative effectiveness of any psychosocial interventions compared with the pharmacologic interventions listed in Key Question 2 for improving short-term and long-term psychosocial outcomes?..... | 87 |
| Key Question 4: In children under 18 years of age treated for disruptive behaviors, are any combined psychosocial and pharmacologic interventions listed in Key Question 2 more effective for improving short-term and long-term psychosocial outcomes than individual interventions?..... | 87 |
| Key Question 5: What are the harms associated with treating children under 18 years of age for disruptive behaviors with either psychosocial or pharmacologic interventions?..... | 87 |
| Overview of the Literature for KQ5 | 87 |
| Second-Generation Antipsychotics..... | 89 |
| Other Second-Generation Antipsychotics..... | 94 |
| Divalproex/Valproate..... | 97 |
| Stimulants | 99 |
| Nonstimulants | 102 |
| Key Question 6: Do interventions intended to address disruptive behaviors and identified in Key Questions 1-4 vary in effectiveness based on patient characteristics (KQ6a), characteristics of the disorder (KQ6b), treatment history of the patient (KQ6c), or characteristics of the treatment (KQ6d)? | 107 |
| Overview of the Literature for KQ6 | 107 |
| Patient Characteristics (KQ6a) | 107 |
| Characteristics of the Disorder (KQ6b) | 108 |
| Treatment History (KQ6c)..... | 109 |
| Characteristics of the Treatment (KQ6d)..... | 110 |
| Discussion | 112 |
| State of the Literature..... | 112 |
| KQ1. Effectiveness of Psychosocial Interventions..... | 112 |
| KQ2. Effectiveness of Pharmacologic Interventions..... | 116 |
| KQ3. Effectiveness of Psychosocial Versus Pharmacologic Interventions..... | 118 |
| KQ4. Effectiveness of Combined Psychosocial and Pharmacologic Interventions | 118 |
| KQ5. Harms of Psychosocial or Pharmacologic Interventions | 118 |
| KQ6. Modifiers of Effectiveness of Interventions..... | 120 |
| Findings in Relationship to What Is Already Known..... | 121 |
| Existing Reviews of Psychosocial Interventions | 121 |
| Existing Reviews of Pharmacological Interventions | 126 |

| | |
|----------------------------------------------------------|------------|
| Applicability | 127 |
| KQ1. Psychosocial Interventions..... | 127 |
| KQ2. Pharmacologic Interventions..... | 128 |
| Strength of Evidence..... | 128 |
| Limitations | 134 |
| Limitations of This Review | 134 |
| Limitations of the Evidence Base | 135 |
| Future Research Needs | 136 |
| Implications for Clinical and Policy Decisionmaking..... | 137 |
| Conclusions..... | 137 |
| References..... | 139 |
| Abbreviations | 154 |

Tables

| | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|
| Table A. Summary of evidence in studies addressing the effectiveness of psychosocial interventions targeting parenting practices on parent-reported changes in disruptive behaviors (KQ1)..... | ES-16 |
| Table B. Summary of evidence in studies addressing the effectiveness of pharmacologic interventions (KQ2) | ES-17 |
| Table 1. PICOTS..... | 3 |
| Table 2. Case definition for disruptive behavior | 9 |
| Table 3. Selected outcomes and comparisons for the strength of evidence assessments | 15 |
| Table 4. Strength of evidence grades and definitions | 16 |
| Table 5. Study characteristics (KQ1)..... | 19 |
| Table 6. Summary of interventions and risk of bias for studies of psychosocial interventions in preschool-age children with DBD | 22 |
| Table 7. Summary of behavior outcomes from studies of a parent-only component (IY-PT) in preschool-age children | 23 |
| Table 8. Summary of behavior outcomes from studies of a parent-only component (Triple P) in preschool-age children | 26 |
| Table 9. Summary of behavior outcomes from studies of a parent-only component (other) in preschool-age children | 29 |
| Table 10. Summary of behavior outcomes from studies of multicomponent intervention (PCIT) in preschool-age children..... | 31 |
| Table 11. Summary of behavior outcomes in studies of other multicomponent interventions in preschool-age children | 34 |
| Table 12. Summary of behavior outcomes reported by ECBI for preschool-age participants..... | 35 |
| Table 13. Summary of behavior outcomes reported by CBCL for preschool-age participants..... | 36 |
| Table 14. Summary of interventions and risk of bias for studies of psychosocial interventions in school-age children with DBD..... | 38 |
| Table 15. Summary of behavior outcomes for studies of parent-only intervention (IY-PT) in school-age children | 40 |
| Table 16. Summary of behavior outcomes for studies of parent-only intervention (PMTO) in school-age children | 41 |

| | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| Table 17. Summary of behavior outcomes for studies of parent-only intervention (other) in school-age children | 42 |
| Table 18. Summary of behavior outcomes for studies of IY interventions in school-age children | 45 |
| Table 19. Summary of behavior outcomes for studies of Coping Power Program for school-age children | 47 |
| Table 20. Summary of behavior outcomes for studies of modular intervention in school-age children | 48 |
| Table 21. Summary of behavior outcomes for studies of the SNAP Under 12 ORP intervention in school-age children..... | 49 |
| Table 22. Summary of behavior outcomes for studies of other interventions in school-age children | 50 |
| Table 23. Outcome summary for change in disruptive behavior symptoms reported by CBCL in studies of school-age children | 52 |
| Table 24. Outcome summary for change in disruptive behavior symptoms reported by ECBI in studies of school-age children | 56 |
| Table 25. Summary of interventions and risk of bias for studies of psychosocial interventions in teenage children with DBD..... | 58 |
| Table 26. Summary of studies of multicomponent interventions (family therapy) for teenage children..... | 59 |
| Table 27. Summary of studies of multicomponent interventions (MST) for teenage children..... | 61 |
| Table 28. Summary of studies of multicomponent interventions (other) for teenage children..... | 65 |
| Table 29. Summary of disruptive behavior outcomes reported by ASEBA in teenage children | 66 |
| Table 30. Posterior probabilities of treatment outcome values being above standard threshold for three instruments (ECBI Intensity, ECBI Problem, CBCL Externalizing T-score) by age group..... | 72 |
| Table 31. Study characteristics (KQ2)..... | 73 |
| Table 32. Difference in disruptive behavior for studies of antipsychotic medications | 76 |
| Table 33. Difference in aggression for studies of antipsychotic medications | 76 |
| Table 34. Difference in disruptive behavior for studies of valproic acid at last followup | 78 |
| Table 35. Difference in disruptive behavior for studies of stimulant medications | 81 |
| Table 36. Difference in disruptive behavior for studies of nonstimulant medications..... | 83 |
| Table 37. Participant discontinuation due to adverse events in published studies | 88 |
| Table 38. Treatment-emergent adverse events occurring in ≥ 5 percent of participants..... | 91 |
| Table 39. Treatment-emergent extrapyramidal symptoms | 91 |
| Table 40. Harms in additional studies of risperidone reporting per participant incidence | 92 |
| Table 41. Harms reported in studies of other second-generation antipsychotics | 95 |
| Table 42. Harms reported in studies of divalproex..... | 97 |
| Table 43. Adverse events reported in ≥ 5 percent of patients receiving extended-release mixed amphetamine salts or placebo | 100 |
| Table 44. Incidence of clinically relevant change from baseline for cardiovascular parameters..... | 100 |
| Table 45. Harms reported in studies of atomoxetine | 103 |

| | |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| Table 46. Adverse events occurring in ≥ 5 percent of patients treated with guanfacine or placebo..... | 105 |
| Table 47. Network meta-analysis of intervention category as a predictor of treatment effect in parent-reported measures of child disruptive behavior among selected studies of psychosocial interventions..... | 115 |
| Table 48. Strength of evidence for effects of psychosocial interventions targeting parenting practices on parent-reported changes in disruptive behaviors in preschool children with DBD | 129 |
| Table 49. Strength of evidence for effects of psychosocial interventions targeting parenting practices on parent-reported ratings of disruptive behaviors in school-age children with DBD | 130 |
| Table 50. Strength of evidence for the effect of psychosocial interventions targeting parenting practices on parent-reported ratings of disruptive behaviors in teenage children with DBD..... | 131 |
| Table 51. Strength of evidence for pharmacologic interventions | 132 |

Figures

| | |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| Figure A. Analytic framework..... | ES-4 |
| Figure B. Literature flow diagram | ES-7 |
| Figure 1. Analytic framework..... | 6 |
| Figure 2. Literature flow diagram..... | 18 |
| Figure 3. Effect size estimates | 69 |
| Figure 4. Summary of estimated overall treatment outcomes (ECBI Intensity Subscale) in studies of preschool, school-age, and adolescent children | 70 |
| Figure 5. Summary of estimated overall treatment outcomes (ECBI Problem Subscale) in studies of preschool, school-age, and adolescent children | 70 |
| Figure 6. Summary of estimated overall treatment outcomes (CBCL Externalizing T-score) in studies of preschool, school-age, and adolescent children | 71 |

Appendixes

| |
|--------------------------------------------------------------------------------|
| Appendix A. Search Strategies |
| Appendix B. Literature Screening Forms |
| Appendix C. Risk of Bias Assessment Forms and Summaries |
| Appendix D. Meta-Analytic Methods |
| Appendix E. Outcome Measures Used in the Meta-Analysis of Intervention Effects |
| Appendix F. Summary of Existing Systematic Reviews |
| Appendix G. Applicability Tables |
| Appendix H. Reasons for Exclusion |
| Appendix I. Pharmacologic Approval Status, Harms, and Indications |
| Appendix J. Key Question 1 Evidence Profile |

Executive Summary

Background

Disruptive behavior disorders (DBDs) are a group of related psychiatric disorders of childhood and adolescence marked by temper tantrums, interpersonal aggression, and defiance. These disorders and related symptoms may manifest in young children as significant behavioral problems at home and difficulties at school. Children with disruptive behaviors in early childhood often experience persistent impairment¹ and are at increased risk for negative developmental outcomes, including substance abuse problems; school problems; and delinquent, violent, and antisocial or criminal behaviors in adolescence.²⁻¹⁴

DBDs are among the most common child and adolescent psychiatric disorders, with recent estimates indicating that 3.5 percent of children ages 3–17 years had behavioral or conduct problems in the period 2005–11.¹⁵ Examples of DBDs include oppositional defiant disorder (ODD), conduct disorder (CD), attention deficit hyperactivity disorder (ADHD) (as categorized in the fourth edition *Diagnostic and Statistical Manual of Mental Disorders*,¹⁶ reclassified as a neurodevelopmental disorder in the fifth edition¹⁷), and DBD not otherwise specified.¹⁸⁻²² Estimates suggest that disruptive behaviors that are problematic but do not meet formal diagnostic criteria may be more common than those meeting formal clinical diagnostic criteria.² The etiology of DBDs is unknown, but temperamental, biological, and environmental factors are associated with increased risk.

Although DBD-specific preventive interventions have been developed, practical considerations, including training requirements and cost, pose challenges to broad implementation.^{23,24} General outpatient psychotherapy and psychotropic medication management, either alone or in combination with one another, are the interventions most commonly used in the treatment of DBDs.^{18,25-28} Psychosocial interventions, including but not limited to psychotherapy, have been developed for some patient subgroups and for some symptoms/symptom clusters. Examples of these interventions include child-level interventions such as cognitive-behavioral therapy (CBT), parent-level interventions such as the Positive Parenting Program (Triple P), and multicomponent interventions such as multisystemic therapy (MST). A wide range of psychotropic medications, including anticonvulsants, antipsychotics, mood stabilizers, and stimulants, have been used to manage children with disruptive behaviors, and their use has increased substantially in recent years. Increasing use has primarily, but not exclusively, been accounted for by increasing use of atypical antipsychotic medications. However, decisional uncertainty exists around the safety and effectiveness of these medications for these childhood disorders.²⁹

Scope and Key Questions

DBD symptoms are often present in the absence of a specific DBD diagnosis. Studies that are intended to assess treatments for conditions such as ADHD, for example, are likely to report changes in disruptive behaviors as outcomes. For this reason, and because a review of ADHD currently exists,³⁰ we focused the current review on studies in which the aim of treatment is specifically a disruptive behavior, with or without a DBD diagnosis, and assessed psychosocial and pharmacologic treatment approaches. We specifically excluded studies of populations of children with ADHD unless the specific focus of treatment was on the non-ADHD disruptive behavior. We also sought studies of concomitant treatment with psychosocial and/or

pharmacologic interventions (i.e., combinations of pharmacologic agents or psychosocial interventions, or medications used in conjunction with psychosocial interventions). We evaluated evidence addressing the following Key Questions (KQs).

Key Questions

KQ1: In children under 18 years of age treated for disruptive behaviors, are any psychosocial interventions more effective for improving short-term and long-term psychosocial outcomes than no treatment or other psychosocial interventions?

KQ2: In children under 18 years of age treated for disruptive behaviors, are alpha-agonists, anticonvulsants, beta-blockers, central nervous system stimulants, first-generation antipsychotics, second-generation (atypical) antipsychotics, and selective serotonin reuptake inhibitors more effective for improving short-term and long-term psychosocial outcomes than placebo or other pharmacologic interventions?

KQ3: In children under 18 years of age treated for disruptive behaviors, what is the relative effectiveness of any psychosocial interventions compared with the pharmacologic interventions listed in KQ2 for improving short-term and long-term psychosocial outcomes?

KQ4: In children under 18 years of age treated for disruptive behaviors, are any combined psychosocial and pharmacologic interventions listed in KQ2 more effective for improving short-term and long-term psychosocial outcomes than individual interventions?

KQ5: What are the harms associated with treating children under 18 years of age for disruptive behaviors with either psychosocial or pharmacologic interventions?

KQ6a: Do interventions intended to address disruptive behaviors and identified in KQs 1–4 vary in effectiveness based on patient characteristics, including sex, age, racial/ethnic minority, family history of disruptive behavior disorders, family history of mental health disorders, history of trauma, and socioeconomic status?

KQ6b: Do interventions intended to address disruptive behaviors and identified in KQs 1–4 vary in effectiveness based on characteristics of the disorder, including specific disruptive behavior or disruptive behavior disorder (e.g., oppositional defiant disorder, conduct disorder, aggression), concomitant psychopathology (e.g., attention deficit hyperactivity disorder or substance abuse), related personality traits and symptom clusters, presence of comorbidities (other than concomitant psychopathology), age of onset, and duration?


KQ6c: Do interventions intended to address disruptive behaviors and identified in KQs 1–4 vary in effectiveness based on treatment history of the patient?

KQ6d: Do interventions intended to address disruptive behaviors and identified in KQs 1–4 vary in effectiveness based on characteristics of the treatment, including duration, delivery, timing, and dose?

Analytic Framework

The analytic framework (Figure A) illustrates how a psychosocial (KQs 1, 3), pharmacologic (KQs 2, 3), or combined (KQ4) intervention for children under 18 years of age treated for disruptive behaviors may result in changes to one or more behavioral outcomes (KQs 1–4), functional outcomes (KQs 1–4), or harms (KQ5). Behavior outcomes include aggressive behavior; violent behavior; delinquent behavior; fighting, property destruction, and rule violations; and compliance with parents, teachers, and institutional rules. Functional outcomes include family functioning/cohesion; school performance; interpersonal/social function and competence; interactions with legal/juvenile justice system; health care system utilization; substance abuse; and health-related quality of life. Patient characteristics (KQ6a), disorder characteristics (KQ6b), treatment history (KQ6c), and treatment characteristics (KQ6d) may change intervention treatment effects.

Figure A. Analytic framework



Methods

Literature Search Strategy

To ensure comprehensive retrieval of relevant studies, we used the following key databases: the MEDLINE[®] medical literature database (via the PubMed[®] interface), EMBASE, the Cochrane Central Register of Controlled Trials, and PsycInfo[®]. We used the Comparative Effectiveness Plus interface for the Iowa Drug Information Service (IDIS) database to identify regulatory information from the following sources: Food and Drug Administration (FDA) approval packages, FDA Advisory Committee Reports, boxed warnings, clinical practice guidelines, Agency for Healthcare Research and Quality (AHRQ) Evidence Reports and Comparative Effectiveness Reviews, and National Institute for Health and Clinical Excellence (NICE) Clinical Guidelines or Technology Appraisal Guidance. We also searched other sources (e.g., Clinicaltrials.gov, meeting abstracts, FDA) for context and relevant data, as well as ongoing trials.

Search strategies (presented in Appendix A of the full report) included broad terms for psychosocial interventions and pharmacologic agents, as well as including interventions by name (e.g., “Parent-Child Interaction Therapy,” “Incredible Years[®],” and “Triple P - Positive Parenting Program[®]” [Triple P]). We used hand searching of recent systematic reviews and other relevant publications to identify additional studies not captured by the database searches. The randomized controlled trials (RCTs) included to assess efficacy were used to assess harms. AHRQ contracts with the Scientific Resource Center (SRC) to obtain information from drug manufacturers. We requested scientific information packets and regulatory information from SRC for individual pharmacologic agents. We received responses from 3 of the 20 requests and confirmed that the studies referenced in the information packets were included in our literature searches.

Inclusion and Exclusion Criteria

Eligible studies had to be published in English in or after 1994, focus on the treatment of disruptive behavior, and include children exhibiting disruptive behaviors as a primary problem (e.g., CD, ODD, and intermittent explosive disorder). We excluded studies published before 1994 because our preliminary search found that in articles published 20 or more years ago, the study populations were inadequately described, rendering a large number of the older studies unusable for this review. We excluded studies of preventive interventions for an at-risk population because our review was focused on studies of individuals who met a clinical threshold for a DBD. We required that eligible studies include a comparison group (i.e., controlled trials, cohort studies). We excluded studies of disruptive behavior secondary to other conditions (e.g., treatment of substance abuse, developmental delay, intellectual disability, and pediatric bipolar disorder). In the case of ADHD, we excluded studies of ADHD-related disruptive behaviors but included studies of non-ADHD-related disruptive behaviors in populations of children with ADHD if the children were identified as also having another DBD. Our quantitative analysis further excluded studies that did not report baseline and end-of-treatment means and standard deviations using one of the three most commonly used outcome measures. Explicit inclusion and exclusion criteria are documented in the abstract screening form and full-text screening form (Appendix B of the full report) and described in more detail in the full report.

Study Selection

Two reviewers independently assessed each abstract. If one reviewer concluded that the article could be eligible based on the abstract, we retained it for review of the full text. Two reviewers independently assessed the full text of each included study, with any disagreements adjudicated by a senior reviewer.

Data Extraction and Synthesis

We extracted data from included studies into evidence tables that report study design, descriptions of the study populations (for applicability), description of the interventions, and baseline and outcome data on constructs of interest. Data were initially extracted by one team member and reviewed for accuracy by a second.

Data are presented in summary tables and analyzed qualitatively in the text. We also employed Bayesian multivariate mixed-treatment (network) meta-analytic methods using data on a subset of included studies ($n = 28$) that met additional criteria for inclusion in the meta-analysis. These additional criteria were that a study was an RCT that employed one or more of the three most prevalent measures of child disruptive behavior in this literature, and reported means and standard deviations at baseline and end of treatment on these measures. To account for the large number of specific interventions employed by the constituent studies, we classified each arm of each included study as an intervention with only a child component, an intervention with only a parent component, or a multicomponent intervention. Multicomponent interventions were defined as those that included two or more of a child component, parent component, or other component (e.g., teacher component, family together component). We considered study treatment arms not identified as one of these three classes as wait-list control or treatment as usual.

Recognizing that these treatment categories are broad and encompass a range of specific interventions, each specific intervention was modeled as a random effect, allowing for variation in treatment effect within each class because of factors not explicitly modeled.

Our primary outcomes for analysis and strength of evidence were parent reports of child disruptive behaviors as assessed using the most common validated measures, such as subscales of the Eyberg Child Behavior Inventory (ECBI) and the Child Behavior Checklist (CBCL).

Risk-of-Bias Assessment of Individual Studies

We used the Cochrane Risk of Bias Tool³¹ to assess risk of bias for RCTs of effectiveness. Reviewers rated six items from five domains of potential sources of bias (i.e., selection, reporting, performance, detection, and attrition) and one item for other sources of bias. To assess risk of bias for study designs other than RCTs, we used the RTI Item Bank³² for nonrandomized controlled studies, and the AMSTAR (A Measurement Tool to Assess Systematic Reviews) tool³³ for systematic reviews and meta-analyses. To assess the risk of bias associated with the reporting of harms, we used an adapted version of the McMaster Assessment of Harms Tool.³⁴ Appendix C of the full report includes questions used in each tool. Two team members independently assessed each included study, with discrepancies resolved through discussion to reach consensus and/or adjudication by a senior reviewer. The results of these assessments were then translated to low, moderate, or high risk-of-bias designations, as described in the full report. Risk-of-bias ratings are in Appendix C of the full report.

Strength of the Body of Evidence

Two senior investigators graded the body of evidence for key intervention/outcome pairs using methods based on the “Methods Guide for Effectiveness and Comparative Effectiveness Reviews.”³⁵ The team reviewed the final strength-of-evidence (SOE) designation. The possible grades were:

- **High:** High confidence that the evidence reflects the true effect. Further research is unlikely to change estimates.
- **Moderate:** Moderate confidence that the evidence reflects the true effect. Further research may change confidence in the estimate of effect and may change the estimate.
- **Low:** Low confidence that the evidence reflects the true effect. Further research is likely to change confidence in the estimate of effect and is likely to change the estimate.
- **Insufficient:** Evidence is either unavailable or does not permit a conclusion.

Applicability


We assessed applicability by identifying potential population, intervention, comparator, outcome, timing, and setting (PICOTS) factors likely to affect the generalizability of results (i.e., applicability to the general population of children and adolescents being treated for disruptive behaviors). We considered factors related to difficulties identifying the target population, the availability of interventions, characteristics of the population such as socioeconomic status and family environment that may be associated with disruptive behaviors, and setting of the intervention as particularly likely to affect applicability.

Results

Article Selection

We identified 7,470 nonduplicative titles or abstracts with potential relevance, with 968 proceeding to full-text review. We excluded 853 studies at full-text review and included 84 unique studies (115 publications) in the review (Figure B). We present findings by intervention and outcome area where possible under each KQ. Sixty-six studies addressed psychosocial interventions (KQ1); 13 addressed pharmacologic interventions (KQ2). In addition to studies of effectiveness, we identified five additional studies that exclusively addressed KQ5 (n = 4) and KQ6 (n = 1). Studies of psychosocial interventions were heterogeneous. We categorized interventions as child focused, parent focused, or multicomponent (i.e., 2 or more of a child, parent, or other type of intervention component). Pharmacologic interventions were antipsychotics, antiepileptics, and two groups of drugs typically used to treat ADHD (stimulants and nonstimulants).

Figure B. Literature flow diagram



^aExcluding discarded duplicates (n = 44).

^bRecords could be excluded for more than one reason.

^c115 publications representing 84 unique studies.

^dA subset of studies (n = 28) met eligibility criteria for inclusion in a quantitative analysis.

KQ1. Effectiveness of Psychosocial Interventions Compared With Other Psychosocial Interventions or No Treatment

Sixty-six studies (59 RCTs and 7 non-RCTs) addressed the effectiveness of psychosocial interventions.

Preschool Children

Twenty-three studies (10 high, 11 moderate, and 2 low risk of bias) evaluated psychosocial interventions for preschool children (under age 5). The active treatment arm in 14 studies consisted of interventions that included only a parent component, and 9 studies were multicomponent. No studies in this age group were of interventions that included only a child component. Most (17 of 23) studies assessed one of three interventions: Incredible Years[®] (IY) (n = 5), Parent-Child Interaction Therapy (PCIT) (n = 7), or Triple P (n = 5). The six other studies each evaluated a distinct intervention.

Three of the five IY studies evaluated only the parent-training component and reported significant improvements on multiple validated measures in the active treatment versus control arms. Among studies reporting outcomes using the ECBI Intensity scale, effect sizes ranged from 0.70 to 0.89. Outcomes did not differ between groups in the other two studies.

All studies assessing Triple P (n = 5) and PCIT (n = 7) reported significantly improved disruptive behaviors as measured by the ECBI Intensity and/or Problem scales in the active treatment versus control arms. Individual Triple P studies reported different measures of clinical significance, with estimates including 23 to 70 percent of children in the treatment arms experiencing clinically significant reliable change on parent reports of child disruptive behavior, 33 to 40 percent of children in the treatment arms remaining above the clinical cutoff on the ECBI Intensity scale, or 25 to 30 percent still meeting diagnostic criteria for DBD.

Individual PCIT studies also reported different measures of clinical significance, with PCIT effects reported as 67 to 100 percent of children in treatment arms experiencing clinically significant change, 56 to 68 percent still meeting ODD diagnostic criteria, or effect sizes for PCIT ranging from 0.83 to more than 3.0.

School-Age Children

Twenty-nine studies (9 high, 19 moderate, and 2 low risk of bias) evaluated psychosocial interventions for school-age children (ages 5–12 years) with disruptive behaviors. The active treatment arm of 1 study was an intervention with only a child component, 11 studies were of interventions with only a parent component, and 18 were studies of multicomponent interventions. Approximately half of the studies (15/29) assessed one of five programs: IY (n = 7), the Parent Management Training Oregon (PMTO[™]) model (n = 2), Coping Power Program (n = 2), Stop Now and Plan[™] Under 12 (SNAP Under 12) Outreach Project (n = 2), and a modular intervention (n = 2). The other studies each assessed a different intervention.

Three of the studies examining the IY intervention examined only the parent-training component in comparison with control. Two of these reported that the treatment arm experienced significantly reduced ECBI Intensity and Problem scales versus control arms (range of reduction on ECBI Intensity scale, 14% to 20% for treatment vs. 4% to 5% for control; range of reduction on ECBI Problem scale, 40% to 47% for treatment vs. 14% to 20% for control). One study reported no difference between groups on the CBCL Externalizing subscale.

The other four IY program studies examined multiple combinations of the child, parent, and teacher training programs with one another and with control arms. Given multiple group

comparisons and multiple outcome measures, results are inconsistent and difficult to summarize succinctly. Two studies reported that the arm with only parent training resulted in greater improvement in child disruptive behavior than control: one study used the ECBI Intensity scale and CBCL Aggression subscale; the other study used the ECBI Intensity scale and CBCL Total Problems scale. Two studies reported that combined parent and child training resulted in significantly reduced disruptive behaviors compared with control, but results were inconsistent across measures, with one study showing significant reductions on the CBCL Aggression subscale but not on the ECBI Intensity scale, and the other study showing significant reductions on both the CBCL Total Problems scale and the ECBI Intensity scale. Finally, one study using teacher-reported aggression as the outcome reported that the combined parent and child training resulted in greater improvement than either the parent training only or control, but that there was no difference between the parent training only and control arms.

The two studies comparing PMTO with treatment as usual both reported significant reductions from baseline to end of treatment, one study reporting 10 percent versus 7 percent change in mean CBCL Externalizing subscale scores and the other reporting 15 percent versus 8 percent mean change in ECBI Intensity scale scores for treatment and control arms, respectively. One of the two studies examining the Coping Power Program reported a 35-percent reduction in Parent Daily Report (PDR) scores at end of treatment over baseline, relative to 17-percent reduction in the comparison arm, but did not report significant differences between groups on other measures of child disruptive behavior; the other study of this intervention did not report significant between-group differences. The two studies evaluating the SNAP ORP both reported significant differences between treatment and control arms on the CBCL Aggression subscale, with percent change from baseline to end of treatment ranging from 10 to 16 percent in the treatment arms relative to 2 to 6 percent in the control arms. Significant changes were also seen on other CBCL subscales. The two studies examining the modular intervention essentially tested its portability and did not include a control arm.

Teenage Children

Fourteen studies (5 high, 5 moderate, and 4 low risk of bias) assessed psychosocial interventions for adolescents (ages 13–17 years) with disruptive behaviors. The active treatment arm of 1 study included only a child component, and 13 studies were of multicomponent interventions. The 13 multicomponent intervention studies included 5 studies of Multisystemic Therapy (MST), 3 studies of Brief Strategic Family Therapy[®] (BSFT), and 1 study of each of 6 different multicomponent interventions.

Four of the five MST studies reported that MST was associated with greater reductions in disruptive behaviors in comparison with control arms, but studies used different outcome measures, making it difficult to report summary effects succinctly. One study defined criminal offenses as its primary outcome measure and reported that the proportion with offenses decreased more significantly over time for teenagers in the MST versus control arm ($p < 0.001$) but did not report significant between-group differences over time on the CBCL Externalizing subscale. One study reported small effect-size differences between MST and treatment as usual on a number of measures, with a 0.12 difference favoring MST in effect sizes for CBCL Externalizing subscale scores (MST effect size, 0.56; tau effect size, 0.44). One study reported significant improvements in MST completers versus individual therapy completers on multiple outcome measures, including child disruptive behaviors as assessed with the Symptom Checklist-90-Revised (SCL-90-R) ($p < 0.05$), family relations as assessed with the 30-item

Family Adaptability and Cohesion Evaluation Scale (FACES-II) ($p < 0.05$), and observational measures of parent-child relations ($p < 0.001$). Finally, one study examined differences between MST and treatment as usual on a number of measures, with effect sizes for parent-reported child disruptive behaviors on the CBCL Externalizing subscale of $d = 0.47$ and $d = 0.28$, respectively ($p < 0.05$).

The three studies of BSFT each reported significant improvements in disruptive behaviors. One study reported reliable improvement of 43 percent in BSFT versus 11 percent in control groups on a CD symptom measure and improvement of 36 percent in BSFT versus 11 percent in control arms on a measure of social aggression. The other two BSFT studies, one examining girls referred for bullying behavior and the other examining boys referred for bullying behavior, both reported significant mean differences in an index score of adolescent risk-taking behavior of -9.3 for BSFT relative to controls ($p < 0.001$) for girls and -6.3 for BSFT relative to controls ($p < 0.001$) for boys.

Meta-Analysis

Results from our Bayesian multivariate mixed treatment (network) meta-analysis on the subset of studies from the qualitative review that met the additional criteria (described previously) for being included in our meta-analysis ($n = 28$) were generally consistent with results from our qualitative synthesis. We defined intervention categories that classified each study arm of each included study as including only a child component, including only a parent component, a multicomponent intervention, or control. Multicomponent interventions were defined as those that included two or more of a child component, parent component, or other component (e.g., teacher component, family together component). All interventions categorized as multicomponent interventions included a parent component. Control arms were defined to include treatment as usual or wait-list control arms. Recognizing that these treatment categories are broad and encompass a range of more specific interventions, we modeled each specific intervention as a random effect. Results from our quantitative analysis indicated that the probability of being best was 43 percent for both multicomponent interventions and for interventions with only a parent component. The probability of being best was 14 percent for interventions with only a child component. The marginal posterior probabilities of remaining above the clinical cutpoint (i.e., exhibiting significant disruptive behavior) at end of treatment on the specific measures included in our meta-analysis (ECBI, CBCL) were nominally higher for the comparison group relative to each intervention group, with multicomponent interventions showing the lowest proportion of children still above the clinical cutpoint post-treatment. Although we considered age-by-treatment interactions, there was not enough balance among the age and treatment combinations to include them in the final model.

KQ2. Effectiveness of Pharmacologic Agents Compared With Other Agents or Placebo

Thirteen studies (12 RCTs and 1 non-RCT) of pharmacologic interventions met criteria for inclusion. No studies were of drugs with an FDA indication for DBD. We considered one RCT to have low risk of bias, seven RCTs to have moderate risk of bias, and four RCTs to have high risk of bias. We considered one nonrandomized study to have high risk of bias. These studies fall into four major categories: antipsychotic or antiepileptic drugs (typically targeted to aggression), and a group of drugs comprising both stimulants and nonstimulants (typically used in children

with comorbid ADHD). Only one study was federally funded; the rest were industry sponsored or partially funded by a pharmaceutical company.

Studies of antipsychotics had mixed results over the short term. Three RCTs (all high risk of bias) addressed risperidone (as initial treatment, to augment stimulants, or as maintenance treatment) compared with placebo. Two studies were small, with 20 and 25 participants, and one was large ($n = 355$). All were short term (1 to 6 months). In one study, aggression scores and Clinical Global Impressions-severity (CGI-S) ratings decreased significantly in the risperidone arm compared with placebo (mean aggression change of -1.9 vs. -0.7 ; $p = 0.0007$ and mean CGI-S change of -2.46 vs. -1.06 ; $p = 0.01$). Another RCT of risperidone as a stimulant adjunct also assessed aggression and reported no significant group differences at followup, and the third RCT, of maintenance with risperidone, reported increases in conduct problems and severity in both groups (increases in Nisonger conduct problem ratings of 5.0 [9.5] in the treatment group and 8.8 [11.2] in placebo), with no significant group differences.

One RCT with high risk of bias ($n = 46$) assessed aripiprazole compared with ziprasidone and reported no significant group differences in aggression, and another RCT comparing quetiapine and placebo ($n = 19$) reported no significant parent-rated changes in aggression but clinician-rated changes on the CGI-S (mean followup score of 3.4 for the treatment group vs. 5.0 for placebo; effect size, 1.6; 95% confidence interval, 0.9 to 3.0; $p = 0.007$).

Results were also mixed in three small RCTs ($n = 121$) of valproic acid, an antiepileptic, with two placebo-controlled studies favoring the intervention (53% to 86% in the treatment arms vs. 8% to 25% in placebo arms considered much improved on the Clinical Global Impressions-improvement (CGI-I) scale or Overt Aggression Scale; $p < 0.01$) and another with no significant difference demonstrated.

Two RCTs (1 moderate and 1 high risk of bias) examined the nonstimulant ADHD medication atomoxetine. Both studies reported that atomoxetine was more effective than placebo in reducing ODD symptoms in children with comorbid ADHD and ODD (oppositional behavior score mean change, -2.7 vs. -0.3 in 1 study; in a second study, 48.3% to 55.7% of atomoxetine participants improved by at least 30% compared with 35.6% of the placebo group). Parent-rated quality of life improved significantly in the atomoxetine group (mean change, 2.6 points) compared with placebo (mean change, -1.6 points) in one RCT.

One RCT of guanfacine extended release with moderate risk of bias reported significant reductions in ODD symptoms compared with placebo (least-square mean change from baseline, -10.9 for guanfacine extended release vs. -6.8 for placebo; $p < 0.001$; effect size, 0.59), again among children with comorbid ADHD and ODD. One RCT with high risk of bias reported that treatment with an extended-release formulation of mixed amphetamine salts significantly improved ODD symptoms compared with placebo (mean change of -0.23 to -0.43 among amphetamine dosage groups vs. -0.30 in placebo group; $p = 0.024$). Another RCT reported that methylphenidate treatment reduced CD symptoms compared with placebo as rated by parents and teachers. Duration of all studies was short, with a range of 4 to 9 weeks, and no studies reported functional outcomes beyond statistically significant shifts on scales, commonly the Overt Aggression Scale and CGI.

KQ3. Effectiveness of Psychosocial Interventions Compared With Pharmacologic Interventions

No head-to-head studies were identified that directly compared psychosocial with pharmacologic interventions for DBD.

KQ4. Effectiveness of Combined Psychosocial and Pharmacologic Interventions Compared With Individual Interventions

No head-to-head studies were identified that assessed the comparative effectiveness of combination interventions.

KQ5. Harms of Psychosocial or Pharmacologic Interventions

Harms of psychosocial interventions are not reported in the literature. The pharmacologic treatment studies in this report were generally small and short term, with typically no followup post-treatment. Studies were powered for effectiveness and not for detection of harms, so harms may be underrepresented in the published literature. Generally, harms reported in included studies were mild or moderate and immediate in nature. Nonetheless, there was significant loss to followup in several pharmacologic studies, some of which was likely due to adverse events. We therefore sought harms data from other sources that might include more extensive and longer term data, including other systematic reviews and FDA package labeling. It is important to note that harms of atypical antipsychotics have been studied extensively, including in recent AHRQ reviews, and the high relative risk of metabolic outcomes is a known adverse effect, particularly for atypical antipsychotics.

In effectiveness studies included in this report, frequently occurring adverse events associated with risperidone included weight gain, sedation, and somnolence. In the largest risperidone study (n = 527), the percent of participants experiencing weight gain ranged from 1.2 to 6.5 across risperidone phases and was 0.6 percent in the placebo arm. Somnolence occurred in 1.7 to 11.6 percent of children receiving risperidone and in 1.2 percent of children receiving placebo. At least 35 percent of children in the acute, continuation, and maintenance risperidone dosing phases and those receiving placebo experienced an adverse event, and extrapyramidal symptoms occurred in less than 2 percent of participants in each phase. Sedation was the most frequently reported harm in a study comparing aripiprazole (sedation occurring in 50% of children) and ziprasidone (sedation occurring in 57% of children), while harms were generally reported more often in the placebo group in an RCT comparing quetiapine and placebo. Decreased mental alertness, diminished emotional expression, and diminished facial expression occurred significantly more frequently in the placebo group than with quetiapine (p values ≤ 0.03).

Adverse events associated with mixed amphetamine salts included sleep delay, insomnia, and anorexia, with mean weight loss ranging from 1.1 to 3.3 pounds across dosage groups. One study of methylphenidate also reported delayed sleep but did not present harms data. Atomoxetine was most frequently associated with fatigue (21.3% to 35% of children in slow- and fast-titration groups and 10.2% of placebo group), nausea (19.7% to 21.7% of treatment groups and 5.1% of placebo), and headache (14.8% to 25% of treatment groups and 15.3% of placebo) in one RCT and with anorexia (33.6% of treatment group) and somnolence (29.9% of treatment group) in another. Guanfacine was associated with somnolence (50.7% of treatment group and 5.1% of placebo) and headache (22.1% of treatment group and 17.9% of placebo).

Also provided in the main report is a summary of FDA labeling data, as well as prior reviews of harms associated with the included drugs. Rates of harms from those sources were typically higher than rates of harms reported in the short-term effectiveness studies and may provide a more complete picture of potential harms. They do not, however, place the harms data in the context of tradeoffs with effectiveness.

KQ6. Factors That Modify Effectiveness of Interventions

We identified 24 studies (37 publications) that addressed KQ6. This question was divided into subquestions about variations in intervention effectiveness due to (a) patient characteristics, (b) characteristics of the disorder, (c) patient treatment history, and (d) treatment characteristics. It is unclear if studies identified as examining these questions were adequately powered to answer them.

We identified 12 studies examining variations in psychosocial intervention effectiveness due to patient characteristics. In general, results were inconsistent, although some evidence exists that the child's sex, maternal characteristics such as depression and anger, and other family functioning variables are associated with the effectiveness of some psychosocial interventions.

Results were inconsistent regarding the effects of baseline severity. One study of preschool children reported that greater severity of behavior problems was associated with greater improvements, but no effect of baseline severity was reported in another study. In a study of school-age children, concomitant developmental delay was associated with less effectiveness of the intervention. In two studies including adolescents, lower levels of psychopathology were associated with better disruptive behavior outcomes. No studies examined whether the effectiveness of psychosocial interventions varied by patient treatment history. Dose of intervention was examined as a treatment characteristic that might mediate intervention effectiveness, but results appear to be inconsistent, with two studies reporting more improvements when parents attended a higher number of training sessions or completed more homework than when they did not and one study reporting no differences in outcomes among children who attended more CBT sessions than those who attended fewer sessions. For psychosocial interventions that include a parent component, either alone or in combination with other components, there is some evidence suggesting that improved parenting practices partially mediate effectiveness. Improvements in child outcomes were associated with positive parenting changes in three studies of preschool children and in three of four studies of school-aged children.

Few studies of pharmacologic interventions reported moderator or mediator analyses. One RCT assessing mixed amphetamine salts reported that changes in aggression ratings were higher for those children with greater baseline ODD severity. One study indicated that atomoxetine was more effective in patients who had previously been treated with a stimulant than in patients who had not.

Discussion

Key Findings

Sixty-six studies examined the effectiveness of psychosocial interventions for children with disruptive behaviors. About half of the studies ($n = 25$) were conducted in the United States; the remaining studies were conducted in Australia ($n = 11$), Canada ($n = 4$), Germany ($n = 3$), Ireland ($n = 2$), Israel ($n = 2$), Italy ($n = 1$), Netherlands ($n = 5$), Norway ($n = 4$), Puerto Rico ($n = 1$), Sweden ($n = 3$), and the United Kingdom ($n = 5$). Twenty-three studies examined psychosocial interventions with preschool-age children, 29 studies examined psychosocial interventions with school-age children, and 14 studies examined psychosocial interventions with adolescents. Interventions in each study's active treatment arm were categorized as including only a child component ($n = 2$), only a parent component ($n = 25$), or multiple components ($n =$

39). Multicomponent interventions were defined as those that included two or more of a child component, parent component, or other component (e.g., teacher component, family together component). All interventions categorized as multicomponent included a parent component. Most of the studies examining psychosocial interventions that met criteria for this review used parent reports of child disruptive behaviors as the primary outcome, most commonly the ECBI or CBCL. Seventeen of the 23 studies examining psychosocial interventions for preschool-age children assessed one of three programs (IY, PCIT, and Triple P). In general, studies provided consistent evidence that each of these interventions resulted in significantly greater improvement on parent reports of child disruptive behavior than controls. Most of the studies examining psychosocial interventions for school-age children examined one of the following programs: IY, PMTO, Coping Power Program, SNAP Under 12, or a modular intervention. In general, included studies provided consistent evidence that IY, PMTO, and SNAP Under 12 resulted in significantly greater improvement on parent reports of child disruptive behaviors than controls. Eight of the 14 studies examining psychosocial interventions for adolescents assessed either MST or BSFT. In general, these studies provided consistent evidence that each of these interventions resulted in significantly greater improvement on parent reports of child disruptive behavior than controls.

Results from our Bayesian multivariate mixed-treatment (network) meta-analysis were generally consistent with our qualitative synthesis. Results indicated that the probability of having the largest effect was the same for multicomponent interventions (43%) and interventions with only a parent component (43%). The probability of having the largest effect was 14 percent for interventions with only a child component. The marginal posterior probabilities of remaining above the clinical cutpoint (i.e., exhibiting significant disruptive behavior) at end of treatment on the specific measures included in our meta-analysis (ECBI, CBCL) were nominally higher for the comparison group relative to each intervention group, with multicomponent interventions showing the lowest proportion of children still above the clinical cutpoint post-treatment. Although we considered age-by-treatment interactions, there was not enough balance among the age and treatment combinations to include them in the final model.

Despite a fairly robust literature on psychopharmacologic drugs as a whole, we identified only 13 studies evaluating short-term outcomes of pharmacologic interventions for inclusion in our review. Medical studies fall into four major categories; antipsychotic or antiepileptic drugs (typically targeted to aggression in children)³⁶ and a group of drugs comprising both stimulants and nonstimulants typically used in children with comorbid ADHD. Of the 12 RCTs, one was assessed as low risk of bias and only one was federally funded. The duration of studies was short, with a range of 4 to 9 weeks. Studies of antipsychotic medications and valproic acid, an antiepileptic medication, had mixed results over the short term. Two RCTs of atomoxetine suggested that it was more effective at reducing ODD symptoms than placebo. One RCT of guanfacine extended release also reported significant reductions over placebo in ODD symptoms. Two RCTs reported that stimulants were more effective than placebo at reducing ODD and CD symptoms.

No head-to-head studies were identified that compared the effectiveness of combined psychosocial and medical interventions or that compared the effectiveness of psychosocial interventions with medical interventions.

No harms of psychosocial interventions were sought or reported. The pharmacologic treatment studies in this report were generally small and short term, with typically no followup post-treatment. Thus, harms reported in those studies were generally mild or moderate and fairly

immediate in nature. Nonetheless, there was significant loss to followup in several studies, some of which was likely due to experiencing adverse events, and we therefore sought harms data from other sources that might include more extensive and longer term data, including other systematic reviews. It is important to note that harms of atypical antipsychotics have been studied extensively, including in recent AHRQ reviews. Adverse events associated with risperidone were generally mild across studies, with weight gain, sedation, and somnolence frequently reported. Sedation was frequently reported with aripiprazole and ziprasidone. Adverse events associated with mixed amphetamine salts included sleep delay, insomnia, and anorexia. Atomoxetine was associated with anorexia and headache. Guanfacine was associated with somnolence and headache.

Although we identified studies that examined whether variations in intervention effectiveness due to (a) patient characteristics, (b) characteristics of the disorder, (c) patient treatment history, and (d) treatment characteristics could be found, it is not clear that the studies were adequately powered to answer these questions. Studies are relatively homogeneous with respect to child age, perhaps implicitly recognizing the potential for child age to modify the effectiveness of both psychosocial and pharmacologic interventions. Twelve studies were identified that examined variations in psychosocial intervention effectiveness due to patient characteristics. In general, results were inconsistent, although some evidence exists that the sex of the child, maternal characteristics such as depression and anger, and other family functioning variables are associated with the effectiveness of some psychosocial interventions.

The most commonly examined characteristic of DBD that might affect intervention effectiveness is baseline severity of child disruptive behaviors and/or the presence of comorbid psychiatric conditions. Results were inconsistent. Some studies suggested that difficult temperament in preschool children and psychopathy in teenagers modified the effectiveness of psychosocial interventions.

No studies examined whether the effectiveness of psychosocial interventions varied by patient treatment history, and one study reported that atomoxetine was more effective in patients who had previously been treated with a stimulant than it was in patients who had not.

Potential mediators of treatment effect were most thoroughly examined in the literature on psychosocial interventions. The variables most commonly examined include baseline severity of symptoms, intervention dose, and positive parenting. In general, there is some support that each of these variables may mediate intervention effectiveness, but results were inconsistent.

Existing Systematic Reviews

We located reviews published from 2005 to 2014 and evaluated each for relevance to our KQs using the review PICOTS (Appendix B of the full report). We identified 22 reviews assessing the effectiveness of psychosocial interventions and 2 reviews assessing the effectiveness of pharmacologic interventions. These reviews are described in the Discussion chapter of the full report.

Strength of Evidence

The evidence to answer KQs about interventions for children with disruptive behavior disorders was insufficient to moderate. Tables A and B (and Tables 49-51 in the full report) summarize the strength of the evidence and provide the assessment of the risk of bias, consistency of findings across trials, directness of the evidence, and precision of the estimate provided by the literature. To assess publication bias in the pharmacologic literature, we sought

study protocols and data from regulatory sources and compared this information with the results in the published literature. We assessed strength of evidence for the effectiveness of interventions using the qualitative and quantitative approaches described in the Methods section.

Table A. Summary of evidence in studies addressing the effectiveness of psychosocial interventions targeting parenting practices on parent-reported changes in disruptive behaviors (KQ1)

| Age Category | Intervention Category | Key Outcome(s) | SOE Grade | Findings |
|------------------------|------------------------------------------|-----------------------------------|----------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Preschool (n = 23) | Child-only interventions (n = 0) | NA | Insufficient | No studies were identified. |
| | Parent-only interventions (n = 14) | Parent-rated disruptive behaviors | Moderate SOE for positive effects of intervention on child behavior | 13 RCTs (5 high, 7 moderate, 1 low risk of bias) and 1 non-RCT with moderate risk of bias were identified. Parent reports of child disruptive behavior outcomes were consistently improved in parenting intervention arms compared with wait-list or treatment-as-usual controls. Differences between modified versions of the same intervention were typically not significant. |
| | Multicomponent interventions (n = 9) | Parent-rated disruptive behaviors | Moderate SOE for positive effects of intervention on child behavior | 9 RCTs (5 high, 3 moderate, 1 low risk of bias) were identified. Parent reports of child disruptive behavior outcomes consistently improved in multicomponent intervention arms compared with wait-list or treatment-as-usual controls. Differences between modified versions of the same intervention were typically not significant. |
| School age (n = 29) | Child-only interventions (n = 1) | Parent-rated disruptive behaviors | Insufficient | 1 RCT with moderate risk of bias reported improvement on parent reports of child disruptive behavior from baseline in both intervention and control groups but no between-group differences. |
| | Parent-only interventions (n = 11) | Parent-rated disruptive behaviors | Moderate SOE for positive effects of intervention on child behavior change | 8 RCTs (2 high, 5 moderate, and 1 low risk of bias) and 3 non-RCTs with high risk of bias were identified. Parent reports of child disruptive behavior consistently improved in intervention groups vs. control, but differences between modified versions of the same intervention were not significant. |
| | Multicomponent interventions (n = 17) | Parent-rated disruptive behaviors | Low SOE for positive effects of intervention on child behavior change | 15 RCTs (3 high, 11 moderate, 1 low risk of bias) and 2 non-RCTs (1 high, 1 moderate risk of bias) were identified. Parent reports of child disruptive behaviors improved from baseline in most active treatment arms but between-group changes were not consistently significantly different. The same effects as measured by multiple scales within an individual study were not always consistent. |

Table A. Summary of evidence in studies addressing the effectiveness of psychosocial interventions targeting parenting practices on parent-reported changes in disruptive behaviors (KQ1) (continued)

| Age Category | Intervention Category | Key Outcome(s) | SOE Grade | Findings |
|---------------------|------------------------------------------|-----------------------------------|----------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Teenage (n = 14) | Child-only interventions (n = 1) | Parent-rated disruptive behaviors | Insufficient | 1 study with high study limitations was identified. |
| | Parent-only interventions (n = 0) | NA | Insufficient | No studies were identified. |
| | Multicomponent interventions (n = 13) | Parent-rated disruptive behaviors | Moderate SOE for positive effects of intervention on child behavior change | 12 RCTs (3 high, 5 moderate, 4 low risk of bias) and 1 RCT with high risk of bias were identified. Parent reports of child disruptive behaviors indicated improved outcomes in treatment arms vs. control arms in most studies. Differences between modified versions of the same intervention were typically not significant. |

KQ = Key Question; NA = not applicable; RCT = randomized controlled trial; SOE = strength of evidence

Table B. Summary of evidence in studies addressing the effectiveness of pharmacologic interventions (KQ2)

| Intervention | Key Outcome(s) | SOE Grade | Findings |
|----------------------------------------------|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Antipsychotics | Disruptive behaviors | Moderate SOE for the effectiveness of antipsychotics in achieving statistically significant improvements in measures of disruptive behaviors over the short term | 3 of 3 RCTs reported significantly greater improvements in treatment group compared with control. Studies were funded by industry and should be replicated by groups without appearance of conflict. |
| | Aggression | Insufficient | There were inconsistent and imprecise outcomes and small numbers of participants (n = 64) in 3 short-term RCTs and 1 cohort study with medium study limitations. Aggression improved significantly in the treatment group vs. control in 1 RCT, there were no group differences in 1 RCT and 1 cohort study, and there was worsening of outcomes in both groups in 1 RCT with no group differences. SOE grade is insufficient due to conflicting results. |
| Stimulants (methylphenidate, amphetamine) | Disruptive behaviors | Low SOE for positive effects on disruptive behaviors | In 2 studies with high risk of bias that used different outcome measures, the treatment groups improved significantly more than placebo (p values ≤ 0.05). |
| Nonstimulants (atomoxetine, guanfacine) | Disruptive behaviors | Moderate SOE for positive effect on disruptive behaviors | 3 RCTs had medium study limitations, adequate sample size (n = 537), and statistically significant change scores of 0.59 to 0.69. |

Table B. Summary of evidence in studies addressing the effectiveness of pharmacologic interventions (KQ2) (continued)

| Intervention | Key Outcome(s) | SOE Grade | Findings |
|-----------------------------------|----------------|-------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Divalproex | Aggression | Low SOE for improvement or remission of aggressive behavior | Improvement in aggression was more than 3 times as likely in treated vs. untreated participants in 3 small RCTs with medium study limitations. |
| High-dose vs. low-dose divalproex | Aggression | Insufficient | In 1 study with medium study limitations, more participants in the high-dose arm than low-dose arm were considered much improved (53% vs. 8%; $p < 0.0008$). |

KQ = Key Question; NA = not applicable; RCT = randomized controlled trial; SOE = strength of evidence

Applicability

The populations studied in both the psychosocial and pharmacologic literature were predominantly male. Approximately half of the studies of psychosocial interventions were of school-age children. We defined a study as focusing on school-age children if it had a sample with a mean age of 5 to 12 years. We established 5 years of age as the lower bound because this is the age at which children typically begin attending kindergarten in the United States. We established 12 years of age as the upper bound because 13 years is regarded as the beginning of adolescence in casual parlance. For precisely these reasons, the age group classification both has face validity in the United States and is somewhat arbitrary.

In addition to the age group definition, our definition of the target population included only children with disruptive behaviors who received treatment in health care settings. We did not restrict our study population to children meeting formal diagnostic criteria for DBD. Rather, we included children without a diagnosed DBD but with disruptive behaviors above a measure-specific threshold on well-validated measures of child disruptive behavior. This may limit applicability to real-world clinical settings.

Applicability of our findings is also limited by restricted access in real-world clinical settings to some of the interventions most commonly examined in the studies included in this review. A vast majority of studies were in the outpatient setting, and they were generally carried out at academic medical centers in the United States. Children served in these settings may differ in important ways from children in other clinical settings.

Many of the pharmacologic studies were very small, and results may not be broadly generalizable. None of the interventions has a specific indication for disruptive behaviors, although they are widely used for these conditions in the United States. Interventions included antipsychotic drugs, an antiepileptic drug, and ADHD drugs (both stimulants and nonstimulants). Of particular importance, all but three of the studies on pharmacologic interventions either were sponsored directly by pharmaceutical companies or were conducted by individuals who are highly supported by those companies. Similarly, many of the psychosocial interventions were evaluated by the developer.

The studies also did not address the effectiveness of psychosocial interventions delivered concurrently with pharmacologic interventions or the common concern of polypharmacy, and thus there may be limited ability to assess applicability in highly complex cases. In reality, many if not most children and adolescents receiving treatment for disruptive behaviors may have multiple codiagnoses and other complex challenges.

Research Gaps

Research needs are both substantive and methodological, and they include both conduct and reporting of research. Randomization and allocation procedures were not adequately described, and blinding was not attempted or addressed in much of the psychosocial literature (KQ1). Future research should also clearly describe the duration of time from baseline to post-treatment and post-treatment to followup, and more clearly describe results from mixed models. Because the psychosocial intervention developer is often the researcher, existing research must be replicated, as the lack of replication introduces the potential for a risk of bias analogous to that introduced by industry-sponsored trials of pharmaceutical interventions.

With no categories of drugs meeting the criteria for high SOE, more research needs to be conducted across the range of potential pharmacologic interventions (KQ2). Importantly, this research should be funded by independent parties, rather than primarily the pharmaceutical industry. Substantially more information is warranted on modifiers of effectiveness by subgroup and on harms of intervention. Longer term studies are essential, as children may remain on medications over substantial periods.

There is a need for specific head-to-head comparisons of psychosocial interventions, evaluation of the effectiveness of psychosocial interventions compared with pharmacologic interventions (KQ3), and evaluation of the effectiveness of combined psychosocial and pharmacologic interventions (KQ4). Parents need this information to make informed decisions about which treatments to seek for their children. Clinicians need answers to these questions to decide which interventions to be trained to deliver and to recommend to their patients. Policymakers need this information to determine how to incentivize providers to provide the care for which there is the most evidence of effectiveness.

Future research should also clearly identify the target population and address the portability of studied interventions from predominantly university research clinics to real-world clinical settings. In the United States, disruptive behaviors are more prevalent among children receiving publicly funded care, who are therefore likely to receive treatment in clinical settings such as community mental health centers. This group of young people may differ in important ways from the children receiving treatment in university-based research clinics. These concerns are consistent with the growing body of literature about the challenges of implementing and disseminating best practices to real-world clinical settings with fidelity.

Limitations of the Evidence Base

There are a number of limitations of the evidence base for this review—some specific to the literature on psychosocial interventions, some specific to the literature on pharmacologic interventions, and some crosscutting.

One important limitation of the psychosocial intervention literature (KQ1) is that, although most included studies were RCTs, overall the literature suffered from a lack of clear identification of primary outcomes and of random-sequence generation and allocation-concealment procedures. In addition, there was frequently no attempt to achieve blinding. Although there are well-recognized and valid reasons that achieving this level of control in studies of these types of interventions is challenging, it brings potential risk of bias into the literature. The lack of clearly identified primary outcomes likely reflects a lack of consensus on the most important outcomes; there are few studies that measure similar outcomes for synthesis. Methodologically, outcomes such as direct observation by a blinded and independent observer

are arguably the most valid. However, direct observations can be expensive and are not always logistically feasible. From the perspective of patient-centered outcomes research, we believe that there is a strong argument to be made in favor of the importance of parent-reported outcomes, even though in the absence of blinding they introduce a risk of bias, because most psychosocial interventions included a parent component. Further, results from mixed models are not always presented in a straightforward manner, making it very difficult to tease out effects of specific treatment approaches.

The issue of publication bias in psychological science is difficult to address, given the current lack of standards regarding the registration of study protocols in social sciences. We attempted to minimize the potential for bias introduced by the “file drawer effect” (i.e., nonpublication of studies with nonsignificant results) by expanding the literature search to include unpublished sources (e.g., meeting abstracts) and asking Key Informants about current research or developments in the field that may not yet be published.

Few studies focused on treating disruptive behaviors with pharmacologic interventions. The drugs used for this purpose are frequently used off label and without a research basis for their use in this particular set of disorders. Many of the studies include mixed populations and report outcomes of overlapping symptoms (e.g., of ADHD and DBD), making it difficult to discern the degree to which the mitigation of ADHD, for example, is in fact driving the results. Most of the studies in this section were small; larger studies are clearly needed. Because of the small number of studies on medication use for DBDs in children, we did not use a formal statistical approach to assess the possibility of publication bias, as it would be unlikely to be informative. We did, however, seek study protocols and records from the FDA and Clinicaltrials.gov to assess reporting as a component of the SOE assessment. We did not find evidence that reporting bias was likely.

Limitations applying equally to the literature on both psychosocial and pharmacologic interventions are difficulties inherent in identifying the target population and the potential for bias introduced by conflicts of interest. We included in our review both studies of children with a formal diagnosis of DBD and children without a formal diagnosis of DBD who scored above a clinical cutoff on a well-validated measure of child disruptive behaviors. A lack of detail in reporting by authors makes it challenging to characterize the populations in the studies.

Conflict of interest is a concern in this evidence base. Most of the studies evaluating a psychosocial intervention for a child disruptive behavior included in this review were conducted either by the developer of the intervention or by an “intellectual descendant” of the developer. Although it is understandable for this to be the case (as it is common to see industry-sponsored clinical drug trials), the strength of the evidence for this body of literature would be strengthened with more studies independently evaluating the interventions.

Finally, there are few direct comparisons of individual interventions and no studies evaluating the efficacy of both behavioral and pharmacologic interventions compared with pharmacologic or behavioral interventions alone (KQ3 or KQ4). Specific interventions were most often compared with a wait-list control group or treatment as usual (variably described).

Conclusions

This review generally suggests that psychosocial interventions for children with DBD that are either multicomponent interventions or interventions that include only a parent component appear likely to be more effective at reducing disruptive child behaviors than interventions that include only a child component or control conditions. Given that all of the multicomponent

interventions included in this study contained a parent component in combination with at least one other component (child component, family component, teacher component, other component), it seems reasonable to conclude that a parent component is important. Very few studies directly support the effectiveness of pharmacologic interventions for children with DBD, but small studies of antipsychotics and stimulants report positive effects in the very short term. No studies examined the effectiveness of these interventions in combination with one another. The most commonly reported outcomes are parent-reported outcomes. Long-term and functional outcomes were less consistently reported. There was variability in the duration of long-term followup and functional outcomes reported.

References

1. Lahey BB, Loeber R, Burke J, et al. Adolescent outcomes of childhood conduct disorder among clinic-referred boys: predictors of improvement. *J Abnorm Child Psychol.* 2002 Aug;30(4):333-48. PMID: 12108765.
2. The Chance of a Lifetime: Preventing Early Conduct Problems and Reducing Crime. London: Sainsbury Centre for Mental Health; 2009. <http://www.ohrn.nhs.uk/resource/policy/SCMHThechanceofalifetime.pdf>. Accessed April 2, 2015.
3. Loeber R. Oppositional defiant disorder and conduct disorder. *Hosp Community Psychiatry.* 1991 Nov;42(11):1099-100, 102. PMID: 1743634.
4. Frick PJ, Kamphaus RW, Lahey BB, et al. Academic underachievement and the disruptive behavior disorders. *J Consult Clin Psychol.* 1991 Apr;59(2):289-94. PMID: 2030190.
5. Loeber R. Antisocial behavior: more enduring than changeable? *J Am Acad Child Adolesc Psychiatry.* 1991 May;30(3):393-7. PMID: 2055875.
6. Loeber R, Green SM, Lahey BB, et al. Differences and similarities between children, mothers, and teachers as informants on disruptive child behavior. *J Abnorm Child Psychol.* 1991 Feb;19(1):75-95. PMID: 2030249.
7. Loeber R, Lahey BB, Thomas C. Diagnostic conundrum of oppositional defiant disorder and conduct disorder. *J Abnorm Psychol.* 1991 Aug;100(3):379-90. PMID: 1918617.
8. Meier MH, Slutske WS, Heath AC, et al. Sex differences in the genetic and environmental influences on childhood conduct disorder and adult antisocial behavior. *J Abnorm Psychol.* 2011 May;120(2):377-88. PMID: 21319923.
9. Murrihy RC, Kidman AD, Ollendick TH. *Clinical Handbook of Assessing and Treating Conduct Problems in Youth.* New York: Springer Science Business Media; 2010.
10. Kutcher S, Aman M, Brooks SJ, et al. International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): clinical implications and treatment practice suggestions. *Eur Neuropsychopharmacol.* 2004 Jan;14(1):11-28. PMID: 14659983.
11. Lahey BB, Miller TL, Gordon RA, et al. Developmental epidemiology of the disruptive behavior disorders. In: Quay HC, Hogan AE, eds. *Handbook of Disruptive Behavior Disorder.* Dordrecht, Netherlands: Kluwer Academic Publishers; 1999.
12. Maughan B, Rowe R, Messer J, et al. Conduct disorder and oppositional defiant disorder in a national sample: developmental epidemiology. *J Child Psychol Psychiatry.* 2004 Mar;45(3):609-21. PMID: 15055379.
13. Loeber R, Burke JD, Lahey BB, et al. Oppositional defiant and conduct disorder: a review of the past 10 years, part I. *J Am Acad Child Adolesc Psychiatry.* 2000 Dec;39(12):1468-84. PMID: 11128323.
14. Burke JD, Loeber R, Birmaher B. Oppositional defiant disorder and conduct disorder: a review of the past 10 years, part II. *J Am Acad Child Adolesc Psychiatry.* 2002 Nov;41(11):1275-93. PMID: 12410070.
15. Perou R, Bitsko RH, Blumberg SJ, et al. Mental health surveillance among children--United States, 2005-2011. *MMWR Surveill Summ.* 2013 May 17;62 Suppl 2:1-35. PMID: 23677130.
16. American Psychiatric Association. Task Force on DSM-IV. *Diagnostic and Statistical Manual of Mental Disorders : DSM-IV.* 4th ed. Washington, DC: American Psychiatric Association; 1994.
17. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders: DSM-5.* 5th ed. Arlington, VA: American Psychiatric Association; 2013.
18. Bonin EM, Stevens M, Beecham J, et al. Costs and longer-term savings of parenting programmes for the prevention of persistent conduct disorder: a modelling study. *BMC Public Health.* 2011;11:803. PMID: 21999434.

19. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry*. 2005 Jun;62(6):593-602. PMID: 15939837.
20. Russo MF, Loeber R, Lahey BB, et al. Oppositional defiant and conduct disorders - validation of the DSMIII-R and an alternative diagnostic option. *J Clin Child Psychol*. 1994 Mar;23(1):56-68.
21. Russo MF, Beidel DC. Comorbidity of childhood anxiety and externalizing disorders - prevalence, associated characteristics, and validation issues. *Clin Psychol Rev*. 1994;14(3):199-221.
22. U.S. Public Health Service, Office of the Surgeon General. *Mental Health: A Report of the Surgeon General*. Rockville, MD: National Institute of Mental Health; 1999.
23. August GJ, Bloomquist ML, Lee SS, et al. Can evidence-based prevention programs be sustained in community practice settings? The Early Risers' Advanced-Stage Effectiveness Trial. *Prev Sci*. 2006 Jun;7(2):151-65. PMID: 16555143.
24. Bloomquist ML, August GJ, Horowitz JL, et al. Moving from science to service: transposing and sustaining the Early Risers prevention program in a community service system. *J Prim Prev*. 2008 Jul;29(4):307-21. PMID: 18581235.
25. Knapp M, McDauid D, Parsonage M, eds. *Mental Health Promotion and Mental Illness Prevention: The Economic Case*. London: Department of Health; 2011.
26. Cooper WO, Arbogast PG, Ding H, et al. Trends in prescribing of antipsychotic medications for US children. *Ambul Pediatr*. 2006;6:79-83. PMID: 16530143.
27. Cooper WO, Federspiel CF, Griffin MR, et al. New use of anticonvulsant medications among children enrolled in the Tennessee Medicaid Program. *Arch Pediatr Adolesc Med*. 1997;151(12):1242-6. PMID: 9412601.
28. Cooper WO, Hickson GB, Fuchs C, et al. New users of antipsychotic medications among children enrolled in TennCare. *Arch Pediatr Adolesc Med*. 2004;158:753-9. PMID: 15289247.
29. Newcorn JH, Ivanov I. Psychopharmacologic treatment of attention-deficit/hyperactivity disorder and disruptive behavior disorders. *Pediatr Ann*. 2007 Sep;36(9):564-74. PMID: 17910204.
30. Charach A, Dashti B, Carson P, et al. Attention Deficit Hyperactivity Disorder: Effectiveness of Treatment in At-Risk Preschoolers; Long-Term Effectiveness in All Ages; and Variability in Prevalence, Diagnosis, and Treatment. Comparative Effectiveness Review No. 44. AHRQ Report No. 12-EHC003-EF. Rockville, MD: Agency for Healthcare Research and Quality; October 2011. www.ncbi.nlm.nih.gov/books/NBK82368/. Accessed April 2, 2015.
31. Higgins JP, Altman DG, Sterne JA. Chapter 8: Assessing the risk of bias in included studies. In: Higgins JP, Green S, eds. *Cochrane Handbook for Systematic Reviews of Interventions*. The Cochrane Collaboration; 2011.
32. Viswanathan M, Ansari MT, Berkman ND, et al. Assessing the risk of bias of individual studies in systematic reviews of health care interventions. In: *Methods Guide for Effectiveness and Comparative Effectiveness Reviews*. AHRQ Publication No. 10(14)-EHC063-EF. Rockville MD: Agency for Healthcare Research and Quality. January 2014. Chapters available at www.effectivehealthcare.ahrq.gov/.
33. Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. *BMC Med Res Methodol*. 2007;7:10. PMID: 17302989.
34. Chou R, Aronson N, Atkins D, et al. AHRQ series paper 4: assessing harms when comparing medical interventions: AHRQ and the effective health-care program. *J Clin Epidemiol*. 2010 May;63(5):502-12. PMID: 18823754.
35. *Methods Guide for Effectiveness and Comparative Effectiveness Reviews*. AHRQ Publication No. 10(14)-EHC063-EF. Rockville, MD: Agency for Healthcare Research and Quality. January 2014. Chapters available at www.effectivehealthcare.ahrq.gov.

36. Munshi KR, Oken T, Guild DJ, et al. The use of antiepileptic drugs (AEDs) for the treatment of pediatric aggression and mood disorders. *Pharmaceuticals*. 2010;3(9):2986-3004.

Background

Disruptive Behavior Disorders (DBDs) are a group of related psychiatric disorders of childhood and adolescence marked by temper tantrums, interpersonal aggression, and defiance. These disorders and related symptoms may manifest in young children as significant behavioral problems at home and difficulties at school. Children with the highest levels of disruptive behavior in early childhood, often experience persistent impairment¹ and are at increased risk for negative developmental outcomes including substance abuse problems, school problems, and delinquent, violent, and antisocial or criminal behaviors in adolescence.²⁻¹⁴

DBDs are among the most common child and adolescent psychiatric disorders, with recent estimates indicating that 3.5% of children between the ages of 3-17 years had behavioral or conduct problems from 2005-2011.¹⁵ Examples of DBDs include Oppositional Defiant Disorder (ODD), Conduct Disorder (CD), attention deficit hyperactivity disorder (ADHD) (as categorized in the fourth edition Diagnostic and Statistical Manual of Mental Disorders;¹⁶ re-classified as a neurodevelopmental disorder in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders)¹⁷ and disruptive behavior disorder not otherwise specified.¹⁸⁻²² Estimates suggest that disruptive behaviors that are problematic but do not meet formal diagnostic criteria may be more common than those meeting formal clinical diagnostic criteria.² The etiology of DBDs is unknown, but temperamental, biological, and environmental factors are associated with increased risk.

DBDs are associated with increased risk for a wide range of negative developmental outcomes including substance abuse problems, school problems, and delinquent, violent, and antisocial or criminal behaviors.²⁻¹⁴ As many of these problems persist into adulthood, the economic costs of DBDs are high. The etiology of DBDs is unknown but temperamental, biological and environmental factors are associated with increased risk. Temperamental risk factors include callous-unemotional traits, behavioral disinhibition, and indicators of limited executive functioning such as having a short attention span.²³ Biological risk factors include lower salivary cortisol levels, lower baseline heart rate levels, and higher increases in heart rate in response to frustration.^{24,25} Low birthweight children also are at increased risk for DBDs.^{26,27}

Environmental risk factors include prenatal exposure to maternal smoking, substance use, illness, and stress.²⁶ Children who have experienced abuse and neglect, early separation from their parents including adoption, and maternal anxiety and depression are also at increased risk.²⁶ Risk attributable to factors such as maternal smoking, substance use, and anxiety and depression during pregnancy have been addressed by more general public health campaigns. Although DBD-specific preventive interventions have been developed, practical considerations including training requirements and cost pose challenges to broad implementation.^{28,29}

Treatment

General outpatient psychotherapy and psychotropic medication management are the most commonly used interventions, either alone or in combination.^{18,30-33} Psychosocial interventions have been developed for some patient subgroups and for some symptoms/symptom clusters. Examples of these interventions include child-level interventions such as Cognitive-Behavioral Therapy (CBT); parent-level interventions such as the Positive Parenting Program (Triple P); and multicomponent interventions such as Multisystemic Therapy (MST).³⁴⁻⁴¹

The use of psychotropic medications to manage disruptive behaviors has increased dramatically and has primarily, but not exclusively, been accounted for by increasing use of

atypical antipsychotic medications.^{31-33,42} Using data from the National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey, Cooper and colleagues³¹ demonstrated that antipsychotic prescribing increased nearly five-fold from 8.6 per 1,000 U.S. children in 1995-96 to 39.4 per 1,000 U.S. children in 2001-02. Furthermore, the medication prescribing increases were greater for non-approved indications including DBDs than for approved indications such as schizophrenia, psychosis, Tourette's syndrome, autism, and mental retardation.

There is wide range of medications used with a significant degree of decisional uncertainty around safety, efficacy, and which combinations to use.⁴³ Classes of medications that have been studied for treatment of disruptive behaviors include antipsychotics, mood stabilizers, anticonvulsants, and psychostimulants.⁴⁴ Combination therapy with antipsychotics and stimulants is commonly used for patients with attention deficit hyperactivity disorder (ADHD) comorbid with DBD or aggression;⁴⁵ however, superiority over monotherapy and tolerability of combined pharmacologic treatment is unclear.

Systematic Reviews and Guidelines

We identified a number of systematic reviews and meta-analyses published recently evaluating pharmacotherapy for youth with disruptive behaviors.⁴⁵⁻⁵³ Other recent reviews evaluated the effectiveness of parenting programs, cognitive behavior therapies, social skills, and other nonpharmacologic treatments such as acupuncture and dietary supplementation.⁵⁴⁻⁶³

The recently published Treatment of Maladaptive Aggression in Youth guidelines^{64,65} from the Center for Education and Research on Mental Health Therapeutics (CERT) recommend psychosocial interventions and address the use of combination therapy. The guidelines suggest initial medication management and psychosocial treatments to address any underlying condition, followed by use of an antipsychotic or mood stabilizer to treat persistent aggression.^{64,65} Data from high quality studies are needed to confirm these recommendations.

Antipsychotic drugs have FDA approval for a limited set of specific indications in children, including bipolar and irritability associated with autism, although not for Disruptive Behavior Disorder. Nonetheless, pediatric use of both first and second-generation antipsychotics has rapidly increased in recent years, including in conditions for which they are not FDA indicated. Recent reviews have concluded that there is an absence of evidence from controlled studies on the long-term efficacy and safety of these drugs in children.⁶⁶ Although there is a recent review of antipsychotics for pediatric patients, this review is not specific to disruptive behavior disorders and concludes that there are important gaps in the literature on the comparative effectiveness and relative safety of these drugs.⁶⁷ The authors of a systematic review of antipsychotic and psychostimulant drug combination therapy for ADHD and DBD noted that most studies were performed over short time periods, and several studies lacked blinding.⁴⁵

A review from the Substance Abuse and Mental Health Services Administration (SAMHSA) describes "promising" practices for treatment and prevention of disruptive behaviors in children.⁶⁸ Despite the existence of these and other reviews of pharmacologic and psychosocial interventions, there remains an absence of clear and accessible guidance for best practice.

Wide variations in clinical management of DBDs, including the use of polypharmacy and tailored psychosocial approaches, frequently administered with little to no adherence to a standard protocol, are described in the literature. In the absence of clearly synthesized information about which interventions are most safe and effective for specific patient subgroups, it is difficult for healthcare providers to make informed treatment recommendations. For

example, individual studies of Problem-Solving Skills Training and Parent-Child Interaction Therapy have reported positive results for children with DBDs, but it is unclear how healthcare providers should select between a child-level intervention, a parent-level intervention, a multicomponent intervention, and pharmacotherapy. The role of early risk factors, family ecology, and treatment history on treatment response remains unclear. Treatment decision dilemmas are further complicated for patients with medical and/or psychiatric comorbidities. The safety of atypical antipsychotics also is an important concern.^{45,50-52}

Scope of the Review

DBDs are a heterogeneous group of conditions; disruptive behaviors are also heterogeneous and are often present in the absence of a specific DBD diagnosis. Studies that are intended to assess treatment for conditions such as ADHD, for example, are likely to report changes in disruptive behaviors as outcomes. For this reason, and because a review of ADHD currently exists,⁶⁹ we focused the current review on studies in which the aim of treatment was specifically a disruptive behavior, with or without a DBD diagnosis. We excluded studies focusing on treating ADHD and other conditions that may include disruptive behaviors, (e.g., autism, developmental disability) but are not intended to assess treatments focused on reducing disruptive behaviors themselves.

This review specifically focused on psychosocial and pharmacologic interventions for disruptive behavior. We also sought studies of combined or co-interventions (i.e., combinations of pharmacologic agents or psychosocial intervention, or medication used in conjunction with psychosocial interventions). We included studies of parent-targeted psychosocial interventions if the study reported changes to child disruptive behavior. For pharmacologic interventions, we targeted the literature on their use in disruptive behavior disorders, focusing on a smaller but more focused literature base. The choice of outcomes on which to focus the analysis and particularly the strength of evidence was challenging for this review. Many different measures are used to assess components of disruptive behavior, not all of which have been validated. We extracted data on behavioral and functional outcomes and emphasized the use of validated measures, particularly the ECBI and CBCL for conducting strength of evidence assessments and in the meta-analysis.

We outline the population, interventions, comparators, outcomes, timing, and setting for the review in the PICOTS (Table 1).

Table 1. PICOTS

| PICOTS | Criteria and Key Question(s) |
|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Population | <ul style="list-style-type: none"> • Children under 18 years of age who are being treated for disruptive behavior or a disruptive behavior disorder (KQs 1-6) |
| Intervention(s) | <ul style="list-style-type: none"> • Psychosocial intervention (KQs 1, 3-6) • Pharmacologic intervention (KQs 2-6) • Combined psychosocial and pharmacologic intervention (KQs 4-6) |
| Comparator | <ul style="list-style-type: none"> • Alternate psychosocial or pharmacologic intervention • Inactive treatment, including waitlist control, active treatment, and placebo |

Table 1. PICOTS (continued)

| PICOTS | Criteria and Key Question(s) | |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Outcomes | <p><u>Behavioral outcomes (KQs 1-4, 6)</u></p> <ul style="list-style-type: none"> • Aggressive behavior • Violent behavior • Delinquent behavior • Fighting, property destruction, and rule violations • Compliance with parents, teachers, and institutional rules <p><u>Functional outcomes (KQs 1-4, 6)</u></p> <ul style="list-style-type: none"> • Family functioning/ cohesion • School performance • Interpersonal/social function and competence • Interactions with legal/juvenile justice system • Health care system utilization • Substance abuse • Health related quality of life | <p><u>Adverse effects / Harms (KQ 5)</u></p> <ul style="list-style-type: none"> • Metabolic effects: weight gain, hyperglycemia and diabetes, hyperlipidemia • Extrapyramidal effects: parkinsonism, acute dystonia, akathisia, tardive dyskinesia • Cardiac adverse effects: prolonged QT/arrhythmias, hypotension, cardiomyopathy • Prolactin-related effects • Allergic reaction • Sudden death • Suicide • Over-medication or inappropriate medication • Negative effects on family dynamics • Stigma • Other harms, as reported |
| Timing | <ul style="list-style-type: none"> • Any length of followup (KQs 1-6) | |
| Setting | <ul style="list-style-type: none"> • Clinical setting, including medical or psychosocial care that is delivered to individuals by clinical professionals, as well as individually focused programs to which clinicians refer their patients. Excludes school wide or system wide settings wherein interventions are targeted more widely. (KQs 1-6) | |

KQ = Key Question; PICOTS = population, comparator, outcomes, timing, setting

Key Questions

The treatments for disruptive behaviors and disruptive behavior disorders include both psychological and pharmacologic approaches. Nonpharmacologic interventions usually are recommended as the initial strategy, but clinicians and families are likely to use both approaches at some point, possibly simultaneously, creating further decisional dilemmas related to co-therapy, polypharmacy, and the role of treatment history. We therefore framed the Key Questions to ascertain the comparative effectiveness of various psychological and pharmacologic treatments aimed at disruptive behaviors, compared both within and between treatment types, and ascertain whether there are combinations of psychological and pharmacologic therapeutic approaches that are optimal.

Key Question 1: In children under 18 years of age treated for disruptive behaviors, are any psychosocial interventions more effective for improving short-term and long-term psychosocial outcomes than no treatment or other psychosocial interventions?

Key Question 2: In children under 18 years of age treated for disruptive behaviors, are alpha-agonists, anticonvulsants, beta-blockers, central nervous system stimulants, first-generation antipsychotics, second-generation (atypical) antipsychotics, and selective serotonin reuptake inhibitors more effective for improving short-term and long-term psychosocial outcomes than placebo or other pharmacologic interventions?

Key Question 3: In children under 18 years of age treated for disruptive behaviors, what is the relative effectiveness of any psychosocial interventions compared with the pharmacologic interventions listed in Key Question 2 for improving short-term and long-term psychosocial outcomes?

Key Question 4: In children under 18 years of age treated for disruptive behaviors, are any combined psychosocial and pharmacologic interventions listed in Key Question 2 more effective for improving short-term and long-term psychosocial outcomes than individual interventions?

Key Question 5: What are the harms associated with treating children under 18 years of age for disruptive behaviors with either psychosocial or pharmacologic interventions?

Key Question 6a: Do interventions intended to address disruptive behaviors and identified in Key Questions 1-4 vary in effectiveness based on patient characteristics, including sex, age, racial/ethnic minority, family history of disruptive behavior disorders, family history of mental health disorders, history of trauma, and socioeconomic status?

Key Question 6b: Do interventions intended to address disruptive behaviors and identified in Key Questions 1-4 vary in effectiveness based on characteristics of the disorder, including specific disruptive behavior or disruptive behavior disorder (e.g., oppositional defiant disorder, conduct disorder, aggression), concomitant psychopathology (e.g., attention deficit hyperactivity disorder or substance abuse), related personality traits and symptom clusters, presence of comorbidities (other than concomitant psychopathology), age of onset, and duration?


Key Question 6c: Do interventions intended to address disruptive behaviors and identified in Key Questions 1-4 vary in effectiveness based on treatment history of the patient?

Key Question 6d: Do interventions intended to address disruptive behaviors and identified in Key Questions 1-4 vary in effectiveness based on characteristics of the treatment, including duration, delivery, timing, and dose?

Analytic Framework

The analytic framework (Figure 1) illustrates the population, interventions, outcomes, and adverse effects that will guide the literature search and synthesis.

Figure 1. Analytic framework



Organization of This Report

We have organized the report by Key Question. For Key Question 1 (psychosocial interventions) we present the studies by age (categorized as preschool, school-age, and adolescent) and then further divide the sections by single or multiple intervention components. For Key Question 2 (pharmacologic interventions) we present the study information by study drug categories. For Key Question 5 we present the harms information from included studies, existing reviews, and gray literature. We limited the meta-analysis to Key Question 1 and more specifically to those outcomes reported using a common and validated outcome measure for disruptive behavior.

Methods

Topic Refinement and Review Protocol

Initially a panel of key informants gave input on the Key Questions (KQs) to be examined; these KQs were posted on the Agency for Healthcare Research and Quality (AHRQ) website for public comment for 4 weeks and revised as needed. We drafted a protocol for the review and recruited technical experts to provide content and methodological expertise on the development of the review.

Searching for the Evidence

Search Strategy

Searches were executed between September 2013 and June 2014. We conducted search update during peer review of the draft report. We developed search strategies using a combination of subject headings (i.e., controlled vocabulary) and keywords (Appendix A). We included broad terms for psychosocial interventions, as well as interventions by name (e.g., “Parent-Child Interaction Therapy”, “Incredible Years”, and “Positive Parenting Program”). We included terms to describe drug classes and individual agents. We built the search strategies in tandem with the refinement of the KQs and Analytic Framework to ensure that the literature retrieval was representative of the project scope. The preliminary results were vetted by clinical and methodologic subject matter experts. We did not conduct a separate search for longitudinal cohort studies of adverse events, but did conduct a separate search for existing systematic reviews and requested drug package inserts to obtain information on harms.

Databases

To ensure comprehensive retrieval of relevant studies, we used the following key databases: the MEDLINE medical literature database (via the PubMed interface), EMBASE, and PsycInfo[®]. We used the Comparative Effectiveness Plus interface for The Iowa Drug Information Service (IDIS) database to identify regulatory information from the following sources: Food and Drug Administration (FDA) approval packages, FDA Advisory Committee Reports, boxed warnings, Priority Clinical Practice Guidelines, AHRQ Evidence Reports and AHRQ Comparative Effectiveness Reviews, Pivotal Studies, National Institute for Health and Clinical Excellence (NICE) Clinical Guidelines or Technology Appraisal Guidance.

Hand Searching

We used hand searching of recent systematic reviews and other relevant publications to identify additional studies not captured by the database searches. We also reviewed the references lists of the included studies.

Gray Literature

We searched the websites of agencies/organizations as well as other sources (e.g., Clinicaltrials.gov, meeting abstracts, FDA) for context and relevant data, in the area of treatment for disruptive behavior disorders in children. We retrieved the medical and statistical evaluations for relevant drugs from the FDA (www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm049872.htm).

For KQ5, we reviewed and extracted information from package inserts, regulatory sources, and unpublished data for all relevant drug interventions to identify data on harms and side effects.

Scientific Information Packets (SIPs)

We requested Scientific Information Packets (SIP) and regulatory information from the Scientific Resource Center (SRC) for individual pharmacologic agents. The SRC SIP coordinator requested information from industry stakeholders and managed the information retrieval. We received responses from three of the 20 requests and confirmed that the studies referenced in the information packets were included in our literature searches.

Screening

We conducted two levels of screening using explicit inclusion and exclusion criteria and documented the assessments using an abstract screening form and full text screening form (Appendix B). The abstract screening form contained questions about the primary exclusion and inclusion criteria for initial screening. We used a more detailed form (full-text screening form) to examine the full-text of references that met criteria for inclusion in abstract review.

Initially, we reviewed the titles and abstracts from all references retrieved by the literature and hand searches. References that met the prespecified criteria for inclusion, as determined by one reviewer, were promoted for second level screening (i.e., full text review). To be excluded at the abstract screening level, two reviewers had to determine, independently, that a reference did not meet one or more criterion for inclusion. Conflicts (i.e., disagreements between reviewers) were promoted for a second level review, as were references with insufficient information to make a decision about eligibility.

All references promoted to full text review were screened by at least two reviewers against the inclusion/exclusion criteria. Discrepancies were resolved by a senior team member or through team consensus. We retained the citations for all retrievals, and recorded the screening results and complete inclusion and exclusion data.

Inclusion and Exclusion Criteria

The inclusion and exclusion criteria for the review were derived from our understanding of the literature, refinement of the review topic with the Task Order Officer and Key Informants, and feedback on the KQs obtained during the public posting period.

Population

The target population for this review is children under 18 years of age who are being treated for a disruptive behavior (Table 2). Eligible studies had to focus on the treatment of the disruptive behavior and include children exhibiting disruptive behaviors as a primary problem (e.g., conduct disorder, oppositional defiant disorder, and intermittent explosive disorder). We considered also, studies that included subjects who were not diagnosed with a disorder but who were being treated for disruptive behaviors that were measured by and found to be above the clinical cutoff on a validated measure.

Table 2. Case definition for disruptive behavior

| Case Definition for Disruptive Behavior |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Behaviors that “violate the rights of others (e.g., aggression, destruction of property) and/or that bring the individual into significant conflict with societal norms or authority figures.” ^a The review will include studies that look at children exhibiting these behaviors as a primary problem, such as the DSM-5 disruptive behaviors disorders like Conduct Disorder, Oppositional Defiant Disorder, and Intermittent Explosive Disorder, though some studies will include subjects who have not been diagnosed with one of these disorders but who are being treated for disruptive behaviors such as early onset aggression. This review will exclude studies where disruptive behaviors are studied as symptoms or comorbidities (e.g., substance abuse, Autism Spectrum Disorder, Pervasive Developmental Disorder, developmental delay, intellectual disability, and Attention Deficit Hyperactivity Disorder, etc.). |

^aAmerican Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fifth edition. Arlington, VA: American Psychiatric Association; 2013. Available at: dsm.psychiatryonline.org.

We included studies of interventions that targeted parents of children with a disruptive behavior if the study explicitly defined the eligible patient population to include a child with a disruptive behavior (as defined above) and the study reported one or more child outcome. We excluded studies of disruptive behavior secondary to other conditions (e.g., treatment of substance abuse, developmental delay, intellectual disability, pediatric bipolar disorder). In the case of ADHD, we excluded studies of ADHD-related disruptive behaviors but included studies of non-ADHD-related disruptive behaviors in populations of children with ADHD if the children were identified as also having another disruptive behavior disorder. Our quantitative analysis further excluded studies that did not report baseline and end of treatment means and standard deviations using one of the three most commonly used outcome measures.

Interventions

We sought studies of psychosocial interventions such as: behavior management training, social skills training; cognitive-behavioral therapy; functional behavioral interventions; parent training; dialectical behavior training; psychotherapy; and contingency management methods. Studies of parent- or family-focused interventions were included if the study included children with a DBD (as defined above) and measured and reported at least one child behavior or functional outcome. We included studies that evaluated an intervention targeting the health or wellbeing of the parent or caretaker of a child with DBD only if the study reported child outcomes. For the purposes of this review, we did not include information technology-based and assisted services, media, diet, or exercise.

We did not include studies of prevention in asymptomatic, undiagnosed, or at-risk participants because we wanted to focus our review on children with disruptive behaviors that would be treated if they presented in healthcare settings. We focused our review on studies that included children who scored above the clinical threshold on a validated scale and/or who were formally diagnosed with a DBD. We did not include studies designed exclusively to assess, measure, screen, or diagnose disease or symptoms. We did not include universal interventions such as those implemented in the school setting, studies of systems-level interventions, or studies of interventions targeting organizational delivery of care. Other excluded interventions were: dietary supplements and specialized diets; allied health interventions (e.g., speech/language therapy, occupational, and physical therapy); complementary and alternative medicine interventions (e.g., acupuncture, herbal, and folk remedies); physical activity and recreational programs (e.g., yoga, exercise training); and invasive medical interventions (e.g., surgery, deep brain stimulation).

Eligible pharmacologic interventions included both FDA-approved medications for the treatment of a behavior disorder or management of disruptive behaviors in children and

medications used off-label for disruptive behavior. We identified specific pharmacologic agents from the following broad classes of drugs: alpha-agonists, anticonvulsants, second-generation (i.e., atypical) antipsychotics, beta-adrenergic blocking agents (i.e., beta-blockers), central nervous system stimulants, first-generation antipsychotics, selective serotonin reuptake inhibitors, mood stabilizers, and antihistamines.

We considered studies of a combined (i.e., co-administered, co-therapy, conjunctive, or adjunctive) intervention that included one or more of the eligible psychosocial or pharmacologic interventions identified in Key Questions 1-3 or was a uniquely described combination intervention designed or implemented specifically to treat children with disruptive behavior.

Outcomes

For Key Questions 1-4 and 6, eligible studies had to report at least one behavioral or functional outcome listed in the Analytic Framework (Figure 1). Studies had to report child outcomes to be considered for inclusion. We extracted information on long-term outcomes when they were reported. For Key Question 5, we included studies that reported harms (i.e., adverse effects) for an intervention included in Key Questions 1-4.

Timing

Eligible studies were not limited to intervention timing or duration of followup, but we limited the search to studies published in or after 1994. We conducted a preliminary screening of records retrieved from a search with no limits to the publication year. We screened approximately 1500 records published 20 or more years ago, and found that the study populations were inadequately described and poorly characterized, rendering a large number of the older studies unusable for this review. In order to include studies of patients meeting the population criteria for this review, the team agreed to limit the retrieval of primary study data to those studies published in or after 1994, as this date cutoff aligns with the availability of the *DSM-IV*.¹⁶

Setting

We focused on interventions in the clinical setting, including medical or psychosocial care delivered to individuals by clinical professionals, as well as individually focused programs to which clinicians refer patients. We excluded studies that were conducted exclusively in hospitalized participants (i.e., in-patients). We also excluded studies of a systems-level intervention (e.g., delivered universally in the school or juvenile detention setting).

Study Characteristics

We sought randomized controlled trials (RCTs) and nonrandomized controlled studies (i.e., prospective and retrospective cohort studies). We did not include case control studies as they are not an optimal study design for assessing causal inferences or measuring treatment effects. We did not include studies without comparators (e.g. case series) for the same reason.

For Key Questions 1-4, we sought original data from primary study publications. We identified and included data from related publications (i.e., publications reporting relevant outcomes from a study reported in a separate publication) if the primary study publication met inclusion criteria for the review. For Key Question 5, we included adverse events and harms data (for interventions identified in Key Questions 1-4) from studies, systematic reviews, and

regulatory reports to augment the harms data collected from the controlled prospective studies meeting the review inclusion criteria.

We did not specify a minimum sample size (i.e., number of participants per arm) for eligible studies. We restricted the review to studies published in English-language papers. TEP confirmed that key discipline specific publications from non-U.S. countries and international conferences present and publish material in English, minimizing the likelihood of language bias. However, we assessed abstracts from non-English language reports to assess the robustness of this assumption.

Data Extraction and Data Management

Data Extraction

We created data extraction forms to collect detailed information on the study characteristics, interventions, comparators, outcomes, outcome measures, and study quality and/or risk of bias (see Study Characteristics and Outcomes Data Files in the Systematic Review Data Repository). We enumerated the variables most important to this topic with input from Key Informants and Technical Experts and used the extraction forms to record participant characteristics, intervention characteristics, outcomes, and potential modifiers of treatment effects from each included study. The forms included detailed instructions and labels to reinforce coding reliability and consisted of items with mutually exclusive and exhaustive answer options to promote consistency. A senior level team member reviewed the data extraction against the original articles for quality control. The study and data abstraction forms were used to develop summary tables across selected groups of studies.

We recorded descriptive data for each study that met the full text screening criteria including study design, year, location, setting, randomization, blinding, elements of study quality, and related publications. We flagged related publications and extracted nonduplicate study data. We categorized location by country with the exception of Puerto Rico, which we categorized separately from the U.S. due to cultural differences in the study population. We recorded the source of funding and authors' competing interest disclosures for all studies included in the review.

We recorded intervention characteristics and components in detail, noting data elements not reported or unavailable from the primary or related study publications. We classified interventions according to their treatment components, specifically: 1) interventions including only a child component; 2) interventions including only a parent component; and 3) multicomponent interventions. Multicomponent interventions were defined as those that included two or more of a child component, parent component, or other component (e.g., teacher component, family together component).

We categorized outcomes broadly as behavioral or functional. We extracted information on how the outcome was measured and the outcome measurement time points. We include broad measures of quality of life and social functioning.

To assess the evidence on harms, we first collected adverse outcomes reported in studies included for effectiveness. We also identified the evidence for harms of pharmacologic interventions used to treat disruptive behavior reported in the gray literature, including integrated safety reports from the U.S. Food and Drug Administration's regulatory documents.

We recorded potential modifiers to determine whether specific variables affected treatment response. We anticipated that patient age and certain disorder characteristics (such as disease severity) would be robust predictors of outcomes.

We also extracted information on intervention delivery, intervention setting, and environmental factors (e.g., parental engagement) that may account for variations in observed treatment effects. The potential modifiers represent categories of variables that we anticipated may be linked to treatment effects. We extracted the reported variables from included studies and organized the information into meaningful groups to permit syntheses.

Data Management

We registered the review protocol (Registration #CRD42014007552) with PROSPERO, an international database of prospectively registered systematic reviews in health and social care. We used DistillerSR (Evidence Partners, Ottawa, Canada) for screening references. We tracked the literature search retrieval and screening results in EndNote. We used forms to extract the study data, and transferred the data to Excel. We deposited the data that were used in the meta-analyses into the Systematic Review Data Repository (SRDR) system.

Assessment of Methodological Risk of Bias of Individual Studies

We assessed the risk of bias of studies for behavioral outcomes of interest specified in the PICOTS (Table 1) according to the guidance in the “Methods Guide for Effectiveness and Comparative Effectiveness Reviews.”⁷⁰ Two senior investigators independently assessed each included study. Disagreements between assessors were resolved through discussion.

We used the Cochrane Risk of Bias Tool⁷¹ (Appendix C) to assess risk of bias for randomized controlled trials (RCTs) of effectiveness. Reviewers rated six items from five domains of potential sources of bias (i.e., selection, reporting, performance, detection, and attrition) and one item for “other” sources of bias. We assessed for detection bias by evaluating outcome measurement and assessment methods to detect effects. We evaluated potential risk of bias associated with fidelity for psychosocial interventions and included those assessments in the category of “other bias.” To assess risk of bias for study designs other than RCTs, we used the RTI Item Bank⁷² for cohort studies (i.e., nonrandomized controlled trials) and the AMSTAR tool for systematic reviews and meta-analyses (Appendix C).⁷³⁻⁷⁵ To assess the risk of bias associated with the reporting of harms, we used a four question modified tool adapted from the McMaster Assessment of Harms Tool (Appendix C).⁷⁶

Determining Risk of Bias Ratings

We assigned studies an overall rating of “low,” “moderate,” or “high” risk of bias. We expected RCTs to receive positive assessments for questions about randomization, allocation concealment, and blinding in order to be designated “low risk of bias.” We considered the feasibility of blinding in psychosocial studies and did not downgrade where it would have been impossible. Cohort studies that received positive scores on all items were assessed as “low risk of bias.” Cohort studies with two or fewer negative ratings were assessed as “moderate risk of bias” and studies with more than two negative scores were assessed as “high risk of bias.” We required that studies assessed for harms reporting receive a positive rating (i.e., affirmative response) on all four questions to receive a rating of “good.” Studies with at least three positive

responses were considered “fair” quality and those with less than three positive responses were assessed as “poor” quality.

Data Synthesis

We examined the appropriateness of each study for inclusion in a meta-analysis. Studies that were too heterogeneous or otherwise unsuitable to contribute data to the meta-analysis were included as part of a narrative synthesis.

Qualitative Synthesis of Results

We qualitatively synthesized the literature based on the data extracted (described above) for each Key Question. We present behavioral outcomes (KQ1 and KQ2) and harms data (KQ5) in summary tables within the text. For the qualitative summary of KQ1, we organized the results by age (preschool, school age, and teenage) and characterized the studies as those that evaluated a child-only, a parent only, or a multicomponent intervention, based on the active treatment arm. We defined multicomponent interventions as those that included two or more of a child component, parent component, or other component (e.g., teacher component, family together component). We further grouped the summary of studies for KQ1 by named interventions (e.g., PCIT, Triple P, and Incredible Years) where possible. This categorization provided an organizational structure to characterize the literature and highlight key findings for similar interventions. For KQ2 we grouped the studies by individual pharmacologic agent or by pharmacologic class.

Quantitative Synthesis of Results

We developed a Bayesian multivariate, mixed treatment (network) meta-analysis to address the comparative effectiveness of psychosocial interventions for improving behavioral outcomes for children treated for disruptive behaviors (Key Question 1). We used Bayesian multivariate, mixed treatment (network) meta-analytic methods⁷⁷⁻⁷⁹ to use both direct and indirect evidence for comparing a large suite of treatments. Network meta-analysis allows for a broader, integrated view of the available evidence, allowing for the relative merits of a set of treatments to be more readily compared. This approach borrows strength from indirect comparisons of interventions that have not been compared head-to-head in the same study. By combining direct and indirect evidence in the same framework, the resulting meta-analysis may be more robust, with more precise meta-estimates, than traditional meta-analyses. In the absence of network meta-analysis, we would have been compelled to construct a number of smaller, separate meta-analyses that would have been less powerful and less comprehensive, with more evidence excluded relative to a unified network meta-analysis. Further, our model was multivariate, in the sense that multiple outcome measures were considered simultaneously; this improves the analysis by recognizing that outcomes are correlated, estimating that correlation directly as part of the analysis. We present additional details of the meta-analysis methods in Appendix D.

Twenty-eight of the 66 studies included in the qualitative review in KQ1 met the additional criteria for inclusion in our meta-analysis. These additional criteria were that the study was an RCT that reported baseline and end-of-treatment means and standard deviations using one (or more) of the three most prevalent of the 16 instruments used in this literature to examine parent reported outcomes: (1) Eyberg Child Behavior Inventory (ECBI), Intensity Subscale; (2) ECBI, Problem Subscale; and (3) Child Behavior Checklist (CBCL), Externalizing (T-score) (see

Appendix E for a description of the instruments). Other instruments were not included in the analysis because of heterogeneity of constructs examined and an inadequate number of studies per measure.

To account for the large suite of interventions employed by the constituent studies, we classified the study arms of each included study according to their treatment components or as a control. Specifically, the treatment arms of each study were classified as one of the following types: (1) interventions including only a child component; (2) interventions including only a parent component; and (3) multicomponent interventions. Multicomponent interventions were defined as those that included two or more of a child component, parent component, or other component (e.g., teacher component, family together component). All interventions classified as multicomponent included a parent component. Study arms not identified by any of these three classes were defined as a control arm (i.e., waitlist control or treatment-as-usual arm). Recognizing that these treatment categories are broad, encompassing a range of specific interventions, each component was modeled as a random effect. This allowed for variation in treatment effect within each class, due to factors not explicitly modeled here. All measurement instruments shared the same study arm treatment effect in our model.

Studies were included in the meta-analysis if they reported baseline and end-of-treatment means and standard deviations from one of the three metrics listed above. The baseline was subtracted from the end-of-treatment mean and used as the response measure, along with the sum of their standard deviations. The three outcomes were modeled jointly as a multivariate normal likelihood, with any unmeasured outcomes treated as missing data; this allowed for the covariance among measures to be accounted for and estimated.

The age of subjects in each study arm was included in the model as a categorical covariate, broadly grouped into either prekindergarten, preteen child or teenage categories. The preteen child was used as the baseline value because it was the most prevalent among studies. The age covariate was combined additively with the intervention component effects and control/treatment-as-usual means to model the observed treatment differences relative to baseline. Though we considered age-by-treatment interactions, there was not enough balance among the age and treatment combinations to include them in the final model.

All unknown parameters were given weakly-informative prior distributions and estimated using Markov chain Monte Carlo⁸⁰ methods via the PyMC 2.3 software package.⁸¹ The model was run for 200,000 iterations, with the first 150,000 samples conservatively discarded as burn-in, leaving 50,000 for inference.

Incorporating Existing Systematic Reviews

We located reviews published between 2005 and 2014 and evaluated each for relevance using the review PICOTS (Appendix B). We summarize review data from relevant psychosocial and pharmacologic interventions in the “Discussion” section of the report and in a table in Appendix F. For the systematic reviews reporting harms, we assessed quality using AMSTAR⁷³ and summarized the findings in KQ5.

Grading the Strength of Evidence

Strength of Evidence Assessments

We referenced the recommendations from the AHRQ EHC Methods Guidance and updated guidance for grading the strength of a body of evidence.^{82,83} In accordance with the methods guidance, we first assessed and graded “domains” using established concepts of the quantity and quality of evidence, and coherence or consistency of findings. Two senior staff independently graded the body of evidence; disagreements were resolved through discussion.

We assessed strength of evidence for the direction or estimate of effect for the behavioral outcomes and interventions listed in Table 3.

Table 3. Selected outcomes and comparisons for the strength of evidence assessments

| Outcome | Intervention | KQ |
|-----------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|-----|
| Change in disruptive behavior | Psychosocial Intervention | KQ1 |
| <ul style="list-style-type: none"> • ECBI, Problem subscale • ECBI, Intensity subscale • CBCL, Externalizing score | <ul style="list-style-type: none"> Child only Parent only Mixed component | |
| Change in disruptive behavior or aggression | Pharmacologic Intervention | KQ2 |
| <ul style="list-style-type: none"> • SDQ • OAS • CGI | <ul style="list-style-type: none"> Second generation antipsychotic Antiepileptic Medications used to ADHD | |

ADHD = attention deficit hyperactivity disorder; CBCL = Child Behavior Checklist; CGI = Clinical Global Impressions; ECBI = Eyberg Child Behavior Inventory; KQ = Key Question; OAS = Overt Aggression Scale; SDQ = Strengths and Difficulties Questionnaire

We assessed an overall evidence grade based on the ratings for the following domains: study limitations; directness; consistency; precision; and reporting bias. We considered additional domains, as appropriate: dose-response association, plausible confounding, and strength of association (i.e., magnitude of effect). The fifth required domain, reporting bias, includes publication bias, selective outcome reporting, and selective analysis reporting.⁸² To assess publication bias in the pharmacologic literature, we sought study protocols and data from regulatory sources and compared this information to the results in the published literature. The issue of publication bias in psychological science is difficult to address given the current lack of standards regarding the registration of study protocols in social sciences. We attempted to minimize the potential for bias introduced by the “file drawer effect” (i.e., nonpublication of studies with nonsignificant results) by expanding the literature search to include unpublished sources (e.g., meeting abstracts) and asking Key Informants about current research or developments in the field that may not yet be published.

Overall Strength of Evidence

We summarize the four grades (high, moderate, low, and insufficient) we used for the overall assessment of the body of evidence in Table 4 (adapted from the AHRQ “Methods Updated Guidance for Grading the Strength of a Body of Evidence”⁸²). When no studies were available for an outcome or comparison of interest, we graded the evidence as insufficient.

Table 4. Strength of evidence grades and definitions^a

| Grade | Definition |
|--------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| High | We are very confident that the estimate of effect lies close to the true effect for this outcome. The body of evidence has few or no deficiencies. We believe that the findings are stable, i.e., another study would not change the conclusions. |
| Moderate | We are moderately confident that the estimate of effect lies close to the true effect for this outcome. The body of evidence has some deficiencies. We believe that the findings are likely to be stable, but some doubt remains. |
| Low | We have limited confidence that the estimate of effect lies close to the true effect for this outcome. The body of evidence has major or numerous deficiencies (or both). We believe that additional evidence is needed before concluding either that the findings are stable or that the estimate of effect is close to the true effect. |
| Insufficient | We have no evidence, we are unable to estimate an effect, or we have no confidence in the estimate of effect for this outcome. No evidence is available or the body of evidence has unacceptable deficiencies, precluding reaching a conclusion. |

^a Excerpted from Berkman et al. 2013⁸⁴

Assessing Applicability

We assessed the applicability of the findings to the population being treated for disruptive behavior disorders and the settings in which treatment occurs. We summarized common features of the study population and documented diagnoses. We considered patient age, intervention setting, treatment history, co-occurring diagnoses, and symptom severity reported in the included studies and the degree to which the populations studied reflect the target population for practice. As resource-poor environments may be limited in the options and types of interventions available, we characterized the resources needed including types of providers or involvement of nonclinical providers or families to implement effective interventions and provide the end users with adequate data on feasibility and implementation planning. We present applicability tables for each intervention in Appendix G.

Findings

Description of Included Studies

The PRISMA⁸⁵ literature flow diagram (Figure 2) reports the number of records retrieved from indexed, published literature and the overall number of records (including unique studies and related publications) retained for all Key Questions (KQs) and the meta-analysis. From our search of the literature we screened 7470 records; we excluded 6502 based on the abstract and title. We retrieved the full text of 968 publications. Of these, 852 were excluded for one or more reasons. Appendix H includes a list of excluded publications and exclusion reasons.


We retained 115 publications, representing 84 unique studies to address one or more KQs in this review. For Key Question 1 (KQ1) we identified 89 publications representing 66 unique studies. For Key Question 2 (KQ2) we identified 15 publications representing 13 unique studies. We included the data from the 13 studies addressing KQ2 and identified an additional three studies for Key Question 5 (KQ5). We found no head-to-head studies assessing the effectiveness of psychosocial versus pharmacologic intervention (Key Question 3) or combined psychosocial and pharmacologic interventions (Key Question 4) for the treatment of disruptive behavior in children. We summarize information on moderators and mediators of intervention effectiveness for Key Question 6 (KQ6) from 23 studies that addressed KQ1 or KQ2. For each KQ, we present findings by intervention and outcome where possible.

Studies of psychosocial interventions (KQ1) were heterogeneous. We categorized studies based on the active study arm and identified psychosocial interventions including only a child component, interventions including only a parent component, or as multicomponent (i.e., two or more of a child, parent, or other type of intervention component) intervention. We identified a subset of studies (n = 28) from KQ1 to contribute data to the network meta-analysis. These studies were RCTs that reported baseline and end of treatment outcomes for at least one intervention and control group (i.e., study arm) using one or more of the three most prevalent measures of disruptive behavior (described above).

Pharmacologic interventions (KQ2) included antipsychotics, antiepileptics, and two groups of drugs (stimulants and nonstimulants) typically used to treat attention deficit hyperactivity disorder (ADHD). We report harms of pharmacologic interventions from 16 studies (reported in 18 papers). To augment the empirical data, we briefly summarized data from the gray literature (i.e., package inserts and FDA reviews) and prior systematic reviews (n = 3) that reported harms associated with the drugs that were included in the literature we assessed for KQ2. We compared the information obtained from the literature and regulatory sources with the Scientific Information Packets to confirm that we identified all relevant reports of harms data.

We present information reported in 37 publications (representing 23 studies) in KQ6 by patient characteristics (KQ6a), intervention characteristics (KQ6b), treatment history (KQ6c) and treatment characteristics (KQ6d).

Figure 2. Literature flow diagram



^aExcluding discarded duplicates (n = 44).

^bRecords could be excluded for more than one reason.

^c115 publications representing 84 unique studies.

^dA subset of studies (n = 28) met eligibility criteria for inclusion in a quantitative analysis.

Key Question 1: In children under 18 years of age treated for disruptive behaviors, are any psychosocial interventions more effective for improving short-term and long-term psychosocial outcomes than no treatment or other psychosocial interventions?

Overview of the Literature for KQ1

This section presents results of studies meeting our review criteria and addressing the effectiveness of psychosocial treatments for disruptive behavior. Sixty-six studies (reported in 89 papers) of psychosocial intervention met the criteria for inclusion. Of the 66 included studies, 59 were randomized controlled trials (RCTs) (6031 was the total number of patients randomized for all studies in this section) and seven were nonrandomized controlled studies (including 1144 participants).⁸⁶⁻⁹² About half of the studies (n = 25) were conducted in the United States;⁹³⁻¹¹⁶ the remaining studies were conducted in: Australia (n = 11); Canada (n = 4); Germany (n = 3); Ireland (n = 2); Israel (n = 2); Netherlands (n = 5); Norway (n = 4); Puerto Rico (n = 1); Sweden (n = 3); and the United Kingdom (n = 5).¹¹⁷⁻¹⁴⁷ For the qualitative synthesis, we group studies by

active psychosocial intervention arm as interventions including only a child component, interventions including only a parent component, or as multicomponent interventions (Table 5). We defined a multicomponent intervention as one that included two or more of a child component, parent component, or other component (e.g., teacher component, family together component).

We report the findings first by age group (preschool age, school age, and teenage) and then by intervention, grouping first by components (e.g., child only, parent only, multicomponent) and then within components by specific interventions. We summarize the group difference in parent reported child disruptive behaviors reported by the Eyberg Child Behavior Inventory (ECBI) Intensity scale, ECBI Problem scale, or Child Behavior Checklist (CBCL) Externalizing scale T-score from baseline to the last followup in tables within each age group.

Table 5. Study characteristics (KQ1)

| Characteristic | | Preschool Age n = 23 | School Age n = 29 | Adolescent n = 14 | All Ages |
|------------------------------------|-----------------------|-------------------------|----------------------|----------------------|-----------|
| Study Design | RCT | 22 | 24 | 13 | 59 |
| | Cohort | 1 | 5 | 1 | 7 |
| Location | USA /Canada | 10 | 13 | 6 | 29 |
| | Europe | 4 | 13 | 7 | 23 |
| | Australia | 8 | 2 | 0 | 11 |
| | Other | 1 | 1 | 1 | 3 |
| Population Characteristics | Mean age, years | 4.26 | 7.98 | 15.34 | 8.21 |
| | Proportion males, % | 68.25 | 77.73 | 71.40 | 72.94 |
| | Randomized | 2011 | 3585 | 1579 | 7175 |
| | Analyzed ^a | 1815 | 3019 | 1471 | 6305 |
| Intervention Component | Child Only | 0 | 1 | 1 | 2 |
| | Parent Only | 14 | 11 | 0 | 25 |
| | Multiple components | 9 | 17 | 13 | 39 |
| Intervention | IY | 5 | 7 | 0 | 12 |
| | Triple P | 5 | 0 | 0 | 5 |
| | PCIT | 7 | 0 | 0 | 7 |
| | MST | 0 | 0 | 5 | 5 |
| | BSFT | 0 | 0 | 3 | 3 |
| | Other | 6 | 22 | 6 | 34 |
| Outcome Measure^b | ECBI | 20 | 10 | 1 | 31 |
| | CBCL | 8 | 15 | 8 | 31 |
| | SDQ | 2 | 4 | 0 | 6 |
| | Observation | 4 | 3 | 0 | 7 |
| | Other | 14 | 22 | 12 | 48 |
| Risk of Bias (Quality) | High | 10 | 9 | 5 | 24 |
| | Moderate | 11 | 18 | 5 | 34 |
| | Low | 2 | 2 | 4 | 8 |
| | Total | 23 | 29 | 14 | 66 |

BSFT = Brief Strategic Family Therapy; CBCL = Child Behavior Checklist; ECBI = Eyberg Child Behavior Inventory; IY = Incredible Years; KQ = Key Question; MST = Multisystemic Therapy; PCIT = Parent-Child Interaction Therapy; RCT = randomized, controlled trial; SDQ = Strengths and Difficulties Questionnaire

^aSome studies do not report the number analyzed.

^bNumbers do not tally as studies could use more than one measure.

The most commonly included named intervention was the Incredible Years (IY) program (12 studies). The IY program is a therapist-led, videotape modeling discussion program. The IY program includes child (IY-CT), parent (IY-PT), and teacher training (IY-TT) programs, which may be delivered individually or in combination with each other. The IY-PT program, for example, trains parents general ways of interacting and communicating with children and operant techniques for handling behavior problems.¹⁴⁸

The next most commonly included named intervention was Parent Child Interaction Therapy (PCIT) (7 studies). PCIT is used primarily with young children with emotional and behavioral disorders emphasizes the quality of the parent-child relationship and parent-child interaction patterns.¹⁴⁹

The third most commonly included named interventions (5 studies each) were the Positive Parenting Program (Triple P) and Multisystemic Therapy (MST). Triple P provides parenting and family support to prevent and treat behavioral and emotional problems in children and teenagers. The program uses a multilevel approach and draws on social learning, cognitive behavioral and developmental theory to teach parenting strategies to develop positive relationships, attitudes and conduct.¹⁵⁰ Multisystemic Therapy (MST) is family-based treatment approach for improving the antisocial behavior. MST is conducted in the youth's home, school, or community. The focus of MST is to teach parents how to be more effective at managing their child's activities and develop positive support systems.¹⁵¹

Brief Strategies Family Therapy (BSFT) was the active intervention in three included studies. BSFT is a short-term office-based model focused on the family to reduce mild to moderate behavior problems in adolescents.¹⁵²

The 34 remaining included studies did not include more than two studies of any other named intervention. Interventions such as Parent Management Training Oregon Model (PMTO), the Coping Power Program, Helping the Noncompliant Child, and the Stop Now and Plan Under 12 Outreach Project (SNAP Under 12) program are representative examples.

Following the qualitative summary of the literature for KQ1, we report the findings from a Bayesian multivariate, mixed treatment (network) meta-analysis of a subset of the KQ1 literature (28 of 66 studies) that met criteria for inclusion in this analysis (as described in Methods above). For the network meta-analysis, we classified the active psychosocial intervention arm, active treatment comparison arms (if applicable), and control arms as interventions including only a child component, interventions including only a parent component, multicomponent interventions (as defined above), or as a control arm (also as defined above).

Key Points for KQ1

Preschool Children

- A majority (17 of 23) of studies of psychosocial interventions for preschool-age children with disruptive behaviors assessed one of three programs: IY (n = 5); PCIT (n = 7); and Triple P (n = 5). The six other studies assessed each assessed a different intervention.
- We categorized 14 studies as examining an intervention with an active treatment arm with only a parent component and nine studies as examining multicomponent interventions. There were no studies in this age group examining an intervention with only a child component as the active treatment.

- In three of five studies assessing only the parent-training component of the IY intervention, outcomes on the ECBI and CBCL were significantly improved in the treatment versus control arms. Outcomes did not differ between groups in two studies.
- In all five studies assessing the Triple P intervention, outcomes on the ECBI were significantly improved in the treatment compared with the control arms.
- In all seven studies assessing PCIT, problem behavior outcomes were significantly improved in the treatment group compared with the control arms. In the two studies comparing adapted versions of PCIT, differences in effects of PCIT versions were not significant.

School-Age Children

- Of the studies that assessed psychosocial interventions for school-age children with disruptive behaviors, the active treatment arm was categorized as including only a child component in 1 study, 11 studies as only a parent component, and 17 studies as multicomponent.
- Five of the 11 interventions identified as including only a parent component examined the parent training program of the IY-PT intervention (n = 3) or PMTO (n = 2). The six other studies each assessed a different intervention.
- Studies assessing IY-PT or PMTO interventions consistently reported greater improvements in child disruptive behaviors in the treatment versus control arms.
- A majority (10 of 17) of the studies examining multicomponent interventions assessed more than one of the IY intervention components delivered together (n = 4), the Coping Power Program (n = 2), a modular intervention (n = 2), or SNAP Under 12 ORP (n = 2). The seven other studies each assessed a different intervention.
- The IY and SNAP Under 12 ORP interventions consistently resulted in greater improvements in child disruptive behaviors than controls.

Teenage Children

- Of the studies that assessed psychosocial interventions for teenagers with disruptive behaviors, the active treatment arm of one study was categorized as including only a child component and of 13 studies to assess multicomponent interventions.
- A majority (8 of 14) of the studies examined one of two interventions: MST (n = 5) and BSFT (n = 3).
- Four of the five studies assessing MST reported significantly greater reductions in child disruptive behaviors for the treatment versus control arms.
- Each of the three studies assessing BSFT reported significantly greater reductions in child disruptive behavior compared with the control arms.

Meta-Analysis

- Results from our Bayesian multivariate, mixed treatment (network) meta-analysis indicated that the probability of having the largest effect was the same for multicomponent interventions (43%) and interventions with only a parent component (43%), followed by interventions with only a child component (14%). All interventions categorized as multicomponent interventions included a parent component and at least one of a child, teacher, family together, or other component. Each of these intervention categories was associated with better outcomes than control arms.

Preschool Children

Description of Included Studies

We identified 23 studies^{87,93,95,98,99,102,107,109,112,114,119,127,129,133,135,138-141,145,153-155} represented in 31 publications^{87,93,95,98,99,102,107,109,112,119,127,129,133,135,138-141,145,153-163} that examined psychosocial interventions for preschool-age children with disruptive behaviors. Of the 23 included studies, 22 were RCTs (10 high, 10 moderate, and 2 low risk of bias)^{93,95,98,99,102,107,109,112,114,119,127,133,135,138-141,145,153-155,158} and one was a prospective nonrandomized controlled study (moderate risk of bias).⁸⁷ Studies were conducted in the United States (n = 9)^{93,95,98,99,102,107,109,112,114} and Australia (n = 9).^{133,135,140,141,145,153-155,164} We identified a single study conducted in one of each country: Canada,¹²⁷ Ireland,¹³⁸ Israel,¹¹⁹ the Netherlands,⁸⁷ and the United Kingdom.¹²⁹ Fourteen of the 23 included studies evaluated interventions including only a parent-component (Table 6). Nine of the 23 included studies evaluated multicomponent interventions. Each type of intervention is discussed separately below.

Table 6. Summary of interventions and risk of bias for studies of psychosocial interventions in preschool-age children with DBD

| Intervention | High Risk of Bias | Moderate Risk of Bias | Low Risk of Bias | All |
|-----------------------|-------------------|-----------------------|------------------|-----------|
| Parent Only | | | | 14 |
| IY-PT | 1 | 3 | 1 | 5 |
| Triple P | 2 | 3 | - | 5 |
| Other | 2 | 2 | - | 4 |
| Multicomponent | | | | 9 |
| PCIT | 3 | 3 | 1 | 7 |
| Other | 2 | - | - | 2 |
| Total | 10 | 11 | 2 | 23 |

IY-PT = Incredible Years-Parent Training; PCIT = Parent-Child Interaction Therapy; Triple P = Positive Parenting Program

Detailed Analysis

Interventions With Only a Parent Component

Of the 14 studies evaluating interventions with only a parent component for preschool-age children with disruptive behaviors, we identified five studies^{87,93,102,129,138} (reported in 8 publications)^{87,93,102,129,138,158,159,163} that examined the Incredible Years– Parent Training (IY-PT) program. We identified five studies of Triple P,^{135,139-141,145} and four RCTs that examined other interventions including only a parent component.^{95,119,127,155}

Incredible Years – Parent Training (IY-PT)

Four RCTs (1 high, 2 moderate, and 1 low risk of bias)^{93,102,129,138} and one prospective cohort study (moderate risk of bias)⁸⁷ evaluated a version of the IY-PT (Table 7). Of these, two RCTs^{129,138} and the prospective cohort study⁸⁷ evaluated the standard version of the IY-PT, one RCT⁹³ evaluated a brief version of the IY-PT, and one RCT (reported in 2 publications)^{102,159} evaluated a nurse-led or therapist-led version of the IY-PT.

Table 7. Summary of behavior outcomes from studies of a parent-only component (IY-PT) in preschool-age children

| Author, Year Design (Risk of Bias) Country: N Randomized | Groups | Behavior Measure | Between-Group Difference ^a |
|---------------------------------------------------------------------------------------------|------------------------------------------------------------|---------------------|-------------------------------------------------------|
| Perrin et al., 2013 ⁹³ RCT (Moderate) United States: 150 | G1: IY-PT G2: WLC | ECBI, Problem | G1 vs. G2: p<0.05 |
| | | ECBI, Intensity | G1 vs. G2: p<0.05 |
| Posthumus et al., 2012 ⁸⁷ NRCT (Moderate) Netherlands: 144 | G1: IY-PT G2: TAU | ECBI, Problem | G1 vs. G2: p=NS |
| | | ECBI, Intensity | G1 vs. G2: p=NS |
| Lavigne et al., 2008 ¹⁰² RCT (High) United States: 117 | G1: PT (Nurse-led) G2: PT (Psychologist-led) G3: MIT | ECBI, Intensity | G1 vs. G3: p=NS G2 vs. G3: p=NS G1 vs. G2: p=NS |
| | | CBCL, Externalizing | G1 vs. G3: p=NS G2 vs. G3: p=NS G1 vs. G2: p=NS |
| Hutchings et al., 2007 ¹²⁹ RCT (Moderate) United Kingdom: 153 | G1: IY-PT G2: WLC | ECBI, Intensity | G1 vs. G2: p<0.05 |
| | | ECBI, Problem | G1 vs. G2: p<0.05 |
| McGilloway et al., 2012 ¹³⁸ and 2014 ¹⁶³ RCT (Low) Ireland: 149 | G1: IY-PT G2: WLC | ECBI, Intensity | G1 vs. G2: p<0.001 |
| | | ECBI, Problem | G1 vs. G2: p<0.001 |

NRCT = nonrandomized controlled trial; RCT = randomized controlled trial; IY = Incredible Years; PT = parent training; MIT = minimal intervention therapy; WLC = waitlist control; TAU = treatment as usual; ECBI = Eyberg Child Behavior Inventory; CBCL = Child Behavior Checklist; NS = nonsignificant; G = group; N = number

^aThe between-group difference refers to the difference in the change from baseline to last followup between the intervention and comparison group. Effect favors G1 unless noted otherwise.

All three of the studies evaluating the IY-PT standard version measured child disruptive behaviors using the ECBI Problem scale.^{87,129,138,163} Two of these studies also used the ECBI Intensity scale and Dyadic Parent-Child Interaction Coding System-Revised (DPICS-R) as additional measures of child disruptive behaviors.^{87,138} One study used the Strengths and Difficulties Questionnaire (SDQ)¹³⁸ and one used the CBCL.^{102,159} Comparison groups included usual care (n = 1),⁸⁷ waitlist control group (n = 3),^{93,129,138} and a group led by a different provider or receiving no interventionist-led training (1 study reported in 2 publications).^{102,159} Timing of the final followup ranged from 3 months to 2 years post-intervention across studies. Table 7 summarizes key outcomes. Briefly, in three of the five studies, the groups receiving IY intervention had significantly improved behavioral outcomes compared with control arms. In one study comparing differing administration of the IY intervention and in comparing IY to usual care, ECBI outcomes did not differ significantly among groups.

The moderate risk of bias prospective cohort study⁸⁷ compared outcomes in 4-year old children [mean age: 4.2 (3.11)] scoring at or above the 80th percentile on the aggressive behavior scale of the CBCL to outcomes in children receiving usual care. Parents of children [n = 72, mean age: 50.3 (3.11) months, mean CBCL aggressive behavior raw score: 21.99 (4.37)] in the intervention group received 18 2-hour IY sessions (BASIC and ADVANCE) focusing on identifying strategies for dealing with child behaviors. Children in the control group [n = 72, mean age: 51.3 (2.53) months, CBCL aggressive behavior mean raw score: 22.49 (4.69)]

received usual care. Groups differed significantly at baseline on age (control group 2 months older than intervention group, $p=0.02$), observed use of critical statements by parents (intervention group parents more critical than control, $p=0.05$), and observed conduct problems (more conduct problem in intervention group vs. control, $p=0.004$). Children did not differ at baseline on parent-rated measures. At final followup (2 years post-intervention), groups did not differ significantly on the ECBI. In observer coding (DPICS-R) of interactions, parents in the intervention group used significantly fewer critical statements than in the control group, and conduct problems decreased significantly in the intervention group compared with the control arm.

One RCT (reported in 2 publications)^{129,158} compared an IY intervention delivered by center staff in social service centers for economically disadvantaged children in the United Kingdom with a waitlist control group. Children included in the study were seen at the centers and had ECBI Intensity scores of 127 or greater or problem scores of 11 or greater, and most had low socioeconomic status. Eighty-six of the 104 children randomized to the IY group [mean age: 46.4 (6.6) months] and 45 of the 47 randomized to the waitlist control group [mean age: 46.2 (4.2) months] completed the followup assessments at 6 months post-treatment. In intention-to-treat analyses, the outcomes on both ECBI scales (intensity scale effect size: 0.89, 95% CI: 0.54 to 1.24; problem scale effect size: 0.63, 95% CI: 0.28 to 0.98) and on the SDQ conduct problems (effect size: 0.33, 95% CI: -0.02 to 0.68) scale were significantly improved (p values <0.05) in the IY group compared with controls. Instances of deviant child behavior coded in observations were lower in the IY group but group differences were not significant (effect size: 0.21; 95% CI: -0.13 to 0.55). Scores on hyperactivity scales (Conners, SDQ) were also significantly lower in the IY group compared with control (p values <0.05), while scores on the SDQ overall deviance scale did not differ significantly between groups.

Another trial conducted in Irish community service centers enrolled 149 children between the ages of 32 and 88 months who were referred to health services organizations for problem behaviors and who scored above the clinical cut offs (127 for Intensity and 11 for problem scale) on a parent-rated ECBI.^{138,163} The IY intervention was delivered by center staff. Ninety-five of the 103 children randomized to the IY group and 42 of 45 in the waitlist control group completed followup final assessments approximately 3 months after the end of treatment. In intention-to-treat analyses, the IY group improved significantly on both ECBI scales (p values <0.001) compared with the control arm (ECBI Intensity effect size: 0.70; 95% CI: 0.4 to 1.1; ECBI Problem subscale effect size: 0.75; 95% CI: 0.4 to 1.1). Scores on measures of hyperactivity, prosocial behavior, and emotional well-being were also significantly improved in the IY arm compared with control (p values <0.01). Child problem behaviors coded in observations also decreased significantly in the IY arm versus the control arm (effect size: 1.07, 95% CI: 0.6 to 1.6), but observations of positive child behavior did not differ significantly between groups. Investigators conducted observations with a subset of children in both groups. Intention-to-treat analyses of the children originally randomized to the IY-PT group at 12-month post-treatment followup assessment demonstrated that treatment effects were maintained from 6-month followup (e.g., end of treatment) to 12-month followup, although effect sizes were nominally – but not statistically significantly – smaller.¹⁶³

A moderate risk of bias RCT⁹³ compared outcomes in three groups: an intervention group randomly allocated to 10 weeks of IY parent training [$n = 89$, mean age: 2.8 (0.61) years]; a non-randomly allocated group receiving the 10-week training [$n = 123$, mean age: 2.90 (0.63) years]; and a randomly allocated waitlist control group [$n = 61$, mean age: 2.7 (0.55) years].⁹³ All

children had Infant-Toddler Social Emotional Assessment Scale scores at or above the 80th percentile. Groups were similar at baseline; however, families in the non-random IY group included more minorities and were more likely to report lower socioeconomic status. Mean baseline T-scores on the ECBI Problem subscale ranged from 60.1 to 62.8 and from 58.3 to 59.2 on the ECBI Intensity scale. At the 12-month followup, outcomes on the ECBI Problem and Intensity subscales and the Parenting Scale were significantly improved in both the IY arms compared with the control group ($p < 0.05$). Mean decreases in negative parenting, child disruptive behaviors, and negative parent-child interaction coded on the DPICS-R were greater in the IY groups compared with the control group and did not differ significantly between the IY groups.

Another high risk of bias RCT evaluated outcomes following 6 to 12-week IY programs led by primary care nurses ($n = 49$ children) or by psychologists ($n = 37$ children) and among a group of children whose parents received the *Incredible Years* book but no specific interventionist-led training ($n = 31$ children).^{102,159} While the study enrolled 117 children, only 91 completed all assessments (77%). All children were between the ages of 3 and 6.11 years, and all had scores above the 90th percentile on the CBCL Externalizing scale and *DSM-IV* diagnoses of Oppositional Defiant Disorder (ODD). The mean baseline CBCL Externalizing score (SD) across groups was 70.7 (5.96) and mean ECBI Intensity score (SD) was 155.44 (27.41). Groups did not differ demographically or in comorbidities (27.4% with concomitant ADHD). At 12-months post-intervention, groups did not differ significantly on any ECBI or CBCL scale, though all groups improved from baseline. Scores on the ECBI were in the normal range for 23.1 percent of children across groups at followup and were in the normal range for 47.9 percent of children on the CBCL Externalizing scale. In equivalence testing, the combined interventionist-led groups and book-only group were equivalent at the 10 percent level (differing by $< 10\%$ at post-treatment and the 12-month followup) on both scales, as were the nurse-led and psychologist-led groups. In dose-effect analyses, effects on both scales improved with increasing training sessions attended.

Positive Parenting Program (Triple P)

Five RCTs (2 high and 3 moderate risk of bias) evaluated a version of Triple P.^{135,139-141,145} Two studies evaluated a self-directed version,^{139,141} two studies evaluated an enhanced version,^{135,140} and one study evaluated an online version (Table 8).¹⁴⁵ All RCTs of Triple P that met criteria for inclusion in this review were conducted in Australia, two in rural populations.

All five studies measured child disruptive behaviors with the ECBI Intensity and Problem subscales. Four of the five studies also used the Parent Daily Report (PDR),^{135,139-141} one study also used the SDQ,¹⁴⁵ and only one study measured one of our protocol-defined functional outcomes.¹⁴⁰ The only study to use direct observation¹⁴⁵ did not use this measure for all participants. Total comparison groups included waitlist control groups ($n = 4$) and usual care or self-directed treatment ($n = 2$). The duration of treatment ranged from 8 to 11 weekly sessions. Timing of last followup was 4 months post-intervention in one study,¹⁴¹ 6 months post-intervention in three studies^{135,139,145} and 1 and 3 years post-intervention in one.^{140,160,162} Table 8 summarizes key outcomes. Overall, ECBI outcomes and mean number of problem behaviors were improved in treatment arms compared with control.

Table 8. Summary of behavior outcomes from studies of a parent-only component (Triple P) in preschool-age children

| Author, Year Design (Risk of Bias) Country: N Randomized | Group | Behavior Measure | Between-Group Difference ^a |
|-----------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------|---------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Connell et al., 1997 ¹⁴¹ RCT (High) Australia: 24 | G1: Triple P (Self-directed family intervention) G2: WLC | ECBI, Intensity (mother report) | G1 vs. G2: p=0.0005 |
| | | ECBI, Intensity (father report) | G1 vs. G2: p=0.0005 |
| | | ECBI, Problem (mother report) | G1 vs. G2: p=0.0005 |
| | | ECBI, Problem (father report) | G1 vs. G2: p=0.0005 |
| Markie-Dadds et al., 2006 ¹³⁵ RCT (Moderate) Australia: 41 | G1: Triple P (Enhanced self-directed) G2: Triple P (Self-directed) G3: WLC | ECBI, Intensity | G1 vs. G3: p<0.001 G2 vs. G3: p<0.001 G1 vs. G2: p<0.01 |
| | | ECBI, Problem | G1 vs. G3: p<0.001 G2 vs. G3: p<0.001 G1 vs. G2: p<0.05 |
| Markie-Dadds et al., 2006 ¹³⁹ RCT (Moderate) Australia: 63 | G1: Triple P (Self-directed) G2: WLC | ECBI, Intensity | G1 vs. G2: p<0.01 |
| | | ECBI, Problem | G1 vs. G2: p<0.01 |
| Sanders et al., 2000 ¹⁴⁰ RCT (Moderate) Australia: 305 | G1: Triple P (Enhanced) G2: Triple P (Standard) G3: Triple P (Self-directed) G4: WLC | ECBI, Intensity (mother report) | G1 vs. G4: p<0.001 G2 vs. G4: p<0.001 G3 vs. G4: p<0.05 G1 vs. G3: p=NS G2 vs. G3: p=NS G1 vs. G2: p=NS |
| | | ECBI, Intensity (father report) | G1 vs. G4: p<0.01 G2 vs. G4: p<0.01 G3 vs. G4: p<0.01 G1 vs. G3: p=NS G2 vs. G3: p=NS G1 vs. G2: p=NS |
| Sanders et al., 2012 ¹⁴⁵ RCT (High) Australia: 116 | G1: Triple P (Online) G2: WLC | ECBI, Intensity | G1 vs. G2: p=0.000 |
| | | ECBI, Problem | G1 vs. G2: p=0.000 |

ECBI = Eyberg Child Behavior Inventory; RCT = randomized controlled trial; WLC = waitlist control; Triple P = Positive Parenting Program; N = number; G = group

^aThe between-group difference refers to the difference in the change from baseline to last followup between the intervention and comparison group. Effect favors G1 unless noted otherwise.

Note: Effect favors G1 unless noted otherwise.

One RCT comparing a 10-week, self-directed iteration of Triple P implemented by parents in rural areas of Australia to a waitlist control group reported improvements in behavioral outcomes in the intervention group [n = 12, mean age: 49.33 (14.05) months] compared with control [n = 11, mean age: 53.18 (11.26) months].¹⁴¹ Children were initially identified based on parent concern and interest in the study. Parents completed a *DSM-IV* diagnostic interview by phone to evaluate for the presence of ADHD (present in 5 intervention and 7 waitlist children), ODD (present in 8 intervention and 6 waitlist children), or conduct disorder (present in 1 treatment and 2 waitlist children). Intervention group parents received printed books and workbooks to work through each week and participated in weekly calls (mean duration of 20 minutes; range: 5 to 30 minutes) with a trained therapist to encourage problem-solving skills. At the end of the 10-week intervention, ECBI scores as rated by mothers and fathers were significantly improved in the intervention group compared with the control (p=0.0005). Mothers, but not fathers, also rated the number of problem behaviors as significantly improved (p=0.016) in the intervention group

compared with control. At post-treatment 33 percent of children in the intervention arm remained above the clinical cut-off (ECBI score=127) for disruptive behavior, compared with 100 percent remaining in the clinical range in the control arm. At followup of seven of 12 intervention groups 4 months after the end of intervention, post-treatment effects were maintained except for an increase in child problem behaviors that remained lower than the mean baseline level. At followup, three of seven children (43%) remained in the clinical range for disruptive behavior on the ECBI.

Another RCT in a rural population compared a similar self-directed version of Triple P plus weekly phone conferences [n = 14, mean age: 47.21 (10.19) months] with self-directed Triple P alone [n = 15, mean age: 47.27 (9.84) months] and with a waitlist control arm [n = 12, mean age: 46.17 (13.29) months].¹³⁵ Children had to have an ECBI Intensity score of ≥ 127 or problem score of ≥ 11 at baseline and parental concern about disruptive behavior. ECBI Problem and Intensity subscale scores and mean number of problem behaviors as rated by mothers were significantly improved in the treatment groups versus control, with significantly greater improvements in the self-directed plus phone arm compared with either other arm (all p values < 0.01). Father-rated measures were not significantly different among groups. At followup 6 months after the end of treatment, effects were maintained for the intervention plus phone group and the intervention alone group, with continuing mother-reported improvements in the level of disruptive behaviors in the latter group. Almost 70 percent (69%, n = 9) of the intervention plus phone group and 57 percent (n = 8) of the intervention alone group showed reliable change on the ECBI Intensity scale at the 6-month followup.

Another RCT of self-directed Triple P [n = 32 at baseline, mean age: 42.91 (9.16) months] compared with a waitlist condition [n = 31 at baseline, mean age: 43.26 (9.10) months] reported similarly improved outcomes after the 10-week intervention in the treatment arm.¹³⁹ Children had to have ECBI Intensity scores of ≥ 127 or problem score of ≥ 11 at baseline and parental concern about disruptive behavior. Scores on the ECBI Intensity and problem scales and the mean number of problem behaviors reported by parents were significantly improved in the treatment group (n = 21 at analysis) compared with control (n = 22 at analysis) at post-treatment (all p values < 0.01 ; significance maintained in intention-to-treat analyses). At followup of 13 children in the intervention group 6 months after the end of treatment, improvements in child behavior were maintained, and 23 percent of children (3/13) showed clinically reliable behavioral improvements.

One RCT (reported in multiple publications) evaluated three variations of Triple P in 3-year old children compared with a waitlist control group (n = 77): self-directed alone (n = 75); self-directed plus 10 hours of therapist-led skills training with observation and feedback (n = 77); and self-directed plus 14 hours of skills training that included training in partner support and observation and feedback (n = 76).^{140,160,162} Families included in the study had at least one indicator of “family adversity,” which included maternal depression, low socioeconomic status or low occupational prestige, relationship conflict, or single parent family, and all children [mean age: 3.4 (3.66)] scored in the clinical range on the ECBI Intensity (≥ 127) or problem (≥ 11) scales. Attrition over the course of the intervention was significant, with 30 percent (66/228) not completing either the post-intervention or 1-year followup assessments. Analyses of attrition indicated that negative affect ratings were higher among parents who did not complete the intervention and that mothers who did not complete the intervention were more likely to rate child behavior negatively. At followup after 15 weeks of intervention, children in the Triple P plus 14-hour training condition had improved outcomes on the ECBI compared with children in

the waitlist or self-directed alone conditions. Fathers of children in either of the conditions that included additional training reported fewer behavior problems compared with fathers of children in the waitlist arm. Fewer negative child behaviors were recorded in observations in both the additional training arms compared with the waitlist control (p values <0.05) in the 14-hour training arm compared with the self-directed arm ($p < 0.05$). At the 12-month post-treatment followup, improvements in child behavior were maintained in the arms with additional training, but differences were not significant. Forty children in the 14-hour training arm, 56 in the 10-hour training arm, 32 in the self-directed only arm, and 21 in the waitlist arm had moved from the clinical range for disruptive behavior to the typical range on the ECBI (differences between all treatment groups and waitlist group significant at $p < 0.01$; differences between the 14-hour and self-directed group significant at $p < 0.05$; differences between the 10-hour arm and self-directed and 14-hour and 10-hour arm not significant). In a followup of 139 participants 3 years after the end of intervention,¹⁶⁰ children continued to improve on measures of problem behavior from baseline but differences among groups were not significant, nor were the numbers of children who met diagnostic criteria for disruptive behavior disorders (range 23.4 to 32% with DBD diagnoses across treatment groups). Teacher ratings of behavior problems also did not differ among groups, and all ratings were in the non-clinical range.

A sub-analysis of 87 children with ADHD included in this RCT¹⁶² assigned to the 14-hour training arm ($n = 26$), the 10-hour arm ($n = 29$), or the waiting list ($n = 32$) had similar outcomes to those in the larger group, with significantly improved behaviors rated on the ECBI in children in the treatment arms compared with control at post-intervention. The mean number of problem behaviors was similarly lower in the treatment arms (all p values < 0.05), and differences between the two treatment arms were not significant. Effects were maintained at the 1-year followup with no significant differences between treatment arms. At least 60 percent of children in each treatment arm met criteria for reliable change on the ECBI ($p = NS$) at the 1-year followup.

Finally, one RCT compared an online version of Triple P ($n = 60$) with internet use as usual ($n = 56$) among parents of children ages 2 to 9 [mean: 4.7 (1.76)] years with elevated ECBI scores.¹⁴⁵ As in the other studies of Triple P, problem behaviors on the ECBI were significantly reduced in the intervention group compared with control at the 6-month followup (ECBI Problem subscale effect size: 0.60; ECBI Intensity subscale effect size: 0.74). Overall SDQ ratings were not significantly different between groups, nor were observed child disruptive behaviors (effect size: 0.14). At least 60 percent of children in the treatment arms were considered clinically improved on the ECBI Problem (60%, $n = 34/57$) and Intensity subscales (65%, $n = 34/52$) at the post-treatment assessment compared with 29 ($n = 14/49$) and 17 ($n = 8/46$) percent in the control group ($p = 0.001$).

Other Interventions With Only a Parent Component

Four RCTs conducted in the United States (high risk of bias),⁹⁵ Canada (high risk of bias),¹²⁷ Israel (moderate risk of bias),¹¹⁹ and Australia (moderate risk of bias)¹⁵⁵ examined other interventions including only a parent component (Table 9).^{95,119,127,155} All interventions targeted parent behaviors related to communication and discipline. One study incorporated technology to enhance the Helping the Noncompliant Child intervention,⁹⁵ one adapted parent-training modalities,¹¹⁹ one evaluated Supportive Expressive Therapy-Parent Child model,¹²⁷ and one randomized children to group program for parents called Tuning into Kids (TIK).¹⁵⁵ Comparison groups included IY parent training, minimal intervention, standard, non-enhanced care, and treatment as usual. The final followup occurred at 6 months in one study,¹⁵⁵ 12 months after the end of intervention in two studies,^{119,127} and was not clearly reported in one.⁹⁵

Table 9. Summary of behavior outcomes from studies of a parent-only component (other) in preschool-age children

| Author, Year Design (Risk of Bias) Country: N Randomized | Groups | Behavior Measure | Between-Group Difference ^a |
|---------------------------------------------------------------------------|-------------------------------------------------------------------|---------------------|------------------------------------------|
| Jones et al, 2013 ⁹⁵ RCT (High) United States: 22 | G1: HNC (technology enhanced) G2: HNC (standard) | ECBI, Problem | G1 vs. G2: 95% CI: -0.51 to 1.56 |
| | | ECBI, Intensity | G1 vs. G2: 95% CI: -0.13 to 2.05 |
| Somech et al., 2012 ¹¹⁹ RCT (Moderate) Israel: 209 | G1: PT G2: WLC | ECBI, Intensity | G1 vs. G2: p<0.001 |
| Cummings et al., 2008 ¹²⁷ RCT (High) Canada: 54 | G1: SET-PC G2: IY-PT | ECBI, Intensity | G1 vs. G2: p=NS |
| | | CBCL, Externalizing | G1 vs. G2: p=NS |
| Havighurst et al., 2013 ¹⁵⁵ RCT (Moderate) Australia: 63 | G1: TIK G2: TAU | ECBI, Problem | G1 vs. G2: p=NS |
| | | ECBI, Intensity | G1 vs. G2: p=NS |

CBCL = Child Behavior Checklist; ECBI = Eyberg Child Behavior Inventory; G = group; HNC = Helping the Noncompliant Child; IY = Incredible Years; N = number; NS = nonsignificant; PT = parent training; RCT = randomized controlled trial; SET-PC = Supportive Expressive Therapy-Parent Child; TIK = Tuning into Kids

^aThe between-group difference refers to the difference in the change from baseline to last followup between the intervention and comparison group. Effect favors G1 unless noted otherwise.

One RCT compared the standard, clinic-based Helping the Noncompliant Child program [n = 8, mean age: 5.75 (2.12) years], which emphasizes parental attention and positive parent-child communication and relationships, with a technology-enhanced version [n = 7, mean age: 5.57 (1.27) years] that included the standard clinic-based training plus smartphones to watch video training, complete skill surveys, and to record interactions for feedback.⁹⁵ Both groups were lower income and had ECBI scores in the clinical range (127 on the intensity scale or 11 on the problem scale), with higher intensity scores in the enhanced intervention group compared with standard intervention [148.86 (22.51) vs. 131.5 (2.87), p=NR]. At the end of intervention (timing of followup after the 8-10 intervention sessions per group not clear), scores on the ECBI Intensity and Problem scales favored the enhanced group versus the standard intervention group with between-group effect sizes of 0.99 (95% CI: -0.13 to 2.05) for intensity and 0.54 (95% CI: -0.51 to 1.56) for the problem scale. Pre-post effect sizes for each group were more than 1.0, and post-scores on both ECBI scales were in the normative range for children in the technology-enhanced arm. Post-scores on the ECBI Intensity scale, but not the problem scale, were in the normative range for the standard treatment group.

Another RCT evaluated an intervention program (Hitkashrut) combining elements of parent training models including parental self-regulation, involvement of fathers, parent-child communication skills, and behavior management compared with undefined minimal intervention.¹¹⁹ Children were eligible for the study if they scored in the clinical or sub-clinical range on a teacher-rated SDQ. Behavior outcomes on the ECBI for children in the treatment arm (n = 140, mean age: 48.51 (7.35) months) were significantly improved (p<0.001, effect size: 0.76) at 1 month post-intervention compared with the control arm [n = 69, mean age: 48.62 (6.59) months]. At followup of 60 percent of participants (96 in intervention group, 29 in control) 1-year post-intervention, conduct problems were significantly reduced from baseline in the Hitkashrut arm (p<0.001) but not in the control group. The odds of reliable improvement in conduct problems were higher in children in the treatment arm than for those in the control arm

(OR=5.09; 95% CI: 2.14 to 12.11) as were the odds of greater improvement in conduct problems from baseline (OR=3.24; 95% CI: 1.30 to 8.02).

One RCT compared the Supportive Expressive Therapy – Parent Child model (n = 27) to the IY-PT program (n = 27).¹²⁷ Supportive Expressive Therapy entails recognizing and adapting dysfunctional parent responses and expectations for child behavior. Both interventions were conducted among children [mean age: 4.2 (0.96)] referred to an outpatient clinic for externalizing behavior disorders, and groups differed at baseline with significantly greater ECBI and CBCL-rated disruptive behaviors in the IY group compared with control (p=0.013). Outcomes at post-intervention among the 18 treatment group completers and 19 IY completers were improved from baseline in both groups with no significant group differences and mean within-groups effect sizes of 0.66 (0.65) and 1.06 (1.57), respectively (p=NS). Observed child negative behaviors decreased over time in both groups, but group differences were not significant. Seven children in the Supportive Expressive Therapy group and 10 in the IY group no longer met the cut-off for disruptive behaviors in the ECBI or CBCL (exact cut-off used not reported) at post-intervention (p=NS). Improvements in outcomes were maintained at the 1-year followup with no group differences. Eight children in the Supportive Expressive Therapy group and six in the IY group were functioning in the normative range at the 1-year followup (p=NS).

Lastly, one moderate risk of bias RCT compared Tuning into Kids (TIK), described as a 6-week long group program for parents of preschool children, against waitlist clinical treatment as usual control.¹⁵⁵ The study sample included 54 children (78% boys) with a mean age of 59.31 (7.38) months. All children had elevated scores on the parent-reported ECBI Intensity score at baseline, with a mean Intensity Score of 169.34 (2.99) in the intervention group and 165.99 (28.82) in the control group. At end of treatment, scores in both groups decreased to 141.26 (23.79) and 157.46 (31.30) for the intervention and TAU groups, respectively (although the group-by-time interaction was not statistically significant). Similar results were reported for the ECBI Problem score [intervention baseline: 23.14 (5.51), end of treatment: 16.86 (6.66); TAU group baseline: 21.00 (8.26), end of treatment: 20.27 (9.04)]. Teacher-rated behavior intensity and problems via the Sutter-Eyberg Student Behavior Inventory were not measured at the end of treatment. At 6-month followup and with two booster sessions after the initial 6-week intervention, mean parent-rated behavior intensity was 148.61 (32.25) and 148.69 (30.36) and behavior problems was 15.57 (9.44) and 16.25 (9.09) for the intervention and control groups, respectively. At 6-month followup, the mean teacher-rated behavior intensity were 101.12 (35.57) and 137.11 (55.39) and behavior problems were 3.94 (6.50) and 10.12 (9.78), for intervention and treatment as usual groups, respectively. The group-by-time interaction was not reported.

Multicomponent Interventions

Of the nine studies evaluating multicomponent interventions for preschool-age children with disruptive behaviors, seven examined PCIT^{98,99,109,112,114,133,153} and two studies examined another multicomponent intervention.^{107,154}

Parent Child Interaction Therapy (PCIT)

Seven RCTs (reported in 10 publications)^{98,99,109,112,114,133,153,156,157,161} evaluated a version of PCIT (Table 10). PCIT focuses on improving parent-child interactions to improve disruptive behaviors and combines child-directed play therapy and parent training in behavior management. Studies were conducted in the United States^{98,99,109,112,114,156,157} and Australia.^{133,153,161} Five studies (3 high and 2 moderate risk of bias) evaluated a standard version of

PCIT.^{98,109,112,114,153,156} One low risk of bias study evaluated a culturally modified version,^{99,157} and one study (moderate risk of bias) evaluated an abbreviated version.^{133,161} Comparison groups included treatment as usual, waitlist control, and alternate versions of PCIT. All of the RCTs measured child disruptive behaviors with the ECBI Intensity subscale and five used a version of the DPICS observation coding system. Five of seven studies also used the ECBI Problem subscale,^{98,99,109,112,114} and three of the seven studies used the CBCL externalizing scale.^{98,99,157} Last followup after the end of treatment ranged from 4 months to a mean of 15.90 months.

Table 10. Summary of behavior outcomes from studies of multicomponent intervention (PCIT) in preschool-age children

| Author, Year Design (Risk of Bias) Country: N Randomized | Groups | Behavior Measure | Between-Group Difference ^a |
|------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|---------------------------------|---------------------------------------------------------------------------------|
| Bagner et al., 2010 ⁹⁸ RCT (High) United States: 28 | G1: PCIT G2: WLC | ECBI, Problem | G1 vs. G2: p=0.000 |
| | | ECBI, Intensity | G1 vs. G2: p=0.000 |
| | | CBCL, Externalizing | G1 vs. G2: p=0.000 |
| | | CBCL, Aggressive behavior | G1 vs. G2: p=0.000 |
| McCabe et al., 2009 ⁹⁹ RCT (Low) United States: 58 | G1: PCIT (standard) G2: PCIT (culturally adapted) G3: TAU | ECBI, Problem | G1, G2 vs. G3: p=NR |
| | | ECBI, Intensity | G1, G2 vs. G3: p=NR |
| | | CBCL, Externalizing | G1, G2 vs. G3: p=NR |
| Nixon et al., 2003 ¹³³ RCT (Moderate) Australia: 54 | G1: PCIT (standard) G2: PCIT (abbreviated) G3: WLC | ECBI, Intensity (mother report) | G1 vs. G3: p<0.01 G2 vs. G3: p<0.001 G1 vs. G2: p=NS |
| | | ECBI, Intensity (father report) | G1 vs. G3: p=NS G2 vs. G3: p<0.05 G1 vs. G2: p=NS |
| | | CBCL, Externalizing | G1 vs. G3: p=NS G2 vs. G3: p=NS G1 vs. G2: p=NS |
| Schuhmann et al., 1998 ¹⁰⁹ RCT (Moderate) United States: 64 | G1: PCIT (Immediate treatment) G2: WLC | ECBI, Problem (mother report) | G1 vs. G2: p<0.01 |
| | | ECBI, Problem (father report) | G1 vs. G2: p=NS |
| | | ECBI, Intensity (mother report) | G1 vs. G2: p<0.01 |
| | | ECBI, Intensity (father report) | G1 vs. G2: p<0.05 |
| Eyberg et al., 1995 ¹¹² RCT (High) United States: 50 | G1: PCIT (Immediate treatment) G2: WLC | ECBI, Problem (mother report) | G1 vs. G2: p<0.00 |
| | | ECBI, Intensity (mother report) | G1 vs. G2: p<0.02 |
| Nixon et al., 2001 ¹⁵³ RCT (High) Australia: 34 | G1: PCIT G2: WLC | ECBI, Intensity | G1 vs. G2: p<0.01 |
| Brestan et al., 1997 ¹¹⁴ RCT (Moderate) United States: 30 | G1: PCIT G2: WLC | ECBI, Problem (mother report) | G1 vs. G2: p=0.0001 |
| | | ECBI, Intensity (mother report) | G1 vs. G2: p=0.0001 |
| | | ECBI, Problem (father report) | G1 vs. G2: p=0.045 |
| | | ECBI, Intensity (father report) | G1 vs. G2: p=0.02 |

ECBI = Eyberg Child Behavior Inventory; RCT = randomized controlled trial; CBCL = Child Behavior Checklist; G = group; N = number; NS = nonsignificant; WLC = waitlist control; PCIT = Parent Child Interaction Therapy; TAU = treatment as usual
^aThe between-group difference refers to the difference in the change from baseline to last followup between the intervention and comparison group. Effect favors G1 unless noted otherwise.

Five RCTs (3 high and 2 moderate risk of bias) compared standard PCIT intervention with a waitlist control group.^{98,109,112,153} The first RCT assessed outcomes in children born premature and exhibiting externalizing behavior problems.^{98,156} Most children were referred to the study by clinical personnel (6% were self-referrals by mothers), and children had to score above the clinically significant range on the CBCL (T-score ≥ 60) to participate. Fourteen children were randomized to immediate PCIT [mean age: 39.7 (14.2) months] and 14 to the waitlist [mean age: 36.5 (13.0) months]. At the end of treatment assessment (4 months), CBCL and ECBI scores were significantly improved for the PCIT group compared with control ($p < 0.01$). Changes were considered clinically significant (meeting magnitude for reliable change and CBCL T-score < 60) in all children in the PCIT group ($n = 11$ at end of treatment), and in four of 14 children in the waitlist arm. At followup of 10 children in the PCT group 8 months after treatment, eight children maintained clinically significant changes and nine demonstrated continued improvement in behaviors from baseline to the final followup.

Another high risk of bias RCT assessed standard PCIT therapy ($n = 37$ families) compared with a waitlist control group ($n = 27$ families) in children with ODD [mean age: 59.2 (12.4) months].¹⁰⁹ Sixty-six percent of the children in the study had concomitant ADHD and 22 percent had conduct disorder. Groups differed at baseline on parental IQ, with higher maternal and paternal IQs among parents in the PCIT group compared with control ($p < 0.05$). At the end of intervention (mean 13 sessions over 4 months), scores on the ECBI Intensity and ECBI Problem scales were significantly improved among the 22 families remaining in the PCIT group compared with the 20 remaining in the control group ($p < 0.05$). At 4 months after the end of intervention treatment gains in the PCIT group were maintained, but the study did not assess within- or between-group differences. An earlier paper¹¹² reporting preliminary data on 50 of the 64 families described in the aforementioned paper¹⁰⁹ also reported greater improvement in the PCIT group as compared to the waitlist control group on both ECBI scales.

A high risk of bias RCT conducted in Australia randomized families to PCIT or waitlist control.¹⁵³ The study sample consisted of 34 children with a mean age of 46.52 (6.83) months in the PCIT group and 46.76 (7.50) months in the waitlist control group. Children met diagnostic criteria for ODD and had a disruptive behavior for at least 6 months. Parents were self-referred to participate. Authors reported pre- and post-intervention symptoms measured by ECBI Intensity scale for the PCIT and waitlist control groups and 6-month post-treatment effects for the PCIT group. The mean ECBI Intensity scores from baseline to end of treatment decreased in both the PCIT [baseline: 166.58 (18.93), end of treatment: 125.24 (21.67)] and waitlist control groups [baseline: 173.82 (22.72), end of treatment = 148.35 (19.05)]. Importantly, the mean scores for the PCIT group were in the normal range at end of treatment but the waitlist control group was not (and the difference was statistically significant).

One moderate risk of bias RCT compared children assigned to receive PCIT or to a waitlist control group. The study sample consisted of 30 children with a mean age of 4.53 (0.90) years. Mother ratings from baseline to end of treatment showed greater decrease on the ECBI Intensity scale for the PCIT group [baseline mean: 173(29.5), end of treatment mean: 133(37.7)] as compared to the waitlist control group [baseline mean: 176 (30.2), end of treatment mean: 170 (36.0)] and the ECBI Problem scale [PCIT baseline mean: 23 (5.8), end of treatment mean: 11 (10.7); WLC baseline mean: 25 (5.4), end of treatment mean: 24 (7.5)]. Similar results are reported for the ECBI problem scale. Two RCTs reported on adapted versions of PCIT—one culturally adapted for Mexican-American children (low risk of bias)^{99,157} and one adapted to include self-directed methods to abbreviate treatment (moderate risk of bias).^{133,161} The first RCT

compared three conditions: standard PCIT [$n = 19$, mean age: 48.9 (92) months]; PCIT culturally adapted for Mexican-Americans by using cultural references and representations [$n = 21$; mean age (SD): 54.3(11.6 months)]; and treatment as usual, which included cognitive-behavioral therapy (CBT) and family therapy [$n = 18$, mean age: 55.1 (15.3) months].^{99,157} Children included in the study were being treated for behavior problems and had a score above the ECBI clinical cut point (more than 127 on Intensity or more than 11 on Problems scale). Overall, 57 percent of families ($n = 33$) completed the full course of treatment, and 93 percent ($n = 54$) completed the post-treatment assessments. At the immediate post-treatment assessment, problem behaviors measured on the ECBI and CBCL were significantly reduced in both the PCIT groups compared with treatment-as-usual, but differences between the PCIT arms were not significant. Children improved on the ECBI from baseline in all three groups (ECBI Intensity scale post-treatment effect sizes: 3.38 in adapted PCIT, 2.14 in PCIT, and 1.78 in control; ECBI Problem scale effect size: 2.84 for adapted PCIT, 1.96 for PCIT, and 1.78 for control). Effect sizes at post-treatment on the CBCL were similarly greater than 1 in the PCIT groups and 0.83 in the control group. Outcomes on observational measures of parent and child-led play and compliance were similarly significantly improved in the PCIT groups compared with control, but no different between PCIT arms. Immediately post-treatment, children in the PCIT groups were below the normative mean for behavior problems on the ECBI Intensity scale and CBCL Externalizing scale, and control children were below the clinical cut-offs. At long-term followup of an unstated number of participants at a mean of 15.90 (4.25) and range 6.58 to 24.47 months after the end of treatment, improvements in problem behaviors were largely maintained, with effect sizes on ECBI and CBCL scales ranging from 0.88 to 3.27 across groups and the largest effect sizes in the adapted PCIT group. Differences between groups were not significant in corrected comparisons at long-term followup, although in uncorrected comparisons, behavior outcomes in the adapted PCIT arm were significantly improved compared with the control arm and did not differ from the standard PCIT group.

The second RCT (moderate risk of bias) compared standard PCIT ($n = 17$ at analysis); an abbreviated version incorporating videotaped trainings ($n = 20$ at analysis); and a waitlist control group ($n = 17$ at analysis) in 54 children with a mean age of 46.75 (6.63) months.^{133,161} Children in the study had to score in the clinical range (≥ 132) on the ECBI Intensity scale, meet *DSM-IV* criteria for ODD, and have been referred for treatment for disruptive behaviors of 6 months or longer duration. The standard PCIT intervention was delivered over 15.5 hours while the abbreviated version was delivered in 9.5 hours. Immediately post-treatment, mother-rated ECBI scores were significantly reduced in both PCIT arms (with no significant differences between the PCIT groups) compared with the waitlist control group ($p < 0.01$). Mothers in the standard PCIT arm also rated problem behaviors in the home as significantly reduced post-treatment compared with the waitlist ($p < 0.05$), but such differences were not seen in the abbreviated PCIT arm. Differences were only significant for father-reported ECBI scores between the abbreviated PCIT arm and the waitlist ($p < 0.05$). Group differences on the CBCL were not significant, nor were reports of observations of child problem behaviors. In corrected comparisons, however, no comparisons of parent-rated measures were significant. Treatment gains were maintained at 6-month and 12-month post-treatment followup, with no significant differences between the PCIT groups. At a final, 2-year followup of 10 children in the standard PCIT group and an unstated number in the abbreviated group, group differences continued to be nonsignificant, and mean ECBI scores for all children were in the non-clinical range (mother-rated ECBI effect size: -0.24 ; father-rated ECBI effects size: -0.21). Fifty-six percent of children in the standard PCIT

arm and 68 percent in the abbreviated group continued to meet criteria for ODD, and 67 to 70 percent in each arm met reliable change criteria for reduction in mother-rated oppositional behavior (group differences not significant).

Other Multicomponent Interventions

Two RCTs (both high risk of bias)^{107,154} evaluated a multicomponent intervention for the treatment of disruptive behavior in preschool-age children (Table 11).

Table 11. Summary of behavior outcomes in studies of other multicomponent interventions in preschool-age children

| Author, Year Design (Risk of Bias) Country: N Randomized | Groups | Behavior Measure | Between-Group Difference ^a |
|-------------------------------------------------------------------------|---------------------------|---------------------|---------------------------------------|
| Jouriles et al., 2001 ¹⁰⁷ RCT (High) United States: 36 | G1: MFT G2: Comparison | CBCL, Externalizing | G1 vs. G2: p<0.05 |
| Sanders et al., 2000 ¹⁵⁴ RCT (High) Australia: 47 | G1: CBFI G2: BFI | CBCL, Total | G1 vs. G2: p=NS |

BFI = behavioral family therapy intervention; CBCL = child behavior checklist; CBFI = cognitive behavior and behavioral family therapy intervention; G = group; MFT = Multigroup family therapy; NS = nonsignificant; RCT = randomized controlled trial

^aThe between-group difference refers to the difference in the change from baseline to last followup between the intervention and comparison group. Effect favors G1 unless noted otherwise.

One multicomponent intervention RCT¹⁰⁷ evaluated child and maternal outcomes at five time points across 16 months for multiple child and parental interventions. Study participants were 36 children [mean age: 5.67 (1.88) years] with a DSM diagnosis of ODD or conduct disorder whose mothers had sought refuge in a battered women’s shelter. Investigators randomly assigned mother-child subject pairs to the intervention group, which received weekly sessions following discharge from a women’s shelter and continuing for 8 months. Children and mothers in the intervention group received individualized counseling; mothers also received training in child management skills. Comparison mother-child subject pairs were encouraged through monthly meetings or phone calls to use existing community or shelter services. Groups were similar at baseline for demographic variables and screening measures. Mean CBCL Externalizing scale score at baseline was 66.28 (10.00) in the treatment group compared with 65.56 (9.13) in the comparison group. The treatment group demonstrated a greater rate of decrease in parent reported disruptive behaviors at the third assessment. CBCL score differences between groups were not significant, but the rate of improvement of problems was greater among children in the intervention group compared with the control group. At the fifth assessment (ending the 16-months) the mean CBCL Externalizing scale score was 49.79 (9.17) in the treatment group and 58.59 (13.62) in the comparison group (p=NR). Children in the intervention group (n = NR) moved into the normative range [i.e., less than one standard deviation above the mean CBCL Externalizing T-score for normative group of 50 (10)] on the CBCL Externalizing scale. Control children remained in the clinical range. By the final assessment, 3 of 18 children in the intervention group and 8 of 18 in the control group (p<0.05) had externalizing problems at clinical levels (vs. 13/18 in each group at baseline).

In a second RCT,¹⁵⁴ parents were randomized to behavioral family therapy intervention (BFI) or an enhanced group receiving cognitive therapy in addition to the family behavior therapy

intervention (CBFI). Both interventions are described as involving both parents and children, although parents are also described as the primary focus of each intervention. Both interventions include teaching a range of positive parenting techniques and strategies for managing misbehavior. The CBFI intervention also includes cognitive therapy components to treat maternal depression. The study sample included 47 families (mean age of children at intake: 4.39 years). All children were diagnosed with either conduct disorder or ODD either alone or in combination with ADHD. There were no significant group-by-time interactions for any parent-reported (CBCL, PDR) or observational measure (Family Observation Schedule), although significant main effects for time were reported for parent reports of child disruptive behavior via CBCL and PDR measures.

Summary of Key Disruptive Behavior Outcomes

We report the behavior outcomes measured by ECBI (Table 12) and CBCL (Table 13) from studies of preschool-age children.

Table 12. Summary of behavior outcomes reported by ECBI for preschool-age participants

| Author (Year) Study Design (Risk of Bias) | Groups Analyzed (N) | Scale | Baseline Mean (SD) | Last Followup Mean (SD) | Between-Group Difference ^a |
|---------------------------------------------------------|----------------------------------------------------------------------------------------------------------|-------------------------------------------|-------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|--------------------------------------------------|
| Bagner et al., 2010 ⁹⁸ RCT (High) | G1: PCIT (11) G2: WLC (14) | ECBI, Problem | G1: 61.8 (9.3) G2: 65.1 (7.9) | 4 months post-baseline G1: 45.6 (5.5) G2: 61.1 (10.8) | p=0.000 |
| | | ECBI, Intensity | G1: 63.4 (12.2) G2: 64.1 (8.1) | 4 months post-baseline G1: 43.0 (4.3) G2: 64.6 (9.5) | p=0.000 |
| Nixon et al., 2003 ¹³³ RCT (Moderate) | G1: PCIT (Standard) (17) G2: PCIT (Abbreviated) (20) G3: WLC (NA) | ECBI, Intensity, (mother report) | G1: 166.6 (18.9) G2: 156.3 (16.8) G3: 173.8 (22.7) | 6 months post-intervention G1: 117.5 (31.7) G2: 126.1 (18.0) G3: NA | p=NS |
| | | ECBI, Intensity, (father report) | G1: 148.3 (24.5) G2: 139.1 (23.2) G3: 147.5 (26.0) | 6 months post-intervention G1: 120.8 (23.7) G2: 115.5 (21.3) G3: NA | p=NS |
| Perrin et al., 2013 ⁹³ RCT (Moderate) | G1: IY-PT (89) G2: WLC (61) | ECBI, Problem | G1: 60.3 (NR) G2: 60.7 (NR) | 12 months post- intervention G1: 51.7 (NR) G2: 59.7 (NR) | -0.6 (95% CI: -0.95 to -0.2), p<0.05 |
| | | ECBI, Intensity | G1: 58.9 (NR) G2: 59 (NR) | 12 months post- intervention G1: 54.8 (NR) G2: 58.8 (NR) | ES= -0.43 (95% CI: -0.79 to -0.07), p<0.05 |
| Jones et al, 2013 ⁹⁵ RCT (High) | G1: HNC (technology enhanced) (7) G2: HNC (standard) (8) | ECBI, Problem | G1: 22.6 (5.2) G2: 20.5 (4.8) | 2 weeks post-intervention G1: 6.14 (5.7) G2: 8.88 (8.2) | ES=0.54 (95% CI: -0.5 to 1.6), p=NS |
| | | ECBI, Intensity | G1: 148.9 (22.5) G2: 131.5 (23.9) | 2 weeks post-intervention G1: 83 (15.3) G2: 91.6 (21.3) | ES=0.99 (95% CI: -0.1 to 2.1), p=NS |
| Somech et al., 2012 ¹¹⁹ RCT (Moderate) | G1: PT (96) G2: WLC (29) | ECBI, Intensity | G1: 87.9 (10.5) G2: 88.3 (13.3) | 12 months G1: 79.8 (12.0) G2: 86.7 (17.0) | OR=3.24 (95% CI: 1.3 to 8.02) |

Table 12. Summary of behavior outcomes reported by ECBI for preschool-age participants (continued)

| Author (Year) Study Design (Risk of Bias) | Groups Analyzed (N) | Scale | Baseline Mean (SD) | Last Followup Mean (SD) | Between-Group Difference ^a |
|----------------------------------------------------|--------------------------------------------------------------------------------------------------|---------------------------|--------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|---------------------------------------|
| Cummings et al., 2008 ¹²⁷ RCT (High) | G1: SET-PC (16) G2: IYPP (16) | ECBI, Intensity (T-score) | G1: 62.5 (4.6) G2: 67.5 (6.7) | 12 months post-intervention G1: 59.2 (6.6) G2: 59.5 (9.1) | p=NS |
| Lavigne et al., 2008 ¹⁰² RCT (High) | G1: PT (Nurse- led) (33) G2: PT (Psychologist- led) (33) G3: MIT (33) | ECBI, Intensity | G1 + G2 + G3: 155.4 (27.4) | 12 months post-intervention (<i>reported as change from baseline</i>) G1: 17.2 G2: 28.6 G3: 19.1 | p=NS |
| Nixon et al., 2014 ¹⁵³ RCT (High) | G1: PCIT (17) G2: WLC (17) | ECBI, Intensity | G1: 166.58 (18.93) G2: 173.82 (22.72) | 6 month post-intervention G1: 117.47 (31.69) G2: NA | NR |

BL = baseline; CI = confidence interval; ECBI = Eyberg Child Behavior Inventory; ES = effect size; G = group; IYPP = Incredible Years Parenting Program; IY-PT = Incredible Years Parent Training; MIT = minimal intervention; PT = parent training; N = number; NA = not applicable; NR = not reported; NS = not significant; OR = odds ratio; PCIT = Parent Child Interaction Therapy RCT = randomized controlled trial; SD = standard deviation; SET-PC = Supportive Expressive Therapy-Parent Child; WLC = waitlist control; TE-HNC = Technology Enhanced Helping the Noncompliant Child
^aThe between-group difference refers to the difference in the change from baseline to last followup between the intervention and comparison group. Effect favors G1 unless noted otherwise.

Table 13. Summary of behavior outcomes reported by CBCL for preschool-age participants

| Author, Year Design (Risk of Bias) | Groups Analyzed (N) | Scale | Baseline Mean (SD) | Last Followup Mean (SD) | Between-Group Difference ^a |
|----------------------------------------------------|----------------------------------------------------------------------------------------------|-------------------------------|------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|---------------------------------------|
| Bagner et al., 2010 ⁹⁸ RCT (High) | G1: PCIT (11) G2: WLC (14) | CBCL, Aggressive Behavior | G1: 70.1 (10.9) G2: 75.8 (11.1) | 4 months post-baseline G1: 51.1 (1.6) G2: 67.7 (10.2) | p=0.000 |
| | | CBCL, Externalizing | G1: 69.4 (9.1) G2: 74.2 (8.9) | 4 months post-baseline G1: 47.9 (6.1) G2: 66.9 (8.4) | p=0.000 |
| Nixon et al., 2003 ¹³³ RCT (High) | G1: PCIT (standard) (17) G2: PCIT (abbreviated) (20) G3: WLC (NA) | CBCL, Externalizing | G1: 25.82 (5.22) G2: 25.2 (7.33) G3: 26.24 (6.26) | 6 months post-intervention G1: 15.24 (7.77) G2: 15.9 (7.33) G3: NA | p=NS |
| Cummings et al., 2008 ¹²⁷ RCT (High) | G1: SET-PC (16) G2: IYPP (16) | CBCL, Externalizing (T-score) | G1: 65 (4.64) G2: 69.89 (7.77) | 12 months post-intervention G1: 57.81 (6.17) G2: 59.50 (9.62) | p=NS |
| Lavigne et al., 2008 ¹⁰² RCT (High) | G1: PT-Nurse led (33) G2: PT-Psychologist led (33) G3: MIT (33) | CBCL, Externalizing (T-score) | G1 + G2 + G3: 70.7 (5.96) | 12 months post-intervention G1 + G2 + G3: NR | p=NS |

Table 13. Summary of behavior outcomes reported by CBCL for preschool-age participants (continued)

| Author, Year Design (Risk of Bias) | Groups Analyzed (N) | Scale | Baseline Mean (SD) | Last Followup Mean (SD) | Between-Group Difference ^a |
|---------------------------------------------------------------------------------------|---------------------------------------------------------------------|---------------------|---------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Jouriles et al., 2001 ¹⁰⁷ RCT (High) | G1: MFT (18) G2: Comparison (18) | CBCL, Externalizing | G1: 66.28 (10) G2: 65.56 (9.13) | 16 months post-intervention G1: 49.79 (9.17) G2: 58.59 (13.62) | p<0.05 |
| McCabe et al., 2009 ⁹⁹ and McCabe et al., 2012 ¹⁵⁷ RCT (Low) | G1: GANA (20) G2: PCIT (15) G3: TAU (13) | CBCL, Externalizing | G1: 66.95 (8.95) G2: 67.21 (11.99) G3: 69.22 (12.27) | 6 to 24 months post-intervention G1: 49.6 (9.01) G2: 53.33 (13.47) G3: 57.46 (14.44) | G1 vs. G3: p=0.04 G1 vs. G2: p=NS G2 vs. G3: p=NS |
| Sanders et al., 2000 ¹⁵⁴ RCT (High) | G1: CBF1 G2: BFI | CBCL, Total | G1: 58.11 (9.74) G2: 66.78 (7.46) | 6 months post-intervention G1: 60.21 (12.70) G2: 67.63 (10.63) | G1 vs. G2: p=NS |

CBCL = Child Behavior Checklist; GANA = Guiando a Niños Activo; G = group; IYPP = Incredible Years Parenting Program; IYP = Incredible Years Program; MFT = Multigroup Family Therapy; MIT = minimal intervention; PT = parent training; N = number; NA = not applicable; NR = not reported; NS = not significant; PCIT = Parent Child Interaction Therapy; RCT = randomized controlled trial; SD = standard deviation; SET-PC = Supportive Expressive Therapy-Parent Child; TAU = treatment as usual; WLC = waitlist control

^aThe between-group difference refers to the difference in the change from baseline to last followup between the intervention and comparison group. Effect favors G1 unless noted otherwise.

School-Age Children

Description of Included Studies

Twenty-nine studies identified as examining psychosocial interventions for school-age children with disruptive behaviors represented in 38 papers. Of the 29 studies, 24 were RCTs^{96,97,100,101,103,105,108,110,113,117,118,121-123,125,126,128,130-132,134,137,147,165} and five were non-RCTs.⁸⁸⁻⁹² The RCTs were conducted in the United States (n = 9),^{96,97,100,101,103,105,108,110,113} Norway (n = 4),^{117,125,126,131} the United Kingdom (n = 3),^{123,130,147} Canada (n = 2),^{121,137} Sweden (n = 2),^{118,122} the Netherlands (n = 2),^{128,132} Australia (n = 1),¹⁶⁵ and Puerto Rico (n = 1).¹³⁴ Of the non-RCTs, studies, one each was conducted in the United States,⁹⁰ Australia,⁹¹ Ireland,⁸⁸ Italy,⁹² and Canada.⁸⁹ We assessed risk of bias as high for nine studies;^{88-91,100,117,118,134,165} moderate in 18 studies;^{92,96,97,101,103,105,108,110,113,122,125,126,128,130-132,137,147} and low for two studies^{121,123} (Table 14).

Interventions were categorized as including only a child component (n = 1),¹³² only a parent component (n = 11),^{88,90,91,113,117,118,121,122,125,130,147} or as multicomponent interventions (n = 17).^{89,92,96,97,100,101,103,105,108,110,123,126,128,131,134,137,165}

Table 14. Summary of interventions and risk of bias for studies of psychosocial interventions in school-age children with DBD

| Intervention | | High Risk of Bias | Moderate Risk of Bias | Low Risk of Bias | All |
|-------------------------|--------------|-------------------|-----------------------|------------------|-----------|
| Single Component | | | | | 12 |
| | Child only | - | 1 | - | 1 |
| | Parent only | 5 | 5 | 1 | 11 |
| Multicomponent | | | | | 17 |
| | IY | - | 4 | - | 4 |
| | Coping Power | 1 | 1 | - | 2 |
| | Modular | - | 2 | - | 2 |
| | SNAP ORP | 1 | 1 | - | 2 |
| | Other | 2 | 4 | 1 | 7 |
| | Total | 9 | 18 | 2 | 29 |

IY = Incredible Years; SNAP ORP = Stop Now and Plan Under 12 Outreach Project

Detailed Analysis

Interventions With Only a Child Component

We included one study (moderate risk of bias) examining interventions with only a child component for school-age children.¹³² Overall, there was a statistically significant positive result for at least one behavioral outcome¹³² and one statistically significant positive result for a functional outcome.¹³² The study included parent-reports of child disruptive behaviors as measured by the CBCL Externalizing subscale and teacher-report (TRF) of child disruptive behaviors.¹³² Investigators randomly assigned 97 aggressive Dutch boys [mean age: 11.2 (0.93) years] to receive a social cognitive intervention program (SCIP), social skills training (SST), or to a waitlist control group.¹³² From baseline to post-treatment (11 weeks), there was a significant main effect for time for parent-reported child disruptive behaviors as measured by the CBCL Externalizing subscale [SCIP baseline mean: 66.78 (9.54), SCIP post-treatment mean: 63.31 (10.75); SST baseline mean: 69.73 (6.55), SST post-treatment mean: 61.60 (8.41); WLC baseline mean: 68.29 (5.88), WLC post-treatment mean: 63.71 (7.06)] but not significant effects of the intervention. Significant time by group interactions favoring SCIP were reported for most of these other variables when comparing children treated with SCIP versus SST.

Interventions With Only a Parent Component

Of the 11 studies examining interventions with only a parent component,^{88,90,91,113,117,118,121,122,125,130,147} eight were RCTs^{117,121,122,125,147,160,166,167} and three of the studies were non-RCTs.^{88,90,91} Of the RCTs, two were rated high,^{117,118} five were moderate^{113,122,125,130,147} and one study was assessed as low¹²¹ risk of bias. The most commonly examined behavioral outcome was general disruptive behavior as measured by parent report using one or more of the CBCL Externalizing scale (n = 4),^{90,117,125,147,166,167} ECBI Problem subscale,^{117,122,147,160,167} ECBI Intensity subscale,^{117,122,147,160,167} SDQ,^{88,91} or PDR,^{122,125,160,166} the most commonly used teacher report measure was the TRF externalizing scale.^{117,125,166} All but one study included at least one of these measures, with the remaining study examining the disruptive behaviors as the percentage of children meeting formal diagnostic criteria for a disruptive behavior disorder using the Schedule for Affective Disorders and Schizophrenia for School-Age Children (KSADS).¹²¹ four studies included functional outcomes, with the most

commonly examined being child social skills as measured by the Social Skills Rating System,^{117,125,166} SCS,¹²² or the Sutter-Eyberg Student Behavior Inventory (SESBI).¹⁶⁰

Of the eight studies that measured general disruptive behavior with one or more parent report measure (e.g., CBCL Externalizing, ECBI Intensity, ECBI Problem, or SDQ), each measured a different active treatment. One compared the Parents Plus Children's Programme to treatment as usual and reported that in comparison to treatment as usual the treatment group displayed significant reductions in conduct problems as measured by the SDQ over 8-weeks of active treatment and at 5-month followup.⁸⁸ One study compared a Skilled Parenting group to a Perceptive Parenting group and reported reductions in conduct problems as measured by the SDQ in both treatment groups but greater reductions in the Skilled Parenting group over 8 weeks of active treatment.⁹¹ One study compared a practitioner-directed parent management training program with a self-directed parent management training program and waitlist control group and reported that the practitioner-directed group and the self-directed group were superior to waitlist control group and that the practitioner-directed group was superior to the self-directed group from pre- to post-treatment and at 6-month followup.¹²² One study compared the Helping the Noncompliant Child intervention to treatment as usual and reported no difference in disruptive behavior improvement between treatment conditions.⁹⁰ One study compared Parent Management Training – Oregon Model (PMTO) to treatment as usual and reported that PMTO was more effective than treatment as usual from pre- to post-treatment and at one-year followup.^{125,166} One study compared a brief version of PMTO to treatment-as-usual and reported that brief-PMTO was more effective than treatment-as-usual from pre- to post-treatment.¹¹⁷ One study compared a standard parent-training program to a more intensive version and reported that both treatments showed improvement from pre- to post-treatment but that the intensive version maintained more improvement at 4-year followup.^{147,167}

The one study that measured child disruptive behavior by the proportion of children [mean age: 7.61 (2.62)] meeting formal diagnostic criteria for a disruptive behavior disorder on the KSADS, compared the Strongest Families intervention to treatment as usual and reported that significantly fewer children in the active treatment group met formal diagnostic criteria for ODD than in the treatment as usual group at 240- and 365-days post-randomization.¹²¹

Incredible Years – Parent Training (IY-PT)

Three RCTs (1 high and 2 moderate risk of bias) evaluated a version of the IY-PT (Table 15). Two studies examined IY-PT compared to a waitlist control;^{118,130} one study examined IY-PT + ADVANCE compared to the standard IY-PT program.¹¹³ All three studies measured child disruptive behaviors using the ECBI Problem subscale, and two studies also used the ECBI Intensity subscale^{118,130} and direct observation of child behaviors (but different behavioral observation coding strategies),^{113,130} and one study used each of the Sutter-Eyberg Child Behavior Inventory-Revised, Intensity subscale,¹¹⁸ the SDQ,¹¹⁸ and CBCL subscales.¹¹³

Table 15. Summary of behavior outcomes for studies of parent-only intervention (IY-PT) in school-age children

| Author, Year Design (Risk of Bias) Country: N Randomized | Groups | Behavior Measure | Between-Group Difference ^a |
|----------------------------------------------------------------------------------------|------------------------------------------|--------------------------------------|------------------------------------------|
| Axberg et al., 2012 ¹¹⁸ RCT (High) Sweden: 62 | G1: IY-PT G2: WLC | ECBI, Problem | G1 vs. G2: p=0.003 |
| | | ECBI, Intensity | G1 vs. G2: p=0.001 |
| Gardner et al., 2006 ¹³⁰ RCT (Moderate) United Kingdom: 76 | G1: IY-PT G2: WLC | ECBI, Problem | G1 vs. G2: p=0.05 |
| | | ECBI, Intensity | G1 vs. G2: p=0.01 |
| Webster-Stratton et al., 1994 ¹¹³ RCT (Moderate) United States: 85 | G1: IY-PT (ADVANCE) G2: IY-PT (basic) | CBCL, Total problems (mother report) | G1 vs. G2: p=NS |
| | | CBCL, Total problems (father report) | G1 vs. G2: p=NS |
| | | ECBI, Problem | G1 vs. G2: p=NS |

CBCL = Child Behavior Checklist; ECBI = Eyberg Child Behavior Inventory; IY-PT = Incredible Years-Parent Training; G = group; N = number; NS = not significant; RCT = randomized controlled trial; WLC = waitlist control

^aThe between-group difference refers to the difference in the change from baseline to last followup between the intervention and comparison group. Effect favors G1 unless noted otherwise.

An RCT conducted in Sweden examined 4 to 8 year old children (85% boys) referred for outpatient child and adolescent psychiatry services meeting diagnostic criteria for ODD. Patients were randomized to IY-PT or waitlist control group.¹¹⁸ From baseline to the end of active treatment the children randomized to the IY-PT group showed significantly more improvement on the parent reported ECBI Intensity subscale [baseline mean: 160.0 (20.3); end of active treatment mean: 128.6 (26.5); change: 20% reduction] and Problem subscale [baseline mean: 20.83 (4.17); end of active treatment mean: 11.13 (7.85); change: 47% reduction] than did children in the waitlist control group [ECBI-I baseline mean: 152.9 (23.6); ECBI-I end of active treatment mean: 147.1 (26.0); change: 4%; ECBI-P baseline mean: 20.41 (6.58); ECBI-P end of active treatment mean: 17.53 (8.01); change: 14% reduction]. Significant differences were not reported on the SECBI-R Intensity subscale or the SDQ.

An RCT conducted in the United Kingdom examined 2 to 9 year old children (74% boys) referred to outpatient services for conduct problems and scoring above the clinical cutoff on the ECBI Problem subscale.¹³⁰ Children receiving IY-PT experienced greater reductions from baseline to post-intervention (14 weeks) on the ECBI Problem subscale [baseline mean: 20.8 (6.5), post-intervention mean: 12.4 (7.8); change: 40% reduction] ECBI Intensity subscale [baseline mean: 152.7 (39.2), post-intervention mean: 130.7 (29.9), change: 14% reduction], and negative behaviors as measured by direct observation [baseline mean: 58.5 (50.6), post-intervention mean: 30.3 (28.6), change: 48% reduction] as compared to children referred to a waitlist control group [ECBI-P baseline mean: 20.3 (7.0), ECBI-P post-intervention mean: 16.3 (8.6), change: 20% reduction; ECBI-I baseline mean: 156.1 (32.9), ECBI-I post-intervention mean: 148.5 (34.7), change: 5% reduction; observed negative behavior baseline mean: 39.9 (37.0), observed negative behavior post-intervention mean: 35.5 (31.5), change: 11% reduction).

One RCT conducted in the United States randomized 3 to 8 year old children (74% boys) scoring above the clinical cutoff on the ECBI, and meeting diagnostic criteria for ODD to receive either IY-PT plus ADVANCE (which includes videotape modeling plus therapist-led discussion focused on family communication, problem solving, and coping skills) or IY-PT.¹¹³ Although

main effects for time are reported for both mother-reported child disruptive behaviors as measured by the ECBI Problem Score [IY-PT ADVANCE baseline mean: 17.04 (7.02), IY-PT ADVANCE post-treatment mean: 10.08 (7.95), IY-PT ADVANCE short-term followup mean: 9.23 (7.10); IY-PT baseline mean: 15.55 (7.71), IY-PT post-treatment mean: 9.52 (5.94), IY-PT short-term followup mean: 6.79 (4.82)], CBCL Behavior Problems subscale [IY-PT ADVANCE baseline mean: 66.21 (8.97), IY-PT ADVANCE post-treatment mean: 58.58 (10.12), IY-PT ADVANCE short-term followup mean: 57.48 (11.05); IY-PT baseline mean: 64.09 (8.55), IY-PT post-treatment mean: 57.82 (9.60), IY-PT short-term followup mean: 55.94 (8.69)], and CBCL Social Competence subscale [IY-PT ADVANCE baseline mean: 38.48 (10.28), IY-PT ADVANCE post-treatment mean: 45.40 (14.47), IY-PT ADVANCE short-term followup mean: 45.76 (10.73); IY-PT baseline mean: 38.00 (12.58), IY-PT post-treatment mean: 43.06 (13.54), IY-PT short-term followup mean: 40.42 (10.76)] indicating significant improvement from baseline to post-treatment and short-term followup on each measure, there were no significant effects for group or the group-by-time interaction indicating no differences between groups or between groups over time. Trends for father-reported outcomes were similar to those for mother-reported outcomes for each of these measures.

Parent Management Training – Oregon Model (PMTO)

Two RCTs (1 high and 1 moderate risk of bias) examined PMTO.^{117,125} One study used the CBCL¹²⁵ and the other study the ECBI¹¹⁷ as its primary measure of child disruptive behaviors (Table 16).

Table 16. Summary of behavior outcomes for studies of parent-only intervention (PMTO) in school-age children

| Author, Year Design (Risk of Bias) Country: N Randomized | Group | Behavior Measure | Between-Group Difference ^a |
|--------------------------------------------------------------------|----------------------------------|-------------------------------|------------------------------------------|
| Ogden et al., 2008 ¹²⁵ RCT (Moderate) Norway: 112 | G1: PMTO G2: Regular services | CBCL, Externalizing (T-score) | G1 vs. G2: p<0.05 |
| | | TRF, Externalizing (T-score) | G1 vs. G2: p=NS |
| Kjober et al., 2012 ¹¹⁷ RCT (High) Norway: 216 | G1: PMTO G2: Regular services | ECBI, Problem | G1 vs. G2: p=0.01 |
| | | ECBI, Intensity | G1 vs. G2: p=0.002 |

PMTO = Parent Management Training Oregon Model; RCT = randomized controlled trial; CBCL = Child Behavior Checklist; ECBI = Eyberg Child Behavior Inventory; N = number; WLC = waitlist control; TRF = Teacher Report Form; NS = not significant

^aThe between-group difference refers to the difference in the change from baseline to last followup between the intervention and comparison group. Effect favors G1 unless noted otherwise.

One RCT randomized 4 to 12 year old children (80% boys) in Norway to receive either PMTO or treatment as usual.¹²⁵ Referrals were made through the normal process at the participating children’s services agencies. Children assigned to PMTO experienced statistically significant greater reductions from baseline to post-treatment (11 to 12 months post-baseline) in parent-reported child disruptive behaviors as measured by the CBCL Externalizing scale [PMTO baseline mean: 66.44 (9.09), post-treatment mean: 59.69 (9.44); treatment as usual baseline mean: 65.61 (10.75), post-treatment mean: 61.22 (9.85)], but not as measured by the Parent Daily Report (PDR). No treatment main effect was reported for teacher-reported child disruptive behaviors as measured by the TRF. No treatment main effect was reported for observed child disruptive behavior.

One RCT compared a brief version of PMTO to treatment as usual with 3 to 12 year old children (69.1% boys) whose parents contacted a primary care agency due to disruptive behaviors.¹¹⁷ Results indicated that the brief version of PMTO was more effective than treatment as usual from pre- to post-treatment on parent-reported ECBI, Intensity [PMTO baseline mean: 124.94 (27.57), PMTO post-treatment mean: 106.06 (27.80); treatment-as-usual baseline mean: 124.76 (28.42); treatment-as-usual post-treatment mean: 114.43 (28.79)], ECBI, Problem [PMTO baseline mean: 15.45 (7.16), PMTO post-treatment mean: 9.79 (7.57); treatment-as-usual baseline mean: 15.02 (7.40); treatment-as-usual post-treatment mean: 11.64 (7.88)], and Merrell externalizing subscale [PMTO baseline mean: 74.17 (19.67), PMTO post-treatment mean: 64.56 (17.95); treatment as usual baseline mean: 73.72 (19.84); treatment-as-usual post-treatment mean: 68.58 (19.20)]. No significant group-by-time interactions for child disruptive behaviors as measured by teacher-reported Merrell externalizing subscale were reported.

Other Interventions With Only a Parent Component

In addition to the IY-PT and PMTO studies discussed above, six other studies examined interventions including only a parent component.^{88,90,91,121,122,147} Three of these six studies measured child disruptive behaviors with the SDQ,^{88,91,122} two studies used the CBCL Externalizing subscale,^{90,147} one study used each of the KSADS,¹²¹ DBRS-R,¹²¹ Ohio Scales subscales,⁹⁰ and ECBI Intensity and Problem Scales (Table 17).¹⁴⁷

Table 17. Summary of behavior outcomes for studies of parent-only intervention (other) in school-age children

| Author, Year Design (Risk of Bias) Country: N Randomized | Groups | Behavior Measure | Between-Group Difference ^a |
|-------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|-------------------------------|-------------------------------------------------------------------------------------------------|
| McGrath et al., 2011 ¹²¹ RCT (Low) Canada: 243 | G1: Parent Education Programme G2: TAU | Diagnosis | G1 vs. G2: p<0.001 |
| Kling et al., 2010 ¹²² RCT (Moderate) Sweden: 159 | G1: PMT (practitioner assisted) G2: PMT (self-directed) G3: WLC | ECBI, Problem | G1 vs. G2: p<0.05 G1 vs. G3: p<0.001 G2 vs. G3: p<0.001 ^b |
| | | ECBI, Intensity | G1 vs. G2: p=NS G1 vs. G3: p<0.001 G2 vs. G3: p<0.001 ^b |
| Coughlin, et al., 2009 ⁸⁸ NRCT (High) Ireland: 74 | G1: Parents Plus Children's Programme G2: TAU | SDQ, Conduct problems | G1 vs. G2: p<0.01 |
| Costin, et al., 2004 ⁹¹ NRCT (High) Australia: 66 | G1: PMT (perceptive) G2: PMT (skilled) | SDQ, Conduct problems | G1 vs. G2: p<0.01 ^b |
| Shapiro et al., 2012 ⁹⁰ NRCT (High) United States: 194 | G1: HNC G2: TAU | CBCL, Externalizing | G1 vs. G2: p=NS |
| Hutchings et al., 2002 ¹⁴⁷ RCT (Moderate) United Kingdom: 42 | G1: Intensive treatment G2: Standard | CBCL, Externalizing (T-score) | G1 vs. G2: p=NS |

CBCL = Child Behavior Checklist; ECBI = Eyberg Child Behavior Inventory; G = group; HNC = Helping the Noncompliant Child; N = number; NRCT = nonrandomized controlled trial; PMT = Parent Management Training; RCT = Randomized Controlled Trial; SDQ = Strengths and Difficulties Questionnaire; TAU = treatment as usual; WLC = waitlist control

^aThe between-group difference refers to the difference in the change from baseline to last followup between the intervention and comparison group. Effect favors G1 unless noted otherwise.

^b Effects favored G2.

One RCT randomized 80 children in Nova Scotia, Canada between the ages of 3 and 7 years (78% boys) with ODD to receive the Parenting the Active Child intervention or treatment as usual.¹²¹ The primary outcome was the percentage of children no longer meeting formal criteria for a KSADS-confirmed ODD diagnosis. In comparison to treatment as usual, children with ODD randomized to receive Parenting the Active Child were significantly less likely to meet ODD diagnostic criteria at 120- and 240-days post-treatment, but were not statistically less likely to meet ODD diagnostic criteria at 365-days post-treatment (percentages by group at each time point were not given). DBRS-R scores were not reported.

One RCT compared a practitioner-directed parent management training program (PMT-P) with a self-directed parent management training program (PMT-S) and waitlist control group in a population of 3 to 10 year old children (60% boys) referred to outpatient clinics in Sweden for disruptive behaviors.¹²² Active treatment was 11 weeks long. Six-month followup data are also provided. In comparison to the children in the waitlist control group, children in both PMT groups experienced statistically significantly greater reductions in parent-reported child disruptive behaviors as measured by the PDR [PMT-P baseline mean: 9.4 (3.8), PMT-P post-treatment mean: 6.0 (4.0), PMT-P 6-month followup mean: 5.0 (3.2); PMT-S baseline mean: 9.7 (3.7), PMT-S post-treatment mean: 7.6 (3.7), PMT-S 6-month followup mean: 6.4 (3.9); WLC baseline mean: 10.6 (3.9), WLC post-treatment mean: 10.1 (4.9), WLC 6-month followup data not reported], ECBI-I [PMT-P baseline mean: 137.5 (20.6), PMT-P post-treatment mean: 118.9 (25.6), PMT-P 6-month followup mean: 115.3 (25.1); PMT-S baseline mean: 137.0 (28.1), PMT-S post-treatment mean: 122.3 (30.8), PMT-S 6-month followup mean: 113.7 (29.7); WLC baseline mean: 140.2 (29.8), WLC post-treatment mean: 139.8 (28.9), WLC 6-month followup data not reported], and ECBI-P [PMT-P baseline mean: 15.5 (5.0), PMT-P post-treatment mean: 10.0 (6.9), PMT-P 6-month followup mean: 8.2 (5.9); PMT-S baseline mean: 15.2 (6.9), PMT-S post-treatment mean: 12.0 (7.5), PMT-S 6-month followup mean: 10.2 (7.1); WLC baseline mean: 16.4 (6.4), WLC post-treatment mean: 16.4 (6.5), WLC 6-month followup data not reported]. No differences were reported in child functional outcomes as measured by the parent-reported Social Competence Scale. Direct comparisons of the PMT-P and PMT-S showed significant between-group effects in favor of PMT-P for child disruptive behaviors as measured by the PDR and ECBI-P (but not the other measures) at post-treatment and that this advantage was stable over the 6-month followup period.

One study using a sequential block design to assign parents of 6 to 11 year old children (80% boys) with disruptive behaviors to the Parents Plus Children's Program (PPCP) or to treatment as usual in outpatient mental health services in Ireland.⁸⁸ Duration of active treatment was 8 weeks long. In comparison to children receiving treatment as usual, children assigned to the PPCP program experienced greater reductions in parent-reported child disruptive behaviors as measured by the SDQ total difficulties score [PPCP baseline mean: 21.19 (6.15), PPCP post-treatment mean: 18.12 (6.23); TAU baseline mean: 22.34 (7.33), TAU post-treatment mean: 22.15 (8.30)] and conduct problems score [PPCP baseline mean: 5.07 (2.06), PPCP post-treatment mean: 3.92 (1.61); TAU baseline mean: 5.28 (2.12), TAU post-treatment mean: 5.53 (2.46)].

One study assigned parents of children (83% boys) with ODD (mean age: 9.5 years) referred to a mental health clinic in metropolitan Melbourne, Australia to a Skilled Parenting group or to a Perceptive Parenting group according to parent preference.⁹¹ Greater reductions in SDQ total difficulties were reported in the Skilled Parenting group [baseline mean: 24.18 (4.70), post-

treatment mean: 20.77 (4.77)] than in the Perceptive Parenting group [baseline mean: 24.17 (4.85), post-treatment mean: 23.44 (7.54)] over 8 weeks of active treatment.

One study sequentially assigned parents of 3 to 9 year old children (73% male) referred with disruptive behaviors to an outpatient clinic in Ohio to receive the Helping the Noncompliant Child parent intervention or to treatment as usual.⁹⁰ Although children in both groups improved on parent-reported measures of child disruptive behaviors, change from baseline to post-treatment in parent-reported child disruptive behaviors as measured by the CBCL Total Problems subscale did not differ significantly between children referred to the Helping the Noncompliant Child intervention group [baseline mean: 68.7 (8.8), post-treatment mean: 64.3 (11.1)] and treatment as usual group [baseline mean: 68.7 (8.4), post-treatment mean: 64.3 (11.3)] or on other parent-reported measures of other constructs.

One RCT randomized 2 to 10 year old children (85% boys) referred for disruptive behaviors to an outpatient clinic in the United Kingdom to receive intensive outpatient treatment or standard treatment.¹⁴⁷ The intensive treatment differed from the standard program primarily by its inclusion of 3 5-hour sessions that included individual units and videotaped recording of parent-child interactions in order to give feedback to parents (average service contact 25 hours in 11 visits over 24 weeks) to the standard outpatient treatment (average service contact 7 hours in 6 visits over 24 weeks). Child disruptive behavior was measured by parent-reported CBCL Externalizing subscale. Parent-reported child disruptive behaviors as measured by the CBCL mean Externalizing T-score for the standard treatment group [baseline mean: 75.3 (5.9), post-treatment: 67.0 (9.23)] and intensive group [baseline mean: 74.2 (9.28), post-treatment mean: 63.9 (11.1)] both decreased from baseline to post-treatment and statistical models showed a main effect for time but no group-by-time interaction. Importantly, only the intensive treatment group had a mean score below the clinical cut-off at post-treatment. A companion paper reporting 4-year followup reported that the intensive treatment group's mean CBCL Externalizing scores remained below the clinical cutoff and that the standard treatment group meaning CBCL scores had worsened such that improvement from baseline was no longer evident at 4-year followup.¹⁶⁷

Multicomponent Interventions

Of the multicomponent intervention studies (n = 17), four studies^{105,110,126,131} examined IY components delivered in combination with each other (IY-PT + IY-CT in three and IY-PT + IY-CT + IY-TT in one); two studies^{128,134} assessed the Coping Power Program; two studies^{97,101} examined the effects of a modular treatment for children with ODD or CD; two studies^{89,137} evaluated the SNAP Under 12 Outreach Project; and seven studies^{92,96,100,103,108,123,165} evaluated a different multicomponent intervention.

Incredible Years (IY)

Four studies examined IY components delivered in combination with each other (3 studies of IY-PT + IY-CT; 1 study of IY-PT + IY-CT + IY-TT) for school-age children (Table 18).^{105,110,126,131}

Table 18. Summary of behavior outcomes for studies of IY interventions in school-age children

| Author, Year Design (Risk of Bias) Country: N Randomized | Groups | Behavior Measure | Between-Group Difference ^a |
|--------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------|-------------------------------------------------------------------------------------------------|
| Larsson et al., 2009 ¹²⁶ RCT (Moderate) Norway: 136 | G1: IY-PT G2: IY-PT + IY-CT G3: WLC | CBCL, Aggression (father report) | G1 vs. G2: p=NS |
| | | CBCL, Aggression (mother report) | G1 vs. G3: p<0.0167 G2 vs. G3: p<0.0167 ^b G1 vs. G2: p=NS |
| | | ECBI, Problem (father report) | G1 vs. G2: p<0.0167 G1 vs. G3: p<0.0167 |
| | | ECBI, Problem (mother report) | G1 vs. G3: p=NS G2 vs. G3: p=NS G1 vs. G2: p=NS |
| | | ECBI, Intensity (father report) | G1 vs. G3: p<0.0167 G2 vs. G3: p=NS G1 vs. G2: p=NS |
| | | ECBI, Intensity (mother report) | G1 vs. G3: p<0.0167 G2 vs. G3: p=NS G1 vs. G2: p=NS |
| Drugli et al., 2006 ¹³¹ RCT (Moderate) Norway: 99 | G1: IY-PT G2: IY-PT + IY-CT G3: WLC | CBCL, Aggression (teacher report) | G2 vs. G1: p<0.05 ^b G2 vs. G3: p<0.01 G1 vs. G3: p=NS |
| Webster-Stratton et al., 1997 ¹¹⁰ RCT (Moderate) United States: 97 | G1: IY-PT G2: IY-CT G3: IY-PT + IY-CT G4: WLC | ECBI, Intensity (mother report) | G1 vs. G2: p=NS |
| | | ECBI, Intensity (father report) | G1 vs. G2: p=NS |
| Webster-Stratton et al., 2004 ¹⁰⁵ RCT (Moderate) United States: 159 | G1: IY-PT G2: IY-PT + IY-TT G3: IY-CT G4: IY-CT + IY-TT G5: IY-PT + IY-CT + IY-TT G6: WLC | ECBI, Intensity (mother report) | G2 vs. G1: p<0.02 ^c |

CBCL = Child Behavior Checklist; ECBI = Eyberg Child Behavior Inventory; G = group; N = number; NRCT = nonrandomized controlled trial; RCT = randomized controlled trial; WLC = waitlist control

^aThe between-group difference refers to the difference in the change from baseline to last followup between the intervention and comparison group. Effect favors G1 unless noted otherwise.

^bGroup by time not significant; only this pairwise contrast was significant.

^cEffects favor G2.

One RCT randomized 4 to 8 year old children (80% boys) referred to two child psychiatry outpatient clinics in Norway due to oppositional or conduct problems to IY-PT, IY-PT plus IY-CT, or to a waitlist control group.¹²⁶ Mother-reported child disruptive behaviors as measured by the ECBI Intensity scale were significantly reduced for IY-PT [baseline mean: 157.1 (24.2), post-treatment mean: 116.5 (27.0)] as compared to the waitlist control group [baseline mean: 159.7 (23.1), post-treatment mean: 137.3 (28.6)] but no significant difference between the IY-PT plus IY-CT [baseline mean: 156.5 (22.0), post-treatment mean: 121.8 (31.9)] and waitlist control group. Mother-reported aggressive behavior as measured by the CBCL Aggression subscale was significantly reduced for the IY-PT [baseline mean: 18.8 (6.8), post-treatment mean: 110 (7.0)] and IY-PT + IY-CT [baseline mean: 21.7 (7.0), post-treatment mean: 13.7 (8.6)] as compared to the waitlist control group [baseline mean: 20.0 (7.7), post-treatment mean: 17.2 (8.2)]. No significant between-group difference was reported for mother-reported ECBI-P. Generally, father-reported child disruptive behaviors correlated strongly with mother-reports.

One RCT included 4 to 8 year old children (80% boys) referred for treatment to two child psychiatric outpatient clinics in Norway by parents due to disruptive behaviors.¹³¹ Children and their parents were randomized to receive IY-PT, IY-PT + IY-CT, or to a waitlist control condition. The PT groups lasted 12-14 weeks. The CT sessions took place over 18 weeks. Results indicate a significant main effect for group on teacher-reported aggression as measured by the Preschool Behavior Questionnaire (PBQ) for children in day care and the aggression subscale of the TRF for children in school from baseline to post-treatment, co-varying baseline scores [PT + CT baseline mean: 3.0 (1.6), PT + CT post-treatment mean: 1.8 (1.5); PT-only baseline mean: 2.7 (1.7), PT-only post-treatment mean: 2.5 (1.4); WLC baseline mean: 3.2 (1.6), WLC post-treatment mean: 3.1 (1.6)]. Teacher-reported child disruptive behavior was significantly reduced in the PT + CT group in comparison to the PT-only ($p < 0.05$) and waitlist control ($p < 0.01$) groups but the PT-only and waitlist control groups did not significantly differ.

One RCT randomly assigned 4 to 8 year old children (75% boys) referred to an outpatient university research clinic in the United States with conduct problems to receive IY-CT, IY-PT, combined IY-CT + IY-PT, or to a waitlist control condition.¹¹⁰ Families were assessed at baseline and 8 months post-baseline (2 months after 6 months of active treatment), and 1-year post-treatment (e.g., 1.5 years post-baseline). At 1-year post-treatment followup, there were significant effects for time for all three active treatment groups on all mother and father-reports of child disruptive behaviors (CBCL Total Behavior problems score, ECBI Intensity score, and PDR score), and child social problem solving via WALLY but no significant group-by-time interactions for any of these variables. Considering all effects together, the IY-CT + IY-PT was superior to IY-CT in that it had an effect on parenting and child behaviors, and was superior to IY-PT in that it had an impact on child social problem solving.

One RCT examined the effect of IY-PT + IY-CT + IY-TT when delivered together in comparison to other combinations of IY components, to individual IY components, and to a waitlist control condition in 4 to 8 year old children (90% boys) with ODD who were referred by their families to an outpatient university research clinic in the United States.¹⁰⁵ Children were randomly assigned to one of the following treatment conditions: IY-PT; IY-PT + IY-TT; IY-CT; IY-CT + IY-TT; IY-PT + IY-CT + IY-TT; or a waitlist control. Although the study mainly reports results from composite measures made up of a number of previously validated measures (composite measures) because they are not themselves validated measures, are excluded from this report, it also reports the percentage of children showing clinically significant improvements at 6 months (post-treatment) and 1-year followup. At 1-year followup (e.g., the last followup), the treatment arms with the highest proportion of children showing clinically significant improvements on mother-reported ECBI-I scores were the IY-PT + IY-TT (84.6%) and IY-CT + IY-TT (81.3%) groups, but the only significant contrasts were between the IY-PT + IY-TT and IY-PT groups (with the combined treatment showing greater change) and the IY-CT group showing more improvement than the IY-PT group. It should also be noted that on teacher reported aggression via the TASB that the IY-CT group was more likely to have shown clinical improvement than the IY-PT + IY-CT + IY-TT group.

Coping Power Program

Two studies^{128,134} assessed the Coping Power Program (Table 19).

Table 19. Summary of behavior outcomes for studies of Coping Power Program for school-age children

| Author, Year Design (Risk of Bias) Country: N Randomized | Groups | Behavior Measure | Between-Group Difference ^a |
|-------------------------------------------------------------------------------------|------------------------------------------|----------------------------------------------------------------|------------------------------------------|
| Van de Wiel et al., 2007 ¹²⁸ RCT (Moderate) The Netherlands: 77 | G1: CPP G2: TAU | CBCL, Externalizing | G1 vs. G2: p=NS |
| | | TRF, Externalizing | G1 vs. G2: p=NS |
| Cabiya et al., 2008 ¹³⁴ RCT (High) Puerto Rico: 278 | G1: CPP (culturally modified) G2: WLC | Bauermeister School Behavior Inventory, Irritability/Hostility | G1 vs. G2: p=NS |

CBCL = Child Behavior Checklist; CPP = Utrecht Coping Power Program; ECBI = Eyberg Child Behavior Inventory; G = group; N = number; NRCT = nonrandomized controlled trial; NS = nonsignificant; RCT = randomized controlled trial; TAU = treatment as usual; WLC = waitlist control

^aThe between-group difference refers to the difference in the change from baseline to last followup between the intervention and comparison group. Effect favors G1 unless noted otherwise.

One RCT assigned children ages 8 to 13 years referred for disruptive behaviors to one of four child psychiatric outpatient clinics or three mental health centers in the Netherlands over a 3-year period to receive either the Coping Power Program (CPP) or treatment as usual.^{128,168} Significant group-by-time interactions were reported only for PDR overt aggression subscale [CPP baseline mean: 2.90 (1.51), CPP post-treatment mean: 1.90 (1.38); treatment as usual baseline mean: 2.46 (1.53); treatment as usual post-treatment mean: 2.05 (1.43)], but not for the other parent-reported measures of child disruptive behavior (e.g., PDR oppositional behavior subscale, CBCL Externalizing Behavior subscale) or for the teacher-reported measure of child disruptive behavior via the TRF externalizing behavior subscale. At 5-year followup, there were no significant differences between the CPP or TAU groups on the NYS Delinquency Scale [CPP mean: 1.2 (1.5); TAU mean: 1.5 (1.5)], but children in the CPP group did report being less likely than children in the TAU group to smoke cigarettes in the past month (CPP % smoked in the last month = 17; TAU % smoked in the last month = 42) and lifetime use of marijuana (CPP % with lifetime marijuana use = 13; TAU % with lifetime marijuana use = 35).¹⁶⁸

A second RCT randomly assigned 278 children from 8 to 13 years of age in Puerto Rico who met *DSM-IV-TR* criteria for a disruptive behavior disorder to receive a culturally sensitive cognitive behavioral intervention (n = 174) or to a waitlist control group (n = 104).¹³⁴ Behavioral outcomes were measured with the Irritability / Hostility subscale of the Bauermeister School Behavior Inventory. Although boys and girls in the treatment group demonstrated more improvement on this subscale score over 12 weeks of than did children in the control group, these differences were not statistically significantly different.

Modular

Two studies^{97,101} (each including multiple papers) examined the effects of a modular treatment for children with ODD or CD (Table 20). The modular treatment included seven components: (1) child CBT/skills training, (2) child medication for ADHD, (3) parent management training, (4) parent-child / family therapy, (5) school programming/teacher consultation, (6) peer relations/community activities development, and (7) case/crisis management.

Table 20. Summary of behavior outcomes for studies of modular intervention in school-age children

| Author, Year Design (Risk of Bias) Country: N Randomized | Groups | Behavior Measure | Between-Group Difference ^a |
|---------------------------------------------------------------------------|------------------------------------------------------------------------|-------------------------------------------|------------------------------------------|
| Kolko et al., 2009 ¹⁰¹ RCT (Moderate) United States: 139 | G1: Modular treatment (community) G2: Modular treatment (clinic) | CBCL, Externalizing | G1 vs. G2: p=NS |
| | | CBCL (teacher report) | G1 vs. G2: p=NS |
| Kolko et al., 2010 ⁹⁷ RCT (Moderate) United States: 163 | G1: Modular treatment G2: EUC | SDQ, Total Score (parent report) | G1 vs. G2: p=NS |
| | | SDQ, Total Score (teacher report) | G1 vs. G2: p=NS |
| | | Individualized Goal Achievement Rating | G1 vs. G2: p<0.0.5 |

CBCL = Child Behavior Checklist; ECBI = Eyberg Child Behavior Inventory; EUC = enhanced usual care; G = group; N = number; NRCT = nonrandomized controlled trial; NS = nonsignificant; RCT = randomized controlled trial; SDQ = Strengths and Difficulties Questionnaire; WLC = waitlist control

^aThe between-group difference refers to the difference in the change from baseline to last followup between the intervention and comparison group. Effect favors G1 unless noted otherwise.

One RCT included children aged 6 to 11 years (85% boys) referred for disruptive behavior disorders to program sites associated with a university medical center in the United States.¹⁰¹ Children and families were randomly assigned to receive the modular treatment either in the community or in an outpatient research clinic setting. Healthy controls were included to provide norms for self-report questionnaires. Results suggest significant improvement in both groups from baseline to post-treatment (6 months) on measures of child disruptive behaviors including the CBCL Externalizing subscale, IOWA Conners Rating Scale oppositional defiant subscale, Self-Report of Antisocial Behavior (SRAB), TRF externalizing behavior, and Child and Adolescent Functional Assessment Scale (CAFAS). There were not group-by-time interactions from baseline to post-treatment or at 3-year followup for any measures indicating that the modular treatment can be successfully implemented in a research clinic or community based setting.

One RCT examines the effectiveness of the same modular treatment adapted for implementation by nurses in primary care settings.⁹⁷ To examine this, children aged 6 to 11 years (65% boys) were enrolled based on parent concerns about disruptive behaviors and scores on the Pediatric Symptoms Checklist (or PSC-17) above the clinical cutoff for externalizing behavior problems to either the nurse-administered modular care (PONI) or to enhanced usual care (EUC). From baseline to 1-year followup, significant group-by-time interactions were seen on the Individualized Goal Achievement Rating (IGAR) average [PONI baseline mean: 1.0 (0.0), post-treatment mean: 2.8 (0.8); EUC baseline mean: 1.0 (0.0), EUC post-treatment mean: 2.6 (0.8)] and Child Health and Illness Profile (CHIP) total score [PONI baseline mean: 47.3 (5.9), PONI post-treatment mean: 49.5 (5.9); EUC baseline mean: 48.7 (6.0), EUC post-treatment mean: 48.9 (6.1)], but not on the parent-reported PSC-17 externalizing score, parent-reported SDQ total score, or teacher-reported SDQ total score even though both groups reported change over time for almost all of these measures.

SNAP Under 12 Outreach Project (SNAP Under 12 ORP)

Two studies evaluated the SNAP Under 12 in Canada (Table 21).^{89,137}

Table 21. Summary of behavior outcomes for studies of the SNAP Under 12 ORP intervention in school-age children

| Author, Year Design (Risk of Bias) Country: N Randomized | Groups | Behavior Measure | Between-Group Difference ^a |
|----------------------------------------------------------------------|-----------------------------|-------------------|------------------------------------------|
| Augimeri et al., 2007 ¹³⁷ RCT (Moderate) Canada: 32 | G1: SNAP ORP G2: Control | CBCL, Aggression | G1 vs. G2: p=0.006 |
| | | CBCL, Delinquency | G1 vs. G2: p=0.007 |
| Lipman et al., 2008 ⁸⁹ NRCT (High) Canada: 339 | G1: SNAP ORP G2: WLC | CBCL, Aggression | G1 vs. G2: p=0.01 |
| | | TRF, Aggression | G1 vs. G2: p=NS |

CBCL = Child Behavior Checklist; ECBI = Eyberg Child Behavior Inventory; G = group; N = number; NRCT = nonrandomized controlled trial; RCT = randomized controlled trial; SNAP ORP = SNAP Under 12 Outreach Project; WLC = waitlist control

^aThe between-group difference refers to the difference in the change from baseline to last followup between the intervention and comparison group. Effect favors G1 unless noted otherwise.

One RCT included children (mean age approximately 9 years; approximately 75% boys) who had police contact within 6 months of referral and/or a T-score on the CBCL Delinquency subscale indicating behavior problems more serious than 98 percent of same-age and same-sex peers.¹³⁷ Children were randomized to receive the SNAP Under 12 12-week outpatient program or to a waitlist control group that participated in a recreation group called the Cool Runner's Club. From baseline to 3 months, children in the SNAP Under 12 group experienced significantly greater declines in parent-reported child disruptive behaviors as measured by the CBCL Delinquency [baseline mean: 8.9, 3-month mean: 4.9, SDs not given] and aggression [baseline mean: 18.8, 3-month mean: 15.5, SDs not given] subscale mean scores than did children referred to the waitlist control group [delinquency subscale baseline mean: 8.9, delinquency subscale 3-month mean: 8.4; aggression subscale baseline mean: 19.4, aggression subscale 3-month mean: 19.0, SDs not given]. At the 3-month point, the two groups switched treatments and from 3 months to 18 months, the children originally referred to SNAP Under 12 continued to make progress and the children originally referred to the waitlist control (who were now receiving SNAP Under 12) also showed improvement (although they never caught up to the other group) on the same measures.¹³⁷

In a second study, investigators recruited boys ages 6 to 11 years from the community to participate in SNAP Under 12 using similar inclusion and exclusion criteria as described in the previous study but allocated children to SNAP Under 12 or the waitlist control recreation group on a first-come, first-served basis rather than being randomized.⁸⁹ In comparison to children initially referred to the waitlist control condition, children initially referred to the SNAP Under 12 showed significantly more improvement on parent-reported child disruptive behaviors as measured by the CBCL Rulebreaking, Aggressive, Conduct Problems, and Total Problems subscales, but not on the CBCL Competence subscale or TRF outcomes.

Other Multicomponent Interventions

Seven studies, each evaluating a different multicomponent intervention, were also identified (Table 22).^{92,96,100,103,108,123,165}

Table 22. Summary of behavior outcomes for studies of other interventions in school-age children

| Author, Year Design (Risk of Bias) Country: N Randomized | Groups | Behavior Measure | Between-Group Difference ^a |
|----------------------------------------------------------------------------|-----------------------------------------------------------------|-------------------------------------|------------------------------------------------------|
| Boylan, et al., 2013 ⁹⁶ RCT (Moderate) United States: 166 | G1: MF-PEP G2: TAU | ODD symptoms | G1 vs. G2: p=NS |
| Scott et al., 2010 ¹²³ RCT (Low) United Kingdom: 112 | G1: SPOKES G2: TAU | ECBI, Intensity | G1 vs. G2: p<0.016 |
| | | ODD symptoms (teacher reported) | G1 vs. G2: p=NS |
| Jouriles et al., 2009 ¹⁰⁰ RCT (High) United States: 66 | G1: Project Support G2: No clinical services | CBCL, Externalizing | G1 vs. G2: p<0.05 |
| | | ECBI, Intensity ^b | G1 vs. G2: p<0.05 ^c |
| Greene et al., 2004 ¹⁰³ RCT (Moderate) United States: 50 | G1: CPS G2: Parent Training | ODDRS | G1 vs. G2: p=NS |
| Kolko et al., 2001 ¹⁰⁸ RCT (Moderate) United States: 54 | G1: CBT G2: Education G3: Home visit | Fire-setting behavior, Child | G1 vs. G2: p<0.06 G1 vs. G3: p<0.06 |
| Masi et al., 2014 ⁹² NRCT (Moderate) Italy: 135 | G1: MTP G2: TAU | CBCL, Externalizing | G1 vs. G2: p=NS |
| | | CBCL, Aggression | G1 vs. G2: p<0.01 ^d |
| Barrett et al., 2000 ¹⁶⁵ RCT (High) Australia: 57 | G1: RST G2: WLC | CBCL, Externalizing (mother report) | G1 vs. G2: p<0.05 |

CBCL = Child Behavior Checklist; CPS = Collaborative Problem Solving; ECBI = Eyberg Child Behavior Inventory; G = group; MTP = multimodal treatment program; N = number; NRCT = nonrandomized controlled trial; ODD = Oppositional Defiant Disorder Rating Scale; RCT = randomized controlled trial; RST = reciprocal skills training; SPOKES = Supporting Parents on Kids Education in Schools; TAU = treatment as usual; WLC = waitlist control

^aThe between-group difference refers to the difference in the change from baseline to last followup between the intervention and comparison group. Effect favors G1 unless noted otherwise.

^bPublication reports as ECBI Problem, but scores indicate ECBI Intensity.

^cDifference was significant at followup but not significant at end of treatment.

^dAs reported in the publication, authors report p values using the “greater than” symbol (e.g., p>X.X). For purposes of this report, we assume that this was an error and that the where the publication references statistical significance and nonsignificance, the intention was to use the “less than” symbol. Effect favors G1 unless noted otherwise.

One RCT evaluated the effectiveness of a CBT as compared to an educational fire safety intervention or a home visit from a firefighter for fire-setting behavior in 54 boys aged 5 to 13 years and referred due to documented fire-setting behavior by the City of Pittsburgh Bureau of Fire, direct parental solicitation, or a mental health practitioner.¹⁰⁸ Children in each of the three intervention groups showed significant improvement on measures of fire involvement, interest and risk, but CBT and fire safety intervention were not more effective at reducing fire-setting behaviors even though the group-by-time interaction approached statistical significance (p<0.06).¹⁰⁸

One RCT assigned children between the ages of 4 and 12 years (68% boys) clinically referred to an outpatient mental health clinic specializing in the treatment of disruptive behavior disorders at a university teaching hospital and meeting criteria for ODD to receive Collaborative Problem Solving (CPS) or parent training based on Barkley’s (1997) 10-week behavior management program.¹⁰³ The primary measure of child disruptive behavior was the parent-rated Oppositional Defiant Disorder Rating Scale (ODDRS). On this measure of parent-reported child disruptive behaviors, there was a significant change from baseline to post-treatment and from baseline to 4-

month followup for children in the CPS group, but the group-by-time interactions from baseline to post-treatment and from baseline to 4-month followup were not significant (means for both groups at each time point are not given). The group-by-time interactions on the Parent-Child Relationship Inventory (PCRI), a measure of one of this reviews functional outcomes, was also not significant.

One RCT assigned children between 8 and 11 years (73% boys) with mood disorders and their families to receive either treatment as usual plus immediate treatment in the multifamily psycho-education program (MF-PEP) or treatment as usual plus waitlist control.⁹⁶ Disruptive behaviors were measured with the Children's Interview of Psychiatric Syndromes (ChIPS) and Parent Form (P-ChIPS). Although MF-PEP was associated with a significant decrease in ODD symptoms from baseline to 12 months followup, there was no significant difference between the MF-PEP [baseline mean: 5.7 (2.1), 12-month followup: 4.5 (2.6)] and the waitlist control groups [baseline mean: 5.4 (2.6), 12-month followup: 4.9 (2.7)] on ODD symptoms. There was also no difference in CD symptoms from baseline to 12-month followup.

One RCT assigned parents of children with a mean just over 5 years of age (71% boys) who were screened for disruptive behaviors with the SDQ in schools in London to either receive the Supporting Parents on Kids Education in Schools (SPOKES) intervention or to receive access to a telephone hotline designed to help parents access treatment as usual in the community over 28 weeks of active treatment.¹²³ In comparison to children in the control group, children receiving SPOKES had significant reductions in child antisocial behavior as measured by parent interview [SPOKES baseline mean: 1.15 (0.44), SPOKES post-treatment mean: 0.91 (0.36); treatment as usual baseline mean: 1.12 (0.49), treatment as usual post-treatment mean: 1.13 (0.49)], parent-reported child disruptive behavior as measured by the ECBI Intensity subscale [SPOKES baseline mean: 119.1 (31.6), SPOKES post-treatment mean: 103.9 (27.3); treatment as usual baseline mean: 115.9 (27.0), treatment as usual post-treatment mean: 113.2 (31.3)], but little difference in teacher-reported oppositional symptoms as measured by a *DSM-IV* questionnaire items.

An additional RCT examining Project Support and was conducted in the United States. Authors examined the effectiveness of Project Support, a family intervention specifically designed to reduce disruptive behaviors in the children of women at a domestic violence shelter.¹⁰⁰ The intervention provides mothers with child behavior management skills and instrumental and emotional support.¹⁰⁰ Although therapists worked primarily alone with mothers, children were regularly included in sessions so that mothers' skill using the new techniques could be evaluated and additional skill building activities could be tailored according to the child's response to them. Child conduct problems were measured by two maternal self-report measures (CBCL Externalizing and ECBI Intensity). Mean CBCL Externalizing scale scores decreased from 67.9 to 57.4 pre- to post-treatment for the Project Support group and from 65.9 to 61.6 for the treatment as usual control group (Cohen's $d=0.66$) and from 142.1 to 102.5 and 129.8 to 102.7 on the ECBI Intensity scale (Cohen's $d=0.17$), respectively.

One moderate risk of bias, prospective cohort study⁹² compared children sequentially assigned to a multimodal treatment program (MTP), which includes once a week sessions for 1 year of individual and group support for children and individual parent training, or treatment as usual (TAU). The study sample consisted of 135 youth with a mean age of 12.0 (2.5) years. Mean CBCL Externalizing scores decreased in the MTP group from 69.73 (7.43) at baseline to 65.58 (7.34) at end of treatment and from 71.49 (7.25) at baseline to 68.58 (7.62) at end of treatment in the treatment as usual group. Mean CBCL Aggressive Behavior scores decreased in

the MTP group from 71.67 (9.03) at baseline to 66.81 (8.52) at end of treatment and from 74.06 (9.77) at baseline to 71.17 (10.00) at end of treatment in the TAU group. The mean CBCL Delinquent Behavior scores decreased in the MTP group from 66.03 (8.07) at baseline to 63.42 (7.51) at end of treatment and in the TAU group from 67.90 (8.31) at baseline to 65.20 (7.92) at end of treatment. This group-by-time interaction was not statistically significant.

Finally, one high risk of bias RCT¹⁶⁵ compared children assigned to a reciprocal skills training (RST), a family-based treatment, against children assigned to a waitlist control group. The study sample consisted of 57 children with a mean age of 8.47 (1.6) years. The intervention group consisted of children referred from a clinic setting and from a pre-treatment hospital setting. Because studies of inpatient hospital settings are excluded from this review, only results for the clinic setting are reported here. On the parent-reported CBCL Externalizing scale, mean scores for the clinic-referred RST group decreased from 67.4 (7.0) at baseline to 59.8 (11.5) end of treatment and from 70.0 (5.8) to 74.0 (5.0) for the waitlist control group. The group-by-time interaction effect was statistically significant. In addition, the percentage of children who no longer met *DSM-IV* criteria for oppositional defiant disorder was significantly reduced in the clinic-referred RST group than in the waitlist control group (72.2% vs. 30%, $p < 0.01$).

Summary of Key Disruptive Behavior Outcomes

We report the behavior outcomes measured by CBCL (Table 23) or ECBI (Table 24) from studies of school-age children.

Table 23. Outcome summary for change in disruptive behavior symptoms reported by CBCL in studies of school-age children

| Author, Year, Design (Risk of Bias) | Group (Participants Analyzed) | Scale | Baseline Mean (SD) | Last Followup Mean (SD) | Between-Group Difference ^a |
|---------------------------------------------------------|---------------------------------------------------------------------------------------------------|----------------------------------|--------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|
| van Manen et al., 2004 ¹³² RCT (Moderate) | G1: Social cognitive (42) G2: Social skills training (40) G3: WLC (NA) | CBCL, Externalizing | G1: 66.8 (9.5) G2: 69.7 (6.6) G3: 68.3 (5.9) | 12 months post-intervention G1: 58.8 (10.8) G2: 59.4 (10.7) G3: NA | G1 vs. G2: $p = NS$ |
| | | TRF | G1: 71.6 (6.7) G2: 71.4 (10.1) G3: 69.0 (9.0) | 12 months post-intervention G1: 64.9 (7.4) G2: 63.1 (10.4) G3: NA | G1 vs. G2: $p = NS$ |
| Larsson et al., 2009 ¹²⁶ RCT (Moderate) | G1: IY-PT (40) G2: IY-PT + IY-CT (48) G3: WLC (NA) | CBCL, Aggression (father report) | G1: 14.8 (5.0) G2: 19.8 (8.4) G3: 17.4 (8.2) | 12 months post-intervention G1: 8.6 (4.3) G2: 12.1 (8.4) G3: NA | G1 vs. G2: $p = NS$ |
| | | CBCL, Aggression (mother report) | G1: 18.8 (6.8) G2: 21.7 (7.0) G3: 20.0 (7.7) | 12 months post-intervention G1: 11 (7.0) G2: 12.7 (7.4) G3: NA | G1 vs. G3: $p < 0.0167$ G2 vs. G3: $p < 0.0167$ G1 vs. G2: $p = NS$ |

Table 23. Outcome summary for change in disruptive behavior symptoms reported by CBCL in studies of school-age children (continued)

| Author, Year, Design (Risk of Bias) | Group (Participants Analyzed) | Scale | Baseline Mean (SD) | Last Followup Mean (SD) | Between-Group Difference ^a |
|----------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|-----------------------------------------------|--------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|
| van de Wiel et al., 2007 ¹²⁸ RCT (Moderate) | G1: CPP (38) G2a: Family Therapy (10) G2b: Behavior therapy (16) | CBCL, Externalizing | G1: 74.6 (6.4) G2a: 77.1 (6.4) G2b: 73.3 (8.9) | End of treatment G1: 69.6 (8.4) G2a: 72.6 (7.9) G2b: 67.8 (9.8) | G1 vs. G2: p=NS Mean improvement: G1 vs. G2a: 0.07; G1 vs. G2b: -0.07 |
| | | TRF, Externalizing | G1: 64.9 (9.9) G2a: 66.4 (7.9) G2b: 65.8 (11.0) | End of treatment G1: 62.4 (10.7) G2: 66.7 (9.5) G3: 60.6 (12.6) | G1 vs. G2: p=NS Mean improvement: G1 vs. G2a: 0.37; G1 vs. G2b: -0.29 |
| Webster-Stratton et al., 1997 ¹¹⁰ RCT (Moderate) | G1: IY-PT (26) G2: IY-CT (24) G3: IY-PT + IY-CT (22) G4: WLC (NR) | CBCL, Total Problems (T-score, mother report) | G1: 65.5 (7.8) G2: 67.1 (7.9) G3: 65.3 (6.1) G4: 67.9 (7.7) | 12 months post-intervention G1: 55.1 (10.6) G2: 58.6 (10.7) G3: 57.7 (8.7) G4: NR | G1 vs. G2: p<0.001 |
| | | CBCL, Total Problems (T-score, father report) | G1: 62.7 (7.9) G2: 64.3 (8.3) G3: 66.2 (7.8) G4: 62.0 (8.6) | 12 months post-intervention G1: 53.5 (8.9) G2: 54.8 (13.1) G3: 57 (11.3) G4: NR | G1 vs. G2: p<0.01 |
| Augimeri et al., 2007 ¹³⁷ RCT (Moderate) | G1: SNAP ORP(16) G2: Control (14) | CBCL, Delinquency | G1: 8.9 (NR) G2: 8.9 (NR) | 18 months G1: 3.1 (NR) G2: 6.5 (NR) | G1 vs. G2: p=0.007 |
| | | CBCL, Aggression | G1: 18.8 (NR) G2: 19.4 (NR) | 18 months G1: 11.0 (NR) G2: 18.1 (NR) | G1 vs. G2: p=0.006 |
| Hutchings et al., 2002 ¹⁴⁷ RCT (Moderate) | G1: PT, intensive (21) G2: Standard treatment (13) | CBCL, Externalizing | G1: 74.2 (9.3) G2: 75.3 (5.9) | 6 months post-intervention G1: 63.9 (11.1) G2: 67 (9.2) | G1 vs. G2: p=NS |

Table 23. Outcome summary for change in disruptive behavior symptoms reported by CBCL in studies of school-age children (continued)

| Author, Year, Design (Risk of Bias) | Group (Participants Analyzed) | Scale | Baseline Mean (SD) | Last Followup Mean (SD) | Between-Group Difference ^a |
|-----------------------------------------------------|---------------------------------------------------------------------------------------------|-------------------------------|--------------------------------------------------|--------------------------------------------------------------------------------|---------------------------------------|
| Lipman et al., 2008 ⁸⁹ NRCT (High) | G1: SNAP ORP (132) G2: WLC (77) | CBCL, Aggression | G1: 80.3 (10.6) G2: 78.1 (9.6) | 6 months post-intervention G1: 72 (11.1) G2: 73.4 (10.7) | G1 vs. G2: p=0.01 |
| | | CBCL, Rulebreaking | G1: 73.2 (6.6) G2: 70.9 (6.9) | 6 months post-intervention G1: 67.5 (8.2) G2: 67.6 (7.2) | G1 vs. G2: p=0.02 |
| | | CBCL, Conduct Problems | G1: 77.6 (8) G2: 75.8 (7.4) | 6 months post-intervention G1: 70.7 (9.6) G2: 72 (7.5) | G1 vs. G2: p=0.01 |
| | G1: SNAP ORP (102) G2: WLC (67) | TRF, Aggression | G1: 67.1 (11.0) G2: 69.1 (10.4) | 6 months post-intervention G1: 66.3 (11.0) G2: 67.7 (12.3) | G1 vs. G2: p=NS |
| | | TRF, Rulebreaking | G1: 64.2 (8.5) G2: 66.1 (8.4) | 6 months post-intervention G1: 63.5 (8.2) G2: 64.0 (9.2) | G1 vs. G2: p=NS |
| | | TRF, Conduct Problems | G1: 66.7 (11.3) G2: 70.2 (12.0) | 6 months post-intervention G1: 65.1 (10.5) G2: 67.7 (12.8) | G1 vs. G2: p=NS |
| Kolko et al., 2009 ¹⁰¹ RCT (Moderate) | G1: Modular treatment (community) (69) G2: Modular treatment (clinic) (70) | CBCL, Externalizing | G1: 29.9 (8.8) G2: 28.9 (9.5) | 36 months post-intervention G1: NR G2: NR | G1 vs. G2: p=NS |
| | G1: Modular treatment (community) (63) G2: Modular treatment (clinic) (66) | TRF | G1: 30.1 (16.2) G2: 30.7 (15.8) | 36 months post-intervention G1: NR G2: NR | G1 vs. G2: p=NS |
| Ogden et al., 2008 ¹²⁵ RCT (Moderate) | G1: PMTO (52) G2: Regular services (45) | CBCL, Externalizing (T-score) | G1: 66.4 (9.1) G2: 59.9 (9.9) | 12 months post-intervention G1: 59.7 (9.4) G2: 90 (9.8) | G1 vs. G2: p<0.05 |
| | G1: PMTO (52) G2: Regular services (45) | TRF, Externalizing (T-score) | G1: 63.9 (9.8) G2: 58.4 (9.2) | 12 months post-intervention G1: 60.7 (10.7) G2: 57.2 (8.6) | G1 vs. G2: p=NS |
| Shapiro et al., 2012 ⁹⁰ NRCT (High) | G1: HNC (Manualized) (70) G2: TAU (124) | CBCL, Externalizing | G1: 71.5 (9.4) G2: 71.3 (9.9) | End of treatment G1: 67.7 (11.2) G2: 66.9 (11.2) | G1 vs. G2: p=NS |

Table 23. Outcome summary for change in disruptive behavior symptoms reported by CBCL in studies of school-age children (continued)

| Author, Year, Design (Risk of Bias) | Group (Participants Analyzed) | Scale | Baseline Mean (SD) | Last Followup Mean (SD) | Between-Group Difference ^a |
|----------------------------------------------------------------|-------------------------------------------------------------------------|-------------------------------------|----------------------------------------------------|-----------------------------------------------------------------------------------|------------------------------------------|
| Jouriles et al., 2009 ¹⁰⁰ RCT (High) | G1: Project support (32) G2: No clinical services (34) | CBCL, Externalizing | G1: 67.9 (NR) G2: 65.9 (NR) | 20 months post-intervention G1: 53.3 (NR) G2: 59.0 (NR) | 0.63 (95% CI: 0.04 to 1.20) ^b |
| Webster-Stratton et al., 1994 ¹¹³ RCT (Moderate) | G1: IY-PT (ADVANCE) (38) G2: IY-PT (basic) (39) | CBCL, Total Problem (mother report) | G1: 66.21 (8.97) G2: 64.09 (8.55) | G1: 57.48 (11.05) G2: 55.94 (8.69) | G1 vs. G2: p=NS |
| | | CBCL, Total Problem (father report) | G1: 64.41 (7.89) G2: 61.54 (9.45) | 13 weeks post-intervention G1: 56.57 (55.45) G2: 55.46 (8.66) | G1 vs. G2: p=NS |
| Masi et al., 2014 ⁹² NRCT (Moderate) | G1: MTP (64) G2: TAU (71) | CBCL, Externalizing | G1: 69.73(7.43) G2: 71.49 (7.25) | 24 months post-intervention G1: 63.57 (9.34) G2: 68.52 (9.10) | G1 vs. G2: p=NS |
| Barrett et al., 2000 ¹⁶⁵ RCT (High) | G1: RST (23) G2: WLC (12) | CBCL, Externalizing (mother report) | G1: 67.4 (7.0) G2: 70.0 (5.8) | End of intervention G1: 59.8 (11.5) G2: 74.0 (5.0) | G1 vs. G2: p<0.05 |

CBCL = Child Behavior Checklist; CPP = Utrecht Coping Power Program; HNC = Helping the Noncompliant Child; IY = Incredible Years; PT = parent training; CT = child training; NA = not applicable; NRCT = nonrandomized controlled trial; NR = not reported; PCOH = prospective cohort study; PMTO = Parent Management Training-Oregon; SNAP ORP = Stop Now and Plan Under 12 Outreach Project; RCT = randomized controlled trial; TRF = Teacher Report Form; WLC = waitlist control

^a The between-group difference refers to the difference in the change from baseline to last followup between the intervention and comparison group. Effect favors G1 unless noted otherwise.

^b Cohen's d (confidence interval) for difference in means between post-intervention and last followup.

Table 24. Outcome summary for change in disruptive behavior symptoms reported by ECBI in studies of school-age children

| Author, Year Design (Risk of Bias) | Group (Participants Analyzed) | Scale | Baseline Mean (SD) | Last Followup Mean (SD) | Between-Group Difference ^a |
|----------------------------------------------------|-------------------------------------------------------------------------|---------------------------------|-------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------|------------------------------------------|
| Larsson et al., 2009 ¹²⁶ RCT (High) | G1: PT (40) G2: PT + CT (48) G3: WLC (NA) | ECBI, Problem (father report) | G1: 16.6 (6.4) G2: 15.6 (6.3) G3: 15.1 (8.4) | 12 month post-intervention G1: 7.0 (5.5) G2: 8.3 (7.5) G3: NA | NR |
| | | ECBI, Problem (mother report) | G1: 20.7 (6.2) G2: 20.2 (6.3) G3: 19.8 (4.8) | 12 months post-intervention G1: 11.1 (8.4) G2: 10.2 (8.1) G3: NA | NR |
| | | ECBI, Intensity (father report) | G1: 140.3 (21.2) G2: 143.8 (23.2) G3: 142.9 (29.7) | 12 months post-intervention G1: 108.9 (22.3) G2: 116.1 (24.3) G3: NA | NR |
| | | ECBI, Intensity (mother report) | G1: 157.1 (24.2) G2: 156.5 (22) G3: 159.7 (23.1) | 12 months post-intervention G1: 121.3 (28.8) G2: 119.1 (31.4) G3: 137.3 (28.6) | NR |
| Jouriles et al., 2009 ¹⁰⁰ RCT (High) | G1: Project support (32) G2: No clinical services (34) | ECBI, Intensity | G1: 142.1 (NR) G2: 129.8 (NR) | 20 months post-intervention G1: 82.8 (NR) G2: 103.8 (NR) | 0.66 (95% CI: 0.03 to 1.26) ^b |
| Kjebi et al., 2012 ¹¹⁷ RCT (High) | G1: PMTO (108) G2: Regular services (108) | ECBI, Problem | G1: 15.5 (7.2) G2: 15.0 (7.4) | 2 weeks post-intervention G1: 9.8 (7.6) G2: 11.6 (7.9) | G1 vs. G2: p=0.01 |
| | | ECBI, Intensity | G1: 124.9 (27.6) G2: 124.8 (28.4) | 2 weeks post-intervention G1: 106.1 (27.8) G2: 114.4 (28.8) | G1 vs. G2: p=0.002 |
| Axberg et al., 2012 ¹¹⁸ RCT (High) | G1: IYP (34) G2: WLC (20) | ECBI, Problem | G1: 20.8 (4.2) G2: 20.4 (6.6) | 12 months post-intervention G1: 11.1 (7.9) G2: 17.5 (8.0) | G1 vs. G2: p=0.003 |
| | | ECBI, Intensity | G1: 160 (20.3) G2: 152.9 (23.6) | 12 months post-intervention G1: 128.6 (26.5) G2: 147.1 (26.0) | G1 vs. G2: p=0.001 |
| Kling et al., 2010 ¹²² RCT (High) | G1: PMT-P (58) G2: PMT-S (61) G3: WLC (NA) | ECBI, Problem | G1: 15.5 (5) G2: 15.2 (6.9) G3: 16.4 (6.4) | 6 months post-intervention G1: 8.2 (5.9) G2: 10.2 (7.1) G3: NA | G1 vs. G2: p<0.05 |
| | | ECBI, Intensity | G1: 137.5 (20.6) G2: 137 (28.1) G3: 140.2 (29.8) | 6 months post-intervention G1: 115.3 (25.1) G2: 113.7 (29.7) G3: NA | G1 vs. G2: p=NS |

Table 24. Outcome summary for change in disruptive behavior symptoms reported by ECBI in studies of school-age children (continued)

| Author, Year Design (Risk of Bias) | Group (Participants Analyzed) | Scale | Baseline Mean (SD) | Last Followup Mean (SD) | Between-Group Difference ^a |
|-------------------------------------------------------|--------------------------------|-----------------|--------------------------------------|--------------------------------------------------------------------------|---------------------------------------|
| Gardner et al., 2006 ¹³⁰ RCT (High) | G1: IY-PT (38) G2: WLC (NA) | ECBI, Problem | G1: 20.8 (6.5) G2: 20.3 (7) | 18 months post baseline G1: 12.9 (9.3) G2: NA | G1 vs. G2 ^c : p=0.05 |
| | | ECBI, Intensity | G1: 152.7 (39.2) G2: 156.1 (32.9) | 18 months post baseline G1: 134 (41) G2: NA | G1 vs. G2 ^c : p=0.01 |
| Brestan et al., 1997 ¹¹⁴ RCT (Moderate) | G1: PCIT G2: WLC | ECBI, Problem | G1: 23 (5.8) G2: 24 (5.4) | End of intervention G1: 11 (10.7) G2: 24 (7.5) | G1 vs. G2: p=0.0001 |
| | | ECBI, Intensity | G1: 173 (29.5) G2: 176 (30.2) | End of intervention G1: 133 (37.7) G2: 170 (36) | G1 vs. G2: p=0.0001 |

CT=Child Training; ECBI=Eyberg Child Behavior Inventory; EOT=end of treatment; IY-PT=Incredible Years Program – Parent Training; NA=Not Applicable; NR=Not Reported; PT=Parent Training; PMTO=Parent Management Training Oregon Model; PMT-P=Parent Management Training- Perceptive; PMT-S=Parent Management Training- Skilled; RCT=Randomized controlled trial; WLC=waitlist control

^aThe between-group difference refers to the difference in the change from baseline to last followup between the intervention and comparison group. Effect favors G1 unless noted otherwise.

^bCohen’s d (confidence interval) for difference in means between post-intervention and last followup.

^c6 months post-intervention.

Teenage Children

Description of Included Studies

We identified 14 studies,^{86,94,104,106,111,115,116,120,124,136,142-144,146} reported in 17 papers^{86,94,104,106,111,115,116,120,124,136,142-144,146,169-171} that evaluated psychosocial interventions for teenagers with disruptive behaviors. Of the 14 included studies, 13 were RCTs (4 high, 5 moderate, and 4 low risk of bias)^{94,104,106,111,115,116,120,124,136,142-144,146} and one was a retrospective cohort study (high risk of bias).⁸⁶ Six of the studies were conducted in the United States;^{94,104,106,111,115,116} three were conducted in Germany;¹⁴²⁻¹⁴⁴ two were conducted in the Netherlands;^{86,136} and one each in the United Kingdom,¹²⁰ Israel,¹⁴⁶ and Sweden.¹²⁴ One study included only a child component.¹⁰⁴ The other 13 studies were multicomponent interventions (Table 25). Of these multicomponent interventions, six were family interventions^{106,115,116,142-144} and five were Multisystemic Therapy (MST).^{94,111,120,124,136} We categorized the other two multicomponent intervention studies as an “other” multicomponent intervention.

Table 25. Summary of interventions and risk of bias for studies of psychosocial interventions in teenage children with DBD

| Intervention | | High Risk of Bias | Moderate Risk of Bias | Low Risk of Bias | All |
|------------------|----------------|-------------------|-----------------------|------------------|-----------|
| Single Component | | | | | 1 |
| | Child only | 1 | - | - | 1 |
| Multicomponent | | | | | 13 |
| | Family therapy | 1 | 2 | 2 | 6 |
| | MST | 1 | 1 | 2 | 5 |
| | Other | 1 | - | - | 2 |
| Total | | 5 | 5 | 4 | 14 |

MST = Multisystemic Therapy

Detailed Analysis

Interventions With Only a Child Component

One single center, RCT (high risk of bias) conducted in the United States examined an intervention with a child component only.¹⁰⁴ This study examined the efficacy of the Adolescents Coping with Depression (CWD-A) course in a population of non-incarcerated adolescents between 13 and 17 years meeting *DSM-IV* criteria for comorbid conduct disorder and depression (n = 93). These results were compared to a control condition utilizing a group intervention focused on life skills and tutoring (LS) only. The CWD-A is a group-based cognitive behavioral intervention typically directed towards depressive symptoms. However, this study also examined its impact on disruptive behavior. Participants were randomized to receive either the CWD-A course (n = 45) or the control LS intervention (n = 48). Approximately 10 adolescents per group (CWD-A group mean: 10.4 participants; LS mean: 9.4 participants) were treated in sixteen 2-hour sessions over the course of 8 weeks. They were then assessed post-treatment and at 6- and 12-month followup using the following dimensional outcome measures: the Beck Depression Inventory-II (BDI-II), the Hamilton Depression Rating Scale (HDRS), the Externalizing Problem Subscale of the Child Behavior Checklist (CBCL), the Children's Global Assessment Scale (CGAS), and the Social Adjustment Scale-Self Report (SAS-R). Mean (SD) age of participants was 15.1 (1.5) years for those in the CWD-A group and 15.1 (1.3) years in the LS control group and 55 percent in the sample were male. Comparing baseline demographic and clinical characteristics, the two randomized groups only differed significantly in gender, the CWD-A group consisting of 60 percent females compared to only 38 percent females in the LS condition. Thus, gender was included as a covariate during analysis.

From baseline to the end of active treatment at 12 months, the children randomized to the CWD-A intervention group showed significant improvement compared to the LS control group in the depressive outcome measures (BDI-II, HDRS, SAS-R). However, no significant reductions were reported in disruptive behaviors as measured by the parent-reported CBCL Externalizing subscale, or in social functioning, as measured by the CGAS.

Multicomponent Interventions

Of the 13 studies of multicomponent interventions for teenage children, six studies examined family interventions including the Brief Strategic Family Therapy (n = 3),^{106,142,144} Parenting with Limits and Love,¹¹⁶ a family behavior therapy intervention,¹¹⁵ and a general family therapy approach (n = 1).¹⁴³ Five of the multicomponent intervention studies evaluated Multisystemic

Therapy (MST).^{94,111,120,124,136} The two other studies each examined a different multicomponent intervention.^{86,146}

Family Therapy

Six studies examined the impact of family therapy interventions on disruptive behaviors and other related outcomes (Table 26).^{106,142-144} Three of these studies were conducted in Germany¹⁴²⁻¹⁴⁴ and three were conducted in the United States.^{106,115,116} Two of the studies measured disruptive behaviors using the self-reported Adolescent Risk Taking Behavior Scale (ARBS),^{142,143} while another study used the conduct disorder and socialized aggression subscales of the parent-reported Revised Behavior Problem Checklist (RBPC) behavior problem scale.¹⁰⁶ Three studies also measured levels of anger and anger expression using the self-report State-Trait Anger Expression Inventory (STAXI)¹⁴²⁻¹⁴⁴ Three studies also included outcomes related to health related quality of life,¹⁴²⁻¹⁴⁴ two included interpersonal functioning outcomes^{142,143} and one measured the impact of the intervention on family functioning.¹⁰⁶

Table 26. Summary of studies of multicomponent interventions (family therapy) for teenage children

| Author, Year Design (Risk of Bias) Country: N Randomized | Group | Behavior Measure | Between-Group Difference ^a |
|-----------------------------------------------------------------------------|-------------------------------------------------------------------------|----------------------------------------------|-----------------------------------------------------------------------|
| Santisteban et al., 2003 ¹⁰⁶ RCT (High) United States: 126 | G1: BSFT G2: Group therapy | RBPC, Conduct problem | G1 vs. G2: p<0.01 |
| | | RBPC, Socialized aggression | G1 vs. G2: p<0.01 |
| Nickel et al., 2006 ¹⁴² RCT (Low) Germany: 40 | G1: BSFT G2: Placebo Intervention Program | STAXI, State-Anger | G1 vs. G2: p<0.001 |
| | | ARBS, Drug use | G1 vs. G2: p<0.001 |
| Nickel et al., 2006 ¹⁴⁴ RCT (Moderate) Germany: 72 | G1: BSFT G2: Placebo Intervention Program | STAXI, State-Anger | G1 vs. G2: p<0.01 |
| Nickel et al., 2005 ¹⁴³ RCT (Low) Germany: 44 | G1: Family therapy G2: Placebo Intervention Program | STAXI, State-Anger | G1 vs. G2: p<0.001 |
| | | ARBS, Drug use | G1 vs. G2: p<0.001 (EOT) G1 vs. G2: p=0.29 (Last FU) |
| Azrin et al., 2001 ¹¹⁵ RCT (High) United States: 56 | G1: FBT G2: ICPS | CBCL, Delinquency | G1 vs. G2: p<0.001 |
| | | YSR, Delinquency | G1 vs. G2: p<0.001 |
| | | ECBI, Problem | G1 vs. G2: p<0.001 |
| | | ECBI, Intensity | G1 vs. G2: p<0.001 |
| | | Court House records: Frequency of arrests | G1 vs. G2: p<0.001 |
| Sells et al., 2011 ¹¹⁶ RCT (Moderate) United States: 38 | G1: PLL G2: TAU | CBCL, Externalizing | G1 vs. G2: p<0.01 |
| | | CBCL, Aggressive Behaviors | G1 vs. G2: p<0.01 |
| | | CBCL, Rule-Breaking Problems | G1 vs. G2: p<0.01 |

EOT = end of treatment; FU = followup; FBT = Family Behavioral Therapy; ICPS = Individual Cognitive Problem Solving; RCT = randomized controlled trial; BSFT = Brief Strategic Family Therapy; PLL = Parenting with Love and Limits; STAXI = State-Trait Anger Expression Inventory; ARBS = Adolescents Risk-taking Behavior Scale

^aThe between-group difference refers to the difference in the change from baseline to last followup between the intervention and comparison group. Effect favors G1 unless noted otherwise.

Three of the four studies examined the delivery of BSFT and its impact on disruptive behavior problems and related outcomes.^{106,142,144} In each of these studies the intervention group receiving BSFT was compared to a control group intervention in which the participants received

either group therapy¹⁰⁶ or another family-based intervention.^{142,144} Each of these studies examined the use of BSFT with a specific population. One study¹⁰⁶ compared the effectiveness of BSFT for a primarily male Hispanic adolescent population (n = 126, mean age: 15.6 years; 75% male) with a general group therapy based intervention. Participants were included based on parental or school complaints of externalizing behavior problems. Compared to the control group, participants receiving the BSFT intervention displayed a significantly greater reduction in behavior problems as measured by the Revised Behavior Problem Checklist (RBPC). Compared to 11 percent of clinically significant improvement in the control group (p=NS), 43 percent of the BSFT group showed reliable improvement in Conduct Disorder measures (p<0.001). Similarly, on the Socialized Aggression scale, 36 percent of BSFT recipients showed reliable improvement (p<0.001) compared to 11 percent of the control population (ns). The treatment group also reported significant reductions in substance use and increased improvements in family functioning as compared to the control group.

Two studies evaluated the impact of BSFT on bullying behaviors: one¹⁴² in a population of adolescent females and the other¹⁴⁴ with adolescent males. The first study compared the effectiveness of BSFT on bullying behavior in a group of 15 year old girls [n = 40, mean age: 15.5 (0.5) years] who had shown direct verbal and/or physical bullying behavior for at least six months to a placebo intervention. The study assessed risk-taking behaviors using the Adolescent Risk Taking Behavior Scale (ARBS), which consisted of seven behavior scales: drug use, smoking, binge drinking, excessive media use, having sex without a condom, having sex while using drugs and alcohol and sexual disinhibition. The study found that girls receiving the BSFT showed significantly greater reductions in adolescent risk taking behavior than those receiving the placebo treatment at both the end of treatment (ARBS score mean difference between groups: -9.3, p<0.001) and after a one year followup assessment (ARBS score mean difference between groups: -8.2, p<0.001). BSFT also led to significant improvements in interpersonal relationships as measured by the Inventory of Interpersonal Problems (IIP-D), as well as reducing levels of anger (STAXI) and increasing health related quality of life (SF-36) as compared to the placebo intervention. These results were reported to have remained relatively stable at one-year followup.

One study¹⁴³ examined the effectiveness of family therapy as a monotherapy for reducing disruptive behaviors and anger compared to a placebo intervention. This study utilized an integrative family therapy model that integrated elements from family systems theory, psychodynamic-oriented therapy, gestalt therapy, and behavioral therapy. Interventions were focused around communication, family rules and each family member's role in the existing problematic family system presentation. Forty-four male adolescents [mean age: 15.2 (0.5)] displaying bullying behavior participated in the study, half randomly assigned (n = 22) to receive a family therapy program for 6 months and the other half assigned (n = 22) to the placebo control group for the same length of time. Consistent with the results from the female [mean age: 15.5 (0.5)] cohort study,¹⁴² this study reported significantly greater reductions in adolescent risky behaviors on all scales of the ARBS (end-of-treatment ARBS score mean difference: -6.3, p<0.001; followup ARBS score mean difference: -3.1, p<0.001) and significant reductions in anger levels on nearly all of the scales measured by the STAXI. Additional reported outcomes included significant improvements in interpersonal relationships, as measured by six of the eight scales on the IIP-D, and significant improvement in health related quality of life (SF-36) as compared to the placebo control group.

One high risk of bias RCT¹¹⁵ compared children assigned to family-behavioral therapy with children assigned to individual cognitive therapy. The study sample consisted of 56 children with

a mean age 15.4 (1.3) years. On the parent-reported CBCL Delinquency scale children assigned to the family-behavioural therapy group experienced greater reductions [baseline mean score: 74.44 (6.70); end of treatment mean score: 63.55 (9.10)] than did children assigned to the individual cognitive therapy group [baseline mean score: 77.40 (8.45); end of treatment mean score: 66.67 (12.11)]. These differences were maintained at 6-month followup. Similar findings were also evident via the parent reported ECBI Problem scale (family behavioural therapy group baseline mean score: 17.86 (8.52); family behavioural therapy group end of treatment mean score: 8.58 (9.09); individual cognitive therapy group baseline mean score: 21.52 (6.12), individual cognitive therapy group end of treatment mean score: 11.95 (9.46)], and ECBI Intensity scale (family behavioural therapy group baseline mean score: 133.55 (38.26); family behavioural therapy group end of treatment mean score: 90.78 (36.37); individual cognitive therapy group baseline mean score: 145.93 (35.58); individual cognitive therapy group end of treatment mean score: 110.35(45.92)].

One moderate risk of bias RCT¹¹⁶ compared Parenting with Limits and Love (PLL), a 6-week group therapy program integrating principles of a structural family therapy approach, against a control group receiving TAU probation services including counseling, community schools, and/or community service. The study sample included 38 teenagers [mean age: 15] (57% boys) who had been referred for criminal offenses. Disruptive behaviors were assessed via the parent-reported CBCL. Mean scores in the intervention group showed greater decrease than in the control group on the CBCL Externalizing subscale (intervention group baseline mean score: 64.07 (15.80), intervention group end of treatment mean score: 56.57 (11.21); control group baseline mean score: 73.08 (9.54), control group end of treatment mean score: 71.83 (10.11)], aggressive behaviors scale (intervention group baseline mean score: 67.43 (12.77), intervention group end of treatment mean score: 58.14 (6.78); control group baseline mean score: 70.83 (14.22), control group end of treatment mean score: 71.67 (13.01)], and rule-breaking behaviors scale (intervention group baseline mean score: 67.29 (10.94), intervention group end of treatment mean score: 60.07 (8.07); control group baseline mean score: 75.33 (7.30), control group end of treatment mean score: 69.33 (9.44)]. The group-by-time interaction for each of these measures was statistically significant.

Multisystemic Therapy

Of the five studies that examined MST, two were conducted in the United States,^{94,111} and one each in the Netherlands,¹³⁶ the United Kingdom,¹²⁰ and Sweden.¹²⁴ All five of these studies were RCTs (1 high, 2 moderate, and 2 low risk of bias). Overall, the treatment effects were positive, with only one study¹²⁴ not demonstrating significance (Table 27).

Table 27. Summary of studies of multicomponent interventions (MST) for teenage children

| Author, Year Design (Risk of Bias) Country: N Randomized | Group | Behavior Measure | Between-Group Difference ^a |
|-----------------------------------------------------------------------------|--------------------|------------------------------------------|------------------------------------------|
| Weiss et al., 2013 ⁹⁴ RCT (Moderate) United States: 164 | G1: MST G2: TAU | CBCL, Externalizing | G1 vs. G2: p<0.05 |
| | | YSR, Externalizing | G1 vs. G2: p<0.05 |
| | | TRF, Externalizing | G1 vs. G2: p=NS |
| | | SRD, Delinquency | G1 vs. G2: p=NS |
| | | SRD, Drug Use | G1 vs. G2: p=NS |
| Borduin et al., 1995 ¹¹¹ RCT (Moderate) United States: 176 | G1: MST G2: IT | Symptom Checklist, 90-item (self-report) | G1 vs. G2: p=NS |
| | | RBPC, z-score (mother report) | G1 vs. G2: p<0.05 |

Table 27. Summary of studies of multicomponent interventions (MST) for teenage children (continued)

| Author, Year Design (Risk of Bias) Country: N Randomized | Group | Behavior Measure | Between-Group Difference ^a |
|-------------------------------------------------------------------------------------------------------------------|------------------------------------------------|--------------------------|------------------------------------------|
| Butler et al., (2011) ¹²⁰ RCT (Low) United Kingdom: 108 | G1: MST G2: Usual Services | CBCL, Aggression | G1 vs. G2: p<0.05 |
| | | CBCL, Delinquency | G1 vs. G2: p<0.05 |
| | | CBCL, Externalizing | G1 vs. G2: p=NS |
| | | YSR, Externalizing | G1 vs. G2: p=NS |
| | | YSR, Aggression | G1 vs. G2: p=NS |
| | | YSR, Delinquency | G1 vs. G2: p=NS |
| Sundell et al., (2008) ¹²⁴ RCT (Low) Sweden: 139 | G1: MST G2: TAU | CBCL, Externalizing | G1 vs. G2: p=NS |
| | | YSR, Externalizing | G1 vs. G2: p=NS |
| Asscher et al., 2013 ¹³⁶ See: Asscher et al., 2014 ¹⁷¹ RCT (High) Netherlands: 256 | G1: MST G2: TAU | CBCL, Externalizing | G1 vs. G2: p<0.05 |
| | | YSR, Externalizing | G1 vs. G2: p<0.05 |
| Asscher et al., 2014 ¹⁷¹ Related to: Asscher et al., 2013 ¹³⁶ | G1: MST G2: TAU | CBCL, Externalizing | G1 vs. G2: p<0.001 |
| | | DBD rating, ODD Subscale | G1 vs. G2: p<0.001 |
| | | DBD rating, CD subscale | G1 vs. G2: p<0.001 |
| | | YSR, Externalizing | G1 vs. G2: p<0.01 |
| | | SRD, Violent offenses | G1 vs. G2: p=NS |
| SRD, Property offenses | G1 vs. G2: p<0.01 | | |

RCT = randomized controlled trial; MST = Multisystemic Therapy; IT = individual therapy; NS = nonsignificant; RBPC = Revised Behavior Problem Checklist; SRD = Self-Reported Delinquency Scale; TAU = treatment as usual; TRF = Teacher Report Form; YSR = Youth Self-Report

^aThe between-group difference refers to the difference in the change from baseline to last followup between the intervention and comparison group. Effect favors G1 unless noted otherwise.

One study^{94,172} conducted in the United States randomly assigned 164 adolescents (83% male) between the ages of 11 and 18 years in one school system's self-contained behavior intervention classrooms to receive MST or treatment as usual. Treatment as usual included behavior management interventions and support provided as part of the classroom structure. At 18-month followup, parent-reported CBCL Externalizing mean scores for the MST group [baseline mean: 25.90 (10.63); end of active treatment mean: 18.20 (10.82); change: 30% reduction] decreased significantly more from baseline to end-of-treatment than those of the control group [baseline mean: 23.40 (9.61); end of active treatment mean: 19.19 (10.36); change: 18% reduction]. The outcomes from the YSR assessment showed similar results, with the MST group [baseline mean: 17.63 (9.03); end of active treatment mean: 13.87 (8.53); change: 21% reduction] showing greater effects than the control group [baseline mean: 17.00 (7.97); end of active treatment mean: 14.22 (7.72); change: 16% reduction]. No significant effect was found based on the TRF of externalizing behaviors or arrest data.

One pretest-posttest control group design (moderate risk of bias)¹¹¹ conducted in the United States compared the effects of MST to individual therapy (IT) on criminal behavior and violent offenses among a group of high-risk juvenile offenders (n = 176, 67% male). Ninety-two participants [mean age: 14.8 (1.5)] were randomly assigned to receive MST, with 77 completing both pre- and post-treatment assessments and receiving an average of 23.9 (8.2) hours of treatment. Out of the 84 participants initially assigned to the IT control group, 63 completed both assessments and received an average of 28.6 (9.8) hours of treatment.

This study demonstrated MST to be significantly more effective than individual therapy based on several outcome measures. From pre-treatment to post-treatment, both mothers and fathers from the MST group showed significant decreases in psychiatric symptomology as measured by the SCL-90-R [mother mean baseline score: 0.12 (1.02); mother mean post-treatment score: -0.15 (0.97); father mean baseline score: -0.06 (0.90); father mean post-treatment score: -0.07 (0.77)]. Their IT counterparts did not show similar reductions in psychiatric symptomatology for either of the parents [mother mean baseline score: 0.04 (1.17); mother mean post-treatment score: 0.20 (1.26); father mean baseline score: 0.06 (1.05); father mean post-treatment score: 0.19 (1.09)]. The study also showed a significant interaction effect for mothers' reports of adolescent disruptive behaviors as measured by the Revised Behavior Problem Checklist (RBPC), with mothers in the MST group reporting a decrease in adolescent behavior problems and mothers of youths in the IT group reporting an increase in behavior problems. Additionally, adolescents in the MST group showed significant positive change in family functioning and cohesion (FACES-II), lower re-arrest rates, and less serious offenses when rearrested. The pattern of lower frequency and decreased seriousness of crimes emerged in both the analysis of the entire sample as well as when analyzing only those that completed treatment.

Three studies^{120,124,136} examined the effectiveness of MST to treatment as usual in more socialized systems offering comprehensive management of disruptive behavior problems (i.e., United Kingdom, Sweden, and The Netherlands). One low risk of bias study¹²⁰ conducted in the United Kingdom compared MST to outcomes for youth working with a Youth Offending Team (YOT). YOTs, like MST, provide a multicomponent intervention that is led by a social worker working with additional team members, such as therapists and probation officers. This study examined the impact of MST versus YOT, or usual services, on offending behavior based on police records (primary outcomes), as well as parent and youth rated reports of disruptive and delinquent behaviors as measured by the CBCL and YSR (secondary outcomes). A group of 108 adolescents between 13 and 17 years of age were allocated to receive either MST [n = 56; mean age: 182.7 (12.3) months; 91% male] or YOT [n = 52; mean age: 180.6 (12.9) months; 90% male]. Based on data derived from police computer records, youth who participated in MST had significantly less nonviolent offending by the end of the followup period (18 months post treatment end). There were no significant differences with regard to violent offending given the low number of youth with violent offense records.

In regards to secondary outcome measures, assessments from baseline to 6 months post-treatment indicated that, for internalizing and externalizing problems, there was no significant difference in disruptive behaviors between the two groups. However, the CBCL scales pertinent to the hypothesis each showed significant interactions favoring MST. For the aggression subscale, MST participants showed significantly more improvement [baseline mean: 69.4 (12.9); 6-month mean: 64.2 (11.4); change: 7.5% reduction] than the YOT group [baseline mean: 66.9 (11.6); 6-month mean: 65.9 (11.9); change: 1.5% reduction]. Similar results occurred with the delinquency subscale, with MST participants again showing significant reductions in [baseline mean: 73.4 (8.3); 6-month mean: 67.9 (8.6); change: 7.5% reduction] compared to the YOT group [baseline mean: 73.0 (7.9); 6-month mean: 70.9 (8.5); change: 2.9% reduction]. Analysis of rates of change also indicated moderate effect sizes in the MST group (aggression effect size: 0.42; delinquency effect size: 0.64) and smaller effect sizes for the YOT group (aggression effect size: 0.09; delinquency effect size: 0.25). While the parent-reported outcomes suggested improvement in disruptive behaviors in the MST group, none of the scales from the YSR yielded

significant interactions. Data regarding longer-term follow up of rate of disruptive behavior were not available.

One multicenter low risk of bias study¹²⁴ examined the effectiveness of MST to treatment as usual in Sweden. Treatment as usual for court-referred youth in Sweden includes referral for social service supports, which work to identify treatment needs. Treatment in the control group was varied and was primarily represented by individual therapy, family therapy, mentoring, or no services. A group of youths between the ages of 12 and 17 fulfilling diagnostic criteria for conduct disorder [n = 156; mean age: 15.0 (1.4) years; 61% male] were randomized to either the treatment (n = 79) or control group (n = 77). Mean enrollment in MST lasted 145.8 (51.6) days. Disruptive and delinquent behavior was assessed by both caregiver and adolescent ratings through the CBCL and YSR, respectively. Additionally, the study looked at delinquency through the Self-Report Delinquency Scale (SRD), substance use measures through multiple self-reporting methods (i.e. AUDIT/DUDIT), and relationships and social competence (i.e. Pittsburgh Youth Study, SCPQ, Social Skills Rating System, school attendance). Pre- to posttest measurements did not demonstrate any significant differences in the MST intervention compared to treatment as usual as measured by the CBCL and YSR measures, nor on the SOC scale. Both groups showed decreased disruptive and delinquent behavior, improvement in social skills and better family relations.

One RCT (high risk of bias)¹³⁶ examined the effectiveness of MST compared to treatment as usual in The Netherlands. In The Netherlands, treatment as usual relies more frequently on in-home services, but also includes individual treatment, some combination of both or no services. The study included 256 adolescents [mean age: 16.02 (1.31) years; 73% male] randomly allocated to either MST or treatment as usual interventions. Researchers used the CBCL Aggression and Delinquency subscales to assess externalizing behaviors and delinquency. Parents also filled out several symptom scales from the Disruptive Behaviors Disorder rating scales. Adolescents self-reported using YSR and SRD assessments. According to both parent and youth self-reports, MST was significantly more effective at reducing externalizing behavior problems [CBCL baseline mean: 23.32 (12.60); CBCL end-of-treatment mean: 17.64 (11.57); change: 24% reduction] than treatment as usual [CBCL baseline mean: 22.55 (12.95); CBCL end-of-treatment mean: 19.25 (10.56); change: 15% reduction]. The YSR showed similar results, with a 16 percent reduction in the MST group and only a 3 percent reduction in the treatment as usual group. MST was also more effective at decreasing ODD and CD, as compared to treatment as usual. With regard to self-report of delinquent behaviors, MST demonstrated significant reductions for property offenses, but no significant effect was found for violent offending. Interestingly, further analysis of other secondary outcomes- such as parent and adolescent cognitions, parenting behavior and peer relationships- and demographic variables yielded unexpected results. While MST was equally effective across ages and ethnicity, the intervention showed larger effects for adolescent cognitions for boys than for girls. At 6-month post-treatment follow-up, there was evidence of sustained effects of MST in comparison to TAU with maintenance of statistically significant reductions in externalizing problems, ODD, and CD, but the number of re-arrests and time to re-arrest did not differ between the groups.¹⁷¹

Other Multicomponent Interventions

One RCT (moderate risk of bias)¹⁴⁶ examined the effect of a semi-structured bibliotherapy intervention aimed to decrease aggressive behavior in youth (Table 28). The study was conducted in the Druze community in Israel, which is a closed society living in generally segregated cities or villages. Seventy-five children (77% male) were randomly and equally

assigned to one of three conditions: child treatment only, mother plus child treatment and no treatment at all. The additional parent group was aimed at increasing parent’s understanding of their child’s aggressive behavior. Researchers measured aggression using a reduced version of the aggression and delinquency subscales of the CBCL questionnaire as reported by parents (CBCL), the adolescents (YSR), and their teachers (TRF). Another parent report, Coping with Children’s Negative Emotions Scale (CCNS), was also used. Both treatment groups, the child group and the parent/child combination group, were more effective at reducing aggressive behavior than no treatment at all. However, the combined intervention was not significantly more effective at reducing disruptive behaviors than the child training only intervention. While obtained means demonstrated a greater decrease in aggressive behavior of the combined treatment intervention, significance was only found with the self-report measure, not with the parent or teacher report. Thus, the researchers’ hypothesis of enhanced outcomes with the additional parent component was only partially supported.

Table 28. Summary of studies of multicomponent interventions (other) for teenage children

| Author, Year Design (Risk of Bias) Country: N Randomized | Group | Behavior Measure | Between-Group Difference ^a |
|-------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|-----------------------------------------|--------------------------------------------------------|
| Shechtman and Birani- Nasaraladin, 2006 ¹⁴⁶ RCT (Moderate) Israel: 75 | G1: Child only treatment G2: Mother plus child G3: Control | Modified CBCL, Aggression (YSR) | G1 vs. G3: p<0.001 G2 vs. G3: p<0.001 |
| | | Modified CBCL, Aggression (TRF) | G1 vs. G3: p<0.001 G2 vs. G3: p<0.001 |
| | | Modified CBCL, Aggression (Parent) | G1 vs. G3: p<0.001 G2 vs. G3: p<0.001 |
| van der Put et al., 2013 ⁸⁶ NRCT (High) Netherlands: 192 | G1: FFT G2: CBT G3: CBT + PT | Official conviction records: Recidivism | G1 vs. G2: p=NS |

NRCT = nonrandomized controlled trial; N = number; FFT = Functional Family Therapy; CBT = Cognitive-Behavioral Therapy; PT = parent training; CBCL = Child Behavior Checklist; TRF = Teacher Report Form; YSR = Youth Self Report; G = group; NS = nonsignificant

^aThe between-group difference refers to the difference in the change from baseline to last followup between the intervention and comparison group. Effect favors G1 unless noted otherwise.

A nonrandomized cohort study (high risk of bias)⁸⁶ conducted in The Netherlands did not report positive treatment effect for disruptive behavior problems (Table 28). The study compared the effectiveness of treatments being offered in a forensic youth outpatient clinic at reducing recidivism. Treatments included functional family therapy (FFT) (n = 55), individual CBT (n = 87), and CBT combined with parent training (n = 50). In addition to these treatments, some youths also participated in Aggression Replacement Training (ART) (n = 27). It should be noted that both FFT and ART were implemented as trial versions and most implementing therapists had not been formally trained in administering these interventions. The official records of the 192 adolescents completing treatment in the outpatient clinic (mean age: 17.0 years; 85% male) were analyzed retrospectively, with occurrences of recidivism serving as the primary outcome measure. The study found no significant differences in 2-year total or violent recidivism rates between the different treatment interventions. However, researchers did find a higher recidivism rate for those youth who had additionally participated in ART (54% recidivism compared to 30% for non-ART juveniles), even after controlling for the type of offense committed (i.e. violent). There was also no significance found in recidivism between the treatment groups as compared to youth who dropped out of treatment (n = 42). The study found a significant interaction between

moderating variables regarding patient characteristics (ethnicity), intensity and frequency of treatment, and the therapist conducting the training.

Summary of Key Disruptive Behavior Outcomes

We report the behavior outcomes measured by CBCL, YRF, or TRF (Table 29) from studies of teenage children.

Table 29. Summary of disruptive behavior outcomes reported by ASEBA^a in teenage children

| Author, Year Study Design (Risk of Bias) | Group (Participants Analyzed) | Scale | Baseline Mean (SD) | Last Followup Mean (SD) | Between-Group Difference ^b |
|----------------------------------------------------|----------------------------------------------------------------------------------------|---------------------|--------------------------------------------------|---------------------------------------------------------------------------------|---------------------------------------|
| Rohde et al., 2004 ¹⁰⁴ RCT (High) | G1: CBT (41) ^c G2: Control (life skills) (46) ^c | CBCL, Externalizing | G1: 27 (15.3) G2: 30.9 (12.8) | 12 months post-intervention G1: 20.8 (15.8) G2: 14 (9.6) | G1 vs. G2: p=NS |
| Weiss et al., 2013 ⁹⁴ RCT (Moderate) | G1: MST (84) G2: Treatment as usual (80) | CBCL, Externalizing | G1: 25.9 (10.6) G2: 23.4 (9.6) | 18 months G1: 18.2 (10.8) G2: 19.2 (10.4) | G1 vs. G2: p<0.05 |
| | | Achenbach (TRF) | G1: 22.9 (12.5) G2: 22.5 (11.7) | 18 months G1: 19.5 (12.4) G2: 20.1 (12.6) | G1 vs. G2: p=NS |
| | | Achenbach (YSR) | G1: 17.6 (9.0) G2: 17.0 (8.0) | 18 months G1: 13.9 (8.5) G2: 14.2 (7.7) | G1 vs. G2: p<0.05 |
| Sundell et al., 2008 ¹²⁴ RCT (Low) | G1: MST (79) G2: Treatment as usual (77) | CBCL, Externalizing | G1: 81.8 (17.6) G2: 77.9 (17.4) | 7 months post-intervention G1: 72.1 (17.1) G2: 69.9 (19.1) | G1 vs. G2: p=NS |
| | | Achenbach (YSR) | G1: 69.4 (14.6) G2: 71 (15.9) | 7 months post-intervention G1: 65.2 (15.6) G2: 64.9 (15.1) | G1 vs. G2: p=NS |
| Asscher et al., 2013 ¹³⁶ RCT (High) | G1: MST (147) G2: Treatment as usual (109) | CBCL, Externalizing | G1: 23.3 (12.6) G2: 22.6 (13.0) | 6 months post randomization G1: 17.6 (11.6) G2: 19.3 (10.6) | G1 vs. G2: p<0.05 |
| | | Achenbach (YSR) | G1: 12.4 (9.3) G2: 12.4 (8.3) | 6 months post randomization G1: 10.4 (7.9) G2: 12.0 (7.6) | G1 vs. G2: p<0.05 |

Table 29. Summary of disruptive behavior outcomes reported by ASEBA^a in teenage children (continued)

| Author, Year Study Design (Risk of Bias) | Group (Participants Analyzed) | Scale | Baseline Mean (SD) | Last Followup Mean (SD) | Between-Group Difference ^b |
|-------------------------------------------------------------------------|---------------------------------------------------------------------------------|------------------------------------------|-------------------------------------------------|---------------------------------------------------------------------|---------------------------------------|
| Butler et al., 2011 ¹²⁰ RCT (Low) | G1: MST (53) G2: Youth offending teams (51) | Achenbach Externalizing (YSR) | G1: 53.8 (10.7) G2: 54.6 (10.2) | 6 months post randomization G1: 52.8 (11) G2: 51 (10.8) | G1 vs. G2: p=NS |
| | | Achenbach Aggression (YSR) | G1: 59.1 (10.4) G2: 59.2 (8.1) | 6 months post randomization G1: 57.3 (10.4) G2: 56.6 (8) | G1 vs. G2: p=NS |
| | | Achenbach Delinquency (YSR) | G1: 65.1 (8.8) G2: 65.6 (8.1) | 6 months post randomization G1: 62.9 (9.8) G2: 63.3 (9.9) | G1 vs. G2: p=NS |
| | | CBCL, Externalizing | G1: 67.7 (8.4) G2: 66.4 (9.8) | 6 months post randomization G1: 63.4 (10.2) G2: 63.7 (9.9) | G1 vs. G2: p=NS |
| | | CBCL, Delinquency | G1: 73.4 (8.3) G2: 73 (7.9) | 6 months post randomization G1: 67.9 (8.6) G2: 70.9 (8.5) | G1 vs. G2: p<0.05 |
| | | CBCL, Aggression | G1: 69.4 (12.9) G2: 66.9 (11.6) | 6 months post randomization G1: 64.2 (11.4) G2: 65.9 (11.9) | G1 vs. G2: p<0.05 |
| Shechtman and Birani-Nasaraladin. 2006 ¹⁴⁶ RCT (Moderate) | G1: Child only treatment (25) G2: Mother plus child (25) G3: Control (25) | Modified CBCL, Aggression (YSR) | G1: 9.7 (NR) G2: 10.6 (NR) G3: 12.7 (NR) | 3 months G1: 5.1 (NR) G2: 3.97 (NR) G3: 10.7 (NR) | G1<G2 ^d G1>G3 G2>G3 |
| | | Modified CBCL, Aggression (TRF) | G1: 13.8 (NR) G2: 11.2 (NR) G3: 11.4 (NR) | G1: 5.04 (NR) G2: 2.88 (NR) G3: 9.44 (NR) | G1=G2 ^d G1>G3 G2>G3 |
| | | Modified CBCL, Aggression (Parent) | G1: 7.2 (NR) G2: 8.1 (NR) G3: 8.9 (NR) | 3 months G1: 4.0 (NR) G2: 3.3 (NR) G3: 9.3 (NR) | G1=G2 ^d G1>G3 G2>G3 |
| Azrin et al., 2001 ¹¹⁵ RCT (High) | G1: FBT (29) G2: ICPS (27) | CBCL, Delinquency | G1: 74.44 (6.70) G2: 77.40 (8.45) | 6 months post-intervention G1: 65.83 (10.25) G2: 64.15 (8.32) | G1 vs. G2: p<0.001 |
| | | YSR, Delinquency | G1: 68.55 (11.0) G2: 69.03(10.31) | 6 months post-intervention G1: 60.67 (6.52) G2: 60.19 (9.0) | G1 vs. G2: p<0.001 |
| | | Courthouse records: Frequency of arrests | G1: 0.93 (1.51) G2: 0.84 (1.02) | 6 months post-intervention G1: 0.51 (0.59) G2: 0.24 (0.29) | G1 vs. G2: p<0.001 |

Table 29. Summary of disruptive behavior outcomes reported by ASEBA^a in teenage children (continued)

| Author, Year Study Design (Risk of Bias) | Group (Participants Analyzed) | Scale | Baseline Mean (SD) | Last Followup Mean (SD) | Between-Group Difference ^b |
|-----------------------------------------------------|-------------------------------|------------------------------|----------------------------------------|-----------------------------------------------------------------------|---------------------------------------|
| Sells et al., 2011 ¹¹⁶ RCT (Moderate) | G1: PLL (19) G2: TAU (19) | CBCL, Externalizing | G1: 64.07 (15.80) G2: 73.08 (9.54) | 12 months post-intervention G1: 56.57 (11.21) G2: 71.83 (10.11) | G1 vs. G2: p<0.01 |
| | | CBCL, Aggressive Behaviors | G1: 67.43 (12.77) G2: 70.83 (14.22) | 12 months post-intervention G1: 58.14 (6.78) G2: 71.67 (13.01) | G1 vs. G2: p<0.01 |
| | | CBCL, Rule-Breaking Problems | G1: 67.29 (10.94) G2: 75.33 (7.30) | 12 months post-intervention G1: 60.07 (8.07) G2: 69.33 (9.44) | G1 vs. G2: p<0.01 |

CBCL = Child Behavior Checklist; CBT = Cognitive-Behavioral Therapy; FBT = Family Behavioral Therapy; ICPS = Individual Cognitive Problem Solving; MST = Multisystemic Therapy; NR = not reported; PLL = Parenting with Love and Limits; RCT = randomized controlled trial; TRF = Teacher Report Form; YSR = Youth Self-Report

^aThe CBCL is part of the Achenbach System of Empirically Based Assessment (ASEBA). There are two other components of the ASEBA - the Teacher's Report Form (TRF) is to be completed by teachers and the Youth Self-Report (YSR) by the child or adolescent.

^bThe between-group difference refers to the difference in the change from baseline to last followup between the intervention and comparison group. Effect favors G1 unless noted otherwise.

^cNumber at last followup.


^d post hoc analysis, p value not reported. F-score significant (p<0.001) for condition by time interaction for all three groups.

Bayesian Meta-Analysis of Psychosocial Interventions

Convergence diagnostics showed no evidence for lack of convergence in the 50,000 samples used for inference. Model fit was assessed using posterior predictive checks,¹⁷³ which revealed no strong evidence of lack of fit.

To aid interpretation, the effect sizes estimated by our model can be interpreted as the expected change in score for the intervention category relative to treatment as usual or control, in standard deviation units (negative values are reductions in score). Thus, a value of -1 is an expected reduction in score of one standard deviation under the associated treatment. The effect size for the multicomponent interventions and interventions with only a parent component had the same estimated value (Figure 3), with a median of -1.2 standard deviations reduction in outcome score (95% credible intervals: -1.6 to -0.9). The estimate for interventions with only a child component was -1.0 (95% credible interval: -1.6 to -0.4).

Figure 3. Effect size estimates



Both the multicomponent intervention category and the interventions with only a parent component had the highest posterior probability (43%) of being the best intervention (defined as having the largest effect size), followed by interventions with only a child component (14%).

Age effects were relatively more subtle, with an additive median effect of -0.4 standard deviations (95% credible interval: -0.6 to -0.3) for preschool relative to school-age children (baseline level), and of -0.1 standard deviations (95% credible interval: -0.5 to 0.2) for adolescents relative to school-age children. These trends were evident across each of the outcome measures included in the analysis.

A summary of estimated overall treatment outcomes is shown in Figures 4-6 for each treatment class, as well as for control/treatment as usual. Results are presented separately for each included outcome measure and age group.

Figure 4. Summary of estimated overall treatment outcomes (ECBI Intensity Subscale) in studies of preschool, school-age, and adolescent children




Figure 5. Summary of estimated overall treatment outcomes (ECBI Problem Subscale) in studies of preschool, school-age, and adolescent children





Figure 6. Summary of estimated overall treatment outcomes (CBCL Externalizing T-score) in studies of preschool, school-age, and adolescent children



All three classes show shifts away from control/treatment as usual, though with high residual variability within class, and overlap among classes.

Random effect variances describe additional variation in the output beyond that accounted for by the factors included in the model. Mean estimates were 0.18 (SD: 0.034) (95% CI: 0.12 to 0.25) for ECBI Intensity score, 0.17 (SD: 0.038) (95% CI: 0.09 to 0.24) for ECBI Problem score, and 0.13 (SD: 0.027) (95% CI: 0.08 to 0.18) for CBCL Externalizing T score.

Using cut points greater than 127 for the ECBI Intensity scale, 11 for the ECBI Problem scale, and 60 for the CBCL Externalizing T-score,^{174,175} we estimated the marginal posterior probabilities of remaining above the cut point on each measure (Table 30). Remaining above the clinical cut point means that children continued to experience clinically significant symptoms. Posterior probabilities of remaining above the cut point are nominally higher for the treatment as usual/control group relative to each of the intervention groups, with multicomponent interventions showing the lowest proportion of children still above the clinical cut off post-treatment.

Table 30. Posterior probabilities of treatment outcome values being above standard threshold for three instruments (ECBI Intensity, ECBI Problem, CBCL Externalizing T-score) by age group

| Instrument | Age Group | Child-Only | Parent-Only | Multicomponent | TAU/Control |
|-------------------------------|------------|------------|-------------|----------------|-------------|
| ECBI, Intensity Subscale | Preschool | 0.34 | 0.16 | 0.17 | 0.95 |
| | School | 0.66 | 0.46 | 0.47 | 0.95 |
| | Adolescent | 0.56 | 0.36 | 0.37 | 0.95 |
| ECBI, Problem Subscale | Preschool | 0.62 | 0.40 | 0.42 | 1 |
| | School | 0.82 | 0.77 | 0.77 | 1 |
| | Adolescent | 0.78 | 0.66 | 0.68 | 1 |
| CBCL, Externalizing (T-score) | Preschool | 0.30 | 0.19 | 0.19 | 1 |
| | School | 0.59 | 0.36 | 0.37 | 1 |
| | Adolescent | 0.48 | 0.31 | 0.31 | 1 |

ECBI = Eyberg Child Behavior Inventory; CBCL = Child Behavior Checklist; TAU = treatment as usual

Note: Standard threshold values: ECBI, Intensity=127, ECBI Problem=11, CBCL, Externalizing T-score=60

For example, this means that 95 percent of school-age children randomized to TAU/Control interventions, 66 percent of school-age children randomized to interventions with only a child component, 46 percent of school-age children randomized to interventions with only a parent component, and 47 percent of school-age children randomized to multicomponent interventions remained above the clinical ECBI Intensity Subscale clinical cutoff at the end of treatment. This suggests that multicomponent interventions are more effective. Similar trends were evident for the other age groups and outcome measures.

For the PCIT intervention, there was some uncertainty regarding whether it was most appropriately classified as a multicomponent intervention (as shown above) or as an intervention with only a parent component. We classified PCIT as a multicomponent intervention primarily because the focus of the intervention – as its name suggests – is on the parent-child interaction and includes the parent and child engaged together in activities. Thus, PCIT is arguably more similar to the family-based interventions included in our multi-component intervention category than it is to an intervention that only includes parents (e.g., our category of interventions that only include a parent component).

Nevertheless, to address this concern, we ran the model under both classifications (i.e., with PCIT categorized as a multicomponent intervention (as shown above) and as an intervention with only a parent component (results not shown) to compare the resulting estimates). Classifying PCIT as an intervention with only a parent component did not significantly change our meta-analysis results, although point estimates of effect were nominally different.

Key Question 2: In children under 18 years of age treated for disruptive behaviors, are alpha-agonists, anticonvulsants, beta-blockers, central nervous system stimulants, first-generation antipsychotics, second-generation (atypical) antipsychotics, and selective serotonin reuptake inhibitors more effective for improving short-term and long-term psychosocial outcomes than placebo or other pharmacologic interventions?

Overview of the Literature for KQ2

This section presents results of studies meeting our review criteria and addressing the effectiveness of pharmacologic treatments for disruptive behavior. Thirteen studies¹⁷⁶⁻¹⁸⁸ (reported in 15 papers)¹⁷⁶⁻¹⁹⁰ of medical intervention met the criteria for inclusion. Medical studies fall into four major categories; antipsychotic, antiepileptic drugs, typically targeted to aggression in children,¹⁹¹ and a group of drugs comprising both stimulants and nonstimulants typically used in children with comorbid ADHD (Table 31). Three studies evaluated short-term quality of life outcomes. No studies were of drugs with an FDA indication for DBD.

Table 31. Study characteristics (KQ2)

| Characteristic | | Antipsychotic | Antiepileptic | Stimulant | Nonstimulant | All |
|------------------------------|-----------------------|---------------|---------------|-----------|--------------|-----------|
| Study design | RCT | 4 | 3 | 2 | 3 | 12 |
| | Cohort | 1 | 0 | 0 | 0 | 1 |
| Location | USA/ Canada | 4 | 3 | 2 | 1 | 10 |
| | Europe | 0 | 0 | 0 | 2 | 2 |
| | Australia | 0 | 0 | 0 | 0 | 0 |
| | Other | 1 | 0 | 0 | 0 | 1 |
| Study Population | Mean age, years | 10.7 | 14.9 | 10.6 | 10.1 | 11.3 |
| | Proportion males, % | 89 | 86 | 79 | 82 | 85 |
| | Randomized | 435 | 108 | 391 | 537 | 1471 |
| | Analyzed ^a | 433 | 105 | 368 | 533 | 1439 |
| Outcome Measure ^b | CGI-S | 3 | 2 | 1 | 0 | 6 |
| | CGI-I | 3 | 1 | 1 | 0 | 5 |
| | OAS | 2 | 3 | 0 | 0 | 5 |
| | SNAP-IV | 0 | 0 | 1 | 2 | 3 |
| | Connors | 2 | 1 | 1 | 1 | 5 |
| | Others | 6 | 6 | 1 | 0 | 13 |
| Source of Funding | Industry | 3 | 1 | 1 | 3 | 8 |
| | Government | 0 | 0 | 1 | 0 | 1 |
| | Mixed | 1 | 2 | 0 | 0 | 3 |
| | Not Reported | 1 | 0 | 0 | 0 | 1 |
| Risk of Bias | High | 2 | 0 | 2 | 1 | 5 |
| | Moderate | 2 | 3 | 0 | 2 | 7 |
| | Low | 1 | 0 | 0 | 0 | 1 |
| Total | | 5 | 3 | 2 | 3 | 13 |

OAS = Overt Aggression Scale; CGI-S = Clinical Global Impressions-Severity-; CGI-I = Clinical Global Impressions-Improvement; SNAP-IV = Swanson, Nolan, and Pelham Rating Scale-Revised

^aSome studies do not report the number analyzed.

^bNumbers do not tally as studies could use more than one measure.

Key Points for KQ2

- Thirteen studies (12 RCTs and 1 cohort study) evaluated pharmacologic treatment for DBDs. One RCT was assessed as low risk of bias; seven were assessed as moderate risk of bias, and four as high risk of bias. The one nonrandomized controlled study was assessed as high risk of bias.
- Almost all studies were wholly or partially funded by a pharmaceutical industry. One study was federally funded.
- The duration of studies was short, with a range of 4 to 10 weeks. One study assessed 6 months of maintenance therapy.
- Studies of antipsychotic medications had mixed results over the short term, including differences in clinician versus parent rated outcomes within the same study.
- Valproic acid, an antiepileptic, also showed mixed results in RCTs, with one placebo-controlled study favoring the intervention, and another study demonstrating no significant difference. In one dosing study, higher doses were associated with greater effectiveness than lower doses.
- In one high risk of bias RCT, stimulants were associated with significant improvements in the ODD subscore of the parent-rated SNAP-IV for children and adolescents with ODD who were treated with mixed amphetamine salts extended release at doses of 30 mg/day over 5 weeks compared to placebo; and in one RCT (high risk of bias), use of methylphenidate (up to 60 mg/day in 2 divided doses) over a 5-week period in a school-aged population with CD symptoms found both teacher and parent ratings of CD problems improved compared to placebo
- In studies of nonstimulant ADHD medications, two RCTs (1 high and 1 moderate risk of bias) reported that atomoxetine was more effective than placebo in significantly reducing ODD symptoms as measured by the Swanson, Nolan, and Pelham Rating Scale-Revised (SNAP-IV) ODD subscore. Results were maintained up to 9 weeks among school-aged children with comorbid ADHD and ODD.
- In one moderate risk of bias RCT, guanfacine extended release significantly reduced oppositional symptoms for up to 9 weeks as measured by the CPRS-R:L oppositional subscale scores compared with placebo among children with ADHD and comorbid ODD.

Detailed Analysis

Antipsychotics

We identified five studies that address the use of atypical antipsychotic medications for the treatment of DBDs (Table 32 and Table 33). The most well studied antipsychotic was risperidone, for which there were three RCTs.^{181,183,186} In addition, one study compared aripiprazole to ziprasidone¹⁸⁸ and one study compared quetiapine to placebo.¹⁸⁰ These studies were funded by the pharmaceutical company that markets the drug studied, except for the aripiprazole and ziprasidone study, for which funding was not specified, but in which all authors had served on the speaker bureau for those manufacturers.

Risperidone

Three studies compared risperidone to placebo, but under different circumstances.^{181,183,186} One compared initial risperidone treatment to placebo, one examined the role of risperidone as

an augmentation to stimulant medication, and the third assessed the role of risperidone as maintenance treatment after initial risperidone treatment.

A low risk of bias RCT¹⁸⁶ measured the effect of risperidone on aggression, as measured by the Ratings of Aggression Against People (RAAP) scale. This study was funded by a combination of NICHD funding and the Janssen Research Foundation, and received low risk of bias scored in all domains. Twenty participants were included with 10 randomized to each arm. The trial lasted 10 weeks and took place at a single U.S. academic medical center outpatient clinic. Participants included 19 male and one female, with a mean age of 9.2 years (range: 6 to 14 years, inclusive). The RAAP score difference from baseline over the final four weeks of the 10-week study was -0.7 for the placebo group and -1.91 for the risperidone group ($p=0.0007$). In addition, the Clinical Global Impressions-Severity (CGI-S) scale was used as a secondary outcome, and the change was significantly greater for the risperidone group compared to the placebo group (-2.46 vs. -1.06, $p=0.01$). The average number of tablets was 5.0 (0.4) for patients treated with placebo and 4.1 (0.3) for patients treated with risperidone.

The study of risperidone as augmentation to stimulant was also an RCT (moderate risk of bias).¹⁸¹ Twenty-five children between the ages of 7 and 12, mostly male (22/25) and with a co-diagnosis of ADHD and symptoms of aggression, were included. The primary measures of aggression were the Children's Aggression Scale, parent (CAS-P) and teacher (CAS-T) versions. Mean dose by the end of the 4-week study was 1.08 mg/day for the risperidone group and 1.04 mg/day for placebo. No significant differences in effect were observed on either version of the CAS or the Clinical Global Impressions (CGI).

Finally, a large multicenter RCT (high risk of bias) examined the role of risperidone as maintenance treatment after an initial 12-week treatment period.¹⁸³ Participants were primarily boys, ages 5 to 17 ($n = 335$) and were randomized to 6 months of risperidone or placebo after an initial 12 weeks of treatment with risperidone. Eligible patients had a *DSM-IV* diagnosis of conduct disorder, ODD, or DBD, not otherwise specified. Outcomes were assessed using the Nisonger Child Behavior rating form, the CGI and CGAS. The study was conducted from 2011-2003 in seven countries in Europe and one country in Africa (S. Africa). During the 6-month maintenance phase of the study, the average risperidone dose was 0.81 mg/day for children less than 50kg and 1.22 mg/day for children who weighed greater than or equal to 50 kg. At the end of the study, Nisonger Child Behavior Rating Form score for Conduct problems increased (worsened) from the end of the acute phase by 5.0 (9.5) points in the risperidone group ($n = 172$) and by 8.8 (11.2) points in the placebo group ($n = 163$). The CGI-S increased (worsened) by 0.6 (1.2) in the risperidone group and 1.2 (1.4) in the placebo group. The CGAS decreased (worsened) by 3.5 (12.4) points in the risperidone group and 10.2 (14.5) points in the placebo group. All differences were statistically significant ($p<0.001$). However, this study is challenged by high attrition, with only 58 percent (100/172) of the treatment group and 38 percent (62/163) of the placebo group completing. Overall, there was little difference between risperidone and placebo in the maintenance treatment.

Table 32. Difference in disruptive behavior for studies of antipsychotic medications

| Author, Year Country (N Randomized) Risk of Bias | Group: Intervention [Dose] (N Analyzed) | Outcome (Measure) | Baseline Mean (SD) | Last Followup Mean (SD) | Change from Baseline to Last Followup | Between- Group Difference ^a |
|-----------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------|----------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------|--------------------------------------------------------------|
| Connor DF, et al., 2008 ¹⁸⁰ United States (19) Moderate | G1: Quetiapine [294 (78) mg/d] (9) G2: Placebo (10) | Disruptive behavior (CGI-S) | G1: 5.9 (0.6) G2: 5.5 (1.2) | Study week 7 G1: 3.4 (1.1) G2: 5.0 (0.6) | G1: NR G2: NR | G1 vs. G2: 1.6 (95% CI: 0.9 to 3.0), p=0.007 |
| Findling RL, et al., 2000 ¹⁸⁶ United States (20) Low | G1: Risperidone [0.028 (0.004) mg/kg/day, range: 0.75 to 1.50 mg/d] (10) G2: Placebo (10) | Disruptive behavior (CGI-S) | G1: NR G2: NR | Study week 10 G1: 2.32 (0.50) G2: 4.92 (0.68) | G1: -2.58 (0.49) G2: -0.08 (0.66) | G1 vs. G2: p=0.003 |
| Reyes M, et al., 2006 ¹⁸³ Multinational (335) High | G1: Risperidone [0.81 (0.34) mg/d; ^b 1.22 (0.36) mg/d ^c] (172) G2: Placebo (163) | Conduct Problems (NCBR) | G1: NR G2: NR | G1: NR G2: NR | G1: 5.0 (9.5) G2: 8.8 (11.2) | G1 vs. G2: p<0.001 |
| | | Disruptive behavior (CGI-S) | G1: NR G2: NR | G1: NR G2: NR | G1: 0.6 (1.2) G2: 1.2 (1.4) | G1 vs. G2: p<0.001 |
| | | Disruptive behavior (CGAS) ^d | G1: NR G2: NR | G1: NR G2: NR | G1: -3.5 (12.4) G2: -10.2 (14.5) | G1 vs. G2: p<0.001 |

CI=confidence interval; NR=not reported; CGI-S=Clinical Global Impressions-Severity; NCBR=Nisonger Child Behavior Rating Form; CGAS=Children's Global Assessment Scale; mg/d=milligram per day; mg/kg/day=milligram per kilogram per day

^a The between-group difference refers to the difference in the change from baseline to last followup between the intervention and comparison group. Effect favors G1 unless noted otherwise.

^b Mean dose during maintenance phase for patients weighing less than 50 kg.

^c Mean dose during maintenance phase for patients weighing 50 kg or more.

^d Higher CGAS score indicates improvement.

Table 33. Difference in aggression for studies of antipsychotic medications

| Author, Year Country (N Randomized) Risk of Bias | Group: Intervention [Dose] (N Analyzed) | Outcome (Measure) | Baseline Mean (SD) | Last Followup Mean (SD) | Change From Baseline to Last Followup | Between- Group Difference ^a |
|--------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------|----------------------|--------------------------------------------------------|--------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------|
| Bastiaens L, 2009 ¹⁸⁸ United States (46) High | G1: Aripiprazole [range: 2.5 to 5.0 mg/d] (20) G2: Ziprasidone [range: 20 to 40 mg/d] (14) | Aggression (OAS) | G1: 6.8 (1.8) G2: 7.4 (2.1) | G1: 2.3 (2.9) G2: 3.1 (2.0) | G1: -4.5 (p=0.0005) G2: -4.3 (p=0.0018) | G1 vs. G2: p=NS |
| Connor DF, et al., 2008 ¹⁸⁰ United States (19) Moderate | G1: Quetiapine [294 (78) mg/d] (9) G2: Placebo (10) | Aggression (OAS) | G1: 73.2 (34.3) G2: 40.4 (23.8) | G1: 43.3 (55.6) G2: 49.4 (27.8) | NR | G1 vs. G2: p=NS |

Table 33. Difference in aggression for studies of antipsychotic medications (continued)

| Author, Year Country (N Randomized) Risk of Bias | Group: Intervention [Dose] (N Analyzed) | Outcome (Measure) | Baseline Mean (SD) | Last Followup Mean (SD) | Change From Baseline to Last Followup | Between- Group Difference ^a |
|---------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|----------------------|------------------------------------------------|-------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|---------------------------------------------------------|
| Findling RL, et al., 2000 ¹⁸⁶ United States (20) Low | G1: Risperidone [0.028 (0.004) mg/kg/d, range: 0.75 to 1.50 mg/d] (10) G2: Placebo (10) | Aggression (RAAPP) | G1: NR G2: NR | Study week 10 G1: 2.24 (0.42) G2: 3.00 (0.30) | G1: -1.65 (0.40) G2: -0.16 (0.54) | G1 vs. G2: p=0.03 |
| Armenteros JL, et al., 2007 ¹⁸¹ United States (25) Moderate | G1: Risperidone [1.08 (0.63) mg/d] (12) G2: Placebo [1.04 (0.52) mg/d] (13) | Aggression (CAS-P) | G1: 12.9 (7.2) G2: 12.1 (5.2) | Data shown in figure only | % improved from baseline G1: 100 G2: 77 | Effect size G1: 7.9 G2: 7.4 p=NS |
| | | Aggression (CAS-T) | G1: 3.9 (3.6) G2: 5.1 (4.5) | G1: NR G2: NR | % improved from baseline G1: 27 G2: NR | G1 vs. G2: p=NS |
| | | Aggression (CGI-S) | G1: 4.5 G2: 4.5 | G1: 3.2 G2: 3.2 | G1: NR G2: NR | G1 vs. G2: p=NS |
| | | Aggression (CGI-I) | G1: NR G2: NR | NR | G1: -1.0 G2: -0.5 % improved from baseline G1: 75 G2: 38 | G1 vs. G2: p=0.06 |

LSM = least square mean; CI = confidence interval; ND = no data; NR = not reported; OAS = Overt Aggression Scale; CGI-S = Clinical Global Impressions-Severity; CGI-I = Clinical Global Impressions-Improvement; RAAPP = Rating of Aggression Against People and/or Property; CAS-P = Children’s Aggression Scale-Parent; CAS-T = Children’s Aggression Scale-Teacher; mg/d = milligram per day

^a The between-group difference refers to the difference in the change from baseline to last followup between the intervention and comparison group.

Aripiprazole Versus Ziprasidone

One nonrandomized, open trial (high risk of bias)¹⁸⁸ measured the difference in effect between aripiprazole and ziprasidone on aggression ratings in a sample of 46 mostly male (36/46) patients between the ages of 6 and 18 at an American outpatient clinic. Patients were eligible for inclusion if they demonstrated clinically significant aggressive behavior, deemed severe enough to warrant pharmacotherapy. Measurements were taken at baseline and after two months of treatment. Participants in both groups had reductions in their scores on the Overt Aggression Scale (OAS). Across groups there was a reduction among completers from 7.1 (1.9) to 2.6 (2.5). There was no difference in effect between the groups. The aripiprazole group had a mean decrease of 4.5 points on the OAS and the ziprasidone group had a mean decrease of 4.3 points on the OAS.

Quetiapine Versus Placebo

One randomized, controlled trial (moderate risk of bias)¹⁸⁰ compared the efficacy of quetiapine versus placebo for reducing aggression, assessed via the parent-rated OAS and clinician-rated CGI. Additional measures were the parent-rated Conners Parent Rating Scale

(CPRS) and Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q). Study participants met criteria for a primary diagnosis of conduct disorder and were documented to have moderate-to-severe aggressive behavior (OAS score ≥ 25) and at least moderate severity of symptoms (CGI-S score ≥ 4).

The study was conducted at a single academic medical center in the United States. Nine patients were randomized to receive quetiapine, and 10 were randomized to receive placebo. Patients were between the ages of 12 and 17, inclusive and were mostly male (14/19). The patients were recruited from a single site and the trial lasted for 7 weeks, including 6 weeks of quetiapine versus placebo. At the end of the study, the average (SD) daily dose of quetiapine was 294 (78) mg. While no difference was observed on the OAS (rated by parents), there was a significant difference in outcomes measured by the CGI (rated by clinicians). The quetiapine group average CGI score fell from 5.9 to 3.4 over six weeks and the placebo group fell from 5.5 to 5.0, for a difference between groups of 1.8 (95% CI: -0.53 to -3.1). The additional measures were CPRS (no significant difference) and Q-LES-Q, which showed an improved quality of life rating for the parents of the children in the quetiapine group (11.3 units) compared with a decrease of 4.1 units in the placebo group ($p=0.005$). Overall, the results were mixed regarding difference between quetiapine and placebo.

Antiepileptics

Valproic Acid

We identified two independent studies and one related pair of studies that addressed the use of valproic acid in the treatment of disruptive behavior in children (Table 34).^{178,184,185,189} These studies were funded by the drug manufacturer, Abbott pharmaceuticals, except for one,¹⁸⁵ which was funded by a grant from the National Institute of Drug Abuse.

Table 34. Difference in disruptive behavior for studies of valproic acid at last followup

| Author, Year Country (N Randomized) Risk of Bias | Group: Intervention [Dose] (N Analyzed) | Outcome (Measure) | Baseline Mean (SD) | Last Followup Mean (SD) | Mean Change | Between- Group Difference ^a |
|-------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|-----------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|----------------------------------------------------------------------|---------------------------------------------------------------------|
| Blader et al., 2009 ¹⁷⁸ United States (30) Moderate | G1: Divalproex [567 \pm 291 mg/d] (14) G2: Placebo (13) | Aggression, retrospective (OAS) | G1: 62.13 (42.63) G2: 61.54 (28.98) | G1: 32.13 (44.14) G2: 35.77 (28.86) | % who met remission criteria G1: 57 G2: 15 | G1 vs. G2: 41.76% difference (95% CI: 10 to 74%) |
| Donovan et al., 2000 ¹⁸⁵ United States (20) Moderate | G1: Divalproex [750-1500 mg/d] (7) G2: Placebo (8) | Aggression symptom improvement (OAS) | G1: NR G2: NR | G1: NR G2: NR | % who improved G1: 86 G2: 25 | G1 vs. G2: $p=0.003$ |
| Steiner et al., 2003 ¹⁸⁴ and Padhy et al., 2011 ¹⁸⁹ United States (71) Moderate | G1: Divalproex [1000 mg] (34) G2: Divalproex [125 mg] (24) | Disruptive behavior (CGI-I) | G1: NR G2: NR | G1: NR G2: NR | % much improved G1: 53 G2: 8 | G1 vs. G2: $p<0.0008$ |

CGI-I = Clinical Global Impressions-Improvement; NS = not significant; OAS = Overt Aggression Scale; mg/d = milligram per day

^aThe between-group difference refers to the difference in the change from baseline to last followup between the intervention and comparison group.

Valproic Acid Versus Placebo

One randomized, placebo-controlled study (moderate risk of bias)¹⁷⁸ measured the effect of valproic acid in reducing aggressive behavior in younger children, from ages 6 to 13 years, with 21 of 27 males, who had aggression persisting after a trial of stimulant medications. Thirty patients were randomized to add-on valproic acid or placebo adjunctive to stimulant medication for eight weeks. The study participants were boys (n = 21) and girls (n = 6) with a diagnosis of ADHD and a co-diagnosis of either ODD or CD. Enrollment occurred between 2004 and 2007 at two academic medical centers in the United States. The mean daily dose of children in the valproic acid group was 567 mg/day (mean serum level: 68.11 mg/liter) and the children assigned to the placebo group had a drug equivalent dose of 685 mg.

The primary outcome was scoring on the Retrospective-Modified Overt Aggression Scale (R-M OAS). Thirteen patients in the placebo group and 14 patients in the valproic acid group were analyzed due to withdrawal prior to first assessment. The scores on the R-M OAS dropped from 41.80 to 32.13 in the valproic acid group and from 53.31 to 35.77 in the placebo group, with no significant difference between groups.

Another placebo-controlled crossover RCT (moderate risk of bias)¹⁸⁵ included children and adolescents, ages 10 to 18, mostly male (16/20) with conduct disorder or oppositional defiant disorder. The study was conducted at an outpatient clinic at an academic medical center in the United States. A blinded assessor rated the modified OAS and the SCL-90 Anger Hostility items. Response was measured as greater than or equal to 70 percent decrease from baseline in the combined scores of these items. The final dose of valproic acid ranged from 750 to 1500 mg per day. In the first 6-week phase of the study, 10 patients were randomized to the valproic acid arm and eight patients responded. None of the 10 patients randomized to the placebo arm responded.

During the second 6-week phase of the study, the participants crossed over to the alternate intervention; six of seven nonresponders to placebo in the initial phase achieved response in the treatment phase. Of the eight who switched from the treatment group to placebo in phase 2, all of whom had responded in phase 1, six relapsed.

High Dose Versus Low Dose Valproic Acid

One moderate risk of bias randomized, placebo-controlled study (reported in two publications)^{184,189} measured the effect of valproic acid on a group of adolescent male patients with a diagnosis of conduct disorder from a correctional facility in California. The trial was 7 weeks long with 6 weeks of active treatment. Data were analyzed from 58 completers, all of whom had at least one offense “against persons.” The study included a (blinded) clinician-reported CGI. In the high dose group (mode=1000 mg/day, n = 34), 53 percent were “very much or much improved,” 29 percent were “minimally improved” and 18 percent were “no change or minimally worse.” In the low dose group (mode=125 mg/day, n = 24) 8 percent were “very much or much improved,” 42 percent were “minimally improved” and 50 percent were “no change or minimally worse.” The second paper of this family¹⁸⁹ focused on the difference between treatment with high or low dose valproic acid on High Distress Conduct Disorder (HDCD) and Low Distress Conduct Disorder (LDCD). In the high dose group, 25 were identified as HDCD and nine with LDCD. Of those with HDCD on high dose valproic acid, 16 showed a response as measured by CGI-I (defined as improved, much improved or very much improved) and nine showed no response (defined as No Response). Of those with HDCD on low dose valproic acid, two were responders and 14 showed no response. Of those with LDCD on high dose valproic acid, two were responders and seven showed no response. Of those with LDCD on low dose valproic acid, none showed response and eight showed no response. Overall,

valproic acid appeared more effective at high dose than low dose, and more effective in the HDCD group than the LDCD group.

Overview of Medications Commonly Used To Treat ADHD

A number of drugs typically used to treat ADHD are also used in the treatment of disruptive behaviors, most often with children who have comorbid ADHD and DBD. They fall into two primary classes: stimulants and nonstimulants.

We identified two studies that evaluated the use of stimulants: methylphenidate¹⁸⁷ and mixed amphetamine salts extended release.¹⁸² We identified three studies (reported in 4 papers) that addressed the use of pharmacologic agents that are nonstimulants: selective norepinephrine reuptake inhibitor atomoxetine^{176,179,190} and the central alpha2A-adrenergic receptor agonist guanfacine.¹⁷⁷ All five studies were RCTs and were conducted in Germany,¹⁷⁶ Italy,¹⁷⁹ and the United States.^{177,182,187} We rated two as moderate risk of bias, and three as high risk of bias. All studies were conducted among school-aged children (range: 6 to 17 years of age).

All studies provided definitions for ODD/CD/DBD, however, most included populations with comorbid ADHD. For the nonstimulant ADHD medications, the two RCTs of atomoxetine^{176,179} (reported in 3 papers^{176,179,190}) studied children with ADHD and comorbid ODD, as defined by the DSM-IV-TR. One RCT of guanfacine studied children with ADHD defined by DSM-IV-TR and oppositional symptoms according to the subscale of the Conners Parent rating Scale Long form (CPRS-R:L).¹⁷⁷ For the ADHD stimulant medications, the RCT of methylphenidate¹⁸⁷ used *DSM-III* criteria for CD with slight modification where two-thirds had comorbid ADHD, as defined by *DSM-IV* criteria. The RCT of amphetamine¹⁸² included children with ODD as defined by *DSM-IV-TR*, 79 percent had comorbid ADHD.

Outcomes efficacy measures for ODD symptoms included either the SNAP-IV ODD subscore or the oppositional subscore of the Conners Parent rating scale. Two papers also reported quality of life.^{179,190} The duration of studies was short, ranging from 4 to 9 weeks. Three of the studies were industry sponsored.^{176,179,182}

Stimulants Overview

Two studies, one industry-funded¹⁸² and one funded in part by the National Institute of Mental Health,¹⁸⁷ assessed as high risk of bias evaluated the use of two different stimulant medications (amphetamine, methylphenidate) among children with DBD (Table 35).

The first was conducted in the United States and evaluated four different doses of mixed amphetamine salts extended release compared to placebo over a 4-week period among children and adolescents aged 6 to 17 years with ODD as defined by *DSM-IV-TR*.¹⁸² Most (79%) had comorbid ADHD; however, results were not presented separately for this subgroup. The mean age of patients was 10.6 years among those who received mixed amphetamine salts extended release and 10.5 years in the placebo group; 69 percent were male. Significant improvements were observed in the ODD subscale of the SNAP-IV parent rating for doses of 30 mg/day (least squares mean difference from baseline: -0.43) compared to placebo ($p < 0.005$).

One RCT (high risk of bias) also conducted in the United States evaluated use of methylphenidate (up to 60 mg/day in 2 divided doses) compared to placebo over a 5-week period among a school-aged population with CD symptoms.¹⁸⁷ Criteria for CD were defined by *DSM-III* with slight modification; two-thirds of the population had comorbid ADHD, as defined by *DSM-IV*. The mean age was 10.2 years in the treatment group and 10.2 years in placebo with 88 and 90

percent proportion of males, respectively. Results found both teacher and parent ratings of CD problems improved compared to placebo.

Table 35. Difference in disruptive behavior for studies of stimulant medications

| Author, Year Country (N Randomized) Risk of Bias | Group: Intervention [Dose] (N Analyzed) | Outcome (Measure) | Baseline Mean (SD) | Last Followup Mean (SD) | Mean Change (SD) | Between-Group Difference ^a |
|--------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------|
| Spencer et al., 2006 ¹⁸² United States (308) High | G1: MAS XR [10 mg/d] (58) G2: MAS XR [20 mg/d] (56) G3: MAS XR [30 mg/d] (64) G4: MAS XR [40 mg/d] (59) G5: Placebo (60) | ODD Symptoms (SNAP-IV ODD, Parent report) | Baseline data in figures only | Followup data in figures only | LSM differences G1: -0.23 G2: -0.26 G3: -0.43 G4: -0.30 | G3 vs. G5: p<0.005 All treatment groups vs. G5: p=0.024 |
| | G1: MAS XR [10 mg/d] (30) G2: MAS XR [20 mg/d] (31) G3: MAS XR [30 mg/d] (34) G4: MAS XR [40 mg/d] (27) G5: Placebo (30) | ODD Symptoms (SNAP-IV ODD, Teacher report) | G1: 1.1 (0.76) G2: 1.24 (0.91) G3: 0.92 (0.81) G4: 1.09 (0.90) G5: 0.91 (0.76) | G1: 0.66 (0.68) G2: 0.72 (0.86) G3: 0.45 (0.58) G4: 0.68 (0.64) G5: 0.95 (0.94) | G1: -0.43 (0.77) G2: -0.45 (0.91) G3: -0.46 (0.57) G4: -0.49 (0.78) G5: 0.09 (0.62) | G1 vs. G5: p=0.047 G2 vs. G5: p=0.043 G3 vs. G5: p=0.003 G4 vs. G5: p=0.059 |
| Klein et al, 1997 ¹⁸⁷ United States (84) High | G1: Methylphenid ate hydrochloride [up to 60 mg/d] (36) G2: Placebo (35) | Conduct problems overall rating (Connor Teaching Rating scale) | G1+ G2: 2.6 (0.7) | G1: 1.3 (0.1) G2: 2.3 (0.1) | NR | p<0.001 |

SNAP-IV = Swanson Nolan and Pelham-IV; ODD = oppositional defiant disorder; LSM = least square mean; MAS = mixed amphetamine salts; NR = not reported; XR = extended release; mg/d = milligram per day

^a The between-group difference refers to the difference in the change from baseline to last followup between the intervention and comparison group.

Amphetamine Salts (Adderall)

One high risk of bias multicenter, randomized, double blind, placebo-controlled study examined the efficacy and safety of mixed amphetamine salts extended release for the treatment of children and adolescents with ODD.¹⁸² Children and adolescents with ODD (n = 308) were randomized 1:1:1:1 to receive active treatment with mixed amphetamine salts extended release 10 mg/day (n = 60), 20 mg/day (n = 58), 30 mg/day (n = 69), or 40 mg/day (n = 61) or placebo (n = 60) for 4 weeks with forced dose escalation after a washout period. Eligible participants were aged 6 to 17 years with ODD as defined by *DSM-IV-TR*. Patients with conduct disorder were excluded. The primary outcome was the ODD subscale of the SNAP-IV parent rating. Secondary outcomes include the ODD subscale of the SNAP-IV teacher ratings, ADHD subscales of the SNAP-IV parent and teacher ratings, the child health questionnaire parent form 50 (CHQ-PF50) and adverse events. A total of 244 patients (79.2%) had comorbid ADHD, however results were not presented among this subgroup. The mean baseline score for the ODD subscale of the SNAP-IV parent rating did not differ by treatment group. In the intention-to-treat

population, statistically significant improvements in oppositional symptoms as measured by the parent-rated SNAP-IV ODD subscale were observed in the least squares mean difference (-0.43) for those in the higher dose (30 mg/day) group compared with the placebo group ($p < 0.005$). Statistically significant improvements for the teacher rated ODD subscale of the SNAP-IV from baseline to endpoint was seen in the intention-to-treat populations who received mixed amphetamine salts extended release 10 mg/day ($p = 0.047$), 20 mg/day ($p = 0.043$), and 30 mg/day ($p = 0.003$), compared to placebo group. Mixed amphetamine salts extended release was associated with improvement in quality of life outcomes, measured with the CHQ, including statistically significant improvements in behavior, physical and psychosocial summary for those in the mixed amphetamine salts extended release 30 and 40 mg/day groups compared to placebo; and for self-esteem in the mixed amphetamine salts extended release 40 mg/day group compared to placebo. When stratified by baseline symptoms in a post hoc reanalysis of the per protocol population, mean changes from baseline in the ODD subscore of the parent rated SNAP-IV was greater for the high baseline ODD severity group.

Methylphenidate (Ritalin)

The second stimulant study that we identified compared methylphenidate to placebo in an RCT including 83 children and adolescents with CD.¹⁸⁷ Participants received methylphenidate ($n = 41$) or placebo ($n = 42$) for 5 weeks with a maximum dose of 60 mg per day in two divided doses to evaluate symptoms of CD. Eligible participants were 6 to 15 years of age and met *DSM-II* criteria for CD, which were slightly modified; moderate to severe impairment rating by teacher or parents, and an IQ greater than 70. *DSM-IV* criteria were used to diagnose ADHD. Primary outcomes were parent and teacher ratings of CD symptoms based on the Conners Teacher Rating Scale, and subscales of the Quay revised behavior problem checklist, and global estimates of the severity of behavioral problems. Participants mean age was 10.2 (2.3) years in the methylphenidate group and 10.2 (2.5) years in the placebo group. All but two children had at least three symptoms of CD, consistent with *DSM-IV* criteria; 69 percent of the population also met *DSM-IV* criteria for ADHD, however, results were given for the entire sample and not by those with comorbid ADHD separately. Baseline teacher overall rating for conduct problems was 2.6 (0.7). Teacher rated overall conduct problems were significantly less for those children taking methylphenidate [1.3 (0.1)] compared to placebo [2.3 (0.1), $p < 0.001$] and factor scores including aggression, conduct problems, and conduct disorder were significantly improved compared to placebo. Teacher ratings of ADHD symptoms were also significantly improved among those who received methylphenidate compared to placebo. Significant improvements on parent ratings of aggression, conduct problems, and conduct disorder were seen in the methylphenidate group compared to placebo. Socialized aggression showed no statistical improvement on either the parent or the teacher ratings. Among 47 elementary school-aged children, classroom observers' ratings showed significant improvements among methylphenidate compared to placebo groups with regards to global rating of conduct problem severity and aggression (Iowa scale).

Nonstimulants

Three studies^{176,177,179} reported in four publications^{176,177,179,190} evaluated the efficacy of nonstimulants on oppositional symptoms among children with ADHD and ODD symptoms (Table 36). All were RCTs and were conducted in Germany, Italy, and the United States. We assessed risk of bias as moderate in two studies^{176,177} and high in one study.¹⁷⁹ All were conducted among school-aged children (range 6 to 17 years of age).

Two RCTs^{176,179} addressed the use of atomoxetine in children with ADHD and comorbid ODD/CD. Atomoxetine is a centrally acting, norepinephrine reuptake inhibitor with minimal affinity for other neurotransmitter receptors. Atomoxetine was approved by the FDA for treatment of ADHD in children, adolescents, and adults in 2002.¹⁹² These two RCTs were designed specifically to examine the effects of treatment on oppositional symptoms in children with ADHD and comorbid ODD defined by the *DSM-IV-TR*. The RCTs included 226 participants in treatment arms, and 91 participants in placebo arms. Participants had an average age of 10.9 and 9.7 years in the treatment groups and 11.1 and 10.0 years in the placebo groups of each trial, respectively. More male subjects were included in both treatment (86%, 93%) and placebo groups (81%, 91%) of each trial, respectively. Both trials evaluated doses titrated up to 1.2 mg per kg per day.

Outcome efficacy measures for ODD symptoms were from the SNAP-IV ODD subscore. Mean (SD) baseline SNAP-IV ODD sub-scores were 15.5 (4.4) and 17.2 (NR) in treatment groups and 15.6 (5.1) and 17.5 (NR) in placebo groups for the 2011¹⁷⁶ and 2009¹⁷⁹ studies, respectively. Both RCTs reported significant improvements in ODD symptoms, as measured by either the SNAP-IV ODD subscale or the Conners Parent rating Scale Long (CPRS-R:L) over an 8- to 9-week period. One study¹⁷⁶ reported significant improvement in quality of life in a separate publication¹⁹⁰ and one study¹⁷⁹ found no significant differences in overall quality of life scores over the 8-week period but did find improvements in certain subdomains (risk avoidance, emotional comfort).

We identified one study that evaluated the use of the nonstimulant guanfacine extended release (1-4 mg/day) in children with ADHD and comorbid ODD.¹⁷⁷ ADHD was defined by the *DSM-IV-TR* and oppositional symptoms according to the subscale of the CPRS-R:L form. Guanfacine extended release is a selective central alpha2A-adrenergic receptor agonist indicated for the treatment of ADHD in children ages 6 to 17 years as monotherapy and as adjunctive therapy to stimulant medication. Guanfacine extended release significantly reduced oppositional symptoms as measured by the CPRS-R:L oppositional subscale scores compared with placebo. The duration of all three studies was short, ranging from 8 to 9 weeks. All of the studies were industry sponsored.

Table 36. Difference in disruptive behavior for studies of nonstimulant medications

| Author, Year Country (N Randomized) Risk of Bias | Group: Intervention [Dose] (N Analyzed) | Outcome (Measure) | Baseline Score, Mean (SD) | Last Followup Mean (SD) | Mean Change (SD) | Between- Group Difference ^a |
|------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|----------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|
| Dittmann et al., 2011 ¹⁷⁶ and Wehmeier et al., 2011 ¹⁹⁰ Germany (180) Moderate | G1: Atomoxetine fast titration [0.5/1.2 mg/kg/day] (44) G2: Atomoxetine slow titration [0.5/0.8/1.2 mg/kg/day] (48) G3: Placebo (37) | ODD behavior (SNAP-IV ODD) | G1: 15.5 (4.1) G2: 15.6 (3.8) G3: 15.6 (5.1) | % who improved by at least 30% G1: 48.3 G2: 55.7 G3: 35.6 | LSM [95% CI] G1: 8.6 [7.2, 9.9] G2: 9.0 [7.7, 10.3] G3: 12.0 [10.6, 13.5] | G1 + G2 vs. G3: effect size: 0.69, p<0.001 G1 vs. G2: effect size: -0.09, p=0.669 |

Table 36. Difference in disruptive behavior for studies of nonstimulant medications (continued)

| Author, Year Country (N Randomized) Risk of Bias | Group: Intervention [Dose] (N Analyzed) | Outcome (Measure) | Baseline Score, Mean (SD) | Last Followup Mean (SD) | Mean Change (SD) | Between- Group Difference ^a |
|-----------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|-------------------------------------|------------------------------------------------------|----------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|
| Dell'Agnello et al., 2009 ¹⁷⁹ Italy (137) High | G1: Atomoxetine [0.5/1.2 mg/kg/day] (105) G2: Placebo (32) | ODD behavior (SNAP-IV ODD) | G1: 17.2 (NR) G2: 17.5 (NR) | G1: 14.5 (NR) G2: 17.2 (NR) | G1: -2.7 (4.1) G2: -0.3 (2.6) | G1 vs. G2: p=0.001 |
| Connor et al., 2010 ¹⁷⁷ United States (217) Moderate | G1: Guanfacine XR [1.0-4.0 mg/d] (136) G2: Placebo (78) | ODD symptoms (CPRS-R:L) | G1: 19.3 (4.7) G2: 19.9 (4.3) | G1: NR G2: NR | Least squares mean reduction G1: -10.9 G2: -6.8 Change score % G1: 56.3 G2: 33.4 | G1 vs. G2: Mean change score effect size 0.59, p<0.001 mean % effect size 0.64 p<0.001 |

SNAP-IV = Swanson Nolan and Pelham-IV; ODD = oppositional defiant disorder; CPRS-R = Conners Parent Rating Scale-Revised; LSM = least square mean; CI = confidence interval; ND = no data; NS = not significant; NR = not reported; XR = extended release; mg/d = milligram per day; mg/kg/day = milligram per kilogram per day

^aThe between-group difference refers to the difference in the change from baseline to last followup between the intervention and comparison group.

Atomoxetine

A moderate risk of bias randomized, double-blind, placebo-controlled, three-arm, multicenter study was conducted in 20 sites in Germany to assess the efficacy of atomoxetine given once daily for 9 weeks (target dose: 1.2 mg/kg/day), using either fast or slow titration, for treating symptoms of ODD in children and adolescents with ADHD and comorbid ODD/CD.¹⁷⁶ Eligible participants were aged 6 to 17 years and met the DSM-IV-TR criteria for ADHD (any subtype) and DSM-IV criteria A through C for ODD; DSM-IV-TR criteria for CD was not an exclusion. Only outpatients were enrolled from primary and secondary sites. Participants were randomized to one of three arms: (1) atomoxetine 0.5 mg/kg/day for 7 days followed by the target dose of 1.2 mg/kg (atomoxetine fast titrating group, n = 60); (2) atomoxetine 0.5 mg/kg/day for 7 days, followed by 0.8 mg/kg/day for 7 days, followed by target doses of 1.2 mg/kg/day (atomoxetine-slow titrating group, n = 61); or (3) placebo (n = 59) for nine weeks, after a 3- to 28-day screening and washout period. The primary outcome was the investigator-rated SNAP-IV ODD subscale score. Other outcomes included the SNAP-IV ADHD subscale score and adverse events. Baseline characteristics were comparable for the three groups [84% male, mean age: 11 (3) years]. Participants DBD comorbidity was 74 percent (n = 134) ODD, 24 percent (n = 44) CD, with one patient meeting criteria for DBD, not otherwise specified and one for adjustment disorder. Baseline mean overall SNAP-IV ODD scores were 15.5 (4.35). Using a mixed effects model for repeated measures, treatment with atomoxetine once daily for nine weeks, pooling fast and slow titration arms, significantly reduced ODD symptoms compared to placebo, as measured by the SNAP-IV ODD score, least square mean treatment group difference at week 9, atomoxetine-pooled minus placebo: -3.2 (95% CI: -5.0 to -1.5), effect size: -0.69, p<0.001. The decrease in ODD symptoms was significant for both the fast and slow titration groups, (least square mean, atomoxetine-fast 8.6 (95% CI: 7.2, 9.9), atomoxetine-slow 9.0 (95% CI: 7.7, 10.3)

compared to placebo 12.0 (95% CI: 10.6, 13.5), $p < 0.001$, effects size -0.74 and $p = 0.003$, effect size -0.65 , respectively). SNAP-IV ODD scores improved at least 30 percent in 48.3 percent of patients in the atomoxetine fast titration group compared with 55.7 percent in the atomoxetine slow titration group and 35.6 percent in the placebo group. There were no significant differences between the atomoxetine fast and atomoxetine slow titration groups. Atomoxetine significantly reduced ADHD symptoms compared to placebo at week 9 as measured by the SNAP-IV ADHD subscale score. Patients in the atomoxetine slow titration group stayed on treatment significantly longer than did patients in the placebo group (HR=3.57; 95% CI: 1.42 to 8.94, $p = 0.007$). Study was sponsored by industry.

A second paper in the family of studies evaluated the outcome of quality of life in the same 9-week trial of atomoxetine (target dose 1.2 mg/kg/day) versus placebo.¹⁹⁰ Quality of life was measured using the parent rated KINDL-R questionnaire total scores and sub-scores on emotional well-being, self-esteem, friends, family, school, and physical well-being, a validated instrument. Family burden of illness was measured using the parent rated FaBel questionnaire, a German version of the Impact on Family Scale. At baseline, the mean overall KINDL-R scores were 62.9 (12.78) and the mean overall FaBel score were 53.8 (12.89). Among those treated with atomoxetine, the KINDL-R total score increased significantly compared to those in the placebo group, (mean change: 2.6 vs. -1.6 points) ANCOVA LS-mean difference, atomoxetine pooled minus placebo: 5.0 (0.8, 9.3), effect size: 0.377, $p = 0.021$), which was clinically relevant. There was no significant difference between the fast and slow titration groups in KINDL total or subscores. Quality of life subscores for emotional well-being, self-esteem, family, and friends increased significantly in patients treated with atomoxetine compared to placebo. There were no statistically significant differences in the KINDL-R school subscore; however the subscore on physical wellbeing was significantly worse for patients in the atomoxetine group compared to placebo. Authors felt the physical wellbeing subscore differences may be related to common treatment adverse effects. No significant treatment effects were seen on family burden, as measured by the FaBel total score. However, the FaBel impact on siblings subscore improved significantly more in the atomoxetine group compared to placebo.

Finally, a multicenter, double blind, placebo-controlled trial (high risk of bias) conducted in Italy evaluated the efficacy of atomoxetine over 8 weeks in improving ADHD and ODD symptoms in children and adolescents with ADHD and comorbid ODD who had been non-responders to a previous parent support intervention.¹⁷⁹ Eligible participants were 6 to 15 years of age, who were diagnosed with ADHD and ODD according to *DSM-IV* criteria, and were required to have a score of at least 1.5 SD above the age norm for the ADHD subscale of the SNAP-IV, a CGI-S score of four or higher at screening and baseline, a SNAP-IV ODD subscale score of at least 15, and a normal intelligence score. All patients were provided open-label, parent support for 6 weeks. Patients who did not respond to the parent support phase (response was defined as an improvement in CGI-S score of 2 or more from baseline and at least a 30 percent decrease from baseline in ADHD sub-score of SNAP-IV) were randomized 3:1 to atomoxetine ($n = 105$) or placebo ($n = 32$) once daily for 8 weeks.

The atomoxetine dose was titrated from 0.5 mg/kg/day to a target dose of 1.2 mg/kg/day in 7 days. The primary efficacy measure was the ADHD subscale score of the SNAP-IV; the ODD subscale score of the SNAP-IV was a secondary outcome. Other outcome measures included health related quality of life as measured by means of the parent-rated child health and illness profile-child edition (CHIP-CE), and adverse events. Of the 156 patients who participated in the parent support phase, 139 were randomized and 137 were included in the efficacy analysis.

Participants mean age was 9.7 (2.2) years in the atomoxetine arm and 10.0 (2.4) years in the placebo arm; 93 percent were males.

Mean baseline SNAP-IV ODD score was 17.5 for atomoxetine and 17.2 in the placebo arm. At the end of 8 week period the SNAP-IV ODD sub score significantly improved in the atomoxetine group compared to placebo [SNAP-IV ODD subscale score mean change: -2.7 (4.1) in the atomoxetine arm vs. -0.3 (2.6) in placebo arm, $p=0.0001$]. There was significant decrease in the ADHD subscale of the SNAP-IV in the atomoxetine arm compared to placebo. There was no significant differences between the mean changes of the CHIP-CE total score between atomoxetine (3.6) and placebo (1.2), $p=0.071$; however the atomoxetine group showed statistically significant differences compared to placebo for the subdomains of risk avoidance ($p=0.013$) and emotional comfort ($p=0.007$). The study was sponsored by industry.

Guanfacine (Intuniv)

A moderate risk of bias multicenter randomized, double blind, placebo-controlled trial conducted in the United States randomized children and adolescents with ADHD and oppositional symptoms 2:1 to receive either guanfacine extended release (n = 138) or placebo (n = 79) once daily for 8 weeks.¹⁷⁷ Eligible participants were between 6 and 12 years of age and had a *DSM-IV-TR* diagnosis of ADHD, a baseline score 24 or higher on the ADHD Rating Scale IV, and a baseline score 14 or higher (males) or 12 or higher (females) on the oppositional subscale of the CPRS-R:L. Following a 3-day to 5-week washout, participants underwent a 5-week dose optimization. During optimization, the dose of guanfacine extended release was increased in 1 mg/week increments to a maximum of 5 mg/day based on tolerance, the CGI-S score, and investigator judgment until the optimal dose was identified. Doses were maintained at the optimal level for 3 weeks. The primary outcome was change from baseline to endpoint in the oppositional subscale of the CPRS-R:L. Other outcomes included ADHD-RS-IV criteria, and adverse events. Participant mean age was 9.4 (1.7) years in the guanfacine extended release group and 9.3 (2.0) years in the placebo group. Mean score at baseline on the oppositional subscale of CPRS-R:L was 19.3 (4.74) in the guanfacine extended release group and 19.9 (4.29) in the placebo arm. Distribution of the optimal dose at the endpoint was: 1 mg (5.1%), 2 mg (27.2%), 3 mg (38.2%), and 4 mg (25%).

Guanfacine extended release significantly reduced oppositional symptoms as measured by the parent-rated CPRS-R:L oppositional subscale scores compared with placebo (least-square mean change from baseline: -10.9 for guanfacine extended release and -6.8 for placebo, $p<0.001$; effect size: 0.59) Least squares mean percentage reductions from baseline were significantly different between guanfacine extended release (56.3%) and placebo (33.4%) groups (effect size: 0.64, $p<0.001$). Significant reductions were observed in clinician-rated ADHD-RS-IV total scores in those treated with guanfacine extended release compared with placebo.

Key Question 3: In children under 18 years of age treated for disruptive behaviors, what is the relative effectiveness of any psychosocial interventions compared with the pharmacologic interventions listed in Key Question 2 for improving short-term and long-term psychosocial outcomes?

We identified no studies that directly compared psychosocial to pharmacologic interventions for DBD.

Key Question 4: In children under 18 years of age treated for disruptive behaviors, are any combined psychosocial and pharmacologic interventions listed in Key Question 2 more effective for improving short-term and long-term psychosocial outcomes than individual interventions?

We identified no studies assessing the comparative effectiveness of combination interventions.

Key Question 5: What are the harms associated with treating children under 18 years of age for disruptive behaviors with either psychosocial or pharmacologic interventions?

Overview of the Literature for KQ5

Harms for psychosocial interventions were not reported in studies included in KQ1. It is important to note that the absence of data on harms does not mean that harms are not present, even for psychosocial interventions. To represent the potential harms of the drugs used to treat disruptive behaviors in children, we combine data from three sources: 1) prior systematic reviews focused on harms of drugs; 2) empirical data from studies meeting our inclusion criteria for harms assessments; and 3) package insert data available from FDA (briefly summarized here and in more detail in Appendix I).

For each drug class we first summarize existing reviews, then describe the available empirical data from the literature search, and finally present the analysis of harms data gathered from the available gray literature (i.e., package inserts and FDA review packages). Sixteen studies^{176-188,193-195} (reported in 18 papers)^{176-188,193-197} of medical intervention met the criteria for inclusion and are described below. We included information from three systematic reviews.

The Package Insert Data sections provide an overview of the common and notable adverse events of each medication. When possible, adverse event data specifically from pediatric patients have been included but it should be noted that studies used to develop package inserts were not, of course, limited to the clinical population of interest in this review. Appendix I includes the pediatric indication for medications referenced in the clinical studies included in this review.

For the drug studies, it is important to note that these data often include children using the medications to treat disruptive behaviors and/or other (non-DBD) medical conditions. We summarize the rate of discontinuation due to adverse events as reported in the published studies in Table 37.

Table 37. Participant discontinuation due to adverse events in published studies

| Author, Year Study Design: Funding Country | Drugs(s) Number Analyzed | Condition(s) Age, Mean (SD) Years | Discontinuation Due to AEs |
|-------------------------------------------------------------------------------------------------------------------|------------------------------------|-------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Spencer et al., 2006 ¹⁸² Connor et al., 2005 ¹⁹⁷ (I-C) RCT: Industry United States | Amphetamine 308 | ODD 10.6 (2.8) | 14 participants in the active treatment groups vs. none in the control group |
| Bastiaens et al., 2009 ¹⁸⁸ NRCT: NR United States | Aripiprazole, Ziprasidone 34 | DBD 11.9 (2.6) | 2 participants on aripiprazole and 6 on ziprasidone |
| Dittmann et al., 2011 ¹⁷⁶ (B-P) RCT: Industry Germany | Atomoxetine 180 | ODD, CD 11 (3) | 8 participants in the active treatment groups (6 in fast titration and 2 in slow titration) vs. 1 in the placebo group |
| Dell'Agnello et al., 2009 ¹⁷⁹ RCT: Industry Italy | Atomoxetine 139 | ODD 9.9 (NR) | 3 participants in the treatment group vs. none in the control group |
| Steiner et al., 2003 ¹⁸⁴ (K-P) RCT: Multiple United States | Divalproex 58 | CD 15.9 (NR) | NR |
| Saxena et al., 2010 ¹⁹³ RCT-OL: Multiple United States | Divalproex 40 | ODD, CD 13.85 (3.03) ^a 12.75 (3.38) ^b | 9 of 20 participants in treatment group did not complete treatment; reasons for discontinuation not given |
| Blader et al., 2009 ¹⁷⁸ RCT: Multiple United States | Divalproex 27 | ODD, CD, AGG Range: 6 to 13 | NR (1 participant in treatment group and 2 in placebo group withdrew) |
| Donovan et al., 2000 ¹⁸⁵ RCT: Multiple United States | Divalproex 20 | ODD, CD 13.8 (2.4) | 1 participant in treatment group and 1 in the placebo group (lack of efficacy) |
| Connor et al., 2010 ¹⁷⁷ RCT: Multiple United States | Guanfacine 214 | ODD 9.4 (1.84) | 14 participants in the active treatment vs. 1 in the placebo group due to AEs; of these 12 in the active treatment vs. none in the placebo group discontinued due to treatment emergent AEs |
| Klein, et al., 1997 ¹⁸⁷ RCT: Government United States | Methylphenidate 71 | ADHD and CD Range: 6 to 15 | 4 participants in treatment group and 5 in placebo group left study (reason NR) |
| Connor et al., 2008 ¹⁸⁰ RCT: Industry United States | Quetiapine 19 | CD, AGG 14.1 (1.6) | 1 participant in the treatment group and 7 in placebo group (5 lack of efficacy and 2 protocol violation) |
| Pandina et al., 2009 ^{196 c} RCT: Industry Multinational | Risperidone 284 | DBD 10.8 (2.9) | 3 participants in the treatment group vs. 2 in the placebo group |
| Reyes et al., 2006 ^{183 d} RCT: Industry Multinational | Risperidone 335 | CD, ODD, DBD-NOS 11.1 (2.95) | 1.7% in the treatment group vs. 0.6% in placebo group |
| Armenteros et al., 2007 ¹⁸¹ RCT: Industry United States | Risperidone 25 | ADHD and AGG 7.3 (3.7) | 1 participant in treatment group and 1 in placebo (both failed to comply with protocol regulations) |

Table 37. Participant discontinuation due to adverse events in published studies (continued)

| Author, Year Study Design: Funding Country | Drugs(s) Number Analyzed | Condition(s) Age, Mean (SD) Years | Discontinuation Due to AEs |
|----------------------------------------------------------------------------|-----------------------------|--------------------------------------|------------------------------------------------------------------------------------------------------------------------------------|
| Findling et al., 2000 ¹⁸⁶ RCT: Multiple United States | Risperidone 20 | CD 9.2 (2.9) | 4 participants in treatment group (1 AE and 3 lack of efficacy) vs. 7 in placebo group (4 lack of benefit, 2 noncompliance, 1 LTF) |
| Ercan et al., 2003 ^{195 e} OL: Not reported Turkey | Risperidone 20 | ODD, CD 10.8 (3.6) | 1 participant withdrew because parents believed the child was not benefitting from the treatment. |
| Penzner et al., 2009 ^{194 e} NRCT: Government United States | SGA; Stimulant 153 | DBD, AGG 11.3 (3) | 7.4% in the SGA alone group vs. 4.2% in the SGA plus stimulant groups for intolerance |

AGG = aggression; AE = adverse event; ADHD = Attention Deficit Hyperactivity Disorder; CD = conduct disorder; DBD = disruptive behavior disorder; DBD-NOS = disruptive behavior disorder not otherwise specified; N = number; NCT ID = National Clinical Trials Identifier; LTF = lost to followup; ODD = oppositional defiant disorder; OL = open label; RCT = randomized controlled trial; SD = standard deviation; SGA = second generation antipsychotic

^a treatment group

^b comparison group

^c See Reyes et al., 2006¹⁸³ for maintenance phase data from the same population

^d Maintenance phase of the Pandina et al., 2009¹⁹⁶ study

^e Not in KQ2

Second-Generation Antipsychotics

Risperidone

Key Points

- Studies were generally short-term with the exception of one trial with a 6-month treatment period. Duration of followup post-treatment was minimal in all studies.
- Adverse events were generally considered mild across studies, with weight gain, sedation, and somnolence frequently reported.

Overview

Use of risperidone, a second-generation antipsychotic, for management of disruptive behavior disorders was documented in a limited number of studies (n = 5).^{181,183,186,194-196} We rated two RCTs as good quality for harms reporting,^{181,186} two as fair,^{183,195,196} and one prospective cohort study as good quality for harms reporting.

Systematic Reviews

We identified three good quality systematic reviews addressing harms of atypical antipsychotics in children and adolescents.^{49,52,198}

One Cochrane review assessed atypical antipsychotic use in individuals aged 18 years and younger diagnosed with a DBD.⁴⁹ Seven of the eight RCTs identified addressed risperidone compared with placebo, and one evaluated quetiapine (summarized below). The primary harms assessed in the review were weight gain and changes in metabolic parameters. Sample sizes in RCTs of risperidone ranged from 13 to 335 (4 studies had 25 or fewer participants), and the review included three of the studies addressed in the current report.^{181,186} Mean doses at end of treatment ranged from 0.98 mg per day to 1.5 mg per day. Mean weight gain in the risperidone

group was 2.37 kg more than in the placebo arm over 6 to 10 weeks in a meta-analysis of two trials (mean difference: 2.37, 95% CI: 0.26 to 4.49). Only one study evaluated metabolic changes and reported no clinically significant changes in mean fasting glucose levels during treatment. The investigators considered the overall quality of the evidence addressing these harms to be low.

Another Agency for Healthcare Research and Quality (AHRQ) review included studies of atypical antipsychotics used for any indication in individuals aged 24 years of age and younger.⁵² Agents included in studies in the review were haloperidol, risperidone, aripiprazole, olanzapine, pimozide, quetiapine, clozapine, and ziprasidone, and median study duration was 8 weeks. The review evaluated harms by drug class and noted fewer extrapyramidal symptoms associated with olanzapine and risperidone compared with haloperidol (low strength of the evidence), and no significant differences between first and second-generation antipsychotics in prolactin-related adverse events (low strength of the evidence). Risperidone was associated with less dyslipidemia and less weight gain than olanzapine (moderate strength of the evidence). Risperidone was also associated with more prolactin-related harms than olanzapine (moderate strength of the evidence) and with more weight gain than aripiprazole (low strength of the evidence).

Finally, one review and meta-analysis evaluated metabolic and neurologic adverse events associated with second-generation antipsychotic use in children with any mental health disorder and included 35 RCTs (4 reported in the current review).¹⁹⁸ In a meta-analysis of 10 RCTs of risperidone of less than 12 weeks duration, weight gain (mean difference: 1.72 kg, 95% CI: 1.17 to 2.26, $p < 0.00001$), prolactin levels (mean difference: 20.70 ng/mL, 95% CI: 16.78 to 24.62, $p < 0.00001$), and change in prolactin from baseline to end of treatment (mean difference: 44.57 ng/mL, 95% CI: 32.24 to 56.90, $p < 0.00001$) were higher in risperidone groups compared with placebo. The odds of clinically significant weight gain were higher in the risperidone arm compared with placebo (OR=2.90, $p = \text{NS}$) as were the odds of extrapyramidal symptoms (OR=3.35, $p < 0.0001$) in the risperidone arm compared with placebo. The review reported no clinically significant changes in laboratory values or blood pressure in seven studies. Blood pressure was elevated in the risperidone group in one study. Olanzapine was associated with greater weight gain than was risperidone in a meta-analysis of two studies (mean difference: 2.41 kg, 95% CI: 0.98 to 3.83, $p = 0.0009$) and with greater BMI change (mean difference: 0.09 kg/m², 95% CI: 0.42 to 1.38, $p = 0.0003$). In studies comparing risperidone at different doses or with other agents (pimozide, clonidine, haloperidol), children in the risperidone arms had weight gain and extrapyramidal symptoms that were typically not significantly different from the comparison group, though higher doses of risperidone were associated with greater weight gain and movement symptoms. In a meta-analysis of three RCTs of risperidone versus placebo of more than 12 weeks duration, mean weight gain was higher in risperidone groups compared with placebo (mean difference: 1.95 kg, 95% CI: 1.14 to 2.75, $p < 0.00001$). Prolactin levels were higher in the risperidone group versus placebo ($p < 0.001$) in one study, as were the odds of extrapyramidal symptoms (OR=3.71, $p = \text{NS}$). The review suggested that risk of metabolic adverse effects is greatest for olanzapine followed by clozapine and quetiapine, while risks were lower for risperidone and aripiprazole. The risk for neurologic harms appeared greatest with risperidone, olanzapine, and aripiprazole.¹⁹⁸

Summary of Studies Reporting Harms Data

One randomized, double blind, placebo-controlled trial (Reyes 2006) assessed risperidone for maintenance treatment of children and adolescents (mean age: 11.1 years) with disruptive

behavior disorders.^{183,196} Patients were eligible to enter the double blind, 6-month maintenance phase of this study after successful treatment with risperidone for a total of 12 weeks. Of the 527 patients who entered the 6-week, open-label, acute treatment phase, five patients did not continue due to adverse effects; in the six-week, single-blind, continuation treatment phase, seven patients discontinued due to adverse effects; finally, during the 6-month maintenance phase, four patients discontinued the study due to adverse effects. Specific adverse effects resulting in discontinuation of study drug were as follows: involuntary muscle contractions, abnormal ECG, paranoid reaction. By the conclusion of the 6-month maintenance phase, 47.7 percent of risperidone-treated patients and 36.2 percent of placebo-treated patients experienced at least one adverse event. The adverse events reported in 5 percent or more of patients are summarized in Table 38. Table 39 summarizes the incidence of extrapyramidal symptoms.

Table 38. Treatment-emergent adverse events occurring in ≥5 percent of participants

| Adverse Event | Acute Phase | Continuation Phase | Maintenance Phase | |
|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-------------------------------|
| | Risperidone (n = 527) n (%) | Risperidone (n = 436) n (%) | Risperidone (n = 172) n (%) | Placebo (n = 163) n (%) |
| Total Adverse Events | 289 (54.8) | 152 (34.9) | 82 (47.7) | 59 (36.2) |
| Headache | 59 (11.2) | 25 (5.5) | 8 (4.7) | 11 (6.7) |
| Rhinitis | 22 (4.2) | 19 (4.4) | 10 (5.8) | 9 (5.5) |
| Upper Respiratory Tract Infection | 14 (2.7) | 13 (3.0) | 13 (7.6) | 9 (5.5) |
| Pharyngitis | 11 (2.1) | 10 (2.3) | 10 (5.8) | 4 (2.5) |
| Abdominal Pain | 27 (5.1) | 16 (3.7) | 6 (3.5) | 3 (1.8) |
| Somnolence | 61 (11.6) | 10 (2.3) | 3 (1.7) | 2 (1.2) |
| Fatigue | 55 (10.4) | 6 (1.4) | 3 (1.7) | 0 (0.0) |
| Increased Appetite | 54 (10.2) | 9 (2.1) | 4 (2.3) | 0 (0.0) |
| Weight Gain | 34 (6.5) | 6 (1.4) | 2 (1.2) | 1 (0.6) |
| Serious Adverse Events | 14 (2.7) | 2 (0.5) | 6 (3.5) | 5 (3.1) |

Table 39. Treatment-emergent extrapyramidal symptoms

| Extrapyramidal Symptom | Acute and Continuation Phases | Maintenance Phase | |
|------------------------|-----------------------------------|-----------------------------------|-------------------------------|
| | Risperidone (n = 527) n (%) | Risperidone (n = 172) n (%) | Placebo (n = 163) n (%) |
| Dystonia | 5 (0.9) | 2 (1.2) | 1 (0.6) |
| Parkinsonism | 2 (0.4) | 1 (0.6) | 0 (0.0) |
| Akathisia | 1 (0.2) | 0 (0.0) | 0 (0.0) |
| Tremor | 1 (0.2) | 0 (0.0) | 0 (0.0) |
| Any EPS Event | 8 (1.5) | 3 (1.7) | 1 (0.6) |

EPS = extrapyramidal symptoms

Another publication¹⁹⁶ from the Reyes RCT¹⁸³ evaluated the incidence of somnolence in a long-term analysis (6 months) of 284 5 to 17 year old children with DBD receiving risperidone (0.25 to 1.5 mg/day) or placebo.¹⁹⁶ In the initial 6-week phase of the trial, 61 children reported somnolence, while in the 6-week open label phase, 10 participants had somnolence. During the double-blind maintenance phase, three children in the risperidone arm and three in the placebo arm reported somnolence, which was generally considered mild and likely related to risperidone in two of the children in the treatment arm and to placebo in one child in that arm. The mean

(SD) duration of somnolence was 34.3 (42) days in the risperidone and 42.3 (50) days in the placebo arm.

Adverse events reported in a 12-week RCT of risperidone compared with placebo¹⁸⁶ [n = 20 with CD or ODD, mean age: 9.2 (2.9) years] were generally mild and transient and included rash, increased appetite, sedation, headache, and irritability (Table 40). Predicted weight gain (based on repeated measures analysis) was greater in the risperidone group compared with placebo [4.2 (0.7) kg vs. 0.74 (0.9) kg, p=0.003]. No participants had dystonia and dyskinesia. One participant in the risperidone arm withdrew from the study due a rash that subsequently resolved. We rated this study as good quality for harms reporting.

Another short-term (8 weeks) RCT¹⁸¹ compared risperidone for treatment-resistant aggression in children with ADHD [n = 12, mean age: 7.3 (3.7) years] with placebo [n = 13, mean age: 8.8 (3.1) years].¹⁸¹ Nineteen children also had CD or ODD diagnoses, and 25 were receiving concomitant stimulants. More children in the placebo group (76.9%) reported an adverse event than in the risperidone group (58.3%, p=NR). Only abdominal pain and vomiting occurred in greater than 10 percent of participants in the risperidone group, while vomiting and somnolence occurred in more than 10 percent of the placebo arm. Weight gain did not differ significantly between groups, and laboratory values remained within normal limits in both groups. Investigators considered adverse events as mild in intensity, and no participants withdrew due to adverse events. Table 40 lists the harms reported by group. We considered this study as good quality for harms reporting.

Table 40. Harms in additional studies of risperidone reporting per participant incidence

| Author, Year Design (Quality) | Groups [dose] (N at Final Analysis) | Harms in Treatment Group: n (%) | Harms in Comparison Group, n (%) |
|-------------------------------------------------------|-----------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Findling et al., 2000 ¹⁸⁶ RCT (Good) | G1: Risperidone (mean 0.028 ± 0.004 mg/kg/day), 6 G2: Placebo, 3 | Increased appetite: 3 Sedation: 3 Headache: 1 Initial insomnia: 1 Restlessness: 1 Irritability: 1 Enuresis: 0 Nausea/emesis: 1 Rash: 1 | Increased appetite: 0 Sedation: 2 Headache: 1 Initial insomnia: 0 Restlessness: 0 Irritability: 0 Enuresis: 1 Nausea/emesis: 1 Rash: 0 |
| Armenteros et al., 2007 ^{181a} RCT (Good) | G1: Risperidone (mean 1.08 ± 0.63), 12 G1: Placebo, 13 | Abdominal pain: 3 (25) Vomiting: 2 (16.7) Somnolence: 1 (8.3) Agitation: 1 (8.3) Increased appetite: 1 (8.3) | Abdominal pain: 1 (7.7) Vomiting: 3 (23.1) Somnolence: 1 (15.4) Agitation: 0 Increased appetite: 0 |

^a Study reports harms occurring in 5 percent or more participants.

In one fair quality, 8-week open label trial of risperidone [final dose, mean: 1.27 (0.42) mg/day] including 21 children with ODD or CD and ADHD [mean age: 10.8 (3.6) years], reported side effects were similarly mild.¹⁹⁵ All children had initial mild sedation, and sleep duration increased by a mean of 0.9 hours on parental observation (range 0-3 hours). Mean weight gain was 1.6 (1.9) kilograms (mean 4% increase). Three participants gained more than 10 percent of their baseline body weight, and one gained approximately 29 percent. No participants developed EPS or had abnormal laboratory values.

One good quality analysis of data on participants (ages 4-19, mean 11.3 years) with ODD or CD enrolled in a cohort study of antipsychotic treatments reported specifically on metabolic adverse effects.¹⁹⁴ Participants received antipsychotics either with stimulants (n = 82) or without

stimulants (n = 71). Most of the 153 participants received either risperidone (33.3%) or aripiprazole (29.4%). The most commonly used stimulants were methylphenidate (13.1%) and D-Amphetamine (10.5%), and participants differed on multiple characteristics at baseline (ADHD comorbidity, use of stimulants prior to study, baseline weight at normal or below normal levels, waist circumference). In analyses controlling for baseline differences, changes in body composition, glucose and lipid parameters, and prolactin levels did not differ between groups, nor did discontinuation rates (4.2% in antipsychotics plus stimulant group vs. 7.4% in the antipsychotics alone arm).

Package Insert Data

Adverse event data for risperidone were gathered from the package insert and FDA approval packages for adolescent use.¹⁹⁹ The other FDA review documents available did not include pediatric data.

Adverse events referenced in the warnings/precautions section of the package insert include: parkinsonism, akathisia, dystonia, tremor, sedation, dizziness, anxiety, blurred vision, nausea, vomiting, upper abdominal pain, stomach discomfort, dyspepsia, diarrhea, salivary hypersecretion, constipation, dry mouth, increased appetite, weight gain, fatigue, rash, nasal congestion, upper respiratory tract infection, nasopharyngitis, and pharyngolaryngeal pain.^{199,200}

When assessing the use of risperidone (0.5-6 mg/day) across all pediatric indications (i.e. schizophrenia, bipolar mania, autistic disorder), the mean change in fasting glucose from baseline was 2.6 mg/dL (n = 135), cholesterol was 0.3 mg/dL (n = 133), LDL was 0.5 mg/dL (n = 22), HDL was -1.9 mg/dL (n = 22), triglycerides was 2.6 mg/dL (n = 138), weight was 2 kg (n = 448), and weight gain (more than 7% increase) was 32.6% (n = 448).^{199,201} Prolactin levels have also been shown to increase from baseline in pediatric patients taking risperidone; which appeared to be dose-dependent relationship.²⁰² This increase has been shown to lead to prolactin-related adverse events such as: lactation nonpuerperal and ejaculation disorder.²⁰² Common adverse events reported in long-term studies (greater than 6 months) included weight gain and psychosis.²⁰² In general, extrapyramidal symptoms, dizziness, somnolence, and increasing salivation, and increased prolactin levels were considered dose-related.²⁰²

The sponsor conducted a literature search, which uncovered safety data from 206 articles in pediatric patients taking risperidone at doses between 0.25 and 12 mg/day or 0.01 and 0.06 mg/kg/day for up to 7 years.²⁰² The most frequently reported adverse events were weight gain (75 articles), sedation (47 articles), and extrapyramidal symptoms (32 articles).²⁰² The most common reasons for discontinuation in these articles included: weight gain (18 articles), extrapyramidal symptoms (11 articles), hyperprolactinemia (8 articles), and sedation (7 articles).²⁰² Serious adverse events reported in 19 patients included: neuroleptic malignant syndrome (9), tardive dyskinesia (4), pancreatitis (2), acute dystonia (1), probably viral encephalitis (1), worsening mitochondrial disorder (1), and increased carbamazepine level (1).²⁰²

Common adverse events reported in pediatric patients with schizophrenia taking risperidone 1 to 3 mg/day (n = 55) for 6 weeks included: sedation (24%), parkinsonism (16%), tremor (11%), akathisia (9%), dizziness (7%), dystonia (2%), and anxiety (7%).¹⁹⁹ In patients taking risperidone 4 to 6 mg/day (n = 51) for 6 weeks the following adverse events were reported: salivary hypersecretion (10%), sedation (12%), parkinsonism (28%), tremor (10%), akathisia (10%), dizziness (14%), dystonia (6%), and anxiety (6%).^{199,200}

Patients taking risperidone (n = 106) in clinical trials discontinued treatment due to dizziness (2%), somnolence (1%), sedation (1%), lethargy (1%), anxiety (1%), balance disorder (1%), hypotension (1%), and palpitation (1%).¹⁹⁹

Other Second-Generation Antipsychotics

Key Points

- Two small, short-term studies addressed quetiapine, aripiprazole, or ziprasidone.
- Adverse events were more frequent in the placebo arm in an RCT comparing quetiapine and placebo, and sedation was frequently reported in both arms in a study comparing aripiprazole and ziprasidone.

Overview of the Literature

Aripiprazole, ziprasidone, and quetiapine were used in the management of disruptive behavior disorders in two studies (1 good¹⁸⁰ and 1 poor quality¹⁸⁸ for harms) meeting our criteria.

Systematic Reviews

The good quality Cochrane review of atypical antipsychotics for DBD⁴⁹ (described above) included one RCT of quetiapine¹⁸⁰ (described in KQ2 above for effectiveness and below for harms). The Cochrane review addressed the adverse effects of weight gain and metabolic changes as primary outcomes and provided no significant analysis of the limited harms data in the study.

One AHRQ-funded review (described above) addressed atypical antipsychotics including quetiapine.⁵² The review reported that quetiapine was associated with significantly less weight gain than olanzapine (moderate strength of the evidence) but with more weight gain when compared with aripiprazole (low strength of the evidence). Quetiapine was also associated with more dyslipidemia than aripiprazole (low strength of the evidence). Aripiprazole was associated with fewer prolactin-related adverse events than placebo (moderate strength of the evidence), and differences between the effects of second generation antipsychotics related to extrapyramidal symptoms, insulin resistance, and sedation were not significant (low strength of the evidence).

Finally, one review and meta-analysis evaluated metabolic and neurologic adverse events associated with second-generation antipsychotic use in children with any mental health disorder. The review included 35 RCTs, four of which are in this review.¹⁹⁸ In a meta-analysis of three studies of quetiapine versus placebo (including the RCT¹⁸⁰ described below), weight gain but not prolactin levels was significantly higher in the quetiapine group (mean difference: 1.41 kg, 95% CI: 1.01 to 1.81). Triglyceride levels, blood pressure, and heart rate were significantly elevated in the quetiapine group compared with placebo in one RCT. The review also included nine RCTs assessing aripiprazole, five of which were combined in meta-analyses. Mean weight gain (mean difference: 0.85 kg, 95% CI: 0.57 to 1.13, $p < 0.00001$) and BMI increase (mean difference: 0.27 kg/m², 95% CI: 0.11 to 0.42, $p = 0.0007$) were higher in aripiprazole groups compared with placebo, and the odds of weight gain were significantly higher in the treatment group (OR=3.66, $p = 0.0003$). Lipids and ECG values did not differ significantly between groups, and prolactin levels were significantly lower in treated participants versus those in placebo arms at endpoint (mean difference: -5.03 ng/mL, 95% CI: -7.80 to -2.26, $p = 0.0004$). Participants receiving risperidone had greater odds of developing extrapyramidal symptoms compared with placebo (OR=3.70, $p < 0.00001$). Studies included in the review did not report significant changes in blood

pressure, heart rate, or laboratory values, and only one short-term study addressed ziprasidone. The review suggested that risks of metabolic adverse effects are greatest for olanzapine followed by clozapine and quetiapine, while risks were lower for risperidone and aripiprazole. The risk for neurologic harms appeared greatest with risperidone, olanzapine, and aripiprazole.

Summary of Studies Reporting Harms Data

One good quality, 7-week RCT (Connor 2008) compared quetiapine and placebo in children with CD and moderate-to-severe aggressive behavior (n = 19 [11 completers], mean age overall: 14.1 years).¹⁸⁰ The mean number of parent-reported side effects and the mean severity did not differ significantly between groups nor did child-reported side effects including sedation, social withdrawal, and weight gain. Three adverse events were reported significantly more often by parents of children in the placebo arm compared with quetiapine: decreased mental alertness (n = 9 in placebo arm vs. n = 3 in quetiapine, p=0.01), diminished emotional expression (n = 7 in placebo arm vs. n = 1 in treatment, p=0.009), and diminished facial expression (n = 6 in placebo arm vs. n = 1 in treatment, p=0.03). Weight gain and prolactin levels did not differ significantly between groups, and laboratory parameters were in normal levels in both groups. Children in the quetiapine group had a higher resting pulse than did children in the placebo arm (p=0.01), and one child in the quetiapine group withdrew due to clinically noticeable akathisia. Table 41 lists harms reported by group.

In a poor quality, open label, nonrandomized study,¹⁸⁸ investigators assessed harms following 8 weeks of either aripiprazole [n = 24, (20 completers)] or ziprasidone [n = 22 (14 completers)] in children (mean age: 11.9 years) with aggressive behavior.¹⁸⁸ Use of stimulant medication was allowed (8% of the aripiprazole group; 36% of the ziprasidone group). Overall 71 percent of study completers experienced harms. Reported harms included sedation (n = 10 in aripiprazole arm vs. n = 8 in ziprasidone arm) and nausea and headaches (reported in 2 participants in each arm). Six children in the ziprasidone arm and two in the aripiprazole arm discontinued the study due to sedation. Table 41 lists harms reported by group.

Table 41. Harms reported in studies of other second-generation antipsychotics

| Author, Year Study Design Quality | Groups (Final Dose), N at Final Analysis | Harms in Treatment Group, n (%) | Harms in Comparison Group, n (%) |
|--------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Connor 2008 ^{180 a} RCT (Good) | G1: Quetiapine (range 200-600 mg/d), 8 G2: Placebo, 3 | Irritability: 7 (78) Restlessness: 7 (78) Sedation: 6 (67) Agitation: 6 (66) Anxiety: 6 (66) Pacing: 4 (44) Social withdrawal: 4 (44) Decreased energy: 3 (33) Decreased mental alertness: 3 (33) Weight gain: 3 (33) Drooling: 2 (22) School refusal: 2 (22) Diminished emotional expression: 1 (11) Diminished facial expression: 1 (11) Muscle stiffness: 1 (11) Overeating: 1 (11) Tremor: 0 (0) | Irritability: 8 (80) Restlessness: 7 (70) Sedation: 9 (90) Agitation: 9 (90) Anxiety: 7 (70) Pacing: 5 (50) Social withdrawal: 5 (50) Decreased energy: 5 (50) Decreased mental alertness: 9 (90) ^b Weight gain: 1 (10) Drooling: 0 (0) School refusal: 4 (40) Diminished emotional expression: 7 (70) ^b Diminished facial expression: 6 (60) ^b Muscle stiffness: 2 (20) Overeating: 2 (20) Tremor: 3 (30) |

Table 41. Harms reported in studies of other second-generation antipsychotics (continued)

| Author, Year Study Design Quality | Groups (Final Dose), N at Final Analysis | Harms in Treatment Group, n (%) | Harms in Comparison Group, n (%) |
|----------------------------------------------------------------------------|------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Bastiaens 2009 ^{188,203} Open label nonrandomized trial (Poor) | G1: Aripiprazole (4.5 ± 2.3 mg), 20 G2: Ziprasidone 42.9 ± 18.0 mg), 14 | Aripiprazole Sedation: 10 (50) Extrapyramidal: 2 (10) Dizziness: 2 (10) Nausea: 2 (10) Headaches: 2 (10) Weight gain: 2 (10) Blurry vision: 0 Agitation: 0 | Ziprasidone Sedation: 8 (57) Extrapyramidal: 0 Dizziness: 4 (29) Nausea: 2 (14) Headaches: 2 (14) Weight gain: 0 Blurry vision: 2 (14) Agitation: 2 (14) |

mg/d = milligram per day; mg = milligram; N = number; G = group; RCT = randomized controlled trial

^aParent-reported harms

^bsignificantly greater in placebo group, $p \leq 0.03$

Package Insert Data

Aripiprazole

The adverse event data for aripiprazole have been gathered from the package insert as well as FDA approval document for the pediatric schizophrenia indication.²⁰⁴ Adverse events referenced in the warnings/precautions section of the package insert include: neuroleptic malignant syndrome, tardive dyskinesia, hyperglycemia/diabetes mellitus, dyslipidemia, body weight gain, orthostatic hypotension, leukopenia, neutropenia, agranulocytosis, seizures, cognitive motor impairment, suicide, and suicidal ideation.²⁰⁵

Pediatric patients (n = 920), aged 6 to 17 years, being treated with aripiprazole for schizophrenia, bipolar mania, or autistic disorder were included in clinical trials that assessed safety.²⁰⁵ Of these patients, 117 were treated for at least 1 year and 465 were treated for at least 180 days.²⁰⁵ Adverse events reported in these trials with a frequency of more than 10 percent included: somnolence, headache, vomiting, extrapyramidal disorder, fatigue, increased appetite, insomnia, nausea, nasopharyngitis, and weight increased.²⁰⁵

Quetiapine

The harms data provided for quetiapine have been gathered from the package insert and FDA approval documents.^{206,207} Only FDA review documents for quetiapine immediate release were assessed. Review documents and adverse event data for quetiapine extended release were not included. The only FDA approval document that contained pediatric harms data was the document assessing QTC prolongation.²⁰⁶

Adverse events referenced in the warnings/precautions section of the package insert include: suicidal thoughts and behaviors, neuroleptic malignant syndrome, hyperglycemia, dyslipidemia, weight gain, tardive dyskinesia, hypotension, increased blood pressure, leukopenia, neutropenia and agranulocytosis, cataracts, hypothyroidism, hyperprolactinemia, and cognitive motor impairment.²⁰⁷

Ziprasidone

Ziprasidone is not FDA approved for use in pediatric patients and therefore safety data in this population are not available.²⁰⁸ Since pediatric adverse events were not represented in any FDA approval document for this medication, information from these reviews has not been included.

Divalproex/Valproate

Key Points

- Three small, short-term RCTs (1 fair and 2 poor quality for harms) addressed divalproex and reported harms including sleep changes, irritability and mood changes, gastrointestinal upset, and appetite changes.

Overview

Data on harms of valproate were available from three small RCTs and FDA packaging.

Systematic Reviews

We found no systematic reviews assessing harms of divalproex.

Studies Reporting Harms Data

We rated one 8-week RCT¹⁷⁸ as fair quality for harms reporting, and two RCTs^{184,185} as poor quality. The fair quality RCT compared divalproex and placebo in 27 children with stimulant-resistant aggression and ADHD and either CD or ODD.¹⁷⁸ Because divalproex was given as add-on therapy with stimulants, many of the reported adverse effects such as anxiety, nail biting, and appetite suppression were attributed to stimulant use. Trends toward a higher rate of treatment-emergent sadness (divalproex: 3 of 14, 20%; placebo: 0 of 13, 0%; p=0.07) and delayed sleep onset (divalproex: 5 of 14, 36%; placebo: 1 of 13, 8%; p=0.08) were noted but not statistically significant. Table 42 outlines reported harms.

One 7-week RCT of 58 adolescent male patients (age 14-18 years) with conduct disorder compared high (500-1500 mg/day) and low (125 mg/day) doses of divalproex.^{184,209} The only adverse effects reported were gastrointestinal upset (n = 1) and sleepiness (n = 6) (Table 42). Side effects typically disappeared within 4 weeks. Another 6-week RCT comparing a dose of 750 to 1500 mg/day of valproex with placebo in children with CD or ODD reported increased appetite in four (20%) of the 20 participants (ages 10 to 18 years) (Table 42).¹⁸⁵

Table 42. Harms reported in studies of divalproex

| Author, Year Design (Quality) | Group [Dose] (N at Final Analysis) | Harms in Treatment Group, n (%) ^a | Harms in Comparison Group, N (%) |
|--------------------------------------------------|------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Blader et al., 2009 ¹⁷⁸ RCT (Fair) | G1: Divalproex [20 mg/kg] (14) G2: Placebo (13) | Insomnia: 7 (50) Crying: 5 (36) Irritability: 5 (36) Anxiety/nervousness: 3 (21) Sadness: 3 (21) Appetite changes: 2 (14) Early waking: 2 (14) Fingernail biting: 2 (14) Nightmares: 2 (14) Overly talkative: 2 (14) Restlessness: 2 (14) Stares into space: 2 (14) Enuresis: 1 (7) Lack of interest: 1 (7) Less talkative: 1 (7) Low energy: 1 (7) Shaking: 1 (7) Tics: 1 (7) Tremors: 1 (7) | Crying: 4 (31) Irritability: 4 (31) Insomnia: 2 (15) Overly talkative: 2 (15) Restlessness: 2 (15) Anxiety/nervousness: 1 (8) Bruises easily: 1 (8) Enuresis: 1 (8) Fingernail biting: 1 (8) Rash: 1 (8) |

Table 42. Harms reported in studies of divalproex (continued)

| Author, Year Design (Quality) | Group [Dose] (N at Final Analysis) | Harms in Treatment Group, n (%) ^a | |
|---------------------------------------------------|----------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|---------------|
| Steiner et al., 2003 ¹⁸⁴ RCT (Poor) | G1: Divalproex, high dose [500-1500 mg/d] (34) G2: Divalproex, low dose [125 mg/d] (24) | G1 + G2: Increased sleepiness: 6 (10) Nausea and vomiting: 1 (2) | |
| Donovan et al., 2000 ¹⁸⁵ RCT (Poor) | G1: Divalproex [750-1500 mg/d] (10) G2: Placebo (10) | Increased appetite: 4 (20) | None reported |

mg/d = milligram per day; RCT = randomized controlled trial; G = group; N = number

^aThere were no reported instances of these harms in the divalproex group: abdominal pain, bruises easily, constipation, dizziness, dry mouth, headache, other (not defined), rash, stomach ache, heart racing, tiredness, trouble walking, unusually happy; and in the placebo group: abdominal pain, bruises easily, constipation, dizziness, dry mouth, headache, other, rash, stomach ache, heart racing, tiredness, trouble walking, unusually happy.

Package Insert Data

The safety information for divalproex sodium was obtained from the package insert.²¹⁰ FDA review documents were not available for this medication. Adverse events referenced in the warnings/precautions section of the package insert include: suicidal behavior or ideation, thrombocytopenia, hyperammonemia, hyperammonemic encephalopathy, hypothermia, hepatotoxicity, and pancreatitis.²¹¹ It is important to note that there is an increased risk of developing fatal hepatotoxicity in patients less than two years of age.²¹⁰ Specifically in pediatric clinical trials, consisting of 76 patients aged 10-17 years taking divalproex extended release for mania and 231 patients aged 12 to 17 years taking divalproex extended release for migraine, common adverse events (reported >5% and twice the rate of placebo) included: nausea, upper abdominal pain, somnolence, increased ammonia, gastritis and rash.²¹⁰

According to the package insert, divalproex safety and tolerability in pediatric patients is similar to what has been observed in adults.²¹⁰ Therefore, the adverse events reported below were not specified for pediatric patients but are included due to the similarity in pediatric safety response. These events are designated by indication.

The following adverse events were reported 89 patients being treated with divalproex for mania: nausea (22%), somnolence (19%), dizziness (12%), vomiting (12%), accidental injury (11%), asthenia (10%), abdominal pain (9%), dyspepsia (9%), and rash (6%).²¹⁰ Adverse events occurring at an incidence rate of greater than 1 percent (no more than 5%), in patients taking divalproex included: chest pain, chills, chills and fever, fever, neck pain, neck rigidity, hypertension, hypotension, palpitations, postural hypotension, tachycardia, vasodilation, anorexia, fecal incontinence, flatulence, gastroenteritis, glossitis, periodontal abscess, ecchymosis, edema, peripheral edema, arthralgia, arthrosis, leg cramps, twitching, abnormal dreams, abnormal gait, agitation, ataxia, catatonic reaction, confusion, depression, diplopia, dysarthria, hallucinations, hypertonia, hypokinesia, insomnia, paresthesia, reflexes increased, tardive dyskinesia, thinking abnormalities, vertigo, dyspnea, rhinitis, alopecia, discoid lupus erythematosus, dry skin, furunculosis, maculopapular rash, seborrhea, amblyopia, conjunctivitis, deafness, dry eyes, ear pain, eye pain, tinnitus, dysmenorrhea, dysuria, and urinary incontinence.²¹⁰

The clinical trials used to gather the following adverse events included patients on other antiepilepsy medications.²¹⁰ Therefore, it is impossible to clearly state if the following reactions are due to divalproex alone in patients with epilepsy.²¹⁰

Treatment emergent adverse events reported in 77 patients taking divalproex as adjunctive therapy for the treatment of complex partial seizures included: headache (31%), asthenia (27%), fever (6%), nausea (48%), vomiting (27%), abdominal pain (23%), diarrhea (13%), anorexia (12%), dyspepsia (8%), constipation (5%), somnolence (27%), tremor (25%), dizziness (25%), diplopia (16%), amblyopia/blurred vision (12%), ataxia (8%), nystagmus (8%), emotional lability (6%), thinking abnormal (6%), amnesia (5%), flu syndrome (12%), infection (12%), bronchitis (5%), rhinitis (5%), alopecia (6%), and weight loss (6%).²¹⁰

In a controlled trial assessing the use of high dose divalproex (n = 131) as monotherapy for the treatment of complex partial seizures the following adverse events were reported: asthenia (21%), nausea (34%), diarrhea (23%), vomiting (23%), abdominal pain (12%), anorexia (11%), dyspepsia (11%), thrombocytopenia (24%), ecchymosis (5%), weight gain (9%), peripheral edema (8%), tremor (57%), somnolence (30%), dizziness (18%), insomnia (15%), nervousness (11%), amnesia (7%), nystagmus (7%), depression (5%), infection (20%), pharyngitis (8%), dyspnea (5%), alopecia (24%), amblyopia/blurred vision (8%), and tinnitus (7%).²¹⁰

In controlled trials encompassing 358 patients treated with divalproex for complex partial seizures the following adverse events were reported in greater than 1 percent of patients but no more than 5 percent: back pain, chest pain, malaise, tachycardia, hypertension, palpitation, increased appetite, flatulence, hematemesis, eructation, pancreatitis, periodontal abscess, petechia, SGOT increased, SGPT increased, myalgia, twitching, arthralgia, leg cramps, myasthenia, anxiety, confusion, abnormal gait, paresthesia, hypertonia, incoordination, abnormal dreams, personality disorder, sinusitis, cough increased, pneumonia, epistaxis, rash, pruritus, dry skin, taste perversion, abnormal vision, deafness, otitis media, urinary incontinence, vaginitis, dysmenorrhea, amenorrhea, and urinary frequency.²¹⁰

Stimulants

Key Points

- One short-term RCT of methylphenidate reported sleep delay as a harm while an RCT of mixed amphetamine salts including more than 300 children reported harms including insomnia and anorexia.

Overview

Two short-term (≤ 5 weeks), placebo-controlled RCTs of poor quality for harms reporting addressed the safety of mixed amphetamine salts (Adderall[®]) in the management of ODD^{182,197} or methylphenidate for CD.¹⁸⁷

Systematic Reviews

We did not identify any systematic reviews addressing harms of these agents.

Summary of Studies Reporting Harms Data

The RCT of methylphenidate in patients with conduct disorder¹⁸⁷ did not describe assessment of adverse events, and the specific types of events were not detailed in the results though the study noted that adverse effects occurred in 84 percent of those receiving methylphenidate and in 46 percent of those receiving placebo. The authors also noted that “only a few instances of delayed sleep with medication were severe.”¹⁸⁷

In a dose-escalation study of mixed amphetamine salts in 308 6 to 17 year olds with ODD, adverse events were typically considered mild, though five participants in the treatment arm reported six severe events (arthrosis, hyperkinesias, insomnia, nervousness, pharyngitis, and one suicide attempt).^{182,197} Fourteen participants in the treatment arm withdrew from the study due to decreased appetite or insomnia. Table 43 outlines harms occurring in at least 5 percent of patients. Mean decrease in weight was significantly greater in the treatment arm compared with control (range: 1.1 to 3.3 pounds across dosage groups from baseline to endpoint).

Table 43. Adverse events reported in ≥5 percent of patients receiving extended-release mixed amphetamine salts or placebo

| Adverse Event n (%) | Mixed Amphetamine Salts | | | | Placebo (n = 60) |
|--------------------------------------|-------------------------|-------------------|-------------------|-------------------|---------------------|
| | 10 mg (n = 60) | 20 mg (n = 58) | 30 mg (n = 69) | 40 mg (n = 61) | |
| Anorexia | 10 (16.7) | 22 (37.9) | 22 (31.9) | 21 (34.4) | 3 (5.0) |
| Insomnia | 8 (13.3) | 14 (24.1) | 16 (23.2) | 17 (27.9) | 5 (8.3) |
| Headache | 11 (18.3) | 10 (17.2) | 11 (15.9) | 16 (26.2) | 9 (15.0) |
| Abdominal Pain | 7 (11.7) | 6 (10.3) | 10 (14.5) | 7 (11.5) | 3 (5.0) |
| Weight Loss | 2 (3.3) | 6 (10.3) | 8 (11.6) | 9 (14.8) | 0 (0) |
| Mean Weight Change (kg) ^a | -0.5 | -1.6 | -1.5 | -1.5 | 0.3 |
| Pharyngitis | 6 (10.0) | 3 (5.2) | 2 (2.9) | 7 (11.5) | 3 (5.0) |
| Nervousness | 3 (5.0) | 4 (6.9) | 5 (7.2) | 5 (8.2) | 0 (0) |
| Emotional Liability | 2 (3.3) | 3 (5.2) | 6 (8.7) | 3 (4.9) | 1 (1.7) |
| Accidental Injury | 1 (1.7) | 4 (6.9) | 2 (2.9) | 4 (6.6) | 3 (5.0) |

^ap<0.001

In an analysis of the cardiovascular effects of mixed amphetamine salts in this study, no statistically significant treatment-related effects were noted for the following parameters: systolic blood pressure, diastolic blood pressure, pulse rate, PR interval, QRS duration, QT interval, or QTcB interval. Investigators qualitatively assessed the incidence of clinically relevant change from baseline (Table 44. I). No patient experienced a systolic blood pressure ≥ 150 mmHg, diastolic blood pressure > 100 mm Hg, pulse ≥ 110 bpm, or QTcB interval ≥ 500 msec.^{182,197}

Table 44. Incidence of clinically relevant change from baseline for cardiovascular parameters

| Adverse Event n (%) | Mixed Amphetamine Salts | | | | Placebo (n = 60) |
|-------------------------------------|-------------------------|-------------------|-------------------|-------------------|---------------------|
| | 10 mg (n = 60) | 20 mg (n = 58) | 30 mg (n = 69) | 40 mg (n = 61) | |
| Systolic Blood Pressure ≥ 20 mm Hg | 2 (3.4) | 2 (3.5) | 4 (6.0) | 3 (5.0) | 1 (1.7) |
| Diastolic Blood Pressure ≥ 10 mm Hg | 4 (6.9) | 7 (12.3) | 10 (14.9) | 12 (20.0) | 11 (18.3) |
| Pulse ≥ 25 bpm | 0 (0.0) | 2 (3.5) | 2 (3.0) | 1 (1.7) | 0 (0.0) |
| QTcB interval ≥ 30 msec | 5 (9.1) | 3 (5.8) | 3 (4.6) | 2 (3.6) | 3 (5.2) |

Package Insert Data

Amphetamine-Dextroamphetamine

The safety information for amphetamine-dextroamphetamine was obtained from the package insert.²¹² The extended release formulation was not assessed in this review. The available FDA review documents did not provide additional harms data in the pediatric population. The long-term effects of amphetamine-dextroamphetamine in the pediatric population have not been well assessed.²¹²

Adverse events referenced in the warnings/precautions section of the package insert include: drug dependence, sudden death in patients with cardiac abnormalities, hypertension, heart rate increase, exacerbation of pre-existing psychotic disorder, mixed/manic episodes in patients with bipolar disorder, hallucinations, delusional thinking, mania, aggression, long-term suppression of growth, seizures, visual disturbances, exacerbation of tics and Tourette's syndrome, and impaired cognitive function.²¹²

The additional adverse reactions reported in the prescribing information did not include a frequency.²¹² These adverse events included: palpitations, tachycardia, elevation of blood pressure, sudden death, myocardial infarction, psychotic episodes at recommended doses, overstimulation, restlessness, dizziness, insomnia, euphoria, dyskinesia, dysphoria, depression, tremor, headache, exacerbation of motor and phonic tics and Tourette's syndrome, seizures, stroke, dryness of the mouth, unpleasant taste, diarrhea, constipation, other gastrointestinal disturbances, anorexia, weight loss, urticaria, rash, hypersensitivity reactions including angioedema and anaphylaxis, Stevens Johnson Syndrome, toxic epidermal necrolysis, impotence, changes in libido, and cardiomyopathy (associated with chronic use).²¹²

Methylphenidate

The adverse event reports available for methylphenidate were gathered from the package insert.²¹³ The package insert utilized for this review included the immediate release and sustained release tablets.²¹³ FDA review documents for this product were not available for assessment.

Adverse events referenced in the warnings/precautions section of the package insert include: sudden death in children with cardiac abnormalities; hypertension; increased heart rate; aggravated symptoms of anxiety, tension, and agitation; mixed/manic episodes in patients with pre-existing bipolar disorder; hallucinations, delusional thinking, or mania; aggression; long-term suppression of growth; seizures; priapism; peripheral vasculopathy; Raynaud's Phenomenon; and visual disturbance.²¹³

More frequent adverse events occurring in children taking methylphenidate included: loss of appetite, abdominal pain, weight loss during prolonged therapy, insomnia, and tachycardia.²¹³ The exact frequency at which these adverse events occurred was not available.²¹³ Additional adverse events reported include: hypersensitivity (including skin rash, urticaria, fever, arthralgia, exfoliative dermatitis, erythema multiforme with histopathological findings of necrotizing vasculitis, and thrombocytopenic purpura); anorexia; nausea; dizziness; palpitations; headache; dyskinesia; drowsiness; blood pressure and pulse changes, both up and down; angina; cardiac arrhythmia, libido changes, toxic psychosis, and Tourette's syndrome (rare).²¹³ Nervousness and insomnia were also reported but could be controlled by decreasing the dosage of methylphenidate and or not taking the medication in the afternoon or evening.²¹³ Adverse events reported but lack definite causal relationships include: abnormal liver function, ranging from transaminase elevation to hepatic coma; isolated cases of cerebral arteritis and/or occlusion; leukopenia and/or anemia; transient depressed mood; aggressive behavior; scalp hair loss.²¹³ Neuroleptic malignant syndrome (NMS) was also reported but occurred most often in patients taking other medications associated with NMS.²¹³

Nonstimulants

Atomoxetine

Overview

Headache and anorexia were common side effects of treatment in the included studies. In the broader literature on atomoxetine (i.e. broader study populations,) the most common adverse events reported in clinical trials in child and adolescent patients (n = 1597) included: abdominal pain (18%), vomiting (11%), nausea (10%), fatigue (8%), irritability (6%), therapeutic response unexpected (2%), weight decreased (3%), decreased appetite (16%), anorexia (3%), headache (19%), somnolence (11%), dizziness (5%), and rash (2%).²¹⁴

Systematic Reviews

We did not identify any systematic reviews addressing harms of atomoxetine.

Summary of Studies Reporting Harms Data

Two double blind, randomized clinical trials compared atomoxetine with placebo for management of oppositional defiant disorder.^{176,179} In both studies, atomoxetine was titrated to a target dose of 1.2 mg/kg/day. One 9-week RCT,¹⁷⁶ considered poor quality for harms reporting, included 180 children between the ages of 6 and 17 years diagnosed with ADHD and either ODD (74.4%) or CD (24.4%) randomized to either fast or slow titrated atomoxetine or placebo. Table 45 summarizes treatment emergent harms. Rates of pre-defined clinically relevant adverse effects were higher in both treatment groups compared with placebo ($p < 0.001$), but rates between treatment arms were not significantly different. One serious adverse event related to treatment (stomach cramps and abdominal pain) occurred in the fast titration arm. Eight participants in the active treatment groups (6 in the fast titration group, 2 in the slow titration group) discontinued the study due to adverse events: nausea and vomiting (n = 3), aggression (n = 1), fatigue (n = 1), headache (n = 1), tachycardia (n = 1), suicidal ideation of moderate severity (n = 1). Analyses of the effects of pretreatment use of psychostimulants and treatment emergent harms were not significant.

Another poor quality RCT enrolled children between the ages of 6 and 15 (mean: 9.9) years with ADHD and ODD symptoms.¹⁷⁹ Harms reported were generally considered mildly or moderately severe with five (undefined) instances of greater severity. Three children discontinued the study due to adverse events (reasons not defined). Body weight increased slightly in the placebo arm and decreased slightly in the atomoxetine arm ($p < 0.001$) as did mean height ($p = 0.021$). Table 45 outlines other harms reported.

Table 45. Harms reported in studies of atomoxetine

| Author, Year Design (Quality) | Group [dose] (N at Final Analysis) | Treatment Group Reported Adverse Events, n (%) | Comparison Group Reported Adverse Events, n (%) |
|---------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Dittman et al., 2011 ¹⁷⁶ RCT (Poor) | G1: Fast Titration atomoxetine [1.2 mg/kg/day] (44) G2: Slow Titration atomoxetine [1.2 mg/kg/day] (48) G3: Placebo [NA] (37) | Fast Titration Any Adverse Event: 70.0% Fatigue: 35.0% Headache: 25.0% Nausea: 21.7% Vomiting: 15.0% Abdominal Pain: 15.0% Anorexia: 15.0% Slow Titration Any Adverse Event: 57.4% Fatigue: 21.3% Headache: 14.8% Nausea: 19.7% Vomiting: 18.0% Abdominal Pain: 13.1% Anorexia: 11.5% | Any Adverse Event: 30.5% Fatigue: 10.2% Headache: 15.3% Nausea: 5.1% Vomiting: 5.1% Abdominal Pain: 0.0% Anorexia: 1.7% |
| Dell'Angelo 2009 ¹⁷⁹ RCT (Poor) | G1: Atomoxetine [1.2 mg/kg/day] (107) G2: Placebo [NA] (32) | Anorexia: 36 (33.6) Somnolence: 32 (29.9) Headache: 23 (21.5) Nausea: 22 (20.6) Abdominal Pain: 16 (15.0) Vomiting: 15 (14.0) Abdominal Pain, Upper: 11 (10.3) Decreased Appetite: 10 (9.3) Nervousness: 7 (6.5) Weight Decreased: 6 (5.6) Insomnia: 5 (4.7) Diarrhea: 4 (3.7) | Anorexia: 3 (9.4) Somnolence: 2 (6.3) Headache: 4 (12.5) Nausea: 0 Abdominal Pain: 2 (6.3) Vomiting: 1 (3.1) Abdominal Pain, Upper: 4 (12.5) Decreased Appetite: 0 Nervousness: 2 (6.3) Weight Decreased: 1 (3.1) Insomnia: 2 (6.3) Diarrhea: 2 (6.3) |

Package Insert Data

The adverse event data from the atomoxetine package insert were gathered from 5382 children or adolescent patients with ADHD participating in clinical trials in which 1625 were treated for longer than 1 year and 2529 were treated for over 6 months.²¹⁴ The original FDA review document contained extensive documentation of harms data.²¹⁵ A summary of this data is provided below.²¹⁵

Adverse events referenced in the warnings/precautions section of the package insert include: suicidal ideation, severe liver injury, cardiovascular events (sudden death, stroke and myocardial infarction), increase in blood pressure and heart rate, orthostasis, syncope, emergent psychotic or manic symptoms, aggressive behavior, hostility, urinary hesitation, urinary retention, and priapism.²¹⁴

The most common adverse events reported in clinical trials in atomoxetine receiving child and adolescent patients (n = 1597) included: abdominal pain (18%), vomiting (11%), nausea (10%), fatigue (8%), irritability (6%), therapeutic response unexpected (2%), weight decreased (3%), decreased appetite (16%), anorexia (3%), headache (19%), somnolence (11%), dizziness (5%), and rash (2%).²¹⁴

Post-marketing reports specifically from adolescent patients revealed the following additional adverse events: paraesthesia, urinary hesitation, urinary retention.²¹⁴ Additional adverse events gathered from post-marketing data representing a combination of adults and

children included: QT prolongation, syncope, Raynaud's phenomenon, lethargy, hypoaesthesia, sensory disturbances, tics, depression and depressed mood, anxiety, libido changes, hyperhidrosis, male pelvic pain, and seizures.²¹⁴ It is important to note that in the patients that reported seizures, existing seizure disorders and additional risk factors for seizures may have been present.²¹⁴

Infrequent serious adverse events reported in the sponsor's new drug application database included: seizure cases (n = 2), angioedema (n = 1), and elevated liver function test (n = 1).²¹⁵ An additional serious adverse event was reported in clinical trials: one patient with syncope.²¹⁵

When compared to methylphenidate, the following adverse events occurred at least twice as frequent in the pediatric atomoxetine group (n = 313): vomiting (13.1%), asthenia (7.0%), allergic reaction (3.5%), sinusitis (3.5%), constipation (3.2%), hostility (3.2%), unexpected benefit (2.9%), abnormal dreams (2.6%), chest pain (2.6%), personality disorder (2.6%), gastrointestinal disorder (1.9%), sleep disorder (1.9%), nausea and vomiting (1.6%), gastroenteritis (1.3%), tooth disorder (1.3%), conjunctivitis (1%), ear disorder (1%), leukopenia (1%), mydriasis (1%), otitis externa (1%), and surgical procedure (1%).²¹⁵

Guanfacine

Overview

In the one medium size study of guanfacine, somnolence, sedation, and headache were frequently reported treatment emergent adverse events.¹⁷⁷ We summarize additional potential adverse events reported in the FDA documentation.

Systematic Reviews

We did not identify any systematic reviews addressing harms of guanfacine.

Summary of Studies Reporting Harms Data

One 9-week, placebo-controlled RCT assessed extended release guanfacine (maximum dose 4 mg/day) in children between the ages of 6 and 12 years diagnosed with ADHD and ODD symptoms.¹⁷⁷ Use of concomitant ADHD medication was not allowed and was discontinued at the beginning of the study washout period. Treatment emergent adverse events occurred more frequently in the treatment group versus placebo (n = 114/136, 83.8% in the treatment arm vs. 45/78, 57.7% in placebo) and most were considered mild or moderate (Table 46). Predefined severe harms occurred in 14 children receiving guanfacine and in no children in the placebo group. Fourteen children in the treatment group (none in the placebo arm) also discontinued the study due to adverse events, which included sedation and somnolence. Baseline heart rate decreased by 11.6 beats per minute compared with 1.2 in the placebo arm. Twenty-five children in the guanfacine arm also developed abnormal heart rhythms during treatment. ECG analyses showed some changes from baseline in both groups but changes were not considered clinically significant. While the study noted contacting participants at 30 days post-treatment to assess for continuing harms, no longer term harms data are reported.

Table 46. Adverse events occurring in ≥5 percent of patients treated with guanfacine or placebo

| Author, Year Design (Quality) | Group [Dose] (N at Final Analysis) | Harms in Treatment Group, N (%) | Harms in Comparison Group, N (%) |
|------------------------------------------|-----------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Connor 2010 ¹⁷⁷ RCT (Poor) | G1: Guanfacine Extended Release [1-4 mg/d] (136) G2: Placebo [NA] (70) | Any Treatment Emergent Adverse Event: 114 (83.8) Somnolence: 69 (50.7) Headache: 30 (22.1) Sedation: 18 (13.2) Upper Abdominal Pain: 16 (11.8) Fatigue: 15 (11.0) Irritability: 10 (7.4) Vomiting: 9 (6.6) Decreased Diastolic Blood Pressure: 8 (5.9) Dizziness: 7 (5.1) Heart Rate < 50 bpm: 7 (5.1) Nausea: 4 (2.9) Upper Respiratory Tract Infection: 4 (2.9) Pharyngolaryngeal Pain: 4 (2.9) Affect Lability: 2 (1.5) Sinus bradycardia: 24 (20.9) | Any Treatment Emergent Adverse Event: 45 (57.7) Somnolence: 4 (5.1) Headache: 14 (17.9) Sedation: 1 (1.3) Upper Abdominal Pain: 2 (2.6) Fatigue: 2 (2.6) Irritability: 4 (5.1) Vomiting: 5 (6.4) Decreased Diastolic Blood Pressure: 1 (1.3) Dizziness: 3 (3.8) Heart Rate < 50 bpm: 1 (1.3) Nausea: 4 (5.1) Upper Respiratory Tract Infection: 4 (5.1) Pharyngolaryngeal Pain: 4 (5.1) Affect Lability: 2 (2.6) Sinus bradycardia: 4 (6.8) |

mg/d = milligram per day; RCT = randomized controlled trial; N = number; G = group; bpm = beats per minute

Package Insert Data

The safety and efficacy of guanfacine in pediatric patients has been reported in the medication package insert and the initial FDA approval documents.^{216,217} Adverse events referenced in the warnings/precautions section of the package insert include: dose dependent decrease in blood pressure and heart rate as well as somnolence and sedation.²¹⁷ Adverse events for guanfacine can be separated by events occurring in patients receiving monotherapy or adjunctive therapy.

Common adverse events occurring in adult and pediatric patients taking guanfacine as monotherapy, at an incidence rate of more than 5 percent, and occurring at least twice as often as placebo included: somnolence, fatigue, nausea, lethargy, and hypotension.²¹⁷ Adverse events reported in short term clinical trials conducted in pediatric patients diagnosed with ADHD and taking guanfacine at fixed doses (incidence rate of more than 2%) included: somnolence/sedation, headache, fatigue, abdominal pain, dizziness, hypotension, dry mouth, nausea, lethargy, dizziness, irritability, decreased appetite, dry mouth, and constipation.²¹⁷

Common adverse events occurring in the adult and pediatric patients taking guanfacine as adjunctive therapy, at an incidence rate of 5 percent or higher and occurring at least twice as often as placebo included: somnolence, fatigue, insomnia, dizziness, and abdominal pain.²¹⁷ Adverse events reported in short term clinical trials conducted in pediatric patients (age 6-17) diagnosed the ADHD and taking guanfacine at fixed doses (incidence ≥2%) included: headache, somnolence, insomnia, fatigue, abdominal pain, dizziness, decreased appetite, nausea, diarrhea, hypotension, affect lability, bradycardia, constipation and dry mouth.²¹⁷

Adverse events reported in additional clinical trials included: atrioventricular block, sinus arrhythmia, dyspepsia, stomach discomfort, vomiting, asthenia, chest pain, hypersensitivity, increased alanine amino transferase, increased weight, convulsion, agitation, anxiety, depression, nightmare, increased urinary frequency, enuresis, asthma, hypertension, and pallor.²¹⁷ Additional common adverse event reported in the original FDA approval document for pediatric patients treated with guanfacine included: fatigue (14%), lethargy (6%), somnolence (30%), sedation

(10%), headache (23%), dizziness (6%), irritability (6%), insomnia (5%), affective lability (2%), nightmare (2%), upper abdominal pain (10%), nausea (6%), dyspepsia (3%), dry mouth (4%), constipation (3%), hypotension (6%), blood pressure decreased (2%), sunburn (2%), appetite decreased (5%).²¹⁶ In addition, 7 percent of patients taking guanfacine experienced hypotension compared to 3 percent of the placebo group.²¹⁷ Adverse events that were considered dose-related in patients taking guanfacine were hypotension, somnolence, sedation, abdominal pain, dizziness, dry mouth, decreased blood pressure, decreased heart rate, and constipation.²¹⁶ Based on these adverse events, it is not surprising that upon abrupt discontinuation of guanfacine, pediatric patients experienced transient rebound increases in blood pressure and heart rate.²¹⁶ Patients in the guanfacine group reported sedative effects more often than placebo (53% and 17% respectively).²¹⁶ These sedative effects included somnolence, sedation, hypersomnia, fatigue, lethargy, and asthenia.²¹⁶ Increased psychiatric related adverse events also occurred more often in guanfacine treated patients including: irritability (5%), affective lability (4%), aggression (1.4% vs. 0.7%), agitation (1.4%), depressed mood (0.8%), and anxiety (0.4%).²¹⁶

In pediatric studies, patients discontinued guanfacine therapy due to (n = 513): hypotension (6), QT interval prolongation (3), bradycardia (1), somnolence (19), sedation (11), fatigue (8), asthenia (1), lethargy (1), dizziness (3), nightmare (1), insomnia (1), and headache (5).²¹⁶ Prolongation of the QT interval was considered a dose and exposure response relationship, i.e. greater exposure to guanfacine places patients at a greater risk of QT prolongation.²¹⁶ Specifically it was reported that the QTc interval would increase by 1 millisecond for every unit (ng/mL) increase in serum guanfacine.²¹⁶

In long term studies (at least 12 months) guanfacine was found to increase patient's weight by an average of 17.2 pounds.²¹⁶ Serious adverse events in these long-term studies included (n = 446): syncope (7), loss of consciousness possibly due to a syncopal episode (1), orthostatic hypotension (1), seizures (2), accidental medication overdoses (2) and intentional medication overdose (1).²¹⁶ According to the literature, the rate of syncope in pediatric populations requiring medical attention have been estimated at 126 to 300 per 100,000 per year.²¹⁶

Post-marketing studies reported that in 21,718 patients taking guanfacine 1 mg/day for 28 days experienced the following adverse events (more than 1% incidence): dry mouth, dizziness, somnolence, fatigue, headache, and nausea.²¹⁷ Additional adverse events reported less frequently include: edema, malaise, tremor, palpitations, tachycardia, paresthesias, vertigo, blurred vision, arthralgia, leg cramps, leg pain, myalgia, confusion, hallucinations, impotence, dyspnea, alopecia, dermatitis, exfoliative dermatitis, pruritus, rash, and alterations in taste.²¹⁷ In addition, syncope was reported in 10 guanfacine treated pediatric patients; which occurred after long exposure to the medication.²¹⁷ The sponsor provided additional post-marketing data by searching FDA's adverse drug reactions (ADRs) and adverse event reporting system (AERS) for guanfacine related adverse events reported between January 1, 1969 to March 31, 2005.²¹⁶ This search uncovered 955 adverse events reported for 309 pediatric patients (age <17).²¹⁶ The most commonly reported adverse events included: somnolence (22 events), drug ineffective (19), aggression (18), fatigue (15), weight increased (15), abnormal behavior (12), tic (12), nausea (11), anger (10), disturbance in attention (10), mania (10), sedation (10), agitation (9), condition aggravated (9), insomnia (9), lethargy (9), vomiting (9), and weight decreased (9).²¹⁶ Serious adverse events identified included: death (3), convulsion (18), loss of consciousness (7), depressed level of consciousness (4), stupor (3), cardiac arrest (2), cardiac failure (2), myocardial infarction (2), syncope (3), chest pain (4), aggression (18), abnormal behavior (12), tic (12),

attention disturbance (10), mania (10), agitation (9), hostility (8), irritability (7), mood swings (7), psychomotor hyperactivity (7), and movement disorder (3).²¹⁶

Studies assessing adverse events in children (ages 6-17) with ADHD receiving guanfacine (4 mg/day) in combination with a stimulant medication revealed the following psychiatric adverse events: irritability, anxiety, insomnia, initial insomnia, depression.²¹⁶ Common adverse events reported in these patients included: fatigue (35%), headache (33%), upper abdominal pain (32%), irritability (23%), somnolence (19%), and insomnia (16%).²¹⁶

Key Question 6: Do interventions intended to address disruptive behaviors and identified in Key Questions 1-4 vary in effectiveness based on patient characteristics (KQ6a), characteristics of the disorder (KQ6b), treatment history of the patient (KQ6c), or characteristics of the treatment (KQ6d)?

Overview of the Literature for KQ6

We identified 24 studies^{88,89,98,100-102,104,106,119,120,122,125,126,129,130,134-136,138,140,179,182,187,218} reported in 37 publications^{88,89,98,100-102,104,106,119,120,122,125,126,129,130,134-136,138,140,156,159,162,163,166,169-172,179,182,187,218-222} that addressed KQ6.

Patient Characteristics (KQ6a)

Psychosocial Interventions

Five studies of preschoolers reported tests for mediation and moderation by patient characteristics. Three of those were in studies of the Incredible Years program, and results were inconsistent.^{138,158,159} One publication¹⁵⁸ reported that single parenthood, low socioeconomic status, and teen parenthood, did not significantly moderate change in ECBI scores over the course of treatment with IY. However, sex, age, and maternal depression were significant moderators with boys in the IY groups having better outcomes compared with girls (effect size: 0.03, $p=0.04$). Younger children also had better conduct problem outcomes compared with older (effect size: 0.03, $p=0.04$), and children of depressed mothers in the IY group had improved outcomes compared with children of depressed mothers in the control group (effect size: 0.05, $p=0.004$). By contrast, a study of the IY parenting intervention,¹³⁸ also examined the impact of patient characteristics such as child age, sex, risk of poverty, disadvantaged socioeconomic status, and risk factors for conduct disorder (single parent, teenage parent, parental depression, family poverty, parental drug use or criminal history) and did not report similarly significant moderation effects for ECBI outcomes. A third study¹⁰² reported that child gender and maternal education were significant effect moderators.¹⁵⁹

One study of Triple P in preschoolers tested for mediation and moderation and did not report that any of the examined variables (family risk factors, baseline maternal rated ECBI Intensity) predicted treatment outcome.^{140,160,162} The study of PCIT in preschoolers testing for mediation by patient characteristics reported that baseline respiratory sinus arrhythmia moderated treatment outcomes.^{98,156}

Four studies of psychosocial interventions for disruptive behaviors in school-age children reported tests for mediation and moderation.

Two studies reported no mediation or moderation of treatment effects for gender¹³⁴ and child welfare system involvement;⁸⁹ one study reported significant moderation by neighborhood²²³ and

another reported that in a test nine potential moderator variables on three outcome variables that children of younger mothers appear to have benefitted more but also that this finding could likely just have been by chance given the number of comparisons.¹²² Finally, one study of the Project Support intervention reports partial mediation of CBCL and ECBI over time within individuals was present for several variables examining characteristics of children's mothers including inconsistency, mother-child psychological aggression, and mother's trauma history. Maternal Global psychiatric symptoms also demonstrated partial mediation and were more strongly related to child outcomes in the Project Support group than in the comparison group.¹⁰⁰

Three studies tested for potential mediation and moderation among the group of studies evaluating psychosocial interventions for teenagers with disruptive behaviors.

Two studies indicated potential moderation of treatment effects by family functioning-related variables.^{106 172} For example, one secondary analysis of data from an RCT comparing MST to treatment as usual reported that families with more adaptive functioning at baseline benefitted more from MST.¹⁷² One study reported that MST had greater positive effect among boys than among girls.¹³⁶

Taken together, there is some evidence that treatment outcomes may vary based on patient characteristics, but results are inconsistent likely due to heterogeneity across individual studies.

Pharmacologic Interventions

No identified studies addressed KQ6a.

Characteristics of the Disorder (KQ6b)

Psychosocial Interventions

Inconsistent results are reported for the potential mediating and moderating impact of baseline severity of child disruptive behaviors for treatment outcomes.^{102,129,158,159} Personality traits such as difficult temperament in preschoolers^{102,159} and psychopathy in teenagers^{120,169} were identified as potential mediators or moderators. The one study that examined the impact of concomitant developmental disabilities in a small subsample of the overall study sample was shown to weaken effectiveness of one intervention in school-age children.⁸⁸

For studies of preschoolers, post-hoc mediator and moderator analyses in one RCT (reported in 2 publications)^{129,158} of IY compared with a waitlist control group tested the effects of multiple variables on outcomes and reported that baseline child deviant behaviors did not significantly moderate ECBI scores. Another RCT (also reported in 2 publications)^{102,159} compared a nurse-led IY intervention, psychologist-led IY, and delivery of the IY book without specific therapist-led intervention to parents assessed multiple potential predictors, mediators, and moderators of outcomes on the CBCL and ECBI. Higher baseline levels of life stress, parent stress, child behavior problems, and parent-child dysfunction were associated with greater improvement on the ECBI Intensity scale and CBCL Externalizing scale, but lower levels of life stress, difficult child temperament, and parent-child dysfunction were associated with greater treatment gains on both measures ($p < 0.01$).

Regarding potential mediation and moderation of treatment effects for school-age children with disruptive behaviors, one study showed that one intervention (PPCP) was more effective for children with behavioral problems (but no developmental delay) than for children with behavioral problems plus developmental delay.⁸⁸ One publication²²⁰ from an RCT¹⁰¹ of school-aged children referred for disruptive behavior and randomized to receive the intervention

described above as Modular in a community or outpatient clinic setting examined associations between characteristics of the primary or comorbid disorders at baseline and end of treatment outcomes. Baseline CD was a strong predictor of persistent CD symptoms over time. This suggests that baseline CD is associated with reduced effectiveness, at least for the intervention examined in this study. Similarly, this study looked at specific ODD symptoms and reported that the ODD hurtful dimension, which is described as spiteful or vindictive behaviors, was also associated with reduced intervention effectiveness.

Studies examining potential mediation and moderation of treatment effect that examined interventions for teenagers with disruptive behaviors reported that psychopathy and family characteristics partially mediated / moderated treatment effect. In one study of MST, MST was found to be more effective in decreasing externalizing problems for youth with less psychopathy (defined as callous/unemotional traits, narcissism, and impulsiveness).¹⁶⁹ Another study of MST similarly reported that youth scoring lower on a measure of callous/unemotional traits and narcissism benefitted more from MST than did youth scoring higher on each of these measures.¹²⁰

Pharmacologic Interventions

Comorbid ODD is commonly present in children and adolescents with ADHD, and studies frequently included participants with both. In the two RCTs of atomoxetine and one RCT of guanfacine, inclusion criteria specified children with ODD *and* comorbid ADHD a priori, based on strict diagnostic criteria.^{176,177,179,190} For the two RCTs of stimulants; the population included a large proportion (nearly two thirds) of patients with comorbid ADHD^{182,187} but because results are not provided for participants with and without ADHD, the added or separate effect of ADHD on effectiveness of the treatment cannot be discerned.

Severity of disease at baseline may be an important mediator in treatment response. Baseline SNAP-IV ODD scores ranged from 15.5 (4.4) in one RCT of atomoxetine¹⁷⁶ to 17.2 (3.3) in a second RCT of atomoxetine.¹⁷⁹ All three RCTs of nonstimulants found significant effects regardless of baseline symptom levels.

One RCT of the stimulant mixed amphetamine salts extended release¹⁸² looked at the treatment effect stratified by baseline severity (based on baseline ODD subscale score ≥ 1.7) in a post hoc reanalysis of the per protocol population. The mean change from baseline in ODD scores on the SNAP-IV ODD parent rating was greater for the high baseline ODD severity group. Of note, the baseline scores were low in almost half of the population of the study.

It is not clear if treatment-related changes in ODD symptoms are independent of changes in ADHD symptoms in this population. One study of atomoxetine¹⁷⁶ used a path analysis to evaluate if the treatment effect on ODD symptoms were influenced through the treatment effect on ADHD and/or CD symptoms; they found a nonadditive effect, implying a negative direct effect of atomoxetine on ODD symptoms. In a post hoc analysis of another atomoxetine RCT, authors found that the percent reduction from baseline to endpoint in oppositional symptoms (CPRS-R:L ODD subscale) and ADHD symptoms were highly correlated ($r=0.74$).

Treatment History (KQ6c)

Psychosocial Interventions

No identified studies addressed KQ6c.

Pharmacologic Interventions

Only one RCT of atomoxetine¹⁷⁶ examined the interaction of treatment history defined as prior treatment with a stimulant on study outcomes. Overall, 44 percent of participants had received prior treatment with stimulant medication. In a post hoc analysis, there was a significant interaction ($p=0.032$) between prior stimulant treatment status and study outcome. Both groups improved over the course of treatment with atomoxetine, but the effect of treatment was greater among the patients with a prior history of stimulant treatment (effect size: 0.860) than for the non-pretreated patients (effect size: 0.165). Replication of this finding in other studies is needed.

Characteristics of the Treatment (KQ6d)

Psychosocial Interventions

Studies of psychosocial interventions for children with disruptive behaviors examining if interventions varied in effectiveness based on characteristics of the treatment primarily evaluated variation based on dose and, for interventions including a parent component either alone or in combination with other components, based on whether changing parenting practices mediated intervention effectiveness.

Four studies examined the potentially moderating impact of dose and reported inconsistent effects.^{102,104,122,126} One RCT conducted in Norway examined the dose-response relationship by comparing intervention effectiveness for mothers attending at least 75 percent of the scheduled sessions to those who did not and reported more improvement on parent reported outcomes of child disruptive behaviors for mothers who attended more than 75 percent of sessions than those who attend less sessions.¹²⁶ One RCT conducted in Sweden reported complete mediation of the effect of parent management training on child disruptive behaviors for dose as defined by a measure of the extent to which parents had completed assigned homework.¹²² One RCT conducted in the United States examined the impact of a cognitive behavioral group therapy for adolescents with depression on comorbid disruptive behaviors, as compared to life skills tutoring. The authors evaluated the impact of dose as defined by group attendance.¹⁰⁴ The interaction of group attendance by treatment arm was nonsignificant. One RCT conducted in the United States examined the impact of IY programs led by primary care nurses (group 1) or psychologists (group 2), in comparison to giving parents the IY book but no specific interventionist-led training.^{102,159} Dose effect analyses suggest that the children of parents who attended more training sessions showed more improvement.¹⁵⁹

Eleven studies examined whether the effectiveness of interventions delivering a parent component, alone or in combination with other intervention components, was mediated by changes in parenting practices, confidence, or stress.^{87,119,120,122,125,129,130,146,158,170,219}

Three studies of preschool-age children examined this potential mediator. One prospective cohort study evaluating IY parent training compared with usual care reported that improvement in child conduct problems was mediated by decreased parental use of critical statements.⁸⁷ One RCT comparing IY to a waitlist control group tested the effects of multiple variables on outcomes,^{129,158} and reported that intervention status correlated with improvement in positive but (not negative) parenting behavior, which in turn was itself correlated with improvements on the ECBI ($p<0.014$). An RCT evaluated an intervention program (Hitkashrut) combining elements of parent training models including parental self-regulation, involvement of fathers, parent-child communication skills, and behavior management compared with undefined minimal

intervention.¹¹⁹ Intervention group changes in child conduct problems from baseline to post-treatment were mediated by changes in parenting practices and parent reported stress.¹¹⁹

Four studies of school-age children examined this potential mediator. One study reported that improved positive parenting skills and that reduced harsh and inconsistent parenting partially mediated intervention effectiveness.¹²² One study reported that reduced harsh and inconsistent parenting skills partially mediated intervention effectiveness, but that improvements in positive parenting skills did not.²¹⁹ Two studies reported that improved positive parenting skills partially mediated parent reported child disruptive behaviors.^{125,130,166}

Pharmacologic Interventions

No identified studies addressed KQ6d.

Discussion

State of the Literature

KQ1. Effectiveness of Psychosocial Interventions

Sixty-six studies examined the effectiveness of psychosocial interventions for children with disruptive behaviors. We categorized these studies broadly by age group as examining preschool (n = 23), school-age (n = 29), or teenage (n = 14) children, and according to whether the active treatment arm was an intervention that included only a child component (n = 2), only a parent component (n = 25), or was a multicomponent intervention (n = 39). Multicomponent interventions were defined as those that included two or more of a child component, parent component, or other component (e.g., teacher component, family together component). Studies within each of these intervention categories were heterogeneous, although several well-known programs were most common.

We included studies of interventions delivered in healthcare settings for children with a formal diagnosis of a disruptive behavior disorder or whose disruptive behaviors were assessed at or above a clinical cutoff on a well-validated measure of child disruptive behaviors. Thus, we excluded from our review studies of preventive or universal interventions, and interventions delivered in non-healthcare settings. These important interventions and populations may be appropriate for a separate review, but were beyond the scope of our review. We also excluded disruptive behaviors in the context of autism or other developmental disabilities. We included studies of children who had conditions such as attention deficit hyperactivity disorder (ADHD) as long as the primary focus of the study was on the treatment of the disruptive behavior. We also focused on parent reports of child disruptive behaviors because they were the most consistently reported outcome in the literature, because other outcomes of interest, especially functional outcomes such as school performance, were not consistently reported.

Preschool Children

Studies examining psychosocial interventions for preschool-age children had an active treatment arm that included only a parent component (n = 14) or were multicomponent interventions (n = 9). Seventeen of the 23 studies included in our review of psychosocial interventions for preschoolers with disruptive behaviors examined one of three interventions: Parent Child Interaction Therapy (PCIT) (n = 7), the Incredible Years Parent Training program (IY-PT) (n = 5), or the Positive Parenting Program (Triple P) (n = 5). The remaining six studies each examined a different intervention.

The seven studies examining PCIT for preschool disruptive behaviors evaluated several versions of PCIT (regular, abbreviated, culturally adapted) in comparison to treatment as usual, a waitlist control group, or another PCIT version. Although most studies measured child disruptive behaviors using the Eyberg Child Behavior Inventory (ECBI) Intensity and/or Problem subscales, most studies included other measures of child disruptive behaviors (e.g., Dyadic Parent-Child Interaction Coding System) and did not clearly identify one outcome measure as primary. All five of these studies reported significant reductions in parent-reported child disruptive behaviors from baseline to post-treatment in comparison to either treatment as usual or a waitlist control group, regardless of which version of PCIT was being evaluated. Consistent differences between versions of PCIT were not reported.

The five studies examining IY-PT for preschool disruptive behaviors evaluated several versions of IY-PT (IY-PT + ADVANCE, IY-PT, IY-PT psychologist led, IY-PT nurse led) in comparison to other versions of IY-PT and waitlist controls. All studies used one of the parent-reported ECBI scales or CBCL scales, and most of the studies included direct observation of child disruptive behaviors. On parent-reported measures of child disruptive behaviors, 5 studies reported improvement from baseline to followup (ranging from post-treatment to 2-year followup) for children in IY-PT. Children in the IY-PT arms consistently showed more improvement than children in waitlist control arms. Consistent differences between versions of IY-PT were not reported.

The five studies examining Triple P for preschool disruptive behaviors evaluated several different versions of Triple P against each other, a waitlist control group, and treatment as usual. Each of these studies reported significant reductions in disruptive behaviors in the Triple P treatment arm as compared to a waitlist control group on parent-reported child disruptive behaviors as measured by one of the ECBI subscales. Self-directed Triple P plus weekly phone conferences was found to be more effective than self-directed Triple P alone,¹³⁵ and self-directed Triple P plus 14 hours of skills training and partner support was more effective than self-directed Triple P plus 10 hours of therapist-led skills training or self-directed Triple P alone.¹⁴⁰

Although six other studies also examined interventions for preschoolers with disruptive behaviors, each examined a different individual intervention making it difficult to make general statements about these interventions.

Overall, most of the reviewed studies on psychosocial interventions for preschool children with disruptive behaviors focused on one of three specific interventions (PCIT, IY-PT, or Triple P). The literature for this age group is limited by difficulties defining the study population, study design limitations even among the RCTs, and lack of consensus about the most important outcomes.

School-Age Children

Seventeen of the 29 studies included in our review of psychosocial interventions for school-age children with disruptive behaviors had an active treatment arm that was a multicomponent intervention. Eleven studies included only a parent component and one study included only a child component. Four of the 15 studies of multicomponent interventions included at least two of the IY components (child training, parent training, and teacher training) in combination with one another, two were of a modular intervention, and two were of SNAP Under 12. The seven remaining studies were each of a different intervention.

Four studies examined more than one IY component in combination with each other. Because these studies test multiple IY component combinations against each other and waitlist control and measure multiple outcomes without designating a primary outcome, this group of studies is difficult to summarize succinctly. A conservative summary is that at least two IY components delivered together are associated with greater decreases in parent-reported child disruptive behavior than waitlist control.

Two studies (each including multiple papers) examined the effects of a community-based version (in comparison to a clinic-based version) or nurse-led version (in comparison to enhanced usual care) of a modular multicomponent intervention for children with ODD or CD. Both studies were therefore essentially testing the “portability” of this intervention. Although the nurse-led version was associated with improvement in goal achievement and overall health, it was not associated with significantly more improvement in parent-reported child disruptive

behaviors than was enhanced usual care. Both the clinic- and community-based versions of the intervention were associated with significant reductions in parent-report child disruptive behaviors.

Two studies (one RCT, one non-RCT) compared the SNAP Under 12 intervention in comparison to a waitlist control group that engaged in recreational group activities. Children in SNAP Under 12 group in both studies showed greater reductions over treatment in parent-reported child disruptive behaviors as measured by the CBCL Aggression and CBCL Delinquency subscales. Only one study has been published for each of the remaining seven multicomponent interventions.

Of the 11 studies examining parent only interventions, three studies examined IY-PT, two studies examined PMTO, and six other studies each examined a different intervention with only a parent component. Two studies examined IY-PT in comparison to a waitlist control group. Each study reported significantly greater reductions on ECBI-I, ECBI-P, or both for children in IY-PT groups compared with the children in the control groups. Both of the studies examining PMTO reported that children receiving PMTO showed greater reductions in parent-reported child disruptive behaviors relative to treatment as usual. It is difficult to make general statements about the other six studies because they are each of a different intervention.

There was only one study including interventions with only a child component for school-age children. The study examined a social cognitive intervention program.¹³² As with the literature examining psychosocial interventions for preschool-age children, the literature on school-age children suggests that there is most support for multicomponent interventions that include a parent component. Overall limitations for the school-age literature are similar to that for preschoolers and are discussed in detail below.

Teenage Children

Thirteen of the 14 included studies examining psychosocial interventions for teenagers with disruptive behaviors had an active treatment arm that was a multicomponent intervention, specifically MST (n = 5) or BSFT (n = 3). The other three studies were each of a different intervention.

All five of the studies examining MST were RCTs. Two of these studies were conducted in the United States: one compared MST to treatment as usual;⁹⁴ the other compared MST to individual therapy.¹¹¹ Both of these studies demonstrated greater reductions in child disruptive behaviors for children receiving MST. The other three studies were conducted in Europe and compared MST to treatment as usual.^{120,124,136} One RCT compared youth randomized to receive MST with youth randomized to receive a treatment as usual intervention that was much more comprehensive than the type of treatment as usual most commonly included in studies conducted in the United States.¹²⁰ This RCT reported that in comparison to youth randomized to the treatment as usual multicomponent intervention youth randomized to MST were less likely to have committed nonviolent offenses and experienced greater reductions in the CBCL Aggression and Delinquency subscales, but did not experience greater reductions in the CBCL Externalizing subscale from baseline to the end of followup.¹²⁰ One RCT compared MST to treatment as usual reporting that youth randomized to receive MST experienced greater decreases in disruptive behaviors as measured by the CBCL Externalizing subscale, ODD and CD as measured by a *DSM-IV* symptoms checklist, and property offenses than did youth randomized to receive treatment as usual.¹³⁶ The final of the RCTs conducted outside the United States compared MST to treatment as usual and reported no difference in disruptive behaviors as

measured by the CBCL Externalizing subscale for youth randomized to receive MST as compared to youth randomized to receive treatment as usual.¹²⁴

Three RCTs examined BSFT in comparison to group therapy¹⁰⁶ or another family-based intervention.^{142,144} Although each of these studies examined the effectiveness of BSFT with a very specific subgroup (Hispanic teenagers)¹⁰⁶ or very specific outcome (bullying),^{142,144} all three reported significant reductions in child behavior problems for the youth randomized to receive BSFT in comparison to group therapy¹⁰⁶ or another multicomponent intervention.^{142,144}

Although it is difficult to make general statements about each of the other four interventions included in this review because there is only one study of each, taken together the literature on psychosocial interventions for teenagers with disruptive behaviors suggests most support for multicomponent interventions such as MST or BSFT. Overall limitations are similar for teenage literature as for the two other age groups and are discussed in detail below.

Summary of Meta-Analysis

We conducted a Bayesian multivariate, mixed treatment (network) meta-analysis using data from RCTs addressing KQ1 that measured parent-reported child disruptive behavior using one of the most prevalent outcome measures (i.e., CBCL Externalizing subscale reported as a T-score, ECBI Intensity subscale, or ECBI Problem subscale) and included the necessary data at baseline and post-treatment for both intervention and control groups. In total, 28 studies were used to fit the model. The baseline was subtracted from the end-of-treatment mean and used as the response measure, along with the sum of their standard deviations. Our outcome variable was a standardized mean effect size. Our predictor variable was the broad category of intervention (child component only, parent component only, multicomponent) with the specific intervention type (PCIT, MST, etc.) defined as a random effect.

The effect sizes for the multicomponent intervention class and for interventions with only a parent component had the largest estimated value (Table 47), both with a median of -1.2 (95% credible interval: -1.6 to -0.9) standard deviations reduction in outcome score. The estimate for interventions with only a child component was -0.9 (95% Credible Interval: -1.6 to -0.4). Accordingly, multicomponent component interventions and interventions with only a parent component had the highest probability of being the best intervention (43% for both), followed by interventions with only a child component (14%).

Table 47. Network meta-analysis of intervention category as a predictor of treatment effect in parent-reported measures of child disruptive behavior among selected studies of psychosocial interventions

| Intervention Class | Posterior Median | Standard Error | 95% Credible Interval |
|--------------------|------------------|----------------|-----------------------|
| Child-only | -0.9 | 0.3 | [-1.6, -0.4] |
| Parent-only | -1.2 | 0.2 | [-1.6, -0.9] |
| Multicomponent | -1.2 | 0.2 | [-1.6, -0.9] |

Age effects were relatively more subtle, with an additive median effect of -0.4 standard deviations (95% credible interval: -0.6 to -0.3) for preschool relative to school-age children (baseline level), and of -0.1 standard deviations (95% credible interval: -0.5 to 0.2) for adolescents relative to school-age children. These trends were evident across each of the outcome measures included in the analysis.

The marginal posterior probabilities of remaining above the cut point were higher for the treatment as usual/control group relative to each intervention group, with multicomponent interventions showing the lowest proportion of children still above the clinical cutoff post-treatment.

Though we considered age-by-treatment interactions, there was not enough balance among the age and treatment combinations to include them in the final model.

Overall Summary of KQ1

Our qualitative and quantitative syntheses generally suggest that available evidence provides the most support for interventions for children with disruptive behaviors that are multicomponent interventions or interventions that include only a parent component. All multicomponent interventions included in this study included a parent component. Our assessment of the overall strength of evidence and limitations of this evidence base are discussed in detail below and in an Evidence Profile (Appendix J). Overall, the evidence base is limited by difficulty defining the study population, study design limitations even among RCTs, and lack of consensus about the most important outcomes.

KQ2. Effectiveness of Pharmacologic Interventions

Despite a fairly robust literature on psychopharmacologic drugs as a whole, few studies have focused specifically on their use in children whose primary indication is a disruptive behavior disorder. Among those studied are four types of drug treatment: antipsychotics, antiepileptics, stimulants typically used with ADHD, and nonstimulants typically used with ADHD. Thirteen studies were identified across all of these drug classes, with the most commonly studied drug being risperidone. All studies were conducted in primarily male patient populations, with ages ranging from 6 to 18 years.

Four antipsychotics were studied: risperidone, quetiapine, aripiprazole, and ziprasidone. All of the antipsychotics are second-generation atypical antipsychotics. Prior systematic reviews have studied these drugs and others for a more general set of indications. We describe the findings of those reviews in below in order to place our more limited review in context. Four antipsychotics were studied: risperidone, quetiapine, aripiprazole, and ziprasidone. All of the antipsychotics are second generation, atypical antipsychotics. There is a large literature base as well as prior systematic reviews that have studied these drugs and others for a more general set of indications and are available.

Among antipsychotics, risperidone was assessed in three studies and the others were each in only one study. Among studies of risperidone, two studied the effectiveness of risperidone as the initial treatment, and one focused on maintenance, comparing continued use of risperidone to discontinuation and replacement with placebo. One study¹⁸⁶ reported a positive effect of risperidone over placebo. The second study¹⁸¹ compared risperidone as augmentation to stimulant medication for patients with ADHD and aggressive behavior after treatment with a stimulant and found no benefit of risperidone over placebo. The final study¹⁸³ was a maintenance study, comparing risperidone to placebo after treatment with risperidone. In this study, the placebo group worsened more than the risperidone group over 6 months.

One open label study²²⁴ compared aripiprazole to ziprasidone and found the two medications to be equally effective in decreasing clinically significant aggressive behavior over two months.

Finally, one study compared the use of quetiapine to placebo and the results were mixed. Although clinicians rated greater improvement in symptoms in the quetiapine group, there was

no difference on parent rated measures, and no difference in CPRS (a rating of general problem behaviors in children). Quality of life was reported to be significantly higher in the treatment group, however.

Overall, these studies were limited by short duration (all but one¹⁸³ were 2 months or less) or high attrition. While head-to-head studies such as that comparing aripiprazole to ziprasidone are useful to compare medications, large, randomized, controlled studies that measure effect size and show consistent benefit of this class of medications over placebo are also needed.

Among antiepileptic drugs, only valproic acid was studied specifically for disruptive behavior disorders. The one placebo-controlled trial¹⁷⁸ reported no benefit for valproic acid, while a small (n = 20) crossover study of slightly older (up to age 18) children reported a benefit for drug. Finally, one study provided valproate to all participants, but compared high and low doses, with greater effects reported for higher doses and in “high distress” conduct disorder relative to “low distress” conduct disorder. All three studies were small, short-term and funded by the manufacturer of the treatment drug.

Medications commonly used for ADHD, both stimulants and nonstimulants, have also been studied for their potentially specifically to manage disruptive behaviors among children with comorbid ADHD and ODD/CD. Among the nonstimulants, Atomoxetine, a centrally acting, norepinephrine reuptake inhibitor, has been approved for treatment of ADHD in children and adolescents and has been used off label for treatment of DBD and ODD symptoms among populations with comorbid ADHD.

Two RCTs^{176,179} reported treatment with atomoxetine (up to 1.2 mg/kg/day) for nine weeks improved ODD symptom scores compared to placebo, among children and adolescents with ADHD and comorbid ODD. One RCT (reported in 2 publications)^{176,190} reported significant improvement in quality of life compared to placebo, over the 9-week period. The other RCT¹⁷⁹ found no significant differences in overall quality of life, but improvement in certain subdomains, including risk avoidance and emotional comfort.

Guanfacine extended release is a selective central alpha2A-adrenergic receptor agonist and is FDA approved for treatment of ADHD in children 6 to 17 years. We identified one low risk of bias RCT of guanfacine extended release (1 to 4 mg/day) that reported significantly reduced oppositional symptoms as measured by the CPRS-R:L oppositional subscale scores compared with placebo.

Although there were a limited number of studies, these three RCTs reported short-term effectiveness in reducing ODD/CD symptoms among children and adolescents with comorbid ADHD and ODD.

One high risk of bias RCT of mixed amphetamine salts extended release demonstrated that higher doses (30 mg/day) were associated with decreased ODD symptoms compared to placebo over a 4-week period among school-aged population with ODD, 79 percent of who also met criteria for ADHD. This study also reported significant improvement in several quality of life measures for children with ODD. One high risk of bias RCT of methylphenidate (up to 60 mg/day in 2 divided doses) among school-aged population with CD symptoms, 69 percent of who also met ADHD criteria, found both teacher and parent ratings of CD problems improved compared to those in the placebo group. Duration of these two studies was short, ranging from 4-5 weeks, which is too short to determine whether there is a long-term treatment effect of stimulants on ODD symptoms. Severity of ODD symptoms at baseline may be important mediator in treatment response, but more data are needed to examine this question.

Overall, studies are lacking that compare children/adolescents with ADHD alone to those with ADHD with ODD and ODD alone in order to evaluate the specific effects of treatment on oppositional symptoms. Comorbid ODD is commonly present in children and adolescents with ADHD, and thus finding populations with ADHD but without ODD symptoms or ODD without ADHD may be challenging. Most importantly, it is unclear whether treatment-related changes in ODD symptoms are independent of changes in ADHD symptoms in this population. Treatment period of 8 to 9 weeks may be too short to determine whether there is a long-term atomoxetine treatment effect on ODD symptoms or quality of life outcomes.

Although combination therapy with antipsychotics and stimulants can be effective for patients with ADHD and comorbid DBD, we found a lack of studies that evaluated combination pharmacologic treatment compared to monotherapy or compared the efficacy of combined behavioral and pharmacologic interventions compared to pharmacologic or behavioral interventions alone. To date, treatment research is almost exclusively supported by the pharmaceutical industry. Given the prevalence of DBDs and the need for high quality data to inform clinical practice, more long-term studies are needed.

KQ3. Effectiveness of Psychosocial Versus Pharmacologic Interventions

No head-to-head studies were found to answer this question.

KQ4. Effectiveness of Combined Psychosocial and Pharmacologic Interventions

No head-to-head studies were found to answer this question.

KQ5. Harms of Psychosocial or Pharmacologic Interventions

No harms of psychosocial interventions were reported. Importantly, a lack of reported harms is not an indication that no harms exist. The psychosocial literature also uniformly failed to note that harms were sought.

The medical treatment studies in this report were generally small and short term, with typically no followup post treatment. Thus, harms reported in those studies were generally mild or moderate and fairly immediate in nature. Nonetheless, there was significant loss to follow up in several studies, some of which was clearly due to experiencing adverse events and the studies were very short term and not powered to identify harms that might be rare. All of the pharmacologic studies included in the empirical literature here were designed and powered for benefit and thus would only be likely to identify common and minor events. Therefore, we sought harms data from other sources that might include more extensive and longer-term data, including other systematic reviews. It is important to note that other studies, including large scale, database analyses have identified harms of antipsychotics in particular to include significantly increased risk of metabolic effects.

Harms of the antiepileptic drug, valproate, were available from three, short-term RCTs. They include short-term changes in sleep pattern, mood changes, gastrointestinal upset and appetite changes. The proportion of patients experiencing these were high some cases (e.g. 50% with insomnia in the treated group versus 15% in placebo), but the numbers of participants included were so low as to likely be unstable. Additional data are available from FDA package inserts and provide more support for these adverse events. Specifically in pediatric clinical trials, consisting

of 76 patients aged 10 to 17 years taking divalproex extended release for mania and 231 patients aged 12 to 17 years taking divalproex extended release for migraine, common adverse events (reported more than 5% and twice the rate of placebo) included: nausea, upper abdominal pain, somnolence, increased ammonia, gastritis and rash.²¹¹

Harms of antipsychotics have been studied extensively, both in the context of effectiveness research and independently, and are reviewed in other systematic reviews. The systematic review data mirror that available in our included studies, namely identifying significant increases in somnolence, fatigue and weight gain.¹⁸³

We identified three good quality systematic reviews addressing harms of atypical antipsychotics in children and adolescents.^{49,52,198} Harms found to be significantly associated with treatment included weight gain and changes in metabolic parameters.⁴⁹ Mean weight gain in the risperidone group was 2.37 kg more than in the placebo arm over 6 to 10 weeks in a meta-analysis of two trials (mean difference: 2.37, 95% CI: 0.26 to 4.49).

Another Agency for Healthcare Research and Quality (AHRQ) review included studies of atypical antipsychotics used for any indication in individuals aged 24 years and younger.⁵² Agents included in studies in the review were haloperidol, risperidone, aripiprazole, olanzapine, pimozide, quetiapine, clozapine, and ziprasidone, and median study duration was 8 weeks. The review evaluated harms by drug class and noted fewer extrapyramidal symptoms associated with olanzapine and risperidone compared with haloperidol (low strength of the evidence), and no significant differences between first and second-generation antipsychotics in prolactin-related adverse events (low strength of the evidence). Risperidone was associated with less dyslipidemia and less weight gain than olanzapine (moderate strength of the evidence). Risperidone was also associated with more prolactin-related harms than olanzapine (moderate strength of the evidence) and with more weight gain than aripiprazole (low strength of the evidence).

Finally, one review and meta-analysis evaluated metabolic and neurologic adverse events associated with second-generation antipsychotic use in children with any mental health disorder and included 35 RCTs (4 reported in the current review).¹⁹⁸ In a meta-analysis of 10 RCTs of risperidone of less than 12 weeks duration, weight gain (mean difference: 1.72 kg, 95% CI: 1.17 to 2.26, $p < 0.00001$), prolactin levels (mean difference: 20.70 ng/mL, 95% CI: 16.78 to 24.62, $p < 0.00001$), and change in prolactin from baseline to end of treatment (mean difference: 44.57 ng/mL, 95% CI: 32.24 to 56.90, $p < 0.00001$) were higher in risperidone groups compared with placebo. The odds of clinically significant weight gain were higher in the risperidone arm compared with placebo (OR=2.90, $p = \text{NS}$) as were the odds of extrapyramidal symptoms (OR=3.35, $p < 0.0001$). The review reported no clinically significant changes in laboratory values or blood pressure in seven studies. Blood pressure was elevated in the risperidone group in one study. In studies comparing risperidone at different doses or with other agents (pimozide, clonidine, haloperidol), children in the risperidone arms had weight gain and extrapyramidal symptoms that were typically not significantly different from the comparison group, though higher doses of risperidone were associated with greater weight gain and movement symptoms.

In a meta-analysis of three studies of quetiapine versus placebo (including the Connor 2008¹⁸⁰ RCT included in the current review), weight gain, but not prolactin levels, was significantly higher in the quetiapine group (mean difference: 1.41 kg, 95% CI: 1.01 to 1.81). Triglyceride levels, blood pressure, and heart rate were significantly elevated in the quetiapine group compared with placebo in one RCT. The review also included nine RCTs assessing aripiprazole, five of which were combined in meta-analyses. Mean weight gain (mean difference: 0.85 kg, 95% CI: 0.57 to 1.13, $p < 0.00001$) and BMI increase (mean difference: 0.27 kg/m² 95%

CI: 0.11 to 0.42, $p=0.0007$) were higher in aripiprazole groups compared with placebo, and the odds of weight gain were significantly higher in the treatment group (OR=3.66, $p=0.0003$). Lipids and ECG values did not differ significantly between groups.

Significant risk of metabolic effects has also been demonstrated to be elevated in large database analyses.²²⁵ Indeed, given the methodologic challenges to reviewing harms in RCTs that are noted above, observational studies such as these are likely to provide more precise estimates of harms. They unfortunately are not necessarily limited to the population of interest in our review, and provide little detailed clinical information.

Harms of stimulants, including methylphenidate and amphetamine salts, which are typically used to treat ADHD and commonly used for DBD, include delay of sleep and anorexia, particularly at higher dosage in the included study. The FDA package insert includes a warning that methylphenidate has been associated with sudden cardiac death in children with existing cardiac abnormalities.

Nonstimulants, including atomoxetine and guanfacine, were associated with increased rates of headache, somnolence, and anorexia.

None of these studies described here, however, explicitly weigh the benefits achieved against these harms, and clinicians and families need to do so including both effectiveness and harms evidence.

KQ6. Modifiers of Effectiveness of Interventions

This question was divided into sub-questions about variations in intervention effectiveness due to a) patient characteristics, b) characteristics of the disorder, c) patient treatment history, and d) treatment characteristics. Although studies examining each of these questions were identified, it is unclear if any of the identified studies were adequately powered to answer these questions.

Regarding variations in the effectiveness of psychosocial interventions due to patient characteristics, it is important to note that most studies included relatively homogeneous age groups (e.g., preschool, school, or adolescent children). That studies were restricted to specific age groups implies widespread, tacit acceptance of the idea that intervention effectiveness varies by child age. At the same time, this aspect of study design limits the ability of included studies to examine this issue. The most commonly examined patient characteristics include child gender, characteristics of the child's mother, and characteristics of the child's family. In general, results were inconsistent and additional examination of these issues is warranted. None of the studies examining pharmacologic interventions addressed the potential for variations in treatment effectiveness based on patient characteristics.

The most commonly examined characteristic of disruptive behavior disorders that was examined for its potential to moderate the effectiveness of psychosocial interventions is the severity of a child's disruptive behaviors at baseline. Results were inconsistent. Difficult temperament and psychopathy were associated with treatment effectiveness in studies with pre-kindergarten age children and studies with teenage children, respectively. More examination of these characteristics is needed.

The severity of a child's disruptive behaviors at baseline and the presence ODD or CD comorbid with ADHD were the characteristics of the disorder that studies of pharmacologic interventions were most likely to examine for their association with differential treatment effectiveness. In general, more disruptive behavior at baseline was associated with greater treatment effectiveness. It is unclear, however, if changes in non-ADHD disruptive behaviors are

independent of changes in ADHD symptoms because of the high prevalence of comorbidity in the study populations.

No studies evaluated variations in the effectiveness of psychosocial interventions due to patient treatment history. One study of atomoxetine indicated that prior treatment with a stimulant was associated with a larger treatment response to atomoxetine.

Studies of psychosocial interventions evaluated variation due to treatment characteristics based on dose – defined by some measure of treatment attendance – and, for interventions including a parent component either alone or in combination with other components, based on whether changing parenting practices mediated intervention effectiveness. The studies defining dose either as session attendance or as homework completion consistently reported greater intervention effects for children whose parents participated more. Similarly, studies examining whether changes in parenting practices were associated with treatment effectiveness consistently provided some support that they were. This is consistent with results from prior reviews.²²⁶

In pharmacologic studies, the role of baseline severity was inconsistent, with no mitigating effect of severity for nonstimulants, but greater effect associated with greater baseline severity in one RCT of the stimulant mixed amphetamine salts ER.¹⁸² It is not clear if treatment-related changes in ODD symptoms are independent of changes in ADHD symptoms in this population. One study of atomoxetine¹⁷⁶ used a path analysis to evaluate if the treatment effect on ODD symptoms were influenced through the treatment effect on ADHD and/or CD symptoms; they found a nonadditive effect, implying a negative direct effect of atomoxetine on ODD symptoms. In a post hoc analysis of another atomoxetine RCT, authors found that the percent reduction from baseline to endpoint in oppositional symptoms (CPRS-R:L ODD subscale) and ADHD symptoms were highly correlated ($r=0.74$).

Findings in Relationship to What Is Already Known

We searched for systematic reviews published between 2005 and 2014. We evaluated each for relevance to our Key Questions using the review PICOTS (Appendix B). We identified 22 reviews assessing the effectiveness of psychosocial interventions and two reviews assessing the effectiveness of pharmacologic interventions.

The reviews of psychosocial interventions included two types: reviews of literature regarding specific interventions such as MST and reviews of more general interventions. These reviews did not address potential harms of psychosocial interventions. The two reviews of pharmacologic interventions addressed the effectiveness of atypical antipsychotic medications, though they were not specific to populations of children treated for disruptive behaviors. We describe information about harms from these two reviews (and one additional review that reported harms only) in KQ5 above.

Existing Reviews of Psychosocial Interventions

Of the 22 identified systematic reviews or meta-analyses of psychosocial interventions, we identified one review specific to the MST literature, one review specific to the CBT literature, two reviews specific to the Triple P literature, one review of Triple P and PCIT, 11 more general reviews, and one review of existing reviews. It is important to note that these reviews may include studies not included in the current review due to different study inclusion and exclusion criteria.

Reviews of MST Literature

A Cochrane review included eight RCTs of MST for behavioral and emotional problems in children between the ages of 10 and 17 years.²²⁷ Few studies addressed outcomes related to externalizing behaviors, but an analysis of three studies reporting CBCL Externalizing scales showed pooled results were not significant (standardized mean difference: -0.18 , 95% CI: -0.46 to 0.09). This review concluded that there is inconclusive evidence of the effectiveness of MST as compared to other interventions.

Reviews of CBT Literature

One meta-analysis included six studies of CBT for violent behavior and reported limited effects of CBT on child behavior (effect size: -0.094), with decreasing effects reported over time as outcome data accumulated.²²⁸ In a cumulative analysis, effect sizes decreased from 0 to -0.95 . This review concluded that this is a medium effect and called for more research into the effectiveness of CBT for violent behavior.

Reviews of Triple P Literature

There were two reviews of the Triple P literature.^{229,230} Both of these reviews were meta-analyses and together reported on more than 100 randomized, nonrandomized, and uncontrolled studies.^{229,230} These reviews both reported small to medium effect sizes for parenting outcomes (0.38 to 0.57), child behavior outcomes (0.35 to 0.52), and parental wellbeing/satisfaction (0.17 to 0.55) over both the short- and long-term.

These reviews also examined potential moderators. One of these reviews examined if factors related to the specific design of the version of the Triple P program that was implemented (group vs. individual) and reported no consistent effect modification by design.²²⁹ This review also reported that treatment effects were consistently lower when measured by father reports than those of mothers, and that younger child age was associated with greater treatment effectiveness. Neither level of initial behavioral severity nor child gender were significant predictors of outcomes. Program completion was also not associated with the effect size.²²⁹

The other review reported that Triple P level and Triple P as a treatment (vs. Triple P as a preventative intervention) were associated with higher effect sizes.²³⁰ Online Triple P had the largest effect sizes for child outcomes; the online and group versions of Triple P had the largest effect sizes for parental relationship outcomes. Study power also moderated treatment effects such that higher effect sizes were found for studies with less than 35 participants in the smallest group compared to studies with greater than 35 participants in the smallest group. Significant effect sizes were found for studies with larger sample sizes. This review also reported that the initial severity of child behaviors moderated effects on parental relationship outcomes. This review also noted that Triple P studies that did not include involvement of a developer of the program ($n = 31$) still produced significant intervention effects on child outcomes.

Reviews of Triple P and PCIT

One meta-analysis examined the effects of PCIT ($n = 13$ studies) and Triple P ($n = 11$ studies) on parent-reported child problem behaviors.²³¹ Children were in the clinical or borderline range for disruptive behaviors in most (but not all) of the studies, and effect sizes in studies reporting between-group comparisons ranged from -1.59 to 5.67 across parent, teacher, father, and observation measures and control groups for PCIT. All forms of PCIT except the abbreviated version had a significant short-term effect on parent-reported child behaviors.

Effect sizes ranged from -0.96 to -0.02 for Triple P across informants and all formats (group, self-directed, etc.). The effect size for PCIT (-1.45) was significantly higher than those for self-directed (-0.51), group (-0.67), and individual Triple P (-0.69) but not for media or enhanced Triple P. Effects sizes for observed outcomes were not significantly different from PCIT and any form of Triple P. Negative parenting behaviors were also improved with both PCIT and Triple P. The review notes that limited evidence addresses effects over the longer term.

More General Reviews

There were 11 general reviews, not restricted to literature about specific interventions. These reviews included RCTs, controlled trials, and quasi-experimental studies published in any country, including studies dating to the 1980s. As in the current review, participants in the studies included in prior systematic reviews were mostly male and typically Caucasian. Most of the included studies were small, with short-term (≤ 6 months) followup. Studies were generally of moderate methodological quality, with reporting of family characteristics, allocation concealment, and randomization methods generally noted as limited. Reviews described variations in inclusion criteria (e.g., requirement of DSM diagnosis of a DBD, only parent-reported problem behaviors) and recruitment methods. A brief summary of each of these reviews is included below.

One meta-analysis included 28 RCTs for a total of 2239 children with disruptive behaviors between the ages of 2 and 12 years.⁵⁹ Fourteen studies assessed variations of the IY program, nine studies evaluated the Triple P, two studies evaluated PCIT, and three studies assessed other approaches such as “Project TEAM.” The investigators rated six of the studies as low or moderate risk of bias. Overall, the studies varied in terms of how they defined their target population with studies using clinical cut-off levels on established measures, DSM diagnoses, or general parent-reported behaviors to establish inclusion. Reporting of parent and family characteristics also varied across studies. Child disruptive behaviors measured on the ECBI Intensity and Problem scales were significantly ($p < 0.001$) reduced in active treatment arms compared with control (weighted mean differences of -20.90 , 95% CI: -26.26 to -15.53 and -6.03 95% CI: -7.70 to -4.36 , respectively). CBCL Externalizing scores and Strengths and Difficulties Questionnaire (SDQ) Conduct scales were also significantly improved in active treatment arms compared with control groups.

Another meta-analysis of 57 RCTs of parenting programs for child disruptive behaviors reported similar results.⁵⁵ In combined analyses of ECBI-Intensity and CBCL scales reported in 24 of these studies, children in the parent management training intervention arms had improved outcomes compared with children in comparison arms (standardized mean difference: -0.67 , 95% CI: -0.91 to -0.42). Investigators’ analysis of other outcomes reported in 36 studies aligned with these meta-analysis findings: for 100 of 170 child behavior outcomes, outcomes were significantly improved in children in treatment groups compared with those in control groups. Meta-analysis of independent observations in seven studies also demonstrated significantly improved outcomes for children in active treatment groups versus control groups (standardized mean difference: -0.44 , 95% CI: -0.66 to -0.23).

A United Kingdom National Health Service review of 37 RCTs of parenting interventions for children with conduct disorder also reported consistent evidence for the short-term effectiveness of parent training programs compared with control groups.²³² Six included studies were assessed as good or adequate quality; the other 31 studies were rated as poor or very poor quality. Pooled

estimates demonstrated significant improvement in treatment groups compared with control on the ECBI, CBCL, and in observer coding of parent-child interactions, while differences between the parent management approaches studies were not consistent.

Another review of seven studies of primarily parent management approaches addressed intervention for children with ODD and reported the greatest effects on child behavior when interventions targeted parents (standardized mean difference: 1.06; 95% CI: 0.70 to 1.41), with smaller effects if only children were targeted (standardized mean difference: 0.93; 95% CI: 0.52 to 1.34).²³³

A meta-analysis including 79 studies reporting on children with externalizing behaviors noted a mean weighted effect size of 0.30 (95% CI: 0.21 to 0.39) for end of treatment child behaviors in studies with comparison groups, 0.68 (95% CI: 0.59 to 0.77) for within group comparison studies, and 0.54 (95% CI: 0.43 to 0.65) in single subject studies.²³⁴ Effect sizes at followup were 0.40 for between-group designs, 0.79 for within groups, and 1.74 for single subject designs. Modifiers across each study type varied, but child age, method of treatment delivery, use of randomization, use of reliability assessment, and number of treatment sessions were significant modifiers of effects in between-group studies, with studies that included children age 9 to 11 years ($n = 2$) had larger effects. Those using individual consultation and controlled learning and those using non-random assignment also had larger effects as did those not reporting a reliability assessment. Finally, studies using between one and five treatment sessions had greater effect sizes than those using more sessions.

Another meta-analysis of 63 studies including children with DBD reported overall effect sizes of 0.42 for child behavior outcomes, 0.47 for parent behaviors, and 0.53 for parental perceptions in the short term and smaller effect sizes in the longer term.²³⁵ Children from families with lower socioeconomic status had less improvement of behaviors than did the children from families with higher socioeconomic status ($p < 0.01$), as did those in studies with groups with more single parents compared to those with fewer single parents ($p < 0.01$). Children with clinically significant baseline levels of disruptive behavior had greater change than did children without such clinically significant behaviors ($p < 0.05$). Socioeconomic status also significantly moderated parent outcomes, with lower socioeconomic status associated with poorer outcomes. In contrast to our findings, treatment modalities involving only the parent were associated with greater positive change than those delivering interventions to the child separately or using a multisystem approach ($p < 0.05$). Change in parent perceptions (confidence, stress) was also greater with parent-only interventions compared with those involving parents and children ($p < 0.05$).

One meta-analysis included 33 studies of psychosocial interventions (including but not limited to behavior therapy, family therapy, CBT, psychodynamic therapy) with untreated comparison groups.²³⁶ These studies included many of the IY and PCIT studies also included in the other meta-analyses, but this review did not separately report results for any specific intervention group. Effect sizes in all 33 studies indicated improvement after treatment in active treatment vs. control arms with an overall mean weighted effect size of 0.62 (95% CI: 0.49 to 0.76). Smaller sample sizes were associated with larger effect sizes as compared to studies with larger sample sizes.

Another meta-analysis of broadly defined psychosocial interventions (including behavioral approaches and non-behavioral approaches such as family systems interventions and nondirective counseling, and named interventions such as variations of IY and PCIT) included 36 RCTs ($n = 3042$ children).²³⁷ The overall effect size (effect sizes for aggression,

oppositiveness, impulsivity, and general externalizing behaviors combined) for psychosocial treatments on disruptive behaviors was 0.82 (SE=0.10, 95% CI: 0.63 to 1.01). Significant moderators of effect included symptom type, with externalizing symptoms showing the largest response. Treatment as usual comparators also yielded larger effects than no treatment control groups, and no treatment controls yielded greater effects than “education, support, and attention” controls. Behavioral treatments demonstrated larger effects on behavioral symptoms than did non-behavioral interventions.

A review including 28 studies including 16 psychosocial interventions for children with disruptive behavior disorders for which there was an evidence base. The authors summarized their results by classifying interventions according to Chambless criteria,²³⁸ as “well established” (e.g., MPTO), “probably efficacious” (e.g., Group Assertiveness Training (peer and counselor led), Anger Control training, Helping the Noncompliant Child, IY (child, parent, and multiple component), Multidimensional Treatment Foster Care, PCIT, Problem Solving Skills Training (multiple versions), Rational-Emotive Mental Health Program, and Triple P standard and enhanced programs), or “possibly efficacious” (e.g., IY with teacher training components, Triple P standard group treatment, First Step to Success, Reaching Educators, Children, and Parents, Self-Administered Treatment Plus Signal Seat, and Group Anger Control Training). The investigators recommend parent training as the first line treatment for young children and that direct child training or multicomponent approaches be used with older children.

A meta-analysis including 71 studies of interventions categorized as either parent management training or CBT reported positive outcomes associated with parent management training interventions.²³⁹ The mean effect size for both interventions combined (also combining parent and teacher-reported measures and observation outcomes) was 0.40 (95% CI: 0.34 to 0.47). The mean effect size for parent management training alone was 0.47 (95% CI: 0.34 to 0.61) and 0.35 (95% CI: 0.25 to 0.47) for CBT alone. In comparisons of effect sizes in children between ages 6 and 12 (ages were too widely varying to allow other comparisons), the effect size for parent management training (0.45, 95% CI: 0.28 to 0.60) was significantly greater than that of CBT (0.23, 95% CI: 0.11 to 0.32) in analyses not controlling for intervention setting (e.g., clinic, school). The difference was not significant in analyses controlling for setting. In moderator analyses, child age was not significantly associated with outcomes of parent management, but older child age was associated with better outcomes in studies of CBT.

A Campbell Collaboration review and meta-analysis included 55 RCTs including children age 5 or younger and focused on prevention of child behaviors such as delinquency, crime, and antisocial behavior.²⁴⁰ Most studies (n = 47) evaluated programs included in the current review such as IY variations, PCIT, and Triple-P. Eight trials assessed home visits by clinicians. Most studies were in the United States (n = 38), and most (n = 37) included fewer than 100 children. The overall weighted mean effect size across all 55 studies was 0.35, a small to medium effect for reducing child behavior problems. Differences between parent training and home visit programs were not significant. In regression analyses, older studies, smaller studies (n<100), and U.S. studies were more likely to have larger effect sizes. Meta-analyses also suggested the presence of publication bias.

Reviews That Include Existing Reviews

Findings in a review of RCTs, quasi-experimental studies, and systematic reviews and meta-analyses conducted for the U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration’s (SAMHSA) Assessing the Evidence Base series of

literature reviews also align with findings in prior syntheses.²⁴¹ The SAMHSA review reports a high level of evidence (defined as confidence in the reported outcomes based on three or more well-conducted RCTs or two RCTs and well-conducted quasi-experimental studies) for both IY and PCIT, noting well-designed RCTs of adequate power, manualized approaches, reliable outcome measurement, and replication in multiple studies. IY and PCIT were also associated with improved externalizing behavior outcomes across age ranges and populations when compared with waitlist control groups, and the review concludes that abbreviated or adapted versions of IY and PCIT are also promising.

Summary of Evidence From Existing Reviews on Moderators and Mediators of Effectiveness

A number of existing reviews examined questions related to moderation and/or mediation of intervention effectiveness including a wide range of demographic and clinical variables. Most of the examined demographic and family process variables were not consistently identified as moderators with the strongest evidence appearing to include severity of baseline child disruptive behaviors, child age, and socioeconomic status.

Regarding the severity of baseline child disruptive behaviors, three existing reviews presented evidence suggesting that severity moderates intervention effectiveness,^{230,235,242} and one review did not.²²⁹ One quasi-systematic review identified six studies assessing baseline child behavior as a moderator. In four of these six studies, higher baseline levels of problem behavior were associated with better outcomes but the other two studies did not.²⁴³ Two previous reviews cited evidence that child age moderated intervention effectiveness,^{229,234} and two studies reported that family socioeconomic status also moderates intervention effectiveness.^{242,244}

Finally, one quasi-systematic review specifically examined if parenting was a mediator of the effectiveness of behavioral parent training for child disruptive behaviors and provided some, but not overwhelming, support for this hypothesis.²²⁶

Existing Reviews of Pharmacological Interventions

We identified two reviews of the effectiveness of pharmacologic interventions for children, though not all of the included studies were specific to populations of children treated for disruptive behaviors. We describe information about harms from these two reviews (and one additional review that reported harms only) in KQ5 above.

One Cochrane review of atypical antipsychotics for disruptive behavior disorders included eight RCTs (7 of risperidone and 1 of quetiapine) and reported limited evidence of effectiveness. In one analysis, scores on the Aberrant Behavior Checklist were 6.49 units lower, which may be clinically significant, and the investigators considered the difference of 8.61 points on the Nisonger Child Behavior scale as likely clinically significant.⁴⁹

In the other included review of pharmacologic interventions, an AHRQ-funded review of antipsychotic use in children and young adults, strength of the evidence was insufficient for comparisons of first versus second-generation antipsychotics, first versus first generation, and first generation versus placebo.⁵² In eight studies of antipsychotics for treatment of disruptive behavior disorders (including 682 children treated for between 4 weeks to 6 months), strength of the evidence was moderate for positive effects of antipsychotics on behavior symptoms and low for positive effects on aggression and anxiety.

Applicability

KQ1. Psychosocial Interventions

Applicability for this literature is largely dependent on the target population and feasibility of the interventions in real-world clinical settings. Our target population was primarily defined by child age and type of disruptive behavior problem. Included psychosocial interventions excluded preventive interventions, were typically multi-faceted and heterogeneous within broad intervention categories, and can be resource intensive relative to time, money, and personnel in the clinical setting.

Approximately half of the studies of psychosocial interventions for child disruptive behaviors were of school-age children, about 30 percent were with preschool-age children, and approximately 20 percent were with teenagers. We defined a study as focusing on school-age children if it had a sample with a mean age between 5 and 12 years. We established 5 years of age as the lower bound because this is the age at which children typically begin attending kindergarten in the United States. We established 12 years of age as the upper bound because 13 years is regarded as the beginning of adolescence in casual parlance. For precisely these reasons, the age group classification we used is somewhat arbitrary, specific to the United States context, and has face validity in the United States. At the same time, many studies of child samples with a mean age between 5 and 12 years also included children with age less than 5 or greater than 12 years.

In addition to the age definition, our definition of the target population included children with disruptive behaviors receiving treatment in healthcare settings. We did not restrict our study population to children meeting formal diagnostic criteria for a disruptive behavior disorder. Rather, we allowed children without a diagnosed DBD but with disruptive behaviors above a measure-specific threshold on a well-validated measure of disruptive behavior to be included. This may limit applicability of our findings because in real-world clinical settings third-party payers may only reimburse for services regarded as medically necessary. We excluded studies of preventive interventions for an at-risk population because our review was focused on studies of individuals who met a clinical threshold for a disruptive behavior disorder.

A potential issue for applicability of these findings is whether patients are able to access and pay for them if insurance does not cover them. However, an evaluation of costs was beyond the scope of this report as it was set up. Applicability of our findings is also limited by restricted access to some of the interventions most commonly examined in the studies included in this review in real-world clinical settings. Many of the included studies were conducted in the outpatient setting and carried out at academic medical centers in the United States. To give just one example, although there was relatively strong evidence in favor of the effectiveness of MST for disruptive behaviors in teenagers, MST is often not available in real-world clinical settings. This is consistent with a growing literature on the challenges of transporting evidence-based multicomponent interventions into real-world clinical settings with fidelity.

Many included studies were also conducted by the intervention developer or by other individuals with a vested interest in the intervention. Although this aspect of study design may be required to ensure treatment fidelity or at least make it more likely that interventions are delivered with fidelity to the model, it may also create a need for independent validation of study results.

KQ2. Pharmacologic Interventions

The populations studied in the studies of pharmacologic interventions for disruptive behavior disorders were almost exclusively male and between the ages of 6 and 18 years. All of the studies were very small, and results may not be broadly generalizable. None of the interventions have a specific indication for disruptive behaviors, although they are used for these conditions in the United States. Interventions included antipsychotic drugs, an antiepileptic drug, and ADHD drugs (both stimulants and nonstimulants). Of particular importance, all but one study on pharmacologic interventions were funded wholly or partially by a pharmaceutical company, or were conducted by individuals who are highly supported by those companies. It is difficult to assess the degree to which these drugs are or are not widely available. The studies also did not address the common concern of polypharmacy and thus there may be limited ability to assess applicability as well as safety concerns in highly complex cases. Polypharmacy with two or more antipsychotic drugs is a commonly used indicator of poor quality care although it clearly occurs. A better understanding of the prevalence, circumstances, and implications of polypharmacy is needed.

In reality, many if not most children and adolescents seeking treatment for disruptive behaviors may have multiple co-diagnoses and other complex challenges. The applicability of this set of studies, in which we limited the population to a specific focus on disruptive behavior treatment, may not capture the overall effect of pharmacologic intervention on these children's lives overall, nor are they likely to be applicable to highly complex cases. The use of pharmacologic interventions for outcomes in cases, for example, of ADHD, autism or other conditions like bipolar is addressed in other reviews.

Strength of Evidence

We assessed strength of evidence for the effectiveness of interventions using the qualitative and quantitative approaches described in the Methods section. Overall, the evidence to answer Key Questions about interventions for children with disruptive behavior disorders was insufficient to moderate. We summarize the strength of the evidence and provide the assessment of the risk of bias, consistency of findings across trials, directness of the evidence, and precision of the estimate provided by the literature (Tables 48-51).

Table 48. Strength of evidence for effects of psychosocial interventions targeting parenting practices on parent-reported changes in disruptive behaviors in preschool children with DBD

| Intervention Category | Study, Risk of Bias (Participants) | Study Limitations | Consistency | Directness | Precision | Reporting | SOE Findings and Magnitude of Effect ^a |
|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|-------------|------------|-----------|------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Child Only (n = 0) | NA | NA | NA | NA | NA | NA | Insufficient |
| Parent Only (n = 14) | RCT: 1 low, ¹³⁸ 7 moderate, ^{93,119,129,135,139,140,155} 5 high ^{95,102,127,141,145} (1466) Cohort: 1 moderate ⁸⁷ (144) | Medium | Consistent | Direct | Precise | Undetected | Moderate SOE for positive effects of intervention on child behavior. Outcomes consistently improved in parenting intervention arms compared with waitlist or treatment as usual controls. Differences between modified versions of the same intervention were typically not significant. Outcomes measured on parent-reported scales, which are a reliable indicator of change in this population. |
| Multicomponent (n = 9) | RCT: 1 low, ⁹⁹ 3 moderate, ^{109,114,133} 5 high, ^{98,107,112,153,154} (401) | Medium | Consistent | Direct | Precise | Undetected | Moderate SOE for positive effects of intervention on child behavior. Outcomes consistently improved in parenting intervention arms compared with waitlist or treatment as usual controls. Differences between modified versions of the same intervention were typically not significant. Outcomes measured on parent-reported scales, which are a reliable indicator of change in this population. |

Table 49. Strength of evidence for effects of psychosocial interventions targeting parenting practices on parent-reported ratings of disruptive behaviors in school-age children with DBD

| Intervention Category | Studies, Risk of Bias (Participants) | Study Limitations | Consistency | Directness | Precision | Reporting | SOE Findings and Magnitude of Effect |
|-------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|--------------|------------|-----------|------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Child Only (n = 1) | RCT: 1 moderate ¹³² (97) | Medium | NA | Direct | NA | Undetected | Insufficient due to a single study. |
| Parent Only (n = 11) | RCT: 1 low, ¹²¹ 5 moderate, ^{113,122,125,130,147} 2 high ^{117,118} (995) Cohort: 3 high ^{88,90,91} (334) | Medium | Consistent | Direct | Precise | Undetected | Moderate SOE for positive effects of intervention on child behavior change. Outcomes significantly improved in intervention groups vs. control but differences between modified versions of the same intervention were not significant. Outcomes measured on parent-reported scales, which are a reliable indicator of change in this population. |
| Multicomponent (n = 17) | RCT: 1 low, ¹²³ 11 moderate, ^{96,97,101,103,105,108,110,126,128,131,137} 3 high ^{100,134,165} (1685) Cohort: 1 high ⁸⁹ 1 moderate ⁹² (474) | Medium | Inconsistent | Direct | Precise | Undetected | Low SOE for positive effects of intervention on child behavior change. Children improved from baseline in most active treatment arms but between group changes not consistently significantly different. Ratings on sub-scales (e.g., EBCI-Intensity, EBCI-Problem) not always consistent. |

Table 50. Strength of evidence for the effect of psychosocial interventions targeting parenting practices on parent-reported ratings of disruptive behaviors in teenage children with DBD

| Intervention Category | Studies, Risk of Bias (Participants) | Study Limitations | Consistency | Directness | Precision | Reporting | SOE Findings and Magnitude of Effect |
|-------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|-------------|------------|-----------|------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Child Only (n = 1) | RCT: 1 High ¹⁰⁴ (93) | High | NA | Direct | NA | Undetected | Insufficient SOE due to single study with high study limitations. |
| Parent Only (n = 0) | NA | NA | NA | NA | NA | NA | Insufficient. |
| Multicomponent (n = 13) | RCT: 4 Low, ^{120,124,142,143} , 5 Moderate, ^{94,111,116,144,146} 3 High ^{106,115,136} (1294) Cohort: 1 High ⁸⁶ (192) | Medium | Consistent | Direct | Precise | Undetected | Moderate SOE for positive effects of intervention on child behavior change. Most studies reported improved outcomes in treatment arms versus control arms. Differences between modified versions of the same intervention were typically not significant. Outcomes measured on parent-reported scales, which are a reliable indicator of change in this population. |

Table 51. Strength of evidence for pharmacologic interventions

| Intervention: Outcome | Design: Studies (Participants) | Limitations | Consistency | Directness | Precision | Reporting | SOE Magnitude of Effect |
|----------------------------------------------------|---------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------|------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Antipsychotics: Disruptive Behavior | RCT: 3 (374) ^{180,183,186} | High risk of bias: 1 ¹⁸³ Moderate risk of bias: 2 ^{180,181} Low risk of bias: 1 ¹⁸⁶ | Consistent | Direct | Precise | Undetected | Moderate SOE for the effectiveness of antipsychotics in achieving statistically significant improvements in measures of disruptive behaviors over the short term. Studies were funded by industry and should be replicated by groups without appearance of conflict. |
| Antipsychotics: Aggression | RCT: 3 (64) ^{180,181,186} Cohort: 1 (36) ¹⁸⁸ | Moderate: 2 ^{180,181} Low: 1 ¹⁸⁶ High: 1 (36) ¹⁸⁸ | Inconsistent | Direct | Imprecise | Undetected | Insufficient SOE based on inconsistent and imprecise outcomes, and small numbers of participants. |
| Stimulants^a | RCT: 2 (391) ^{182,187} | High risk of bias: 2 ^{182,187} | Consistent | Direct | Precise | Undetected | Low SOE based on only two high risk of bias studies that used different outcome measures. |
| Nonstimulants^b | RCT: 3 (537) ^{176,177,179} | High risk of bias: 1 ¹⁷⁹ Moderate risk of bias: 2 ^{176,177} | Consistent | Direct | Precise | Undetected | Moderate SOE for the effect of nonstimulants on disruptive behaviors with 3 studies, adequate numbers, and statistically significant change scores of 0.59 to 0.69. |

Table 51. Strength of evidence for pharmacologic interventions (continued)

| Intervention: Outcome | Design: Studies (Participants) | Limitations | Consistency | Directness | Precision | Reporting | <i>SOE</i> Magnitude of Effect |
|--------------------------|-------------------------------------|-------------------------------------------------|-------------|------------|-----------|------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Divalproex | RCT: 3 (108) ^{178,184,185} | Moderate risk of bias: 3 ^{178,184,185} | Consistent | Direct | Precise | Undetected | Low SOE for improvement or remission associated with aggressive behavior, with “success” more than threefold likely in treated versus untreated. SOE remains low due to only 3 small studies with moderate risk of bias. Insufficient evidence that higher doses are more effective than lower doses given one study with moderate risk of bias. |

^aIncludes methylphenidate and amphetamine

^bIncludes atomoxetine and guanfacine

Limitations

Limitations of This Review

This was a focused review on treatments for recognized disruptive behavior disorders at the individual level. Our focus was on treatments within a clinical setting or that might be a referral from a clinical setting. Therefore, we did not include ecologic approaches and psychosocial interventions that have been studied in settings such as juvenile delinquency settings and schools. These are important components of the overall therapeutic environment for disruptive behavior disorders and have been reviewed elsewhere.

We classified a heterogeneous group of interventions into the three broad categories of interventions that only include a child component, interventions that only include a parent component, or multi-component interventions. We defined multicomponent interventions as those that included two or more of a child component, parent component, or other component (e.g., teacher component, family together component). To account for the fact these treatment categories are broad, encompassing a range of specific interventions, each component was modeled as a random effect. This allowed for variation in treatment effect within each class. It is also worth noting that we classified PCIT as a multi-component intervention because, as its name suggests, the focus of the intervention is on the parent-child interaction and includes the parent and child engaged together in activities. Out of concern that PCIT in particular may also reasonably be classified as an intervention with only a parent component, we ran our quantitative model under both classifications (i.e., with PCIT categorized as a multi-component intervention and as an intervention with only a parent component). Classifying PCIT as an intervention with only a parent component did not significantly change our meta-analysis results, although point estimates of effect were nominally different.

We also excluded studies that focused on the treatment of other psychiatric conditions likely to have comorbid features of DBD. These would include, for example, ADHD, autism, and bipolar disorder. These are important and prevalent conditions and our review is intended to provide evidence on a very specific set of interventions in a defined group of participants. Clinical decisions need to be made with all of the available information, potentially from other reviews, particularly in complex clinical scenarios.

We did not limit inclusion to studies of individuals with a DSM diagnosis of DBD, but we did limit to those studies that provided some evidence that participants were beyond a validated clinical cutoff. Given the diversity of DBDs and a lack of consistent approach to assessing or reporting them, this is not a perfect approach. It is possible that some studies that did focus on DBDs were missed due to the reporting of the papers. We also focused on the outcomes that were by far the most commonly reported in the literature – e.g., parent reports of their child’s disruptive behaviors – via measures assessing externalizing behaviors. Functional outcomes are also important. We recognize that parent reports of their child’s disruptive behaviors are potentially biased, particularly when study designs did not include blinding. We also recognize that there are outcomes of interest such as emotional and psychological states beyond those that we specified in our protocol, but to widen the scope would have been infeasible for this review. Similarly, there is substantial overlap between several other psychological conditions and DBDs, including in particular ADHD. We did not include studies that focused primarily on treating ADHD, although some of these studies may also include evidence about disruptive behaviors as a component of ADHD. There are good reviews of ADHD treatment, including one by AHRQ,⁶⁹

and we would point readers to those as additional information. We did include a number of studies that used traditional ADHD drugs but were focused on the disruptive behaviors themselves.

We were unable to review DBD interventions by etiology, although we understand that disruptive behaviors may stem from many causes (e.g. trauma), and these play into decisions about treatment and therapy.

Limitations of the Evidence Base

KQ1. Psychosocial Interventions

A number of methodological limitations exist in the literature base for child disruptive behavior disorders. First, identifying the target population is difficult. We included in our review both studies of children with a formal diagnosis of a disruptive behavior disorder and children without a formal diagnosis of a disruptive behavior disorder who scored above a clinical cutoff on a well-validated measure of child disruptive behaviors, but lack of detail in reporting by authors makes it challenging to fully and accurately characterize the populations in the studies.

Second, although most included studies were RCTs, overall the literature suffered from a lack of consistent and complete reporting. In particular, primary outcomes are rarely identified, and random sequence generation and allocation concealment rarely described. In addition, there was frequently no attempt to achieve blinding. Although there are well-recognized and valid reasons that achieving this level of control in the studies is challenging, if not impossible, it does bring some degree of potential risk of bias into the literature as a whole.

Third, the field lacks consensus on the most important outcomes. Few studies measure similar outcomes for synthesis. Methodologically, outcomes such as direct observation by a blinded and independent observer are arguably the most valid. However, direct observations can be expensive and are not always logistically feasible. From the perspective of patient-centered outcomes research, we believe that there is a strong argument in this literature to be made in favor of the importance of parent reported outcomes. However, most of the studied interventions included a parent component either alone or in combination with other components which introduces a potential risk of bias especially considering that blinding was not always feasible, and when parent reported outcomes were included multiple measures of similar constructs were used within and across studies. The reliance of the literature on parent reported outcomes and their potential for bias is a significant limitation of the evidence base.

Fourth, conflict of interest is a concern in this evidence base. Most of the studies evaluating a psychosocial intervention for a child disruptive behavior included in this review were conducted either by the developer of the intervention or by an “intellectual descendant” of the developer. Although it is understandable for this to be the case (much like it is understandable to see industry-sponsored clinical drug trials), the strength of the evidence for this body of literature would be strengthened with more studies independently evaluating the interventions.

Fifth, there are few direct comparisons of individual interventions. Specific interventions were most often compared to a waitlist control group or treatment as usual (variably described). When comparisons of active treatments were included, it was most often a comparison of different versions of a specific intervention. Further, results from mixed models are not always presented in a straightforward manner, making it very difficult to tease out effects of specific treatment approaches.

KQ2. Pharmacologic Interventions

There were surprisingly few studies focused on treating disruptive behaviors with pharmacologic interventions, which reflects the fact that these drugs are frequently used off label and without a research basis for their use in this particular set of disorders. Indications for the drugs reviewed here include a range of conditions, including but not limited to ADHD, schizophrenia, bipolar disorder, and seizures (complete list in Appendix I). As such, many of the studies include mixed populations and report outcomes of overlapping symptoms (e.g. of ADHD and DBD) making it difficult to discern the degree to which the mitigation of ADHD, for example, is in fact driving the results. Most of the studies in this section were small and larger studies are clearly needed.

Finally, it is a particular weakness that almost all studies were funded by the pharmaceutical company making the drug being studied. There is a clear need for replication and for independently funded studies.

KQ3 and KQ4. Combined Interventions

There were no studies to evaluate the efficacy of both behavioral and pharmacologic interventions compared to pharmacologic or behavioral interventions alone. Given that the clinical reality for many, if not most, families is that they use a multipronged approach for treatment of their children with DBDs, these studies are needed.

Future Research Needs

Research needs are both substantive and methodologic, and include both conduct and reporting of research. As noted above, randomization and allocation approaches were consistently not adequately described, and blinding was not attempted or addressed in much of the psychosocial literature. Future research should also clearly describe the duration of time from baseline to post-treatment and post-treatment to followup, and more clearly describe results from mixed models. Because the intervention developer is often the researcher, existing research must be replicated, as the lack of replication introduces the potential for a risk of bias analogous to that introduced by industry-sponsored trials of pharmaceutical interventions.

There is a need for specific, head-to-head comparisons of psychosocial interventions, evaluate the effectiveness of psychosocial interventions as compared to pharmacologic interventions (KQ3), and the effectiveness of combined psychosocial and pharmacologic intervention (KQ4). Additionally, prospective longitudinal studies examining implementation of these interventions in real-world community practice, including cultural adaptations, are also needed. End users urgently need this information to make informed decisions about which treatments to seek for their children. Clinicians need answers to these questions to decide which interventions to be trained to deliver and to recommend to their patients. Policymakers need this information to determine how to incentivize the provision of care for which there is the most evidence of effectiveness.

Future research should also clearly identify the target population and address the portability of studied interventions from predominantly university research clinics to real-world clinical settings. In the United States, disruptive behaviors are more prevalent among children receiving publicly funded care, and who are therefore likely to receive treatment in clinical settings such as community mental health centers. This group of young people may differ in important ways from the children receiving treatment in university-based research clinics. There is a growing

body of literature about the challenges of implementing and disseminating best practices to real-world clinical settings with fidelity.²⁴⁵

Implications for Clinical and Policy Decisionmaking

Qualitatively and quantitatively, our review suggests that psychosocial interventions that include a parent component either alone or in combination with other components have the greatest probability of being most effective. This suggests that parents of children with disruptive behavior disorders should seek interventions that include a parent component. Clinicians providing care to this patient population should reconsider their current practices and clinicians referring families to specialty care should look to make referrals to clinicians whose interventions include a parent component. Researchers should consider more rigorously designed evaluations including of the potential harms of psychosocial interventions for this population, and policymakers and third party payers might consider writing clinical practice guidelines and reimbursement strategies that reflect this evidence.

There is less consistent evidence from the pharmacologic literature, but moderate SOE available for the use of antipsychotics and nonstimulant drugs. Parents of children with disruptive behaviors may, in consultation with their healthcare providers, want to consider the potential benefits of these pharmacologic options in the context of what is known about their risks. Many if not most clinicians providing pharmacologic care to this patient population are likely already aware of the potential benefits and harms of associated with use of these medications. Researchers may see potential for additional research on the effectiveness of these medications for this patient population. The implications for policymakers and third party payers are somewhat less clear.

Although we know from studies of other childhood disorders such as depression that combined psychosocial and pharmacologic intervention has benefits over either intervention alone,²⁴⁶ there is currently insufficient evidence to make similar conclusions for the treatment of children with disruptive behaviors. In reality, families of children with DBDs and the clinicians working with them are likely facing an array of treatment approaches to combat a complex set of symptoms or expressions of psychiatric conditions. This report should be assessed within the context of other reviews and primary literature. It provides evidence for one piece of a complex puzzle.

Conclusions

This review suggests that psychosocial interventions for children with disruptive behavior disorders that are multicomponent interventions or interventions that include only a parent component are likely to be more effective at reducing problem behaviors than psychosocial interventions that include only a child component or treatment as usual. As defined in this study, all multicomponent interventions included a parent component. Thus, it seems likely that a parent component is important. There are very few studies directly supporting the effectiveness of pharmacologic interventions for children with disruptive behavior disorders, but small studies of antipsychotics and stimulants report positive effects in the very short term. There are no studies examining the effectiveness of these interventions in combination with one another. The most commonly reported outcomes are parent-reported outcomes. Long-term and functional outcomes were not consistently reported. There was variability in the duration of long-term followup and functional outcomes reported. To date, treatment research is almost exclusively supported by the pharmaceutical industry. Given the prevalence of DBDs and the need for high

quality data to inform clinical practice, more long-term studies are needed as are studies aimed at treating DBD separate from comorbid ADHD.

References

1. Lahey BB, Loeber R, Burke J, et al. Adolescent outcomes of childhood conduct disorder among clinic-referred boys: predictors of improvement. *J Abnorm Child Psychol.* 2002 Aug;30(4):333-48. PMID: 12108765.
2. The Chance of a Lifetime: Preventing Early Conduct Problems and Reducing Crime. London: Sainsbury Centre for Mental Health; 2009. Available at: http://www.centreformentalhealth.org.uk/pdfs/chance_of_a_lifetime.pdf Accessed April 2, 2015.
3. Loeber R. Oppositional defiant disorder and conduct disorder. *Hosp Community Psychiatry.* 1991 Nov;42(11):1099-100, 102. PMID: 1743634.
4. Frick PJ, Kamphaus RW, Lahey BB, et al. Academic underachievement and the disruptive behavior disorders. *J Consult Clin Psychol.* 1991 Apr;59(2):289-94. PMID: 2030190.
5. Loeber R. Antisocial behavior: more enduring than changeable? *J Am Acad Child Adolesc Psychiatry.* 1991 May;30(3):393-7. PMID: 2055875.
6. Loeber R, Green SM, Lahey BB, et al. Differences and similarities between children, mothers, and teachers as informants on disruptive child behavior. *J Abnorm Child Psychol.* 1991 Feb;19(1):75-95. PMID: 2030249.
7. Loeber R, Lahey BB, Thomas C. Diagnostic conundrum of oppositional defiant disorder and conduct disorder. *J Abnorm Psychol.* 1991 Aug;100(3):379-90. PMID: 1918617.
8. Meier MH, Slutske WS, Heath AC, et al. Sex differences in the genetic and environmental influences on childhood conduct disorder and adult antisocial behavior. *J Abnorm Psychol.* 2011 May;120(2):377-88. PMID: 21319923.
9. Murrihy RC, Kidman AD, Ollendick TH. *Clinical handbook of assessing and treating conduct problems in youth.* New York: Springer Science Business Media; 2010.
10. Kutcher S, Aman M, Brooks SJ, et al. International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): clinical implications and treatment practice suggestions. *Eur Neuropsychopharmacol.* 2004 Jan;14(1):11-28. PMID: 14659983.
11. Lahey BB, Miller TL, Gordon RA, et al. Developmental epidemiology of the disruptive behavior disorders. In: Quay HC, Hogan AE, eds. *Handbook of Disruptive Behavior Disorder.* Dordrecht, Netherlands: Kluwer Academic Publishers; 1999.
12. Maughan B, Rowe R, Messer J, et al. Conduct disorder and oppositional defiant disorder in a national sample: developmental epidemiology. *J Child Psychol Psychiatry.* 2004 Mar;45(3):609-21. PMID: 15055379.
13. Loeber R, Burke JD, Lahey BB, et al. Oppositional defiant and conduct disorder: a review of the past 10 years, part I. *J Am Acad Child Adolesc Psychiatry.* 2000 Dec;39(12):1468-84. PMID: 11128323.
14. Burke JD, Loeber R, Birmaher B. Oppositional defiant disorder and conduct disorder: a review of the past 10 years, part II. *J Am Acad Child Adolesc Psychiatry.* 2002 Nov;41(11):1275-93. PMID: 12410070.
15. Perou R, Bitsko RH, Blumberg SJ, et al. Mental health surveillance among children--United States, 2005-2011. *MMWR Surveill Summ.* 2013 May 17;62 Suppl 2:1-35. PMID: 23677130.
16. American Psychiatric Association. *Task Force on DSM-IV. Diagnostic and statistical manual of mental disorders : DSM-IV. Fourth edition.* Washington, D.C.: American Psychiatric Association; 1994.
17. American Psychiatric Association. *Diagnostic and statistical manual of mental disorders: DSM-V. Fifth edition.* Arlington, VA: American Psychiatric Association; 2013.

18. Bonin EM, Stevens M, Beecham J, et al. Costs and longer-term savings of parenting programmes for the prevention of persistent conduct disorder: a modelling study. *BMC Public Health*. 2011;11:803. PMID: 21999434.
19. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry*. 2005 Jun;62(6):593-602. PMID: 15939837.
20. Russo MF, Loeber R, Lahey BB, et al. Oppositional Defiant and Conduct Disorders - Validation of the DSMIII-R and an Alternative Diagnostic Option. *Journal of Clinical Child Psychology*. 1994 Mar;23(1):56-68.
21. Russo MF, Beidel DC. Comorbidity of Childhood Anxiety and Externalizing Disorders - Prevalence, Associated Characteristics, and Validation Issues. *Clinical Psychology Review*. 1994;14(3):199-221.
22. U. S. Department of Health and Human Services. *Mental Health: A Report of the Surgeon General*. Rockville, MD: U. S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Mental Health Services, National Institutes of Health, National Institute of Mental Health; 1999.
23. McKinney C, Morse M. Assessment of Disruptive Behavior Disorders: Tools and Recommendations. *Professional Psychology-Research and Practice*. 2012 Dec;43(6):641-9.
24. van Goozen SH, Matthys W, Cohen-Kettenis PT, et al. Salivary cortisol and cardiovascular activity during stress in oppositional-defiant disorder boys and normal controls. *Biol Psychiatry*. 1998 Apr 1;43(7):531-9. PMID: 9547933.
25. Loeber R, Green SM, Lahey BB, et al. Findings on disruptive behavior disorders from the first decade of the Developmental Trends Study. *Clin Child Fam Psychol Rev*. 2000 Mar;3(1):37-60. PMID: 11228766.
26. Latimer K, Wilson P, Kemp J, et al. Disruptive behaviour disorders: a systematic review of environmental antenatal and early years risk factors. *Child Care Health Dev*. 2012 Sep;38(5):611-28. PMID: 22372737.
27. Loeber R, Burke JD, Pardini DA. Development and etiology of disruptive and delinquent behavior. *Annu Rev Clin Psychol*. 2009;5:291-310. PMID: 19154139.
28. August GJ, Bloomquist ML, Lee SS, et al. Can evidence-based prevention programs be sustained in community practice settings? The Early Risers' Advanced-Stage Effectiveness Trial. *Prev Sci*. 2006 Jun;7(2):151-65. PMID: 16555143.
29. Bloomquist ML, August GJ, Horowitz JL, et al. Moving from science to service: transposing and sustaining the Early Risers prevention program in a community service system. *J Prim Prev*. 2008 Jul;29(4):307-21. PMID: 18581235.
30. Knapp M, McDaid D, Parsonage M, eds. *Mental health promotion and mental illness prevention: The economic case*. London: Department of Health; 2011.
31. Cooper WO, Arbogast PG, Ding H, et al. Trends in prescribing of antipsychotic medications for US children. *Ambul Pediatr*. 2006;6:79-83. PMID: 16530143.
32. Cooper WO, Federspiel CF, Griffin MR, et al. New use of anticonvulsant medications among children enrolled in the Tennessee Medicaid Program. *Arch Pediatr Adolesc Med*. 1997;151(12):1242-6. PMID: 9412601.
33. Cooper WO, Hickson GB, Fuchs C, et al. New users of antipsychotic medications among children enrolled in TennCare. *Arch Pediatr Adolesc Med*. 2004;158:753-9. PMID: 15289247.
34. Henggeler SW, Melton GB, Smith LA. Family preservation using multisystemic therapy: an effective alternative to incarcerating serious juvenile offenders. *J Consult Clin Psychol*. 1992 Dec;60(6):953-61. PMID: 1460157.
35. Alexander J, Parsons BV. *Functional Family Therapy*. Monterey, CA: Brooks/Cole; 1982.

36. Wells KC, Egan J. Social learning and systems family therapy for childhood oppositional disorder: comparative treatment outcome. *Compr Psychiatry*. 1988 Mar-Apr;29(2):138-46. PMID: 3370964.
37. Hembree-Kigin TL, McNeil CB. *Parent-Child Interaction Therapy*. New York: Plenum Press; 1995.
38. Kazdin AE, Siegel TC, Bass D. Cognitive problem-solving skills training and parent management training in the treatment of antisocial behavior in children. *J Consult Clin Psychol*. 1992 Oct;60(5):733-47. PMID: 1401389.
39. Cunningham NR, Ollendick TH. Comorbidity of anxiety and conduct problems in children: implications for clinical research and practice. *Clin Child Fam Psychol Rev*. 2010 Dec;13(4):333-47. PMID: 20809124.
40. Kolko DJ, Pardini DA. ODD dimensions, ADHD, and callous-unemotional traits as predictors of treatment response in children with disruptive behavior disorders. *J Abnorm Psychol*. 2010 Nov;119(4):713-25. PMID: 21090875.
41. Goldstein AP, Glick B, Gibbs JC. *Aggression replacement training: A comprehensive intervention for aggressive youth*; Revised Edition. Champaign, IL: Research Press; 1998.
42. Tcheremissine OV, Lieving LM. Pharmacological aspects of the treatment of conduct disorder in children and adolescents. *CNS Drugs*. 2006;20(7):549-65. PMID: 16800715.
43. Newcorn JH, Ivanov I. Psychopharmacologic treatment of attention-deficit/hyperactivity disorder and disruptive behavior disorders. *Pediatr Ann*. 2007 Sep;36(9):564-74. PMID: 17910204.
44. Connor DF, Glatt SJ, Lopez ID, et al. Psychopharmacology and aggression. I: A meta-analysis of stimulant effects on overt/covert aggression-related behaviors in ADHD. *J Am Acad Child Adolesc Psychiatry*. 2002 Mar;41(3):253-61. PMID: 11886019.
45. Linton D, Barr AM, Honer WG, et al. Antipsychotic and psychostimulant drug combination therapy in attention deficit/hyperactivity and disruptive behavior disorders: a systematic review of efficacy and tolerability. *Curr Psychiatry Rep*. 2013 May;15(5):355. PMID: 23539465.
46. Duhig MJ, Saha S, Scott JG. Efficacy of risperidone in children with disruptive behavioural disorders. *J Paediatr Child Health*. 2013 Jan;49(1):19-26. PMID: 22050179.
47. Hanwella R, Senanayake M, de Silva V. Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis. *BMC Psychiatry*. 2011;11:176. PMID: 22074258.
48. Hazell PL, Kohn MR, Dickson R, et al. Core ADHD symptom improvement with atomoxetine versus methylphenidate: a direct comparison meta-analysis. *J Atten Disord*. 2011 Nov;15(8):674-83. PMID: 20837981.
49. Loy JH, Merry SN, Hetrick SE, et al. Atypical antipsychotics for disruptive behaviour disorders in children and youths. *Cochrane Database Syst Rev*. 2012;9:CD008559. PMID: 22972123.
50. McKinney C, Renk K. Atypical antipsychotic medications in the management of disruptive behaviors in children: safety guidelines and recommendations. *Clinical Psychology Review*. 2011 Apr;31(3):465-71. PMID: 21130552.
51. Pringsheim T, Gorman D. Second-generation antipsychotics for the treatment of disruptive behaviour disorders in children: a systematic review. *Can J Psychiatry*. 2012 Dec;57(12):722-7. PMID: 23228230
52. Seida JC, Schouten JR, Boylan K, et al. Antipsychotics for children and young adults: a comparative effectiveness review. *Pediatrics*. 2012 Mar;129(3):e771-84. PMID: 22351885.

53. van Wyk GW, Hazell PL, Kohn MR, et al. How oppositionality, inattention, and hyperactivity affect response to atomoxetine versus methylphenidate: a pooled meta-analysis. *J Atten Disord*. 2012 May;16(4):314-24. PMID: 21289234.
54. Bloch MH, Qawasmi A. Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: systematic review and meta-analysis. *J Am Acad Child Adolesc Psychiatry*. 2011 Oct;50(10):991-1000. PMID: 21961774.
55. Dretzke J, Davenport C, Frew E, et al. The clinical effectiveness of different parenting programmes for children with conduct problems: a systematic review of randomised controlled trials. *Child Adolesc Psychiatry Ment Health*. 2009;3(1):7. PMID: 19261188.
56. Furlong M, McGilloway S, Bywater T, et al. Cochrane review: behavioural and cognitive-behavioural group-based parenting programmes for early-onset conduct problems in children aged 3 to 12 years (Review). *Evid Based Child Health*. 2012 Mar 7;8(2):318-692. PMID: 23877886.
57. Lee MS, Choi TY, Kim JI, et al. Acupuncture for treating attention deficit hyperactivity disorder: a systematic review and meta-analysis. *Chin J Integr Med*. 2011 Apr;17(4):257-60. PMID: 21509667.
58. Lee PC, Niew WI, Yang HJ, et al. A meta-analysis of behavioral parent training for children with attention deficit hyperactivity disorder. *Res Dev Disabil*. 2012 Nov-Dec;33(6):2040-9. PMID: 22750360.
59. Michelson D, Davenport C, Dretzke J, et al. Do evidence-based interventions work when tested in the "real world?" a systematic review and meta-analysis of parent management training for the treatment of child disruptive behavior. *Clin Child Fam Psychol Rev*. 2013 Mar;16(1):18-34. PMID: 23420407.
60. Sonuga-Barke EJ, Brandeis D, Cortese S, et al. Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments. *Am J Psychiatry*. 2013 Mar 1;170(3):275-89. PMID: 23360949.
61. Storebo OJ, Skoog M, Damm D, et al. Social skills training for Attention Deficit Hyperactivity Disorder (ADHD) in children aged 5 to 18 years. *Cochrane Database Syst Rev*. 2011(12):CD008223. PMID: 22161422.
62. Weisz JR, Kuppens S, Eckshtain D, et al. Performance of evidence-based youth psychotherapies compared with usual clinical care: a multilevel meta-analysis. *JAMA Psychiatry*. 2013 Jul;70(7):750-61. PMID: 23754332.
63. Zwi M, Jones H, Thorgaard C, et al. Parent training interventions for Attention Deficit Hyperactivity Disorder (ADHD) in children aged 5 to 18 years. *Cochrane Database Syst Rev*. 2011(12):CD003018. PMID: 22161373.
64. Knapp P, Chait A, Pappadopulos E, et al. Treatment of maladaptive aggression in youth: CERT guidelines I. Engagement, assessment, and management. *Pediatrics*. 2012 Jun;129(6):e1562-76. PMID: 22641762.
65. Scotto Rosato N, Correll CU, Pappadopulos E, et al. Treatment of maladaptive aggression in youth: CERT guidelines II. Treatments and ongoing management. *Pediatrics*. 2012 Jun;129(6):e1577-86. PMID: 22641763.
66. Vitiello B, Correll C, van Zwieten-Boot B, et al. Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns. *Eur Neuropsychopharmacol*. 2009 Sep;19(9):629-35. PMID: 19467582.
67. Seida JC, Schouten JR, Mousavi SS, et al. First- and Second-Generation Antipsychotics for Children and Young Adults. Comparative Effectiveness Review No. 39. AHRQ Publication No.: 11(12)-EHC077-EF. Rockville, MD: Agency for Healthcare Research and Quality; Feb 2012. <http://effectivehealthcare.ahrq.gov/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productID=835> Accessed April 2, 2015.

68. Burns B, Fisher S, Ganju V, et al. Evidence-based and promising practices: Interventions for disruptive behavior disorders. Substance Abuse and Mental Health Services Administration; 2011. <http://store.samhsa.gov/shin/content/SMA11-4634CD-DVD/EBPsPromisingPractices-IDBD.pdf> Accessed April 2, 2015.
69. Charach A, Dashti B, Carson P, et al. Attention Deficit Hyperactivity Disorder: Effectiveness of Treatment in At-Risk Preschoolers; Long-Term Effectiveness in All Ages; and Variability in Prevalence, Diagnosis, and Treatment. Comparative Effectiveness Review No. 44. AHRQ Report No.: 12-EHC003-EF. Rockville, MD: Agency for Healthcare Research and Quality; October 2011. <http://www.ncbi.nlm.nih.gov/books/NBK82368/> Accessed April 2, 2015.
70. Viswanathan M, Ansari MT, Berkman ND, et al. Assessing the Risk of Bias of Individual Studies in Systematic Reviews of Health Care Interventions. AHRQ Publication No. 12-EHC047-EF. Rockville MD: Agency for Healthcare Research and Quality; 2012.
71. Higgins JP, Altman DG, Sterne JA. Chapter 8: Assessing the risk of bias in included studies. In: Higgins JP, Green S, eds. Cochrane handbook for systematic reviews of interventions. The Cochrane Collaboration; 2011.
72. Viswanathan M, Berkman ND. Development of the RTI item bank on risk of bias and precision of observational studies. *J Clin Epidemiol*. 2012 Feb;65(2):163-78. PMID: 21959223.
73. Shea BJ, Hamel C, Wells GA, et al. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. *J Clin Epidemiol*. 2009 Oct;62(10):1013-20. PMID: 19230606.
74. Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. *BMC Med Res Methodol*. 2007;7:10. PMID: 17302989
75. Shea BJ, Bouter LM, Peterson J, et al. External validation of a measurement tool to assess systematic reviews (AMSTAR). *PLoS One*. 2007;2(12):e1350. PMID: 18159233.
76. Chou R, Aronson N, Atkins D, et al. AHRQ series paper 4: assessing harms when comparing medical interventions: AHRQ and the effective health-care program. *J Clin Epidemiol*. 2010 May;63(5):502-12. PMID: 18823754.
77. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. *Stat Med*. 2004 Oct 30;23(20):3105-24. PMID: 15449338
78. Wei Y, Higgins JP. Bayesian multivariate meta-analysis with multiple outcomes. *Stat Med*. 2013 Jul 30;32(17):2911-34. PMID: 23386217.
79. Lumley T. Network meta-analysis for indirect treatment comparisons. *Stat Med*. 2002 Aug 30;21(16):2313-24. PMID: 12210616.
80. Brooks S, Gelman A, Jones G, et al. Handbook of Markov Chain Monte Carlo. CRC Press; 2011.
81. Patil A, Huard D, Fonnesbeck CJ. PyMC: Bayesian Stochastic Modelling in Python. *J Stat Softw*. 2010 Jul;35(4):1-81. PMID: 21603108.
82. Berkman ND, Lohr KN, Ansari MT, et al. Grading the Strength of a Body of Evidence When Assessing Health Care Interventions for the Effective Health Care Program of the Agency for Healthcare Research and Quality: An Update. Methods Guide for Comparative Effectiveness Reviews (Prepared by the RTI-UNC Evidence-based Practice Center under Contract No 290-2007-10056-I). AHRQ Publication No. 13(14)-EHC 130-EF. Rockville, MD: Agency for Healthcare Research and Quality; November 2013. <http://effectivehealthcare.ahrq.gov/ehec/products/457/1752/methods-guidance-grading-evidence-131118.pdf> Accessed April 2, 2015.

83. Owens DK, Lohr KN, Atkins D, et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions--agency for healthcare research and quality and the effective health-care program. *J Clin Epidemiol*. 2010 May;63(5):513-23. PMID: 19595577.
84. Berkman ND, Lohr KN, Ansari M, et al. Grading the Strength of a Body of Evidence When Assessing Health Care Interventions for the Effective Health Care Program of the Agency for Healthcare Research and Quality: An Update. *Methods Guide for Effectiveness and Comparative Effectiveness Reviews*. Rockville (MD); 2008.
85. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *J Clin Epidemiol*. 2009 Oct;62(10):e1-34. PMID: 19631507.
86. van der Put CE, Asscher JJ, Stams GJ, et al. Recidivism after treatment in a forensic youth-psychiatric setting: the effect of treatment characteristics. *Int J Offender Ther Comp Criminol*. 2013 Sep;57(9):1120-39. PMID: 22811475.
87. Posthumus JA, Raaijmakers MA, Maassen GH, et al. Sustained effects of incredible years as a preventive intervention in preschool children with conduct problems. *J Abnorm Child Psychol*. 2012 May;40(4):487-500. PMID: 22006348.
88. Coughlin M, Sharry J, Fitzpatrick C, et al. A controlled clinical evaluation of the parents plus children's programme: a video-based programme for parents of children aged 6 to 11 with behavioural and developmental problems. *Clin Child Psychol Psychiatry*. 2009 Oct;14(4):541-58. PMID: 19759073.
89. Lipman EL, Kenny M, Sniderman C, et al. Evaluation of a community-based program for young boys at-risk of antisocial behaviour: results and issues. *J Can Acad Child Adolesc Psychiatry*. 2008;17(1):12-9. PMID: 18392161.
90. Shapiro JP, Youngstrom JK, Youngstrom EA, et al. Transporting a manualized treatment for children's disruptive behavior to a community clinic. *Journal of Contemporary Psychotherapy*. 2012;42(4):215-25.
91. Costin J, Lichte C, Hill-Smith A, et al. Parent group treatments for children with Oppositional Defiant Disorder. *AeJAMH (Australian e-Journal for the Advancement of Mental Health)*. 2004;3(1).
92. Masi G, Milone A, Paciello M, et al. Efficacy of a multimodal treatment for disruptive behavior disorders in children and adolescents: focus on internalizing problems. *Psychiatry Res*. 2014 Nov 30;219(3):617-24. PMID: 25060833.
93. Perrin EC, Sheldrick RC, McMenamy JM, et al. Improving Parenting Skills for Families of Young Children in Pediatric Settings: A Randomized Clinical Trial. *JAMA Pediatr*. 2013 Nov 4; PMID: 24190691.
94. Weiss B, Han S, Harris V, et al. An Independent Randomized Clinical Trial of Multisystemic Therapy With Non-Court-Referred Adolescents With Serious Conduct Problems. *J Consult Clin Psychol*. 2013 Aug 12; PMID: 23937347.
95. Jones DJ, Forehand R, Cuellar J, et al. Technology-Enhanced Program for Child Disruptive Behavior Disorders: Development and Pilot Randomized Control Trial. *J Clin Child Adolesc Psychol*. 2013 Aug 7; PMID: 23924046.
96. Boylan K, Macpherson HA, Fristad MA. Examination of disruptive behavior outcomes and moderation in a randomized psychotherapy trial for mood disorders. *J Am Acad Child Adolesc Psychiatry*. 2013 Jul;52(7):699-708. PMID: 23800483.
97. Kolko DJ, Campo JV, Kelleher K, et al. Improving access to care and clinical outcome for pediatric behavioral problems: a randomized trial of a nurse-administered intervention in primary care. *J Dev Behav Pediatr*. 2010 Jun;31(5):393-404. PMID: 20495474.

98. Bagner DM, Sheinkopf SJ, Vohr BR, et al. Parenting intervention for externalizing behavior problems in children born premature: an initial examination. *J Dev Behav Pediatr.* 2010 Apr;31(3):209-16. PMID: 20375736.
99. McCabe K, Yeh M. Parent-child interaction therapy for Mexican Americans: a randomized clinical trial. *J Clin Child Adolesc Psychol.* 2009 Sep;38(5):753-9. PMID: 20183659.
100. Jouriles EN, McDonald R, Rosenfield D, et al. Reducing conduct problems among children exposed to intimate partner violence: a randomized clinical trial examining effects of Project Support. *J Consult Clin Psychol.* 2009 Aug;77(4):705-17. PMID: 19634963.
101. Kolko DJ, Dorn LD, Bukstein OG, et al. Community vs. clinic-based modular treatment of children with early-onset ODD or CD: a clinical trial with 3-year follow-up. *J Abnorm Child Psychol.* 2009 Jul;37(5):591-609. PMID: 19221871.
102. Lavigne JV, Lebailly SA, Gouze KR, et al. Treating oppositional defiant disorder in primary care: a comparison of three models. *J Pediatr Psychol.* 2008 Jun;33(5):449-61. PMID: 17956932.
103. Greene RW, Ablon JS, Goring JC, et al. Effectiveness of collaborative problem solving in affectively dysregulated children with oppositional-defiant disorder: initial findings. *J Consult Clin Psychol.* 2004 Dec;72(6):1157-64. PMID: 15612861.
104. Rohde P, Clarke GN, Mace DE, et al. An efficacy/effectiveness study of cognitive-behavioral treatment for adolescents with comorbid major depression and conduct disorder. *J Am Acad Child Adolesc Psychiatry.* 2004 Jun;43(6):660-8. PMID: 15167082.
105. Webster-Stratton C, Reid MJ, Hammond M. Treating children with early-onset conduct problems: intervention outcomes for parent, child, and teacher training. *J Clin Child Adolesc Psychol.* 2004 Mar;33(1):105-24. PMID: 15028546.
106. Santisteban DA, Coatsworth JD, Perez-Vidal A, et al. Efficacy of brief strategic family therapy in modifying Hispanic adolescent behavior problems and substance use. *J Fam Psychol.* 2003 Mar;17(1):121-33. PMID: 12666468.
107. Jouriles EN, McDonald R, Spiller L, et al. Reducing conduct problems among children of battered women. *J Consult Clin Psychol.* 2001 Oct;69(5):774-85. PMID: 11680554.
108. Kolko DJ. Efficacy of cognitive-behavioral treatment and fire safety education for children who set fires: initial and follow-up outcomes. *J Child Psychol Psychiatry.* 2001 Mar;42(3):359-69. PMID: 11321205.
109. Schuhmann EM, Foote RC, Eyberg SM, et al. Efficacy of parent-child interaction therapy: interim report of a randomized trial with short-term maintenance. *J Clin Child Psychol.* 1998 Mar;27(1):34-45. PMID: 9561935.
110. Webster-Stratton C, Hammond M. Treating children with early-onset conduct problems: a comparison of child and parent training interventions. *J Consult Clin Psychol.* 1997 Feb;65(1):93-109. PMID: 9103739.
111. Borduin CM, Mann BJ, Cone LT, et al. Multisystemic treatment of serious juvenile offenders: long-term prevention of criminality and violence. *J Consult Clin Psychol.* 1995 Aug;63(4):569-78. PMID: 7673534.
112. Eyberg SM, Boggs SR, Algina J. Parent-child interaction therapy: a psychosocial model for the treatment of young children with conduct problem behavior and their families. *Psychopharmacol Bull.* 1995;31(1):83-91. PMID: 7675994.
113. Webster-Stratton C. Advancing videotape parent training: a comparison study. *J Consult Clin Psychol.* 1994 Jun;62(3):583-93. PMID: 8063985.
114. Brestan EV, Eyberg SM, Boggs SR, et al. Parent-child interaction therapy: Parents' perceptions of untreated siblings. *Child Fam Behav Ther.* 1997;19(3):13-28.

115. Azrin NH, Donohue B, Teichner GA, et al. A controlled evaluation and description of individual-cognitive problem solving and family-behavior therapies in dually-diagnosed conduct-disordered and substance-dependent youth. *J Child Adolesc Subst Abuse*. 2001;11(1):1-43.
116. Sells SP, Early KW, Smith TE. Reducing Adolescent Oppositional and Conduct Disorders: An Experimental Design Using the Parenting with Love and Limits® Model. *Professional Issues in Criminal Justice*. 2011;6(3).
117. Kjobli J, Ogden T. A randomized effectiveness trial of brief parent training in primary care settings. *Prev Sci*. 2012 Dec;13(6):616-26. PMID: 22956303.
118. Axberg U, Broberg AG. Evaluation of "the incredible years" in Sweden: the transferability of an American parent-training program to Sweden. *Scand J Psychol*. 2012 Jun;53(3):224-32. PMID: 22621727
119. Somech LY, Elizur Y. Promoting self-regulation and cooperation in pre-kindergarten children with conduct problems: a randomized controlled trial. *J Am Acad Child Adolesc Psychiatry*. 2012 Apr;51(4):412-22. PMID: 22449647.
120. Butler S, Baruch G, Hickey N, et al. A randomized controlled trial of multisystemic therapy and a statutory therapeutic intervention for young offenders. *J Am Acad Child Adolesc Psychiatry*. 2011 Dec;50(12):1220-35 e2. PMID: 22115143.
121. McGrath PJ, Lingley-Pottie P, Thurston C, et al. Telephone-based mental health interventions for child disruptive behavior or anxiety disorders: randomized trials and overall analysis. *J Am Acad Child Adolesc Psychiatry*. 2011 Nov;50(11):1162-72. PMID: 22024004.
122. Kling A, Forster M, Sundell K, et al. A randomized controlled effectiveness trial of parent management training with varying degrees of therapist support. *Behav Ther*. 2010 Dec;41(4):530-42. PMID: 21035616.
123. Scott S, Sylva K, Doolan M, et al. Randomised controlled trial of parent groups for child antisocial behaviour targeting multiple risk factors: the SPOKES project. *J Child Psychol Psychiatry*. 2010 Jan;51(1):48-57. PMID: 19732250.
124. Sundell K, Hansson K, Lofholm CA, et al. The transportability of multisystemic therapy to Sweden: short-term results from a randomized trial of conduct-disordered youths. *J Fam Psychol*. 2008 Aug;22(4):550-60. PMID: 18729669.
125. Ogden T, Hagen KA. Treatment effectiveness of Parent Management Training in Norway: a randomized controlled trial of children with conduct problems. *J Consult Clin Psychol*. 2008 Aug;76(4):607-21. PMID: 18665689.
126. Larsson B, Fossum S, Clifford G, et al. Treatment of oppositional defiant and conduct problems in young Norwegian children : results of a randomized controlled trial. *Eur Child Adolesc Psychiatry*. 2009 Jan;18(1):42-52. PMID: 18563473.
127. Cummings JG, Wittenberg JV. Supportive expressive therapy--Parent child version: An exploratory study. *Psychotherapy (Chic)*. 2008 Jun;45(2):148-64. PMID: 22122414.
128. van de Wiel NM, Matthys W, Cohen-Kettenis PT, et al. The effectiveness of an experimental treatment when compared to care as usual depends on the type of care as usual. *Behav Modif*. 2007 May;31(3):298-312. PMID: 17438344.
129. Hutchings J, Gardner F, Bywater T, et al. Parenting intervention in Sure Start services for children at risk of developing conduct disorder: pragmatic randomised controlled trial. *BMJ*. 2007 Mar 31;334(7595):678. PMID: 17350966.
130. Gardner F, Burton J, Klimes I. Randomised controlled trial of a parenting intervention in the voluntary sector for reducing child conduct problems: outcomes and mechanisms of change. *J Child Psychol Psychiatry*. 2006 Nov;47(11):1123-32. PMID: 17076751.

131. Drugli MB, Larsson B. Children aged 4-8 years treated with parent training and child therapy because of conduct problems: generalisation effects to day-care and school settings. *Eur Child Adolesc Psychiatry*. 2006 Oct;15(7):392-9. PMID: 16614786.
132. van Manen TG, Prins PJ, Emmelkamp PM. Reducing aggressive behavior in boys with a social cognitive group treatment: results of a randomized, controlled trial. *J Am Acad Child Adolesc Psychiatry*. 2004 Dec;43(12):1478-87. PMID: 15564817.
133. Nixon RD, Sweeney L, Erickson DB, et al. Parent-child interaction therapy: a comparison of standard and abbreviated treatments for oppositional defiant preschoolers. *J Consult Clin Psychol*. 2003 Apr;71(2):251-60. PMID: 12699020.
134. Cabiya JJ, Padilla-Cotto L, González K, et al. Effectiveness of a cognitive-behavioral intervention for Puerto Rican children. *Revista Interamericana de Psicología*. 2008;42(2):195-202.
135. Markie-Dadds C, Sanders MR. A Controlled Evaluation of an Enhanced Self-Directed Behavioural Family Intervention for Parents of Children With Conduct Problems in Rural and Remote Areas. *Behaviour Change*. 2006;23(1):55-72.
136. Asscher JJ, Deković M, Manders WA, et al. A randomized controlled trial of the effectiveness of multisystemic therapy in the Netherlands: Post-treatment changes and moderator effects. *J Exp Criminol*. 2013;9(2):169-87.
137. Augimeri LK, Farrington DP, Koegl CJ, et al. The SNAPTM Under 12 Outreach Project: Effects of a community based program for children with conduct problems. *J Child Fam Stud*. 2007;16(6):799-807.
138. McGilloway S, Mhaille GN, Bywater T, et al. A parenting intervention for childhood behavioral problems: A randomized controlled trial in disadvantaged community-based settings. *J Consult Clin Psychol*. 2012;80(1):116-27. PMID: 22148879.
139. Markie-Dadds C, Sanders MR. Self-Directed Triple P (Positive Parenting Program) for Mothers with Children at-Risk of Developing Conduct Problems. *Behav Cogn Psychother*. 2006;34(3):259-75.
140. Sanders MR, Markie-Dadds C, Tully LA, et al. The triple P-positive parenting program: a comparison of enhanced, standard, and self-directed behavioral family intervention for parents of children with early onset conduct problems. *J Consult Clin Psychol*. 2000 Aug;68(4):624-40. PMID: 10965638.
141. Connell S, Sanders MR, Markie-Dadds C. Self-directed behavioral family intervention for parents of oppositional children in rural and remote areas. *Behav Modif*. 1997 Oct;21(4):379-408. PMID: 9337598.
142. Nickel M, Luley J, Krawczyk J, et al. Bullying girls - changes after brief strategic family therapy: a randomized, prospective, controlled trial with one-year follow-up. *Psychother Psychosom*. 2006;75(1):47-55. PMID: 16361874.
143. Nickel MK, Krawczyk J, Nickel C, et al. Anger, interpersonal relationships, and health-related quality of life in bullying boys who are treated with outpatient family therapy: a randomized, prospective, controlled trial with 1 year of follow-up. *Pediatrics*. 2005 Aug;116(2):e247-54. PMID: 16061577.
144. Nickel MK, Muehlbacher M, Kaplan P, et al. Influence of family therapy on bullying behaviour, cortisol secretion, anger, and quality of life in bullying male adolescents: A randomized, prospective, controlled study. *Can J Psychiatry*. 2006 May;51(6):355-62. PMID: 16786816.
145. Sanders MR, Baker S, Turner KM. A randomized controlled trial evaluating the efficacy of Triple P Online with parents of children with early-onset conduct problems. *Behav Res Ther*. 2012 Nov;50(11):675-84. PMID: 22982082.
146. Shechtman Z, Birani-Nasaraladin D. Treating mothers of aggressive children: a research study. *Int J Group Psychother*. 2006 Jan;56(1):93-112. PMID: 16555426.
147. Hutchings J, Appleton P, Smith M, et al. Evaluation of two treatments for children with severe behaviour problems: Child behaviour and maternal mental health outcomes. *Behav Cogn Psychother*. 2002 Jul;30(3):279-95.

148. Webster-Stratton C. Randomized trial of two parent-training programs for families with conduct-disordered children. *J Consult Clin Psychol.* 1984 Aug;52(4):666-78. PMID: 6470293.
149. Funderburk B, Eyberg S. History of parent-child interaction therapy. In: Norcross JC, VandenBos GR, Freedheim DK, American Psychological Association., eds. *History of psychotherapy : continuity and change.* 2nd ed. Washington, DC: American Psychological Association; 2011.
150. Sanders MR. Development, evaluation, and multinational dissemination of the triple P-Positive Parenting Program. *Annu Rev Clin Psychol.* 2012;8:345-79. PMID: 22149480.
151. Henggeler SW. Efficacy studies to large-scale transport: the development and validation of multisystemic therapy programs. *Annu Rev Clin Psychol.* 2011;7:351-81. PMID: 21443449.
152. Szapocznik J, Williams RA. Brief Strategic Family Therapy: twenty-five years of interplay among theory, research and practice in adolescent behavior problems and drug abuse. *Clin Child Fam Psychol Rev.* 2000 Jun;3(2):117-34. PMID: 11227062.
153. Nixon RDV. Changes in hyperactivity and temperament in behaviourally disturbed preschoolers after parent-child interaction therapy (PCIT). *Behaviour Change.* 2001;18(3):168-76.
154. Sanders MR, McFarland M. Treatment of depressed mothers with disruptive children: A controlled evaluation of cognitive behavioral family intervention. *Behav Ther.* 2000 //Winter;31(1):89-112.
155. Havighurst SS, Wilson KR, Harley AE, et al. "Tuning into Kids": reducing young children's behavior problems using an emotion coaching parenting program. *Child Psychiatry Hum Dev.* 2013 Apr;44(2):247-64. PMID: 22820873.
156. Bagner DM, Graziano PA, Jaccard J, et al. An initial investigation of baseline respiratory sinus arrhythmia as a moderator of treatment outcome for young children born premature with externalizing behavior problems. *Behav Ther.* 2012 Sep;43(3):652-65. PMID: 22697452.
157. McCabe K, Yeh M, Lau A, et al. Parent-child interaction therapy for Mexican Americans: results of a pilot randomized clinical trial at follow-up. *Behav Ther.* 2012 Sep;43(3):606-18. PMID: 22697448
158. Gardner F, Hutchings J, Bywater T, et al. Who benefits and how does it work? Moderators and mediators of outcome in an effectiveness trial of a parenting intervention. *J Clin Child Adolesc Psychol.* 2010;39(4):568-80. PMID: 20589567.
159. Lavigne JV, Lebailly SA, Gouze KR, et al. Predictor and moderator effects in the treatment of oppositional defiant disorder in pediatric primary care. *J Pediatr Psychol.* 2008 Jun;33(5):462-72. PMID: 17956931.
160. Sanders MR, Bor W, Morawska A. Maintenance of treatment gains: a comparison of enhanced, standard, and self-directed Triple P-Positive Parenting Program. *J Abnorm Child Psychol.* 2007 Dec;35(6):983-98. PMID: 17610061.
161. Nixon RD, Sweeney L, Erickson DB, et al. Parent-child interaction therapy: one- and two-year follow-up of standard and abbreviated treatments for oppositional preschoolers. *J Abnorm Child Psychol.* 2004 Jun;32(3):263-71. PMID: 15228175.
162. Bor W, Sanders MR, Markie-Dadds C. The effects of the Triple P-Positive Parenting Program on preschool children with co-occurring disruptive behavior and attentional/hyperactive difficulties. *J Abnorm Child Psychol.* 2002 Dec;30(6):571-87. PMID: 12481972.
163. McGilloway S, NiMhaille G, Bywater T, et al. Reducing child conduct disorder behaviour and improving parent mental health in disadvantaged families: a 12-month follow-up and cost analysis of a parenting intervention. *Eur Child Adolesc Psychiatry.* 2014 Sep;23(9):783-94. PMID: 25183424
164. Rugino TA, Samsoc TC. Leveteracetam in autistic children: an open-label study. *J Dev Behav Pediatr.* 2002 Aug;23(4):225-30. PMID: 12177568.
165. Barrett P, Turner C, Rombouts S, et al. Reciprocal skills training in the treatment of externalising behaviour disorders in childhood: A preliminary investigation. *Behaviour Change.* 2000;17(4):221-34.

166. Hagen KA, Ogden T, Bjornebekk G. Treatment outcomes and mediators of parent management training: a one-year follow-up of children with conduct problems. *J Clin Child Adolesc Psychol.* 2011;40(2):165-78. PMID: 21391015.
167. Hutchings J, Lane E, Kelly J. Comparison of Two Treatments for Children with Severely Disruptive Behaviours: A Four-Year Follow-up. *Behav Cogn Psychother.* 2004;32(1):15-30.
168. Zonneville-Bender MJS, Matthys W, Van De Wiel NMH, et al. Preventive Effects of Treatment of Disruptive Behavior Disorder in Middle Childhood on Substance Use and Delinquent Behavior. *Journal of the American Academy of Child & Adolescent Psychiatry.* 2007;46(1):33-9. PMID: 17195727.
169. Manders WA, Dekovic M, Asscher JJ, et al. Psychopathy as predictor and moderator of multisystemic therapy outcomes among adolescents treated for antisocial behavior. *J Abnorm Child Psychol.* 2013 Oct;41(7):1121-32. PMID: 23756854.
170. Dekovic M, Asscher JJ, Manders WA, et al. Within-intervention change: mediators of intervention effects during multisystemic therapy. *J Consult Clin Psychol.* 2012 Aug;80(4):574-87. PMID: 22563638
171. Asscher JJ, Deković M, Manders W, et al. Sustainability of the effects of multisystemic therapy for juvenile delinquents in the Netherlands: Effects on delinquency and recidivism. *J Exp Criminol.* 2014;10(2):227-43.
172. Weiss B, Han SS, Tran NT, et al. Test of "Facilitation" vs. "Proximal Process" Moderator Models for the Effects of Multisystemic Therapy on Adolescents with Severe Conduct Problem. *J Abnorm Child Psychol.* 2014 Nov 12 PMID: 25387903.
173. Gelman A, Shalizi CR. Philosophy and the practice of Bayesian statistics. *Br J Math Stat Psychol.* 2013 Feb;66(1):8-38. PMID: 22364575.
174. Achenbach TMR, LA. Manual for the ASEBA preschool forms and profiles: An integrated System of Multi-informant assessment. Research Center for Children Youth and Families. 2000
175. Eyberg S. Parent and teacher behavior inventories for the assessment of conduct problem behaviors in children. *Innovations in clinical practice: A source book.* Vol. 11. 1992:261-70.
176. Dittmann RW, Schacht A, Helsberg K, et al. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany. *J Child Adolesc Psychopharmacol.* 2011 Apr;21(2):97-110. PMID: 21488751.
177. Connor DF, Findling RL, Kollins SH, et al. Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial. *CNS Drugs.* 2010 Sep;24(9):755-68. PMID: 20806988.
178. Blader JC, Schooler NR, Jensen PS, et al. Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy. *Am J Psychiatry.* 2009 Dec;166(12):1392-401. PMID: 19884222.
179. Dell'Agnello G, Maschietto D, Bravaccio C, et al. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study. *Eur Neuropsychopharmacol.* 2009 Nov;19(11):822-34. PMID: 19716683.
180. Connor DF, McLaughlin TJ, Jeffers-Terry M. Randomized controlled pilot study of quetiapine in the treatment of adolescent conduct disorder. *J Child Adolesc Psychopharmacol.* 2008 Apr;18(2):140-56. PMID: 18439112.
181. Armenteros JL, Lewis JE, Davalos M. Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: a placebo-controlled pilot study. *J Am Acad Child Adolesc Psychiatry.* 2007 May;46(5):558-65. PMID: 17450046.

182. Spencer TJ, Abikoff HB, Connor DF, et al. Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study. *Clin Ther*. 2006 Mar;28(3):402-18. PMID: 16750455.
183. Reyes M, Buitelaar J, Toren P, et al. A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. *Am J Psychiatry*. 2006 Mar;163(3):402-10. PMID: 16513860.
184. Steiner H, Petersen ML, Saxena K, et al. Divalproex sodium for the treatment of conduct disorder: a randomized controlled clinical trial. *J Clin Psychiatry*. 2003 Oct;64(10):1183-91. PMID: 14658966.
185. Donovan SJ, Stewart JW, Nunes EV, et al. Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled crossover design. *Am J Psychiatry*. 2000 May;157(5):818-20. PMID: 10784478.
186. Findling RL, McNamara NK, Branicky LA, et al. A double-blind pilot study of risperidone in the treatment of conduct disorder. *J Am Acad Child Adolesc Psychiatry*. 2000 Apr;39(4):509-16. PMID: 10761354.
187. Klein RG, Abikoff H, Klass E, et al. Clinical efficacy of methylphenidate in conduct disorder with and without attention deficit hyperactivity disorder. *Arch Gen Psychiatry*. 1997 Dec;54(12):1073-80. PMID: 9400342.
188. Bastiaens L. A non-randomized, open study with aripiprazole and ziprasidone for the treatment of aggressive behavior in youth in a community clinic. *Community Ment Health J*. 2009 Feb;45(1):73-7. PMID: 18597173.
189. Padhy R, Saxena K, Remsing L, et al. Symptomatic response to divalproex in subtypes of conduct disorder. *Child Psychiatry Hum Dev*. 2011 Oct;42(5):584-93. PMID: 21706221.
190. Wehmeier PM, Schacht A, Dittmann RW, et al. Effect of atomoxetine on quality of life and family burden: results from a randomized, placebo-controlled, double-blind study in children and adolescents with ADHD and comorbid oppositional defiant or conduct disorder. *Qual Life Res*. 2011 Jun;20(5):691-702. PMID: 21136299.
191. Munshi KR, Oken T, Guild DJ, et al. The Use of Antiepileptic Drugs (AEDs) for the Treatment of Pediatric Aggression and Mood Disorders. *Pharmaceuticals*. 2010;3(9):2986-3004. PMID: doi:10.3390/ph3092986.
192. Strattera (atomoxetine) [package insert]. Indianapolis, IN: Eli Lilly and Company; 2014.
193. Saxena K, Mora L, Torres E, et al. Divalproex sodium-ER in outpatients with disruptive behavior disorders: a three month open label study. *Child Psychiatry Hum Dev*. 2010 Jun;41(3):274-84. PMID: 20043204.
194. Penzner JB, Dudas M, Saito E, et al. Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality. *J Child Adolesc Psychopharmacol*. 2009 Oct;19(5):563-73. PMID: 19877981.
195. Ercan ES, Kutlu A, Cikoglu S, et al. Risperidone in children and adolescents with conduct disorder: A single-center, open-label study. *Current Therapeutic Research - Clinical and Experimental*. 2003 01 Jan;64(1):55-64. PMID: 24944356.
196. Pandina GJ, Zhu Y, Cornblatt B. Cognitive function with long-term risperidone in children and adolescents with disruptive behavior disorder. *J Child Adolesc Psychopharmacol*. 2009 Dec;19(6):749-56. PMID: 20035593.
197. Connor DF, Spencer TJ. Short-term cardiovascular effects of mixed amphetamine salts extended release in children and adolescents with oppositional defiant disorder. *CNS Spectr*. 2005 Oct;10(10 Suppl 15):31-8. PMID: 17151574.

198. Pringsheim T, Lam D, Ching H, et al. Metabolic and neurological complications of second-generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials. *Drug Saf.* 2011 Aug 1;34(8):651-68. PMID: 21751826.
199. Risperdal (risperidone) [package insert]. Titusville, NJ: Janssen Pharmaceuticals Inc.; 2007.
200. Risperdal (risperidone) [package insert]. Titusville, NJ: Janssen Pharmaceuticals Inc.; 2014.
201. Risperdal [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2014. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020272s073,020588s062,021444s048lbl.pdf. Accessed April 2, 2015.
202. Risperdal Medical Review - Pediatric Approval. 20-272/S045/S046, 20-588/S036/S037, 21-444/S020/S021. Silver Spring, MD: Food and Drug Administration Center for Drug Evaluation and Research; 2007. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/020272_s046_risperdal_toc.cfm. Accessed April 2, 2015.
203. Modafinil: serious skin reactions. *Prescribe Int.* 2007 Apr;16(88):71. PMID: 17465032
204. Abilify (aripiprazole) [package insert]. Rockville, MD: Otsuka America Pharmaceutical I; 2014.
205. Abilify [package insert]. Rockville, MD: Otsuka America Pharmaceutical, Inc.; 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021436s037,021713s029,021729s021,021866s022lbl.pdf. Accessed April 2, 2015.
206. Seroquel Medical Review - QT Prolongation Review. 020639Orig1s049. Silver Spring, MD: Food and Drug Administration Center for Drug Evaluation and Research; 2011. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/020639Orig1s049MedR.pdf. Accessed April 2, 2015.
207. Seroquel [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020639s061lbl.pdf. Accessed April 2, 2015.
208. Geodon [package insert]. New York, NY: Pfizer; October 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020825s049,020919s035lbl.pdf. Accessed April 2, 2015.
209. Khanzode LA, Saxena K, Kraemer H, et al. Efficacy profiles of psychopharmacology: divalproex sodium in conduct disorder. *Child Psychiatry Hum Dev.* 2006 Fall;37(1):55-64. PMID: 16927177
210. Depacon (valproate/valproic acid) [package insert]. North Chicago, IL: Inc. A; 2014.
211. Depakote [package insert]. North Chicago, IL: AbbVie Inc.; July 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/018723s048lbl.pdf. Accessed April 2, 2015.
212. Adderall [package insert]. Pomona, NY: Barr Laboratories; 2007. http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/011522s040lbl.pdf. Accessed April 2, 2015.
213. Ritalin [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/010187s077lbl.pdf. Accessed April 2, 2015.
214. Strattera [package insert]. Indianapolis, IN: Eli Lilly and Company; 2014. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021411s044lbl.pdf. Accessed April 2, 2015.
215. Strattera Medical Review - Original Approval. 21-411. Silver Spring, MD: Food and Drug Administration Center for Drug Evaluation and Research; 2002. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-411_Strattera.cfm. Accessed April 2, 2015.
216. Intuniv Medical Review - Original Approval. 22-037. Silver Spring, MD: Food and Drug Administration Center for Drug Evaluation and Research; 2009. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022037s000medr.pdf. Accessed April 2, 2015.
217. Intuniv [package insert]. Wayne, PA: Shire US Inc.; 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022037s009lbl.pdf. Accessed April 2, 2015.

218. Beauchaine TP, Webster-Stratton C, Reid MJ. Mediators, moderators, and predictors of 1-year outcomes among children treated for early-onset conduct problems: a latent growth curve analysis. *J Consult Clin Psychol*. 2005 Jun;73(3):371-88. PMID: 15982136.
219. Fossum S, Morch WT, Handegard BH, et al. Parent training for young Norwegian children with ODD and CD problems: predictors and mediators of treatment outcome. *Scand J Psychol*. 2009 Apr;50(2):173-81. PMID: 19170971.
220. Kolko DJ, Pardini DA. ODD dimensions, ADHD, and callous-unemotional traits as predictors of treatment response in children with disruptive behavior disorders. *J Abnorm Psychol*. 2010;119(4):713-25. PMID: 21090875.
221. Shenk CE, Dorn LD, Kolko DJ, et al. Prior exposure to interpersonal violence and long-term treatment response for boys with a disruptive behavior disorder. *J Trauma Stress*. 2014 Oct;27(5):585-92. PMID: 25270151.
222. Wolff JC, Greene RW, Ollendick TH. Differential responses of children with varying degrees of reactive and proactive aggression to two forms of psychosocial treatment. *Child Fam Behav Ther*. 2008;30(1):37-50.
223. Lochman JE, Wells KC, Qu L, et al. Three year follow-up of coping power intervention effects: evidence of neighborhood moderation? *Prev Sci*. 2013 Aug;14(4):364-76. PMID: 23065350.
224. Mojtabai R. Serious emotional and behavioral problems and mental health contacts in American and British children and adolescents. *J Am Acad Child Adolesc Psychiatry*. 2006 Oct;45(10):1215-23. PMID: 17003667.
225. Bobo WV, Cooper WO, Stein CM, et al. Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. *JAMA Psychiatry*. 2013 Oct;70(10):1067-75. PMID: 23965896
226. Forehand R, Lafko N, Parent J, et al. Is parenting the mediator of change in behavioral parent training for externalizing problems of youth? *Clinical Psychology Review*. 2014 Dec;34(8):608-19. PMID: 25455625.
227. Littell JH, Campbell M, Green S, et al. Multisystemic Therapy for social, emotional, and behavioral problems in youth aged 10-17. *Cochrane Database of Systematic Reviews*. 2005(4)
228. Ozabaci N. Cognitive behavioural therapy for violent behaviour in children and adolescents: A meta-analysis. *Children and Youth Services*. 2011;33(10):1989-93.
229. Nowak C, Heinrichs N. A comprehensive meta-analysis of Triple P-Positive Parenting Program using hierarchical linear modeling: effectiveness and moderating variables. *Clin Child Fam Psychol Rev*. 2008 Sep;11(3):114-44. PMID: 18509758.
230. Sanders MR, Kirby JN, Tellegen CL, et al. The Triple P-Positive Parenting Program: a systematic review and meta-analysis of a multi-level system of parenting support. *Clinical Psychology Review*. 2014 Jun;34(4):337-57. PMID: 24842549.
231. Thomas R, Zimmer-Gembeck MJ. Behavioral outcomes of Parent-Child Interaction Therapy and Triple P-Positive Parenting Program: a review and meta-analysis. *J Abnorm Child Psychol*. 2007 Jun;35(3):475-95. PMID: 17333363.
232. Dretzke J, Frew E, Davenport C, et al. The effectiveness and cost-effectiveness of parent training/education programmes for the treatment of conduct disorder, including oppositional defiant disorder, in children. *Health Technol Assess*. 2005 Dec;9(50):iii, ix-x, 1-233. PMID: 16336845
233. Bradley MC, Mandell D. Oppositional defiant disorder: A systematic review of evidence of intervention effectiveness. *Journal of Experimental Criminology*. 2005;1(3):343-65.
234. Maughan DR, Christiansen, E., Jensen, W.R., Olympia, D., & Clark, E. Behavioral parent training as a treatment for externalizing behaviors and disruptive behavior disorders: A meta-analysis. *School Psychology Review*. 2005;34:267-86.

235. Lundahl BW, Risser, H.J., & Lovejoy, M.C. . A meta-analysis of parent training: Moderators and follow-up effects. *Clinical Psychology Review*. 2006;26:86-104.
236. Fossum S, Handegard BH, Martinussen M, et al. Psychosocial interventions for disruptive and aggressive behaviour in children and adolescents: a meta-analysis. *Eur Child Adolesc Psychiatry*. 2008 Oct;17(7):438-51. PMID: 18427863.
237. Comer JS, Chow C, Chan PT, et al. Psychosocial treatment efficacy for disruptive behavior problems in very young children: a meta-analytic examination. *J Am Acad Child Adolesc Psychiatry*. 2013 Jan;52(1):26-36. PMID: 23265631.
238. Eyberg SM, Nelson MM, Boggs SR. Evidence-based psychosocial treatments for children and adolescents with disruptive behavior. *Journal of Clinical Child and Adolescent Psychology*. 2008;37(1):215-37.
239. McCart MR, Priester PE, Davies WH, et al. Differential effectiveness of behavioral parent-training and cognitive-behavioral therapy for antisocial youth: a meta-analysis. *J Abnorm Child Psychol*. 2006 Aug;34(4):527-43. PMID: 16838122.
240. Piquero AR, Farrington, D.P., Welsh, B.C., Tremblay, R. & Jennings, W.G. Effects of early family/parent training programs on antisocial behavior and delinquency. *Journal of Experimental Criminology*. 2009;5:83-120.
241. Johnson MH, George P, Armstrong MI, et al. Behavioral Management for Children and Adolescents: Assessing the Evidence. *Psychiatr Serv*. 2013 Dec 17PMID: 24343339.
242. Reyno SM, McGrath PJ. Predictors of parent training efficacy for child externalizing behavior problems--a meta-analytic review. *J Child Psychol Psychiatry*. 2006 Jan;47(1):99-111. PMID: 16405646
243. Shelleby EC, Shaw DS. Outcomes of Parenting Interventions for Child Conduct Problems: A Review of Differential Effectiveness. *Child Psychiatry Hum Dev*. 2014 Jan 4PMID: 24390592.
244. Leijten P, Raaijmakers MA, de Castro BO, et al. Does socioeconomic status matter? A meta-analysis on parent training effectiveness for disruptive child behavior. *J Clin Child Adolesc Psychol*. 2013;42(3):384-92. PMID: 23461526.
245. Fixsen D, Naoom S, Blase K, et al. Implementation Research: A Synthesis of the Literature. Louis de la Parte Florida Mental Health Institute, The National Implementation Research Network. FMHI Publication #231. Tampa, FL: University of South Florida; 2005.
246. March J, Silva S, Petrycki S, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. *Jama*. 2004 Aug 18;292(7):807-20. PMID: 15315995.

Abbreviations

| | |
|-----------|-----------------------------------------------------------------|
| AABC | Adolescent Antisocial Behavior Checklist |
| AACAP | American Academy of Child and Adolescent Psychiatry |
| AARS | Adolescent Anger Rating Scale |
| AAQ | Barratt Aggressive Acts Questionnaire |
| ABC | Aberrant Behavior Checklist |
| ABC-IS | Aberrant Behavior Checklist-Irritability Subscale |
| ABI | Adaptive Behavior Inventory |
| ADHD | Attention Deficit Hyperactivity Disorder |
| AGG | Aggression |
| AIAQ | Anger Irritability and Aggression Questionnaire |
| AIAQ | Anger Irritability and Assault Questionnaire |
| APS | Adolescent Psychopathology Scale |
| APSD | Antisocial Process Screening Device |
| AQ or AGQ | Aggression Questionnaire (Buss-Perry Aggression Questionnaire) |
| ARBS | Adolescent Risk Taking Behavior Scale |
| ART | Aggression Replacement Training |
| ATP | Adolescent Transitions Program |
| ATX | Atomoxetine |
| BASC | Behavior Assessment System for Children |
| BASC-2 | Behavior Assessment System for Children, Second Edition |
| BASIC | Behavioral and Affective Skills in Coping |
| BDHI | Buss-Durkee Hostility Inventory |
| BPC | Brief Problem Checklist |
| BPI-01 | Behavior Problem Inventory |
| BSFT | Brief Strategic Family Therapy |
| CAFAS | Child and Adolescent Functioning Scale |
| CANS-MH | Child and Adolescent Needs and Strength-Mental Health |
| CAS | Children's Aggression Scale |
| CAS-P | Children's Aggression Scale, Parent Rated |
| CAS-T | Children's Aggression Scale, Teacher Rated |
| CBCL | Child Behavior Checklist |
| CBRS | Conners Comprehensive Behavior Rating Scales |
| CBT | Cognitive-Behavioral Therapy |
| CBQ | Children's Behavior Questionnaire |
| CCNES | Coping with Children's Negative Emotions Scale |
| CD | Conduct Disorder |
| CERT | Center for Education and Research on Mental Health Therapeutics |
| CGAS | Children's Global Assessment Scale |
| CGI-C | Clinical Global Impressions, Change Scores |
| CGI-I | Clinical Global Impressions, Improvement Item |

| | |
|---------|-----------------------------------------------------------------------|
| CGI-S | Clinical Global Impressions, Severity |
| CI | Confidence Interval |
| CNS | Central Nervous System |
| CON | Control |
| CPPRG | Conduct Problems Prevention Research Group |
| CPRS | Children's Psychiatric Rating Scale |
| CPRS | Conners Parent Rating Scale |
| CPRS-RS | Conners Parent Rating Scale, Revised |
| CPS | Collaborative Problem Solving |
| CrPTRC | Conners Parent and Teacher Rating Checklist, Revised Short Form |
| CRS | Conners Rating Scale |
| CSBS | Children's Social Behavior Scale |
| CSI-4 | Children Symptom Inventory-4 |
| CT | Child Training |
| CTRS | Conners Teacher Rating Scale |
| CWD-A | Adolescents Coping with Depression |
| CWL | Caregiver Wish List |
| DARE | Drug Abuse Resistance Education |
| DBD | Disruptive Behavior Disorder |
| DB-DOS | Disruptive Behavior Diagnostic Observation Scale |
| DBD-NOS | Disruptive Behavior Disorder-not otherwise specified |
| DBR | Direct Behavior Rating |
| DBS | Disruptive Behavior Scale |
| DISC | Diagnostic Interview Schedule for Children |
| DOF | Direct Observation Form |
| DPICS | Dyadic Parent-Child Interaction Coding System III |
| DSM-IV | Diagnostic and Statistical Manual of Mental Disorders, Fourth edition |
| ECBI | Eyberg Child Behavior Inventory |
| ECI-4 | Early Childhood Inventory-4 |
| EPS | Emergent Extrapyramidal Symptoms |
| FDA | Food and Drug Administration |
| FFT | Functional Family Therapy |
| FSE | Educational Fire Safety Intervention |
| FT | Family Training |
| G | Group |
| GCJS | Global Clinical Judgements Scale |
| HNC | Helping the Noncompliant Child |
| HSQ | Home Situations Questionnaire |
| HVF | Home Visit from a Firefighter |
| IAB | Interview for Antisocial Behavior |
| ICD | International Classification of Diseases |

| | |
|--------|----------------------------------------------------------------------------|
| IIP-D | Inventory of Interpersonal Problems |
| INT | Intervention |
| ITT | Intention to treat |
| IY | Incredible Years |
| IY-CT | Incredible Years Child Training |
| IY-PT | Incredible Years Parent Training |
| IY-TT | Incredible Years Teacher Training |
| K-DBDS | Kiddie Disruptive Behavior Disorders Schedule |
| KQ | Key Question |
| KSADS | Schedule for Affective Disorders and Schizophrenia for School-Age Children |
| LHA | Life History of Aggression |
| LSM | Least Square Mean |
| MAS XR | Mixed Amphetamine Salts Extended Release |
| MDD | Major Depressive Disorder |
| MST | Multisystemic Therapy |
| MTFC | Multidimensional Treatment Foster Care |
| N | Number |
| NA | Not Applicable |
| NAMCS | National Ambulatory Medical Care Survey |
| NCBRF | Nisonger Child Behavior Rating Form |
| ND | No Data |
| NHAMCS | National Hospital Ambulatory Medical Care Survey |
| NMA | Network Meta-analysis |
| NR | Not Reported |
| NYTRS | New York Teacher Rating Scale for Disruptive and Antisocial Behavior |
| OAS | Overt Aggression Scale |
| ODD | Oppositional Defiant Disorder |
| PAI-A | Personality Assessment Inventory-Adolescent |
| PATHS | Promoting Alternative Thinking Strategies |
| PBSS | Positive Behavioral Support System |
| PCIT | Parent-Child Interaction Therapy |
| PDR | Parent Daily Report |
| P-GBI | General Behavior Inventory, Parent Vision |
| PICOTS | Population, Intervention, Comparator, Outcomes, Timing, Setting |
| PMT | Parent Management Training |
| PMT-O | Parent Management Training-Oregon |
| POS | Play Observation |
| PRA | Proactive and Reactive Aggression Scale |
| PS | Parenting Scale |
| PSC-17 | Pediatric Symptom Checklist |
| PSI | Parenting Stress Index |

| | |
|----------|------------------------------------------------------------------------------|
| PSI/SF | Parenting Stress Index Short Version |
| PSST | Problem-Solving Skills Training |
| PT | Parent Training |
| QOL | Quality of Life |
| QRBC | Quay Revised Behavior Checklist |
| QT | Interval between Q-wave and T-wave |
| QTcB | Heart-rate corrected QT interval |
| RAAPP | Rating of Aggression Against People and/or Property |
| RBPC | Revised Behavior Problem Checklist |
| RCOH | Retrospective cohort study |
| RCT | Randomized Controlled Trial |
| R-CTRS | Conners Teacher Rating Scale, Revised |
| RPQ | Reactive-Proactive Aggression Questionnaire |
| R-TRPA | Reactive and Proactive Rating Scale, Teacher Revised |
| SAMHSA | Substance Abuse and Mental Health Services Administration |
| SCIP | Social Cognitive Intervention Program |
| SCL-90 | Symptom Checklist, 90-item |
| SD | Standard Deviation |
| SDQ | Strengths and Difficulties Questionnaire |
| SESBI | Sutter-Eyberg Student Behavior Inventory |
| SET-PC | Supportive Expressive Therapy-Parent Child |
| SGA | Second-generation Antipsychotics |
| SIP | Scientific Information Packets |
| SKAMP | Swanson Kotkin Atkins M-Flynn and Pelham Scale |
| SNAP-IV | Swanson Nolan and Pelham-IV |
| SNAP ORP | Stop Now and Plan Under 12 Outreach Project |
| SOE | Strength of Evidence |
| SRC | Scientific Resource Center |
| SRD | Self-report Delinquency Scale |
| SRDR | Systematic Review Data Repository |
| SSQ | School Situations Questionnaire |
| SSRI | Selective Serotonin Reuptake Inhibitors |
| SSS | Sensation Seeking Scale |
| SST | Social Skills Training |
| STAXI | State-Trait Anger and Expression of Anger Inventory |
| SUDD | Substance Use Disorder Diagnosis Schedule |
| TAU | Treatment As Usual |
| TCIT | Teacher-Child Interaction Training |
| T-MAY | Treatment of Maladaptive Aggression in Youth |
| TPA | Top Problems Assessment |
| TRAAY | Treatment Recommendations for the use of Antipsychotics for Aggressive Youth |

| | |
|----------|-----------------------------------------|
| TRF | Teacher Report Form |
| Triple P | Positive Parenting Program |
| VAQ | Vitiello Aggression Questionnaire |
| VAS-TO | Visual Analogue Scale of Target Outcome |
| VPA | Valproic Acid |
| WLC | Waitlist Control |
| YOT | Youth Offending Team |
| YSR | Youth Self Report |
| XR | Extended release |

Appendix A. Search Strategies

Table A-1. MEDLINE search strategies updated (PubMed interface) December 11, 2013

| Search terms | Results |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|
| Psychosocial interventions | |
| #1 attention deficit and disruptive behavior disorders[mh:noexp] OR conduct disorder[mh] OR (mental disorders[mh] AND aggression[mh]) OR externalizing behavior*[tiab] OR externalizing behaviour*[tiab] OR oppositional defian*[tiab] OR conduct disorder*[tiab] OR disruptive behavior disorder*[tiab] OR antisocial personality disorder[mh] OR conduct problems[tiab] OR antisocial behavior*[tiab] | 23579 |
| #2 therapy[sh] OR therapeutics[mh] OR teaching[mh] OR psychotherapy[mh] OR treatment outcome[mh] OR "Adolescent Transitions Program"[tiab] OR "Anger control training"[tiab] OR "Assertive training"[tiab] OR "Behavioral parent training"[tiab] OR "Brief Strategic Family Therapy"[tiab] OR "Collaborative Problem Solving"[tiab] OR "Coping Power"[tiab] OR "Early Risers Skills for Success"[tiab] OR "Skills for Success Program"[tiab] OR "First Step to Success"[tiab] OR "Functional Family Therapy"[tiab] OR "Helping the Noncompliant Child"[tiab] OR "Incredible Years"[tiab] OR "Interpersonal skills training"[tiab] OR "Multidimensional Family Therapy"[tiab] OR "Multidimensional Treatment Foster Care"[tiab] OR "Multisystemic Therapy"[tiab] OR "Multi-systemic Therapy"[tiab] OR "Parent Management Training"[tiab] OR "Parent-Child Interaction Therapy"[tiab] OR "Positive Parenting Program"[tiab] OR "Problem Solving Skills Training"[tiab] OR "Positive Behavioral Support System"[tiab] OR "Promoting Alternative Thinking Strategies"[tiab] OR "Second Step"[tiab] OR "Self-Control training"[tiab] OR "Teacher-Child Interaction Training"[tiab] OR "Teacher Child Interaction Training"[tiab] | 6753849 |
| #3 eng[la] AND (child[mh] OR adolescent[mh]) | 1775464 |
| #4 newspaper article[pt] OR letter[pt] OR comment[pt] OR case reports[pt] OR review[pt] OR practice guideline[pt] OR news[pt] OR editorial[pt] OR historical article[pt] OR meta-analysis[pt] OR legal cases[pt] OR published erratum[pt] OR congresses[pt] OR jsubsetk | 4996769 |
| #5 (#1 AND #2 AND #3) NOT #4 | 3181 |
| #6 (oppositional defian*[tiab] OR conduct disorder*[tiab] OR disruptive behavior disorder*[tiab] OR disruptive behaviour disorder*[tiab] OR conduct problem*[tiab] OR antisocial behavior*[tiab] OR antisocial behaviour*[tiab] OR ((externaliz*[tiab] OR aggressi*[tiab]) AND (behavior*[tiab] OR behaviour*))) NOT medline[sb] | 3745 |
| #7 (therapy[tiab] OR effectiveness[tiab] OR efficacy[tiab] OR outcome[tiab] OR treatment*[tiab] OR randomized[tiab] OR "Adolescent Transitions Program"[tiab] OR "Anger control training"[tiab] OR "Assertive training"[tiab] OR "Behavioral parent training"[tiab] OR "Brief Strategic Family Therapy"[tiab] OR "Collaborative Problem Solving"[tiab] OR "Coping Power"[tiab] OR "Early Risers Skills for Success"[tiab] OR "Skills for Success Program"[tiab] OR "First Step to Success"[tiab] OR "Functional Family Therapy"[tiab] OR "Helping the Noncompliant Child"[tiab] OR "Incredible Years"[tiab] OR "Interpersonal skills training"[tiab] OR "Multidimensional Family Therapy"[tiab] OR "Multidimensional Treatment Foster Care"[tiab] OR "Multisystemic Therapy"[tiab] OR "Multi-systemic Therapy"[tiab] OR "Parent Management Training"[tiab] OR "Parent-Child Interaction Therapy"[tiab] OR "Positive Parenting Program"[tiab] OR "Problem Solving Skills Training"[tiab] OR "Positive Behavioral Support System"[tiab] OR "Promoting Alternative Thinking Strategies"[tiab] OR "Second Step"[tiab] OR "Self-Control training"[tiab] OR "Teacher-Child Interaction Training"[tiab] OR "Teacher Child Interaction Training"[tiab]) NOT medline[sb] | 388791 |
| #8 (child*[tiab] OR youth*[tiab] OR adolescen*[tiab] OR teen*[tiab] OR preschool*[tiab] OR parent*[tiab] OR family[tiab] OR families[tiab] OR juvenile*[tiab] OR school-age*[tiab]) NOT medline[sb] | 149580 |
| #9 #6 AND #7 AND #8 | 564 |
| #10 #5 OR #9 (Medline and non-indexed results) | 3745 |
| Pharmacologic interventions | |
| #11 attention deficit and disruptive behavior disorders[mh:noexp] OR conduct disorder[mh] OR (mental disorders[mh] AND aggression[mh]) OR externalizing behavior*[tiab] OR externalizing behaviour*[tiab] OR oppositional defian*[tiab] OR conduct disorder*[tiab] OR disruptive behavior disorder*[tiab] OR antisocial personality disorder[mh] OR conduct problems[tiab] OR antisocial behavior*[tiab] | 23579 |

| Search terms | Results |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|
| #12 "drug therapy" [Subheading] OR "Drug Therapy"[Mesh] OR "Antipsychotic Agents"[Mesh] OR "Antipsychotic Agents" [Pharmacological Action] OR "Adrenergic alpha-Agonists"[Mesh] OR "Adrenergic alpha-2 Receptor Agonists"[Mesh] OR "Anticonvulsants"[Mesh] OR "Anticonvulsants" [Pharmacological Action] OR "Serotonin Uptake Inhibitors"[Mesh] OR "Serotonin Uptake Inhibitors" [Pharmacological Action] OR "Central Nervous System Stimulants"[Mesh] | 2353195 |
| #13 eng[la] AND (child[mh] OR adolescent[mh]) | 1775464 |
| #14 newspaper article[pt] OR letter[pt] OR comment[pt] OR case reports[pt] OR review[pt] OR practice guideline[pt] OR news[pt] OR editorial[pt] OR historical article[pt] OR meta-analysis[pt] OR legal cases[pt] OR published erratum[pt] OR congresses[pt] OR jsubsetk | 4996769 |
| #15 (#11 AND #12 AND #13) NOT #14 | 685 |
| Pharmacologic or psychosocial interventions | |
| #16 #15 OR #10 (all results) | 3781 |
| #17 #10 NOT #15 | 3096 |

Key: [mh] Medical Subject Heading; [tiab] title/abstract word; [pt] publication type; [sh] subheading;

*Note: numbers do not tally as some articles are excluded in more than one category

After duplicates were removed, this search contributed 1678 records to the existing 2407 in the database, for a total of 4085 records.

Table A-2. MEDLINE search strategies updated (PubMed interface) January 13, 2014

| Search terms | Results |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|
| #1 "aggressive behavior"[tiab] OR "aggressive behaviors"[tiab] OR "aggressive behavior"[tiab] OR "aggressive behaviours"[tiab] OR "aggressive children"[tiab] OR "aggressive child"[tiab] OR "aggressive adolescent"[tiab] OR "aggressive adolescents"[tiab] OR "adolescent aggression"[tiab] OR "child aggression"[tiab] OR "antisocial behavior"[tiab] OR "antisocial behaviors"[tiab] OR "antisocial behaviour"[tiab] OR "antisocial behaviours"[tiab] OR "aggressive disruptive"[tiab] OR "Attention Deficit and Disruptive Behavior Disorders"[Mesh:NoExp] OR "behavior disorder"[tiab] OR "behavior disorders"[tiab] OR "behaviour disorder"[tiab] OR "behaviour disorders"[tiab] OR "conduct disorder"[tiab] OR "conduct disorders"[tiab] OR "Conduct Disorder"[mesh] OR "conduct problems"[tiab] OR "disruptive behavior"[tiab] OR "disruptive behaviour"[tiab] OR "disruptive behaviors"[tiab] OR "disruptive behaviours"[tiab] OR "externalizing disorder" OR "externalizing disorders" OR "externalizing behavior"[tiab] OR "externalizing behaviors"[tiab] OR "externalizing behaviour"[tiab] OR "externalizing behaviours"[tiab] OR "externalizing problem behavior"[tiab] OR "externalizing problem behaviors"[tiab] OR "externalizing problem behaviour"[tiab] OR "externalizing problem behaviours"[tiab] OR "oppositional defiant"[tiab] OR "oppositional defiance"[tiab] OR oppositionality[tiab] OR ((Aggression[Mesh] OR aggression[tiab] OR bullying[tiab] OR noncompliant[tiab] OR defiance[tiab] OR defiant[tiab] OR disruptive[tiab] OR oppositional[tiab] OR antisocial[tiab] OR "Psychomotor Agitation"[mesh]) AND ("Child Behavior"[mesh] OR "Adolescent Behavior"[mesh] OR behavior[tiab] OR behaviour[tiab] OR behaviors[tiab] OR behaviours[tiab] OR conduct[tiab])) | 36627 |
| #2 "anger management"[tiab] OR "anger control"[tiab] OR "behavior management"[tiab] OR "behaviour management"[tiab] OR "behavioral management"[tiab] OR "behavioural management"[tiab] OR "behavioral support"[tiab] OR "behavioural support"[tiab] OR "cognitive therapy"[tiab] OR "cognitive behavior therapy"[tiab] OR "cognitive behaviour therapy"[tiab] OR "CBT"[tiab] OR "cognitive behavioral therapy"[tiab] OR "cognitive behavioural therapy"[tiab] OR "conflict management"[tiab] OR counseling[tiab] OR "coping power"[tiab] OR "Counseling"[Mesh] OR "drug therapy"[tiab] OR "early intervention"[tiab] OR "family therapy"[tiab] OR "multisystemic therapy"[tiab] OR "multi-systemic therapy"[tiab] OR "multidimensional treatment"[tiab] OR "multidimensional therapy"[tiab] OR "nonpharmacologic therapy"[tiab] OR "nondrug therapy"[tiab] OR "non-drug therapy"[tiab] OR "parent training"[tiab] OR "parent engagement"[tiab] OR "parent management"[tiab] OR "parenting skills"[tiab] OR "parenting intervention"[tiab] OR "parenting interventions"[tiab] OR "family training"[tiab] OR "family education"[tiab] OR "family intervention"[tiab] OR "family interventions"[tiab] OR "pharmacologic therapy"[tiab] OR "pharmacologic treatment"[tiab] OR "Problem Solving"[Mesh] OR "problem solving"[tiab] OR "Psychology, Applied"[Mesh] OR psychoeducation[tiab] OR "psychosocial therapy"[tiab] OR "psychosocial intervention"[tiab] OR "psychosocial interventions"[tiab] OR "psychosocial approach"[tiab] OR "psychosocial approaches"[tiab] OR "psychosocial treatment"[tiab] OR | 4613496 |

| Search terms | Results |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|
| "psychosocial support"[tiab] OR "Psychotherapy"[Mesh] OR psychotherap*[tiab] OR "skills training"[tiab] OR "symptom management"[tiab] OR teaching[tiab] OR "Therapeutics"[Mesh:NoExp] OR treatment[tiab] OR therapy[tiab] OR training[tiab] OR "Treatment Outcome"[Mesh] OR "Adrenergic alpha-2 Receptor Agonists" [Pharmacological Action] OR "Adrenergic alpha-2 Receptor Agonists"[Mesh] OR "alpha-2 agonist"[tiab] OR "alpha-2 agonists"[tiab] OR "Antidepressive Agents"[Mesh] OR "Antidepressive Agents" [Pharmacological Action] OR antidepressant[tiab] OR antidepressants[tiab] OR "Antipsychotic Agents"[Mesh] OR "Antipsychotic Agents" [Pharmacological Action] OR antipsychotics[tiab] OR antipsychotic[tiab] OR "mood stabilizer"[tiab] OR "mood stabilizing"[tiab] OR "mood stabilizers"[tiab] OR psychostimulant[tiab] OR psychostimulants[tiab] OR "Serotonin Uptake Inhibitors"[Mesh] OR "SSRI"[tiab] OR "SSRIs"[tiab] OR "selective serotonin reuptake inhibitors"[tiab] OR "Serotonin Uptake Inhibitors" [Pharmacological Action] OR stimulants[tiab] OR "Central Nervous System Stimulants"[Mesh] OR "Central Nervous System Stimulants" [Pharmacological Action] OR "Sympatholytics"[Mesh] OR "Sympatholytics" [Pharmacological Action] OR sympatholytic[tiab] OR sympatholytics[tiab] | |
| #3 #1 AND #2 AND english[la] AND (child[mh] OR adolescent[mh] OR child*[tiab] OR teen*[tiab] OR adolescent*[tiab] OR adolescence[tiab] OR pediatric[tiab] OR paediatric*[tiab]) | 6076 |
| #4 newspaper article[pt] OR letter[pt] OR comment[pt] OR case reports[pt] OR review[pt] OR practice guideline[pt] OR news[pt] OR editorial[pt] OR historical article[pt] OR meta-analysis[pt] OR legal cases[pt] OR published erratum[pt] OR congresses[pt] OR jsubsetk | 5028324 |
| #5 #3 NOT #4 | 4695 |

Key: [mh] Medical Subject Heading; [tiab] title/abstract word; [pt] publication type; [sh] subheading;

*Note: numbers do not tally as some articles are excluded in more than one category

This search, less the duplicates, contributed 2716 citations for a total of 6801 records for initial screening

Table A-3. PsycINFO (via ProQuest interface) search results, November 26, 2013

| Search terms | Results |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|
| PsycInfo- psychosocial | |
| #1 SU.EXACT("Conduct Disorder") OR SU.EXACT("Oppositional Defiant Disorder") OR SU.EXACT("Antisocial Personality Disorder") OR (disruptive behavior disorder OR disruptive behavior disorders) | 11181 |
| #2 SU.EXACT.EXPLODE("Treatment") OR SU.EXACT.EXPLODE("Medicinal Herbs and Plants") OR SU.EXACT.EXPLODE("Dietary Supplements") OR SU.EXACT.EXPLODE("Nutrition") OR SU.EXACT.EXPLODE("Vitamins") OR SU.EXACT("Drug Therapy") OR SU.EXACT.EXPLODE("Behavior Therapy") | 573194 |
| #3 #1 and #2 | 2580 |
| #4 #3, limited children and adolescents | 1558 |
| #5 #3, limited to 2003-2013 publication date | 1323 |
| #6 #3 limited to peer reviewed, scholarly journals | 1719 |
| #7 #3 limited to research methodology (Empirical Study OR Quantitative Study OR Treatment Outcome/Clinical Trial OR Longitudinal Study OR Followup Study OR Retrospective Study OR Prospective Study OR Field Study) | 1200 |
| #8 #3 AND #4 AND #5 AND #6 AND #7 | 412 |
| PsycInfo- pharmacologic | |
| #9 SU.EXACT("Conduct Disorder") OR SU.EXACT("Oppositional Defiant Disorder") OR SU.EXACT("Antisocial Personality Disorder") OR (disruptive behavior disorder OR disruptive behavior disorders) | 11181 |
| #10 (SU.EXACT.EXPLODE("Adrenergic Blocking Drugs") OR SU.EXACT.EXPLODE("Adrenergic Drugs")) OR (SU.EXACT.EXPLODE("Anticonvulsive Drugs") OR SU.EXACT.EXPLODE("Antidepressant Drugs")) OR (SU.EXACT.EXPLODE("Drug Augmentation") OR SU.EXACT.EXPLODE("Drug Therapy")) OR SU.EXACT.EXPLODE("Neuroleptic Drugs") OR antipsychotic | 142032 |
| #11 #9 AND #10 | 643 |

| Search terms | | Results |
|---------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|
| #12 | #11, limited to children and adolescents | 436 |
| #13 | #11, limited to 2003-2013 | 384 |
| #14 | #11, limited to peer reviewed, scholarly journals | 540 |
| #15 | #11, limited to research methodology ((Empirical Study OR Quantitative Study OR Treatment Outcome/Clinical Trial OR Longitudinal Study OR Followup Study OR Retrospective Study OR Prospective Study OR Field Study) | 398 |
| #16 | #11 AND #12 AND #13 AND #14 AND #15 | 170 |
| PsycInfo- psychosocial and pharmacologic interventions | | |
| #17 | #8 OR #16 | 425 |

Table A-4. Embase search strategy (OvidSP interface, includes MEDLINE results), April 18, 2014

| Search terms | | Search results |
|--------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
| #1 | conduct disorder/ or behavior disorder/ or disruptive behavior/ or oppositional defiant disorder/ or aggression/ or intermittent explosive disorder/ or disruptive mood dysregulation disorder.mp | 80970 |
| #2 | exp antidepressant agent/ or exp neuroleptic agent/ or exp serotonin uptake inhibitor/ or exp central stimulant agent/ or exp adrenergic receptor blocking agent/ or exp alpha 2 adrenergic receptor stimulating agent/ | 811935 |
| #3 | #1 AND #2 | 13405 |
| #4 | #3 NOT (review or conference paper or conference abstract or editorial or letter or note or short survey).pt. or case report/ or practice guideline/ or systematic review/ or meta analysis/ | 5115 |
| #5 | #4 limit to (human and english language and exclude medline journals and yr="1994 - Current" and (infant <to one year> or child <unspecified age> or preschool child <1 to 6 years> or school child <7 to 12 years> or adolescent <13 to 17 years>)) | 70 |

Key: [mh] Medical Subject Heading; [la] language; [tiab] title/abstract word; [pt] publication type; [sh] subheading

Appendix B. Literature Screening Forms

Primary Literature Abstract Screening Form

| First Author, Year: _____ Endnote Reference ID #: _____ Abstractor Initials: ___ _ _ | | | | |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|----|------------------|
| Primary Inclusion/Exclusion Criteria | | | | |
| X-1 | 1. Reports original research (i.e., not commentaries, literature reviews, or systematic reviews) <i>NOTE: If the publication appears relevant to the topic, consider whether it should be retained for "review for references" (see check boxes below the form). These publications will be flagged for review, but not promoted for full text screening.</i> | Yes | No | Cannot Determine |
| X-2 | 2. Measures the relationship between a psychosocial or pharmacologic intervention and an outcome (i.e., not a descriptive study). | Yes | No | Cannot Determine |
| X-3 | 3. Population is children (youth). <i>NOTE: If the intervention targets parent/caregiver, the study must report at least one child outcome.</i> | Yes | No | Cannot Determine |
| X-4 | 4. Population has a disruptive behavior disorder which a) meets standardized disease classification or criteria for diagnosis of a disruptive behavior disorder (includes oppositional-defiant disorder and conduct disorder); OR b) is characterized by maladaptive behavior(s) assessed using a standardized behavior checklist, tool or measure. | Yes | No | Cannot Determine |
| X-5 | 5. Study is conducted in a healthcare setting. <i>NOTE: Do not include studies conducted exclusively in the juvenile justice system or school setting; do not include systems-level, universal, or preventive interventions; do not include studies conducted exclusively in hospitalized (i.e. inpatient) participants.</i> | Yes | No | Cannot Determine |
| X-6 | 6. The study includes an alternate treatment or intervention for comparison to measure effectiveness. | Yes | No | Cannot Determine |
| <p>Retain for:</p> <p><input type="checkbox"/> Background/Discussion <input type="checkbox"/> Review of references <input type="checkbox"/> Harms data <input type="checkbox"/> Other _____</p> <p>COMMENTS:</p> | | | | |

Primary Literature Full-Text Screening Form

| | | | |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|----|
| First Author, Year: _____ Endnote Reference ID #: _____ Abstractor Initials: _____ | | | |
| If response to item #1-6 is "No" the form is complete. Consider whether the reference should be retained for background, review of references, team review, harms, or other reason, and then submit the form to move to the next reference. | | | |
| X-1 | 1. Reports original research (i.e., not commentaries, literature reviews, or systematic reviews) <i>NOTE: If the publication appears relevant to the topic, consider whether it should be retained for "review for references" (see check boxes below the form). These publications will be flagged for review, but not promoted for full text screening.</i> | Yes | No |
| X-2 | 2. The study measures the relationship between a psychosocial or pharmacologic intervention and an outcome (i.e., not a descriptive study). If "Yes", check one: <ul style="list-style-type: none"> <input type="radio"/> Randomized controlled trial <input type="radio"/> Nonrandomized controlled trial <input type="radio"/> Prospective cohort with concurrent control group <input type="radio"/> Retrospective cohort (groups NOT defined by outcome) <input type="radio"/> Other _____ | Yes | No |
| X-3 | 3. The study population is children (youth). <i>NOTE: If the intervention targets parent/caregiver, the study must report at least one child outcome.</i> | Yes | No |
| X-4 | 4. The study population has a disruptive behavior disorder which: a) meets standardized disease classification or criteria for diagnosis of a disruptive behavior disorder (includes oppositional-defiant disorder and conduct disorder); OR b) is characterized by maladaptive behavior(s) assessed using a standardized behavior checklist, tool or measure. If "No", target population described as children with ADHD? <ul style="list-style-type: none"> <input type="radio"/> Yes <input type="radio"/> No | Yes | No |
| X-5 | 5. The study is conducted in a healthcare setting. <i>NOTE: Do not include studies conducted exclusively in the juvenile justice system or school setting; do not include systems-level, or universal interventions; do not include studies conducted exclusively in hospitalized (i.e. inpatient) participants.</i> | Yes | No |
| X-6 | 6. The study includes an alternate treatment or intervention for comparison to measure effectiveness. If "Yes", check one: <ul style="list-style-type: none"> <input type="radio"/> Compares two or more psychosocial interventions <input type="radio"/> Compares two or more pharmacologic interventions <input type="radio"/> Compares one or more psychosocial interventions with one or more pharmacologic interventions <input type="radio"/> Compares one or more combined psychosocial and pharmacologic interventions with another intervention <input type="radio"/> Compares one or more psychosocial interventions with an inactive control (e.g., waitlist) <input type="radio"/> Compares one or more psychosocial interventions with usual care <input type="radio"/> Compares one or more pharmacologic interventions with a control (e.g., placebo, untreated) <input type="radio"/> Compares one or more combined psychosocial and pharmacologic interventions with a control | Yes | No |
| X-7 | 7. The study reports an outcome of interest for the population (youth) with disruptive behavior. | Yes | No |
| X-8 | 8. Addresses Key Question (s) | Yes | No |
| | In children under 18 years of age treated for disruptive behaviors: ____ (KQ1) are any psychosocial interventions more effective for improving short-term and long-term psychosocial outcomes than no treatment or other psychosocial interventions? ____ (KQ2) are alpha-agonists, anticonvulsants, beta-blockers, central nervous system stimulants, first-generation antipsychotics, second-generation (atypical) antipsychotics, and selective serotonin reuptake inhibitors more effective for improving short-term and long-term psychosocial outcomes than placebo or other pharmacologic interventions? ____ (KQ3) what is the relative effectiveness of psychosocial interventions compared with the pharmacologic interventions listed in Key Question 2 for improving short-term and long-term psychosocial outcomes? ____ (KQ4) are combined psychosocial and pharmacologic interventions more effective for improving short-term and long-term psychosocial outcomes than individual interventions? ____ (KQ5) what are the harms of treatment associated with either psychosocial or pharmacologic interventions? Do interventions intended to address disruptive behaviors and identified in Key Questions 1-4 vary in | | |

| | | | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--|
| | <p>effectiveness based on:</p> <p>____ (KQ6a) patient characteristics, including gender, age, race/ethnic minority, family history of disruptive behavior disorders, family history of mental health disorders, history of trauma, and socioeconomic status?</p> <p>____ (KQ6b) characteristics of the disorder, including specific disruptive behavior or disruptive behavior disorder (e.g., oppositional defiant disorder, conduct disorder, aggression), concomitant psychopathology (e.g., attention deficit hyperactivity disorder or substance abuse), related personality traits and symptom clusters, presence of co-morbidities, age of onset, and duration?</p> <p>____ (KQ6c) treatment history of the patient?</p> <p>____ (KQ6d) characteristics of the treatment, including duration, delivery, timing, and dose?</p> | | |
| <p>Retain for:</p> <p><input type="checkbox"/> Background/Discussion <input type="checkbox"/> Review of references <input type="checkbox"/> Team Review <input type="checkbox"/> Harms <input type="checkbox"/> Other</p> <p>COMMENTS:</p> | | | |

Existing Reviews Relevance Screening Form

| | |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|
| First Author, Year: _____ Reference ID #: _____ Reviewer Initials: ___ ___ ___ | |
| PICOTS | Comments |
| Includes appropriate population ? | |
| Addresses target interventions ? | |
| Includes studies with comparators (treatment approach to no treatment, placebo, or comparative interventions/combinations of interventions)? | |
| Addresses target outcomes (including adverse effects/harms)? | |
| Includes studies in target setting ? | |
| Other | |
| Study types specified? Circle applicable: RCT, controlled trials, observational studies (retrospective/prospective cohort studies, case-control, case series), individual case studies, other: _____ | |
| When was the literature search conducted? Specify timeframe: _____ | |
| Recommendation: | |

Appendix C. Risk of Bias Assessment Forms and Summaries

Cochrane Risk of Bias Assessment Tool

| Ref ID: _____ Reviewer _____ | | | | | | |
|------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|-------------------|
| Domain | Description | High Risk of Bias | Low Risk of Bias | Unclear Risk of Bias | Reviewer Assessment | Reviewer Comments |
| <i>Selection bias</i> Random sequence generation | Described the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups | Selection bias (biased allocation to interventions) due to inadequate generation of a randomized sequence | Random sequence generation method should produce comparable groups | Not described in sufficient detail | High Low Unclear | |
| <i>Selection bias</i> Allocation concealment | Described the method used to conceal the allocation sequence in sufficient detail to determine whether intervention allocations could have been foreseen before or during enrollment | Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment | Intervention allocations likely could not have been foreseen in before or during enrollment | Not described in sufficient detail | High Low Unclear | |
| <i>Reporting bias</i> Selective reporting | Stated how the possibility of selective outcome reporting was examined by the authors and what was found | Reporting bias due to selective outcome reporting | Selective outcome reporting bias not detected | Insufficient information to permit judgment † | High Low Unclear | |
| <i>Other bias</i> Other sources of bias | Any important concerns about bias not addressed above* | Bias due to problems not covered elsewhere in the table | No other bias detected | There may be a risk of bias, but there is either insufficient information to assess whether an important risk of bias exists or insufficient rationale or evidence that an identified problem will introduce bias | High Low Unclear | |

* If particular questions/entries were pre-specified in the study's protocol, responses should be provided for each question/entry.

(continued) Ref ID: _____ Reviewer _____
 Assess each main or class of outcomes for each of the following. Indicate the specific outcome.
Outcome:

| Domain | Description | High Risk of Bias | Low Risk of Bias | Unclear Risk of Bias | Reviewer Assessment | Reviewer Comments |
|-------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|-------------------|
| <i>Performance bias</i> Blinding (participants and personnel) | Described all measures used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. Provided any information relating to whether the intended blinding was effective. | Performance bias due to knowledge of the allocated interventions by participants and personnel during the study. | Blinding was likely effective. | Not described in sufficient detail | High Low Unclear | |
| <i>Detection bias</i> Blinding (outcome assessment) | Described all measures used, if any, to blind outcome assessors from knowledge of which intervention a participant received. Provided any information relating to whether the intended blinding was effective. | Detection bias due to knowledge of the allocated interventions by outcome assessors. | Blinding was likely effective. | Not described in sufficient detail | High Low Unclear | |
| <i>Attrition bias</i> Incomplete outcome data | Described the completeness of outcome data for each main outcome, including attrition and exclusions from the analysis. Stated whether attrition and exclusions were reported, the numbers in each intervention group (compared with total randomized participants), reasons for attrition/exclusions where reported. | Attrition bias due to amount, nature or handling of incomplete outcome data. | Handling of incomplete outcome data was complete and unlikely to have produced bias | Insufficient reporting of attrition/exclusions to permit judgment (e.g., number randomized not stated, no reasons for missing data provided) | High Low Unclear | |

* If particular questions/entries were pre-specified in the study's protocol, responses should be provided for each question/entry.

Criteria for Judging Risk of Bias Using the Cochrane Risk of Bias Assessment Tool*

| Bias | Judgment | Criteria |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| RANDOM SEQUENCE GENERATION Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence. | 'Low risk' of bias. | <p>The investigators describe a random component in the sequence generation process such as:</p> <ul style="list-style-type: none"> • Referring to a random number table; • Using a computer random number generator; • Coin tossing; • Shuffling cards or envelopes; • Throwing dice; • Drawing of lots; • Minimization*. <p>*Minimization may be implemented without a random element, and this is considered to be equivalent to being random.</p> |
| | 'High risk' of bias. | <p>The investigators describe a non-random component in the sequence generation process. Usually, the description would involve some systematic, non-random approach, for example:</p> <ul style="list-style-type: none"> • Sequence generated by odd or even date of birth; • Sequence generated by some rule based on date (or day) of admission; • Sequence generated by some rule based on hospital or clinic record number. <p>Other non-random approaches happen much less frequently than the systematic approaches mentioned above and tend to be obvious. They usually involve judgement or some method of non-random categorization of participants, for example:</p> <ul style="list-style-type: none"> • Allocation by judgement of the clinician; • Allocation by preference of the participant; • Allocation based on the results of a laboratory test or a series of tests; • Allocation by availability of the intervention. |
| | 'Unclear risk' of bias. | Insufficient information about the sequence generation process to permit judgement of 'Low risk' or 'High risk'. |
| ALLOCATION CONCEALMENT Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment. | 'Low risk' of bias. | <p>Participants and investigators enrolling participants could not foresee assignment because one of the following, or an equivalent method, was used to conceal allocation:</p> <ul style="list-style-type: none"> • Central allocation (including telephone, web-based and pharmacy-controlled randomization); • Sequentially numbered drug containers of identical appearance; • Sequentially numbered, opaque, sealed envelopes. |
| | 'High risk' of bias. | <p>Participants or investigators enrolling participants could possibly foresee assignments and thus introduce selection bias, such as allocation based on:</p> <ul style="list-style-type: none"> • Using an open random allocation schedule (e.g. a list of random numbers); • Assignment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or nonopaque or not sequentially numbered); • Alternation or rotation; • Date of birth; • Case record number; • Any other explicitly unconcealed procedure. |
| | 'Unclear risk' of bias. | Insufficient information to permit judgement of 'Low risk' or 'High risk'. This is usually the case if the method of concealment is not described or not described in sufficient detail to allow a definite judgement – for example if the use of assignment envelopes is described, but it remains unclear whether envelopes were sequentially numbered, opaque and sealed. |

| Bias | Judgment | Criteria |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| SELECTIVE REPORTING Reporting bias due to selective outcome reporting. | 'Low risk' of bias. | Any of the following: <ul style="list-style-type: none"> The study protocol is available and all of the study's pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way; The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified (convincing text of this nature may be uncommon). |
| | 'High risk' of bias. | Any one of the following: <ul style="list-style-type: none"> Not all of the study's pre-specified primary outcomes have been reported; One or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not pre-specified; One or more reported primary outcomes were not pre-specified (unless clear justification for their reporting is provided, such as an unexpected adverse effect); One or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis; The study report fails to include results for a key outcome that would be expected to have been reported for such a study. |
| | 'Unclear risk' of bias. | Insufficient information to permit judgement of 'Low risk' or 'High risk'. It is likely that the majority of studies will fall into this category. |
| OTHER BIAS Bias due to problems not covered elsewhere in the table. | 'Low risk' of bias. | The study appears to be free of other sources of bias. |
| | 'High risk' of bias. | There is at least one important risk of bias. For example, the study: <ul style="list-style-type: none"> Had a potential source of bias related to the specific study design used; or Has been claimed to have been fraudulent; or Had some other problem. |
| | 'Unclear risk' of bias. | There may be a risk of bias, but there is either: <ul style="list-style-type: none"> Insufficient information to assess whether an important risk of bias exists; or Insufficient rationale or evidence that an identified problem will introduce bias. |
| BLINDING OF PARTICIPANTS AND PERSONNEL Performance bias due to knowledge of the allocated interventions by participants and personnel during the study. | 'Low risk' of bias. | Any one of the following: <ul style="list-style-type: none"> No blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influenced by lack of blinding; Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken. |
| | 'High risk' of bias. | Any one of the following: <ul style="list-style-type: none"> No blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding; Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken, and the outcome is likely to be influenced by lack of blinding. |
| | 'Unclear risk' of bias. | Any one of the following: <ul style="list-style-type: none"> Insufficient information to permit judgment of 'Low risk' or 'High risk'; The study did not address this outcome. |

| Bias | Judgment | Criteria |
|------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| BLINDING OF OUTCOME ASSESSMENT Detection bias due to knowledge of the allocated interventions by outcome assessors. | 'Low risk' of bias. | Any one of the following: <ul style="list-style-type: none"> No blinding of outcome assessment, but the review authors judge that the outcome measurement is not likely to be influenced by lack of blinding; Blinding of outcome assessment ensured, and unlikely that the blinding could have been broken. |
| | 'High risk' of bias. | Any one of the following: <ul style="list-style-type: none"> No blinding of outcome assessment, and the outcome measurement is likely to be influenced by lack of blinding; Blinding of outcome assessment, but likely that the blinding could have been broken and the outcome measurement is likely to be influenced by lack of blinding. |
| | 'Unclear risk' of bias. | Any one of the following: <ul style="list-style-type: none"> Insufficient information to permit judgment of 'Low risk' or 'High risk'; The study did not address this outcome. |
| INCOMPLETE OUTCOME DATA Attrition bias due to amount, nature, or handling of incomplete outcome data. | 'Low risk' of bias. | Any one of the following: <ul style="list-style-type: none"> No missing outcome data; Reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias); Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups; For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate; For continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size; Missing data have been imputed using appropriate methods. |
| | 'High risk' of bias. | Any one of the following: <ul style="list-style-type: none"> Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups; For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate; For continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size; 'As-treated' analysis done with substantial departure of the intervention received from that assigned at randomization; Potentially inappropriate application of simple imputation. |
| | 'Unclear risk' of bias. | Any one of the following: <ul style="list-style-type: none"> Insufficient reporting of attrition/exclusions to permit judgement of 'Low risk' or 'High risk' (e.g. number randomized not stated, no reasons for missing data provided); The study did not address this outcome. |
| * Adapted from the Cochrane Collaboration | | |

RTI Bank Risk of Bias Assessment Form

| | | | | |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|------------|-----------------|
| Ref ID: _____ Reviewer _____ | | | | |
| | | No | Yes | Comments |
| Questions to Assess the Risk of Bias | | | | |
| Q1 | Do the inclusion/exclusion criteria vary across the comparison groups of the study? | | | |
| Q2 | Does the strategy for recruiting participants into the study differ across groups? | | | |
| Q3 | Is the selection of the comparison group inappropriate, after taking into account feasibility and ethical considerations? | | | |
| Q4 | Was the outcome assessor not blinded to the intervention or exposure status of participants? | | | |
| Q5 | Were valid and reliable measures, implemented consistently across all study participants used to assess inclusion/exclusion criteria, intervention/exposure outcomes, participant health benefits and harms, and confounding? | | | |
| Q6 | Was the length of followup different across study groups? | | | |
| Q7 | In cases of high loss to followup (or differential loss to followup), was the impact assessed (e.g., through sensitivity analysis or other adjustment method)? | | | |
| Questions to Assess Confounding | | | | |
| Q8 | Any attempt to balance the allocation between the groups or match groups (e.g., through stratification, matching, propensity scores)? | | | |
| Q9 | Were the important confounding variables taken into account in the design and/or analysis (e.g., through matching, stratification, interaction terms, multivariate analysis, or other statistical adjustment such as instrumental variables)? | | | |
| Questions to Assess Precision | | | | |
| Q10 | Are the statistical methods used to assess the primary benefit outcomes inadequate? | | | |
| Q11 | Are the statistical methods used to assess the main harm or adverse event outcomes inadequate? | | | |
| <p><i>Based on cohort questions from: Viswanathan M, Berkman ND, Dryden DM, et al. Assessing Risk of Bias and Confounding in Observational Studies of Interventions or Exposures: Further Development of the RTI Item Bank [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Aug. Available from: http://www.ncbi.nlm.nih.gov/books/NBK154461/</i></p> | | | | |

Risk of Bias Assessment Form: Harms Reporting

| Reviewer: _____ Ref ID: _____ | | | |
|-----------------------------------------------------------------------------------------------------------|-----|----|----------|
| Question | Yes | No | Comments |
| Were the harms predefined using standardized or precise definitions? (McHarms) | | | |
| Are all pre-specified harms reported? (RTI case series) | | | |
| Did the author(s) use STANDARD scale(s) or checklist(s) for harms collection? (McHarms) | | | |
| Are the statistical methods used to assess the main harm or adverse event outcomes adequate? (RTI cohort) | | | |

Quality Assessment Form (AMSTAR): Systematic Reviews

| | |
|------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|
| 1. Was <i>a priori</i> design provided? | <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Can't answer <input type="checkbox"/> Not applicable |
| 2. Was there duplicate study selection and data extraction? | <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Can't answer <input type="checkbox"/> Not applicable |
| 3. Was a comprehensive literature search performed? | <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Can't answer <input type="checkbox"/> Not applicable |
| 4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? | <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Can't answer <input type="checkbox"/> Not applicable |
| 5. Was a list of studies (included and excluded) provided? | <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Can't answer <input type="checkbox"/> Not applicable |
| 6. Were the characteristics of the included studies provided? | <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Can't answer <input type="checkbox"/> Not applicable |
| 7. Was the scientific quality of the included studies assessed and documented? | <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Can't answer <input type="checkbox"/> Not applicable |
| 8. Was the scientific quality of the included studies used appropriately in formulating conclusions? | <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Can't answer <input type="checkbox"/> Not applicable |
| 9. Were the methods used to combine the findings of studies appropriate? | <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Can't answer <input type="checkbox"/> Not applicable |
| 10. Was the likelihood of publication bias assessed? | <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Can't answer <input type="checkbox"/> Not applicable |
| 11. Was the conflict of interest included? | <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Can't answer <input type="checkbox"/> Not applicable |

Adapted from: Shea BJ et al., BMC Medical Research Methodology 2007

Assessment of Overall Risk of Bias for Individual Studies

There are three categories for describing the overall risk of bias for assessed studies: low risk of bias; moderate risk of bias; and high risk of bias.

Cochrane Risk of Bias Assessment Tool

Use for risk of bias assessments for *randomized controlled trials (RCTs)*.

The tool includes seven items in six domains:

- Selection Bias (*2 items*)
- Reporting bias (*1 item*)
- Other bias (*1 item*)
- Performance bias (*1 item*)
- Detection bias (*1 item*)
- Attrition bias (*1 item*)

The overall risk of bias for an RCT is calculated from individual domain assessments:

- **Low:** “low” for all domains.
- **Moderate:** “unclear” for one or more domains and no known important limitation that could invalidate its results.
- **High:** “high” for one or more domains.

RTI Bank Risk of Bias Assessment Form

Use for risk of bias assessments for *cohort/non-randomized controlled studies*.

The form includes eleven items in three domains:

- Risk of Bias (*7 items*)
- Confounding (*2 items*)
- Precision (*2 items*)

The overall risk of bias for a cohort/non-randomized controlled study is calculated from individual domain assessments:

- **Low:** all “positive”
- **Moderate:** two or fewer “negative”
- **High:** more than two “negative”

Table C-1. Risk of bias assessment summary for KQ1 RCTs

| Citation | AgeCat | Random Sequence Generation | Allocation Conceal | Selective Reporting | Other Bias | Outcome(s) | Blinding (pts, personnel) | Blinding (outcome assess) | Incomplete Outcome Data | Low | High | Unclear | Overall Score |
|-----------------------------------------|--------|----------------------------|--------------------|---------------------|------------|---------------------------------------------------------------------------|---------------------------|---------------------------|-------------------------|-----|------|---------|---------------|
| Perrin et al., 2013 ¹ | PRE-K | L | U | L | U | ECBI | H | H | L | 3 | 2 | 2 | Moderate |
| Jones, et al., 2013 ² | PRE-K | U | U | L | L | ECBI problem, ECBI intensity | U | U | H | 2 | 1 | 4 | High |
| Somech et al., 2012 ³ | PRE-K | L | U | U | L | ECBI Intensity | U | U | L | 3 | 0 | 4 | Moderate |
| Cummings et al., 2008 ⁴ | PRE-K | L | L | U | H | CBCL,ECBI | H | H | H | 2 | 4 | 1 | High |
| Lavigne, et al., 2008 ⁵ | PRE-K | U | U | U | H | ECBI, CBCL | U | U | U | 0 | 1 | 6 | High |
| Hutchings et al., 2007 ⁶ | PRE-K | L | L | L | L | ECBI | H | L | L | 6 | 1 | 0 | Moderate |
| Markie-Dadds, et al., 2006 ⁷ | PRE-K | U | U | U | U | ECBI Intensity, ECBI Problem, PDR | U | U | L | 1 | 0 | 6 | Moderate |
| McGilloway, et al., 2012 ⁸ | PRE-K | L | L | U | H | ECBI | L | L | L | 5 | 1 | 1 | Low |
| Markie-Dadds, et al., 2006 ⁹ | PRE-K | L | U | U | U | ECBI Intensity, ECBI Problem, PDR | H | H | H | 1 | 3 | 3 | Moderate |
| Sanders et al., 2000 ¹⁰ | PRE-K | U | U | U | L | ECBI, PDR, PS, PSOC, ADAS, PPC, PASS | H | H | H | 1 | 3 | 3 | Moderate |
| Connell, et al., 1997 ¹¹ | PRE-K | L | U | U | U | ECBI (intensity), ECBI (problem), PDRC | H | U | L | 2 | 1 | 4 | High |
| Sanders, et al., 2012 ¹² | PRE-K | L | u | U | H | ECBI intensity, ECBI problem, SDQ | H | U | L | 2 | 2 | 3 | High |
| Jouriles, et al., 2001 ¹³ | PRE-K | U | U | U | H | CBCL, direct observation | U | U | U | 0 | 1 | 6 | High |
| Bagner, et al., 2010 ¹⁴ | PRE-K | L | U | U | L | CBCL (externalizing), CBCL (aggression), ECBI (intensity), ECBI (problem) | H | H | H | 2 | 3 | 2 | High |

| Citation | AgeCat | Random Sequence Generation | Allocation Conceal | Selective Reporting | Other Bias | Outcome(s) | Blinding (pts, personnel) | Blinding (outcome assess) | Incomplete Outcome Data | Low | High | Unclear | Overall Score |
|---------------------------------------------|--------|----------------------------|--------------------|---------------------|------------|------------------------------|---------------------------|---------------------------|-------------------------|-----|------|---------|---------------|
| McCabe, et al., 2009 ¹⁵ | PRE-K | L | U | U | L | ECBI, CBCL, ARSMA-II | L | L | L | 5 | 0 | 2 | Low |
| Schuhmann et al., 1998 ¹⁶ | PRE-K | L | L | U | L | DPICS | U | L | H | 4 | 1 | 2 | Moderate |
| Eyberg et al., 1995 ¹⁷ | PRE-K | U | U | U | L | ECBI intensity, ECBI problem | H | U | H | 1 | 2 | 4 | High |
| Nixon, et al., 2003 ¹⁸ | PRE-K | U | U | U | L | ECBI Intensity, DPICS | U | H | L | 2 | 1 | 4 | Moderate |
| Sells, et al., 2011 ¹⁹ | PRE-K | U | U | U | U | | H | H | L | 1 | 2 | 4 | Moderate |
| Sanders, et al., 2000 ²⁰ | PRE-K | U | U | U | U | | H | H | U | 0 | 2 | 5 | High |
| Havighurst, et al., 2013 ²¹ | PRE-K | L | L | U | L | | H | H | U | 3 | 2 | 2 | Moderate |
| Nixon, et al., 2001 ²² | PRE-K | U | U | U | U | | H | H | U | 0 | 2 | 5 | High |
| van Manen et al., 2004 ²³ | SCHOOL | U | L | U | U | CBCL, TOPS, TRA, SCRS, SCST | U | U | H | 1 | 1 | 5 | Moderate |
| Kjobli, et al., 2012 ²⁴ | SCHOOL | L | U | U | U | ECBI, CBCL | H | H | L | 2 | 2 | 3 | High |
| Axberg, et al., 2012 ²⁵ | SCHOOL | U | U | U | H | ECBI | H | H | L | 1 | 3 | 3 | High |
| McGrath, et al., 2011 ²⁶ | SCHOOL | L | L | L | L | K-SADS | U | L | L | 6 | 0 | 1 | Low |
| Kling, et al., 2010 ²⁷ | SCHOOL | U | U | U | L | PDR, ECB1, ECBIP | U | U | L | 2 | 0 | 5 | Moderate |
| Ogden et al., 2008 ²⁸ | SCHOOL | L | L | U | L | CBCL, SSRS, PDR | U | U | L | 4 | 0 | 3 | Moderate |
| Gardner, et al., 2006 ²⁹ | SCHOOL | L | L | U | U | ECBI | U | U | L | 3 | 0 | 4 | Moderate |
| Webster-Stratton et al., 1994 ³⁰ | SCHOOL | U | U | U | L | CBCL, ECBI, DPICS | U | U | U | 1 | 0 | 6 | Moderate |
| Hutchings, et al., 2002 ³¹ | SCHOOL | U | U | U | U | ECBI | U | U | L | 1 | 0 | 6 | Moderate |
| Scott et al., 2010 ³² | SCHOOL | L | L | L | U | PACS, ECBI | L | L | L | 6 | 0 | 1 | Low |

| Citation | AgeCat | Random Sequence Generation | Allocation Conceal | Selective Reporting | Other Bias | Outcome(s) | Blinding (pts, personnel) | Blinding (outcome assess) | Incomplete Outcome Data | Low | High | Unclear | Overall Score |
|---------------------------------------------|--------|----------------------------|--------------------|---------------------|------------|---------------------------------------------------|---------------------------|---------------------------|-------------------------|-----|------|---------|---------------|
| Larsson, et al., 2009 ³³ | SCHOOL | U | U | U | L | ECBI, CBCL, KSADS-PL | U | U | L | 2 | 0 | 5 | Moderate |
| van de Wiel et al., 2007 ³⁴ | SCHOOL | U | U | U | U | CBCL, CBCL,TRF | U | U | L | 1 | 0 | 6 | Moderate |
| Drugli, et al., 2006 ³⁵ | SCHOOL | U | U | U | H | ECBI, CBCL, KSANS | H | H | L | 1 | 3 | 3 | Moderate |
| Webster-Stratton et al., 2004 ³⁶ | SCHOOL | U | U | U | L | ECBI, CBCL | U | U | U | 1 | 0 | 6 | Moderate |
| Cabiya et al., 2008 ³⁷ | SCHOOL | U | U | U | H | BSBI, CDI | U | L | H | 1 | 2 | 4 | High |
| Webster-Stratton et al., 1997 ³⁸ | SCHOOL | U | U | U | L | CBCL,EBCI Intensity, PDR | U | U | L | 2 | 0 | 5 | Moderate |
| Boylan, et al., 2013 ³⁹ | SCHOOL | U | U | U | U | ChIPS, P-ChIPS, CDRS-R, MRS, MSI | U | L | L | 2 | 0 | 5 | Moderate |
| Augimeri et al., 2007 ⁴⁰ | SCHOOL | U | U | U | H | CBCL | U | U | L | 1 | 1 | 5 | Moderate |
| Kolko, et al., 2001 ⁴¹ | SCHOOL | L | U | U | L | FHS, CP w, fire, CFI, SUFA | U | U | L | 3 | 0 | 4 | Moderate |
| Kolko, et al., 2010 ⁴² | SCHOOL | L | U | U | L | PSC-17; SDQ | U | H | L | 3 | 1 | 3 | Moderate |
| Kolko, et al., 2009 ⁴³ | SCHOOL | L | U | U | L | KSADS, TRE, CBCL | U | U | L | 3 | 0 | 4 | Moderate |
| Greene, et al., 2004 ⁴⁴ | SCHOOL | U | U | U | U | PCRI, PSI.ODBRS, C6I, KSADS-E | U | U | L | 1 | 0 | 6 | Moderate |
| Jouriles, et al., 2009 ⁴⁵ | SCHOOL | L | H | U | L | CBCL-EXT, ECBI | H | H | U | 2 | 3 | 2 | High |
| Barrett, et al., 2000 ⁴⁶ | SCHOOL | U | U | U | U | | H | H | U | 0 | 2 | 5 | High |
| Brestan, et al., 1997 ⁴⁷ | SCHOOL | U | U | U | L | | H | H | L | 2 | 2 | 3 | Moderate |
| Rohde et al., 2004 ⁴⁸ | TEEN | L | L | H | H | Conduct Disorder, BDI-II, HDRS, CBCL, CGAS, SAS-R | L | L | U | 4 | 2 | 1 | High |
| Weiss et al., 2013 ⁴⁹ | TEEN | U | U | U | L | CBCL | U | U | L | 2 | 0 | 5 | Moderate |
| Butler, et al., 2011 ⁵⁰ | TEEN | L | L | U | L | arrest records | U | L | L | 5 | 0 | 2 | Low |

| Citation | AgeCat | Random Sequence Generation | Allocation Conceal | Selective Reporting | Other Bias | Outcome(s) | Blinding (pts, personnel) | Blinding (outcome assess) | Incomplete Outcome Data | Low | High | Unclear | Overall Score |
|----------------------------------------|--------|----------------------------|--------------------|---------------------|------------|-----------------------------------|---------------------------|---------------------------|-------------------------|-----|------|---------|---------------|
| Asscher et al., 2013 ⁵¹ | TEEN | L | U | L | U | CBCL - parents + YSR | U | H | L | 3 | 1 | 3 | High |
| Borduin et al., 1995 ⁵² | TEEN | L | U | U | U | symptom checklist, RPBX, FACES II | U | U | H | 1 | 1 | 5 | Moderate |
| Sundell et al., 2008 ⁵³ | TEEN | L | L | L | L | CBCL | U | U | L | 5 | 0 | 2 | Low |
| Shechtman, et al., 2006 ⁵⁴ | TEEN | U | U | U | U | CBCL, CCNES | U | U | L | 1 | 0 | 6 | Moderate |
| Santisteban et al., 2003 ⁵⁵ | TEEN | U | U | U | L | RBPC | U | U | H | 1 | 1 | 5 | High |
| Nickel, et al., 2006 ⁵⁶ | TEEN | L | L | L | L | ARBS, STAXI, SF-36 | L | L | L | 7 | 0 | 0 | Low |
| Nickel, et al., 2005 ⁵⁷ | TEEN | L | L | L | L | ARBS, STAXI | L | L | L | 7 | 0 | 0 | Low |
| Nickel, et al., 2006 ⁵⁸ | TEEN | L | L | U | U | Salivary, STAXI | U | L | L | 4 | 0 | 3 | Moderate |
| Azrin, et al., 2001 ⁵⁹ | TEEN | H | U | U | L | | H | L | H | 2 | 3 | 2 | High |

Table C-2. Risk of bias assessment summary for KQ1 cohort/nonrandomized controlled studies

| Author, Year | Inclusion/exclusion criteria across groups | Recruitment strategy across groups | Selection of the comparison group | Outcome assessor blinding | Valid & reliable measures across study participants | Length of followup different across groups | Assessment of impact of high loss to followup | Balancing allocation between groups/matching groups | Accounting for confounding factors | Adequacy of statistical methods to assess primary outcomes | Adequacy of statistical methods to assess harms or adverse events outcomes | Rating |
|----------------------------------------|--------------------------------------------|------------------------------------|-----------------------------------|---------------------------|-----------------------------------------------------|--------------------------------------------|-----------------------------------------------|-----------------------------------------------------|------------------------------------|------------------------------------------------------------|----------------------------------------------------------------------------|--------|
| van der Put et al., 2013 ⁶⁰ | + | + | - | - | - | - | NA | - | - | + | NA | Poor |
| Koegl et al., 2008 ⁶¹ | + | - | + | - | + | + | - | + | + | + | NA | Poor |
| Posthumus et al., 2012 ⁶² | + | + | + | - | + | + | NA | + | + | + | NA | Fair |
| Lipman et al., 2008 ⁶³ | + | + | + | - | + | + | - | - | + | + | NA | Poor |
| Costin et al., 2004 ⁶⁴ | + | + | + | - | + | + | - | - | - | - | NA | Poor |
| Coughlin 2009 ⁶⁵ | + | + | + | - | + | + | - | - | - | + | NA | Poor |
| Shapiro et al., 2012 ⁶⁶ | + | + | + | - | + | - | + | - | + | + | NA | Poor |
| Foster et al., 2007 ⁶⁷ | + | + | + | - | + | - | - | NA | - | + | NA | Poor |
| Masi et al., 2014 ⁶⁸ | + | + | + | - | + | + | NA | + | + | + | NA | Fair |

Table C-3. Risk of bias assessment summary for KQ2 RCTs

| Citation (Family) | Drug | Random Sequence Generation | Allocation Conceal | Selective Reporting | Other Bias | Outcome(s) | Blinding (pts/personnel) | Blinding (outcome assess) | Incomplete Outcome Data | Low | High | Unclear | Overall Score |
|-----------------------------------------|-----------------|----------------------------|--------------------|---------------------|------------|------------------------|--------------------------|---------------------------|-------------------------|-----|------|---------|---------------|
| Dittmann et al., 2011 ⁶⁹ | Atomoxetine | L | L | U | L | ECBI, SNAP | U | U | H | 3 | 1 | 3 | Moderate |
| Connor et al., 2010 ⁷⁰ | Guanfacine | L | L | L | L | CPRS | U | U | L | 5 | 0 | 2 | Moderate |
| Saxena et al., 2010 ⁷¹ | Divalproex | H | U | L | H | CGI; OAS | H | H | H | 1 | 5 | 1 | High |
| Blader et al., 2009 ⁷² | Divalproex | L | U | L | U | OAS | U | H | L | 3 | 2 | 2 | Moderate |
| Dell'Agnello et al., 2009 ⁷³ | Atomoxetine | U | U | L | L | SWAR-IV, CGI-S, CPRS-S | U | U | L | 3 | 0 | 4 | High |
| Connor et al., 2008 ⁷⁴ | Quetiapine | U | U | L | U | CGI-S; OAS; CPRS-CP | L | L | L | 4 | 1 | 2 | Moderate |
| Armenteros et al., 2007 ⁷⁵ | Risperidone | U | U | L | U | CAS; CGI | L | L | L | 4 | 1 | 2 | Moderate |
| Spencer et al., 2006 ⁷⁶ | Amphetamine | U | U | L | L | SNAP | U | U | L | 3 | 0 | 4 | High |
| Reyes et al., 2006 ⁷⁷ | Risperidone | U | U | L | U | CGI; CGAS | U | U | H | 1 | 2 | 4 | High |
| Steiner et al., 2003 ⁷⁸ | Divalproex | U | U | L | U | CGI | U | L | L | 3 | 1 | 3 | Moderate |
| Donovan et al., 2000 ⁷⁹ | Divalproex | U | U | L | L | OAS | L | L | L | 3 | 0 | 4 | Moderate |
| Findling et al., 2000 ⁸⁰ | Risperidone | L | L | L | U | CBCL; CPRS | L | L | L | 6 | 0 | 1 | Low |
| Klein et al., 1997 ⁸¹ | Methylphenidate | H | H | L | U | CTRS; IOWA | H | H | L | 2 | 4 | 1 | High |

Table C-4. Risk of bias assessment summary for KQ2 cohort/nonrandomized controlled studies

| Author, Year | Inclusion/exclusion criteria across groups | Recruitment strategy across groups | Selection of the comparison group | Outcome assessor blinding | Valid & reliable measures across study participants | Length of followup different across groups | Assessment of impact of high loss to followup | Balancing allocation between groups/matching groups | Accounting for confounding factors | Adequacy of statistical methods to assess primary outcomes | Adequacy of statistical methods to assess harms or adverse events outcomes | Rating |
|--------------------------------------|--------------------------------------------|------------------------------------|-----------------------------------|---------------------------|-----------------------------------------------------|--------------------------------------------|-----------------------------------------------|-----------------------------------------------------|------------------------------------|------------------------------------------------------------|----------------------------------------------------------------------------|--------|
| Bastiaens et al., 2009 ⁸² | + | + | + | - | + | + | + | - | - | - | - | Poor |

Table C-5. Risk of bias assessment summary for KQ5 studies reporting harms

| Author, Year | Were the harms predefined using standardized or precise definitions? | Were all pre-specified harms reported? | Did the author(s) use STANDARD scale(s) or checklist(s) for harms collection? | Were the statistical methods used to assess the main harm adequate? | Rating |
|--------------------------------------------------------------------------|-----------------------------------------------------------------------------|-----------------------------------------------|--------------------------------------------------------------------------------------|----------------------------------------------------------------------------|---------------|
| Dittmann et al., 2011 ⁶⁹ | + | Unsure | - | - | Poor |
| Dell'Agnello et al., 2009 ⁷³ | - | Unsure | - | + | Poor |
| Connor et al., 2010 ⁷⁰ | + | Unsure | Unsure | + | Poor |
| Bastiaens et al., 2009 ⁸² | - | Unsure | + | + | Poor |
| Connor et al., 2008 ⁷⁴ | + | + | + | + | Good |
| Spencer et al., 2006 ⁷⁶ and Connor et al., 2005 ⁸³ | - | Unsure | Unsure | + | Poor |
| Steiner et al., 2003 ⁷⁸ | - | Unsure | Unsure | - | Poor |
| Donovan et al., 2000 ⁷⁹ | - | Unsure | Unsure | + | Poor |
| Blader et al., 2009 ⁷² | + | Unsure | + | + | Fair |
| Ercan et al., 2003 ⁸⁴ | + | + | - | + | Fair |
| Armenteros et al., 2007 ⁷⁵ | + | + | + | + | Good |
| Penzner et al., 2009 ⁸⁵ | + | + | + | + | Good |
| Reyes et al., 2006 ⁷⁷ and Pandina et al., 2009 ⁸⁶ | - | Unsure | + | + | Fair |
| Findling et al., 2000 ⁸⁰ | + | + | + | + | Good |
| Klein et al., 1997 ⁸¹ | - | Unsure | - | - | Poor |

Table C-6. Summary of quality assessment for KQ5 existing reviews reporting harms

| Author, Year | A priori design | Duplicate study selection/ extraction | Comprehensive literature search | Status of publication as exclusion criterion | Included and excluded studies provided | Characteristics of included studies provided | Quality assessed | Quality used appropriately | Synthesis methods appropriate | Publication bias assessed | Conflict of interest stated | Rating |
|---------------------------------------|------------------------|----------------------------------------------|----------------------------------------|-----------------------------------------------------|-----------------------------------------------|-----------------------------------------------------|-------------------------|-----------------------------------|--------------------------------------|----------------------------------|------------------------------------|---------------|
| Loy et al., 2012 ⁸⁷ | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | NA | Yes | Good |
| Seida et al., 2012 ⁸⁸ | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Good |
| Pringsheim et al., 2011 ⁸⁹ | Yes | Yes | No | Yes | No | yes | Yes | Yes | Yes | No | Yes | Good |

References for Appendix C

1. Perrin EC, Sheldrick RC, McMenamy JM, et al. Improving Parenting Skills for Families of Young Children in Pediatric Settings: A Randomized Clinical Trial. *JAMA Pediatr.* 2013 Nov 4;PMID: 24190691
2. Jones DJ, Forehand R, Cuellar J, et al. Technology-Enhanced Program for Child Disruptive Behavior Disorders: Development and Pilot Randomized Control Trial. *J Clin Child Adolesc Psychol.* 2013 Aug 7;PMID: 23924046
3. Somech LY, Elizur Y. Promoting self-regulation and cooperation in pre-kindergarten children with conduct problems: a randomized controlled trial. *J Am Acad Child Adolesc Psychiatry.* 2012 Apr;51(4):412-22. PMID: 22449647
4. Cummings JG, Wittenberg JV. Supportive expressive therapy--Parent child version: An exploratory study. *Psychotherapy (Chic).* 2008 Jun;45(2):148-64. PMID: 22122414
5. Lavigne JV, Lebailly SA, Gouze KR, et al. Treating oppositional defiant disorder in primary care: a comparison of three models. *J Pediatr Psychol.* 2008 Jun;33(5):449-61. PMID: 17956932
6. Hutchings J, Gardner F, Bywater T, et al. Parenting intervention in Sure Start services for children at risk of developing conduct disorder: pragmatic randomised controlled trial. *BMJ.* 2007 Mar 31;334(7595):678. PMID: 17350966
7. Markie-Dadds C, Sanders MR. A Controlled Evaluation of an Enhanced Self-Directed Behavioural Family Intervention for Parents of Children With Conduct Problems in Rural and Remote Areas. *Behaviour Change.* 2006;23(1):55-72.
8. McGilloway S, Mhaille GN, Bywater T, et al. A parenting intervention for childhood behavioral problems: A randomized controlled trial in disadvantaged community-based settings. *J Consult Clin Psychol.* 2012;80(1):116-27. PMID: 22148879
9. Markie-Dadds C, Sanders MR. Self-Directed Triple P (Positive Parenting Program) for Mothers with Children at-Risk of Developing Conduct Problems. *Behav Cogn Psychother.* 2006;34(3):259-75.
10. Sanders MR, Markie-Dadds C, Tully LA, et al. The triple P-positive parenting program: a comparison of enhanced, standard, and self-directed behavioral family intervention for parents of children with early onset conduct problems. *J Consult Clin Psychol.* 2000 Aug;68(4):624-40. PMID: 10965638
11. Connell S, Sanders MR, Markie-Dadds C. Self-directed behavioral family intervention for parents of oppositional children in rural and remote areas. *Behav Modif.* 1997 Oct;21(4):379-408. PMID: 9337598
12. Sanders MR, Baker S, Turner KM. A randomized controlled trial evaluating the efficacy of Triple P Online with parents of children with early-onset conduct problems. *Behav Res Ther.* 2012 Nov;50(11):675-84. PMID: 22982082
13. Jouriles EN, McDonald R, Spiller L, et al. Reducing conduct problems among children of battered women. *J Consult Clin Psychol.* 2001 Oct;69(5):774-85. PMID: 11680554
14. Bagner DM, Sheinkopf SJ, Vohr BR, et al. Parenting intervention for externalizing behavior problems in children born premature: an initial examination. *J Dev Behav Pediatr.* 2010 Apr;31(3):209-16. PMID: 20375736
15. McCabe K, Yeh M. Parent-child interaction therapy for Mexican Americans: a randomized clinical trial. *J Clin Child Adolesc Psychol.* 2009 Sep;38(5):753-9. PMID: 20183659
16. Schuhmann EM, Foote RC, Eyberg SM, et al. Efficacy of parent-child interaction therapy: interim report of a randomized trial with short-term maintenance. *J Clin Child Psychol.* 1998 Mar;27(1):34-45. PMID: 9561935

17. Eyberg SM, Boggs SR, Algina J. Parent-child interaction therapy: a psychosocial model for the treatment of young children with conduct problem behavior and their families. *Psychopharmacol Bull.* 1995;31(1):83-91. PMID: 7675994
18. Nixon RD, Sweeney L, Erickson DB, et al. Parent-child interaction therapy: a comparison of standard and abbreviated treatments for oppositional defiant preschoolers. *J Consult Clin Psychol.* 2003 Apr;71(2):251-60. PMID: 12699020
19. Sells SP, Early KW, Smith TE. Reducing Adolescent Oppositional and Conduct Disorders: An Experimental Design Using the Parenting with Love and Limits® Model. *Professional Issues in Criminal Justice.* 2011;6(3)
20. Sanders MR, McFarland M. Treatment of depressed mothers with disruptive children: A controlled evaluation of cognitive behavioral family intervention. *Behav Ther.* 2000 //Winter;31(1):89-112.
21. Havighurst SS, Wilson KR, Harley AE, et al. "Tuning into Kids": reducing young children's behavior problems using an emotion coaching parenting program. *Child Psychiatry Hum Dev.* 2013 Apr;44(2):247-64. PMID: 22820873
22. Nixon RDV. Changes in hyperactivity and temperament in behaviourally disturbed preschoolers after parent-child interaction therapy (PCIT). *Behaviour Change.* 2001;18(3):168-76.
23. van Manen TG, Prins PJ, Emmelkamp PM. Reducing aggressive behavior in boys with a social cognitive group treatment: results of a randomized, controlled trial. *J Am Acad Child Adolesc Psychiatry.* 2004 Dec;43(12):1478-87. PMID: 15564817
24. Kjobli J, Ogden T. A randomized effectiveness trial of brief parent training in primary care settings. *Prev Sci.* 2012 Dec;13(6):616-26. PMID: 22956303
25. Axberg U, Broberg AG. Evaluation of "the incredible years" in Sweden: the transferability of an American parent-training program to Sweden. *Scand J Psychol.* 2012 Jun;53(3):224-32. PMID: 22621727
26. McGrath PJ, Lingley-Pottie P, Thurston C, et al. Telephone-based mental health interventions for child disruptive behavior or anxiety disorders: randomized trials and overall analysis. *J Am Acad Child Adolesc Psychiatry.* 2011 Nov;50(11):1162-72. PMID: 22024004
27. Kling A, Forster M, Sundell K, et al. A randomized controlled effectiveness trial of parent management training with varying degrees of therapist support. *Behav Ther.* 2010 Dec;41(4):530-42. PMID: 21035616
28. Ogden T, Hagen KA. Treatment effectiveness of Parent Management Training in Norway: a randomized controlled trial of children with conduct problems. *J Consult Clin Psychol.* 2008 Aug;76(4):607-21. PMID: 18665689
29. Gardner F, Burton J, Klimes I. Randomised controlled trial of a parenting intervention in the voluntary sector for reducing child conduct problems: outcomes and mechanisms of change. *J Child Psychol Psychiatry.* 2006 Nov;47(11):1123-32. PMID: 17076751
30. Webster-Stratton C. Advancing videotape parent training: a comparison study. *J Consult Clin Psychol.* 1994 Jun;62(3):583-93. PMID: 8063985
31. Hutchings J, Appleton P, Smith M, et al. Evaluation of two treatments for children with severe behaviour problems: Child behaviour and maternal mental health outcomes. *Behav Cogn Psychother.* 2002 Jul;30(3):279-95.
32. Scott S, Sylva K, Doolan M, et al. Randomised controlled trial of parent groups for child antisocial behaviour targeting multiple risk factors: the SPOKES project. *J Child Psychol Psychiatry.* 2010 Jan;51(1):48-57. PMID: 19732250

33. Larsson B, Fossum S, Clifford G, et al. Treatment of oppositional defiant and conduct problems in young Norwegian children : results of a randomized controlled trial. *Eur Child Adolesc Psychiatry*. 2009 Jan;18(1):42-52. PMID: 18563473
34. van de Wiel NM, Matthys W, Cohen-Kettenis PT, et al. The effectiveness of an experimental treatment when compared to care as usual depends on the type of care as usual. *Behav Modif*. 2007 May;31(3):298-312. PMID: 17438344
35. Drugli MB, Larsson B. Children aged 4-8 years treated with parent training and child therapy because of conduct problems: generalisation effects to day-care and school settings. *Eur Child Adolesc Psychiatry*. 2006 Oct;15(7):392-9. PMID: 16614786
36. Webster-Stratton C, Reid MJ, Hammond M. Treating children with early-onset conduct problems: intervention outcomes for parent, child, and teacher training. *J Clin Child Adolesc Psychol*. 2004 Mar;33(1):105-24. PMID: 15028546
37. Cabiya JJ, Padilla-Cotto L, González K, et al. Effectiveness of a cognitive-behavioral intervention for Puerto Rican children. *Revista Interamericana de Psicología*. 2008;42(2):195-202.
38. Webster-Stratton C, Hammond M. Treating children with early-onset conduct problems: a comparison of child and parent training interventions. *J Consult Clin Psychol*. 1997 Feb;65(1):93-109. PMID: 9103739
39. Boylan K, Macpherson HA, Fristad MA. Examination of disruptive behavior outcomes and moderation in a randomized psychotherapy trial for mood disorders. *J Am Acad Child Adolesc Psychiatry*. 2013 Jul;52(7):699-708. PMID: 23800483
40. Augimeri LK, Farrington DP, Koegl CJ, et al. The SNAPTM Under 12 Outreach Project: Effects of a community based program for children with conduct problems. *J Child Fam Stud*. 2007;16(6):799-807.
41. Kolko DJ. Efficacy of cognitive-behavioral treatment and fire safety education for children who set fires: initial and follow-up outcomes. *J Child Psychol Psychiatry*. 2001 Mar;42(3):359-69. PMID: 11321205
42. Kolko DJ, Campo JV, Kelleher K, et al. Improving access to care and clinical outcome for pediatric behavioral problems: a randomized trial of a nurse-administered intervention in primary care. *J Dev Behav Pediatr*. 2010 Jun;31(5):393-404. PMID: 20495474
43. Kolko DJ, Dorn LD, Bukstein OG, et al. Community vs. clinic-based modular treatment of children with early-onset ODD or CD: a clinical trial with 3-year follow-up. *J Abnorm Child Psychol*. 2009 Jul;37(5):591-609. PMID: 19221871
44. Greene RW, Ablon JS, Goring JC, et al. Effectiveness of collaborative problem solving in affectively dysregulated children with oppositional-defiant disorder: initial findings. *J Consult Clin Psychol*. 2004 Dec;72(6):1157-64. PMID: 15612861
45. Jouriles EN, McDonald R, Rosenfield D, et al. Reducing conduct problems among children exposed to intimate partner violence: a randomized clinical trial examining effects of Project Support. *J Consult Clin Psychol*. 2009 Aug;77(4):705-17. PMID: 19634963
46. Barrett P, Turner C, Rombouts S, et al. Reciprocal skills training in the treatment of externalising behaviour disorders in childhood: A preliminary investigation. *Behaviour Change*. 2000;17(4):221-34.
47. Brestan EV, Eyberg SM, Boggs SR, et al. Parent-child interaction therapy: Parents' perceptions of untreated siblings. *Child Fam Behav Ther*. 1997;19(3):13-28.
48. Rohde P, Clarke GN, Mace DE, et al. An efficacy/effectiveness study of cognitive-behavioral treatment for adolescents with comorbid major depression and conduct disorder. *J Am Acad Child Adolesc Psychiatry*. 2004 Jun;43(6):660-8. PMID: 15167082

49. Weiss B, Han S, Harris V, et al. An Independent Randomized Clinical Trial of Multisystemic Therapy With Non-Court-Referred Adolescents With Serious Conduct Problems. *J Consult Clin Psychol*. 2013 Aug 12;PMID: 23937347
50. Butler S, Baruch G, Hickey N, et al. A randomized controlled trial of multisystemic therapy and a statutory therapeutic intervention for young offenders. *J Am Acad Child Adolesc Psychiatry*. 2011 Dec;50(12):1220-35 e2. PMID: 22115143
51. Asscher JJ, Deković M, Manders WA, et al. A randomized controlled trial of the effectiveness of multisystemic therapy in the Netherlands: Post-treatment changes and moderator effects. *J Exp Criminol*. 2013;9(2):169-87.
52. Borduin CM, Mann BJ, Cone LT, et al. Multisystemic treatment of serious juvenile offenders: long-term prevention of criminality and violence. *J Consult Clin Psychol*. 1995 Aug;63(4):569-78. PMID: 7673534
53. Sundell K, Hansson K, Lofholm CA, et al. The transportability of multisystemic therapy to Sweden: short-term results from a randomized trial of conduct-disordered youths. *J Fam Psychol*. 2008 Aug;22(4):550-60. PMID: 18729669
54. Shechtman Z, Birani-Nasaraladin D. Treating mothers of aggressive children: a research study. *Int J Group Psychother*. 2006 Jan;56(1):93-112. PMID: 16555426
55. Santisteban DA, Coatsworth JD, Perez-Vidal A, et al. Efficacy of brief strategic family therapy in modifying Hispanic adolescent behavior problems and substance use. *J Fam Psychol*. 2003 Mar;17(1):121-33. PMID: 12666468
56. Nickel M, Luley J, Krawczyk J, et al. Bullying girls - changes after brief strategic family therapy: a randomized, prospective, controlled trial with one-year follow-up. *Psychother Psychosom*. 2006;75(1):47-55. PMID: 16361874
57. Nickel MK, Krawczyk J, Nickel C, et al. Anger, interpersonal relationships, and health-related quality of life in bullying boys who are treated with outpatient family therapy: a randomized, prospective, controlled trial with 1 year of follow-up. *Pediatrics*. 2005 Aug;116(2):e247-54. PMID: 16061577
58. Nickel MK, Muehlbacher M, Kaplan P, et al. Influence of family therapy on bullying behaviour, cortisol secretion, anger, and quality of life in bullying male adolescents: A randomized, prospective, controlled study. *Can J Psychiatry*. 2006 May;51(6):355-62. PMID: 16786816
59. Azrin NH, Donohue B, Teichner GA, et al. A controlled evaluation and description of individual-cognitive problem solving and family-behavior therapies in dually-diagnosed conduct-disordered and substance-dependent youth. *J Child Adolesc Subst Abuse*. 2001;11(1):1-43.
60. van der Put CE, Asscher JJ, Stams GJ, et al. Recidivism after treatment in a forensic youth-psychiatric setting: the effect of treatment characteristics. *Int J Offender Ther Comp Criminol*. 2013 Sep;57(9):1120-39. PMID: 22811475
61. Koegl CJ, Farrington DP, Augimeri LK, et al. Evaluation of a targeted cognitive-behavioral program for children with conduct problems--the SNAP Under 12 Outreach Project: service intensity, age and gender effects on short- and long-term outcomes. *Clin Child Psychol Psychiatry*. 2008 Jul;13(3):419-34. PMID: 18783124
62. Posthumus JA, Raaijmakers MA, Maassen GH, et al. Sustained effects of incredible years as a preventive intervention in preschool children with conduct problems. *J Abnorm Child Psychol*. 2012 May;40(4):487-500. PMID: 22006348

63. Lipman EL, Kenny M, Sniderman C, et al. Evaluation of a community-based program for young boys at-risk of antisocial behaviour: results and issues. *J Can Acad Child Adolesc Psychiatry*. 2008;17(1):12-9. PMID: 18392161
64. Costin J, Lichte C, Hill-Smith A, et al. Parent group treatments for children with Oppositional Defiant Disorder. *AeJAMH (Australian e-Journal for the Advancement of Mental Health)*. 2004;3(1)
65. Coughlin M, Sharry J, Fitzpatrick C, et al. A controlled clinical evaluation of the parents plus children's programme: a video-based programme for parents of children aged 6 to 11 with behavioural and developmental problems. *Clin Child Psychol Psychiatry*. 2009 Oct;14(4):541-58. PMID: 19759073
66. Shapiro JP, Youngstrom JK, Youngstrom EA, et al. Transporting a manualized treatment for children's disruptive behavior to a community clinic. *Journal of Contemporary Psychotherapy*. 2012;42(4):215-25.
67. Foster EM, Olchowski AE, Webster-Stratton CH. Is stacking intervention components cost-effective? An analysis of the Incredible Years program. *J Am Acad Child Adolesc Psychiatry*. 2007 Nov;46(11):1414-24. PMID: 18049291
68. Masi G, Milone A, Paciello M, et al. Efficacy of a multimodal treatment for disruptive behavior disorders in children and adolescents: focus on internalizing problems. *Psychiatry Res*. 2014 Nov 30;219(3):617-24. PMID: 25060833
69. Dittmann RW, Schacht A, Helsberg K, et al. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany. *J Child Adolesc Psychopharmacol*. 2011 Apr;21(2):97-110. PMID: 21488751
70. Connor DF, Findling RL, Kollins SH, et al. Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial. *CNS Drugs*. 2010 Sep;24(9):755-68. PMID: 20806988
71. Saxena K, Mora L, Torres E, et al. Divalproex sodium-ER in outpatients with disruptive behavior disorders: a three month open label study. *Child Psychiatry Hum Dev*. 2010 Jun;41(3):274-84. PMID: 20043204
72. Blader JC, Schooler NR, Jensen PS, et al. Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy. *Am J Psychiatry*. 2009 Dec;166(12):1392-401. PMID: 19884222
73. Dell'Agnello G, Maschietto D, Bravaccio C, et al. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study. *Eur Neuropsychopharmacol*. 2009 Nov;19(11):822-34. PMID: 19716683
74. Connor DF, McLaughlin TJ, Jeffers-Terry M. Randomized controlled pilot study of quetiapine in the treatment of adolescent conduct disorder. *J Child Adolesc Psychopharmacol*. 2008 Apr;18(2):140-56. PMID: 18439112
75. Armenteros JL, Lewis JE, Davalos M. Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: a placebo-controlled pilot study. *J Am Acad Child Adolesc Psychiatry*. 2007 May;46(5):558-65. PMID: 17450046
76. Spencer TJ, Abikoff HB, Connor DF, et al. Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter,

- randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study. *Clin Ther*. 2006 Mar;28(3):402-18. PMID: 16750455
77. Reyes M, Buitelaar J, Toren P, et al. A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. *Am J Psychiatry*. 2006 Mar;163(3):402-10. PMID: 16513860
78. Steiner H, Petersen ML, Saxena K, et al. Divalproex sodium for the treatment of conduct disorder: a randomized controlled clinical trial. *J Clin Psychiatry*. 2003 Oct;64(10):1183-91. PMID: 14658966
79. Donovan SJ, Stewart JW, Nunes EV, et al. Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled crossover design. *Am J Psychiatry*. 2000 May;157(5):818-20. PMID: 10784478
80. Findling RL, McNamara NK, Branicky LA, et al. A double-blind pilot study of risperidone in the treatment of conduct disorder. *J Am Acad Child Adolesc Psychiatry*. 2000 Apr;39(4):509-16. PMID: 10761354
81. Klein RG, Abikoff H, Klass E, et al. Clinical efficacy of methylphenidate in conduct disorder with and without attention deficit hyperactivity disorder. *Arch Gen Psychiatry*. 1997 Dec;54(12):1073-80. PMID: 9400342
82. Bastiaens L. A non-randomized, open study with aripiprazole and ziprasidone for the treatment of aggressive behavior in youth in a community clinic. *Community Ment Health J*. 2009 Feb;45(1):73-7. PMID: 18597173
83. Connor DF, Spencer TJ. Short-term cardiovascular effects of mixed amphetamine salts extended release in children and adolescents with oppositional defiant disorder. *CNS Spectr*. 2005 Oct;10(10 Suppl 15):31-8. PMID: 17151574
84. Ercan ES, Kutlu A, Cikoglu S, et al. Risperidone in children and adolescents with conduct disorder: A single-center, open-label study. *Current Therapeutic Research - Clinical and Experimental*. 2003 01 Jan;64(1):55-64. PMID: 24944356
85. Penzner JB, Dudas M, Saito E, et al. Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality. *J Child Adolesc Psychopharmacol*. 2009 Oct;19(5):563-73. PMID: 19877981
86. Pandina GJ, Zhu Y, Cornblatt B. Cognitive function with long-term risperidone in children and adolescents with disruptive behavior disorder. *J Child Adolesc Psychopharmacol*. 2009 Dec;19(6):749-56. PMID: 20035593
87. Loy JH, Merry SN, Hetrick SE, et al. Atypical antipsychotics for disruptive behaviour disorders in children and youths. *Cochrane Database Syst Rev*. 2012;9:CD008559. PMID: 22972123
88. Seida JC, Schouten JR, Mousavi SS, et al. First- and Second-Generation Antipsychotics for Children and Young Adults. Comparative Effectiveness Review No. 39. AHRQ Publication No.: 11(12)-EHC077-EF. Rockville, MD: Agency for Healthcare Research and Quality; Feb 2012. <http://effectivehealthcare.ahrq.gov/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productID=835>
89. Pringsheim T, Lam D, Ching H, et al. Metabolic and neurological complications of second-generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials. *Drug Saf*. 2011 Aug 1;34(8):651-68. PMID: 21751826

Appendix D. Meta-Analytic Methods

We developed a meta-analysis to address Key Question 1, which concerns the comparative effectiveness of psychosocial interventions for improving psychosocial outcomes for children treated for disruptive behaviors. We employed a Bayesian multivariate, mixed treatment (network) meta-analytic methods¹⁻³ to use both direct and indirect evidence for comparing a large suite of treatments.

Of the 16 instruments used to measure treatment outcomes, we included studies that employed one or more of the four most prevalent instruments: 1) Eyberg Child Behavior Inventory (ECBI), Intensity Subscale; 2) ECBI, Problem Scale; 3) Child Behavior Checklist (CBCL), Externalizing (T-score); 4) CBCL, Externalizing (raw score). Studies were included in the meta-analysis if they reported baseline and end-of-treatment (EOT) means and standard deviations from one of the four metrics listed above. In total, 28 studies were used to fit the model. The baseline was subtracted from the EOT mean and used as the response measure.

Equation 1. Response measure equals end of treatment mean minus the baseline mean

$$d_i = y_i^{(eot)} - y_i^{(bl)}$$

The response expected values m were modeled jointly as a multivariate normal likelihood, with any unmeasured outcomes treated as missing data; this allowed for the covariance among measures to be accounted for and estimated.

Equation 2. Expected value response modeled jointly as multivariate normal distribution

$$\begin{pmatrix} m_1 \\ m_2 \\ m_3 \\ m_4 \end{pmatrix}_i \sim \text{MVN}(\mu, \Sigma)$$

To accommodate the large suite of interventions employed by the constituent studies, we classified each intervention according to the treatment components that comprised them. Specifically, the treatment arms of each study were classified as one of the following types: 1) child-only treatment; 2) parent-only treatment; or 3) multicomponent treatment. Thus, a given treatment arm was specified by a vector of indicator variables.

Equation 3. Treatment arm, X , specified by a vector of indicator variables, child-only, parent-only, and multicomponent

$$X_i = \begin{bmatrix} x_c \\ x_p \\ x_f \end{bmatrix}_i$$

Those not identified by any of these three classes were considered either control or treatment-as-usual arms, encoded by a zero vector. Recognizing that these treatment categories are broad,

encompassing a range of specific interventions, each component was modeled as a random effect.

Equation 4. Child-only treatment category modeled as a Gaussian random effect

$$\beta_J^{(c)} \sim N(\mu_\beta^{(c)}, \tau_\beta^{(c)})$$

Equation 5. Parent-only treatment category modeled as a Gaussian random effect

$$\beta_J^{(p)} \sim N(\mu_\beta^{(p)}, \tau_\beta^{(p)})$$

Equation 6. Multicomponent treatment category modeled as a Gaussian random effect

$$\beta_J^{(f)} \sim N(\mu_\beta^{(f)}, \tau_\beta^{(f)})$$

This allowed for variation in treatment effect within each class, due to factors not explicitly modeled here. All measurement instruments shared the same study arm treatment effect in our model, but the effect was scaled by the standard deviation of the outcome variable.

The age of subjects in each study arm was included in the model as a categorical covariate, broadly grouped into pre-kindergarten, school age, or teenage categories. The school age child was used as the baseline value because it was the most prevalent among studies. The age covariate was combined additively with the intervention component effects and control/treatment-as-usual means to model the observed treatment differences relative to baseline. Though we considered age-by-treatment interactions, there was not enough balance among the age and treatment combinations to include them in the final model. We also considered including the study age distribution as a covariate, but this was ultimately left out of the final model based on poor deviance information criterion (DIC) scores.

Outcome means, treatment effects, and the age covariate were combined to calculate expected response (treatment difference) in an additive linear model.

Equation 7. Expected responses calculated from additive linear model of outcome mean, treatment effect, and age covariate

$$\theta_i = m_{j(i)k} + X_i\beta + \alpha x_{age}$$

The likelihood of the observed differences was specified as a Gaussian distribution, with the observed standard error of the treatment effect (the sum of the baseline and EOT standard deviations) as the standard deviation of the estimates.

Equation 8. Likelihood of observed differences, specified as a Gaussian distribution, and standard deviation of estimate derived from the standard error of the treatment effect

$$d_i \sim N(\theta_i, \sigma^2)$$

All unknown parameters were given weakly-informative prior distributions and estimated using Markov chain Monte Carlo⁴ methods via the PyMC 2.3 software package.⁵ The model was run for 200,000 iterations, with the first 150,000 samples conservatively discarded as burn-in, leaving 50,000 for inference.

References for Appendix D

1. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. *Stat Med.* 2004 Oct 30;23(20):3105-24. PMID: 15449338
2. Lumley T. Network meta-analysis for indirect treatment comparisons. *Stat Med.* 2002 Aug 30;21(16):2313-24. PMID: 12210616
3. Wei Y, Higgins JP. Bayesian multivariate meta-analysis with multiple outcomes. *Stat Med.* 2013 Jul 30;32(17):2911-34. PMID: 23386217
4. Brooks S, Gelman A, Jones G, et al. *Handbook of Markov Chain Monte Carlo.* CRC Press; 2011.
5. Patil A, Huard D, Fonnesbeck CJ. PyMC: Bayesian Stochastic Modelling in Python. *J Stat Softw.* 2010 Jul;35(4):1-81. PMID: 21603108

Appendix E. Outcome Measures Used in the Meta-Analysis of Intervention Effects

The Bayesian multivariate, mixed treatment (network) meta-analysis used data from a subset of RCTs identified as addressing KQ1 that measured parent-reported child disruptive behavior using one of the following outcome measures: 1) ECBI Intensity subscale; 2) ECBI Problem subscale; 3) CBCL externalizing subscale reported as a T-score. These three measures were the most prevalent in the literature.

The Eyberg Child Behavior Inventory (ECBI)^{1,2} is an inventory used in the assessment of disruptive behaviors in children ages 2 through 16 that occur in the home and in school. The ECBI is completed by parents and assesses behaviors on two scales: an Intensity Scale, which indicates how often the behaviors occur, and a Problem Scale, which identifies the specific behaviors that are cause problems for the parent. The Intensity Scale uses a frequency of occurrence rating: from *Never* (1) to *Always* (7). The sum of the Intensity Scale item ratings ranges from 36 to 252. The Problem Scale consists of a "Yes" or "No" problem identification rating for each item. The count of the "Yes" responses yields a problem score with a range from 0 to 36. The clinical cutoffs are 127 and 11 on the Intensity and Problem scales, respectively.

The Child Behavior Checklist (CBCL)³ is part of the Achenbach System of Empirically Based Assessments (ASEBA). The target population for the CBCL is children between the ages of 6 and 18. The pre-2001 version was intended for children ages 4 to 18 years. A version of the CBCL is also available for children ages 1 ½ to 5 years of age. The CBCL obtains reports from parents, other close relatives, and/or guardians regarding children's competencies and behavioral/emotional problems. Parents provide information for 20 competence items covering their child's activities, social relations, and school performance. The CBCL/6-18 has 118 items that describe specific behavioral and emotional problems, plus two open-ended items for reporting additional problems. Parents rate their child for how true each item is now or within the past 6 months using the following scale: 0 = not true (as far as you know); 1 = somewhat or sometimes true; 2 = very true or often true. Responses to items are aggregated to generate a total score, externalizing subscale score, internalizing subscale score, empirically based syndrome scales, and/or DSM-oriented scales.

References for Appendix E

1. Eyberg SM, Sutter J, Pincus D. Eyberg Child Behavior Inventory and Sutter-Eyberg Student Behavior Inventory-Revised. Psychological Assessment Resources, Inc., 16204 N. Florida Avenue, Lutz, FL 33549-8119; Telephone: 800-331-8378; FAX: 800-727-9329; E-mail: custsupp@parinc.com; Web: www.parinc.com.
2. Eyberg S. Parent and teacher behavior inventories for the assessment of conduct problem behaviors in children. *Innovations in clinical practice: A source book*. 1992;11:261-70.
3. Achenbach TM. Child Behavior Checklist. ASEBA Research Center for Children, Youth, and Families, 1 South Prospect Street, Burlington, VT 05401-3456; Telephone: 802-264-6432; FAX: 802-264-6433; E-mail: mail@ASEBA.org; Web: www.ASEBA.org.

Appendix F. Summary of Existing Systematic Reviews

Table F-1. Existing reviews of psychosocial interventions for DBD

| Author, Year | Focus Area | Inclusion Criteria | Outcome(s) | # Studies Included | Key Findings |
|--------------------------------------------|-------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Dretzke, J., et al. (2009) ¹ | Group based parent training programs | <ul style="list-style-type: none"> • Children with a conduct problems • Aged younger than 18 years | <ul style="list-style-type: none"> • Child behavior using a standardized measure | 57 RCTs | <ul style="list-style-type: none"> • Parent and independent reports were significantly better for intervention groups • Insufficient evidence for relative effectiveness of different approaches to delivering parenting programs. |
| Littell, J. H., et al. (2005) ² | Multisystemic Therapy (MST) | <ul style="list-style-type: none"> • Literature from 1985 to January 2003 • Children with social, emotional, and/or behavioral problems • Aged 10 to 17 years | <ul style="list-style-type: none"> • Crime and delinquency • Child behavior and psychosocial outcomes | 8 studies | <ul style="list-style-type: none"> • ITT analysis found no significant differences between MST and usual services in arrests or convictions • Inconclusive evidence of the effectiveness of MST compared with other interventions with youth |
| Comer, J.S., et al. (2013) ³ | Psychosocial treatment | <ul style="list-style-type: none"> • RCTs • Children with DBD • Aged younger than 8 years at baseline | <ul style="list-style-type: none"> • Pooled analyses • General externalizing symptoms • Overall disruptive behavior symptoms | 36 controlled trials 3,042 children | <ul style="list-style-type: none"> • Largest effect sizes associated with behavioral treatment, older and male youth. • Effects largest for general externalizing problems and weakest for impulsivity and hyperactivity. |
| McCart, M. R., et al. (2006) ⁴ | Behavioral parent-training (BPT) and cognitive-behavioral therapy (CBT) | <ul style="list-style-type: none"> • Youth with antisocial behavior problems | <ul style="list-style-type: none"> • Youth demographic variables were examined as potential moderators of the effectiveness | 76 studies Of these, 71 were included in analyses: 30 BPT studies and 41 CBT studies | <ul style="list-style-type: none"> • Child age moderated outcome • BPT had a stronger effect for preschool and school-aged youth and CBT had a stronger effect for adolescents |
| Dretzke, J., et al. (2005) ⁵ | Parent training programs | <ul style="list-style-type: none"> • Children with conduct disorder • Aged younger than 18 years | <ul style="list-style-type: none"> • Clinical effectiveness • Cost-effectiveness | 37 RCTs | <ul style="list-style-type: none"> • Six included studies were assessed as good or adequate quality • Many (n=31) of the studies that met the review inclusion and exclusion criteria were assessed as being of poor methodological quality. |
| Fossum, S., et al. | Psychotherapy | <ul style="list-style-type: none"> • 1987-2008 | <ul style="list-style-type: none"> • Aggressive behaviors | 65 studies (4,971) | <ul style="list-style-type: none"> • Effect sizes were larger in |

| Author, Year | Focus Area | Inclusion Criteria | Outcome(s) | # Studies Included | Key Findings |
|---------------------------------------------------------------------------------|-----------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (2008) ⁶ | | • | | patients) ; Of these 33 studies compared a psychosocial intervention with an untreated comparison group | studies of behavioral interventions compared to studies of family therapeutic interventions. |
| Ozabaci, N. (2011) ⁷ | Cognitive behavioural therapy (CBT) | <ul style="list-style-type: none"> • Children and adolescents demonstrating high levels of violence • 1997-2009 | • Aggressive behavior | 6 studies | • CBT reduced violence |
| Eyberg, S. M., et al. (2008) ⁸ update of Brestan and Eyberg, 1998 | Psychosocial treatments | <ul style="list-style-type: none"> • Literature from 1996 to 2007 • Child and adolescent disruptive behavior, including oppositional defiant disorder and conduct disorder | • Child and adolescent disruptive behavior | 16 EBTs identified (up from 12 in the earlier report) | • Studies were evaluated using criteria for EBTs developed by the task force on promotion and dissemination of psychological procedures |
| Bradley, M. C. and D. Mandell (2005) ⁹ | Interventions for ODD | • Children diagnosed with ODD | • Outcomes in 6 domains | 7 studies | <ul style="list-style-type: none"> • Greatest effects on child behavior when interventions targeted parents • Smaller effects if only children were targeted |
| Johnson, M.H., et al., (2013) ¹⁰ | Behavioral interventions implemented in the community | • Children or adolescents with problem behaviors or at elevated risk | <ul style="list-style-type: none"> • Changes in externalizing behavior • Inattention symptoms • Social and organization skills | 12 RCTs (4 family-centered behavioral intervention studies; 3 school-based behavioral intervention studies; and 5 integrated behavioral intervention studies) | • Rated level of evidence as high for behavioral management |
| Michelson, D., et al. (2013) ¹¹ | Parent management training (PMT) including IY and Triple P and others | <ul style="list-style-type: none"> • RCTs • Studies of children consistent with guidelines on recommended target population for PMT | <ul style="list-style-type: none"> • Disruptive behavior problems (using a standardized outcome measure) • Child disruptive behavior across different settings | 28 RCTs 2239 participants | <ul style="list-style-type: none"> • Significant overall advantage for PMT compared with waitlist control conditions. • No significant differences in effect size estimates according to setting • Six studies assessed as low or moderate risk of bias |
| Shelleby , E.C., et al. (2014) ¹² | Individual or group parent training | • Children with conduct | • Moderators of | 6 studies assessing baseline child | • Majority of studies on |

| Author, Year | Focus Area | Inclusion Criteria | Outcome(s) | # Studies Included | Key Findings |
|----------------------------------------------------------|--------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | <ul style="list-style-type: none"> problems • Studies that examined moderators of parenting intervention effectiveness | <ul style="list-style-type: none"> effectiveness including baseline level of problem behavior, sociodemographic and family process risks | <ul style="list-style-type: none"> behavior as a moderator 13 studies examining the mediating effect of sociodemographic and family process risks | <ul style="list-style-type: none"> sociodemographic and family process risks found nonsignificant association with differential intervention effectiveness • Studies of child baseline behavior suggest that increased problem behaviors at baseline are associated with increased benefit from interventions. |
| Piquero, A. R., et al. (2009) ¹³ | Parent training or support | <ul style="list-style-type: none"> • RCT • Children under 5 years | <ul style="list-style-type: none"> • Antisocial behavior • Delinquency • Parent, teacher, direct observation of child problem behavior | 55 studies | <ul style="list-style-type: none"> • early family/parent training was effective for antisocial behavior and delinquency, |
| Maughan, D. R., et al. (2005) ¹⁴ | Behavioral Parent Training (BPT) | <ul style="list-style-type: none"> • 1966-2001 • Children ages 3 to 16 years • Controlled studies, pre-post studies, and single subject design | <ul style="list-style-type: none"> • Externalizing behavior | 79 studies | <ul style="list-style-type: none"> • CBT was beneficial in all studies designs • Parent reported outcomes may inflate effectiveness |
| Lundahl, B. W., et al. (2006) ¹⁵ | Parent training programs | <ul style="list-style-type: none"> • For studies of children with ADHD, had to include a outcome for DBD separate from ADHD • Controlled studies reporting means and SDs, pre and post treatment for intervention and control groups | <ul style="list-style-type: none"> • Child disruptive behavior • Parent behavior • Parental perception | 63 studies (69 behavioral experimental groups and 14 nonbehavioral experimental groups) | <ul style="list-style-type: none"> • Parent training was least effective for economically disadvantaged families • Individually delivered parent training compared to group delivery was more effective for low SES families |
| Thomas, R. and M. J. Zimmer-Gembeck (2007) ¹⁶ | Parent-Child Interaction Therapy and Triple P-Positive Parenting Program | <ul style="list-style-type: none"> • Children ages 3 to 12 years | <ul style="list-style-type: none"> • | 24 studies | <ul style="list-style-type: none"> • Positive effects of both interventions, but effects varied depending on intervention length, components, and source of outcome data. |
| Sanders, M. R., et al. (2014) ¹⁷ | Triple P-Positive Parenting Program | <ul style="list-style-type: none"> • 1979-2013 • RCTs, non-RCTs, and uncontrolled studies | <ul style="list-style-type: none"> • Child behavior • Parenting practice • Parenting satisfaction | 116 studies 101 studies (16,099 families) analyzed quantitatively | <ul style="list-style-type: none"> • Study approach, study power, Triple P level, and baseline severity of child problems produced moderated the intervention effects |
| Reyno, S. M. and | Parenting training | <ul style="list-style-type: none"> • 1980-2004 | <ul style="list-style-type: none"> • Child disruptive | 31 studies | <ul style="list-style-type: none"> • Maternal mental health and SES |

| Author, Year | Focus Area | Inclusion Criteria | Outcome(s) | # Studies Included | Key Findings |
|-------------------------------------------------|-------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| P. J. McGrath (2006) ¹⁸ | | <ul style="list-style-type: none"> Prevention and treatment studies | behavior <ul style="list-style-type: none"> Child, parent and family variables that predict treatment outcome and dropout | | were predictors of treatment response |
| Nowak, C. and N. Heinrichs (2008) ¹⁹ | Triple P Positive Parenting Program | <ul style="list-style-type: none"> 1970-2007 | <ul style="list-style-type: none"> Parenting skill, child problem behavior or parent-child wellbeing using a validated scale | 55 studies (11, 797 families) | <ul style="list-style-type: none"> larger effects found on parent report as compared to observational measures Greater intervention effects associated with intensive formats and initially more distressed families. |
| Leijten, P., et al. (2013) ²⁰ | Parent training | <ul style="list-style-type: none"> Before 1/31/2010 Children aged 12 and younger | <ul style="list-style-type: none"> Child disruptive behavior reported as mean and SD on a standardized measure SES and baseline DBD severity as predictors of intervention effectiveness | 75 studies | <ul style="list-style-type: none"> SES interaction with baseline severity Samples of disadvantaged families with lower baseline severity benefitted less from parent management training than non-disadvantaged families with lower baseline severity DBD. SES did not predict effect sizes for patients with severe DBD at baseline |
| Kaminski, J. W., et al. (2008) ²¹ | Parent training | <ul style="list-style-type: none"> 1990-2002 Unclear if nonrandomized studies were included Children aged 7 and younger | <ul style="list-style-type: none"> Parenting measures Child measures Parent-child interaction | 77 studies including 45 RCTs | <ul style="list-style-type: none"> Increasing positive parent-child interactions and emotional communication skills, teaching parents to use time out and parenting consistency, and parental practice of new skills with their children during parent training sessions were associated with larger effects. |
| Forehand, R., et al. (2014) ²² | Behavioral Parent Training | <ul style="list-style-type: none"> Children ages 2 to 18 years Intervention and prevention RCTs | <ul style="list-style-type: none"> Parenting behavior Child externalizing behavior | 16 studies (3 intervention and 13 prevention studies) | <ul style="list-style-type: none"> |

References for Appendix F

1. Dretzke J, Davenport C, Frew E, et al. The clinical effectiveness of different parenting programmes for children with conduct problems: a systematic review of randomised controlled trials. *Child Adolesc Psychiatry Ment Health*. 2009;3(1):7. PMID: 19261188
2. Littell JH, Campbell M, Green S, et al. Multisystemic Therapy for social, emotional, and behavioral problems in youth aged 10-17. *Cochrane Database of Systematic Reviews*. 2005(4)
3. Comer JS, Chow C, Chan PT, et al. Psychosocial treatment efficacy for disruptive behavior problems in very young children: a meta-analytic examination. *J Am Acad Child Adolesc Psychiatry*. 2013 Jan;52(1):26-36. PMID: 23265631
4. McCart MR, Priester PE, Davies WH, et al. Differential effectiveness of behavioral parent-training and cognitive-behavioral therapy for antisocial youth: a meta-analysis. *J Abnorm Child Psychol*. 2006 Aug;34(4):527-43. PMID: 16838122
5. Dretzke J, Frew E, Davenport C, et al. The effectiveness and cost-effectiveness of parent training/education programmes for the treatment of conduct disorder, including oppositional defiant disorder, in children. *Health Technol Assess*. 2005 Dec;9(50):iii, ix-x, 1-233. PMID: 16336845
6. Fossum S, Handegard BH, Martinussen M, et al. Psychosocial interventions for disruptive and aggressive behaviour in children and adolescents: a meta-analysis. *Eur Child Adolesc Psychiatry*. 2008 Oct;17(7):438-51. PMID: 18427863
7. Ozabaci N. Cognitive behavioural therapy for violent behaviour in children and adolescents: A meta-analysis. *Children and Youth Services*. 2011;33(10):1989-93.
8. Eyberg SM, Nelson MM, Boggs SR. Evidence-based psychosocial treatments for children and adolescents with disruptive behavior. *Journal of Clinical Child and Adolescent Psychology*. 2008;37(1):215-37.
9. Bradley MC, Mandell D. Oppositional defiant disorder: A systematic review of evidence of intervention effectiveness. *Journal of Experimental Criminology*. 2005;1(3):343-65.
10. Johnson MH, George P, Armstrong MI, et al. Behavioral Management for Children and Adolescents: Assessing the Evidence. *Psychiatr Serv*. 2013 Dec 17PMID: 24343339
11. Michelson D, Davenport C, Dretzke J, et al. Do evidence-based interventions work when tested in the "real world?" a systematic review and meta-analysis of parent management training for the treatment of child disruptive behavior. *Clin Child Fam Psychol Rev*. 2013 Mar;16(1):18-34. PMID: 23420407
12. Shelleby EC, Shaw DS. Outcomes of Parenting Interventions for Child Conduct Problems: A Review of Differential Effectiveness. *Child Psychiatry Hum Dev*. 2014 Jan 4PMID: 24390592
13. Piquero AR, Farrington, D.P., Welsh, B.C., Tremblay, R. & Jennings, W.G. Effects of early family/parent training programs on antisocial behavior and delinquency. *Journal of Experimental Criminology*. 2009;5:83-120.
14. Maughan DR, Christiansen, E., Jenson, W.R., Olympia, D., & Clark, E. Behavioral parent training as a treatment for externalizing behaviors and disruptive behavior disorders: A meta-analysis. *School Psychology Review*. 2005;34:267-86.
15. Lundahl BW, Risser, H.J., & Lovejoy, M.C. . A meta-analysis of parent training: Moderators and follow-up effects. *Clinical Psychology Review*. 2006;26:86-104.

16. Thomas R, Zimmer-Gembeck MJ. Behavioral outcomes of Parent-Child Interaction Therapy and Triple P-Positive Parenting Program: a review and meta-analysis. *J Abnorm Child Psychol*. 2007 Jun;35(3):475-95. PMID: 17333363
17. Sanders MR, Kirby JN, Tellegen CL, et al. The Triple P-Positive Parenting Program: a systematic review and meta-analysis of a multi-level system of parenting support. *Clinical Psychology Review*. 2014 Jun;34(4):337-57. PMID: 24842549
18. Reyno SM, McGrath PJ. Predictors of parent training efficacy for child externalizing behavior problems--a meta-analytic review. *J Child Psychol Psychiatry*. 2006 Jan;47(1):99-111. PMID: 16405646
19. Nowak C, Heinrichs N. A comprehensive meta-analysis of Triple P-Positive Parenting Program using hierarchical linear modeling: effectiveness and moderating variables. *Clin Child Fam Psychol Rev*. 2008 Sep;11(3):114-44. PMID: 18509758
20. Leijten P, Raaijmakers MA, de Castro BO, et al. Does socioeconomic status matter? A meta-analysis on parent training effectiveness for disruptive child behavior. *J Clin Child Adolesc Psychol*. 2013;42(3):384-92. PMID: 23461526
21. Kaminski JW, Valle LA, Filene JH, et al. A meta-analytic review of components associated with parent training program effectiveness. *J Abnorm Child Psychol*. 2008 May;36(4):567-89. PMID: 18205039
22. Forehand R, Lafko N, Parent J, et al. Is parenting the mediator of change in behavioral parent training for externalizing problems of youth? *Clinical Psychology Review*. 2014 Dec;34(8):608-19. PMID: 25455625

Appendix G. Applicability Tables

Table G-1. Applicability of evidence for psychosocial interventions

| Domain | Description of applicability of evidence |
|--------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Population | The population studied included children from ages 1.5 - 18 years, inclusive, and 72% male. The inclusion criteria varied from strict diagnostic criteria for a disruptive behavior disorder (typically ODD) to more vague assessments of disruptive behaviors typically operationalized as above a clinical cutoff on a well-validated parent-report measure. |
| Intervention | Psychosocial interventions for disruptive behaviors included interventions with a child, parent, or family component (single component interventions) and multicomponent interventions that included more than one of those individual components. Within each of these broad categories, individual interventions were heterogeneous. |
| Comparators | The studies compared active treatment to treatment as usual or to a wait list control group. |
| Outcomes | Parent report of child disruptive behaviors was by far the most commonly reported outcomes. The CBCL externalizing subscale, ECBI Intensity subscale, ECBI Problem subscale, and SDQ were the most commonly used parent-reported measures. Child self-report, teacher report, and direct observations of child disruptive behaviors were reported. Measures of functional outcomes were far less common. |
| Setting | The vast majority of studies was in the outpatient setting and generally carried out at academic medical centers in the United States. Several studies were conducted at specialty centers including a psychiatric day treatment program and domestic violence shelter. |

Table G-2. Applicability of evidence for antipsychotic medications

| Domain | Description of applicability of evidence |
|--------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Population | The population studied included children ages 6-17, inclusive, and 83% male. The inclusion criteria varied from strict diagnostic criteria of ODD and CD to more vague assessments of aggressive behavior "severe enough to warrant pharmacotherapy." One study ¹ studied aggression in patients with ADHD exclusively. |
| Intervention | The intervention medications, Aripiprazole, Quetiapine, Risperidone, and Ziprasidone are not FDA approved for treatment of disruptive behavior in children, but are used routinely in clinical practice in the US. |
| Comparators | Only one of the studies (5102) studied two medications head-to-head. The other studies compared the active medication to placebo. |
| Outcomes | The most common measures were the OAS and CGI. The OAS specifically addresses aggressive behavior symptoms and the CGI addresses improvement of symptoms compared to baseline. |
| Setting | The studies were all in the outpatient setting and generally carried out at academic medical centers in the US, with one (5102) at a community outpatient clinic. |

Notes: Abbreviations: ADHD – Attention Deficit Hyperactivity Disorder; CD – Conduct Disorder; CGI – Clinical Global Impression; OAS – Ongoing Abuse Screen; ODD – Oppositional Defiant Disorder

Table G-3. Applicability of evidence for antiepileptic medications

| Domain | Description of applicability of evidence |
|--------------|----------------------------------------------------------------------------------------------------------------------------------------|
| Population | The population studied included children from ages 6 to 18 years, inclusive, and 90% male. |
| Intervention | The intervention, valproic acid, is not FDA approved for disruptive behaviors in children, but is used in clinical practice in the US. |
| Comparators | Valproic acid compared to placebo or to low dose valproic acid. |

| | |
|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Outcomes | The most common measures were the OAS and CGI. The OAS specifically addresses aggressive behavior symptoms and the CGI addresses improvement of symptoms compared to baseline. |
| Setting | The largest of the three studies (n=58) analyzed patients from a correctional facility, which indicates a higher acuity of disruptive behaviors. The other studies were conducted in outpatient clinics. |

Table G-4. Applicability of evidence for nonstimulant medications

| Domain | Description of applicability of evidence |
|--------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Population | The population studied included school-aged children and adolescents, ages 6-17 years, and mostly male (69%-92%). Inclusion criteria included specifically children with ADHD and co-morbid ODD based on strict diagnostic criteria of ODD/CD. |
| Intervention | The intervention medications include the selective norepinephrine reuptake inhibitor atomoxetine and Guanfacine extended release, a selective central alpha2A-adrenergic receptor agonist; both of which are approved for the treatment of ADHD, but are not FDA approved for treatment of disruptive behavior in children. |
| Comparators | All studies compared the active medication to placebo. One study (665) had three arms that compared fast to slow titration of atomoxetine with target dose in both arms of 1.2mg/kg/d. |
| Outcomes | Primary outcomes were the change from baseline in the Swanson, Nolan, and Pelham Rating Scale-Revised (SNAP-IV) ODD subscore, or the oppositional subscale of the Conners Parent Rating Scale-Revised: Long Form (CPRS-R: L) measured at 8-9 weeks of treatment. |
| Setting | The studies were all in the outpatient setting at centers in the US, Germany, and Italy. |

Table G-5. Applicability of evidence for ADHD stimulant medications

| Domain | Description of applicability of evidence |
|--------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Population | The population studied included school-aged children and adolescents, 6-17 years; and mostly male (69-90%). Patient population had ODD symptoms based on strict diagnostic criteria; and majority had co-morbid ADHD (66% to 79%) |
| Intervention | The intervention medications included methylphenidate and mixed amphetamine salts extended release (MAS XR); both of which are approved for treatment of ADHD; but are not FDA approved for disruptive behaviors in children. |
| Comparators | All studies compared the active medication to placebo. One study (1650) compared four different doses of MAS XR (10 mg, 20 mg, 30 mg, and 40 mg/d) to placebo. |
| Outcomes | Primary outcomes were the ODD subscore of the SNAP-IV and parent and teacher ratings of CD symptoms based on the Conners Teacher Rating Scale, and subscales of the Quay revised behavior problem checklist, measured after 4-5 weeks of treatment. |
| Setting | The two studies were conducted in the outpatient setting at centers in the US. |

Appendix H. Reasons for Exclusion

| Exclusion Code | Exclusion Reason | Count |
|----------------|-----------------------------------------------------------------------------------------------------------------------|-------|
| X-1 | Not original research | 67 |
| X-2 | Does not measure the relationship between a psychosocial or pharmacologic intervention and an outcome | 158 |
| X-2a | Not an eligible study design | 9 |
| X-3 | Not youth | 30 |
| X-4 | No standardized disruptive behavior disorder classification or symptom assessment meeting a clinical threshold cutoff | 319 |
| X-4a | At-risk population or preventive intervention | 5 |
| X-5 | Not conducted in an outpatient healthcare setting | 177 |
| X-6 | Does not include an alternate treatment or control group for comparison to measure effectiveness | 256 |
| X-7 | Does not report an outcome of interest for the population (youth) with disruptive behavior | 125 |
| X-7a | Does not report data for an outcome of interest by group | 7 |
| X-8 | Does not address a Key Question | 134 |
| X-9 | Duplicate | 7 |
| X-10 | Unavailable | 28 |
| X-11 | Older than 20 years | 198 |
| X-12 | Non-English | 5 |

References for Appendix H

Records excluded at full-text level screening; listed alphabetically by first author last name

1. Stereotactic neurosurgery for aggressive behaviour. *Med J Aust* 1973 Apr 21;1(16):779-80. PMID: 4575087. **X-11**
2. A cognitive-ecological approach to preventing aggression in urban settings: initial outcomes for high-risk children. *J Consult Clin Psychol* 2002 Feb;70(1):179-94. PMID: 11860044. **X-5**
3. A more compassionate model for treating children with severe mental disturbances. *Psychiatr Serv* 2003 Nov;54(11):1529-31. PMID: 14600314. **X-1, X-2, X-3, X-5, X-6**
4. Modafinil: serious skin reactions. *Prescrire Int* 2007 Apr;16(88):71. PMID: 17465032. **X-1, X-2, X-4**
5. Fluoxetine: new indication. Depression in children: too many uncertainties. *Prescrire Int* 2008 Oct;17(97):186-7. PMID: 19534039. **X-1, X-4**
6. Antisocial Personality Disorder: The NICE Guideline on Treatment, Management and Prevention. The Collaborating Centre for Mental Health. Leicester, UK: The British Psychological Society and The Royal College of Psychiatrists; 2010. **X-1**
7. Disruptive behavior disorders. *J Okla State Med Assoc* 2011 Jul-Aug;104(7-8):324-5. PMID: 22013872. **X-10**
8. Impact of Early Intervention on Psychopathology, Crime, and Well-Being at Age 25. *Am J Psychiatry* 2014 Sep 15; PMID: 25219348. **X-3, X-5**
9. Abrahamse ME, Junger M, Chavannes EL, et al. Parent-child interaction therapy for preschool children with disruptive behaviour problems in the Netherlands. *Child Adolesc Psychiatry Ment Health* 2012;6(1):24. PMID: 22694924. **X-2, X-6**
10. Abrahamse ME, Junger M, Chavannes EL, et al. Parent-child interaction therapy for preschool children with disruptive behaviour problems in the Netherlands. *Child and Adolescent Psychiatry and Mental Health* 2012;6. **X-6**
11. Abramovitch R, Konstantareas M, Sloman L. An observational assessment of change in two groups of behaviourally disturbed boys. *J Child Psychol Psychiatry* 1980 Apr;21(2):133-41. PMID: 7372743. **X-11**
12. Accurso EC, Garland AF. Child, Caregiver, and Therapist Perspectives on Therapeutic Alliance in Usual Care Child Psychotherapy. *Psychol Assess* 2014 Oct 13; PMID: 25314097. **X-2, X-6**
13. Accurso EC, Hawley KM, Garland AF. Psychometric properties of the Therapeutic Alliance Scale for Caregivers and Parents. *Psychol Assess* 2013 Mar;25(1):244-52. PMID: 23088205. **X-2, X-6**
14. Acker LE, Acker MA, Pearson D. Generalized imitative affection: relationship to prior kinds of imitation training. *J Exp Child Psychol* 1973 Aug;16(1):111-25. PMID: 4722555. **X-11**
15. Adams AL, Meaden P. A 12-Week Comparison Regarding Symptom Improvement in an Urban University-Based Outpatient Child Psychiatry Clinic. *Am J Ther* 2013 Jun 18; PMID: 23782761. **X-2a**
16. Adams D, Allen D. Assessing the need for reactive behaviour management strategies in children with intellectual disability and severe challenging behaviour. *J Intellect Disabil Res* 2001 Aug;45(Pt 4):335-43. PMID: 11489055. **X-2, X-4, X-6**
17. al Ansari A, Gouthro S, Ahmad K, et al. Hospital-based behavior modification program for adolescents: evaluation and predictors of outcome. *Adolescence* 1996 Summer;31(122):469-76. PMID: 8726904. **X-5, X-6, X-8**
18. Altman K, Hobbs S, Roberts M, et al. Control of disruptive behavior by manipulation of reinforcement density and item difficulty subsequent to errors. *Appl Res Ment Retard* 1980;1(3-4):193-208. PMID: 7337457. **X-11**
19. Aman M, Buitelaar J, De Smedt G, et al. Pharmacotherapy of Disruptive Behavior and Item Changes on a Standardized Rating Scale: Pooled Analysis of Risperidone Effects in Children with Subaverage IQ. *Journal of Child and Adolescent Psychopharmacology* 2005;15(2):220-32. **X-4**
20. Aman MG, Binder C, Turgay A. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. *J Child Adolesc Psychopharmacol* 2004 Summer;14(2):243-54. PMID: 15319021. **X-4, X-6**

21. Aman MG, Bukstein OG, Gadow KD, et al. What does risperidone add to parent training and stimulant for severe aggression in child attention-deficit/hyperactivity disorder? *Journal of the American Academy of Child & Adolescent Psychiatry* 2014;53(1):47-60. PMID: 24342385. **X-4**
22. Aman MG, Hollway JA, Leone S, et al. Effects of risperidone on cognitive-motor performance and motor movements in chronically medicated children. *Res Dev Disabil* 2009 Mar-Apr;30(2):386-96. PMID: 18768293. **X-4**
23. Aman MG, Kasper W, Manos G, et al. Line-item analysis of the Aberrant Behavior Checklist: results from two studies of aripiprazole in the treatment of irritability associated with autistic disorder. *J Child Adolesc Psychopharmacol* 2010 Oct;20(5):415-22. PMID: 20973712. **X-1, X-4, X-7**
24. Aman MG, McDougale CJ, Scahill L, et al. Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial. *J Am Acad Child Adolesc Psychiatry* 2009 Dec;48(12):1143-54. PMID: 19858761. **X-4**
25. Aman MG, Werry JS. The effects of methylphenidate and haloperidol on the heart rate and blood pressure of hyperactive children with special reference to time of action. *Psychopharmacologia* 1975 Aug 21;43(2):163-8. PMID: 1103207. **X-11**
26. Amaya MM, Reinecke MA, Silva SG, et al. Parental marital discord and treatment response in depressed adolescents. *J Abnorm Child Psychol* 2011 Apr;39(3):401-11. PMID: 20957515. **X-4**
27. Amery B, Minichiello MD, Brown GL. Aggression in hyperactive boys: response to d-amphetamine. *J Am Acad Child Psychiatry* 1984 May;23(3):291-4. PMID: 6736494. **X-11**
28. Amminger GP, Berger GE, Schafer MR, et al. Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study. *Biol Psychiatry* 2007 Feb 15;61(4):551-3. PMID: 16920077. **X-4, X-6, X-7, X-8**
29. Anderson L, Vostanis P, O'Reilly M. Three-year follow-up of a family support service cohort of children with behavioural problems and their parents. *Child Care Health Dev* 2005 Jul;31(4):469-77. PMID: 15948884. **X-6, X-7, X-8**
30. Anderson RM, Kauffman JM. Use of state mental health centers in training teachers of children with behavior disorders. *J Sch Health* 1970 Dec;40(10):523-5. PMID: 5203062. **X-11**
31. Angrist B, Gershon S. Clinical effects of amphetamine and L-DOPA on sexuality and aggression. *Compr Psychiatry* 1976 Nov-Dec;17(6):715-22. PMID: 991603. **X-11**
32. Ansari AA, Gouthro S, Ahmad K, et al. Hospital-based behavior modification program for adolescents: Evaluation and predictors of outcome. *Adolescence* 1996;31(122):469-76. **X-5, X-6**
33. Apolito A. Primary prevention: a breakthrough in sight. *Am J Psychoanal* 1978 Summer;38(2):121-7. PMID: 707672. **X-11**
34. Apsche JA, Bass CK, Zeiter JS, et al. Family mode deactivation therapy in a residential setting: Treating adolescents with conduct disorder and multi-axial diagnosis. *International Journal of Behavioral Consultation and Therapy* 2008;4(4):328-39. **X-4, X-7**
35. Armstrong H, Wilks C, McEvoy L, et al. Group therapy for parents of youths with a conduct disorder. *Cmaj* 1994 Oct 1;151(7):939-44. PMID: 7922930. **X-2, X-3, X-6**
36. Arnesen RB, Libby R, Miller PH. Altering the behavior of an aggressive institutionalized boy through paradoxical communication. *J Nerv Ment Dis* 1973 Jul;157(1):63-5. PMID: 4713308. **X-11**
37. Arnold LE, Kirilcuk V, Corson SA, et al. Levoamphetamine and dextroamphetamine: differential effect on aggression and hyperkinesis in children and dogs. *Am J Psychiatry* 1973 Feb;130(2):165-70. PMID: 4568123. **X-11**
38. Athens ES, Vollmer TR. An investigation of differential reinforcement of alternative behavior without extinction. *J Appl Behav Anal* 2010 Winter;43(4):569-89. PMID: 21541145. **X-4, X-6, X-7**
39. Atkins MS, Graczyk PA, Frazier SL, et al. Toward A New Model for Promoting Urban Children's Mental Health: Accessible, Effective, and Sustainable School-Based Mental Health Services. *School Psychology Review* 2003;32(4):503-14. **X-2, X-4, X-5, X-6**

40. August GJ, Egan EA, Realmuto GM, et al. Parceling component effects of a multifaceted prevention program for disruptive elementary school children. *J Abnorm Child Psychol* 2003 Oct;31(5):515-27. PMID: 14561059. **X-5, X-6**
41. August GJ, Hektner JM, Egan EA, et al. The early risers longitudinal prevention trial: examination of 3-year outcomes in aggressive children with intent-to-treat and as-intended analyses. *Psychol Addict Behav* 2002 Dec;16(4 Suppl):S27-39. PMID: 12502275. **X-5, X-6**
42. August GJ, Lee SS, Bloomquist ML, et al. Dissemination of an evidence-based prevention innovation for aggressive children living in culturally diverse, urban neighborhoods: the Early Risers effectiveness study. *Prev Sci* 2003 Dec;4(4):271-86. PMID: 14598999. **X-5**
43. August GJ, Piehler TF, Bloomquist ML. Being "SMART" About Adolescent Conduct Problems Prevention: Executing a SMART Pilot Study in a Juvenile Diversion Agency. *J Clin Child Adolesc Psychol* 2014 Sep 25:1-15. PMID: 25256135. **X-1, X-5**
44. Axberg U, Broberg AG. Evaluation of "the incredible years" in Sweden: The transferability of an American parent-training program to Sweden. *Scandinavian Journal of Psychology* 2012;53(3):224-32. **X-9**
45. Axelrad ME, Butler AM, Dempsey J, et al. Treatment effectiveness of a brief behavioral intervention for preschool disruptive behavior. *J Clin Psychol Med Settings* 2013 Sep;20(3):323-32. PMID: 23575970. **X-6, X-8**
46. Axelrad ME, Garland BH, Love KB. Brief behavioral intervention for young children with disruptive behaviors. *J Clin Psychol Med Settings* 2009 Sep;16(3):263-9. PMID: 19424780. **X-6, X-8**
47. Ayres CM. Serpasil treatment of adolescents with behavior disorders. *Dis Nerv Syst* 1960 Feb;21:91-5. PMID: 13795365. **X-11**
48. Azrin NH, Gottlieb L, Hughart L, et al. Eliminating self-injurious behavior by educative procedures. *Behav Res Ther* 1975 Jun;13(2-3):101-11. PMID: 1164365. **X-11**
49. Bachmann M, Bachmann CJ, John K, et al. The effectiveness of child and adolescent psychiatric treatments in a naturalistic outpatient setting. *World Psychiatry* 2010 Jun;9(2):111-7. PMID: 20671900. **X-4, X-7**
50. Baeza I, de la Serna E, Calvo-Escalona R, et al. Antipsychotic use in children and adolescents: a 1-year follow-up study. *J Clin Psychopharmacol* 2014 Oct;34(5):613-9. PMID: 25154009. **X-2, X-5, X-6**
51. Bagner DM, Boggs SR, Eyberg SM. Evidence-Based School Behavior Assessment of Externalizing Behavior in Young Children. *Educ Treat Children* 2010 Feb;33(1):65-83. PMID: 21687781. **X-2, X-6, X-8**
52. Bagner DM, Eyberg SM. Father involvement in parent training: when does it matter? *J Clin Child Adolesc Psychol* 2003 Dec;32(4):599-605. PMID: 14710469. **X-2, X-6**
53. Bagner DM, Eyberg SM. Parent-child interaction therapy for disruptive behavior in children with mental retardation: a randomized controlled trial. *J Clin Child Adolesc Psychol* 2007 Jul-Sep;36(3):418-29. PMID: 17658985. **X-4**
54. Bagner DM, Graziano PA. Barriers to success in parent training for young children with developmental delay: the role of cumulative risk. *Behav Modif* 2013 May;37(3):356-77. PMID: 23188886. **X-4**
55. Bagner DM, Rodriguez GM, Blake CA, et al. Home-Based Preventive Parenting Intervention for at-Risk Infants and Their Families: An Open Trial. *Cogn Behav Pract* 2013 Aug 1;20(3):334-48. PMID: 25414568. **X-6**
56. Bandou N, Koike K, Matuura H. Predictive familial risk factors and pharmacological responses in ADHD with comorbid disruptive behavior disorders. *Pediatr Int* 2010 Jun;52(3):415-9. PMID: 19912555. **X-4, X-7**
57. Banerjee S, Ayyash HF. Does atomoxetine increase the risk of aggression and hostility in children with attention deficit hyperactivity disorder? *Arch Dis Child Educ Pract Ed* 2008 Aug;93(4):131-2. PMID: 18644903. **X-1, X-2, X-4, X-5, X-6, X-7**
58. Bangs ME, Hazell P, Danckaerts M, et al. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder. *Pediatrics* 2008 Feb;121(2):e314-20. PMID: 18245404. **X-4**

59. Bank L, Marlowe JH, Reid JB, et al. A comparative evaluation of parent-training interventions for families of chronic delinquents. *J Abnorm Child Psychol* 1991 Feb;19(1):15-33. PMID: 2030245. **X-11**
60. Barbero JAJ, García MP, Galindo FJF, et al. Alternativa psicofamiliar al tratamiento precoz de los problemas de conducta: La escuela de padres. *Anales de Psiquiatría* 2009;25(3):142-5. **X-1, X-2, X-12**
61. Bardill DR. Behavior contracting and group therapy with preadolescent males in a residential treatment setting. *Int J Group Psychother* 1972 Jul;22(3):333-42. PMID: 5054380. **X-11**
62. Barker ED, Vitaro F, Lacourse E, et al. Testing the developmental distinctiveness of male proactive and reactive aggression with a nested longitudinal experimental intervention. *Aggress Behav* 2010 Mar-Apr;36(2):127-40. PMID: 20052694. **X-4**
63. Barker P, Fraser IA. A controlled trial of haloperidol in children. *Br J Psychiatry* 1968 Jul;114(512):855-7. PMID: 4874167. **X-11**
64. Barkley RA, Shelton TL, Crosswait C, et al. Preliminary findings of an early intervention program with aggressive hyperactive children. *Ann N Y Acad Sci* 1996 Sep 20;794:277-89. PMID: 8853609. **X-5**
65. Barkley RA, Shelton TL, Crosswait C, et al. Multi-method psycho-educational intervention for preschool children with disruptive behavior: preliminary results at post-treatment. *J Child Psychol Psychiatry* 2000 Mar;41(3):319-32. PMID: 10784079. **X-5**
66. Barlett CP, Anderson CA. Reappraising the situation and its impact on aggressive behavior. *Pers Soc Psychol Bull* 2011 Dec;37(12):1564-73. PMID: 21975949. **X-2, X-7**
67. Barlow J. The Webster Stratton "Incredible Years" parent training programme reduces conduct problems in children. *Evid Based Ment Health* 2007 Aug;10(3):86. PMID: 17652568. **X-1**
68. Barmann BC, Croyle-Barmann C. Use of contingent-interrupted music in the treatment of disruptive behavior while riding a bus. *Psychol Rep* 1980 Aug;47(1):269-70. PMID: 7422768. **X-11**
69. Barrera M, Jr., Biglan A, Taylor TK, et al. Early elementary school intervention to reduce conduct problems: a randomized trial with Hispanic and non-Hispanic children. *Prev Sci* 2002 Jun;3(2):83-94. PMID: 12088139. **X-4, X-6, X-8**
70. Bartunkova Z, Cerny L, Drtilova J, et al. Propericiazin, diazepam, chlorpromazine and placebo in a doubleblind trial in pedopsychiatric therapy. *Act Nerv Super (Praha)* 1972;14(2):83-4. PMID: 4402693. **X-11**
71. Baruch G, Vrouva I, Wells C. Outcome findings from a parent training programme for young people with conduct problems. *Child and Adolescent Mental Health* 2011;16(1):47-54. **X-6**
72. Bastiaans J, van der Ploeg HM. Control and regulation of aggression. *Psychother Psychosom* 1978;29(1-4):40-8. PMID: 724962. **X-11**
73. Bay-Hinitz AK, Peterson RF, Quilitch HR. Cooperative games: a way to modify aggressive and cooperative behaviors in young children. *J Appl Behav Anal* 1994 Fall;27(3):435-46. PMID: 7928788. **X-5**
74. Becker EA, Crismon ML, Shafer A, et al. SSRI Use and Behavioral Disruption Among Children and Adolescents at Austin State Hospital. *Tex Med* 2009 May;105(5):e1-5. PMID: 19421919. **X-4, X-5**
75. Beckett PG, Lennox K, Grisell JL. Responsibility and reward in treatment. A comparative follow-up study of adolescents. *J Nerv Ment Dis* 1968 Mar;146(3):257-63. PMID: 5645901. **X-11**
76. Behar LB. The Preschool Behavior Questionnaire. *J Abnorm Child Psychol* 1977;5(3):265-75. PMID: 903521. **X-11**
77. Bentovim A. Disobedience and violent behaviour in children: family pathology and family treatment--II. *Br Med J* 1976 Apr 24;1(6016):1004-6. PMID: 1268515. **X-11**
78. Bernal ME, Klinnert MD, Schultz LA. Outcome evaluation of behavioral parent training and client-centered parent counseling for children with conduct problems. *J Appl Behav Anal* 1980 Winter;13(4):677-91. PMID: 7204284. **X-11**
79. Biederman J, Mick E, Faraone SV, et al. Risperidone for the Treatment of Affective Symptoms in Children with Disruptive Behavior Disorder: A Post Hoc Analysis of Data from a 6-Week, Multicenter, Randomized, Double-Blind, Parallel-Arm Study. *Clinical Therapeutics: The*

International Peer-Reviewed Journal of Drug Therapy 2006;28(5):794-800. **X-4**

80. Bierman KL, Coie JD, Dodge KA, et al. The effects of the fast track program on serious problem outcomes at the end of elementary school. *J Clin Child Adolesc Psychol* 2004 Dec;33(4):650-61. PMID: 15498733. **X-5**

81. Bierman KL, Coie JD, Dodge KA, et al. Using the Fast Track randomized prevention trial to test the early-starter model of the development of serious conduct problems. *Dev Psychopathol* 2002 Fall;14(4):925-43. PMID: 12549710. **X-2, X-5**

82. Bierman KL, Nix RL, Heinrichs BS, et al. Effects of Head Start REDI on Children's Outcomes 1 Year Later in Different Kindergarten Contexts. *Child Dev* 2013 May 3 PMID: 23647355. **X-4, X-5**

83. Bierman KL, Nix RL, Maples JJ, et al. Examining clinical judgment in an adaptive intervention design: The fast track program. *J Consult Clin Psychol* 2006 Jun;74(3):468-81. PMID: 16822104. **X-2**

84. Bjørknes R, Kjøbli J, Manger T, et al. Parent training among ethnic minorities: Parenting practices as mediators of change in child conduct problems. *Family Relations* 2012;61(1):101-14. **X-4**

85. Bjorknes R, Manger T. Can parent training alter parent practice and reduce conduct problems in ethnic minority children? A randomized controlled trial. *Prev Sci* 2013 Feb;14(1):52-63. PMID: 23135877. **X-4**

86. Blader JC. Pharmacotherapy and postdischarge outcomes of child inpatients admitted for aggressive behavior. *J Clin Psychopharmacol* 2006 Aug;26(4):419-25. PMID: 16855463. **X-2, X-5**

87. Blustein J. Intervention with excessively aggressive children. Conceptual and ethical issues. *Ann N Y Acad Sci* 1996 Sep 20;794:308-17. PMID: 8853611. **X-2, X-10**

88. Bodenmann G, Cina A, Ledermann T, et al. The efficacy of the Triple P-Positive Parenting Program in improving parenting and child behavior: a comparison with two other treatment conditions. *Behav Res Ther* 2008 Apr;46(4):411-27. PMID: 18313033. **X-4**

89. Boelhouwer C, Henry CE, Glueck BC, Jr. Positive spiking: a double-blind control study on its

significance in behavior disorders, both diagnostically and therapeutically. *Am J Psychiatry* 1968 Oct;125(4):473-81. PMID: 4886101. **X-11**

90. Boggs SR, Eyberg SM, Edwards DL, et al. Outcomes of Parent-Child Interaction Therapy: A Comparison of Treatment Completers and Study Dropouts One to Three Years Later. *Child & Family Behavior Therapy* 2004;26(4):1-22. **X-2, X-6**

91. Boisjoli R, Vitaro F, Lacourse E, et al. Impact and clinical significance of a preventive intervention for disruptive boys: 15-year follow-up. *Br J Psychiatry* 2007 Nov;191:415-9. PMID: 17978321. **X-5**

92. Bolstad OD, Johnson SM. Self-regulation in the modification of disruptive classroom behavior. *J Appl Behav Anal* 1972 Winter;5(4):443-54. PMID: 16795368. **X-11**

93. Bolton P, Bass J, Betancourt T, et al. Interventions for depression symptoms among adolescent survivors of war and displacement in northern Uganda: a randomized controlled trial. *JAMA* 2007 Aug 1;298(5):519-27. PMID: 17666672. **X-4**

94. Bonin EM, Stevens M, Beecham J, et al. Costs and longer-term savings of parenting programmes for the prevention of persistent conduct disorder: a modelling study. *BMC Public Health* 2011;11:803. PMID: 21999434. **X-1, X-7**

95. Borden LA, Herman KC, Stormont M, et al. Latent profile analysis of observed parenting behaviors in a clinic sample. *J Abnorm Child Psychol* 2014 Jul;42(5):731-42. PMID: 24141708. **X-1, X-2, X-6**

96. Borduin CM, Schaeffer CM, Heiblum N. A randomized clinical trial of multisystemic therapy with juvenile sexual offenders: effects on youth social ecology and criminal activity. *J Consult Clin Psychol* 2009 Feb;77(1):26-37. PMID: 19170451. **X-4**

97. Borowsky IW, Mozayeny S, Stuenkel K, et al. Effects of a primary care-based intervention on violent behavior and injury in children. *Pediatrics* 2004 Oct;114(4):e392-9. PMID: 15466063. **X-4**

98. Borrero CS, Vollmer TR. Experimental analysis and treatment of multiply controlled problem behavior: a systematic replication and extension. *J*

Appl Behav Anal 2006 Fall;39(3):375-9. PMID: 17020218. **X-4, X-5, X-6, X-7, X-8**

99. Bowers L, Ross J, Nijman H, et al. The scope for replacing seclusion with time out in acute inpatient psychiatry in England. *J Adv Nurs* 2012 Apr;68(4):826-35. PMID: 21749438. **X-2, X-3, X-4, X-5, X-6, X-7, X-8**

100. Boyle CL, Sanders MR, Lutzker JR, et al. Erratum to: An Analysis of Training, Generalization, and Maintenance Effects of Primary Care Triple P for Parents of Preschool-Aged Children with Disruptive Behavior. *Child Psychiatry Hum Dev* 2014 Oct 16;44(10):1172-9. PMID: 25319510. **X-1**

101. Bradley C. Bensedrine and dexedrine in the treatment of children's behavior disorders. *Pediatrics* 1950 Jan;5(1):24-37. PMID: 15404645. **X-11**

102. Brent DA, Perper JA, Moritz G, et al. Familial risk factors for adolescent suicide: a case-control study. *Acta Psychiatr Scand* 1994 Jan;89(1):52-8. PMID: 8140907. **X-2**

103. Brestan EV, Jacobs JR, Rayfield AD, et al. A consumer satisfaction measure for parent-child treatments and its relation to measures of child behavior change. *Behavior Therapy* 1999;30(1):17-30. **X-6**

104. Broad J, Burke J, Byford SR, et al. Clinical application of the Children's Action Tendency Scale. *Psychol Rep* 1986 Aug;59(1):71-4. PMID: 3737819. **X-11**

105. Brookman-Frazee L, Haine RA, Baker-Ericzen M, et al. Factors associated with use of evidence-based practice strategies in usual care youth psychotherapy. *Adm Policy Ment Health* 2010 May;37(3):254-69. PMID: 19795204. **X-2, X-6, X-7, X-8**

106. Broota A, Sehgal R. Management of Conduct Disorders through Cognitive Behavioural Intervention. *Psychological Studies* 2004;49(1):69-72. **X-4**

107. Brotman LM, Dawson-McClure S, Gouley KK, et al. Older siblings benefit from a family-based preventive intervention for preschoolers at risk for conduct problems. *J Fam Psychol* 2005 Dec;19(4):581-91. PMID: 16402873. **X-4**

108. Brotman LM, Gouley KK, Chesir-Teran D, et al. Prevention for preschoolers at high risk for

conduct problems: immediate outcomes on parenting practices and child social competence. *J Clin Child Adolesc Psychol* 2005 Dec;34(4):724-34. PMID: 16232069. **X-5, X-7**

109. Brotman LM, Gouley KK, Huang KY, et al. Effects of a psychosocial family-based preventive intervention on cortisol response to a social challenge in preschoolers at high risk for antisocial behavior. *Arch Gen Psychiatry* 2007 Oct;64(10):1172-9. PMID: 17909129. **X-4**

110. Brotman LM, Gouley KK, Huang KY, et al. Preventive intervention for preschoolers at high risk for antisocial behavior: long-term effects on child physical aggression and parenting practices. *J Clin Child Adolesc Psychol* 2008 Apr;37(2):386-96. PMID: 18470775. **X-5**

111. Brotman LM, Klein RG, Kamboukos D, et al. Preventive intervention for urban, low-income preschoolers at familial risk for conduct problems: a randomized pilot study. *J Clin Child Adolesc Psychol* 2003 Jun;32(2):246-57. PMID: 12679283. **X-4, X-6, X-8**

112. Brotman LM, O'Neal CR, Huang KY, et al. An experimental test of parenting practices as a mediator of early childhood physical aggression. *J Child Psychol Psychiatry* 2009 Mar;50(3):235-45. PMID: 19220626. **X-4**

113. Brown TL, Henggeler SW, Schoenwald SK, et al. Multisystemic treatment of substance abusing and dependent juvenile delinquents: Effects on school attendance at posttreatment and 6-month follow-up. *Children's Services: Social Policy, Research, & Practice* 1999;2(2):81-93. **X-10**

114. Bruggen P, Westland P. Difficult to place adolescents. Are more resources required? *J Adolesc* 1979 Sep;2(3):245-50. PMID: 512128. **X-11**

115. Budman C, Coffey BJ, Shechter R, et al. Aripiprazole in children and adolescents with Tourette disorder with and without explosive outbursts. *J Child Adolesc Psychopharmacol* 2008 Oct;18(5):509-15. PMID: 18928415. **X-4, X-6**

116. Budney AJ, Hughes JR, Moore BA, et al. Marijuana abstinence effects in marijuana smokers maintained in their home environment. *Arch Gen Psychiatry* 2001 Oct;58(10):917-24. PMID: 11576029. **X-2, X-4**

117. Buitelaar JK, van der Gaag RJ, Cohen-Kettenis P, et al. A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. *J Clin Psychiatry* 2001 Apr;62(4):239-48. PMID: 11379837. **X-5**
118. Bulinski L. Post accessive social policy in the rehabilitation of adolescents following TBI. *Med Sci Monit* 2011 Jan;17(1):CR14-25. PMID: 21169906. **X-4, X-6**
119. Burdon AP, Neely JH. Chronic school failure in boys: a short-term group therapy and educational approach. *Am J Psychiatry* 1966 May;122(11):1211-9. PMID: 5909449. **X-11**
120. Burke K, Brennan L, Cann W. Promoting protective factors for young adolescents: ABCD Parenting Young Adolescents Program randomized controlled trial. *J Adolesc* 2012 Oct;35(5):1315-28. PMID: 22677166. **X-4**
121. Burke RV, Howard MR, Peterson JL, et al. Visual performance feedback: effects on targeted and nontargeted staff. *Behav Modif* 2012 Sep;36(5):687-704. PMID: 22457341. **X-2, X-3**
122. Burke RV, Kuhn BR, Peterson JL, et al. "Don't kick me out!": Day treatment for two preschool children with severe behavior problems. *Clinical Case Studies* 2010;9(1):28-40. **X-6**
123. Burquest B. The violent girl. *Adolescence* 1981 Winter;16(64):749-64. PMID: 6120625. **X-11**
124. Bywater T, Hutchings J, Linck P, et al. Incredible Years parent training support for foster carers in Wales: a multi-centre feasibility study. *Child Care Health Dev* 2011 Mar;37(2):233-43. PMID: 20854449. **X-4**
125. Calarge CA, Nicol G, Xie D, et al. Correlates of weight gain during long-term risperidone treatment in children and adolescents. *Child Adolesc Psychiatry Ment Health* 2012;6(1):21. PMID: 22643087. **X-4, X-6**
126. Caldwell CH, Rafferty J, Reischl TM, et al. Enhancing parenting skills among nonresident African American fathers as a strategy for preventing youth risky behaviors. *Am J Community Psychol* 2010 Mar;45(1-2):17-35. PMID: 20082239. **X-4, X-5, X-6**
127. Caldwell MF, Malterer M, Umstead D, et al. A retrospective evaluation of adjunctive risperidone treatment in severely behaviorally disordered boys receiving psychosocial treatment. *J Child Adolesc Psychopharmacol* 2008 Feb;18(1):34-43. PMID: 18294087. **X-5**
128. Calogeras RC, Camp NM. Drug use and aggression. *Bull Menninger Clin* 1975 Jul;39(4):329-44. PMID: 1156706. **X-11**
129. Camp BW, Blom GE, Hebert F, et al. "Think aloud": a program for developing self-control in young aggressive boys. *J Abnorm Child Psychol* 1977;5(2):157-69. PMID: 886092. **X-11**
130. Campbell M, Adams PB, Small AM, et al. Lithium in hospitalized aggressive children with conduct disorder: a double-blind and placebo-controlled study. *J Am Acad Child Adolesc Psychiatry* 1995 Apr;34(4):445-53. PMID: 7751258. **X-5**
131. Campbell M, Cohen IL, Small AM. Drugs in aggressive behavior. *J Am Acad Child Psychiatry* 1982 Mar;21(2):107-17. PMID: 7040529. **X-11**
132. Campbell M, Fish B, Korein J, et al. Lithium and chlorpromazine: a controlled crossover study of hyperactive severely disturbed young children. *J Autism Child Schizophr* 1972 Jul-Sep;2(3):234-63. PMID: 4567547. **X-11**
133. Cantwell DP. Hyperactivity and antisocial behavior. *J Am Acad Child Psychiatry* 1978 Spring;17(2):252-62. PMID: 659744. **X-11**
134. Carlson GA, Lavelle J, Bromet EJ. Medication treatment in adolescents vs. adults with psychotic mania. *J Child Adolesc Psychopharmacol* 1999;9(3):221-31. PMID: 10521014. **X-2, X-4**
135. Carr EG, Durand VM. Reducing behavior problems through functional communication training. *J Appl Behav Anal* 1985 Summer;18(2):111-26. PMID: 2410400. **X-11**
136. Carrion VG, Kletter H, Weems CF, et al. Cue-centered treatment for youth exposed to interpersonal violence: a randomized controlled trial. *J Trauma Stress* 2013 Dec;26(6):654-62. PMID: 24490236. **X-4**
137. Castellanos-Ryan N, Seguin JR, Vitaro F, et al. Impact of a 2-year multimodal intervention for disruptive 6-year-olds on substance use in adolescence: randomised controlled trial. *Br J*

- Psychiatry 2013;203:188-95. PMID: 23929441. **X-4a**
138. Castillo SC, Holmes GR, Cuccaro ML, et al. Group intervention with second graders at risk for behavioral problems: a pilot study. *Psychol Rep* 1997 Apr;80(2):415-8. PMID: 9129361. **X-5, X-6, X-7**
139. Cauce AM, Cruz R, Corona M, et al. The face of the future: risk and resilience in minority youth. *Nebr Symp Motiv* 2011;57:13-32. PMID: 21166303. **X-1**
140. Cefai J, Smith D, Pushak RE. Parenting Wisely: Parent Training via CD-ROM with an Australian Sample. *Child & Family Behavior Therapy* 2010 2010/03/03;32(1):17-33. **X-4**
141. Celani DP. A structural analysis of the obsessional character: a Fairbairnian perspective. *Am J Psychoanal* 2007 Jun;67(2):119-40. PMID: 17533379. **X-1, X-2, X-4**
142. Chamberlain P, Leve LD, Degarmo DS. Multidimensional treatment foster care for girls in the juvenile justice system: 2-year follow-up of a randomized clinical trial. *J Consult Clin Psychol* 2007 Feb;75(1):187-93. PMID: 17295579. **X-5**
143. Chamberlain P, Price J, Leve LD, et al. Prevention of behavior problems for children in foster care: outcomes and mediation effects. *Prev Sci* 2008 Mar;9(1):17-27. PMID: 18185995. **X-4, X-5**
144. Chaplin JE, Kristrom B, Jonsson B, et al. Improvements in behaviour and self-esteem following growth hormone treatment in short prepubertal children. *Horm Res Paediatr* 2011;75(4):291-303. PMID: 21304250. **X-4**
145. Chapple ED. Rehabilitation of character disturbed adolescents through productive participation. *Rehabil Rec* 1973 Sep-Oct;14(5):1-7. PMID: 4731738. **X-11**
146. Chessick RD. The psychotherapy of borderland patients. *Am J Psychother* 1966 Oct;20(4):600-14. PMID: 5972567. **X-11**
147. Chhangur RR, Weeland J, Overbeek G, et al. ORCHIDS: an observational randomized controlled trial on childhood differential susceptibility. *BMC Public Health* 2012;12:917. PMID: 23107225. **X-1, X-4, X-7, X-8**
148. Choi AN, Lee MS, Lee JS. Group Music Intervention Reduces Aggression and Improves Self-esteem in Children with Highly Aggressive Behavior: A Pilot Controlled Trial. *Evid Based Complement Alternat Med* 2010 Jun;7(2):213-7. PMID: 18955314. **X-5, X-8**
149. Chorpita BF, Weisz JR, Daleiden EL, et al. Long-Term Outcomes for the Child STEPs Randomized Effectiveness Trial: A Comparison of Modular and Standard Treatment Designs With Usual Care. *J Consult Clin Psychol* 2013 Aug 26; PMID: 23978169. **X-8**
150. Chronis-Tuscano A, O'Brien KA, Johnston C, et al. The relation between maternal ADHD symptoms & improvement in child behavior following brief behavioral parent training is mediated by change in negative parenting. *Journal of Abnormal Child Psychology* 2011;39(7):1047-57. **X-4, X-6, X-8**
151. Clark SE, Jerrott S. Effectiveness of Day Treatment for Disruptive Behaviour Disorders: What is the Long-term Clinical Outcome for Children? *J Can Acad Child Adolesc Psychiatry* 2012 Aug;21(3):204-12. PMID: 22876266. **X-4, X-6, X-8**
152. Coats KI. Cognitive self-instructional training approach for reducing disruptive behavior of young children. *Psychol Rep* 1979 Feb;44(1):127-34. PMID: 461602. **X-11**
153. Coccaro EF, Kavoussi RJ, Hauger RL. Serotonin function and antiaggressive response to fluoxetine: a pilot study. *Biol Psychiatry* 1997 Oct 1;42(7):546-52. PMID: 9376450. **X-3**
154. Cohen M, Freedman N, Engelhardt DM, et al. Family interaction patterns, drug treatment, and change in social aggression. *Arch Gen Psychiatry* 1968 Jul;19(1):50-6. PMID: 5661009. **X-11**
155. Cohen RL. DEVELOPMENTS IN THE ISOLATION THERAPY OF BEHAVIOR DISORDERS OF CHILDREN. *Curr Psychiatr Ther* 1963;3:180-7. PMID: 14284460. **X-11**
156. Colmant SA, Merta RJ. Using the sweat lodge ceremony as group therapy for Navajo youth. *Journal for Specialists in Group Work* 1999;24(1):55-73. **X-2**
157. Conduct Problems Prevention Research G. The Difficulty of Maintaining Positive Intervention Effects: A Look at Disruptive Behavior, Deviant Peer Relations, and Social Skills During the Middle

School Years. *J Early Adolesc* 2010 Aug 1;30(4):PMID: 24319308. **X-4**

158. Conduct Problems Prevention Research Group. Initial impact of the Fast Track prevention trial for conduct problems: I. The high-risk sample. *Conduct Problems Prevention Research Group. J Consult Clin Psychol* 1999 Oct;67(5):631-47. PMID: 10535230. **X-5**

159. Conduct Problems Prevention Research Group. Evaluation of the first 3 years of the Fast Track prevention trial with children at high risk for adolescent conduct problems. *J Abnorm Child Psychol* 2002 Feb;30(1):19-35. PMID: 11930969. **X-2, X-5**

160. Conduct Problems Prevention Research Group. Fast track randomized controlled trial to prevent externalizing psychiatric disorders: findings from grades 3 to 9. *J Am Acad Child Adolesc Psychiatry* 2007 Oct;46(10):1250-62. PMID: 17885566. **X-5, X-6**

161. Conduct Problems Prevention Research Group. The effects of the fast track preventive intervention on the development of conduct disorder across childhood. *Child Dev* 2011 Jan-Feb;82(1):331-45. PMID: 21291445. **X-4**

162. Connor DF, Findling RL, Kollins SH, et al. Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: A randomized, double-blind, placebo-controlled trial. *CNS Drugs* 2010;24(9):755-68. **X-4**

163. Cook MN, Crisostomo PS, Simpson TS, et al. Effectiveness of an intensive outpatient program for disruptive children: initial findings. *Community Ment Health J* 2014 Feb;50(2):164-71. PMID: 23299227. **X-6**

164. Cooper LJ, Wacker DP, Sasso GM, et al. Using parents as therapists to evaluate appropriate behavior of their children: application to a tertiary diagnostic clinic. *J Appl Behav Anal* 1990 Fall;23(3):285-96. PMID: 2249965. **X-11**

165. Copping VE, Warling DL, Benner DG, et al. A child trauma treatment pilot study. *Journal of Child and Family Studies* 2001;10(4):467-75. **X-4, X-6**

166. Corr PJ, Kumari V. Effect of D-amphetamine on emotion-potentiated startle in healthy humans:

implications for psychopathy and antisocial behaviour. *Psychopharmacology (Berl)* 2013 Jan;225(2):373-9. PMID: 22864946. **X-2, X-3**

167. Costantino G, Malgady RG, Rogler LH. Storytelling through pictures: Culturally sensitive psychotherapy for Hispanic children and adolescents. *Journal of Clinical Child Psychology* 1994;23(1):13-20. **X-4, X-10**

168. Costin J, Chambers SM. Parent management training as a treatment for children with oppositional defiant disorder referred to a mental health clinic. *Clin Child Psychol Psychiatry* 2007 Oct;12(4):511-24. PMID: 18095534. **X-6, X-8, X-10**

169. Cotter KL, Bacallao M, Smokowski PR, et al. Parenting Interventions Implementation Science: How Delivery Format Impacts the Parenting Wisely Program. *Research on Social Work Practice* 2013;1049731513490811. **X-10**

170. Crane DR, Hillin HH, Jakubowski SF. Costs of Treating Conduct Disordered Medicaid Youth with and without Family Therapy. *American Journal of Family Therapy* 2005;33(5):403-13. **X-2, X-3, X-6, X-8**

171. Cueva JE, Overall JE, Small AM, et al. Carbamazepine in aggressive children with conduct disorder: a double-blind and placebo-controlled study. *J Am Acad Child Adolesc Psychiatry* 1996 Apr;35(4):480-90. PMID: 8919710. **X-5**

172. Cunningham CE, Bremner R, Boyle M. Large group community-based parenting programs for families of preschoolers at risk for disruptive behaviour disorders: utilization, cost effectiveness, and outcome. *J Child Psychol Psychiatry* 1995 Oct;36(7):1141-59. PMID: 8847377. **X-4a**

173. Cunningham MA, Pillai V, Rogers WJ. Haloperidol in the treatment of children with severe behaviour disorders. *Br J Psychiatry* 1968 Jul;114(512):845-54. PMID: 4874166. **X-11**

174. Cunningham PB, Foster SL, Warner SE. Culturally relevant family-based treatment for adolescent delinquency and substance abuse: understanding within-session processes. *J Clin Psychol* 2010 Aug;66(8):830-46. PMID: 20564683. **X-1, X-2, X-6, X-7, X-8**

175. Cunningham RM, Whiteside LK, Chermack ST, et al. Dating violence: outcomes following a brief motivational interviewing intervention among at-risk

- adolescents in an urban emergency department. *Acad Emerg Med* 2013 Jun;20(6):562-9. PMID: 23758302. **X-4**
176. Curtis NM, Ronan KR, Borduin CM. Multisystemic treatment: a meta-analysis of outcome studies. *J Fam Psychol* 2004 Sep;18(3):411-9. PMID: 15382965. **X-1**
177. Curtis NM, Ronan KR, Heiblum N, et al. Dissemination and effectiveness of multisystemic treatment in New Zealand: a benchmarking study. *J Fam Psychol* 2009 Apr;23(2):119-29. PMID: 19364207. **X-5, X-6**
178. Da Fonseca D, Cury F, Santos A, et al. How to increase academic performance in children with oppositional defiant disorder? An implicit theory effect. *J Behav Ther Exp Psychiatry* 2010 Sep;41(3):234-7. PMID: 20170904. **X-7, X-8**
179. Dadds MR, Cauchi AJ, Wimalaweera S, et al. Outcomes, moderators, and mediators of empathic-emotion recognition training for complex conduct problems in childhood. *Psychiatry Res* 2012 Oct 30;199(3):201-7. PMID: 22703720. **X-4**
180. Danforth JS. Altering the function of commands presented to boys with oppositional and hyperactive behavior. *Anal Verbal Behav* 2002;18:31-49. PMID: 22477227. **X-6**
181. Dangel RF, Deschner JP, Rasp RR. Anger control training for adolescents in residential treatment. *Behav Modif* 1989 Oct;13(4):447-58. PMID: 2818462. **X-11**
182. Davis DL, Boster LH. Cognitive-behavioral-expressive interventions with aggressive and resistant youths. *Child Welfare* 1992 Nov-Dec;71(6):557-73. PMID: 1424948. **X-11**
183. Davis TN, Dacus S, Strickland E, et al. The effects of a weighted vest on aggressive and self-injurious behavior in a child with autism. *Dev Neurorehabil* 2013 Jun;16(3):210-5. PMID: 23278839. **X-4, X-5, X-6, X-7, X-8**
184. Day C, Michelson D, Thomson S, et al. Evaluation of a peer led parenting intervention for disruptive behaviour problems in children: community based randomised controlled trial. *BMJ* 2012;344:e1107. PMID: 22416059. **X-4**
185. de Koning P, Mak M, de Vries MH, et al. Eltoprazine in aggressive mentally handicapped patients: a double-blind, placebo- and baseline-controlled multi-centre study. The Eltoprazine Aggression Research Group. *Int Clin Psychopharmacol* 1994 Sep;9(3):187-94. PMID: 7814828. **X-3, X-4**
186. Dean AJ, Bor W, Adam K, et al. A randomized, controlled, crossover trial of fish oil treatment for impulsive aggression in children and adolescents with disruptive behavior disorders. *J Child Adolesc Psychopharmacol* 2014 Apr;24(3):140-8. PMID: 24689967. **X-2, X-8**
187. Degarmo DS, Forgatch MS. Efficacy of Parent Training for Stepfathers: From Playful Spectator and Polite Stranger to Effective Stepfathering. *Parent Sci Pract* 2007 Nov;7(4):331-55. PMID: 19173011. **X-4**
188. DeGarmo DS, Patterson GR, Forgatch MS. How do outcomes in a specified parent training intervention maintain or wane over time? *Prev Sci* 2004 Jun;5(2):73-89. PMID: 15134313. **X-4**
189. Delva-Tauiiili J. Does brief Aikido training reduce aggression of youth? *Percept Mot Skills* 1995 Feb;80(1):297-8. PMID: 7624209. **X-8, X-10**
190. Devlin S, Healy O, Leader G, et al. Comparison of behavioral intervention and sensory-integration therapy in the treatment of challenging behavior. *J Autism Dev Disord* 2011 Oct;41(10):1303-20. PMID: 21161577. **X-4, X-6, X-7, X-8**
191. Diego MA, Field T, Hernandez-Reif M, et al. Aggressive adolescents benefit from massage therapy. *Adolescence* 2002 Fall;37(147):597-607. PMID: 12458696. **X-2**
192. Dishion TJ, Andrews DW. Preventing escalation in problem behaviors with high-risk young adolescents: immediate and 1-year outcomes. *J Consult Clin Psychol* 1995 Aug;63(4):538-48. PMID: 7673531. **X-4**
193. Dishion TJ, Brennan LM, Shaw DS, et al. Prevention of Problem Behavior Through Annual Family Check-Ups in Early Childhood: Intervention Effects From Home to Early Elementary School. *J Abnorm Child Psychol* 2013 Sep 11; PMID: 24022677. **X-4**
194. Dishion TJ, Brennan LM, Shaw DS, et al. Prevention of problem behavior through annual family check-ups in early childhood: intervention effects from home to early elementary school. *J*

- Abnorm Child Psychol 2014;42(3):343-54. PMID: 24022677. **X-4**
195. Dittman CK, Farruggia SP, Palmer ML, et al. Predicting success in an online parenting intervention: the role of child, parent, and family factors. *J Fam Psychol* 2014 Apr;28(2):236-43. PMID: 24611694. **X-5, X-6**
196. Dodge KA, Godwin J. Social-information-processing patterns mediate the impact of preventive intervention on adolescent antisocial behavior. *Psychol Sci* 2013 Apr;24(4):456-65. PMID: 23406610. **X-4a**
197. Dogra A, Veeraraghavan V. A study of psychological intervention of children with aggressive conduct disorder. *Indian Journal of Clinical Psychology* 1994;21(1):28-32. **X-10**
198. Donohue B, Azrin NH, Lawson H, et al. Improving initial session attendance of substance abusing and conduct disordered adolescents: A controlled study. *Journal of Child & Adolescent Substance Abuse* 1998;8(1):1-13. **X-2, X-7**
199. Doob AN, Wood LE. Catharsis and aggression: effects of annoyance and retaliation on aggressive behavior. *J Pers Soc Psychol* 1972 May;22(2):156-62. PMID: 5024076. **X-11**
200. Doolittle JC. Immunizing children against possible antisocial effects of viewing television violence: a curricular intervention. *Percept Mot Skills* 1980 Oct;51(2):498. PMID: 7443368. **X-11**
201. Dorn LD, Kolko DJ, Shenk CE, et al. Influence of treatment for disruptive behavior disorders on adrenal and gonadal hormones in youth. *J Clin Child Adolesc Psychol* 2011;40(4):562-71. PMID: 21722028. **X-7**
202. Drabman R, Spitalnik R. Social isolation as a punishment procedure: a controlled study. *J Exp Child Psychol* 1973 Oct;16(2):236-49. PMID: 4773588. **X-11**
203. Dubow EF, Huesmann LR, Eron LD. Mitigating aggression and promoting prosocial behavior in aggressive elementary schoolboys. *Behav Res Ther* 1987;25(6):527-31. PMID: 3426514. **X-11**
204. Ducharme JM, Atkinson L, Poulton L. Success-based, noncoercive treatment of oppositional behavior in children from violent homes. *J Am Acad Child Adolesc Psychiatry* 2000 Aug;39(8):995-1004. PMID: 10939227. **X-6, X-7**
205. Ducharme JM, Harris K, Milligan K, et al. Sequential evaluation of reinforced compliance and graduated request delivery for the treatment of noncompliance in children with developmental disabilities. *J Autism Dev Disord* 2003 Oct;33(5):519-26. PMID: 14594331. **X-4**
206. Ducharme JM, Spencer T, Davidson A, et al. Errorless compliance training: building a cooperative relationship between parents with brain injury and their oppositional children. *Am J Orthopsychiatry* 2002 Oct;72(4):585-95. PMID: 15792043. **X-4, X-6, X-7, X-8**
207. Dunbar F, Kusumakar V, Daneman D, et al. Growth and Sexual Maturation During Long-Term Treatment With Risperidone. *The American Journal of Psychiatry* 2004;161(5):918-20. **X-4**
208. Dunsmore JC, Booker JA, Ollendick TH. Parental Emotion Coaching and Child Emotion Regulation as Protective Factors for Children with Oppositional Defiant Disorder. *Soc Dev* 2013 Aug 1;22(3) PMID: 24187441. **X-2, X-5, X-6, X-7, X-8**
209. Dura-Vila G, Klasen H, Makatini Z, et al. Mental health problems of young refugees: duration of settlement, risk factors and community-based interventions. *Clin Child Psychol Psychiatry* 2013 Oct;18(4):604-23. PMID: 23104967. **X-2, X-4, X-6**
210. Eames C, Daley D, Hutchings J, et al. The impact of group leaders' behaviour on parents acquisition of key parenting skills during parent training. *Behav Res Ther* 2010 Dec;48(12):1221-6. PMID: 20932512. **X-3, X-7, X-8**
211. Eddy JM, Reid JB, Stoolmiller M, et al. Outcomes During Middle School for an Elementary School-Based Preventive Intervention for Conduct Problems: Follow-Up Results From a Randomized Trial. *Behavior Therapy* 2003;34(4):535-52. **X-4, X-5**
212. Edwards VE. Side effects of clonazepam therapy. *Proc Aust Assoc Neurol* 1974;11:199-202. PMID: 4219957. **X-11**
213. Effron AS, Freedman AM. The treatment of behavior disorders in children with benadryl. *J Pediatr* 1953 Feb;42(2):261-6. PMID: 13023526. **X-11**

214. Eisen P. Levels of psychotherapy: a study of intimacy. *Aust N Z J Psychiatry* 1973 Sep;7(3):169-73. PMID: 4520538. **X-11**
215. Eisen P. The infantile roots of adolescent violence. *Am J Psychoanal* 1976 Fall;36(3):211-8. PMID: 1008101. **X-11**
216. Elias LC, Marturano EM, Motta AM, et al. Treating boys with low school achievement and behavior problems: comparison of two kinds of intervention. *Psychol Rep* 2003 Feb;92(1):105-16. PMID: 12674267. **X-4**
217. Ellis ML, Lindsey MA, Barker ED, et al. Predictors of engagement in a school-based family preventive intervention for youth experiencing behavioral difficulties. *Prev Sci* 2013 Oct;14(5):457-67. PMID: 23420474. **X-5, X-6, X-7, X-8**
218. Eme R. Male life-course-persistent antisocial behavior: the most important pediatric mental health problem. *Arch Pediatr Adolesc Med* 2010 May;164(5):486-7. PMID: 20439801. **X-1, X-2, X-3, X-4, X-5, X-6, X-7, X-8**
219. Endrass J, Rossegger A, Urbaniok F, et al. Procedures for preventing juvenile violence in Switzerland: the Zurich model. *New Dir Youth Dev* 2011 Spring;2011(129):79-87. PMID: 21491574. **X-2, X-5, X-6, X-8**
220. Enebrink P, Hogstrom J, Forster M, et al. Internet-based parent management training: a randomized controlled study. *Behav Res Ther* 2012 Apr;50(4):240-9. PMID: 22398153. **X-5**
221. Ercan ES, Akyol Ardic U, Kabukcu Basay B, et al. Atomoxetine response in the inattentive and combined subtypes of attention deficit hyperactivity disorder: a retrospective chart review. *Atten Defic Hyperact Disord* 2013 Dec;5(4):377-85. PMID: 23737214. **X-4, X-6, X-8**
222. Ercan ES, Ardic UA, Kutlu A, et al. No Beneficial Effects of Adding Parent Training to Methylphenidate Treatment for ADHD + ODD/CD Children: A 1-Year Prospective Follow-Up Study. *J Atten Disord* 2014 Apr 20;18(2):145-57. PMID: 22522574. **X-4**
223. Ercan ES, Uysal T, Ercan E, et al. Aripiprazole in children and adolescents with conduct disorder: A single-center, open-label study. *Pharmacopsychiatry* 2012;45(1):13-9. **X-6**
224. Ercan ES, Varan A, Deniz Ü. Effects of Combined Treatment on Turkish Children Diagnosed with Attention-Deficit/Hyperactivity Disorder: A Preliminary Report. *Journal of Child and Adolescent Psychopharmacology* 2005;15(2):203-19. **X-4**
225. Erdogan A, Yurteri N. Aripiprazole treatment in the adolescent patients with inhalants use disorders and conduct disorder: A retrospective case analysis. *Yeni Symposium: psikiyatri, nöroloji ve davranış bilimleri dergisi* 2010;48(3):229-33. **X-6, X-8**
226. Evans ME, Boothroyd RA, Greenbaum PE, et al. Outcomes associated with clinical profiles of children in psychiatric crisis enrolled in intensive, in-home interventions. *Mental Health Services Research* 2001;3(1):35-44. **X-6**
227. Eyberg S, Boggs S, Jaccard J. Does maintenance treatment matter? *J Abnorm Child Psychol* 2014;42(3):355-66. PMID: 24413969. **X-6**
228. Eyberg SM, Funderburk BW, Hembree-Kigin TL, et al. Parent-child interaction therapy with behavior problem children: One and two year maintenance of treatment effects in the family. *Child & Family Behavior Therapy* 2001;23(4):1-20. **X-6**
229. Eysbouts Y, Poulton A, Salmelainen P. Stimulant medication in pre-school children in New South Wales. *J Paediatr Child Health* 2011 Dec;47(12):870-4. PMID: 21658150. **X-4, X-6, X-7**
230. Faretra G, Dooher L, Dowling J. Comparison of haloperidol and fluphenazine in disturbed children. *Am J Psychiatry* 1970 May;126(11):1670-3. PMID: 5443653. **X-11**
231. Farmer CA, Arnold LE, Bukstein OG, et al. The treatment of severe child aggression (TOSCA) study: Design challenges. *Child Adolesc Psychiatry Ment Health* 2011;5(1):36. PMID: 22074813. **X-1, X-2**
232. Fayyad JA, Farah L, Cassir Y, et al. Dissemination of an evidence-based intervention to parents of children with behavioral problems in a developing country. *Eur Child Adolesc Psychiatry* 2010 Aug;19(8):629-36. PMID: 20169380. **X-5, X-6, X-8**
233. Feil EG, Gordon D, Waldron H, et al. Development and Pilot Testing of an Internet-based Parenting Education Program for Teens and Pre-Teens: Parenting Wisely. *The Family Psychologist* 2011;27(22):22-6. **X-5, X-6**

234. Fernandez MA, Butler AM, Eyberg SM. Treatment outcome for low socioeconomic status African American families in parent-child interaction therapy: A pilot study. *Child & Family Behavior Therapy* 2011;33(1):32-48. **X-6**
235. Fernandez MA, Eyberg SM. Predicting treatment and follow-up attrition in parent-child interaction therapy. *J Abnorm Child Psychol* 2009 Apr;37(3):431-41. PMID: 19096926. **X-8**
236. Fernandez MA, Eyberg SM. Predicting treatment and follow-up attrition in parent-child interaction therapy. *Journal of Abnormal Child Psychology* 2009;37(3):431-41. **X-2, X-6, X-7, X-8**
237. Fernández-Mayoralas DM, Fernández-Jaén A, Muñoz-Jareño N, et al. Treatment with paliperidone in children with behavior disorders previously treated with risperidone: An open-label trial. *Clinical Neuropharmacology* 2012;35(5):227-30. **X-4, X-6**
238. Field CE, Nash HM, Handwerk ML, et al. A modification of the token economy for nonresponsive youth in family-style residential care. *Behav Modif* 2004 May;28(3):438-57. PMID: 15104871. **X-5, X-6, X-8**
239. Fields EM. The effects of Deanol in children with organic and functional behavior disorders. *N Y State J Med* 1961 Mar 15;61:901-5. PMID: 13699373. **X-11**
240. Findling RL, Aman MG, Eerdeken M, et al. Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. *Am J Psychiatry* 2004 Apr;161(4):677-84. PMID: 15056514. **X-4, X-6**
241. Findling RL, Kusumakar V, Daneman D, et al. Prolactin levels during long-term risperidone treatment in children and adolescents. *J Clin Psychiatry* 2003 Nov;64(11):1362-9. PMID: 14658952. **X-4, X-6**
242. Findling RL, Mankoski R, Timko K, et al. A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder. *J Clin Psychiatry* 2014 Jan;75(1):22-30. PMID: 24502859. **X-4**
243. Finkelstein JW, Susman EJ, Chinchilli VM, et al. Estrogen or testosterone increases self-reported aggressive behaviors in hypogonadal adolescents. *J Clin Endocrinol Metab* 1997 Aug;82(8):2433-8. PMID: 9253313. **X-2, X-4**
244. Fish B. An approach to prevention in infants at risk for schizophrenia. *Developmental deviations from birth to 10 years. J Am Acad Child Psychiatry* 1976 Winter;15(1):62-82. PMID: 1254848. **X-11**
245. Fisher DC, Wollersheim JP. Social reinforcement: a treatment component in verbal self-instructional training. *J Abnorm Child Psychol* 1986 Mar;14(1):41-8. PMID: 3950220. **X-11**
246. Fisher WW, Thompson RH, Hagopian LP, et al. Facilitating tolerance of delayed reinforcement during functional communication training. *Behav Modif* 2000 Jan;24(1):3-29. PMID: 10641365. **X-4, X-5, X-6, X-7**
247. Fleischman MJ. A replication of Patterson's "Intervention for boys with conduct problems". *J Consult Clin Psychol* 1981 Jun;49(3):342-51. PMID: 7276323. **X-11**
248. Fleisher SJ, Berkovitz IH, Briones L, et al. Antisocial behavior, school performance, and reactions to loss: the value of group counseling and communication skills training. *Adolesc Psychiatry* 1987;14:546-55. PMID: 3618939. **X-11**
249. Forehand RL, Merchant MJ, Parent J, et al. An examination of a Group Curriculum for parents of young children with disruptive behavior. *Behav Modif* 2011 May;35(3):235-51. PMID: 21478243. **X-4**
250. Forgatch MS, DeGarmo DS. Parenting through change: an effective prevention program for single mothers. *J Consult Clin Psychol* 1999 Oct;67(5):711-24. PMID: 10535238. **X-4**
251. Forgatch MS, Degarmo DS, Beldavs ZG. An efficacious theory-based intervention for stepfamilies. *Behav Ther* 2005;36(4):357-65. PMID: 16718303. **X-4**
252. Forgatch MS, Patterson GR, Degarmo DS, et al. Testing the Oregon delinquency model with 9-year follow-up of the Oregon Divorce Study. *Dev Psychopathol* 2009 Spring;21(2):637-60. PMID: 19338702. **X-4**
253. Foster EM, Olchowski AE, Webster-Stratton CH. Is stacking intervention components cost-effective? An analysis of the Incredible Years

- program. *J Am Acad Child Adolesc Psychiatry* 2007 Nov;46(11):1414-24. PMID: 18049291. **X-2a, X-7a**
254. Foster RM. Parenting the child with a behavior disorder: a family approach. *Pediatr Ann* 1977 Oct;6(10):637-45. PMID: 909733. **X-11**
255. Fraiberg S. Technical aspects of the analysis of a child with a severe behavior disorder. *J Am Psychoanal Assoc* 1962 Apr;10:338-67. PMID: 13894444. **X-11**
256. Frampton I, McArthur C, Crowe B, et al. Beyond parent training: predictors of clinical status and service use two to three years after Scallywags. *Clin Child Psychol Psychiatry* 2008 Oct;13(4):593-608. PMID: 18927143. **X-4a**
257. Frankel F, Myatt R, Cantwell DP, et al. Parent-assisted transfer of children's social skills training: effects on children with and without attention-deficit hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry* 1997 Aug;36(8):1056-64. PMID: 9256585. **X-4**
258. Fraone G, Wilson S, Casamassimo PS, et al. The effect of orally administered midazolam on children of three age groups during restorative dental care. *Pediatr Dent* 1999 Jul-Aug;21(4):235-41. PMID: 10436477. **X-4, X-6**
259. Freedman AM, Kremer MW, Robertiello R, et al. The treatment of behavior disorders in children with tolserol. *J Pediatr* 1955 Sep;47(3):369-72. PMID: 13252532. **X-11**
260. Freitag C. Neurobiology and treatment of adolescent female conduct disorder: FemNAT-CD consortium: a new European cooperation. *Eur Child Adolesc Psychiatry* 2014 Aug;23(8):723-4. PMID: 24682583. **X-1**
261. Fried RI, Sherman J. Self-help for troubled teens: Delancey Street in the desert. *Ohio Med* 1991 Mar;87(3):95-6. PMID: 2030889. **X-11**
262. Frölich J, Döpfner M, Berner W, et al. Behandlungseffekte kombinierter kognitiver Verhaltenstherapie mit Elternteraining bei hyperkinetischen Kindern. *Praxis der Kinderpsychologie und Kinderpsychiatrie* 2002;51(6):476-93. **X-6, X-10**
263. Funderburk BW, Eyberg SM, Newcomb K, et al. Parent-child interaction therapy with behavior problem children: Maintenance of treatment effects in the school setting. *Child & Family Behavior Therapy* 1998;20(2):17-38. **X-6**
264. Fung AL. Intervention for aggressive victims of school bullying in Hong Kong: a longitudinal mixed-methods study. *Scand J Psychol* 2012 Aug;53(4):360-7. PMID: 22670574. **X-5, X-6**
265. Furlong M, McGilloway S. The longer term experiences of parent training: a qualitative analysis. *Child Care Health Dev* 2014 Sep 24; PMID: 25256901. **X-2, X-7**
266. Gabel S, Swanson AJ, Shindledecker R. Aggressive children in a day treatment program: changed outcome and possible explanations. *Child Abuse Negl* 1990;14(4):515-23. PMID: 2289182. **X-11**
267. Gada SS, Kanumakala S. Helping parents solve stressful life problems enhances the effectiveness of interventions for child aggression and antisocial behaviour. *Evid Based Ment Health* 2003 Nov;6(4):120. PMID: 14585793. **X-1**
268. Gadow KD, Arnold LE, Molina BS, et al. Risperidone added to parent training and stimulant medication: effects on attention-deficit/hyperactivity disorder, oppositional defiant disorder, conduct disorder, and peer aggression. *J Am Acad Child Adolesc Psychiatry* 2014 Sep;53(9):948-59.e1. PMID: 25151418. **X-4**
269. Gadow KD, Nolan EE. Methylphenidate and comorbid anxiety disorder in children with both chronic multiple tic disorder and ADHD. *J Atten Disord* 2011 Apr;15(3):246-56. PMID: 20378921. **X-4**
270. Gadow KD, Nolan EE, Sverd J. Methylphenidate in hyperactive boys with comorbid tic disorder: II. Short-term behavioral effects in school settings. *J Am Acad Child Adolesc Psychiatry* 1992 May;31(3):462-71. PMID: 1592778. **X-11**
271. Gadow KD, Nolan EE, Sverd J, et al. Methylphenidate in aggressive-hyperactive boys: I. Effects on peer aggression in public school settings. *J Am Acad Child Adolesc Psychiatry* 1990 Sep;29(5):710-8. PMID: 2228923. **X-11**
272. Garcia D, Bagner DM, Pruden SM, et al. Language Production in Children With and At Risk for Delay: Mediating Role of Parenting Skills. *J Clin Child Adolesc Psychol* 2014 Apr 30:1-12. PMID: 24787263. **X-7, X-8**

273. Gardner F, Shaw DS, Dishion TJ, et al. Randomized prevention trial for early conduct problems: effects on proactive parenting and links to toddler disruptive behavior. *J Fam Psychol* 2007 Sep;21(3):398-406. PMID: 17874925. **X-5, X-6**
274. Gardner FE. Positive interaction between mothers and conduct-problem children: is there training for harmony as well as fighting? *J Abnorm Child Psychol* 1987 Jun;15(2):283-93. PMID: 3611525. **X-11**
275. Gardner HL, Forehand R, Roberts M. Time-out with children. Effects of an explanation and brief parent training on child and parent behaviors. *J Abnorm Child Psychol* 1976;4(3):277-88. PMID: 972210. **X-11**
276. Garland AF, Accurso EC, Haine-Schlagel R, et al. Searching for elements of evidence-based practices in children's usual care and examining their impact. *J Clin Child Adolesc Psychol* 2014;43(2):201-15. PMID: 24555882. **X-6**
277. Garland EJ, Kutcher S, Virani A. 2008 position paper on using SSRIs in children and adolescents. *Journal of the Canadian Academy of Child and Adolescent Psychiatry* 2009;18(2):160-5. PMID: 2009493705. **X-1, X-2, X-3, X-4, X-5, X-6**
278. Garner B, Phillips LJ, Schmidt HM, et al. Pilot study evaluating the effect of massage therapy on stress, anxiety and aggression in a young adult psychiatric inpatient unit. *Aust N Z J Psychiatry* 2008 May;42(5):414-22. PMID: 18478478. **X-4, X-5**
279. Garza-Trevino ES, Hollister LE, Overall JE, et al. Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. *Am J Psychiatry* 1989 Dec;146(12):1598-601. PMID: 2686478. **X-11**
280. Gauvain M, Perez SM. Mother-child planning and child compliance. *Child Dev* 2008 May-Jun;79(3):761-75. PMID: 18489426. **X-2, X-4**
281. Gerra G, Zaimovic A, Giucastro G, et al. Serotonergic function after (+/-)3,4-methylenedioxymethamphetamine ('Ecstasy') in humans. *Int Clin Psychopharmacol* 1998 Jan;13(1):1-9. PMID: 9988361. **X-2, X-3, X-4**
282. Gershon ES. Antisocial behavior. *Arch Gen Psychiatry* 1995 Nov;52(11):900-1. PMID: 7487338. **X-1**
283. Gersten JC, Langner TS, Eisenberg JG, et al. Stability and change in types of behavioral disturbance of children and adolescents. *J Abnorm Child Psychol* 1976;4(2):111-27. PMID: 1084892. **X-11**
284. Gervan S, Granic I, Solomon T, et al. Paternal involvement in Multisystemic Therapy: effects on adolescent outcomes and maternal depression. *J Adolesc* 2012 Jun;35(3):743-51. PMID: 22104757. **X-2**
285. Gibbs A, Moor S, Frampton C, et al. Impact of psychosocial interventions on children with disruptive and emotional disorders treated in a health camp. *Aust N Z J Psychiatry* 2008 Sep;42(9):789-99. PMID: 18696283. **X-5, X-6**
286. Giovannetti A, Trombetta N. Pretreatment of problem youths with clozapin in preparation for group psychotherapy. *Pharmakopsychiatr Neuropsychopharmakol* 1974 Sep;7(5):230-6. PMID: 4445196. **X-11**
287. Gladstone T. Brief, personality-targeted, teacher-delivered CBT interventions reduce depression, anxiety and conduct disorder symptoms in high-risk adolescents. *Evid Based Ment Health* 2013 Nov 28 PMID: 24288201. **X-4, X-5, X-8**
288. Glavin J, Witt PA. Recreation for the conduct disorder child. *Except Child* 1969 Summer;35(10):787-91. PMID: 5808752. **X-11**
289. Glennon J, Purper-Ouakil D, Bakker M, et al. Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challenges. *Eur Child Adolesc Psychiatry* 2014 Dec;23(12):1149-60. PMID: 24337449. **X-1**
290. Glod CA, Teicher MH, Butler M, et al. Modifying quiet room design enhances calming of children and adolescents. *J Am Acad Child Adolesc Psychiatry* 1994 May;33(4):558-66. PMID: 8005909. **X-5**
291. Goldbeck L, Schmid K. Effectiveness of autogenic relaxation training on children and adolescents with behavioral and emotional problems. *J Am Acad Child Adolesc Psychiatry* 2003 Sep;42(9):1046-54. PMID: 12960704. **X-4, X-6, X-8**
292. Goldstein AP, Sherman M, Gershaw NJ, et al. Training aggressive adolescents in prosocial

- behavior. *J Youth Adolesc* 1978 Mar;7(1):73-92. PMID: 24408723. **X-11**
293. Golubchik P, Sever J, Zalsman G, et al. Methylphenidate in the treatment of female adolescents with cooccurrence of attention deficit/hyperactivity disorder and borderline personality disorder: a preliminary open-label trial. *Int Clin Psychopharmacol* 2008 Jul;23(4):228-31. PMID: 18446088. **X-4**
294. Gomez D, Bridges AJ, Andrews AR, III, et al. Delivering parent management training in an integrated primary care setting: Description and preliminary outcome data. *Cognitive and Behavioral Practice* 2014;21(3):296-309. **X-6**
295. Gottfredson D, Kumpfer K, Polizzi-Fox D, et al. The Strengthening Washington D.C. Families project: a randomized effectiveness trial of family-based prevention. *Prev Sci* 2006 Mar;7(1):57-74. PMID: 16555144. **X-4, X-5, X-8**
296. Graham-Bermann SA, Howell KH, Lilly M, et al. Mediators and moderators of change in adjustment following intervention for children exposed to intimate partner violence. *J Interpers Violence* 2011 Jun;26(9):1815-33. PMID: 20587468. **X-4, X-6, X-8**
297. Granic I, O'Hara A, Pepler D, et al. A dynamic systems analysis of parent-child changes associated with successful "real-world" interventions for aggressive children. *J Abnorm Child Psychol* 2007 Oct;35(5):845-57. PMID: 17549621. **X-5, X-6**
298. Grasmann D, Stadler C. VIA—Intensivtherapeutischer Behandlungsansatz bei Störungen des Sozialverhaltens. *Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie* 2011;39(1):23-31. **X-10, X-12**
299. Green JM, Wood AJ, Kerfoot MJ, et al. Group therapy for adolescents with repeated self harm: randomised controlled trial with economic evaluation. *BMJ* 2011;342:d682. PMID: 21459975. **X-4**
300. Greenbaum PE, Turner C, Cook EW, 3rd, et al. Dentists' voice control: effects on children's disruptive and affective behavior. *Health Psychol* 1990;9(5):546-58. PMID: 2226384. **X-11**
301. Grizenko N. Outcome of multimodal day treatment for children with severe behavior problems: A five-year follow-up. *Journal of the American Academy of Child & Adolescent Psychiatry* 1997;36(7):989-97. **X-6**
302. Grizenko N, Papineau D, Sayegh L. A comparison of day treatment and outpatient treatment for children with disruptive behaviour problems. *Can J Psychiatry* 1993 Aug;38(6):432-5. PMID: 8402437. **X-11**
303. Grizenko N, Sayegh L. Evaluation of the effectiveness of a psychodynamically oriented day treatment program for children with behaviour problems: a pilot study. *Can J Psychiatry* 1990 Aug;35(6):519-25. PMID: 2207986. **X-11**
304. Groenman AP, Oosterlaan J, Rommelse NN, et al. Stimulant treatment for attention-deficit hyperactivity disorder and risk of developing substance use disorder. *Br J Psychiatry* 2013 Aug;203(2):112-9. PMID: 23846996. **X-4, X-7, X-8**
305. Gross D, Fogg L, Webster-Stratton C, et al. Parent training of toddlers in day care in low-income urban communities. *J Consult Clin Psychol* 2003 Apr;71(2):261-78. PMID: 12699021. **X-4**
306. Gross DA, Belcher HM, Ofonedu ME, et al. Study protocol for a comparative effectiveness trial of two parent training programs in a fee-for-service mental health clinic: can we improve mental health services to low-income families? *Trials* 2014;15:70. PMID: 24581245. **X-1**
307. Grow LL, Kelley ME, Roane HS, et al. Utility of extinction-induced response variability for the selection of mands. *J Appl Behav Anal* 2008 Spring;41(1):15-24. PMID: 18468276. **X-4, X-6, X-8**
308. Guez G, Gill-Lev I. A psychoeducational group for adolescent girls to facilitate egalitarian, non-abusive relationships. *Int J Group Psychother* 2009 Jul;59(3):385-405. PMID: 19548786. **X-2, X-4**
309. Gundersen K, Svartdal F. Aggression replacement training in Norway: Outcome evaluation of 11 Norwegian student projects. *Scandinavian journal of educational research* 2006;50(1):63-81. **X-4**
310. Günther T, Herpertz-Dahlmann B, Jolles J, et al. The Influence of Risperidone on Attentional Functions in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Co-Morbid Disruptive Behavior Disorder. *Journal of Child and Adolescent Psychopharmacology* 2006;16(6):725-35. **X-4, X-6**

311. Gustafsson PA, Birberg-Thornberg U, Duchon K, et al. EPA supplementation improves teacher-rated behaviour and oppositional symptoms in children with ADHD. *Acta Paediatr* 2010 Oct;99(10):1540-9. PMID: 20491709. **X-4, X-8**
312. Gustle LH, Hansson K, Sundell K, et al. Blueprints in Sweden. Symptom load in Swedish adolescents in studies of Functional Family Therapy (FFT), Multisystemic Therapy (MST) and Multidimensional Treatment Foster Care (MTFC). *Nord J Psychiatry* 2007;61(6):443-51. PMID: 18236311. **X-1, X-2, X-6, X-7**
313. Gutstein RR. Percutaneous tuberculin therapy in behavior disorders of children. *J Indiana State Med Assoc* 1946 Mar;39:113-5. PMID: 21016328. **X-11**
314. Guttman HA. The child's participation in conjoint family therapy. *J Am Acad Child Psychiatry* 1975 Summer;14(3):490-9. PMID: 1141568. **X-11**
315. Guzder J, Paisley V, Robertson-Hickling H, et al. Promoting Resilience in High-risk Children in Jamaica: A Pilot Study of a Multimodal Intervention. *J Can Acad Child Adolesc Psychiatry* 2013 May;22(2):125-30. PMID: 23667358. **X-5**
316. Gvozdjakova A, Kucharska J, Ostatnikova D, et al. Ubiquinol improves symptoms in children with autism. *Oxid Med Cell Longev* 2014;2014:798957. PMID: 24707344. **X-4, X-6**
317. Haas M, Karcher K, Pandina GJ. Treating disruptive behavior disorders with risperidone: a 1-year, open-label safety study in children and adolescents. *J Child Adolesc Psychopharmacol* 2008 Aug;18(4):337-45. PMID: 18759643. **X-6**
318. Haas SM, Waschbusch DA, Pelham WE, Jr., et al. Treatment response in CP/ADHD children with callous/unemotional traits. *J Abnorm Child Psychol* 2011 May;39(4):541-52. PMID: 21188627. **X-2, X-4, X-6**
319. Haine-Schlagel R, Fettes DL, Garcia AR, et al. Consistency with Evidence-Based Treatments and Perceived Effectiveness of Children's Community-Based Care. *Community Ment Health J* 2013 Jan 8 PMID: 23296551. **X-2, X-3, X-6, X-8**
320. Haine-Schlagel R, Fettes DL, Garcia AR, et al. Consistency with evidence-based treatments and perceived effectiveness of children's community-based care. *Community Ment Health J* 2014 Feb;50(2):158-63. PMID: 23296551. **X-1, X-6**
321. Hall S, Warren ME. Teaching to improve parent-child interaction: an educational case study. *Acad Psychiatry* 2012 Nov 1;36(6):465-7. PMID: 23154694. **X-2, X-3, X-4, X-6, X-7, X-8**
322. Halldorsdottir T, Ollendick TH, Ginsburg G, et al. Treatment Outcomes in Anxious Youth with and without Comorbid ADHD in the CAMS. *J Clin Child Adolesc Psychol* 2014 Oct 13:1-7. PMID: 25310142. **X-4**
323. Hamilton J. Taming the 'monster child'. Tips for handling behavior problems. *Dent Teamwork* 1995 Sep-Oct;8(5):47-9. PMID: 9485694. **X-10**
324. Hamilton JD. The practical search. *J Am Acad Child Adolesc Psychiatry* 2007 Mar;46(3):418-22. PMID: 17314728. **X-1, X-2**
325. Hammond JE. DRUGS FOR TREATMENT OF CHILDREN WITH BEHAVIOR DISORDERS: TOWARD A MORE SPECIFIC USE OF THEM. *Med Times* 1964 May;92:421-6. PMID: 14146040. **X-11**
326. Handen BL, Hardan AY. Open-label, prospective trial of olanzapine in adolescents with subaverage intelligence and disruptive behavioral disorders. *J Am Acad Child Adolesc Psychiatry* 2006 Aug;45(8):928-35. PMID: 16865035. **X-4, X-6**
327. Hanisch C, Freund-Braier I, Hautmann C, et al. Detecting effects of the indicated prevention Programme for Externalizing Problem behaviour (PEP) on child symptoms, parenting, and parental quality of life in a randomized controlled trial. *Behav Cogn Psychother* 2010 Jan;38(1):95-112. PMID: 19995467. **X-7b**
328. Hanish LD, Tolani PH. Patterns of change in family-based aggression prevention. *J Marital Fam Ther* 2001 Apr;27(2):213-26. PMID: 11314554. **X-4**
329. Hanley GP, Piazza CC, Fisher WW, et al. On the effectiveness of and preference for punishment and extinction components of function-based interventions. *J Appl Behav Anal* 2005 Spring;38(1):51-65. PMID: 15898474. **X-4, X-5, X-6, X-8**
330. Hansson K, Olsson M, Cederblad M. A salutogenic investigation and treatment of conduct

- disorder (CD). *Nord J Psychiatry* 2004;58(1):5-16. PMID: 14985149. **X-2, X-6**
331. Harrison-Woolrych M, Garcia-Quiroga J, Ashton J, et al. Safety and usage of atypical antipsychotic medicines in children: a nationwide prospective cohort study. *Drug Saf* 2007;30(7):569-79. PMID: 17604408. **X-2, X-6**
332. Harwood MD, Eyberg SM. Therapist verbal behavior early in treatment: relation to successful completion of parent-child interaction therapy. *J Clin Child Adolesc Psychol* 2004 Sep;33(3):601-12. PMID: 15271617. **X-2, X-3, X-6, X-7**
333. Harwood MD, Eyberg SM. Child-directed interaction: prediction of change in impaired mother-child functioning. *J Abnorm Child Psychol* 2006 Jun;34(3):335-47. PMID: 16708275. **X-6**
334. Hautmann C, Hoijtink H, Eichelberger I, et al. One-year follow-up of a parent management training for children with externalizing behaviour problems in the real world. *Behav Cogn Psychother* 2009 Jul;37(4):379-96. PMID: 19619384. **X-6, X-8**
335. Havighurst SS, Duncombe M, Frankling E, et al. An Emotion-Focused Early Intervention for Children with Emerging Conduct Problems. *J Abnorm Child Psychol* 2014 Sep 25 PMID: 25249470. **X-5**
336. Hawes DJ, Dadds MR. The treatment of conduct problems in children with callous-unemotional traits. *J Consult Clin Psychol* 2005 Aug;73(4):737-41. PMID: 16173862. **X-6, X-8**
337. Hawes DJ, Dadds MR. Stability and malleability of callous-unemotional traits during treatment for childhood conduct problems. *J Clin Child Adolesc Psychol* 2007 Jul-Sep;36(3):347-55. PMID: 17658979. **X-6**
338. Hawes DJ, Dadds MR, Brennan J, et al. Revisiting the treatment of conduct problems in children with callous-unemotional traits. *Aust N Z J Psychiatry* 2013 Jul;47(7):646-53. PMID: 23574876. **X-2, X-6, X-7, X-8**
339. Hawkins RO, Axelrod MI. Increasing the on-task homework behavior of youth with behavior disorders using functional behavioral assessment. *Behav Modif* 2008 Nov;32(6):840-59. PMID: 18490267. **X-6, X-8**
340. Hazell P, Becker K, Nikkanen EA, et al. Relationship between atomoxetine plasma concentration, treatment response and tolerability in attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. *Atten Defic Hyperact Disord* 2009 Dec;1(2):201-10. PMID: 20234828. **X-7**
341. Hazell P, Zhang S, Wolańczyk T, et al. Comorbid oppositional defiant disorder and the risk of relapse during 9 months of atomoxetine treatment for attention-deficit/hyperactivity disorder. *European Child & Adolescent Psychiatry* 2006;15(2):105-10. **X-4**
342. Heath GA, Gayton WF, Hardesty VA. Childhood firesetting. *Can Psychiatr Assoc J* 1976 Jun;21(4):229-37. PMID: 963672. **X-11**
343. Hektner JM, August GJ, Bloomquist ML, et al. A 10-year randomized controlled trial of the Early Risers conduct problems preventive intervention: effects on externalizing and internalizing in late high school. *J Consult Clin Psychol* 2014 Apr;82(2):355-60. PMID: 24447007. **X-5**
344. Hemphill SA, Littlefield L. Evaluation of a short-term group therapy program for children with behavior problems and their parents. *Behav Res Ther* 2001 Jul;39(7):823-41. PMID: 11419613. **X-4**
345. Hemphill SA, Littlefield L. Child and family predictors of therapy outcome for children with behavioral and emotional problems. *Child Psychiatry Hum Dev* 2006 Spring;36(3):329-49. PMID: 16362239. **X-2, X-6**
346. Hemphill SA, Tollit M, Herrenkohl TI. Protective Factors Against the Impact of School Bullying Perpetration and Victimization on Young Adult Externalizing and Internalizing Problems. *J Sch Violence* 2014;13(1):125-45. PMID: 25419190. **X-2**
347. Hendriks V, van der Schee E, Blanken P. Matching adolescents with a cannabis use disorder to multidimensional family therapy or cognitive behavioral therapy: treatment effect moderators in a randomized controlled trial. *Drug Alcohol Depend* 2012 Sep 1;125(1-2):119-26. PMID: 22560728. **X-4**
348. Henggeler SW, Letourneau EJ, Chapman JE, et al. Mediators of change for multisystemic therapy with juvenile sexual offenders. *J Consult Clin Psychol* 2009 Jun;77(3):451-62. PMID: 19485587. **X-4**

349. Henneberger AK, Varga SM, Moudy A, et al. Family Functioning and High Risk Adolescents' Aggressive Behavior: Examining Effects by Ethnicity. *J Youth Adolesc* 2014 Nov 22 PMID: 25416227. **X-2, X-5**
350. Herbert SD, Harvey EA, Roberts JL, et al. A randomized controlled trial of a parent training and emotion socialization program for families of hyperactive preschool-aged children. *Behav Ther* 2013 Jun;44(2):302-16. PMID: 23611079. **X-4, X-8**
351. Herman KC, Borden LA, Reinke WM, et al. The Impact of the Incredible Years Parent, Child, and Teacher Training Programs on Children's Co-Occurring Internalizing Symptoms. *Sch Psychol Q* 2011 Sep;26(3):189-201. PMID: 25197205. **X-2, X-7**
352. Herman KC, Reinke WM, Bradshaw CP, et al. Integrating the Family Check-Up and the parent Coping Power program. *Adv Sch Ment Health Promot* 2012 Jul 1;5(3):208-19. PMID: 23585776. **X-1**
353. Hibel LC, Granger DA, Cicchetti D, et al. Salivary biomarker levels and diurnal variation: associations with medications prescribed to control children's problem behavior. *Child Dev* 2007 May-Jun;78(3):927-37. PMID: 17517013. **X-2, X-4**
354. Hilton RC, Rengasamy M, Mansoor B, et al. Impact of treatments for depression on comorbid anxiety, attentional, and behavioral symptoms in adolescents with selective serotonin reuptake inhibitor-resistant depression. *J Am Acad Child Adolesc Psychiatry* 2013 May;52(5):482-92. PMID: 23622849. **X-8**
355. Hinshaw SP, Owens EB, Wells KC, et al. Family processes and treatment outcome in the MTA: negative/ineffective parenting practices in relation to multimodal treatment. *J Abnorm Child Psychol* 2000 Dec;28(6):555-68. PMID: 11104317. **X-4**
356. Hintikka U, Viinamaki H, Pelkonen M, et al. Clinical recovery in cognitive functioning and self-image among adolescents with major depressive disorder and conduct disorder during psychiatric inpatient care. *Am J Orthopsychiatry* 2003 Apr;73(2):212-22. PMID: 12769242. **X-2, X-5, X-6, X-7, X-8**
357. Hirschberg W. Sozialtherapie bei Jugendlichen mit Störungen des Sozialverhaltens—Ergebnisse und Katamnesen. *Praxis der Kinderpsychologie und Kinderpsychiatrie* 1999;48(4):247-59. **X-6, X-10**
358. Högström J, Enebrink P, Ghaderi A. The moderating role of child callous-unemotional traits in an Internet-based parent-management training program. *Journal of Family Psychology* 2013;27(2):314-23. **X-5**
359. Hogstrom J, Enebrink P, Melin B, et al. Eighteen-Month Follow-Up of Internet-Based Parent Management Training for Children with Conduct Problems and the Relation of Homework Compliance to Outcome. *Child Psychiatry Hum Dev* 2014 Sep 19 PMID: 25236326. **X-5**
360. Hogue A, Dauber S. Assessing fidelity to evidence-based practices in usual care: the example of family therapy for adolescent behavior problems. *Eval Program Plann* 2013 Apr;37:21-30. PMID: 23314000. **X-2, X-7, X-8**
361. Holtrop K, McNeil Smith S, Scott JC. Associations between Positive Parenting Practices and Child Externalizing Behavior in Underserved Latino Immigrant Families. *Fam Process* 2014 Oct 6 PMID: 25287585. **X-2, X-4**
362. Horner RH, Day HM, Sprague JR, et al. Interspersed requests: a nonaversive procedure for reducing aggression and self-injury during instruction. *J Appl Behav Anal* 1991 Summer;24(2):265-78. PMID: 1890047. **X-11**
363. Hornsveld RHJ, Nijman HLI, Hollin CR, et al. Aggression control therapy for violent forensic psychiatric patients: Method and clinical practice. *International Journal of Offender Therapy and Comparative Criminology* 2008;52(2):222-33. **X-1, X-10**
364. Horowitz B, Pawel MA, O'Connor P. Frontline reports: the August Aichhorn Center for Adolescent Residential Care. *Psychiatr Serv* 2001 Oct;52(10):1391-2. PMID: 11585959. **X-1, X-2, X-5, X-6, X-7**
365. Hudley C, Friday J. Attributional bias and reactive aggression. *Am J Prev Med* 1996 Sep-Oct;12(5 Suppl):75-81. PMID: 8909627. **X-5**
366. Huessy HR, Wright AL. The use of imipramine in children's behavior disorders. *Acta Paedopsychiatr* 1970 Dec;37(7):194-9. PMID: 4927115. **X-11**

367. Hupp SD, Reitman D, Forde DA, et al. Advancing the assessment of parent-child interactions: development of the Parent Instruction-Giving Game with Youngsters. *Behav Ther* 2008 Mar;39(1):91-106. PMID: 18328874. **X-2, X-6**
368. Husted J, Johnson T, Redwing L. Multi-dimensional adolescent treatment with American Indians. *Am Indian Alsk Native Ment Health Res* 1995;6(3):23-30. PMID: 8555351. **X-4, X-5, X-6**
369. Hustoft K, Larsen TK, Auestad B, et al. Predictors of involuntary hospitalizations to acute psychiatry. *Int J Law Psychiatry* 2013 Mar-Apr;36(2):136-43. PMID: 23395506. **X-2, X-4, X-5, X-6**
370. Hutchings J. Evaluating a behaviourally based parent training group: Outcomes for parents, children and health visitors. *Behavioural and Cognitive Psychotherapy* 1996;24(2):149-70. **X-6**
371. Hutchings J, Lane E. Parenting and the development and prevention of child mental health problems. *Curr Opin Psychiatry* 2005 Jul;18(4):386-91. PMID: 16639130. **X-1**
372. Hutt ML, Dates BG. Reliabilities and interrelationships of two HABGT scales in a male delinquent population. *J Pers Assess* 1977 Aug;41(4):353-7. PMID: 886427. **X-11**
373. Hyde LW, Shaw DS, Gardner F, et al. Dimensions of callousness in early childhood: links to problem behavior and family intervention effectiveness. *Dev Psychopathol* 2013 May;25(2):347-63. PMID: 23627949. **X-4, X-5, X-7, X-8**
374. Ialongo N, Poduska J, Werthamer L, et al. The distal impact of two first-grade preventive interventions on conduct problems and disorder in early adolescence. *Journal of Emotional and Behavioral Disorders* 2001;9(3):146-60. **X-5**
375. Iglesias A. Pediatric emotional dysregulation and behavioral disruptiveness treated with hypnosis: a time-series design. *Int J Clin Exp Hypn* 2014;62(1):70-83. PMID: 24256480. **X-2, X-4, X-6, X-10**
376. Iglesias A, Iglesias A. Pediatric emotional dysregulation and behavioral disruptiveness treated with hypnosis: a time-series design. *Int J Clin Exp Hypn* 2014;62(1):70-83. PMID: 24256480. **X-2, X-6**
377. Ireland JL, Sanders MR, Markie-Dodds C. The impact of parent training on marital functioning: A comparison of two group versions of the Triple P-Positive Parenting Program for parents of children with early-onset conduct problems. *Behavioural and Cognitive Psychotherapy* 2003;31(02):127-42. **X-4**
378. Irvine AB, Gelatt VA, Hammond M, et al. A Randomized Study of Internet Parent Training Accessed From Community Technology Centers. *Prev Sci* 2014 Oct 29; PMID: 25351866. **X-4, X-5**
379. Ise E, Kierfeld F, Dopfner M. One-Year Follow-Up of Guided Self-Help for Parents of Preschool Children With Externalizing Behavior. *J Prim Prev* 2014 Oct 21; PMID: 25331981. **X-4**
380. Ison MS. Training in social skills: an alternative technique for handling disruptive child behavior. *Psychol Rep* 2001 Jun;88(3 Pt 1):903-11. PMID: 11508042. **X-5, X-6**
381. Itil TM, Rizzo AE. Behavior and quantitative EEG correlations during treatment of behavior-disturbed adolescents. *Electroencephalogr Clin Neurophysiol* 1967 Jul;23(1):81. PMID: 4165577. **X-11**
382. Jacobs RH, Becker-Weidman EG, Reinecke MA, et al. Treating depression and oppositional behavior in adolescents. *J Clin Child Adolesc Psychol* 2010;39(4):559-67. PMID: 20589566. **X-4**
383. Jagers RJ, Morgan-Lopez AA, Flay BR. The impact of age and type of intervention on youth violent behaviors. *J Prim Prev* 2009 Nov;30(6):642-58. PMID: 19953325. **X-4, X-5, X-8**
384. Javelot H, Glay-Ribau C, Ligier F, et al. Methylphenidate-risperidone combination in child psychiatry: A retrospective analysis of 44 cases. *Ann Pharm Fr* 2014 May;72(3):164-77. PMID: 24780832. **X-4**
385. Jenkins RL. Behavior disorders of childhood. *Am Fam Physician GP* 1970 May;1(5):68-73. PMID: 5267227. **X-11**
386. Jensen PS, Hinshaw SP, Swanson JM, et al. Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): implications and applications for primary care providers. *J Dev Behav Pediatr* 2001 Feb;22(1):60-73. PMID: 11265923. **X-4**
387. Jenson JM, Dieterich WA. Effects of a skills-based prevention program on bullying and bully

- victimization among elementary school children. *Prev Sci* 2007 Dec;8(4):285-96. PMID: 17968657. **X-4, X-5**
388. Jent JF, Niec LN. Cognitive Behavioral Principles Within Group Mentoring: A Randomized Pilot Study. *Child Fam Behav Ther* 2009 Jul;31(3):203-19. PMID: 20582243. **X-4**
389. Jerrell JM. Neurological and cardiovascular adverse events associated with antimanic treatment in children and adolescents. *CNS Neurosci Ther* 2010 Spring;16(1):25-31. PMID: 19769597. **X-2, X-6, X-7**
390. Jerrott S, Clark SE, Fearon I. Day treatment for disruptive behaviour disorders: can a short-term program be effective? *J Can Acad Child Adolesc Psychiatry* 2010 May;19(2):88-93. PMID: 20467544. **X-2a**
391. Johnson RJ, Kaplan HB. Gender, aggression, and mental health intervention during early adolescence. *J Health Soc Behav* 1988 Mar;29(1):53-64. PMID: 3367029. **X-11**
392. Jones K, Daley D, Hutchings J, et al. Efficacy of the Incredible Years Basic parent training programme as an early intervention for children with conduct problems and ADHD. *Child Care Health Dev* 2007 Nov;33(6):749-56. PMID: 17944785. **X-4, X-5**
393. Jones K, Daley D, Hutchings J, et al. Efficacy of the Incredible Years Programme as an early intervention for children with conduct problems and ADHD: long-term follow-up. *Child Care Health Dev* 2008 May;34(3):380-90. PMID: 18410644. **X-4, X-5, X-7**
394. Jordans MJ, Tol WA, Ndayisaba A, et al. A controlled evaluation of a brief parenting psychoeducation intervention in Burundi. *Soc Psychiatry Psychiatr Epidemiol* 2013 Nov;48(11):1851-9. PMID: 23224723. **X-4, X-5**
395. Joshi PK, Rosenberg LA. Children's behavioral response to residential treatment. *J Clin Psychol* 1997 Oct;53(6):567-73. PMID: 9316811. **X-5, X-6**
396. Jurecska DE, Hamilton EB, Peterson MA. Effectiveness of the Coping Power Program in middle-school children with disruptive behaviours and hyperactivity difficulties. *Support for Learning* 2011;26(4):168-72. **X-4, X-5**
397. Kacir CD, Gordon DA. Parenting adolescents wisely: The effectiveness of an interactive videodisk parent training program in Appalachia. *Child & Family Behavior Therapy* 1999;21(4):1-22. **X-4**
398. Kalkan Ucar S, Ozbaran B, Demiral N, et al. Clinical overview of children with mucopolysaccharidosis type III A and effect of Risperidone treatment on children and their mothers psychological status. *Brain Dev* 2010 Feb;32(2):156-61. PMID: 19217229. **X-4**
399. Kalke T, Glanton A, Cristalli M. Positive behavioral interventions and supports: using strength-based approaches to enhance the culture of care in residential and day treatment education environments. *Child Welfare* 2007 Sep-Oct;86(5):151-74. PMID: 18422053. **X-5, X-6, X-7, X-8**
400. Karatzias T, Ferguson S, Chouliara Z, et al. Effectiveness and acceptability of group psychoeducation for the management of mental health problems in survivors of child sexual abuse (CSA). *Int J Group Psychother* 2014 Oct;64(4):492-514. PMID: 25188564. **X-4**
401. Karpenko V, Owens JS, Evangelista NM, et al. Clinically significant symptom change in children with attention-deficit/hyperactivity disorder: does it correspond with reliable improvement in functioning? *J Clin Psychol* 2009 Jan;65(1):76-93. PMID: 19051273. **X-4, X-6, X-8**
402. Kayser KH, Wacker DP, Derby KM, et al. A rapid method for evaluating the necessity for both a behavioral intervention and methylphenidate. *J Appl Behav Anal* 1997 Spring;30(1):177-80. PMID: 9157098. **X-4, X-5, X-6, X-8**
403. Kazdin AE. Premature termination from treatment among children referred for antisocial behavior. *J Child Psychol Psychiatry* 1990 Mar;31(3):415-25. PMID: 2318922. **X-11**
404. Kazdin AE, Bass D, Siegel T, et al. Cognitive-behavioral therapy and relationship therapy in the treatment of children referred for antisocial behavior. *J Consult Clin Psychol* 1989 Aug;57(4):522-35. PMID: 2768614. **X-11**
405. Kazdin AE, Durbin KA. Predictors of child-therapist alliance in cognitive-behavioral treatment of children referred for oppositional and antisocial behavior. *Psychotherapy* 2012;49(2):202-17. **X-6**

406. Kazdin AE, Esveldt-Dawson K, French NH, et al. Effects of parent management training and problem-solving skills training combined in the treatment of antisocial child behavior. *J Am Acad Child Adolesc Psychiatry* 1987 May;26(3):416-24. PMID: 3597299. **X-11**
407. Kazdin AE, Esveldt-Dawson K, French NH, et al. Problem-solving skills training and relationship therapy in the treatment of antisocial child behavior. *J Consult Clin Psychol* 1987 Feb;55(1):76-85. PMID: 3571662. **X-11**
408. Kazdin AE, Holland L, Crowley M. Family experience of barriers to treatment and premature termination from child therapy. *J Consult Clin Psychol* 1997 Jun;65(3):453-63. PMID: 9170769. **X-2, X-6, X-7**
409. Kazdin AE, Wassell G. Therapeutic changes in children, parents, and families resulting from treatment of children with conduct problems. *J Am Acad Child Adolesc Psychiatry* 2000 Apr;39(4):414-20. PMID: 10761342. **X-6**
410. Kazdin AE, Whitley M, Marciano PL. Child-therapist and parent-therapist alliance and therapeutic change in the treatment of children referred for oppositional, aggressive, and antisocial behavior. *J Child Psychol Psychiatry* 2006 May;47(5):436-45. PMID: 16671927. **X-6**
411. Kazdin AE, Whitley MK. Treatment of parental stress to enhance therapeutic change among children referred for aggressive and antisocial behavior. *J Consult Clin Psychol* 2003 Jun;71(3):504-15. PMID: 12795574. **X-7**
412. Kazdin AE, Whitley MK. Comorbidity, case complexity, and effects of evidence-based treatment for children referred for disruptive behavior. *J Consult Clin Psychol* 2006 Jun;74(3):455-67. PMID: 16822103. **X-6**
413. Kazdin AE, Whitley MK. Pretreatment social relations, therapeutic alliance, and improvements in parenting practices in parent management training. *J Consult Clin Psychol* 2006 Apr;74(2):346-55. PMID: 16649879. **X-3, X-6, X-7, X-8**
414. Kennedy J, Mitchell JB, Klerman LV, et al. A day school approach to aggressive adolescents. *Child Welfare* 1976 Dec;55(10):712-24. PMID: 1001075. **X-11**
415. Kethineni S, Blimling L, Bozarth JM, et al. Youth violence: an exploratory study of a treatment program in a central Illinois county. *Int J Offender Ther Comp Criminol* 2004 Dec;48(6):697-720. PMID: 15538027. **X-10**
416. Kettlewell PW, Kausch DF. The generalization of the effects of a cognitive-behavioral treatment program for aggressive children. *J Abnorm Child Psychol* 1983 Mar;11(1):101-14. PMID: 6853873. **X-11**
417. Kewley GD. Risperidone in comorbid ADHD and OCC/CD. *Journal of the American Academy of Child & Adolescent Psychiatry* 1999;38(11):1327-8. **X-1, X-6**
418. Khantzian EJ. An ego/self theory of substance dependence: a contemporary psychoanalytic perspective. *NIDA Res Monogr* 1980 Mar;30:29-33. PMID: 6779190. **X-11**
419. Khanzode LA, Saxena K, Kraemer H, et al. Efficacy profiles of psychopharmacology: divalproex sodium in conduct disorder. *Child Psychiatry Hum Dev* 2006 Fall;37(1):55-64. PMID: 16927177. **X-6, X-7**
420. Kierfeld F, Ise E, Hanisch C, et al. Effectiveness of telephone-assisted parent-administered behavioural family intervention for preschool children with externalizing problem behaviour: a randomized controlled trial. *Eur Child Adolesc Psychiatry* 2013 Sep;22(9):553-65. PMID: 23463180. **X-4**
421. Killeen MR. Marital conflict management skills, parenting style, and early-onset conduct problems: processes and pathways. *J Child Fam Nurs* 2000 Mar-Apr;3(2):110-1. PMID: 11271139. **X-2, X-10**
422. Kim E, Cain KC, Webster-Stratton C. The preliminary effect of a parenting program for Korean American mothers: a randomized controlled experimental study. *Int J Nurs Stud* 2008 Sep;45(9):1261-73. PMID: 17996239. **X-4**
423. Kimonis ER, Bagner DM, Linares D, et al. Parent Training Outcomes among Young Children with Callous-Unemotional Conduct Problems with or At-Risk for Developmental Delay. *J Child Fam Stud* 2014 Feb 1;23(2):437-48. PMID: 24511217. **X-4**
424. King B, Zwi K, Nunn K, et al. Use of risperidone in a paediatric population: an

- observational study. *J Paediatr Child Health* 2003 Sep-Oct;39(7):523-7. PMID: 12969207. **X-4, X-6, X-8**
425. Kinnen C, Döpfner M. Zusammenhang von Therapeutischer Beziehung mit Symptomminderung und Behandlungszufriedenheit in der Behandlung von Kindern und Jugendlichen mit ADHS und/oder Störungen des Sozialverhaltens. *Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie* 2013;41(2):133-44. **X-2, X-6, X-8, X-10**
426. Kjøbli J, Hukkelberg S, Ogden T. A randomized trial of group parent training: Reducing child conduct problems in real-world settings. *Behaviour Research and Therapy* 2013;51(3):113-21. **X-4**
427. Kliman GW. Analyst in the nursery. Experimental application of child analytic techniques in a therapeutic nursery: the cornerstone method. *Psychoanal Study Child* 1975;30:477-510. PMID: 1197519. **X-11**
428. Klingsporn MJ, Force RC, Burdsal C. The effectiveness of various degrees and circumstances of program completion of young male offenders in a residential treatment center. *J Clin Psychol* 1990 Jul;46(4):491-500. PMID: 2212054. **X-11**
429. Klorman R, Brumaghim JT, Salzman LF, et al. Comparative effects of methylphenidate on attention-deficit hyperactivity disorder with and without aggressive/noncompliant features. *Psychopharmacol Bull* 1989;25(1):109-13. PMID: 2772109. **X-11**
430. Knight RA, Ronis ST, Zakireh B. Bootstrapping persistence risk indicators for juveniles who sexually offend. *Behav Sci Law* 2009 Nov-Dec;27(6):878-909. PMID: 19937923. **X-2, X-4, X-5, X-6, X-7, X-8**
431. Knox L, Guerra NG, Williams KR, et al. Preventing children's aggression in immigrant Latino families: a mixed methods evaluation of the Families and Schools Together program. *Am J Community Psychol* 2011 Sep;48(1-2):65-76. PMID: 21253821. **X-4, X-5**
432. Koda VH, Halperin JM, Newcorn JH, et al. Gender differences in the prolactin response to fenfluramine challenge in children with disruptive behavior disorders. *Ann N Y Acad Sci* 1996 Sep 20;794:369-71. PMID: 8853619. **X-2, X-6, X-7, X-10**
433. Kodak T, Miltenberger RG, Romaniuk C. The effects of differential negative reinforcement of other behavior and noncontingent escape on compliance. *J Appl Behav Anal* 2003 Fall;36(3):379-82. PMID: 14596581. **X-4, X-5, X-6, X-8**
434. Kodak T, Northup J, Kelley ME. An evaluation of the types of attention that maintain problem behavior. *J Appl Behav Anal* 2007 Spring;40(1):167-71. PMID: 17471800. **X-2, X-6, X-7**
435. Kogan SM, Brody GH, Chen YF. Natural mentoring processes deter externalizing problems among rural African American emerging adults: a prospective analysis. *Am J Community Psychol* 2011 Dec;48(3-4):272-83. PMID: 21293917. **X-2, X-4, X-5, X-8**
436. Kohlhoff J, Morgan S. Parent-child interaction therapy for toddlers: A pilot study. *Child & Family Behavior Therapy* 2014;36(2):121-39. **X-6**
437. Kolko DJ, Lindhiem O, Hart J, et al. Evaluation of a booster intervention three years after acute treatment for early-onset disruptive behavior disorders. *J Abnorm Child Psychol* 2014;42(3):383-98. PMID: 23494526. **X-9**
438. Konstantareas MM, Homatidis S. Aggressive and prosocial behaviours before and after treatment in conduct-disordered children and in matched controls. *J Child Psychol Psychiatry* 1984 Oct;25(4):607-20. PMID: 6480733. **X-11**
439. Kotsopoulos S, Walker S, Beggs K, et al. A clinical and academic outcome study of children attending a day treatment program. *Can J Psychiatry* 1996 Aug;41(6):371-8. PMID: 8862856. **X-4, X-5, X-6**
440. Kuhn DE, Hardesty SL, Luczynski K. Further evaluation of antecedent social events during functional analysis. *J Appl Behav Anal* 2009 Summer;42(2):349-53. PMID: 19949523. **X-2, X-6, X-7, X-8**
441. Kumar GV. Impact of rational-emotive behaviour therapy (REBT) on adolescents with conduct disorder (CD). *Journal of the Indian Academy of Applied Psychology* 2009;35(spec iss):103-11. **X-5, X-6**
442. Kuperman S, Calarge C, Kolar A, et al. An open-label trial of aripiprazole in the treatment of aggression in male adolescents diagnosed with

- conduct disorder. *Ann Clin Psychiatry* 2011 Nov;23(4):270-6. PMID: 22073384. **X-6**
443. Kupfer DJ, Detre T, Jacqueline K. "Deviant" behavior patterns in school children, application of KDS-TM-14. *Psychol Rep* 1974 Aug;35(1):183-91. PMID: 4420969. **X-11**
444. Kupietz SS, Balka EB. Alterations in the vigilance performance of children receiving amitriptyline and methylphenidate pharmacotherapy. *Psychopharmacology (Berl)* 1976 Oct 20;50(1):29-33. PMID: 827759. **X-11**
445. Lacourse E, Cote S, Nagin DS, et al. A longitudinal-experimental approach to testing theories of antisocial behavior development. *Dev Psychopathol* 2002 Fall;14(4):909-24. PMID: 12549709. **X-5**
446. Lahey BB, Loeber R, Burke J, et al. Adolescent outcomes of childhood conduct disorder among clinic-referred boys: predictors of improvement. *J Abnorm Child Psychol* 2002 Aug;30(4):333-48. PMID: 12108765. **X-2, X-6, X-8**
447. Laje G, Bernert R, Morse R, et al. Pharmacological treatment of disruptive behavior in Smith-Magenis syndrome. *Am J Med Genet C Semin Med Genet* 2010 Nov 15;154C(4):463-8. PMID: 20981776. **X-4, X-8**
448. Lakes KD, Kettler RJ, Schmidt J, et al. The CUIDAR Early Intervention Parent Training Program for Preschoolers at Risk for Behavioral Disorders: An Innovative Practice for Reducing Disparities in Access to Service. *J Early Interv* 2009 Mar 1;31(2):167-78. PMID: 23620645. **X-4, X-6, X-8**
449. Larson JD, Calamari JE, West JG, et al. Aggression management with disruptive adolescents in the residential setting: Integration of a cognitive-behavioral component. *Residential Treatment for Children & Youth* 1998;15(4):1-9. **X-5, X-6**
450. Larsson B, Fossum S, Clifford G, et al. Treatment of oppositional defiant and conduct problems in young Norwegian children: Results of a randomized controlled trial. *European Child & Adolescent Psychiatry* 2009;18(1):42-52. **X-9**
451. Larzelere RE, Cox RB, Jr., Smith GL. Do nonphysical punishments reduce antisocial behavior more than spanking? a comparison using the strongest previous causal evidence against spanking. *BMC Pediatr* 2010;10:10. PMID: 20175902. **X-2, X-8**
452. Lavigne JV, LeBailly SA, Gouze KR, et al. Predictors and correlates of completing behavioral parent training for the treatment of oppositional defiant disorder in pediatric primary care. *Behav Ther* 2010 Jun;41(2):198-211. PMID: 20412885. **X-7, X-8**
453. Lazerson DB. "I must be good if i can teach!" -- peer tutoring with aggressive and withdrawn children. *J Learn Disabil* 1980 Mar;13(3):152-7. PMID: 7381310. **X-11**
454. LeBlanc JC, Binder CE, Armenteros JL, et al. Risperidone reduces aggression in boys with a disruptive behaviour disorder and below average intelligence quotient: analysis of two placebo-controlled randomized trials. *Int Clin Psychopharmacol* 2005 Sep;20(5):275-83. PMID: 16096518. **X-1, X-4**
455. Lees DG, Fergusson DM, Frampton CM, et al. A pilot study to evaluate the efficacy of adding a structured home visiting intervention to improve outcomes for high-risk families attending the Incredible Years Parent Programme: study protocol for a randomised controlled trial. *Trials* 2014;15:66. PMID: 24568271. **X-1**
456. Leff SS, Gullan RL, Paskewich BS, et al. An initial evaluation of a culturally adapted social problem-solving and relational aggression prevention program for urban African-American relationally aggressive girls. *J Prev Interv Community* 2009;37(4):260-74. PMID: 19830622. **X-5**
457. Leijten P, Shaw DS, Gardner F, et al. The Family Check-Up and Service Use in High-Risk Families of Young Children: A Prevention Strategy with a Bridge to Community-Based Treatment. *Prev Sci* 2014 Mar 20; PMID: 24643281. **X-4**
458. Lepanto J. Targeting problem behaviors. *Behav Healthc* 2009 Nov-Dec;29(10):32, 4. PMID: 20063649. **X-1, X-2, X-5, X-6, X-7, X-8**
459. Leung C, Sanders MR, Leung S, et al. An outcome evaluation of the implementation of the Triple P-Positive Parenting Program in Hong Kong. *Fam Process* 2003 Winter;42(4):531-44. PMID: 14979223. **X-4**
460. Leve LD, Chamberlain P, Reid JB. Intervention outcomes for girls referred from juvenile justice:

- effects on delinquency. *J Consult Clin Psychol* 2005 Dec;73(6):1181-5. PMID: 16392991. **X-5**
461. Levinson BM. Pet psychotherapy: use of household pets in the treatment of behavior disorder in childhood. *Psychol Rep* 1965 Dec;17(3):695-8. PMID: 5892572. **X-11**
462. Lewis JA, Young R. Deanol and methylphenidate in minimal brain dysfunction. *Clin Pharmacol Ther* 1975 May;17(5):534-40. PMID: 1092513. **X-11**
463. Lewis JC, Glasser N. Evolution of a treatment approach to families: group family therapy. *Int J Group Psychother* 1965 Oct;15(4):506-15. PMID: 5829258. **X-11**
464. Lewis RE. The effectiveness of Families First services: An experimental study. *Children and Youth Services Review* 2005 5//;27(5):499-509. **X-4**
465. Li MH. A model parent group for enhancing aggressive children's social competence in Taiwan. *Int J Group Psychother* 2009 Jul;59(3):407-19. PMID: 19548787. **X-4, X-5, X-6, X-8**
466. Liber JM, De Boo GM, Huizenga H, et al. School-based intervention for childhood disruptive behavior in disadvantaged settings: A randomized controlled trial with and without active teacher support. *J Consult Clin Psychol* 2013 Dec;81(6):975-87. PMID: 23834227. **X-5**
467. Lichtwarck-Aschoff A, Hasselman F, Cox R, et al. A characteristic destabilization profile in parent-child interactions associated with treatment efficacy for aggressive children. *Nonlinear Dynamics Psychol Life Sci* 2012 Jul;16(3):353-79. PMID: 22695153. **X-5, X-6**
468. Liddle HA, Dakof GA, Henderson C, et al. Implementation outcomes of Multidimensional Family Therapy-Detention to Community: a reintegration program for drug-using juvenile detainees. *Int J Offender Ther Comp Criminol* 2011 Jun;55(4):587-604. PMID: 20427547. **X-4, X-5, X-7, X-8**
469. Lien-Thorne S, Kamps D. Replication study of the first step to success early intervention program. *Behavioral Disorders* 2005;31(1):18-32. **X-4, X-5, X-6, X-8**
470. Linares LO, Stovall-McClough KC, Li M, et al. Salivary cortisol in foster children: a pilot study. *Child Abuse Negl* 2008 Jun;32(6):665-70. PMID: 18582935. **X-2, X-6, X-7**
471. Lindhiem O, Kolko DJ. Trajectories of symptom reduction and engagement during treatment for childhood behavior disorders: differences across settings. *J Abnorm Child Psychol* 2010 Oct;38(7):995-1005. PMID: 20414715. **X-2, X-6, X-7**
472. Lindhiem O, Kolko DJ. Trajectories of symptom reduction during treatment for behavior problems in pediatric primary-care settings. *Adm Policy Ment Health* 2011 Nov;38(6):486-94. PMID: 21301952. **X-6**
473. Lindhiem O, Shaffer A, Kolko DJ. Quantifying Discipline Practices Using Absolute Versus Relative Frequencies: Clinical and Research Implications for Child Welfare. *J Interpers Violence* 2013 Oct 7 PMID: 24106146. **X-3, X-6, X-7, X-8**
474. Lindsay G, Strand S. Evaluation of the national roll-out of parenting programmes across England: the parenting early intervention programme (PEIP). *BMC Public Health* 2013 Oct 19;13(1):972. PMID: 24138747. **X-4, X-5, X-7, X-8**
475. Lindsay G, Strand S, Davis H. A comparison of the effectiveness of three parenting programmes in improving parenting skills, parent mental-well being and children's behaviour when implemented on a large scale in community settings in 18 English local authorities: the parenting early intervention pathfinder (PEIP). *BMC Public Health* 2011;11:962. PMID: 22208676. **X-4**
476. Lindsay RL, Leone S, Aman MG. Discontinuation of risperidone and reversibility of weight gain in children with disruptive behavior disorders. *Clin Pediatr (Phila)* 2004 Jun;43(5):437-44. PMID: 15208748. **X-2, X-4, X-6**
477. Lipman EL, Boyle MH, Cunningham C, et al. Testing effectiveness of a community-based aggression management program for children 7 to 11 years old and their families. *J Am Acad Child Adolesc Psychiatry* 2006 Sep;45(9):1085-93. PMID: 16926616. **X-4**
478. Livingston R, Taylor JL, Crawford SL. Factors related to length of hospitalization of children with mental disorders. *Hosp Community Psychiatry* 1990 Feb;41(2):193-5. PMID: 2303224. **X-11**
479. Lobitz WC. A simple stimulus cue for controlling disruptive classroom behavior.

- Methodological implications for behavior change procedures. *J Abnorm Child Psychol* 1974 Jun;2(2):143-52. PMID: 4430817. **X-11**
480. Lochman JE. Effects of different treatment lengths in cognitive behavioral interventions with aggressive boys. *Child Psychiatry Hum Dev* 1985 Fall;16(1):45-56. PMID: 4064791. **X-11**
481. Lochman JE, Baden RE, Boxmeyer CL, et al. Does a Booster Intervention Augment the Preventive Effects of an Abbreviated Version of the Coping Power Program for Aggressive Children? *J Abnorm Child Psychol* 2013 Feb 16; PMID: 23417235. **X-4**
482. Lochman JE, Baden RE, Boxmeyer CL, et al. Does a booster intervention augment the preventive effects of an abbreviated version of the coping power program for aggressive children? *J Abnorm Child Psychol* 2014;42(3):367-81. PMID: 23417235. **X-9**
483. Lochman JE, Boxmeyer C, Powell N, et al. Masked intervention effects: Analytic methods for addressing low dosage of intervention. *New Directions for Evaluation* 2006;2006(110):19-32. **X-4**
484. Lochman JE, Lampron LB, Burch PR, et al. Client characteristics associated with behavior change for treated and untreated aggressive boys. *J Abnorm Child Psychol* 1985 Dec;13(4):527-38. PMID: 4078184. **X-11**
485. Lochman JE, Wells KC. Contextual social-cognitive mediators and child outcome: a test of the theoretical model in the Coping Power program. *Dev Psychopathol* 2002 Fall;14(4):945-67. PMID: 12549711. **X-4**
486. Lochman JE, Wells KC. The Coping Power program at the middle-school transition: universal and indicated prevention effects. *Psychol Addict Behav* 2002 Dec;16(4 Suppl):S40-54. PMID: 12502276. **X-5**
487. Lochman JE, Wells KC. Effectiveness of the Coping Power Program and of Classroom Intervention With Aggressive Children: Outcomes at a 1-Year Follow-Up. *Behavior Therapy* 2003;34(4):493-515. **X-4**
488. Lochman JE, Wells KC. The coping power program for preadolescent aggressive boys and their parents: outcome effects at the 1-year follow-up. *J Consult Clin Psychol* 2004 Aug;72(4):571-8. PMID: 15301641. **X-4**
489. Lochman JE, Wells KC, Qu L, et al. Three year follow-up of coping power intervention effects: evidence of neighborhood moderation? *Prev Sci* 2013 Aug;14(4):364-76. PMID: 23065350. **X-2a, X-4**
490. Lochmann J, FitzGerald D, Gage S, et al. Effects of a social-cognitive intervention for aggressive deaf children: The Coping Power Program. *JADARA-ROCHESTER NY-* 2001;35(2):39-61. **X-10**
491. Long P, Forehand R, Wierson M, et al. Does parent training with young noncompliant children have long-term effects? *Behav Res Ther* 1994 Jan;32(1):101-7. PMID: 8135705. **X-6, X-8**
492. Lorandos DA. Adolescents in residential treatment: a six-year comparison. *Adolesc Psychiatry* 1990;17:473-8. PMID: 2240432. **X-11**
493. Love AR, Mueller CW, Tolman RT, et al. Frequency, Level, and Rate of Improvement for Treatment Targets in a Children's Mental Health Community-Based Intensive In-Home Therapeutic Setting. *Adm Policy Ment Health* 2013 Mar 9; PMID: 23474672. **X-4, X-6, X-7**
494. Love AR, Mueller CW, Tolman RT, et al. Frequency, level, and rate of improvement for treatment targets in a children's mental health community-based intensive in-home therapeutic setting. *Adm Policy Ment Health* 2014 Jul;41(4):421-33. PMID: 23474672. **X-1, X-6**
495. Luce SC, Christian WP, Anderson SR, et al. Development of a continuum of services for children and adults with autism and other severe behavior disorders. *Res Dev Disabil* 1992;13(1):9-25. PMID: 1585026. **X-11**
496. Luiselli JK, Pace GM, Dunn EK. Effects of behavior-contingent and fixed-time release contingencies on frequency and duration of therapeutic restraint. *Behav Modif* 2006 Jul;30(4):442-55. PMID: 16723424. **X-2, X-4, X-5, X-6, X-7, X-8, X-10**
497. Luk ES, Staiger P, Mathai J, et al. Comparison of treatments of persistent conduct problems in primary school children: a preliminary evaluation of a modified cognitive-behavioural approach. *Aust N Z J Psychiatry* 1998 Jun;32(3):379-86. PMID: 9672727. **X-4**
498. Luk ES, Staiger PK, Mathai J, et al. Children with persistent conduct problems who dropout of

- treatment. *Eur Child Adolesc Psychiatry* 2001 Mar;10(1):28-36. PMID: 11315533. **X-4**
499. Luk ESL, Staiger P, Mathai J, et al. Comparison of treatments of persistent conduct problems in primary school children: A preliminary evaluation of a modified cognitive-behavioural approach. *Australian and New Zealand Journal of Psychiatry* 1998;32(3):379-86. **X-10**
500. Luk ESL, Staiger P, Mathai J, et al. Evaluation of outcome in child and adolescent mental health services: Children with persistent conduct problems. *Clinical Child Psychology and Psychiatry* 2001;6(1):109-24. **X-6, X-10**
501. Lytton GJ, Knobel M. Diagnosis and treatment of behavior disorders in children. *Dis Nerv Syst* 1959 Aug;20:334-40. PMID: 14419219. **X-11**
502. Maag JW, Howell KW. Serving troubled youth or a troubled society? *Except Child* 1991 Sep;58(1):75-6; discussion 7-9. PMID: 1954973. **X-11**
503. MacMillan CM, Korndorfer SR, Rao S, et al. A comparison of divalproex and oxcarbazepine in aggressive youth with bipolar disorder. *J Psychiatr Pract* 2006 Jul;12(4):214-22. PMID: 16883146. **X-4**
504. Madsen PS, Conte JR. Single subject research in occupational therapy: a case illustration. *Am J Occup Ther* 1980 Apr;34(4):263-7. PMID: 7369087. **X-11**
505. Maeda E. Activity programming for the aggressive child. *Am J Occup Ther* 1960 Jul-Aug;14:223-6. PMID: 14419707. **X-11**
506. Mahoney JL. School extracurricular activity participation as a moderator in the development of antisocial patterns. *Child Dev* 2000 Mar-Apr;71(2):502-16. PMID: 10834480. **X-2, X-5, X-6**
507. Malmberg JL, Field CE. Preventative behavioral parent training: A preliminary investigation of strategies for preventing at-risk children from developing later conduct problems. *Child & Family Behavior Therapy* 2013;35(3):212-27. **X-4, X-6, X-7, X-8**
508. Malone RP, Bennett DS, Luebbert JF, et al. Aggression classification and treatment response. *Psychopharmacol Bull* 1998;34(1):41-5. PMID: 9564197. **X-5**
509. Malone RP, Delaney MA, Luebbert JF, et al. A double-blind placebo-controlled study of lithium in hospitalized aggressive children and adolescents with conduct disorder. *Arch Gen Psychiatry* 2000 Jul;57(7):649-54. PMID: 10891035. **X-5**
510. Malone RP, Luebbert JF, Delaney MA, et al. Nonpharmacological response in hospitalized children with conduct disorder. *J Am Acad Child Adolesc Psychiatry* 1997 Feb;36(2):242-7. PMID: 9031577. **X-2, X-5, X-6, X-7**
511. Mandell DS, Guevara JP, Rostain AL, et al. Economic grand rounds: medical expenditures among children with psychiatric disorders in a Medicaid population. *Psychiatr Serv* 2003 Apr;54(4):465-7. PMID: 12663833. **X-2**
512. Marini JL, Sheard MH, Bridges CI, et al. An evaluation of the double-blind design in a study comparing lithium carbonate with placebo. *Acta Psychiatr Scand* 1976 May;53(5):343-54. PMID: 785950. **X-11**
513. Marlowe RH, Madsen CH, Jr., Bowen CE, et al. Severe classroom behavior problems: teachers or counsellors. *J Appl Behav Anal* 1978 Spring;11(1):53-66. PMID: 649528. **X-11**
514. Martens WH. Multisystemic therapy for antisocial juveniles: suggestions for improvement. *Int J Offender Ther Comp Criminol* 2004 Jun;48(3):389-94. PMID: 15142315. **X-1, X-2, X-3, X-4, X-5, X-6**
515. Martin A, Krieg H, Esposito F, et al. Reduction of restraint and seclusion through collaborative problem solving: a five-year prospective inpatient study. *Psychiatr Serv* 2008 Dec;59(12):1406-12. PMID: 19033167. **X-2, X-4, X-5, X-6**
516. Martin CA, Cook C, Woodring JH, et al. Caffeine use: association with nicotine use, aggression, and other psychopathology in psychiatric and pediatric outpatient adolescents. *ScientificWorldJournal* 2008;8:512-6. PMID: 18516472. **X-2**
517. Martinez CR, Jr., Eddy JM. Effects of culturally adapted parent management training on Latino youth behavioral health outcomes. *J Consult Clin Psychol* 2005 Oct;73(5):841-51. PMID: 16287384. **X-4**
518. Masi G, Manfredi A, Milone A, et al. Predictors of nonresponse to psychosocial treatment in children and adolescents with disruptive behavior disorders. *J*

- Child Adolesc Psychopharmacol 2011 Feb;21(1):51-5. PMID: 21309697. **X-5, X-6**
519. Masi G, Milone A, Manfredi A, et al. Effectiveness of lithium in children and adolescents with conduct disorder: a retrospective naturalistic study. *CNS Drugs* 2009;23(1):59-69. PMID: 19062775. **X-6**
520. Masi G, Muratori P, Manfredi A, et al. Response to treatments in youth with disruptive behavior disorders. *Compr Psychiatry* 2013 Oct;54(7):1009-15. PMID: 23683839. **X-7a**
521. Mast JE, Antonini TN, Raj SP, et al. Web-based parenting skills to reduce behavior problems following abusive head trauma: a pilot study. *Child Abuse Negl* 2014 Sep;38(9):1487-95. PMID: 24844734. **X-4**
522. Matos M, Bauermeister JJ, Bernal G. Parent-child interaction therapy for Puerto Rican preschool children with ADHD and behavior problems: a pilot efficacy study. *Fam Process* 2009 Jun;48(2):232-52. PMID: 19579907. **X-4**
523. Matos M, Torres R, Santiago R, et al. Adaptation of parent-child interaction therapy for Puerto Rican families: a preliminary study. *Fam Process* 2006 Jun;45(2):205-22. PMID: 16768019. **X-6**
524. Mattes JA. Comparative effectiveness of carbamazepine and propranolol for rage outbursts. *J Neuropsychiatry Clin Neurosci* 1990 Spring;2(2):159-64. PMID: 2136070. **X-11**
525. Mazaheri R, Eshghi A, Bashardoost N, et al. Assessment of intranasal midazolam administration with a dose of 0.5 mg/kg in behavior management of uncooperative children. *J Clin Pediatr Dent* 2008 Winter;32(2):95-9. PMID: 18389672. **X-4, X-6, X-10**
526. McAuley R. Training parents to modify conduct problems in their children. *J Child Psychol Psychiatry* 1982 Jul;23(3):335-42. PMID: 7107748. **X-11**
527. McClain DB, Wolchik SA, Winslow E, et al. Developmental cascade effects of the New Beginnings Program on adolescent adaptation outcomes. *Dev Psychopathol* 2010 Nov;22(4):771-84. PMID: 20883581. **X-4, X-6, X-7, X-8**
528. McCleary L, Ridley T. Parenting adolescents with ADHD: evaluation of a psychoeducation group. *Patient Educ Couns* 1999 Sep;38(1):3-10. PMID: 14528566. **X-4**
529. McCloskey SG, Snow DL, Tamis-LeMonda CS. An evaluation of the effects of INSIGHTS on the behavior of inner city primary school children. *J Prim Prev* 2005 Nov;26(6):567-84. PMID: 16237502. **X-5**
530. McCord J. Competence in long-term perspective. *Psychiatry* 1991 Aug;54(3):227-37. PMID: 1946824. **X-11**
531. McCormick E, Kerns SE, McPhillips H, et al. Training pediatric residents to provide parent education: a randomized controlled trial. *Acad Pediatr* 2014 Jul-Aug;14(4):353-60. PMID: 24976347. **X-4**
532. McElroy SL. Recognition and treatment of DSM-IV intermittent explosive disorder. *J Clin Psychiatry* 1999;60 Suppl 15:12-6. PMID: 10418808. **X-1, X-3**
533. McKay MM, Harrison ME, Gonzales J, et al. Multiple-family groups for urban children with conduct difficulties and their families. *Psychiatr Serv* 2002 Nov;53(11):1467-8. PMID: 12407277. **X-1, X-4, X-6, X-7, X-8**
534. McKee TE, Harvey E, Danforth JS, et al. The relation between parental coping styles and parent-child interactions before and after treatment for children with ADHD and oppositional behavior. *J Clin Child Adolesc Psychol* 2004 Mar;33(1):158-68. PMID: 15028550. **X-4, X-6, X-8**
535. McKibbin E, King J. Activity group counseling for learning-disabled children with behavior problems. *Am J Occup Ther* 1983 Sep;37(9):617-23. PMID: 6624859. **X-11**
536. McLaughlin M. An experiment. *Nurs Times* 1974 Jan 31;70(5):166-7. PMID: 4822646. **X-11**
537. McMenamy J, Sheldrick RC, Perrin EC. Early intervention in pediatrics offices for emerging disruptive behavior in toddlers. *Journal of Pediatric Health Care* 2011;25(2):77-86. **X-2, X-6**
538. McNamara E, Evans M, Hill W. The reduction of disruptive behaviour in two secondary school classes. *Br J Educ Psychol* 1986 Jun;56 (Pt 2):209-15. PMID: 3730274. **X-11**
539. McNeil CB, Herschell AD, Gurwitsch RH, et al. Training foster parents in parent-child interaction

therapy. *Education & Treatment of Children* 2005;28(2):182-96. **X-2, X-6**

540. Mendel S. An adolescent group within a milieu setting. *Journal of Child & Adolescent Group Therapy* 1995;5(1):47-51. **X-1, X-2, X-6**

541. Menting AT, de Castro BO, Wijngaards-de Meij LD, et al. A trial of parent training for mothers being released from incarceration and their children. *J Clin Child Adolesc Psychol* 2014;43(3):381-96. PMID: 23915290. **X-4**

542. Middleton MB, Cartledge G. The effects of social skills instruction and parental involvement on the aggressive behaviors of African American males. *Behav Modif* 1995 Apr;19(2):192-210. PMID: 7726817. **X-5, X-6**

543. Milani A, Nikmanesh Z, Farnam A. Effectiveness of Mindfulness-Based Cognitive Therapy (MBCT) in Reducing Aggression of Individuals at the Juvenile Correction and Rehabilitation Center. *Int J High Risk Behav Addict* 2013 Dec;2(3):126-31. PMID: 24971290. **X-5**

544. Miles A. Changes in the attitudes to authority of patients with behaviour disorders in a therapeutic community. *Br J Psychiatry* 1969 Sep;115(526):1049-57. PMID: 5386994. **X-11**

545. Miller NV, Haas SM, Waschbusch DA, et al. Behavior therapy and callous-unemotional traits: effects of a pilot study examining modified behavioral contingencies on child behavior. *Behav Ther* 2014 Sep;45(5):606-18. PMID: 25022772. **X-4, X-5, X-6**

546. Millichap JG. Drugs in the management of learning and behavior disorders in school children. *IMJ Ill Med J* 1974 Apr;145(4):322-3. PMID: 4151138. **X-11**

547. Mlele TJ, Wiley YV. 43. *Br J Psychiatry* 1986 Sep;149:373-6. PMID: 3779305. **X-11**

548. Money J, Wiedeking C, Walker P, et al. 47,XXX and 46,XY males with antisocial and/or sex-offending behavior: antiandrogen therapy plus counseling. *Psychoneuroendocrinology* 1975;1(2):165-76. PMID: 1234655. **X-11**

549. Mordock JD. Treatment issues for the disruptive child. Diagnosis and interventions require flexibility. *Behav Healthc Tomorrow* 1999 Dec;8(6):41-2, 4, 6. PMID: 10747584. **X-10**

550. Moretti MM, Obsuth I. Effectiveness of an attachment-focused manualized intervention for parents of teens at risk for aggressive behaviour: The Connect Program. *J Adolesc* 2009 Dec;32(6):1347-57. PMID: 19766302. **X-6**

551. Morgan M. Conduct disorders. *Nursing (Lond)* 1981 Apr;1(24):1036-7. PMID: 6965125. **X-11**

552. Morris E, Le Huray C, Skagerberg E, et al. Families changing families: The protective function of multi-family therapy for children in education. *Clin Child Psychol Psychiatry* 2013 Jul 9 PMID: 23838692. **X-4, X-5**

553. Morris E, Le Huray C, Skagerberg E, et al. Families changing families: the protective function of multi-family therapy for children in education. *Clin Child Psychol Psychiatry* 2014 Oct;19(4):617-32. PMID: 23838692. **X-4**

554. Morrison JR, Minkoff K. Explosive personality as a sequel to the hyperactive-child syndrome. *Compr Psychiatry* 1975 Jul-Aug;16(4):343-8. PMID: 1157478. **X-11**

555. Mottram L, Berger-Gross P. An intervention to reduce disruptive behaviours in children with brain injury. *Pediatr Rehabil* 2004 Apr-Jun;7(2):133-43. PMID: 15204584. **X-4**

556. Mukhopadhyay P, Chakrabartii M. Token economy and cognitive modification in the treatment of study behaviour problem in children: A comparative study. *Indian Journal of Clinical Psychology* 1996;23(2):142-5. **X-10**

557. Muntz R, Hutchings J, Edwards RT, et al. Economic evaluation of treatments for children with severe behavioural problems. *J Ment Health Policy Econ* 2004 Dec;7(4):177-89. PMID: 15701933. **X-7**

558. Muratori P, Polidori L, Lambruschi F, et al. Un modello di trattamento in setting di gruppo per i disturbi da comportamento dirompente in età evolutiva: Il «Pisa-Coping Power Program». *Psicologia Clinica dello Sviluppo* 2013;17(3):411-28. **X-10, X-11**

559. Murphy CJ, Siv AM. A one year study of mode deactivation therapy: Adolescent residential patients with conduct and personality disorders. *International Journal of Behavioral Consultation and Therapy* 2011;7(1):33-40. **X-5, X-6, X-8**

560. Myeroff R, Mertlich G, Gross J. Comparative effectiveness of holding therapy with aggressive children. *Child Psychiatry Hum Dev* 1999 Summer;29(4):303-13. PMID: 10422354. **X-4**
561. Nada PJ. Heart rate variability in the assessment and biofeedback training of common mental health problems in children. *Med Arh* 2009;63(5):244-8. PMID: 20380120. **X-2, X-6, X-7, X-8**
562. Najdowski AC, Wallace MD, Ellsworth CL, et al. Functional analyses and treatment of precursor behavior. *J Appl Behav Anal* 2008 Spring;41(1):97-105. PMID: 18468282. **X-2**
563. Nantel-Vivier A, Pihl RO, Young SN, et al. Serotonergic contribution to boys' behavioral regulation. *PLoS One* 2011;6(6):e20304. PMID: 21673801. **X-2, X-7**
564. Niccols A. Immediate and short-term outcomes of the 'COPEing with Toddler Behaviour' parent group. *J Child Psychol Psychiatry* 2009 May;50(5):617-26. PMID: 19076262. **X-4**
565. Nicolson R, Craven-Thuss B, Smith J. A prospective, open-label trial of galantamine in autistic disorder. *J Child Adolesc Psychopharmacol* 2006 Oct;16(5):621-9. PMID: 17069550. **X-4**
566. Nihira K, Yusin A, Sinay R. Perception of parental behavior by adolescents in crisis. *Psychol Rep* 1975 Dec;37(3 Pt 1):787-93. PMID: 1197556. **X-11**
567. Nilsen W. Fostering futures: a preventive intervention program for school-age children in foster care. *Clin Child Psychol Psychiatry* 2007 Jan;12(1):45-63. PMID: 17378079. **X-4a**
568. Nitkowski D, Petermann F, Buttner P, et al. Behavior modification of aggressive children in child welfare: evaluation of a combined intervention program. *Behav Modif* 2009 Jul;33(4):474-92. PMID: 19571325. **X-5**
569. Nitkowski D, Petermann F, Büttner P, et al. Behavior modification of aggressive children in child welfare: Evaluation of a combined intervention program. *Behavior Modification* 2009;33(4):474-92. **X-5**
570. Nix RL, Bierman KL, McMahon RJ. How attendance and quality of participation affect treatment response to parent management training. *J Consult Clin Psychol* 2009 Jun;77(3):429-38. PMID: 19485585. **X-6**
571. Nixon RDV, Sweeney L, Erickson DB, et al. Parent-child interaction therapy: A comparison of standard and abbreviated treatments for oppositional defiant preschoolers. *Journal of Consulting and Clinical Psychology* 2003;71(2):251-60. **X-9**
572. Nixon RDV, Sweeney L, Erickson DB, et al. Parent-Child Interaction Therapy: One- and Two-Year Follow-Up of Standard and Abbreviated Treatments for Oppositional Preschoolers. *Journal of Abnormal Child Psychology* 2004;32(3):263-71. **X-9**
573. Nock MK, Kazdin AE. Randomized controlled trial of a brief intervention for increasing participation in parent management training. *J Consult Clin Psychol* 2005 Oct;73(5):872-9. PMID: 16287387. **X-2, X-6, X-7, X-8**
574. Novaes CM, Ponde MP, Freire AC. Control of psychomotor agitation and aggressive behavior in patients with autistic disorder: a retrospective chart review. *Arq Neuropsiquiatr* 2008 Sep;66(3B):646-51. PMID: 18949256. **X-2, X-4, X-6, X-7, X-8**
575. Nyhan WL. The Lesch-Nyhan syndrome. *Dev Med Child Neurol* 1978 Jun;20(3):376-80. PMID: 307504. **X-11**
576. Nylander I. The development of antisocial behaviour in children. *Acta Paedopsychiatr* 1981 Jun;47(2):71-80. PMID: 7027730. **X-11**
577. Obsuth I, Moretti MM, Holland R, et al. Conduct disorder: new directions in promoting effective parenting and strengthening parent-adolescent relationships. *J Can Acad Child Adolesc Psychiatry* 2006 Feb;15(1):6-15. PMID: 18392190. **X-6, X-8**
578. O'Callaghan P, Branham L, Shannon C, et al. A pilot study of a family focused, psychosocial intervention with war-exposed youth at risk of attack and abduction in north-eastern Democratic Republic of Congo. *Child Abuse Negl* 2014 Jul;38(7):1197-207. PMID: 24636358. **X-4**
579. O'Callaghan PM, Allen KD, Powell S, et al. The efficacy of noncontingent escape for decreasing children's disruptive behavior during restorative dental treatment. *J Appl Behav Anal* 2006 Summer;39(2):161-71. PMID: 16813038. **X-4**

580. O'Connor TG, Matias C, Futh A, et al. Social learning theory parenting intervention promotes attachment-based caregiving in young children: randomized clinical trial. *J Clin Child Adolesc Psychol* 2013;42(3):358-70. PMID: 23020146. **X-3, X-5, X-7, X-8**
581. Oettinger L, Jr. Meratran; preliminary report of a new drug for the treatment of behavior disorders in children. *Dis Nerv Syst* 1955 Oct;16(10):299-302. PMID: 13261892. **X-11**
582. Ogden T, Amlund Hagen K. What works for whom? Gender differences in intake characteristics and treatment outcomes following Multisystemic Therapy. *J Adolesc* 2009 Dec;32(6):1425-35. PMID: 19619894. **X-7a**
583. Ogden T, Hagen KA. Multisystemic Treatment of Serious Behaviour Problems in Youth: Sustainability of Effectiveness Two Years after Intake. *Child and Adolescent Mental Health* 2006;11(3):142-9. **X-4**
584. Ogden T, Halliday-Boykins CA. Multisystemic treatment of antisocial adolescents in Norway: Replication of clinical outcomes outside of the US. *Child and Adolescent Mental Health* 2004;9(2):77-83. **X-4**
585. Olds DL, Holmberg JR, Donelan-McCall N, et al. Effects of Home Visits by Paraprofessionals and by Nurses on Children: Follow-up of a Randomized Trial at Ages 6 and 9 Years. *JAMA Pediatr* 2013 Dec 2 PMID: 24296904. **X-4, X-6, X-8**
586. O'Leary KD, Kent RN. A behavioral consultation program for parents and teachers of children with conduct problems. *Proc Annu Meet Am Psychopathol Assoc* 1976(64):89-95. PMID: 946689. **X-11**
587. O'Neal CR, Brotman LM, Huang KY, et al. Understanding relations among early family environment, cortisol response, and child aggression via a prevention experiment. *Child Dev* 2010 Jan-Feb;81(1):290-305. PMID: 20331668. **X-4, X-8**
588. O'Neill D, McGilloway S, Donnelly M, et al. A cost-effectiveness analysis of the Incredible Years parenting programme in reducing childhood health inequalities. *Eur J Health Econ* 2013 Feb;14(1):85-94. PMID: 21853340. **X-7**
589. O'Neill H, & Woodward, R. . Evaluation of the Parenting Wisely CD-ROM parent-training programme: An Irish replication. *Irish Journal of Psychology* 2002;23(1-2):62-72. **X-4, X-5, X-6**
590. Oord SV, Ponsioen AJ, Geurts HM, et al. A Pilot Study of the Efficacy of a Computerized Executive Functioning Remediation Training With Game Elements for Children With ADHD in an Outpatient Setting: Outcome on Parent- and Teacher-Rated Executive Functioning and ADHD Behavior. *J Atten Disord* 2012 Aug 9 PMID: 22879577. **X-4**
591. Oosterlaan J, Sergeant JA. Effects of reward and response cost on response inhibition in AD/HD, disruptive, anxious, and normal children. *J Abnorm Child Psychol* 1998 Jun;26(3):161-74. PMID: 9650623. **X-4, X-6, X-7, X-8**
592. Ordway MR, Sadler LS, Dixon J, et al. Lasting Effects of an Interdisciplinary Home Visiting Program on Child Behavior: Preliminary Follow-Up Results of a Randomized Trial. *J Pediatr Nurs* 2013 May 15 PMID: 23685264. **X-4, X-5**
593. Orimoto TE, Mueller CW, Hayashi K, et al. Community-based treatment for youth with co- and multimorbid disruptive behavior disorders. *Administration and Policy in Mental Health and Mental Health Services Research* 2014;41(2):262-75. **X-2, X-6**
594. Orrell-Valente JK, Pinderhughes EE, Valente E, Jr., et al. If it's offered, will they come? Influences on parents' participation in a community-based conduct problems prevention program. *Am J Community Psychol* 1999 Dec;27(6):753-83. PMID: 10723534. **X-2, X-4, X-5, X-6**
595. Oruche UM, Gerkenmeyer JE, Carpenter JS, et al. Predicting outcomes among adolescents with disruptive disorders being treated in a system of care program. *Journal of the American Psychiatric Nurses Association* 2013;19(6):335-44. **X-6**
596. Osborn SG, West DJ. Do young delinquents really reform? *J Adolesc* 1980 Jun;3(2):99-114. PMID: 7381077. **X-11**
597. Ostberg M, Rydell AM. An efficacy study of a combined parent and teacher management training programme for children with ADHD. *Nord J Psychiatry* 2012 Apr;66(2):123-30. PMID: 22150634. **X-7a**
598. Owens JS, Murphy CE, Richerson L, et al. Science to practice in underserved communities: the effectiveness of school mental health programming. *J*

- Clin Child Adolesc Psychol 2008 Apr;37(2):434-47. PMID: 18470779. **X-5, X-8**
599. Palermo MT, Di Luigi M, Dal Forno G, et al. Externalizing and oppositional behaviors and karate-do: the way of crime prevention. A pilot study. *Int J Offender Ther Comp Criminol* 2006 Dec;50(6):654-60. PMID: 17068190. **X-2, X-8**
600. Pandina GJ, Bilder R, Harvey PD, et al. Risperidone and cognitive function in children with disruptive behavior disorders. *Biological Psychiatry* 2007;62(3):226-34. **X-4**
601. Pantin H, Prado G, Lopez B, et al. A randomized controlled trial of Familias Unidas for Hispanic adolescents with behavior problems. *Psychosom Med* 2009 Nov;71(9):987-95. PMID: 19834053. **X-4**
602. Paprocki J, Versiani M. A double-blind comparison between loxapine and haloperidol by parenteral route in acute schizophrenia. *Curr Ther Res Clin Exp* 1977 Jan;21(1):80-100. PMID: 12922. **X-11**
603. Parent V, Guay M-C, Lageix P, et al. Cognitive remediation impacts on children with conduct disorder. *Annual Review of CyberTherapy and Telemedicine* 2007;5:85-91. **X-1, X-5, X-6**
604. Parish-Plass J, Lufi D. Combining physical activity with a behavioral approach in the treatment of young boys with behavior disorders. *Small Group Research* 1997;28(3):357-69. **X-2, X-7**
605. Patterson GR. Interventions for boys with conduct problems: multiple settings, treatments, and criteria. *J Consult Clin Psychol* 1974 Aug;42(4):471-81. PMID: 4847255. **X-11**
606. Patterson GR, Forgatch MS, Degarmo DS. Cascading effects following intervention. *Dev Psychopathol* 2010 Nov;22(4):949-70. PMID: 20883592. **X-1, X-7, X-8**
607. Patterson GR, Reid JB. Intervention for families of aggressive boys: a replication study. *Behav Res Ther* 1973 Nov;11(4):383-94. PMID: 4777636. **X-11**
608. Patterson J, Barlow J, Mockford C, et al. Improving mental health through parenting programmes: block randomised controlled trial. *Arch Dis Child* 2002 Dec;87(6):472-7. PMID: 12456542. **X-4**
609. Pelosi AA, Friedman H. The activity period in group psychotherapy. *Psychiatr Q* 1974;48(2):223-9. PMID: 4438476. **X-11**
610. Pepler D, Walsh M, Yuile A, et al. Bridging the gender gap: interventions with aggressive girls and their parents. *Prev Sci* 2010 Sep;11(3):229-38. PMID: 20107897. **X-4**
611. Petermann F. Situation-oriented assessment and reduction of aggressive behavior. *Int J Rehabil Res* 1980;3(4):561-4. PMID: 7203761. **X-11**
612. Petermann U, Nitkowski D, Polchow D, et al. Therapiestudie: Langfristige effekte des trainings mit aggressiven kindern. *Kindheit und Entwicklung* 2007;16(3):143-51. **X-6, X-8, X-12**
613. Petermann U, Petermann F, Büttner P, et al. Effektivität kinderverhaltenstherapeutischer maßnahmen in der jugendhilfe: Das training mit aggressiven kindern. *Verhaltenstherapie* 2008;18(2):101-8. **X-10, X-12**
614. Pfeffer CR, Plutchik R, Mizruchi MS, et al. Assaultive behavior in child psychiatric inpatients, outpatients, and nonpatients. *J Am Acad Child Adolesc Psychiatry* 1987 Mar;26(2):256-61. PMID: 3584028. **X-11**
615. Phillips BN. Problem behavior in the elementary school. *Child Dev* 1968 Sep;39(3):895-903. PMID: 5687334. **X-11**
616. Phillips J, Morgan S, Cawthorne K, et al. Pilot evaluation of parent-child interaction therapy delivered in an Australian community early childhood clinic setting. *Aust N Z J Psychiatry* 2008 Aug;42(8):712-9. PMID: 18622779. **X-6**
617. Platt JE, Campbell M, Grega DM, et al. Cognitive effects of haloperidol and lithium in aggressive conduct-disorder children. *Psychopharmacol Bull* 1984 Winter;20(1):93-7. PMID: 6718655. **X-11**
618. Plueck J, Eichelberger I, Hautmann C, et al. Effectiveness of a Teacher-Based Indicated Prevention Program for Preschool Children with Externalizing Problem Behavior. *Prev Sci* 2014 Apr 22; PMID: 24752568. **X-6, X-8**
619. Pogge DL, Young K, Insalaco B, et al. Use of atypical antipsychotic medications in adolescent psychiatric inpatients: a comparison with inpatients who did not receive antipsychotic medications during

- their stay. *Int J Clin Pract* 2007 Jun;61(6):896-902. PMID: 17504351. **X-2, X-4, X-5, X-6**
620. Polanczyk G, Faraone SV, Bau CH, et al. The impact of individual and methodological factors in the variability of response to methylphenidate in ADHD pharmacogenetic studies from four different continents. *Am J Med Genet B Neuropsychiatr Genet* 2008 Dec 5;147B(8):1419-24. PMID: 18802923. **X-1, X-4, X-5**
621. Pond DA. Behavior disorders of the adolescent. Student mental health. *Trans Med Soc Lond* 1970;86:116-21. PMID: 5494689. **X-11**
622. Presnall N, Webster-Stratton CH, Constantino JN. Parent training: equivalent improvement in externalizing behavior for children with and without familial risk. *J Am Acad Child Adolesc Psychiatry* 2014 Aug;53(8):879-87. PMID: 25062595. **X-2a**
623. Price JM, Roesch S, Walsh NE. Effectiveness of the KEEP Foster Parent Intervention during an Implementation Trial. *Child Youth Serv Rev* 2012 Dec;34(12):2487-94. PMID: 23359633. **X-4**
624. Price JM, Roesch S, Walsh NE, et al. Effects of the KEEP Foster Parent Intervention on Child and Sibling Behavior Problems and Parental Stress During a Randomized Implementation Trial. *Prev Sci* 2014 Nov 25; PMID: 25418812. **X-4**
625. Prinz RJ, Miller GE. Family-based treatment for childhood antisocial behavior: experimental influences on dropout and engagement. *J Consult Clin Psychol* 1994 Jun;62(3):645-50. PMID: 8063993. **X-7, X-8**
626. Pritchard D, Hoerger M, Mace FC, et al. Clinical translation of animal models of treatment relapse. *Journal of the Experimental Analysis of Behavior* 2014;101(3):442-9. **X-4, X-6**
627. Prows CA, Nick TG, Saldana SN, et al. Drug-metabolizing enzyme genotypes and aggressive behavior treatment response in hospitalized pediatric psychiatric patients. *J Child Adolesc Psychopharmacol* 2009 Aug;19(4):385-94. PMID: 19702490. **X-2, X-4, X-5, X-6, X-7**
628. Puig-Antich J. Major depression and conduct disorder in prepuberty. *J Am Acad Child Psychiatry* 1982 Mar;21(2):118-28. PMID: 7069078. **X-11**
629. Quinn D. The conduct-disordered child—a psychiatric nursing approach. *Nurs Times* 1977 Mar 24;73(12):426-7. PMID: 854429. **X-11**
630. Raine A, Portnoy J, Liu J, et al. Reduction in behavior problems with omega-3 supplementation in children aged 8-16 years: a randomized, double-blind, placebo-controlled, stratified, parallel-group trial. *J Child Psychol Psychiatry* 2014 Aug 22; PMID: 25146492. **X-2**
631. Rawson HE. Residential short-term camping for children with behavior problems: a behavior-modification approach. *Child Welfare* 1973 Oct;52(8):511-20. PMID: 4780764. **X-11**
632. Realmuto GM, August GJ, Egan EA. Testing the goodness-of-fit of a multifaceted preventive intervention for children at risk for conduct disorder. *Can J Psychiatry* 2004 Nov;49(11):743-52. PMID: 15633852. **X-6, X-7**
633. Reid JB, Eddy JM, Fetrow RA, et al. Description and immediate impacts of a preventive intervention for conduct problems. *Am J Community Psychol* 1999 Aug;27(4):483-517. PMID: 10573832. **X-5**
634. Reid MJ, Webster-Stratton C, Baydar N. Halting the development of conduct problems in head start children: the effects of parent training. *J Clin Child Adolesc Psychol* 2004 Jun;33(2):279-91. PMID: 15136193. **X-4, X-5, X-6, X-7, X-8**
635. Reisinger JJ. Unprogrammed learning of differential attention by fathers of oppositional children. *J Behav Ther Exp Psychiatry* 1982 Sep;13(3):203-8. PMID: 7142410. **X-11**
636. Renshaw DC. Understanding the hyperactive child. *IMJ Ill Med J* 1976 Apr;149(4):351-4. PMID: 5361. **X-11**
637. Rey JM, Denshire E, Wever C, et al. Three-year outcome of disruptive adolescents treated in a day program. *Eur Child Adolesc Psychiatry* 1998 Mar;7(1):42-8. PMID: 9563813. **X-6**
638. Richman DM, Berg WK, Wacker DP, et al. Using pretreatment and posttreatment assessments to enhance and evaluate existing treatment packages. *J Appl Behav Anal* 1997 Winter;30(4):709-12. PMID: 9433796. **X-4, X-6, X-7**
639. Richman DM, Wacker DP, Cooper-Brown LJ, et al. Stimulus characteristics within directives:

- effects on accuracy of task completion. *J Appl Behav Anal* 2001 Fall;34(3):289-312. PMID: 11678525. **X-2, X-6**
640. Rifkin A, Karajgi B, Dicker R, et al. Lithium treatment of conduct disorders in adolescents. *Am J Psychiatry* 1997 Apr;154(4):554-5. PMID: 9090346. **X-5**
641. Riggs PD. Clinical approach to treatment of ADHD in adolescents with substance use disorders and conduct disorder. *J Am Acad Child Adolesc Psychiatry* 1998 Mar;37(3):331-2. PMID: 9519639. **X-1**
642. Riggs PD, Hall SK, Mikulich-Gilbertson SK, et al. A randomized controlled trial of pemoline for attention-deficit/hyperactivity disorder in substance-abusing adolescents. *J Am Acad Child Adolesc Psychiatry* 2004 Apr;43(4):420-9. PMID: 15187802. **X-4, X-6**
643. Riggs PD, Leon SL, Mikulich SK, et al. An open trial of bupropion for ADHD in adolescents with substance use disorders and conduct disorder. *J Am Acad Child Adolesc Psychiatry* 1998 Dec;37(12):1271-8. PMID: 9847499. **X-4, X-6**
644. Riggs PD, Mikulich-Gilbertson SK, Davies RD, et al. A randomized controlled trial of fluoxetine and cognitive behavioral therapy in adolescents with major depression, behavior problems, and substance use disorders. *Arch Pediatr Adolesc Med* 2007 Nov;161(11):1026-34. PMID: 17984403. **X-4**
645. Rimm DC, Hill GA, Brown NN, et al. Group-assertive training in treatment of expression of inappropriate anger. *Psychol Rep* 1974 Jun;34(3):791-8. PMID: 4846914. **X-11**
646. Robbins MS, Szapocznik J, Horigian VE, et al. Brief strategic family therapy for adolescent drug abusers: a multi-site effectiveness study. *Contemp Clin Trials* 2009 May;30(3):269-78. PMID: 19470315. **X-4**
647. Roberts D. An evaluation of a community-based basic parenting programme: a two-year follow-up. *Community Pract* 2012 Feb;85(2):27-31. PMID: 22439447. **X-2, X-4, X-6, X-7, X-8**
648. Robinson BA, Winiarski DA, Brennan PA, et al. Social Context, Parental Monitoring, and Multisystemic Therapy Outcomes. *Psychotherapy (Chic)* 2014 Nov 3 PMID: 25365153. **X-6**
649. Rodman FR. SETTING LIMITS FOR AGGRESSIVE CHILDREN. *Ment Hosp* 1964 Nov;15:606. PMID: 14228744. **X-11**
650. Rodriguez GM, Bagner DM, Graziano PA. Parent Training for Children Born Premature: A Pilot Study Examining the Moderating Role of Emotion Regulation. *Child Psychiatry Hum Dev* 2013 May 17 PMID: 23681677. **X-4**
651. Rodriguez GM, Bagner DM, Graziano PA. Parent training for children born premature: a pilot study examining the moderating role of emotion regulation. *Child Psychiatry Hum Dev* 2014 Apr;45(2):143-52. PMID: 23681677. **X-4**
652. Roke Y, Buitelaar JK, Boot AM, et al. Risk of hyperprolactinemia and sexual side effects in males 10-20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone. *J Child Adolesc Psychopharmacol* 2012 Dec;22(6):432-9. PMID: 23234586. **X-2, X-6**
653. Roke Y, van Harten PN, Buitelaar JK, et al. Antipsychotic-induced hyperprolactinemia and testosterone levels in boys. *Horm Res Paediatr* 2012;77(4):235-40. PMID: 22538969. **X-2, X-6, X-7**
654. Roke Y, van Harten PN, Buitelaar JK, et al. Bone mineral density in male adolescents with autism spectrum disorders and disruptive behavior disorder with or without antipsychotic treatment. *Eur J Endocrinol* 2012 Dec;167(6):855-63. PMID: 23011870. **X-4**
655. Rollin SA, Potts I, Kaiser-Ulrey C, et al. Middle school internships for at-risk youth: a proven intervention. *Ethn Dis* 2003 Summer;13(3 Suppl 3):S3-99-101. PMID: 14552464. **X-5, X-6**
656. Romano E, Thornhill S, Lacourse E. An 8-year follow-up study of profiles and predictors of methylphenidate use in a nationwide sample of boys. *J Pediatr* 2009 Nov;155(5):721-7. PMID: 19643442. **X-2**
657. Ronan KR, Kendall PC. Non-self-controlled adolescents: applications of cognitive-behavioral therapy. *Adolesc Psychiatry* 1990;17:479-505. PMID: 2240433. **X-11**
658. Roscoe EM, Kindle AE, Pence ST. Functional analysis and treatment of aggression maintained by preferred conversational topics. *J Appl Behav Anal* 2010 Winter;43(4):723-7. PMID: 21541156. **X-2, X-4, X-6, X-7, X-8**

659. Rose J, Loftus M, Flint B, et al. Factors associated with the efficacy of a group intervention for anger in people with intellectual disabilities. *Br J Clin Psychol* 2005 Sep;44(Pt 3):305-17. PMID: 16238879. **X-4**
660. Rosenbaum JB. Gender-specific problems in the treatment of young women. *Am J Psychoanal* 1977 Fall;37(3):215-21. PMID: 596477. **X-11**
661. Rosenberg RM, Mueller BC. Preschool antisocial children. Psychodynamic considerations and implications for treatment. *J Am Acad Child Psychiatry* 1968 Jul;7(3):421-41. PMID: 5666078. **X-11**
662. Rosenthal L. Some dynamics of resistance and therapeutic management in adolescent group therapy. *Psychoanal Rev* 1971 Fall;58(3):353-66. PMID: 5150683. **X-11**
663. Rowland MD, Halliday-Boykins CA, Henggeler SW, et al. A Randomized Trial of Multisystemic Therapy With Hawaii's Felix Class Youths. *Journal of Emotional and Behavioral Disorders* 2005;13(1):13-23. **X-4**
664. Ruby E, Sher L. Prevention of suicidal behavior in adolescents with post-traumatic stress disorder. *Int J Adolesc Med Health* 2013;25(3):283-93. PMID: 23843573. **X-1, X-2, X-4, X-5, X-6, X-7, X-8**
665. Ryan SR, Stanger C, Thostenson J, et al. The impact of disruptive behavior disorder on substance use treatment outcome in adolescents. *J Subst Abuse Treat* 2013 May-Jun;44(5):506-14. PMID: 23228436. **X-8**
666. Sachdeva S, Goldman G, Mustata G, et al. Naturalistic outcomes of evidence-based therapies for borderline personality disorder at a university clinic: a quasi-randomized trial. *J Am Psychoanal Assoc* 2013 Jun;61(3):578-84. PMID: 23720029. **X-3, X-4**
667. Safer DJ. Establishing boundary lines for families of children with behavior disorders. *Psychiatr Q Suppl* 1968;42 Pt 1:86-97. PMID: 4190009. **X-11**
668. Salmon K, Dadds MR, Allen J, et al. Can emotional language skills be taught during parent training for conduct problem children? *Child Psychiatry Hum Dev* 2009 Dec;40(4):485-98. PMID: 19373551. **X-7**
669. Salmon K, Dittman C, Sanders M, et al. Does adding an emotion component enhance the Triple P-Positive Parenting Program? *J Fam Psychol* 2014 Apr;28(2):244-52. PMID: 24588606. **X-4**
670. Salzer S, Cropp C, Jaeger U, et al. Psychodynamic therapy for adolescents suffering from co-morbid disorders of conduct and emotions in an in-patient setting: A randomized controlled trial. *Psychological Medicine* 2014;44(10):2213-22. **X-5**
671. Salzman C, Green AI, Rodriguez-Villa F, et al. Benzodiazepines combined with neuroleptics for management of severe disruptive behavior. *Psychosomatics* 1986 Jan;27(1 Suppl):17-22. PMID: 3952250. **X-11**
672. Sanchez LE, Armenteros JL, Small AM, et al. Placebo response in aggressive children with conduct disorder. *Psychopharmacol Bull* 1994;30(2):209-13. PMID: 7831457. **X-2, X-5, X-6, X-7, X-8**
673. Sanders LM, Schaechter J, Serwint JR. Conduct disorder. *Pediatr Rev* 2007 Nov;28(11):433-4; discussion 4. PMID: 17974708. **X-1, X-2, X-5, X-6, X-7**
674. Sanders MR, Christensen AP. A comparison of the effects of child management and planned activities training in five parenting environments. *J Abnorm Child Psychol* 1985 Mar;13(1):101-17. PMID: 3973246. **X-11**
675. Sanders MR, Dittman CK, Farruggia SP, et al. A comparison of online versus workbook delivery of a self-help positive parenting program. *J Prim Prev* 2014 Jun;35(3):125-33. PMID: 24500106. **X-5**
676. Sanders MR, Montgomery DT, Brechman-Toussaint ML. The mass media and the prevention of child behavior problems: the evaluation of a television series to promote positive outcomes for parents and their children. *J Child Psychol Psychiatry* 2000 Oct;41(7):939-48. PMID: 11079436. **X-2, X-8**
677. Sanders MR, Plant K. Programming for generalization to high and low risk parenting situations in families with oppositional developmentally disabled preschoolers. *Behav Modif* 1989 Jul;13(3):283-305. PMID: 2764862. **X-11**
678. Santinello M, Cristini F, Vieno A, et al. "Volunteering by chance" to promote civic responsibility and civic engagement: does it work? *J Prev Interv Community* 2012 Jan;40(1):64-79. PMID: 22242782. **X-4, X-5**

679. Santos RG, Chartier MJ, Whalen JC, et al. Effectiveness of school-based violence prevention for children and youth: a research report. *Health Q* 2011 Apr;14 Spec No:80-91. PMID: 24956430. *X-4, X-5*
680. Sarne Y, Mandel J, Goncalves MH, et al. Imipramine binding to blood platelets and aggressive behavior in offenders, schizophrenics and normal volunteers. *Neuropsychobiology* 1995;31(3):120-4. PMID: 7609859. *X-2, X-3, X-4, X-5*
681. Satterfield JH, Satterfield BT, Cantwell DP. Three-year multimodality treatment study of 100 hyperactive boys. *J Pediatr* 1981 Apr;98(4):650-5. PMID: 7205499. *X-11*
682. Saxena K, Silverman MA, Chang K, et al. Baseline predictors of response to divalproex in conduct disorder. *J Clin Psychiatry* 2005 Dec;66(12):1541-8. PMID: 16401155. *X-4, X-5*
683. Scahill L. How do I decide whether or not to use medication for my child with autism? Should I try behavior therapy first? *J Autism Dev Disord* 2008 Jul;38(6):1197-8. PMID: 18463973. *X-1, X-5*
684. Scahill L, Sukhodolsky DG, Bearss K, et al. Randomized trial of parent management training in children with tic disorders and disruptive behavior. *J Child Neurol* 2006 Aug;21(8):650-6. PMID: 16970865. *X-4, X-6*
685. Scarboro ME, Forehand R. Effects of two types of response-contingent time-out on compliance and oppositional behavior of children. *J Exp Child Psychol* 1975 Apr;19(2):252-64. PMID: 1151283. *X-11*
686. Schaeffer CM, Borduin CM. Long-term follow-up to a randomized clinical trial of multisystemic therapy with serious and violent juvenile offenders. *J Consult Clin Psychol* 2005 Jun;73(3):445-53. PMID: 15982142. *X-4*
687. Scharer KM. Helping disturbed children change their passive-aggressive behavior through milieu therapy. *ANA Publ* 1979(NP-59):275-92. PMID: 259410. *X-11*
688. Scharfstein DO, Manski CF, Anthony JC. On the construction of bounds in prospective studies with missing ordinal outcomes: application to the good behavior game trial. *Biometrics* 2004 Mar;60(1):154-64. PMID: 15032785. *X-2, X-4, X-5, X-6, X-8*
689. Schechter DS, Willheim E. When parenting becomes unthinkable: intervening with traumatized parents and their toddlers. *J Am Acad Child Adolesc Psychiatry* 2009 Mar;48(3):249-53. PMID: 19242290. *X-1, X-2, X-3, X-4, X-5, X-6*
690. Scheeringa MS, Weems CF, Cohen JA, et al. Trauma-focused cognitive-behavioral therapy for posttraumatic stress disorder in three-through six year-old children: a randomized clinical trial. *J Child Psychol Psychiatry* 2011 Aug;52(8):853-60. PMID: 21155776. *X-4*
691. Scheres A, Oosterlaan J, Sergeant JA. Response inhibition in children with DSM-IV subtypes of AD/HD and related disruptive disorders: the role of reward. *Child Neuropsychol* 2001 Sep;7(3):172-89. PMID: 12187474. *X-2, X-6, X-7, X-8*
692. Schmidt MH, Mocks P, Lay B, et al. Does oligoantigenic diet influence hyperactive/conduct-disordered children--a controlled trial. *Eur Child Adolesc Psychiatry* 1997 Jun;6(2):88-95. PMID: 9257090. *X-2, X-5*
693. Schmidt MH, Möcks P, Lay B, et al. Does oligoantigenic diet influence hyperactive/conduct-disordered children—a controlled trial. *European Child & Adolescent Psychiatry* 1997;6(2):88-95. *X-2, X-5, X-6*
694. Schoenwald SK, Chapman JE, Sheidow AJ, et al. Long-term youth criminal outcomes in MST transport: the impact of therapist adherence and organizational climate and structure. *J Clin Child Adolesc Psychol* 2009 Jan;38(1):91-105. PMID: 19130360. *X-4, X-7*
695. Schoenwald SK, Garland AF, Southam-Gerow MA, et al. Adherence Measurement in Treatments for Disruptive Behavior Disorders: Pursuing Clear Vision through Varied Lenses. *Clin Psychol (New York)* 2011 Dec 1;18(4):331-41. PMID: 22563149. *X-1, X-2, X-4, X-5, X-6, X-8*
696. Scholer SJ, Reich SM, Boshers RB, et al. A brief program improves counseling of mothers with children who have persistent aggression. *J Interpers Violence* 2012 Apr;27(6):991-1004. PMID: 22204948. *X-2, X-3, X-4*
697. Schuppert HM, Giesen-Bloo J, van Gemert TG, et al. Effectiveness of an emotion regulation group training for adolescents--a randomized controlled pilot study. *Clin Psychol Psychother* 2009 Nov-Dec;16(6):467-78. PMID: 19630069. *X-4, X-7, X-8*

698. Schuppert HM, Timmerman ME, Bloo J, et al. Emotion regulation training for adolescents with borderline personality disorder traits: a randomized controlled trial. *J Am Acad Child Adolesc Psychiatry* 2012 Dec;51(12):1314-23 e2. PMID: 23200288. **X-4, X-7, X-8**
699. Schvehla TJ, Mandoki MW, Sumner GS. Clonidine therapy for comorbid attention deficit hyperactivity disorder and conduct disorder: preliminary findings in a children's inpatient unit. *South Med J* 1994 Jul;87(7):692-5. PMID: 8023201. **X-5, X-6**
700. Scott S. Deciding whether interventions for antisocial behaviour work: principles of outcome assessment, and practice in a multicentre trial. *Eur Child Adolesc Psychiatry* 2001;10 Suppl 1:159-70. PMID: 11794557. **X-1, X-7**
701. Scott S, Briskman J, O'Connor TG. Early prevention of antisocial personality: long-term follow-up of two randomized controlled trials comparing indicated and selective approaches. *Am J Psychiatry* 2014 Jun;171(6):649-57. PMID: 24626738. **X-2a**
702. Segal D, Chen PY, Gordon DA, et al. Development and evaluation of a parenting intervention program: Integration of scientific and practical approaches. *International Journal of Human-Computer Interaction* 2003;15(3):453-67. **X-4**
703. Serra-Pinheiro MA, Mattos P, Souza I, et al. The effect of methylphenidate on oppositional defiant disorder comorbid with attention deficit/hyperactivity disorder. *Arq Neuropsiquiatr* 2004 Jun;62(2B):399-402. PMID: 15273834. **X-6**
704. Shabry F, Wolk JA. Granulocytopenia in children after phenothiazine therapy. *Am J Psychiatry* 1980 Mar;137(3):374-5. PMID: 6101935. **X-11**
705. Shaffer A, Lindhiem O, Kolko DJ, et al. Bidirectional relations between parenting practices and child externalizing behavior: a cross-lagged panel analysis in the context of a psychosocial treatment and 3-year follow-up. *J Abnorm Child Psychol* 2013 Feb;41(2):199-210. PMID: 22821450. **X-6, X-8**
706. Shagass C, Bittle RM. Therapeutic effects of LSD: a follow-up study. *J Nerv Ment Dis* 1967 Jun;144(6):471-8. PMID: 4860930. **X-11**
707. Shamo AE, Tauer CA. Ethically questionable research with children: the fenfluramine study. *Account Res* 2002 Jul-Dec;9(3-4):143-66. PMID: 12816124. **X-1, X-2, X-4, X-5**
708. Shapiro A. Problems of behaviour disorder and delinquency in adolescents and its treatment. *J Bras Psiquiatr* 1968;17(1):7-23. PMID: 5760627. **X-11**
709. Shapiro JP, Welker CJ, Jacobson BJ. A naturalistic study of psychotherapeutic methods and client in-therapy functioning in a child community setting. *J Clin Child Psychol* 1997 Dec;26(4):385-96. PMID: 9418177. **X-6**
710. Shaw DS, Dishion TJ, Supplee L, et al. Randomized trial of a family-centered approach to the prevention of early conduct problems: 2-year effects of the family check-up in early childhood. *J Consult Clin Psychol* 2006 Feb;74(1):1-9. PMID: 16551138. **X-4**
711. Shechtman Z. The relation of client behavior and therapist helping skills to reduced aggression of boys in individual and group treatment. *Int J Group Psychother* 2004 Oct;54(4):435-54. PMID: 15388400. **X-4, X-5**
712. Shechtman Z, Leichtenritt J. The association of process with outcomes in child group therapy. *Psychother Res* 2010 Jan;20(1):8-21. PMID: 19634048. **X-4, X-5, X-6, X-7**
713. Shelton TL, Barkley RA, Crosswait C, et al. Multimethod psychoeducational intervention for preschool children with disruptive behavior: two-year post-treatment follow-up. *J Abnorm Child Psychol* 2000 Jun;28(3):253-66. PMID: 10885683. **X-5**
714. Sherk CE, Dorn LD, Kolko DJ, et al. Predicting treatment response for oppositional defiant and conduct disorder using pre-treatment adrenal and gonadal hormones. *Journal of Child and Family Studies* 2012;21(6):973-81. **X-8**
715. Sherburne S, Utley B, McConnell S, et al. Decreasing violent or aggressive theme play among preschool children with behavior disorders. *Except Child* 1988 Oct;55(2):166-72. PMID: 3191930. **X-11**
716. Sheridan SM, Ryoo JH, Garbacz SA, et al. The efficacy of conjoint behavioral consultation on parents and children in the home setting: Results of a randomized controlled trial. *J Sch Psychol* 2013 Dec;51(6):717-33. PMID: 24295145. **X-5**

717. Shipley D. Safety net. *Ment Health Today* 2014 Jul-Aug;12-3. PMID: 25195232. **X-1**
718. Shytle RD, Silver AA, Sheehan KH, et al. Neuronal nicotinic receptor inhibition for treating mood disorders: Preliminary controlled evidence with mecamylamine. *Depression and Anxiety* 2002;16(3):89-92. **X-2, X-4**
719. Siassi I. Lithium treatment of impulsive behavior in children. *J Clin Psychiatry* 1982 Dec;43(12):482-4. PMID: 6819289. **X-11**
720. Sidora-Arcoleo K, Anson E, Lorber M, et al. Differential effects of a nurse home-visiting intervention on physically aggressive behavior in children. *J Pediatr Nurs* 2010 Feb;25(1):35-45. PMID: 20117675. **X-4, X-8**
721. Sieving RE, McMorris BJ, Secor-Turner M, et al. Prime Time: 18-Month Violence Outcomes of a Clinic-Linked Intervention. *Prev Sci* 2013 Apr 2 PMID: 23543359. **X-4**
722. Signorovitch J, Erder MH, Xie J, et al. Comparative effectiveness research using matching-adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. *Pharmacoepidemiol Drug Saf* 2012 May;21 Suppl 2:130-7. PMID: 22552988. **X-1, X-4**
723. Sinzig J, Döpfner M, Lehmkuhl G. Long-acting methylphenidate has an effect on aggressive behavior in children with attention-deficit/hyperactivity disorder. *Journal of Child and Adolescent Psychopharmacology* 2007;17(4):421-32. **X-4**
724. Sinzig J, Dopfner M, Lehmkuhl G, et al. Long-acting methylphenidate has an effect on aggressive behavior in children with attention-deficit/hyperactivity disorder. *J Child Adolesc Psychopharmacol* 2007 Aug;17(4):421-32. PMID: 17822338. **X-4**
725. Slavkin ML. What every clinician needs to know about juvenile firesetters. *Psychiatr Serv* 2002 Oct;53(10):1237-8. PMID: 12364667. **X-1, X-2**
726. Smith C. Mental health of children and young people in hospital. *Paediatr Nurs* 2009 Jun;21(5):28-31. PMID: 19552248. **X-1, X-2, X-4, X-5, X-6, X-7**
727. Smith JD, Dishion TJ, Shaw DS, et al. Negative Relational Schemas Predict the Trajectory of Coercive Dynamics During Early Childhood. *J Abnorm Child Psychol* 2014 Sep 11 PMID: 25208813. **X-2, X-4**
728. Smith JD, Knoble NB, Zerr AA, et al. Family check-up effects across diverse ethnic groups: reducing early-adolescence antisocial behavior by reducing family conflict. *J Clin Child Adolesc Psychol* 2014;43(3):400-14. PMID: 24731120. **X-4**
729. Smith TE, Sells SP, Rodman J, et al. Reducing adolescent substance abuse and delinquency: Pilot research of a family-oriented psychoeducation curriculum. *Journal of Child & Adolescent Substance Abuse* 2006;15(4):105-15. **X-6**
730. Smolkowski K, Biglan A, Barrera M, et al. Schools and homes in partnership (SHIP): long-term effects of a preventive intervention focused on social behavior and reading skill in early elementary school. *Prev Sci* 2005 Jun;6(2):113-25. PMID: 15889626. **X-5, X-7**
731. Snyder J, McEachern A, Schrepferman L, et al. Contribution of peer deviancy training to the early development of conduct problems: mediators and moderators. *Behav Ther* 2010 Sep;41(3):317-28. PMID: 20569781. **X-2, X-4, X-5, X-6, X-7, X-8**
732. Snyder R, Turgay A, Aman M, et al. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. *J Am Acad Child Adolesc Psychiatry* 2002 Sep;41(9):1026-36. PMID: 12218423. **X-4**
733. Soleimani S, Sharif F, Mani A, et al. The Effect of Conflict Resolution Training on Children's Behavioral Problems in Shiraz, Southern Iran: A Randomized Controlled Trial. *Int J Community Based Nurs Midwifery* 2014 Jul;2(3):185-95. PMID: 25349861. **X-4**
734. Solholm R, Kjobli J, Christiansen T. Early initiatives for children at risk-development of a program for the prevention and treatment of behavior problems in primary services. *Prev Sci* 2013 Dec;14(6):535-44. PMID: 23404660. **X-1, X-2, X-5, X-6**
735. Solomon M, Ono M, Timmer S, et al. The effectiveness of parent-child interaction therapy for families of children on the autism spectrum. *J Autism Dev Disord* 2008 Oct;38(9):1767-76. PMID: 18401693. **X-4**

736. Solovey De Milechnin G. Conduct problems in children and hypnosis. *Dis Nerv Syst* 1955 Aug;16(8):249-53. PMID: 13241327. **X-11**
737. Somogyi I, Vetro A, Szentistvanyi I, et al. Lithium treatment of aggressive children and the EEG. *Acta Paediatr Hung* 1988;29(3-4):365-72. PMID: 3151984. **X-11**
738. Spada S, Bomba M, Donati C, et al. Risperidone in età pediatrica: Tollerabilità ed efficacia nei soggetti con disturbo da comportamento dirompente. *Giornale di Neuropsichiatria dell'Età Evolutiva* 2011;31(2):149-53. **X-10, X-12**
739. Spence D. Bad medicine: medicated minors. *BMJ* 2010;341:c3907. PMID: 20659982. **X-1**
740. Spijkers W, Jansen DE, Reijneveld SA. Effectiveness of Primary Care Triple P on child psychosocial problems in preventive child healthcare: a randomized controlled trial. *BMC Med* 2013 Nov 11;11(1):240. PMID: 24207163. **X-4, X-8**
741. Spoth RL, Redmond C, Shin C. Reducing adolescents' aggressive and hostile behaviors: randomized trial effects of a brief family intervention 4 years past baseline. *Arch Pediatr Adolesc Med* 2000 Dec;154(12):1248-57. PMID: 11115311. **X-5, X-7**
742. Spuij M, Prinzie P, Dekovic M, et al. The effectiveness of Grief-Help, a cognitive behavioural treatment for prolonged grief in children: study protocol for a randomised controlled trial. *Trials* 2013 Nov 20;14(1):395. PMID: 24252587. **X-4, X-7, X-8**
743. Stadler C, Grasmann D, Fegert JM, et al. Heart rate and treatment effect in children with disruptive behavior disorders. *Child Psychiatry Hum Dev* 2008 Sep;39(3):299-309. PMID: 18058222. **X-2, X-6**
744. Staller JA. Psychopharmacologic treatment of aggressive preschoolers: a chart review. *Prog Neuropsychopharmacol Biol Psychiatry* 2007 Jan 30;31(1):131-5. PMID: 17007977. **X-2, X-6, X-8**
745. Stanger C, Noel V. A social skills and parental training intervention for disruptive boys reduces substance use behaviours in adolescence. *Evid Based Ment Health* 2013 Dec 12 PMID: 24336694. **X-1**
746. Stein DB. Outpatient behavioral management of aggressiveness in adolescents: A response cost paradigm. *Aggressive Behavior* 1999;25(5):321-30. **X-6, X-7**
747. Stein DB, Smith ED. The "REST" program: a new treatment system for the oppositional defiant adolescent. *Adolescence* 1990 Winter;25(100):891-904. PMID: 2275444. **X-11**
748. Steinberg GG, Troshinsky C, Steinberg HR. Dextroamphetamine-responsive behavior disorder in school children. *Am J Psychiatry* 1971 Aug;128(2):174-9. PMID: 4939589. **X-11**
749. Sternbach O. Arrested ego development and its treatment in conduct disorders and neuroses of childhood. *Nerv Child* 1947 Jul;6(3):306-17. PMID: 20254531. **X-11**
750. Stevens L, Zhang W, Peck L, et al. EPA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. *Lipids* 2003 Oct;38(10):1007-21. PMID: 14669965. **X-8**
751. Stocks JD, Taneja BK, Baroldi P, et al. A phase 2a randomized, parallel group, dose-ranging study of molindone in children with attention-deficit/hyperactivity disorder and persistent, serious conduct problems. *J Child Adolesc Psychopharmacol* 2012 Apr;22(2):102-11. PMID: 22372512. **X-6**
752. Strayhorn JM, Weidman CS. Reduction of attention deficit and internalizing symptoms in preschoolers through parent-child interaction training. *J Am Acad Child Adolesc Psychiatry* 1989 Nov;28(6):888-96. PMID: 2808259. **X-11**
753. Stroh G. The function of in-service training in the management of disturbed children. *J Child Psychol Psychiatry* 1968 Dec;9(3):189-201. PMID: 5730947. **X-11**
754. Stubblefield RL. Adolescent behaviour disorders. Evaluation and treatment. *Tex State J Med* 1962 Apr;58:284-7. PMID: 13917945. **X-11**
755. Sukhodolsky DG, Gorman BS, Scahill L, et al. Exposure and response prevention with or without parent management training for children with obsessive-compulsive disorder complicated by disruptive behavior: a multiple-baseline across-responses design study. *J Anxiety Disord* 2013 Apr;27(3):298-305. PMID: 23602943. **X-2a, X-7a**
756. Sukhodolsky DG, Vitulano LA, Carroll DH, et al. Randomized trial of anger control training for adolescents with Tourette's syndrome and disruptive

- behavior. *J Am Acad Child Adolesc Psychiatry* 2009 Apr;48(4):413-21. PMID: 19242384. **X-4, X-6, X-8**
757. Sundell K, Hansson K, Löfholm CA, et al. The transportability of multisystemic therapy to Sweden: Short-term results from a randomized trial of conduct-disordered youths. *Journal of Family Psychology* 2008;22(4):550-60. **X-9**
758. Suveg C, Hudson JL, Brewer G, et al. Cognitive-behavioral therapy for anxiety-disordered youth: secondary outcomes from a randomized clinical trial evaluating child and family modalities. *J Anxiety Disord* 2009 Apr;23(3):341-9. PMID: 19216048. **X-4**
759. Svanborg P, Thernlund G, Gustafsson PA, et al. Atomoxetine improves patient and family coping in attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in Swedish children and adolescents. *Eur Child Adolesc Psychiatry* 2009 Dec;18(12):725-35. PMID: 19466476. **X-4**
760. Svendsen BB, Willadsen J. THE USE OF HALOPERIDOL (SERENASE (R)) IN CHLORPROTIXEN RESISTANT PATIENTS. *Acta Psychiatr Scand* 1963;39:Suppl169:351-5. PMID: 14078687. **X-11**
761. Swanson JM, Kraemer HC, Hinshaw SP, et al. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. *J Am Acad Child Adolesc Psychiatry* 2001 Feb;40(2):168-79. PMID: 11211365. **X-4**
762. Swanson JW, Swartz MS, Van Dorn RA, et al. Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. *Br J Psychiatry* 2008 Jul;193(1):37-43. PMID: 18700216. **X-3, X-4**
763. Swart GT, Siman E, Stewart SL. The use of Pro Re Nata or Statim medications for behavioral control: a summary of experience at a tertiary care children's mental health center. *J Child Adolesc Psychopharmacol* 2011 Feb;21(1):67-77. PMID: 21288118. **X-2, X-4, X-5**
764. Swart J, Apsche J. Mindfulness, mode deactivation, and family therapy: A winning combination for treating adolescents with complex trauma and behavioral problems. *International Journal of Behavioral Consultation and Therapy* 2014;9(2):9-14. **X-5**
765. Tamm L, Trello-Rishel K, Riggs P, et al. Predictors of treatment response in adolescents with comorbid substance use disorder and attention-deficit/hyperactivity disorder. *J Subst Abuse Treat* 2013 Feb;44(2):224-30. PMID: 22889694. **X-4, X-7, X-8**
766. Tanner VL, Holliman WB. Effectiveness of assertiveness training in modifying aggressive behaviors of young children. *Psychol Rep* 1988 Feb;62(1):39-46. PMID: 3363075. **X-11**
767. Tavormina JB, Henggeler SW, Gayton WF. Age trends in parental assessments of the behavior problems of their retarded children. *Ment Retard* 1976 Feb;14(1):38-9. PMID: 1250150. **X-11**
768. Taylor E, Schachar R, Thorley G, et al. Which boys respond to stimulant medication? A controlled trial of methylphenidate in boys with disruptive behaviour. *Psychol Med* 1987 Feb;17(1):121-43. PMID: 3554290. **X-11**
769. Teixeira EH, Celeri EV, Jacintho ACA, et al. Clozapine in severe conduct disorder. *Journal of Child and Adolescent Psychopharmacology* 2013;23(1):44-8. **X-6**
770. Ter-Stepanian M, Grizenko N, Zappitelli M, et al. Clinical response to methylphenidate in children diagnosed with attention-deficit hyperactivity disorder and comorbid psychiatric disorders. *Can J Psychiatry* 2010 May;55(5):305-12. PMID: 20482957. **X-4, X-7**
771. Theise R, Huang KY, Kamboukos D, et al. Moderators of intervention effects on parenting practices in a randomized controlled trial in early childhood. *J Clin Child Adolesc Psychol* 2014;43(3):501-9. PMID: 24063291. **X-2, X-4, X-7**
772. Theodore LA, Bray MA, Kehle TJ, et al. Randomization of group contingencies and reinforcers to reduce classroom disruptive behavior. *Journal of School Psychology* 2001;39(3):267-77. **X-5**
773. Thomas CR. Evidence-based practice for conduct disorder symptoms. *J Am Acad Child Adolesc Psychiatry* 2006 Jan;45(1):109-14. PMID: 16327588. **X-1, X-2, X-5, X-6, X-7, X-8**
774. Thorell LB. The Community Parent Education Program (COPE): treatment effects in a clinical and a community-based sample. *Clin Child Psychol*

Psychiatry 2009 Jul;14(3):373-87. PMID: 19515754. **X-7a**

775. Tiernan K, Foster SL, Cunningham PB, et al. Predicting Early Positive Change in Multisystemic Therapy With Youth Exhibiting Antisocial Behaviors. *Psychotherapy (Chic)* 2014 May 26; PMID: 24866967. **X-4, X-6**

776. Timmer SG, Ware LM, Urquiza AJ, et al. The effectiveness of parent-child interaction therapy for victims of interparental violence. *Violence Vict* 2010;25(4):486-503. PMID: 20712147. **X-6**

777. Timmons-Mitchell J, Bender MB, Kishna MA, et al. An independent effectiveness trial of multisystemic therapy with juvenile justice youth. *J Clin Child Adolesc Psychol* 2006 Jun;35(2):227-36. PMID: 16597218. **X-4**

778. Tolan PH, Gorman-Smith D, Henry D, et al. The benefits of booster interventions: evidence from a family-focused prevention program. *Prev Sci* 2009 Dec;10(4):287-97. PMID: 19513845. **X-4, X-8**

779. Tremblay RE, McCord J, Boileau H, et al. Can disruptive boys be helped to become competent? *Psychiatry* 1991 May;54(2):148-61. PMID: 1852848. **X-11**

780. Troost PW, Althaus M, Lahuis BE, et al. Neuropsychological effects of risperidone in children with pervasive developmental disorders: a blinded discontinuation study. *J Child Adolesc Psychopharmacol* 2006 Oct;16(5):561-73. PMID: 17069545. **X-4**

781. Turgay A, Binder C, Snyder R, et al. Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. *Pediatrics* 2002 Sep;110(3):e34. PMID: 12205284. **X-4**

782. Uliaszek AA, Wilson S, Mayberry M, et al. A pilot intervention of multifamily dialectical behavior group therapy in a treatment-seeking adolescent population: Effects on teens and their family members. *The Family Journal* 2014;22(2):206-15. **X-4, X-6**

783. van Bokhoven I, Matthys W, van Goozen SHM, et al. Adolescent outcome of disruptive behaviour disorder in children who had been treated in inpatient and day-treatment settings. *European Child & Adolescent Psychiatry* 2006;15(2):79-87. **X-5, X-6, X-7**

784. van de Wiel NM, van Goozen SH, Matthys W, et al. Cortisol and treatment effect in children with disruptive behavior disorders: a preliminary study. *J Am Acad Child Adolesc Psychiatry* 2004 Aug;43(8):1011-8. PMID: 15266196. **X-2, X-6**

785. Van De Wiel NMH, Matthys W, Cohen-Kettenis P, et al. Application of the Utrecht Coping Power Program and Care as Usual to Children With Disruptive Behavior Disorders in Outpatient Clinics: A Comparative Study of Cost and Course of Treatment. *Behavior Therapy* 2003;34(4):421-36. **X-6, X-7**

786. van den Hoofdakker BJ, Nauta MH, van der Veen-Mulders L, et al. Behavioral parent training as an adjunct to routine care in children with attention-deficit/hyperactivity disorder: moderators of treatment response. *J Pediatr Psychol* 2010 Apr;35(3):317-26. PMID: 19633060. **X-4**

787. van Krevelen DA, Maresca A, Schreurs-Dijkstra M. [Evaluation of Tegretol in the treatment of behavior disorders in children. Methodology and results]. *Acta Paedopsychiatr* 1970 Dec;37(7):222-34. PMID: 4927118. **X-11**

788. van Loon LM, Granic I, Engels RC. The Role of Maternal Depression on Treatment Outcome for Children with Externalizing Behavior Problems. *J Psychopathol Behav Assess* 2011 Jun;33(2):178-86. PMID: 21765595. **X-6**

789. van Oorsouw WM, Israel ML, von Heyn RE, et al. Side effects of contingent shock treatment. *Res Dev Disabil* 2008 Nov-Dec;29(6):513-23. PMID: 17945467. **X-2, X-5, X-8**

790. van Praag HM, Dols LC, Schut T. Biochemical versus psychopathological action profile of neuroleptics: a comparative study of chlorpromazine and oxypertine in acute psychotic disorders. *Compr Psychiatry* 1975 May-Jun;16(3):255-63. PMID: 237735. **X-11**

791. Van Ryzin MJ, Dishion TJ. The impact of a family-centered intervention on the ecology of adolescent antisocial behavior: modeling developmental sequelae and trajectories during adolescence. *Dev Psychopathol* 2012 Aug;24(3):1139-55. PMID: 22781876. **X-4**

792. Vance JE. Aggressive youth: healing biology with relationship. *Ann N Y Acad Sci* 1997 Jan 15;807:587-9. PMID: 9071405. **X-1**

793. Vancraeyveldt C, Verschueren K, Wouters S, et al. Improving Teacher-Child Relationship Quality and Teacher-Rated Behavioral Adjustment Amongst Externalizing Preschoolers: Effects of a Two-Component Intervention. *J Abnorm Child Psychol* 2014 Jul 16;PMID: 25028283. **X-5**
794. Vanschoonlandt F, Vanderfaeillie J, Van Holen F, et al. Development of an intervention for foster parents of young foster children with externalizing behavior: theoretical basis and program description. *Clin Child Fam Psychol Rev* 2012 Dec;15(4):330-44. PMID: 22983481. **X-4**
795. Vassilopoulos SP, Brouzos A, Andreou E. A Multi-Session Attribution Modification Program for Children with Aggressive Behaviour: Changes in Attributions, Emotional Reaction Estimates, and Self-Reported Aggression. *Behav Cogn Psychother* 2014 Apr 25;1-11. PMID: 24762404. **X-5**
796. Vetro A, Pallag P, Szentistvanyi LI, et al. Treatment of childhood aggressivity with lithium. *Agressologie* 1981 Nov;22(E):27-30. PMID: 7332046. **X-11**
797. Villodas MT, McBurnett K, Kaiser N, et al. Additive Effects of Parent Adherence on Social and Behavioral Outcomes of a Collaborative School-Home Behavioral Intervention for ADHD. *Child Psychiatry Hum Dev* 2013 Sep 17;PMID: 24043560. **X-4, X-6, X-8**
798. Villodas MT, McBurnett K, Kaiser N, et al. Additive effects of parent adherence on social and behavioral outcomes of a collaborative school-home behavioral intervention for ADHD. *Child Psychiatry Hum Dev* 2014 Jun;45(3):348-60. PMID: 24043560. **X-6, X-8**
799. Vimpani GV. Prescribing stimulants for disruptive behaviour disorders: sometimes against the best interests of the child? *J Paediatr Child Health* 1997 Feb;33(1):9-11. PMID: 9069037. **X-1, X-2**
800. Vitaro F, Barker ED, Brendgen M, et al. Pathways explaining the reduction of adult criminal behaviour by a randomized preventive intervention for disruptive kindergarten children. *J Child Psychol Psychiatry* 2012 Jul;53(7):748-56. PMID: 22211635. **X-4**
801. Vitaro F, Brendgen M, Pagani L, et al. Disruptive behavior, peer association, and conduct disorder: testing the developmental links through early intervention. *Dev Psychopathol* 1999 Spring;11(2):287-304. PMID: 16506535. **X-5, X-6**
802. Vitaro F, Tremblay RE. Impact of a prevention program on aggressive children's friendships and social adjustment. *J Abnorm Child Psychol* 1994 Aug;22(4):457-75. PMID: 7963078. **X-4**
803. Votruba-Drzal E, Coley RL, Maldonado-Carreno C, et al. Child care and the development of behavior problems among economically disadvantaged children in middle childhood. *Child Dev* 2010 Sep-Oct;81(5):1460-74. PMID: 20840234. **X-2, X-4, X-5, X-6, X-7, X-8**
804. Wachlarowicz M, Snyder J, Low S, et al. The moderating effects of parent antisocial characteristics on the effects of Parent Management Training-Oregon (PMTO). *Prev Sci* 2012 Jun;13(3):229-40. PMID: 22274595. **X-5, X-7, X-8**
805. Waddell C, Lipman E, Offord D. Conduct disorder: practice parameters for assessment, treatment, and prevention. *Can J Psychiatry* 1999 Oct;44 Suppl 2:35s-40s. PMID: 10566117. **X-1**
806. Wade SL, Stancin T, Kirkwood M, et al. Counselor-assisted problem solving (CAPS) improves behavioral outcomes in older adolescents with complicated mild to severe TBI. *J Head Trauma Rehabil* 2014 May-Jun;29(3):198-207. PMID: 23640543. **X-4**
807. Wahler RG, Fox JJ. Solitary toy play and time out: a family treatment package for children with aggressive and oppositional behavior. *J Appl Behav Anal* 1980 Spring;13(1):23-39. PMID: 7364699. **X-11**
808. Walsh WJ, Glab LB, Haakenson ML. Reduced violent behavior following biochemical therapy. *Physiol Behav* 2004 Oct 15;82(5):835-9. PMID: 15451647. **X-3, X-6**
809. Ware LM, Novotny ES, Coyne L. A therapeutic nursery evaluation study. *Bull Menninger Clin* 2001 Fall;65(4):522-48. PMID: 11761495. **X-5, X-6**
810. Warner J. Scapegoat in the family. *Spec Educ* 1972 Sep;61(3):19-20. PMID: 5071551. **X-11**
811. Warren K, Moberg DP, McDonald L. FAST and the arms race: the interaction of group aggression and the families and schools together program in the aggressive and delinquent behaviors of inner-city

- elementary school students. *J Prim Prev* 2006 Jan;27(1):27-45. PMID: 16421656. **X-4, X-5**
812. Waschbusch DA, Carrey NJ, Willoughby MT, et al. Effects of methylphenidate and behavior modification on the social and academic behavior of children with disruptive behavior disorders: the moderating role of callous/unemotional traits. *J Clin Child Adolesc Psychol* 2007 Oct-Dec;36(4):629-44. PMID: 18088220. **X-4**
813. Watt BD, Hoyland M, Best D, et al. Treatment participation among children with conduct problems and the role of telephone reminders. *Journal of Child and Family Studies* 2007;16(4):522-30. **X-2, X-4, X-6, X-7, X-8**
814. Waxman D. Hypnosis in the psychotherapy of neurotic illness. *Br J Med Psychol* 1975 Dec;48(4):339-48. PMID: 1225350. **X-11**
815. Weaver CM, Shaw DS, Crossan JL, et al. Parent-Child Conflict and Early Childhood Adjustment in Two-Parent Low-Income Families: Parallel Developmental Processes. *Child Psychiatry Hum Dev* 2014 Mar 8 PMID: 24610382. **X-4**
816. Webster-Stratton C. Randomized trial of two parent-training programs for families with conduct-disordered children. *J Consult Clin Psychol* 1984 Aug;52(4):666-78. PMID: 6470293. **X-11**
817. Webster-Stratton C. Early-onset conduct problems: does gender make a difference? *J Consult Clin Psychol* 1996 Jun;64(3):540-51. PMID: 8698948. **X-6**
818. Webster-Stratton C. Preventing conduct problems in Head Start children: strengthening parenting competencies. *J Consult Clin Psychol* 1998 Oct;66(5):715-30. PMID: 9803690. **X-5**
819. Webster-Stratton C, Reid J, Hammond M. Social skills and problem-solving training for children with early-onset conduct problems: who benefits? *J Child Psychol Psychiatry* 2001 Oct;42(7):943-52. PMID: 11693589. **X-2a, X-7a**
820. Webster-Stratton C, Reid MJ, Hammond M. Preventing conduct problems, promoting social competence: a parent and teacher training partnership in head start. *J Clin Child Psychol* 2001 Sep;30(3):283-302. PMID: 11501247. **X-4, X-5, X-6**
821. Weis R, Wilson NL, Whitemarsh SM. Evaluation of a voluntary, military-style residential treatment program for adolescents with academic and conduct problems. *J Clin Child Adolesc Psychol* 2005 Dec;34(4):692-705. PMID: 16232066. **X-5**
822. Weiss G, Werry J, Minde K, et al. Studies on the hyperactive child. V. The effects of dextroamphetamine and chlorpromazine on behaviour and intellectual functioning. *J Child Psychol Psychiatry* 1968 Dec;9(3):145-56. PMID: 4893343. **X-11**
823. Weiss M, Panagiotopoulos C, Giles L, et al. A naturalistic study of predictors and risks of atypical antipsychotic use in an attention-deficit/hyperactivity disorder clinic. *J Child Adolesc Psychopharmacol* 2009 Oct;19(5):575-82. PMID: 19877982. **X-2, X-4**
824. Weissman MM, Pilowsky DJ, Wickramaratne PJ, et al. Remissions in Maternal Depression and Child Psychopathology: A STAR*D-Child Report. *JAMA: Journal of the American Medical Association* 2006;295(12):1389-98. **X-4**
825. Weisz JR, Chorpita BF, Palinkas LA, et al. Testing standard and modular designs for psychotherapy treating depression, anxiety, and conduct problems in youth: a randomized effectiveness trial. *Arch Gen Psychiatry* 2012 Mar;69(3):274-82. PMID: 22065252. **X-7**
826. Weisz JR, Suwanlert S, Chaiyasit W, et al. Thai and American perspectives on over- and undercontrolled child behavior problems: exploring the threshold model among parents, teachers, and psychologists. *J Consult Clin Psychol* 1988 Aug;56(4):601-9. PMID: 3198820. **X-11**
827. Werba BE, Eyberg SM, Boggs SR, et al. Predicting outcome in parent-child interaction therapy: success and attrition. *Behav Modif* 2006 Sep;30(5):618-46. PMID: 16894233. **X-2, X-7**
828. Werry JS, Aman MG. Methylphenidate and haloperidol in children. Effects on attention, memory, and activity. *Arch Gen Psychiatry* 1975 Jun;32(6):790-5. PMID: 1093506. **X-11**
829. Westrupp E, Northam E, Lee K, et al. Reducing and preventing internalizing and externalizing behavior problems in children with type 1 diabetes: a randomized controlled trial of the Triple P-Positive Parenting Program. *Pediatr Diabetes* 2014 Aug 29 PMID: 25168676. **X-4**
830. Whalley LJ, Robinson TJ, McIsaac M, et al. Psychiatric referrals from Scottish children's

- hearings: a comparative study. *J Child Psychol Psychiatry* 1978 Jul;19(3):269-78. PMID: 681469. **X-11**
831. Whitfield GW. Validating school social work: An evaluation of a cognitive-behavioral approach to reduce school violence. *Research on Social Work Practice* 1999;9(4):399-426. **X-2a**
832. Whitmore EA, Mikulich SK, Ehlers KM, et al. One-year outcome of adolescent females referred for conduct disorder and substance abuse/dependence. *Drug Alcohol Depend* 2000 May 1;59(2):131-41. PMID: 10891626. **X-6**
833. Wildman BG, Langkamp DL. Impact of location and availability of behavioral health services for children. *J Clin Psychol Med Settings* 2012 Dec;19(4):393-400. PMID: 23053830. **X-2, X-3, X-6, X-7, X-8**
834. Wilens TE, Spencer TJ, Swanson JM, et al. Combining methylphenidate and clonidine: a clinically sound medication option. *J Am Acad Child Adolesc Psychiatry* 1999 May;38(5):614-9; discussion 9-22. PMID: 10230195. **X-1**
835. Williamson AA, Dierkhising CB, Guerra NG. Brief report: piloting the Positive Life Changes (PLC) program for at-risk adolescents. *J Adolesc* 2013 Jun;36(3):623-8. PMID: 23582978. **X-4, X-5, X-6, X-8**
836. Williford AP, Shelton TL. Using mental health consultation to decrease disruptive behaviors in preschoolers: adapting an empirically-supported intervention. *J Child Psychol Psychiatry* 2008 Feb;49(2):191-200. PMID: 18211278. **X-4**
837. Willock B. From acting out to interactive play. *Int J Psychoanal* 1990;71 (Pt 2):321-34. PMID: 2365551. **X-11**
838. Winsberg BG, Bialer I, Kupietz S, et al. Effects of imipramine and dextroamphetamine on behavior of neuropsychiatrically impaired children. *Am J Psychiatry* 1972 May;128(11):1425-31. PMID: 4553490. **X-11**
839. Winsberg BG, Press M, Bialer I, et al. Dextroamphetamine and methylphenidate in the treatment of hyperactive-aggressive children. *Pediatrics* 1974 Feb;53(2):236-41. PMID: 4590730. **X-11**
840. Winsberg BG, Yepes LE, Bialer I. Pharmacologic management of children with hyperactive/aggressive/inattentive behavior disorders. Suggestions for the pediatrician. *Clin Pediatr (Phila)* 1976 May;15(5):471-7. PMID: 4253. **X-11**
841. Wodarski JS. Prevention of adolescent reoccurring violence and alcohol abuse: a multiple site evaluation. *J Evid Based Soc Work* 2010 Jul;7(4):280-301. PMID: 20799128. **X-7**
842. Wodarski JS, Pedi SJ. The empirical evaluation of the effects of different group treatment strategies against a controlled treatment strategy on behavior exhibited by antisocial children, behaviors of the therapist, and two self-rating scales that measure antisocial behavior. *J Clin Psychol* 1978 Apr;34(2):471-81. PMID: 681526. **X-11**
843. Wood RJ, Wood AR, Mullins DT. Back to school: recommendations to assist mentally ill, post-incarcerated youth return to school. *J Sch Health* 2008 Sep;78(9):514-7. PMID: 18786044. **X-1, X-2**
844. Woods DW, Piacentini JC, Scahill L, et al. Behavior therapy for tics in children: Acute and long-term effects on psychiatric and psychosocial functioning. *Journal of Child Neurology* 2011;26(7):858-65. **X-4**
845. Xeniditis K, Russell A, Murphy D. Management of people with challenging behaviour. *Advances in Psychiatric Treatment* 2001;7(2):109-16. PMID: 2001351137. **X-1, X-2, X-3, X-4, X-5, X-6**
846. Yeager DS, Trzesniewski KH, Dweck CS. An implicit theories of personality intervention reduces adolescent aggression in response to victimization and exclusion. *Child Dev* 2013 May-Jun;84(3):970-88. PMID: 23106262. **X-4, X-5, X-7, X-8**
847. Yepes LE, Balka EB, Winsberg BG, et al. Amitriptyline and methylphenidate treatment of behaviorally disordered children. *J Child Psychol Psychiatry* 1977 Jan;18(1):39-52. PMID: 320219. **X-11**
848. Yu JW, Buka SL, McCormick MC, et al. Behavioral problems and the effects of early intervention on eight-year-old children with learning disabilities. *Matern Child Health J* 2006 Jul;10(4):329-38. PMID: 16474990. **X-2, X-4, X-6, X-8**
849. Zafra-Cabeza A, Rivera DE, Collins LM, et al. A Risk-based Model Predictive Control Approach to

Adaptive Interventions in Behavioral Health. IEEE Trans Control Syst Technol 2011 Jul 1;19(4):891-901. PMID: 21643450. **X-1, X-2**

850. Zapletalek M, Hametova M, Rydlova E. Isofloxythepin in restless oligophrenic children. Act Nerv Super (Praha) 1989 Dec;31(4):265. PMID: 2576920. **X-11**

851. Zarcone JR, Lindauer SE, Morse PS, et al. Effects of risperidone on destructive behavior of persons with developmental disabilities: III. Functional analysis. Am J Ment Retard 2004 Jul;109(4):310-21. PMID: 15176916. **X-3, X-4, X-6, X-7, X-8**

852. Zimmerman FT, Burgemeister BB. Action of methyl-phenidylacetate (ritalin) and reserpine in behavior disorders in children and adults. Am J Psychiatry 1958 Oct;115(4):323-8. PMID: 13583220. **X-11**

853. Zubrick SR, Ward KA, Silburn SR, et al. Prevention of child behavior problems through universal implementation of a group behavioral family intervention. Prev Sci 2005 Dec;6(4):287-304. PMID: 16160760. **X-4, X-5**

Appendix I. Pharmacologic Approval Status, Harms, and Indications

The harms data provided in this section were gathered from analyzing available gray literature (i.e. package inserts and FDA review packages). FDA approval packages were limited to those available on the FDA website that contained a “Medical Review” section of the document. Upon further analysis, approval packages that did not assess pediatric safety data were not included. Table I-1 includes the pediatric indication for medications referenced in the clinical studies included in this review. Medications that have not been approved as safe and effective in pediatric patients; therefore are only FDA approved in adults are referenced in Table I-2. Notable boxed warnings, contraindications, and warnings/precautions that would be relevant to consider in the pediatric population were included. As a result, the data provided in this chart is not an all-inclusive list of these package insert sections. For complete data please see the corresponding package insert.

Updated: September 28, 2014

Table I-1. FDA-approved pediatric medications included in literature review

| Drug | FDA Approved Pediatric Indication | Boxed Warning | Contraindications | Warnings/ Precautions |
|--------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Guanfacine ¹ | Treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications | --- | --- | <ul style="list-style-type: none"> ● Dose-dependent decreases in blood pressure and heart rate. ● Somnolence and sedation |
| Divalproex sodium ² | <ul style="list-style-type: none"> ● Treatment of manic episodes associated with bipolar disorder ● Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures ● Prophylaxis of migraine headaches | <ul style="list-style-type: none"> ● Hepatotoxicity, including fatalities, usually during the first 6 months of treatment. Children under the age of two years and patients with mitochondrial disorders are at higher risk. ● Pancreatitis, including fatal hemorrhagic cases. | <ul style="list-style-type: none"> ● Hepatic disease or significant hepatic dysfunction, ● Known mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG), ● Suspected POLG-related disorder in children under two years of age, ● Urea cycle disorders. | <ul style="list-style-type: none"> ● Suicidal behavior or ideation ● Thrombocytopenia; monitor platelet counts and coagulation test. ● Hyperammonemia and hyperammonemic encephalopathy; measure ammonia level if unexplained lethargy and vomiting or changes in mental status, and also with concomitant topiramate use; consider discontinuation of therapy. ● Hypothermia |
| Aripiprazole ³ | <ul style="list-style-type: none"> ● Treatment of schizophrenia: Adolescents (ages 13-17) ● Acute treatment of manic or mixed episodes associated with bipolar I disorder as monotherapy and as an adjunct to lithium or valproate: Pediatric Patients (ages 10-17) ● Treatment of irritability associated with autistic disorder: Pediatric Patients (ages 6-17 years) | <ul style="list-style-type: none"> ● Children, adolescents, and young adults are at increased risk of suicidal thinking and behavior when taking this medication. | --- | <ul style="list-style-type: none"> ● Neuroleptic Malignant Syndrome: Manage with immediate discontinuation and close monitoring. ● Tardive Dyskinesia: Discontinue if clinically appropriate. ● Metabolic Changes: Atypical antipsychotic drugs have been associated with metabolic changes that include hyperglycemia/diabetes mellitus, dyslipidemia, and body weight gain ● Orthostatic Hypotension: Use with caution in patients with known cardiovascular or cerebrovascular disease ● Leukopenia, Neutropenia, and Agranulocytosis: Patients with a history of a clinically significant low |

| Drug | FDA Approved Pediatric Indication | Boxed Warning | Contraindications | Warnings/ Precautions |
|--------------------------|--------------------------------------------------------------|----------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | | | <p>white blood cell count (WBC) or a drug-induced leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy and discontinuation of aripiprazole should be considered at the first sign of a clinically significant decline in WBC in the absence of other causative factors.</p> <ul style="list-style-type: none"> ● Seizures/Convulsions: Use cautiously in patients with a history of seizures or with conditions that lower the seizure threshold. ● Potential for Cognitive and Motor Impairment: Use caution when operating machinery. ● Suicide: The possibility of a suicide attempt is inherent in schizophrenia and bipolar disorder. |
| Atomoxetine ⁴ | Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) | Increased risk of suicidal ideation in children or adolescents | <ul style="list-style-type: none"> ● Atomoxetine use within 2 weeks after discontinuing MAOI or other drugs that affect brain monoamine concentrations. ● Pheochromocytoma or history thereof ● Severe Cardiovascular Disorders that might deteriorate with clinically important increases in HR and BP. | <ul style="list-style-type: none"> ● Severe Liver Injury – Should be discontinued and not restarted in patients with jaundice or laboratory evidence of liver injury. ● Serious Cardiovascular Events – Sudden death, stroke and myocardial infarction have been reported in association with atomoxetine treatment. Patients should have a careful history and physical exam to assess for presence of cardiovascular disease. Atomoxetine generally should not be used in children or adolescents with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems that may place them at increased vulnerability to its |

| Drug | FDA Approved Pediatric Indication | Boxed Warning | Contraindications | Warnings/ Precautions |
|--------------------------------------------|-----------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | | | <p>noradrenergic effects.</p> <ul style="list-style-type: none"> ● Emergent Cardiovascular Symptoms – Patients should undergo prompt cardiac evaluation. ● Effects on Blood Pressure and Heart Rate – Increase in blood pressure and heart rate; orthostasis and syncope may occur. Use with caution in patients with hypertension, tachycardia, or cardiovascular or cerebrovascular disease. ● Emergent Psychotic or Manic Symptoms – Consider discontinuing treatment if such new symptoms occur. ● Bipolar Disorder – Screen patients to avoid possible induction of a mixed/manic episode. ● Aggressive behavior or hostility should be monitored. ● Effects on Urine Outflow – Urinary hesitancy and retention may occur. ● Priapism – Prompt medical attention is required in the event of suspected priapism. ● Growth – Height and weight should be monitored in pediatric patients. ● Concomitant Use of Potent CYP2D6 Inhibitors or Use in patients known to be CYP2D6 PMs – Dose adjustment of atomoxetine may be necessary. |
| Amphetamine-Dextroamphetamine ⁵ | Treatment of Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy | <ul style="list-style-type: none"> ● Administration of amphetamine for prolonged periods of time may lead to drug dependence due to the high risk of abuse and must be avoided ● Misuse of amphetamine | <ul style="list-style-type: none"> ● Advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, known hypersensitivity or | <ul style="list-style-type: none"> ● Serious Cardiovascular Events: Sudden Death and Pre Existing Structural Cardiac Abnormalities or Other Serious Heart Problems <ul style="list-style-type: none"> ○ Sudden death has been reported in association with CNS stimulant treatment at usual doses in children and adolescents with |

| Drug | FDA Approved Pediatric Indication | Boxed Warning | Contraindications | Warnings/ Precautions |
|------|-----------------------------------|--------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | <p>may cause sudden death and serious cardiovascular adverse events.</p> | <p>idiosyncrasy to the sympathomimetic amines, glaucoma.</p> <ul style="list-style-type: none"> ● Agitated states. ● Patients with a history of drug abuse. ● During or within 14 days following the administration of monoamine oxidase inhibitors (hypertensive crises may result). | <p>structural cardiac abnormalities or other serious heart problems.</p> <ul style="list-style-type: none"> ○ Hypertension and Other Cardiovascular Conditions: Stimulant medications cause a modest increase in average blood pressure (about 2-4 mmHg) and average heart rate (about 3-6 bpm), and individuals may have larger increases. ○ Assessing Cardiovascular Status in Patients being Treated with Stimulant Medications: Children, adolescents, or adults who are being considered for treatment with stimulant medications should have a careful history (including assessment for a family history of sudden death or ventricular arrhythmia) and physical exam to assess for the presence of cardiac disease, and should receive further cardiac evaluation if findings suggest such disease (e.g., electrocardiogram and echocardiogram). ● Psychiatric Adverse Events <ul style="list-style-type: none"> ○ Preexisting Psychosis: Administration of stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a pre-existing psychotic disorder. ○ Bipolar Disorder: Particular care should be taken in using stimulants to treat ADHD in patients with comorbid bipolar disorder because of concern for possible induction of a mixed/ |

| Drug | FDA Approved Pediatric Indication | Boxed Warning | Contraindications | Warnings/ Precautions |
|------|-----------------------------------|---------------|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | | | <p>manic episode in such patients.</p> <ul style="list-style-type: none"> ○ Emergence of New Psychotic or Manic Symptoms: Treatment emergent psychotic or manic symptoms, e.g., hallucinations, delusional thinking, or mania in children and adolescents without a prior history of psychotic illness or mania can be caused by stimulants at usual doses. ○ Aggression: Aggressive behavior or hostility is often observed in children and adolescents with ADHD, and has been reported in clinical trials and the post-marketing experience of some medications indicated for the treatment of ADHD. ○ Long-Term Suppression of Growth: Careful follow-up of weight and height in children ages 7 to 10 years who were randomized to either methylphenidate or non-medication treatment groups over 14 months, as well as in naturalistic subgroups of newly methylphenidate-treated and non-medication treated children over 36 months (to the ages of 10 to 13 years), suggests that consistently medicated children (i.e., treatment for 7 days per week throughout the year) have a temporary slowing in growth rate (on average, a total of about 2 cm less growth in height and 2.7 kg less growth in weight over 3 years), without evidence of growth rebound during this |

| Drug | FDA Approved Pediatric Indication | Boxed Warning | Contraindications | Warnings/ Precautions |
|------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | | | <p>period of development.</p> <ul style="list-style-type: none"> ○ Seizures: there is some clinical evidence that stimulants may lower the convulsive threshold in patients with prior history of seizures, in patients with prior EEG abnormalities in absence of seizures, and, very rarely, in patients without a history of seizures and no prior EEG evidence of seizures. ○ Visual disturbances: Difficulties with accommodation and blurring of vision have been reported with stimulant treatment. <ul style="list-style-type: none"> ● Should be used with caution in patients who use other sympathomimetic drugs. ● Amphetamines have been reported to exacerbate motor and phonic tics and Tourette's syndrome. ● Amphetamines may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or vehicles; the patient should therefore be cautioned accordingly. |
| Methylphenidate ⁶ | Attention Deficit Disorders (previously known as Minimal Brain Dysfunction in Children). Other terms being used to describe the behavioral syndrome below include: Hyperkinetic Child Syndrome, Minimal Brain Damage, Minimal Cerebral Dysfunction, Minor Cerebral Dysfunction. | --- | <ul style="list-style-type: none"> ● Marked anxiety, tension, and agitation since the drug may aggravate these symptoms. ● Glaucoma ● Motor tics or with a family history or diagnosis of Tourette's syndrome. ● Treatment with monoamine oxidase inhibitors, and also within a minimum of 14 days | <ul style="list-style-type: none"> ● Serious Cardiovascular Events: <ul style="list-style-type: none"> ○ Sudden Death and Preexisting Structural Cardiac Abnormalities or Other Serious Heart Problems - Sudden death has been reported in association with CNS stimulant treatment at usual doses in children and adolescents with structural cardiac abnormalities or other serious heart problems. ○ Hypertension and Other |

| Drug | FDA Approved Pediatric Indication | Boxed Warning | Contraindications | Warnings/ Precautions |
|------|-----------------------------------|---------------|-----------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | | <p>following discontinuation of a monoamine oxidase inhibitor (hypertensive crises may result).</p> | <p>Cardiovascular Conditions Stimulant medications cause a modest increase in average blood pressure (about 2-4 mmHg) and average heart rate (about 3-6 bpm), and individuals may have larger increases.</p> <ul style="list-style-type: none"> ○ Assessing Cardiovascular Status in Patients being Treated with Stimulant Medications Children, adolescents, or adults who are being considered for treatment with stimulant medications should have a careful history (including assessment for a family history of sudden death or ventricular arrhythmia) and physical exam to assess for the presence of cardiac disease, and should receive further cardiac evaluation if findings suggest such disease (e.g., electrocardiogram and echocardiogram). ● Psychiatric Adverse Events <ul style="list-style-type: none"> ○ Pre-existing Psychosis: Administration of stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a pre-existing psychotic disorder. ○ Bipolar Disorder: Particular care should be taken in using stimulants to treat ADHD in patients with comorbid bipolar disorder because of concern for possible induction of a mixed/ manic episode in such patients. ○ Emergence of New Psychotic or Manic Symptoms: Treatment |

| Drug | FDA Approved Pediatric Indication | Boxed Warning | Contraindications | Warnings/ Precautions |
|------|-----------------------------------|---------------|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | | | <p>emergent psychotic or manic symptoms, e.g., hallucinations, delusional thinking, or mania in children and adolescents without a prior history of psychotic illness or mania can be caused by stimulants at usual doses.</p> <ul style="list-style-type: none"> ○ Aggression: Aggressive behavior or hostility is often observed in children and adolescents with ADHD, and has been reported in clinical trials and the post-marketing experience of some medications indicated for the treatment of ADHD. ● Long-term suppression of growth: Careful follow-up of weight and height in children ages 7 to 10 years who were randomized to either methylphenidate or non-medication treatment groups over 14 months, as well as in naturalistic subgroups of newly methylphenidate-treated and non-medication treated children over 36 months (to the ages of 10 to 13 years), suggests that consistently medicated children (i.e., treatment for 7 days per week throughout the year) have a temporary slowing in growth rate (on average, a total of about 2 cm less growth in height and 2.7 kg less growth in weight over 3 years), without evidence of growth rebound during this period of development. ● Seizures: There is some clinical evidence that stimulants may lower the convulsive threshold in patients with prior history of seizures, in patients with prior EEG abnormalities in absence of seizures, and, very |

| Drug | FDA Approved Pediatric Indication | Boxed Warning | Contraindications | Warnings/ Precautions |
|------|-----------------------------------|---------------|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | | | <p>rarely, in patients without a history of seizures and no prior EEG evidence of seizures.</p> <ul style="list-style-type: none"> ● Priapism: Prolonged and painful erections, sometimes requiring surgical intervention, have been reported with methylphenidate products in both pediatric and adult patients. ● Peripheral Vasculopathy, Including Raynaud's Phenomenon: Stimulants, including methylphenidate, used to treat ADHD are associated with peripheral vasculopathy, including Raynaud's phenomenon. ● Visual Disturbance: Difficulties with accommodation and blurring of vision have been reported with stimulant treatment. ● Use in Children Under Six Years of Age: should not be used in children under 6 years, since safety and efficacy in this age group have not been established. ● Drug Dependence methylphenidate should be given cautiously to patients with a history of drug dependence or alcoholism. Chronic abusive use can lead to marked tolerance and psychological dependence with varying degrees of abnormal behavior. Frank psychotic episodes can occur, especially with parenteral abuse. Careful supervision is required during withdrawal from abusive use, since severe depression may occur. Withdrawal following chronic therapeutic use may unmask symptoms of the underlying disorder that may require follow-up. |

| Drug | FDA Approved Pediatric Indication | Boxed Warning | Contraindications | Warnings/ Precautions |
|-------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | | | <ul style="list-style-type: none"> ● Patients with an element of agitation may react adversely; discontinue therapy if necessary. ● Periodic CBC, differential, and platelet counts are advised during prolonged therapy. ● Drug treatment is not indicated in all cases of this behavioral syndrome and should be considered only in light of the complete history and evaluation of the child. The decision to prescribe should depend on the physician's assessment of the chronicity and severity of the child's symptoms and their appropriateness for his/her age. Prescription should not depend solely on the presence of 1 or more of the behavioral characteristics. When these symptoms are associated with acute stress reactions, treatment with methylphenidate is usually not indicated. |
| Quetiapine ⁷ | <ul style="list-style-type: none"> ● Schizophrenia ● Bipolar I disorder manic episodes ● Bipolar disorder, depressive episodes | Suicidal Thoughts and Behaviors: Increased risk of suicidal thoughts and behavior in children, adolescents, and young adults taking antidepressants. | --- | <ul style="list-style-type: none"> ● Neuroleptic Malignant Syndrome (NMS): Manage with immediate discontinuation and close monitoring ● Metabolic Changes: Atypical antipsychotics have been associated with metabolic changes. These metabolic changes include hyperglycemia, dyslipidemia, and weight gain. ● Tardive Dyskinesia: Discontinue if clinically appropriate. ● Hypotension: Use with caution in patients with known cardiovascular or cerebrovascular disease. ● Increased Blood Pressure in Children and Adolescents: Monitor blood pressure at the beginning of, and |

| Drug | FDA Approved Pediatric Indication | Boxed Warning | Contraindications | Warnings/ Precautions |
|------|-----------------------------------|---------------|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | | | <p>periodically during treatment in children and adolescents</p> <ul style="list-style-type: none"> ● Leukopenia, Neutropenia and Agranulocytosis: Monitor complete blood count frequently during the first few months of treatment in patients with a preexisting low white cell count or a history of leukopenia/neutropenia and discontinue at the first sign of a decline in WBC in absence of other causative factors. ● Cataracts: Lens changes have been observed in patients during long-term quetiapine treatment. Lens examination is recommended when starting treatment and at 6-month intervals during chronic treatment. ● Hypothyroidism: In controlled trials in children and adolescent patients with schizophrenia or bipolar mania, the incidence of shifts for thyroid function values at any time for quetiapine treated patients and placebo-treated patients for elevated TSH was 2.9% (8/280) vs. 0.7% (1/138), respectively and for decreased total thyroxine was 2.8% (8/289) vs. 0% (0/145, respectively). ● Hyperprolactinemia: In controlled trials in children and adolescent patients with bipolar mania or schizophrenia, the incidence of shifts in prolactin levels to a value (>20 µg/L males; > 26 µg/L females at any time) was 13.4% (18/134) for quetiapine compared to 4% (3/75) for placebo in males and 8.7% (9/104) for quetiapine compared to 0% (0/39) for placebo in females. ● Potential for Cognitive and Motor |

| Drug | FDA Approved Pediatric Indication | Boxed Warning | Contraindications | Warnings/ Precautions |
|--------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | | | <p>Impairment - Since quetiapine has the potential to impair judgment, thinking, or motor skills, patients should be cautioned about performing activities requiring mental alertness.</p> |
| Risperidone ⁸ | <ul style="list-style-type: none"> ● Treatment of schizophrenia. Efficacy was established in 2 short-term trials in adolescents (ages 13 to 17 years) ● Treatment (monotherapy) of acute manic or mixed episodes associated with Bipolar I Disorder. Efficacy was established in one short-term trial in children and adolescents (ages 10 to 17 years) ● Treatment of irritability associated with autistic disorder, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods. Efficacy was established in 3 short-term trials in children and adolescents (ages 5 to 17 years) | --- | --- | <ul style="list-style-type: none"> ● Neuroleptic Malignant Syndrome: Manage with immediate discontinuation and close monitoring. ● Tardive dyskinesia: Consider discontinuing if clinically indicated. ● Metabolic Changes: Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/ cerebrovascular risk. These metabolic changes include hyperglycemia, dyslipidemia, and weight gain. ● Hyperprolactinemia: Prolactin elevations occur and persist during chronic administration. ● Orthostatic hypotension: For patients at risk, consider a lower starting dose and slower titration. ● Leukopenia, Neutropenia, and Agranulocytosis: Perform complete blood counts in patients with a history of clinically significant low white blood cell count (WBC). Consider discontinuing if a clinically significant decline in WBC occurs in the absence of other causative factors. ● Potential for cognitive and motor impairment: Use caution when operating machinery. ● Seizures: Use cautiously in patients with a history of seizures or with conditions that lower the seizure threshold. |

Table I-2. FDA-approved adult medications (prescribed off label in pediatric patients) included in literature review

| Drug | FDA Approved Adult Indication | Boxed Warning | Contraindications | Warnings/ Precautions |
|--------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Ziprasidone ⁹ | <ul style="list-style-type: none"> ● Treatment of schizophrenia. ● Acute treatment as monotherapy of manic or mixed episodes associated with bipolar I disorder ● Maintenance treatment of bipolar I disorder as an adjunct to lithium or valproate. ● Acute treatment of agitation in schizophrenic patients. | --- | <ul style="list-style-type: none"> ● Do not use in patients with a known history of QT prolongation. ● Do not use in patients with recent acute myocardial infarction ● Do not use in patients with uncompensated heart failure ● Do not use in combination with other drugs that have demonstrated QT prolongation. | <ul style="list-style-type: none"> ● QT Interval Prolongation: should be avoided in patients with bradycardia, hypokalemia or hypomagnesemia, congenital prolongation of the QT interval, or in combination with other drugs that have demonstrated QT prolongation ● Neuroleptic Malignant Syndrome (NMS): Potentially fatal symptom complex has been reported with antipsychotic drugs. Manage with immediate discontinuation of drug and close monitoring. ● Tardive Dyskinesia - May develop acutely or chronically ● Metabolic Changes: Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk. These metabolic changes include hyperglycemia, dyslipidemia, and weight gain. ● Rash: Discontinue in patients who develop a rash without an identified cause ● Orthostatic Hypotension: Use with caution in patients with known cardiovascular or cerebrovascular disease ● Leukopenia, Neutropenia, and Agranulocytosis has been reported with antipsychotics. Patients with a pre-existing low white blood cell count (WBC) or a history of leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy and should |

| Drug | FDA Approved Adult Indication | Boxed Warning | Contraindications | Warnings/ Precautions |
|------|-------------------------------|---------------|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | | | <p>discontinue at the first sign of a decline in WBC in the absence of other causative factors.</p> <ul style="list-style-type: none"> ● Seizures: Use cautiously in patients with a history of seizures or with conditions that lower seizure threshold ● Potential for Cognitive and Motor impairment: Patients should use caution when operating machinery ● Suicide Closely supervise high-risk patients |

Table I-3. Serious adverse events reported across medications*

| | Guanfacine | Divalproex | Aripiprazole | Atomoxetine | Amphetamine / Dextroamphetamine | Methylphenidate | Quetiapine | Risperidone | Ziprasidone |
|-----------------------------------|------------|------------|--------------|-------------|------------------------------------|-----------------|------------|-------------|-------------|
| Suicide attempt | | | • | | | | | • | • |
| Suicidal ideation | | | • | • | | | | | |
| QT prolongation | • | | | • | | | • | • | • |
| Death | • | | | • | • | • | | • | |
| Stroke | | | | • | • | | | | |
| Myocardial Infarction | • | | | • | • | | | | • |
| Orthostatic hypotension | • | | • | | | | | • | • |
| Angioedema | | | • | • | • | | | • | • |
| Cardiac arrest | • | | | | | | | | |
| Neuroleptic malignant syndrome | | | • | | | • | • | • | • |
| Steven-Johnson syndrome | | | | | • | | • | | |
| Mania/hypomania | • | | | | • | • | | • | • |
| Extrapyramidal symptoms/ disorder | | | • | | | | • | • | • |
| Tardive dyskinesia | | • | • | | | | • | • | • |
| Abnormal LFTs | | | | • | | | | | |
| Respiratory system disorders | | | | | | | | • | • |
| Pancreatitis | | • | | | | | • | • | |
| Seizures/ convulsions | • | | • | • | • | • | | • | • |
| Syncope | • | | | • | | | • | | • |

*Events gathered from all available harms data including: clinical trial data and post-marketing experience

Table I-4. Selected adverse events observed across medications*

| | Guanfacine | Divalproex Sodium | Aripiprazole | Atomoxetine | Amphetamine-Dextroamphetamine | Methylphenidate | Quetiapine | Risperidone | Ziprasidone |
|-------------------------------|------------|-------------------|--------------|-------------|-------------------------------|-----------------|------------|-------------|-------------|
| Somnolence | • | • | • | • | | | • | • | • |
| Weight Loss | | • | | • | • | • | | | |
| Weight Gain | • | • | • | | | | • | • | • |
| Tachycardia | • | • | | • | • | • | • | | • |
| Decrease alkaline phosphatase | | | | • | | | | | |
| Hyperprolactinemia | | | | | | | • | • | |
| Aggression | • | | • | • | • | • | • | | |
| Hypotension | • | • | | | | | • | • | |
| Hypertension | • | • | | • | • | • | | | |
| Decreased heart rate | • | | | | | | | | |
| Increased heart rate | | | | • | • | • | • | • | |
| Dyslipidemia | | | • | | | | • | • | • |
| Hyperglycemia | | | • | | | | • | • | • |
| Leukopenia | | | • | • | | • | • | • | • |
| Neutropenia | | | • | | | | • | • | • |

*Events gathered from all available harms data including: clinical trial data and post-marketing experience

Table I-5. Pharmacologic agents considered for DBD review

| Drug Class Individual agent (proprietary name) | | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>Alpha-agonists</p> <ul style="list-style-type: none"> • Clonidine • Guanfacine (Intuniv®) | <p>First-generation antipsychotics</p> <ul style="list-style-type: none"> • Chlorpromazine • Fluphenazine • Haloperidol • Loxapine • Perphenazine • Prochlorperazine • Thiothixene • Thioridazine • Trifluoperazine | <p>Selective serotonin reuptake inhibitors (SSRI)</p> <ul style="list-style-type: none"> • Fluoxetine • Sertraline • Citalopram • Escitalopram • Paroxetine • Fluvoxamine |
| <p>Anticonvulsants</p> <ul style="list-style-type: none"> • Carbamazepine (Tegretol®) • Oxcarbazepine (Trileptal®) • Divalproex sodium (Depakote®) • Lamotrigine (Lamictal®) • Valproate/ Valproic acid | <p>Second-generation (atypical) antipsychotics</p> <ul style="list-style-type: none"> • Aripiprazole (Abilify®) • Asenapine (Saphris®) • Clozapine (Clozaril®) • Iloperidone (Fanapt®) • Lurasidone (Latuda®) • Olanzapine (Zyprexa®) • Olanzapine/Fluoxetine (Symbyax®) • Paliperidone (Invega®) • Quetiapine (Seroquel®) • Risperidone (Risperdal®) • Ziprasidone (Geodon®) | <p>Other (e.g., antihistamines, benzodiazepines, mood stabilizers, non-SSRI antidepressants)</p> <ul style="list-style-type: none"> • Lithium • Atomoxetine (Strattera®) • Naltrexone • Hydroxyzine • Clonazepam (Klonopin®) • Levetiracetam (Keppra®) • Lorazepam (Ativan®) • Bupropion |
| <p>Beta-blockers</p> <ul style="list-style-type: none"> • Propranolol • Metoprolol • Pindolol • Nadolol | | |
| <p>Central nervous system (CNS) stimulants</p> <ul style="list-style-type: none"> • Amphetamine-Dextroamphetamine (Adderall®) • Methylphenidate (Ritalin®) • Lisdexamfetamine (Vyvanse®) | | |

Table I-6. FDA approval status for drugs included in the DBD review

| Generic Name (Trade Name) | Indication(s) | Approved For |
|---------------------------------------|-------------------------------------------------------------------------------------------------|-------------------------------------------------|
| Amphetamine Salts (Adderall) | Attention Deficit Hyperactivity Disorder (ADHD) | Children (3 +) |
| | Narcolepsy | Children (6 +) |
| Aripiprazole (Abilify) ¹⁰ | Schizophrenia | Adults and adolescents (13–17 years) |
| | Bipolar disorder (manic/mixed) monotherapy or adjunctive to lithium or valproate | Adults and children (10–17 years) |
| | Adjunctive treatment of major depressive disorder | Adults |
| | Irritability Associated with autistic disorder | Children (6–17 years) |
| | Acute treatment of agitation | Adults |
| Atomoxetine (Strattera) ¹¹ | Attention Deficit Hyperactivity Disorder (ADHD) | Adults and children (6-18) |
| Divalproex (Depakote) | Bipolar Disorder (manic episodes) | Adults and children (10 +) |
| | Seizures | |
| | Migraine Headaches | |
| Guanfacine (Intuniv) ¹² | Attention Deficit Hyperactivity Disorder (ADHD) and adjunctive therapy to stimulant medications | Children and adolescents (6-17) |
| Methylphenidate (Ritalin) | Attention Deficit Disorders (ADD) | Children and adults (6 + years) |
| Quetiapine (Seroquel) ¹³ | Schizophrenia | Adults and adolescents (13–17 years) |
| | Bipolar disorder (acute manic) | Adults, children, and adolescents (10–17 years) |
| | Bipolar disorder (depression) | Adults |
| | Bipolar disorder (maintenance) | |
| | Adjunctive therapy for major depressive disorder | |
| Risperidone (Risperdal) ¹⁴ | Schizophrenia | Adults and adolescents (13–17 years) |
| | Bipolar disorder (manic/mixed) | Adults and adolescents (10–17 years) |
| | Irritability associated with autism | Children (5–16 years) |
| Valproate/Valproic Acid (Depacon) | Epilepsy | Children and adults (10 + years) |
| Ziprasidone (Geodon) | Schizophrenia | Adults |
| | Bipolar disorder (manic/mixed) | |
| | Bipolar disorder (maintenance) | |
| | Acute agitation in patients with schizophrenia | |

References for Appendix I

1. Intuniv [package insert]. Wayne, PA: Shire US Inc.; 2013.
2. Depakote [package insert]. North Chicago, IL: AbbVie Inc.; July 2013.
3. Abilify [package insert]. Rockville, MD: Otsuka America Pharmaceutical, Inc.; 2013.
4. Strattera [package insert]. Indianapolis, IN: Eli Lilly and Company; 2014.
5. Adderall [package insert]. Pomona, NY: Barr Laboratories; 2007.
6. Ritalin [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2013.
7. Seroquel [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2013.
8. Risperdal [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2014.
9. Geodon [package insert]. New York, NY: Pfizer; October 2012.
10. Abilify Medical Review - Schizophrenia in Pediatric Patients. Silver Spring, MD: Food and Drug Administration Center for Drug Evaluation and Research; 2007.
11. Strattera Medical Review - Original Approval. Silver Spring, MD: Food and Drug Administration Center for Drug Evaluation and Research; 2002.
12. Intuniv Medical Review - Original Approval. Silver Spring, MD: Food and Drug Administration Center for Drug Evaluation and Research; 2009.
13. Seroquel Medical Review - QT Prolongation Review. Silver Spring, MD: Food and Drug Administration Center for Drug Evaluation and Research; 2011.
14. Risperdal Medical Review - Pediatric Approval. Silver Spring, MD: Food and Drug Administration Center for Drug Evaluation and Research; 2007.

Appendix J. Key Question 1 Evidence Profile

Table J-1. Evidence summary of psychosocial intervention effects on parent-rated disruptive behavior in studies of preschool age children

| Studies | N | Risk of Bias | Intervention vs. Control | Head-to-Head Comparison | SOE Comments |
|-----------------------------|--------|-------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|
| Child Only (n=0) | | | | | |
| NA | NA | NA | NA | NA | O |
| Parent Only (n=14) | | | | | |
| RCT: 13 ¹⁻¹³ | (1466) | Low: 1 ⁸ Moderate: 7 ^{1,3,6,7,9,10,13} High: 5 ^{2,4,5,11,12} | Outcomes consistently improved in intervention arms compared with waitlist or treatment as usual controls. Significant: Intervention > WLC or TAU (9) ^{1,3,6-12} Nonsignificant: Intervention > TAU (1) ¹³ | Differences between modified versions of the same intervention were typically not significant. Significant: Intervention vs. modified intervention (1) ⁷ Nonsignificant: Intervention vs. modified intervention (4) ^{2,4,5,10} | ++ |
| NRCT: 1 ¹⁴ | (144) | Moderate: 1 ¹⁴ | Nonsignificant: Intervention > WLC or TAU (1) ¹⁴ | NA | O |
| Multicomponent (n=9) | | | | | |
| RCT: 9 | (401) | Low: 1 ¹⁵ Moderate: 3 ¹⁶⁻¹⁸ High: 5 ¹⁹⁻²³ | Outcomes consistently improved in intervention arms compared with waitlist or treatment as usual controls. Significant: Intervention > WLC or TAU (8) ¹⁵⁻²² | Differences between modified versions of the same intervention were typically not significant. Nonsignificant: Intervention vs. modified intervention (3) ^{15,16,23} | ++ |

O = Insufficient, + = Low, ++ = Moderate, +++ = High

Table J-2. Evidence summary of psychosocial intervention effects on parent-rated disruptive behavior in studies of school age children

| Studies | N | Risk of Bias | Intervention vs. Control | Head-to-Head Comparison | SOE Comments |
|------------------------------|--------|--------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| Child Only (n=1) | | | | | |
| RCT: 1 ¹ | (97) | Low: 0 Moderate: 1 ¹ High: 0 | Outcomes improved in intervention arms compared with waitlist control group Significant: SCIP, SST > WLC (1) ¹ | Differences between the active intervention groups were not significant Nonsignificant: SCIP > SST (1) ¹ | O |
| Parent Only (n=11) | | | | | |
| RCT: 8 ²⁻⁹ | (995) | Low: 1 ⁴ Moderate: 5 ⁵⁻⁹ High: 2 ^{2,3} | Outcomes significantly improved in intervention groups vs. control Significant: (6) ²⁻⁷ | Differences between modified versions of the same intervention were not significant Nonsignificant: (3) ^{5,8,9} | ++ |
| Cohort: 3 ¹⁰⁻¹² | (334) | Low: 0 Moderate: 0 High: 3 ¹⁰⁻¹² | Outcomes significantly improved in intervention groups vs. control Significant: Intervention > TAU (1) ¹⁰ Nonsignificant: Intervention vs. TAU (1) ¹¹ | Differences between modified versions of the same intervention were significant Significant: PMT skilled > PMT perceptive (1) ¹² | + |
| Multicomponent (n=17) | | | | | |
| RCT: 15 ¹³⁻²⁷ | (1685) | Low: 1 ¹⁵ Moderate: 11 ^{13,14,17-22,24-26} High: 3 ^{16,23,27} | Improved from baseline in most active treatment arms but between group changes not consistently significantly different Significant: (4) ^{16,20,24,27} Nonsignificant: (5) ^{13,14,19,23,26} Inconsistent: (2) ^{15,18} | Improved from baseline in most active treatment arms but between group changes not consistently significantly different Significant: (2) ^{20,25} Nonsignificant: (3) ^{17,21,26} Inconsistent: (1) ²² | + <i>Inconsistent outcomes reported by different measures/rating scales</i> |
| Cohort: 2 ^{28,29} | (474) | Low: 0 Moderate: 1 ²⁹ High: 1 ²⁸ | Outcomes significantly improved in intervention groups vs. WLC or TAU Significant: (2) ^{28,29} | NA | ++ |

O = Insufficient, + = Low, ++ = Moderate, +++ = High

Table J-3. Evidence summary of psychosocial intervention effects on parent-rated disruptive behavior in studies of teenage children

| Studies | N | Risk of Bias | Intervention vs. Control | Head-to-Head Comparison | SOE Comments |
|-------------------------------------|--------|-----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|---------------------------------|
| Child Only^a (n=1) | | | | | |
| RCT: 1 ¹ | (93) | Low: 0 Moderate: 0 High: 1 ¹ | Intervention > Control Significant: (1)¹ | NA | O |
| Parent Only (n=0) | | | | | |
| NA | NA | NA | NA | NA | O |
| Multicomponent (n=13) | | | | | |
| RCT: 12 ²⁻¹³ | (1294) | Low: 4 ^{3,4,8,9} Moderate: 5 ^{2,7,10,11,13} High: 3 ^{5,6,12} | Most studies reported improved outcomes in treatment arms versus control arms. Significant: (10)^{2-4,6-11,13} | Differences between interventions were significant. Significant: (2)^{5,12} | ++ |
| Cohort: 1 ¹⁴ | (192) | Low: 0 Moderate: 0 High: 1 ¹⁴ | NA | Nonsignificant: CBT vs. FFT vs. CBT + Parent training (1) ¹⁴ | O <i>Outcome: recidivism</i> |

O = Insufficient, + = Low, ++ = Moderate, +++ = High

Table J-4. Evidence profile for studies included in the meta-analysis

| Intervention Category (arms) | Total N | Effect measure | Probability of being best | Overall SOE |
|------------------------------|---------|--------------------------------------------|---------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| TAU/WLC (n=50) | 1348 | NA | NA | <ul style="list-style-type: none"> • Strong evidence that of the 4 arms, this is the inferior |
| Child only (n=6) | 190 | -1.0 (95% credible interval: -1.6 to -0.4) | 15 | <ul style="list-style-type: none"> • Strong evidence that each of these are better than TAU • Weak evidence that of these 3 arms multi-component and parent only are best |
| Parent only (n=41) | 1540 | -1.2 (95% credible interval: -1.6 to -0.9) | 43 | |
| Multicomponent (n=32) | 929 | -1.2 (95% credible interval: -1.6 to -0.9) | 43 | |

Notes: Table represents quantitative mixed effects model of a subset of studies from qualitative review. The model included RCTs that reported baseline and end-of-treatment group mean and standard deviation from ECBI- Intensity, ECBI- Problem, and/or CBCL- Externalizing T-score). For more details on the selection of studies, see the methods in the Full Report.

Includes studies from KQ1 for children of all ages (i.e., psychosocial interventions for preschool age, school age, and teenage participants). The treatment arms of each study were classified as one of the following types: 1) interventions including only a child component; 2) interventions including only a parent component; and 3) multicomponent interventions. Those not identified by any of these three classes were considered either control or treatment-as-usual arms. The number of arms exceeds the number of included studies as studies could contribute data from more than one arm per intervention type.

The effect sizes estimated by the model can be interpreted as the expected change in score for the intervention category relative to treatment as usual or control.

This summary does not include risk of bias ratings, as those assessments are made at the individual study level, and not at the level of a treatment arm.

References for Appendix J

1. Perrin EC, Sheldrick RC, McMenamy JM, et al. Improving Parenting Skills for Families of Young Children in Pediatric Settings: A Randomized Clinical Trial. *JAMA Pediatr.* 2013 Nov 4;PMID: 24190691
2. Jones DJ, Forehand R, Cuellar J, et al. Technology-Enhanced Program for Child Disruptive Behavior Disorders: Development and Pilot Randomized Control Trial. *J Clin Child Adolesc Psychol.* 2013 Aug 7;PMID: 23924046
3. Somech LY, Elizur Y. Promoting self-regulation and cooperation in pre-kindergarten children with conduct problems: a randomized controlled trial. *J Am Acad Child Adolesc Psychiatry.* 2012 Apr;51(4):412-22. PMID: 22449647
4. Cummings JG, Wittenberg JV. Supportive expressive therapy--Parent child version: An exploratory study. *Psychotherapy (Chic).* 2008 Jun;45(2):148-64. PMID: 22122414
5. Lavigne JV, Lebailly SA, Gouze KR, et al. Treating oppositional defiant disorder in primary care: a comparison of three models. *J Pediatr Psychol.* 2008 Jun;33(5):449-61. PMID: 17956932
6. Hutchings J, Gardner F, Bywater T, et al. Parenting intervention in Sure Start services for children at risk of developing conduct disorder: pragmatic randomised controlled trial. *BMJ.* 2007 Mar 31;334(7595):678. PMID: 17350966
7. Markie-Dadds C, Sanders MR. A Controlled Evaluation of an Enhanced Self-Directed Behavioural Family Intervention for Parents of Children With Conduct Problems in Rural and Remote Areas. *Behaviour Change.* 2006;23(1):55-72.
8. McGilloway S, Mhaille GN, Bywater T, et al. A parenting intervention for childhood behavioral problems: A randomized controlled trial in disadvantaged community-based settings. *J Consult Clin Psychol.* 2012;80(1):116-27. PMID: 22148879
9. Markie-Dadds C, Sanders MR. Self-Directed Triple P (Positive Parenting Program) for Mothers with Children at-Risk of Developing Conduct Problems. *Behav Cogn Psychother.* 2006;34(3):259-75.
10. Sanders MR, Markie-Dadds C, Tully LA, et al. The triple P-positive parenting program: a comparison of enhanced, standard, and self-directed behavioral family intervention for parents of children with early onset conduct problems. *J Consult Clin Psychol.* 2000 Aug;68(4):624-40. PMID: 10965638
11. Connell S, Sanders MR, Markie-Dadds C. Self-directed behavioral family intervention for parents of oppositional children in rural and remote areas. *Behav Modif.* 1997 Oct;21(4):379-408. PMID: 9337598
12. Sanders MR, Baker S, Turner KM. A randomized controlled trial evaluating the efficacy of Triple P Online with parents of children with early-onset conduct problems. *Behav Res Ther.* 2012 Nov;50(11):675-84. PMID: 22982082
13. Havighurst SS, Wilson KR, Harley AE, et al. "Tuning into Kids": reducing young children's behavior problems using an emotion coaching parenting program. *Child Psychiatry Hum Dev.* 2013 Apr;44(2):247-64. PMID: 22820873
14. Posthumus JA, Raaijmakers MA, Maassen GH, et al. Sustained effects of incredible years as a preventive intervention in preschool children with conduct problems. *J Abnorm Child Psychol.* 2012 May;40(4):487-500. PMID: 22006348
15. McCabe K, Yeh M. Parent-child interaction therapy for Mexican Americans: a randomized clinical trial. *J Clin Child Adolesc Psychol.* 2009 Sep;38(5):753-9. PMID: 20183659
16. Nixon RD, Sweeney L, Erickson DB, et al. Parent-child interaction therapy: a comparison of standard and abbreviated treatments for oppositional defiant preschoolers. *J Consult Clin Psychol.* 2003 Apr;71(2):251-60. PMID: 12699020

17. Schuhmann EM, Foote RC, Eyberg SM, et al. Efficacy of parent-child interaction therapy: interim report of a randomized trial with short-term maintenance. *J Clin Child Psychol.* 1998 Mar;27(1):34-45. PMID: 9561935
18. Brestan EV, Eyberg SM, Boggs SR, et al. Parent-child interaction therapy: Parents' perceptions of untreated siblings. *Child Fam Behav Ther.* 1997;19(3):13-28.
19. Bagner DM, Sheinkopf SJ, Vohr BR, et al. Parenting intervention for externalizing behavior problems in children born premature: an initial examination. *J Dev Behav Pediatr.* 2010 Apr;31(3):209-16. PMID: 20375736
20. Jouriles EN, McDonald R, Spiller L, et al. Reducing conduct problems among children of battered women. *J Consult Clin Psychol.* 2001 Oct;69(5):774-85. PMID: 11680554
21. Eyberg SM, Boggs SR, Algina J. Parent-child interaction therapy: a psychosocial model for the treatment of young children with conduct problem behavior and their families. *Psychopharmacol Bull.* 1995;31(1):83-91. PMID: 7675994
22. Nixon RDV. Changes in hyperactivity and temperament in behaviourally disturbed preschoolers after parent-child interaction therapy (PCIT). *Behaviour Change.* 2001;18(3):168-76.
23. Sanders MR, McFarland M. Treatment of depressed mothers with disruptive children: A controlled evaluation of cognitive behavioral family intervention. *Behav Ther.* 2000 //Winter;31(1):89-112.
24. van Manen TG, Prins PJ, Emmelkamp PM. Reducing aggressive behavior in boys with a social cognitive group treatment: results of a randomized, controlled trial. *J Am Acad Child Adolesc Psychiatry.* 2004 Dec;43(12):1478-87. PMID: 15564817
25. Kjobli J, Ogden T. A randomized effectiveness trial of brief parent training in primary care settings. *Prev Sci.* 2012 Dec;13(6):616-26. PMID: 22956303
26. Axberg U, Broberg AG. Evaluation of "the incredible years" in Sweden: the transferability of an American parent-training program to Sweden. *Scand J Psychol.* 2012 Jun;53(3):224-32. PMID: 22621727
27. McGrath PJ, Lingley-Pottie P, Thurston C, et al. Telephone-based mental health interventions for child disruptive behavior or anxiety disorders: randomized trials and overall analysis. *J Am Acad Child Adolesc Psychiatry.* 2011 Nov;50(11):1162-72. PMID: 22024004
28. Kling A, Forster M, Sundell K, et al. A randomized controlled effectiveness trial of parent management training with varying degrees of therapist support. *Behav Ther.* 2010 Dec;41(4):530-42. PMID: 21035616
29. Ogden T, Hagen KA. Treatment effectiveness of Parent Management Training in Norway: a randomized controlled trial of children with conduct problems. *J Consult Clin Psychol.* 2008 Aug;76(4):607-21. PMID: 18665689
30. Gardner F, Burton J, Klimes I. Randomised controlled trial of a parenting intervention in the voluntary sector for reducing child conduct problems: outcomes and mechanisms of change. *J Child Psychol Psychiatry.* 2006 Nov;47(11):1123-32. PMID: 17076751
31. Webster-Stratton C. Advancing videotape parent training: a comparison study. *J Consult Clin Psychol.* 1994 Jun;62(3):583-93. PMID: 8063985
32. Hutchings J, Appleton P, Smith M, et al. Evaluation of two treatments for children with severe behaviour problems: Child behaviour and maternal mental health outcomes. *Behav Cogn Psychother.* 2002 Jul;30(3):279-95.

33. Coughlin M, Sharry J, Fitzpatrick C, et al. A controlled clinical evaluation of the parents plus children's programme: a video-based programme for parents of children aged 6 to 11 with behavioural and developmental problems. *Clin Child Psychol Psychiatry*. 2009 Oct;14(4):541-58. PMID: 19759073
34. Shapiro JP, Youngstrom JK, Youngstrom EA, et al. Transporting a manualized treatment for children's disruptive behavior to a community clinic. *Journal of Contemporary Psychotherapy*. 2012;42(4):215-25.
35. Costin J, Lichte C, Hill-Smith A, et al. Parent group treatments for children with Oppositional Defiant Disorder. *AeJAMH (Australian e-Journal for the Advancement of Mental Health)*. 2004;3(1)
36. Boylan K, Macpherson HA, Fristad MA. Examination of disruptive behavior outcomes and moderation in a randomized psychotherapy trial for mood disorders. *J Am Acad Child Adolesc Psychiatry*. 2013 Jul;52(7):699-708. PMID: 23800483
37. Kolko DJ, Campo JV, Kelleher K, et al. Improving access to care and clinical outcome for pediatric behavioral problems: a randomized trial of a nurse-administered intervention in primary care. *J Dev Behav Pediatr*. 2010 Jun;31(5):393-404. PMID: 20495474
38. Scott S, Sylva K, Doolan M, et al. Randomised controlled trial of parent groups for child antisocial behaviour targeting multiple risk factors: the SPOKES project. *J Child Psychol Psychiatry*. 2010 Jan;51(1):48-57. PMID: 19732250
39. Jouriles EN, McDonald R, Rosenfield D, et al. Reducing conduct problems among children exposed to intimate partner violence: a randomized clinical trial examining effects of Project Support. *J Consult Clin Psychol*. 2009 Aug;77(4):705-17. PMID: 19634963
40. Kolko DJ, Dorn LD, Bukstein OG, et al. Community vs. clinic-based modular treatment of children with early-onset ODD or CD: a clinical trial with 3-year follow-up. *J Abnorm Child Psychol*. 2009 Jul;37(5):591-609. PMID: 19221871
41. Larsson B, Fossum S, Clifford G, et al. Treatment of oppositional defiant and conduct problems in young Norwegian children : results of a randomized controlled trial. *Eur Child Adolesc Psychiatry*. 2009 Jan;18(1):42-52. PMID: 18563473
42. van de Wiel NM, Matthys W, Cohen-Kettenis PT, et al. The effectiveness of an experimental treatment when compared to care as usual depends on the type of care as usual. *Behav Modif*. 2007 May;31(3):298-312. PMID: 17438344
43. Drugli MB, Larsson B. Children aged 4-8 years treated with parent training and child therapy because of conduct problems: generalisation effects to day-care and school settings. *Eur Child Adolesc Psychiatry*. 2006 Oct;15(7):392-9. PMID: 16614786
44. Greene RW, Ablon JS, Goring JC, et al. Effectiveness of collaborative problem solving in affectively dysregulated children with oppositional-defiant disorder: initial findings. *J Consult Clin Psychol*. 2004 Dec;72(6):1157-64. PMID: 15612861
45. Webster-Stratton C, Reid MJ, Hammond M. Treating children with early-onset conduct problems: intervention outcomes for parent, child, and teacher training. *J Clin Child Adolesc Psychol*. 2004 Mar;33(1):105-24. PMID: 15028546
46. Cabiya JJ, Padilla-Cotto L, González K, et al. Effectiveness of a cognitive-behavioral intervention for Puerto Rican children. *Revista Interamericana de Psicología*. 2008;42(2):195-202.
47. Augimeri LK, Farrington DP, Koegl CJ, et al. The SNAPTM Under 12 Outreach Project: Effects of a community based program for children with conduct problems. *J Child Fam Stud*. 2007;16(6):799-807.

48. Kolko DJ. Efficacy of cognitive-behavioral treatment and fire safety education for children who set fires: initial and follow-up outcomes. *J Child Psychol Psychiatry*. 2001 Mar;42(3):359-69. PMID: 11321205
49. Webster-Stratton C, Hammond M. Treating children with early-onset conduct problems: a comparison of child and parent training interventions. *J Consult Clin Psychol*. 1997 Feb;65(1):93-109. PMID: 9103739
50. Barrett P, Turner C, Rombouts S, et al. Reciprocal skills training in the treatment of externalising behaviour disorders in childhood: A preliminary investigation. *Behaviour Change*. 2000;17(4):221-34.
51. Lipman EL, Kenny M, Sniderman C, et al. Evaluation of a community-based program for young boys at-risk of antisocial behaviour: results and issues. *J Can Acad Child Adolesc Psychiatry*. 2008;17(1):12-9. PMID: 18392161
52. Masi G, Milone A, Paciello M, et al. Efficacy of a multimodal treatment for disruptive behavior disorders in children and adolescents: focus on internalizing problems. *Psychiatry Res*. 2014 Nov 30;219(3):617-24. PMID: 25060833
53. Rohde P, Clarke GN, Mace DE, et al. An efficacy/effectiveness study of cognitive-behavioral treatment for adolescents with comorbid major depression and conduct disorder. *J Am Acad Child Adolesc Psychiatry*. 2004 Jun;43(6):660-8. PMID: 15167082
54. Weiss B, Han S, Harris V, et al. An Independent Randomized Clinical Trial of Multisystemic Therapy With Non-Court-Referred Adolescents With Serious Conduct Problems. *J Consult Clin Psychol*. 2013 Aug 12; PMID: 23937347
55. Butler S, Baruch G, Hickey N, et al. A randomized controlled trial of multisystemic therapy and a statutory therapeutic intervention for young offenders. *J Am Acad Child Adolesc Psychiatry*. 2011 Dec;50(12):1220-35 e2. PMID: 22115143
56. Sundell K, Hansson K, Lofholm CA, et al. The transportability of multisystemic therapy to Sweden: short-term results from a randomized trial of conduct-disordered youths. *J Fam Psychol*. 2008 Aug;22(4):550-60. PMID: 18729669
57. Santisteban DA, Coatsworth JD, Perez-Vidal A, et al. Efficacy of brief strategic family therapy in modifying Hispanic adolescent behavior problems and substance use. *J Fam Psychol*. 2003 Mar;17(1):121-33. PMID: 12666468
58. Asscher JJ, Deković M, Manders WA, et al. A randomized controlled trial of the effectiveness of multisystemic therapy in the Netherlands: Post-treatment changes and moderator effects. *J Exp Criminol*. 2013;9(2):169-87.
59. Borduin CM, Mann BJ, Cone LT, et al. Multisystemic treatment of serious juvenile offenders: long-term prevention of criminality and violence. *J Consult Clin Psychol*. 1995 Aug;63(4):569-78. PMID: 7673534
60. Nickel M, Luley J, Krawczyk J, et al. Bullying girls - changes after brief strategic family therapy: a randomized, prospective, controlled trial with one-year follow-up. *Psychother Psychosom*. 2006;75(1):47-55. PMID: 16361874
61. Nickel MK, Krawczyk J, Nickel C, et al. Anger, interpersonal relationships, and health-related quality of life in bullying boys who are treated with outpatient family therapy: a randomized, prospective, controlled trial with 1 year of follow-up. *Pediatrics*. 2005 Aug;116(2):e247-54. PMID: 16061577
62. Nickel MK, Muehlbacher M, Kaplan P, et al. Influence of family therapy on bullying behaviour, cortisol secretion, anger, and quality of life in bullying male adolescents: A randomized, prospective, controlled study. *Can J Psychiatry*. 2006 May;51(6):355-62. PMID: 16786816

63. Shechtman Z, Birani-Nasaraladin D. Treating mothers of aggressive children: a research study. *Int J Group Psychother.* 2006 Jan;56(1):93-112. PMID: 16555426
64. Azrin NH, Donohue B, Teichner GA, et al. A controlled evaluation and description of individual-cognitive problem solving and family-behavior therapies in dually-diagnosed conduct-disordered and substance-dependent youth. *J Child Adolesc Subst Abuse.* 2001;11(1):1-43.
65. Sells SP, Early KW, Smith TE. Reducing Adolescent Oppositional and Conduct Disorders: An Experimental Design Using the Parenting with Love and Limits® Model. *Professional Issues in Criminal Justice.* 2011;6(3)
66. van der Put CE, Asscher JJ, Stams GJ, et al. Recidivism after treatment in a forensic youth-psychiatric setting: the effect of treatment characteristics. *Int J Offender Ther Comp Criminol.* 2013 Sep;57(9):1120-39. PMID: 22811475